data_2ro5_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2ro5 _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . 0.492 ' HA ' ' HB2' ' B' ' 37' ' ' PHE . . . . . . . . 0 N--CA 1.457 -0.08 0 N-CA-C 113.459 0.911 . . . . 1.1299999999999999 113.459 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.679 ' H ' ' HB2' ' B' ' 37' ' ' PHE . 10.6 p -110.28 -48.02 3.22 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 114.968 -1.015 . . . . 1.0900000000000001 109.893 172.007 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 78.68 51.65 5.43 Favored Glycine 0 N--CA 1.446 -0.646 0 CA-C-N 115.431 -0.804 . . . . 0.32000000000000001 112.912 172.001 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.794 HG21 ' HB ' ' B' ' 36' ' ' ILE . 1.5 tp -107.99 107.17 22.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 N-CA-C 109.273 -0.64 . . . . 1.0900000000000001 109.273 172.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.745 ' HA ' ' O ' ' B' ' 34' ' ' LEU . 44.2 t -78.28 133.73 29.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-N 116.102 -0.499 . . . . 1.1299999999999999 110.565 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.558 ' HB3' ' CD1' ' B' ' 36' ' ' ILE . 0.4 OUTLIER -129.69 123.06 30.22 Favored 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 107.387 -1.338 . . . . 2.6099999999999999 107.387 -178.237 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' ARG . . . . . 0.514 ' HA ' ' HA ' ' B' ' 33' ' ' PRO . 0.0 OUTLIER -83.82 103.02 12.76 Favored 'General case' 0 C--N 1.314 -0.947 0 N-CA-C 107.754 -1.202 . . . . 3.4100000000000001 107.754 173.246 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.786 HG23 HD12 ' B' ' 34' ' ' LEU . 0.2 OUTLIER -9.97 -102.53 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.13 0 O-C-N 125.291 1.619 . . . . 1.0700000000000001 114.595 -175.4 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . 0.524 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 27.9 p-10 163.33 -165.03 0.01 OUTLIER 'General case' 0 CA--C 1.506 -0.722 0 N-CA-C 107.86 -1.163 . . . . 1.1299999999999999 107.86 175.175 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . 0.478 ' HA ' ' HG2' ' B' ' 30' ' ' GLU . 12.8 p-10 -80.97 14.38 2.27 Favored 'General case' 0 C--N 1.318 -0.796 0 O-C-N 123.376 0.423 . . . . 2.2599999999999998 111.284 -176.648 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -129.96 -55.14 1.13 Allowed 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 109.931 -0.396 . . . . 1.23 109.931 176.799 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.545 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 135.79 7.48 1.82 Allowed Glycine 0 N--CA 1.444 -0.776 0 C-N-CA 120.606 -0.807 . . . . 0.25 113.156 -179.014 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.671 ' HG2' HG23 ' B' ' 17' ' ' VAL . 0.5 OUTLIER -77.76 156.03 30.81 Favored 'General case' 0 CA--C 1.495 -1.149 0 CA-C-N 117.813 0.806 . . . . 0.88 109.912 178.304 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 1.039 HG23 HG23 ' B' ' 16' ' ' VAL . 0.8 OUTLIER -112.2 115.09 48.89 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.86 0 N-CA-C 107.508 -1.293 . . . . 1.99 107.508 167.954 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.694 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 46.9 t -73.35 98.21 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 CA-C-N 114.801 -1.09 . . . . 1.0600000000000001 109.355 -174.281 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.503 ' HB ' ' O ' ' B' ' 14' ' ' GLY . 33.7 mm -83.96 106.97 8.98 Favored Pre-proline 0 N--CA 1.448 -0.529 0 O-C-N 123.844 0.715 . . . . 1.5600000000000001 109.907 179.849 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.694 ' HD3' ' O ' ' A' ' 17' ' ' VAL . 58.6 Cg_exo -47.1 143.86 9.56 Favored 'Trans proline' 0 N--CA 1.455 -0.784 0 C-N-CA 122.958 2.439 . . . . 0.34999999999999998 112.391 174.769 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.905 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -62.4 -15.58 49.87 Favored 'General case' 0 C--O 1.206 -1.236 0 CA-C-N 115.427 -0.806 . . . . 2.1299999999999999 110.763 -179.405 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.684 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 9.6 pt-20 -64.0 -24.07 67.57 Favored 'General case' 0 CA--C 1.532 0.278 0 N-CA-C 112.307 0.484 . . . . 1.3200000000000001 112.307 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.2 mp -87.34 -45.24 16.24 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.24 0 N-CA-C 108.2 -1.037 . . . . 1.0800000000000001 108.2 -179.303 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . 0.708 ' HA ' ' HB2' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -62.96 -26.95 69.07 Favored 'General case' 0 C--N 1.333 -0.137 0 CA-C-N 115.393 -0.822 . . . . 2.02 109.516 173.322 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 34.9 ttm180 -64.41 -49.15 72.67 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 114.94 -1.027 . . . . 3.3999999999999999 110.712 172.683 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 17.7 m -63.41 -27.41 69.28 Favored 'General case' 0 CA--C 1.532 0.265 0 CA-C-O 121.09 0.471 . . . . 1.1499999999999999 110.781 171.166 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.771 ' HB3' HG13 ' A' ' 28' ' ' ILE . 2.2 mm? -69.81 -22.13 63.33 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.038 -0.528 . . . . 1.1599999999999999 110.688 172.764 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.421 ' HB2' ' O ' ' A' ' 26' ' ' LEU . 0.0 OUTLIER 67.33 23.75 9.17 Favored 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 123.574 0.75 . . . . 3.6800000000000002 111.306 -174.218 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.771 HG13 ' HB3' ' A' ' 26' ' ' LEU . 3.6 mt -113.24 -159.68 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 116.013 -0.54 . . . . 1.1000000000000001 109.959 -176.77 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.67 ' H ' HG21 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -159.21 -159.41 0.76 Allowed 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 117.786 0.266 . . . . 3.0699999999999998 111.545 -169.208 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . 0.496 ' HG2' ' HA ' ' B' ' 12' ' ' ASP . 59.0 mp0 -70.28 32.73 0.04 OUTLIER 'General case' 0 N--CA 1.469 0.515 0 C-N-CA 123.613 0.765 . . . . 1.23 112.673 178.303 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.53 ' H ' ' C ' ' A' ' 29' ' ' ARG . . . -148.59 23.92 1.34 Allowed Glycine 0 N--CA 1.44 -1.072 0 N-CA-C 110.297 -1.121 . . . . 0.35999999999999999 110.297 173.178 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.632 ' O ' HG13 ' B' ' 10' ' ' ILE . 14.8 t0 -83.04 122.51 77.77 Favored Pre-proline 0 C--N 1.326 -0.447 0 CA-C-N 114.774 -0.713 . . . . 1.26 109.751 175.663 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.682 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 9.7 Cg_endo -85.66 149.2 9.92 Favored 'Trans proline' 0 N--CA 1.433 -2.03 0 C-N-CA 122.367 2.045 . . . . 1.3 110.522 175.753 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.787 HD13 HG22 ' B' ' 10' ' ' ILE . 0.9 OUTLIER -140.0 150.95 45.07 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 120.386 -0.526 . . . . 1.21 109.739 174.887 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.67 ' HB3' ' HB3' ' A' ' 47' ' ' LYS . 36.1 tt0 -103.48 110.27 22.24 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 107.05 -1.463 . . . . 1.1200000000000001 107.05 -178.802 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.774 ' HB ' HG21 ' B' ' 6' ' ' ILE . 2.1 mp -85.52 107.81 16.6 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.981 0 O-C-N 124.113 0.883 . . . . 1.1599999999999999 108.757 -179.218 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' PHE . . . . . 0.65 ' HB2' ' H ' ' B' ' 4' ' ' THR . 6.2 p90 -149.38 127.34 11.89 Favored 'General case' 0 C--N 1.313 -0.988 0 CA-C-N 115.875 -0.602 . . . . 2.0099999999999998 109.555 177.36 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.482 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 2.1 p -80.02 142.2 14.25 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.071 0 CA-C-N 115.941 -0.572 . . . . 1.05 110.004 -178.375 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.544 ' OD2' ' HD3' ' A' ' 40' ' ' ARG . 28.9 t70 -87.6 -43.08 12.25 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.904 -0.589 . . . . 1.1100000000000001 111.722 -175.474 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . 0.559 ' HG3' ' HG3' ' A' ' 43' ' ' GLU . 0.0 OUTLIER -138.42 -90.05 0.22 Allowed 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 112.797 0.666 . . . . 2.8799999999999999 112.797 -167.473 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 31.4 t70 -100.76 -71.91 0.69 Allowed 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.025 0.441 . . . . 1.53 110.85 -177.772 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.554 ' HA3' HD13 ' B' ' 26' ' ' LEU . . . -133.34 24.12 3.77 Favored Glycine 0 N--CA 1.445 -0.75 0 C-N-CA 120.466 -0.873 . . . . 0.34000000000000002 112.123 -178.845 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.559 ' HG3' ' HG3' ' A' ' 40' ' ' ARG . 1.5 mt-10 -98.1 109.86 22.54 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 109.081 -0.711 . . . . 1.97 109.081 176.017 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.485 ' O ' ' HA ' ' B' ' 45' ' ' ILE . 1.6 t -90.0 134.25 29.59 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.875 0 N-CA-C 109.461 -0.57 . . . . 1.0600000000000001 109.461 178.339 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.827 HG13 HG13 ' B' ' 45' ' ' ILE . 1.5 mp -109.08 122.72 64.19 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 N-CA-C 108.131 -1.063 . . . . 1.01 108.131 -177.095 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.788 HD13 HD11 ' B' ' 46' ' ' LEU . 4.9 mt -106.07 117.77 34.89 Favored 'General case' 0 C--N 1.319 -0.741 0 O-C-N 123.869 0.731 . . . . 1.1299999999999999 109.728 178.286 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.67 ' HB3' ' HB3' ' A' ' 35' ' ' GLU . 15.8 ttmt -119.17 127.69 53.54 Favored 'General case' 0 C--N 1.311 -1.099 0 CA-C-N 115.73 -0.668 . . . . 1.25 111.959 -171.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.547 ' HA ' ' O ' ' A' ' 33' ' ' PRO . 3.2 ptmt -44.88 -15.03 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.451 0 N-CA-C 116.656 2.095 . . . . 1.0900000000000001 116.656 -170.758 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . 0.706 ' CD1' HG21 ' B' ' 7' ' ' VAL . 27.1 t80 73.59 -55.9 0.66 Allowed 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 112.627 0.602 . . . . 2.1400000000000001 112.627 171.066 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.672 ' OG ' ' HD3' ' A' ' 51' ' ' PRO . 7.3 p -54.69 -41.67 91.04 Favored Pre-proline 0 CA--C 1.54 0.582 0 N-CA-C 112.439 0.533 . . . . 1.95 112.439 -174.312 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.672 ' HD3' ' OG ' ' A' ' 50' ' ' SER . 60.7 Cg_endo -103.3 14.74 0.27 Allowed 'Trans proline' 0 N--CA 1.451 -0.99 0 C-N-CA 123.063 2.509 . . . . 0.59999999999999998 111.192 168.737 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 3.0 mt . . . . . 0 N--CA 1.444 -0.734 0 CA-C-N 115.194 -0.912 . . . . 1.4199999999999999 108.549 -168.843 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 3' ' ' ALA . . . . . 0.516 ' HA ' ' HB2' ' A' ' 37' ' ' PHE . . . . . . . . 0 C--O 1.233 0.206 0 CA-C-O 122.058 0.932 . . . . 1.1000000000000001 113.037 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 4' ' ' THR . . . . . 0.65 ' H ' ' HB2' ' A' ' 37' ' ' PHE . 5.4 p -110.8 -48.72 3.1 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 114.473 -1.239 . . . . 0.97999999999999998 109.661 171.473 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 78.4 51.38 5.66 Favored Glycine 0 N--CA 1.45 -0.419 0 CA-C-N 115.453 -0.794 . . . . 0.33000000000000002 112.843 172.122 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 6' ' ' ILE . . . . . 0.774 HG21 ' HB ' ' A' ' 36' ' ' ILE . 1.4 tp -107.44 106.84 21.42 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 N-CA-C 109.317 -0.623 . . . . 1.1000000000000001 109.317 173.573 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . 0.732 ' HA ' ' O ' ' A' ' 34' ' ' LEU . 25.2 t -78.1 135.2 26.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 116.124 -0.489 . . . . 1.0800000000000001 110.469 179.447 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . 0.418 ' HD3' ' N ' ' B' ' 9' ' ' ARG . 0.8 OUTLIER -133.36 122.51 23.89 Favored 'General case' 0 N--CA 1.439 -0.999 0 N-CA-C 107.345 -1.354 . . . . 2.3599999999999999 107.345 -178.871 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 9' ' ' ARG . . . . . 0.542 ' HA ' ' HA ' ' A' ' 33' ' ' PRO . 18.3 ttp180 -81.7 104.57 12.19 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 108.596 -0.89 . . . . 3.2000000000000002 108.596 172.986 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 10' ' ' ILE . . . . . 0.787 HG22 HD13 ' A' ' 34' ' ' LEU . 0.3 OUTLIER -10.79 -101.27 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 O-C-N 125.631 1.832 . . . . 1.0700000000000001 114.234 -175.701 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . 0.652 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 2.4 p-10 162.2 -169.87 0.01 OUTLIER 'General case' 0 CA--C 1.512 -0.502 0 N-CA-C 107.672 -1.233 . . . . 1.1799999999999999 107.672 176.043 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 12' ' ' ASP . . . . . 0.496 ' HA ' ' HG2' ' A' ' 30' ' ' GLU . 3.3 p30 -78.13 7.74 5.82 Favored 'General case' 0 C--N 1.325 -0.463 0 O-C-N 123.174 0.296 . . . . 2.3900000000000001 111.251 -177.608 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 13' ' ' LEU . . . . . 0.405 ' HB3' ' HD2' ' B' ' 15' ' ' ARG . 2.4 tm? -119.03 -61.53 1.63 Allowed 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 109.8 -0.445 . . . . 1.1000000000000001 109.8 171.603 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 14' ' ' GLY . . . . . 0.503 ' O ' ' HB ' ' A' ' 18' ' ' ILE . . . 137.72 14.78 0.77 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.265 -0.969 . . . . 0.23000000000000001 113.257 -178.565 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 15' ' ' ARG . . . . . 0.687 ' HG2' HG23 ' A' ' 17' ' ' VAL . 0.3 OUTLIER -81.08 154.68 26.68 Favored 'General case' 0 CA--C 1.493 -1.23 0 CA-C-O 121.659 0.743 . . . . 1.3899999999999999 109.72 177.325 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 16' ' ' VAL . . . . . 1.039 HG23 HG23 ' A' ' 16' ' ' VAL . 3.9 m -107.7 108.52 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.219 0 N-CA-C 106.998 -1.482 . . . . 1.97 106.998 170.357 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 17' ' ' VAL . . . . . 0.671 HG23 ' HG2' ' A' ' 15' ' ' ARG . 47.3 t -70.88 96.52 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.352 0 CA-C-N 114.597 -1.183 . . . . 1.0600000000000001 109.206 -174.354 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . 0.545 ' HB ' ' O ' ' A' ' 14' ' ' GLY . 34.3 mm -85.0 108.38 15.15 Favored Pre-proline 0 N--CA 1.449 -0.519 0 CA-C-N 115.401 -0.818 . . . . 1.6100000000000001 110.299 -177.612 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 19' ' ' PRO . . . . . 0.678 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 58.5 Cg_exo -47.29 141.79 13.23 Favored 'Trans proline' 0 N--CA 1.456 -0.724 0 C-N-CA 122.876 2.384 . . . . 0.33000000000000002 112.702 174.78 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 20' ' ' LYS . . . . . 0.954 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -59.3 -15.15 14.27 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.444 -0.798 . . . . 2.3199999999999998 111.789 178.207 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . 0.678 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 12.9 pt-20 -64.14 -26.16 68.41 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-O 120.706 0.288 . . . . 1.9199999999999999 111.45 -179.767 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 5.3 mp -87.16 -44.1 16.05 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.354 0 N-CA-C 107.901 -1.148 . . . . 1.24 107.901 -177.284 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 23' ' ' ARG . . . . . 0.599 ' HA ' ' HB2' ' B' ' 26' ' ' LEU . 0.0 OUTLIER -63.99 -26.32 68.52 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-N 115.147 -0.933 . . . . 1.8500000000000001 109.897 174.972 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 24' ' ' ARG . . . . . . . . . . . . . 32.3 ttm180 -65.58 -50.14 66.2 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.674 -0.694 . . . . 3.6899999999999999 110.917 172.213 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 28.2 m -63.29 -21.53 66.31 Favored 'General case' 0 CA--C 1.531 0.233 0 CA-C-O 121.527 0.68 . . . . 1.1599999999999999 110.47 174.4 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . 0.62 ' HB3' HG13 ' B' ' 28' ' ' ILE . 1.6 mm? -74.21 -20.93 60.02 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.505 -0.77 . . . . 1.1100000000000001 110.915 173.399 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 27' ' ' ARG . . . . . 0.455 ' HB2' ' O ' ' B' ' 26' ' ' LEU . 0.0 OUTLIER 67.37 28.47 7.83 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 123.33 0.652 . . . . 3.77 110.827 -173.892 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 28' ' ' ILE . . . . . 0.878 HG21 ' H ' ' B' ' 29' ' ' ARG . 5.7 mt -121.49 -163.28 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.051 -0.522 . . . . 1.2 110.399 -176.657 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 29' ' ' ARG . . . . . 0.878 ' H ' HG21 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -157.93 -158.38 0.73 Allowed 'General case' 0 N--CA 1.467 0.414 0 C-N-CA 122.046 0.138 . . . . 2.7599999999999998 111.054 -169.87 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 30' ' ' GLU . . . . . 0.478 ' HG2' ' HA ' ' A' ' 12' ' ' ASP . 58.9 mp0 -69.33 30.84 0.03 OUTLIER 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 112.95 0.722 . . . . 1.1799999999999999 112.95 178.666 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 31' ' ' GLY . . . . . 0.511 ' H ' ' C ' ' B' ' 29' ' ' ARG . . . -145.56 25.68 1.82 Allowed Glycine 0 N--CA 1.441 -1.006 0 N-CA-C 110.073 -1.211 . . . . 0.34999999999999998 110.073 172.503 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 32' ' ' ASP . . . . . 0.547 ' O ' HG13 ' A' ' 10' ' ' ILE . 8.6 t70 -82.0 121.5 79.09 Favored Pre-proline 0 C--N 1.324 -0.538 0 CA-C-N 114.6 -0.8 . . . . 1.29 110.224 176.002 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 33' ' ' PRO . . . . . 0.734 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 7.8 Cg_endo -83.06 147.02 12.97 Favored 'Trans proline' 0 N--CA 1.433 -2.048 0 C-N-CA 122.163 1.909 . . . . 1.1000000000000001 110.432 173.351 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . 0.786 HD12 HG23 ' A' ' 10' ' ' ILE . 1.0 OUTLIER -137.53 149.28 46.63 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 109.6 -0.519 . . . . 1.1699999999999999 109.6 173.431 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 35' ' ' GLU . . . . . 0.71 ' HB3' ' HE3' ' B' ' 47' ' ' LYS . 45.8 tt0 -101.81 111.32 23.54 Favored 'General case' 0 C--N 1.297 -1.694 0 N-CA-C 107.242 -1.392 . . . . 1.1000000000000001 107.242 178.89 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 36' ' ' ILE . . . . . 0.794 ' HB ' HG21 ' A' ' 6' ' ' ILE . 2.8 mp -85.19 108.01 16.62 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.77 0 O-C-N 124.329 1.018 . . . . 1.3200000000000001 108.831 -179.678 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 37' ' ' PHE . . . . . 0.679 ' HB2' ' H ' ' A' ' 4' ' ' THR . 7.6 p90 -150.44 127.66 11.3 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 116.003 -0.544 . . . . 2.0299999999999998 109.866 176.851 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 38' ' ' VAL . . . . . 0.523 ' HA ' ' HA ' ' B' ' 44' ' ' VAL . 1.6 p -79.94 145.23 9.53 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 CA-C-N 116.446 -0.343 . . . . 0.89000000000000001 110.562 -177.529 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 39' ' ' ASP . . . . . 0.611 ' OD2' ' HD3' ' B' ' 40' ' ' ARG . 18.2 t70 -82.58 -47.39 12.18 Favored 'General case' 0 C--N 1.326 -0.439 0 O-C-N 123.966 0.791 . . . . 1.1399999999999999 111.318 -175.569 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 40' ' ' ARG . . . . . 0.611 ' HD3' ' OD2' ' B' ' 39' ' ' ASP . 0.7 OUTLIER -144.82 -78.75 0.19 Allowed 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 113.189 0.811 . . . . 3.3700000000000001 113.189 -176.457 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -97.63 -65.45 0.96 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.039 0.447 . . . . 1.3200000000000001 111.512 -171.096 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 42' ' ' GLY . . . . . 0.486 ' HA3' ' HD2' ' A' ' 48' ' ' LYS . . . -145.9 16.97 1.77 Allowed Glycine 0 N--CA 1.442 -0.912 0 C-N-CA 120.79 -0.719 . . . . 0.35999999999999999 111.651 -178.155 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 43' ' ' GLU . . . . . 0.686 ' HA ' ' O ' ' A' ' 46' ' ' LEU . 2.3 pm0 -91.96 107.36 19.16 Favored 'General case' 0 N--CA 1.445 -0.683 0 N-CA-C 109.835 -0.431 . . . . 2.0699999999999998 109.835 176.619 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 44' ' ' VAL . . . . . 0.578 ' HB ' HD12 ' A' ' 46' ' ' LEU . 2.1 t -89.33 131.69 35.98 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 109.536 -0.542 . . . . 1.02 109.536 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 45' ' ' ILE . . . . . 0.827 HG13 HG13 ' A' ' 45' ' ' ILE . 1.6 mp -107.06 120.64 58.73 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 N-CA-C 108.065 -1.087 . . . . 0.95999999999999996 108.065 -178.302 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 46' ' ' LEU . . . . . 0.788 HD11 HD13 ' A' ' 46' ' ' LEU . 0.9 OUTLIER -109.7 116.48 31.78 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 109.442 -0.577 . . . . 1.05 109.442 177.531 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 47' ' ' LYS . . . . . 0.71 ' HE3' ' HB3' ' B' ' 35' ' ' GLU . 0.0 OUTLIER -127.71 141.81 51.5 Favored 'General case' 0 C--N 1.318 -0.774 0 C-N-CA 119.372 -0.931 . . . . 1.3899999999999999 113.083 -177.722 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 48' ' ' LYS . . . . . 0.683 ' HE2' ' HG3' ' B' ' 51' ' ' PRO . 5.2 ptmt -43.4 -12.88 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.177 0 N-CA-C 118.157 2.651 . . . . 1.1899999999999999 118.157 -166.171 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 49' ' ' TYR . . . . . 0.741 ' CD1' HG22 ' A' ' 7' ' ' VAL . 22.4 t80 71.87 -55.77 0.66 Allowed 'General case' 0 N--CA 1.475 0.809 0 N-CA-C 113.374 0.879 . . . . 2.1000000000000001 113.374 172.738 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 50' ' ' SER . . . . . 0.691 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 33.9 t -51.15 -57.02 15.35 Favored Pre-proline 0 CA--C 1.535 0.369 0 C-N-CA 122.867 0.467 . . . . 1.77 111.11 -175.186 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 51' ' ' PRO . . . . . 0.691 ' HD3' ' HB3' ' B' ' 50' ' ' SER . 48.9 Cg_endo -89.58 13.51 2.37 Favored 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 121.995 1.796 . . . . 0.59999999999999998 111.229 171.052 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 52' ' ' ILE . . . . . . . . . . . . . 3.0 mt . . . . . 0 N--CA 1.448 -0.571 0 CA-C-N 114.97 -1.014 . . . . 1.3899999999999999 108.487 -172.763 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . 0.422 ' HA ' ' HB2' ' B' ' 37' ' ' PHE . . . . . . . . 0 CA--C 1.523 -0.095 0 CA-C-O 121.54 0.686 . . . . 1.1299999999999999 111.204 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.408 ' OG1' ' HA ' ' B' ' 37' ' ' PHE . 17.9 p -92.29 -50.34 5.7 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.227 -0.897 . . . . 1.0900000000000001 111.756 -177.957 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 79.78 49.69 5.96 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.46 -0.876 . . . . 0.32000000000000001 113.208 175.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.742 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.1 tp -107.39 113.18 42.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 N-CA-C 109.17 -0.678 . . . . 1.0900000000000001 109.17 173.731 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.724 ' HA ' ' O ' ' B' ' 34' ' ' LEU . 39.7 t -83.43 135.52 24.65 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-O 120.922 0.391 . . . . 1.1299999999999999 110.798 -178.477 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.573 ' HB3' ' CD1' ' B' ' 36' ' ' ILE . 6.8 tpp180 -129.23 123.25 31.5 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 107.568 -1.271 . . . . 2.6099999999999999 107.568 -179.352 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ARG . . . . . 0.528 ' N ' ' HD3' ' A' ' 8' ' ' ARG . 4.9 tpp180 -84.43 104.44 14.44 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 108.328 -0.99 . . . . 3.4100000000000001 108.328 173.19 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.71 HG23 HD12 ' B' ' 34' ' ' LEU . 0.2 OUTLIER -12.23 -103.67 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.115 0 O-C-N 125.365 1.666 . . . . 1.0700000000000001 114.701 -176.515 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . 0.568 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 5.8 p-10 161.35 -160.27 0.0 OUTLIER 'General case' 0 CA--C 1.512 -0.485 0 N-CA-C 107.937 -1.134 . . . . 1.1299999999999999 107.937 177.019 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -72.66 -22.88 60.85 Favored 'General case' 0 C--N 1.323 -0.576 0 O-C-N 123.386 0.429 . . . . 2.2599999999999998 110.878 -178.455 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -98.42 -60.52 1.53 Allowed 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.29 -0.414 . . . . 1.23 110.233 178.287 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.453 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 136.43 18.7 0.7 Allowed Glycine 0 N--CA 1.445 -0.735 0 C-N-CA 120.073 -1.061 . . . . 0.25 113.393 -179.186 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.67 ' HG2' HG23 ' B' ' 17' ' ' VAL . 0.0 OUTLIER -79.1 153.35 30.22 Favored 'General case' 0 CA--C 1.507 -0.693 0 CA-C-N 118.028 0.914 . . . . 0.88 109.621 179.569 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.805 HG23 HD12 ' B' ' 46' ' ' LEU . 98.0 t -104.4 100.32 10.25 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.455 0 N-CA-C 107.628 -1.249 . . . . 1.99 107.628 172.353 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.756 HG23 ' HG2' ' B' ' 15' ' ' ARG . 91.0 t -68.14 98.89 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.909 0 CA-C-N 115.068 -0.969 . . . . 1.0600000000000001 110.21 -173.43 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.731 HG21 HD12 ' A' ' 22' ' ' ILE . 8.7 mt -92.25 114.02 60.96 Favored Pre-proline 0 N--CA 1.445 -0.708 0 CA-C-N 115.643 -0.708 . . . . 1.5600000000000001 110.778 -178.551 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.6 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 47.5 Cg_exo -46.08 145.89 4.89 Favored 'Trans proline' 0 N--CA 1.458 -0.599 0 C-N-CA 123.1 2.533 . . . . 0.34999999999999998 112.821 174.168 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.811 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -60.85 -16.47 41.63 Favored 'General case' 0 C--O 1.211 -0.949 0 CA-C-N 115.478 -0.783 . . . . 2.1299999999999999 111.353 179.321 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.6 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 11.1 pt-20 -66.1 -19.91 65.99 Favored 'General case' 0 C--O 1.236 0.363 0 N-CA-C 111.767 0.284 . . . . 1.3200000000000001 111.767 -178.283 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.731 HD12 HG21 ' A' ' 18' ' ' ILE . 5.0 mp -87.49 -50.8 13.48 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.635 0 N-CA-C 107.854 -1.165 . . . . 1.0800000000000001 107.854 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . 0.561 ' HA ' ' HB2' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -56.1 -31.98 63.75 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 115.492 -0.776 . . . . 2.02 110.358 171.879 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 10.2 ttt180 -63.55 -52.26 61.87 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.313 -0.858 . . . . 3.3999999999999999 110.943 174.29 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 22.5 m -66.53 -22.75 66.16 Favored 'General case' 0 C--O 1.222 -0.353 0 CA-C-O 121.182 0.515 . . . . 1.1499999999999999 110.697 175.525 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.736 ' HB3' HG13 ' A' ' 28' ' ' ILE . 2.0 mm? -65.81 -19.71 65.98 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.865 -0.607 . . . . 1.1599999999999999 110.614 173.928 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.531 ' HB2' ' O ' ' A' ' 26' ' ' LEU . 0.3 OUTLIER 72.3 21.36 3.84 Favored 'General case' 0 N--CA 1.466 0.358 0 O-C-N 124.066 0.854 . . . . 3.6800000000000002 110.371 -172.746 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.736 HG13 ' HB3' ' A' ' 26' ' ' LEU . 3.0 mt -122.18 -163.0 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.726 -0.67 . . . . 1.1000000000000001 110.175 -174.154 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.697 ' H ' HG21 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -153.18 -161.41 1.28 Allowed 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 111.481 0.178 . . . . 3.0699999999999998 111.481 -167.944 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -73.79 36.62 0.09 Allowed 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 121.961 0.886 . . . . 1.23 111.51 179.351 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.558 ' H ' ' C ' ' A' ' 29' ' ' ARG . . . -152.19 24.78 0.89 Allowed Glycine 0 N--CA 1.44 -1.099 0 CA-C-N 114.15 -1.387 . . . . 0.35999999999999999 109.894 174.026 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.597 ' O ' HG13 ' B' ' 10' ' ' ILE . 13.2 t0 -82.95 124.54 76.66 Favored Pre-proline 0 C--N 1.326 -0.436 0 CA-C-N 114.512 -0.844 . . . . 1.26 109.931 175.68 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.706 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 4.7 Cg_endo -82.94 152.5 14.5 Favored 'Trans proline' 0 N--CA 1.435 -1.939 0 C-N-CA 122.187 1.924 . . . . 1.3 110.719 173.777 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.793 HD12 HG22 ' B' ' 10' ' ' ILE . 0.6 OUTLIER -140.66 152.8 45.66 Favored 'General case' 0 C--N 1.305 -1.362 0 N-CA-C 109.14 -0.689 . . . . 1.21 109.14 171.994 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.896 ' HB3' ' HD2' ' A' ' 47' ' ' LYS . 39.4 tt0 -105.87 111.24 23.81 Favored 'General case' 0 CA--C 1.486 -1.515 0 N-CA-C 107.501 -1.296 . . . . 1.1200000000000001 107.501 -179.051 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.894 HG13 HD21 ' A' ' 46' ' ' LEU . 2.5 mp -85.17 110.21 19.09 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.98 0 O-C-N 124.648 1.217 . . . . 1.1599999999999999 108.478 -179.169 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' PHE . . . . . 0.63 ' HB2' ' H ' ' B' ' 4' ' ' THR . 1.8 p90 -150.55 124.61 9.34 Favored 'General case' 0 C--N 1.313 -1.02 0 CA-C-N 116.162 -0.472 . . . . 2.0099999999999998 109.747 175.6 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.517 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 1.7 p -80.83 136.34 23.4 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 CA-C-O 121.149 0.5 . . . . 1.05 110.778 -178.33 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.661 ' HB3' ' HG3' ' A' ' 40' ' ' ARG . 9.8 t70 -75.59 -45.01 40.14 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.036 -0.984 . . . . 1.1100000000000001 110.68 -175.498 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . 0.661 ' HG3' ' HB3' ' A' ' 39' ' ' ASP . 7.6 mtp180 -132.13 -73.35 0.52 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.672 -0.694 . . . . 2.8799999999999999 112.267 -165.807 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -129.67 -65.11 0.85 Allowed 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.284 -0.871 . . . . 1.53 111.09 -173.408 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.56 ' HA3' HD13 ' B' ' 26' ' ' LEU . . . -131.88 6.36 5.46 Favored Glycine 0 CA--C 1.501 -0.832 0 CA-C-N 114.838 -1.074 . . . . 0.34000000000000002 111.812 -173.852 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.562 ' HA ' ' O ' ' B' ' 46' ' ' LEU . 2.2 pm0 -93.58 105.69 17.71 Favored 'General case' 0 N--CA 1.443 -0.793 0 CA-C-O 121.009 0.433 . . . . 1.97 109.929 175.317 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.594 HG12 HG21 ' A' ' 36' ' ' ILE . 2.0 t -88.82 132.31 34.0 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.988 0 CA-C-N 115.566 -0.743 . . . . 1.0600000000000001 109.864 178.907 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.849 HG13 HG13 ' B' ' 45' ' ' ILE . 1.4 mp -110.11 115.96 51.06 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 N-CA-C 108.239 -1.023 . . . . 1.01 108.239 -177.372 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 1.022 HD11 HD11 ' B' ' 46' ' ' LEU . 0.5 OUTLIER -109.48 116.76 32.41 Favored 'General case' 0 C--N 1.319 -0.759 0 O-C-N 123.703 0.627 . . . . 1.1299999999999999 109.584 -178.871 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.896 ' HD2' ' HB3' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -122.84 150.37 42.95 Favored 'General case' 0 C--O 1.215 -0.732 0 C-N-CA 119.066 -1.054 . . . . 1.25 112.169 179.121 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.548 ' HA ' ' O ' ' A' ' 33' ' ' PRO . 1.5 ptmt -44.92 -16.45 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.24 0 N-CA-C 117.13 2.27 . . . . 1.0900000000000001 117.13 -168.188 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . 0.754 ' CD1' HG22 ' B' ' 7' ' ' VAL . 19.9 t80 74.35 -50.36 0.68 Allowed 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 112.689 0.625 . . . . 2.1400000000000001 112.689 174.293 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.705 ' HB3' ' HD3' ' A' ' 51' ' ' PRO . 22.7 t -48.1 -50.83 52.95 Favored Pre-proline 0 CA--C 1.538 0.493 0 C-N-CA 122.585 0.354 . . . . 1.95 111.395 -177.368 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.705 ' HD3' ' HB3' ' A' ' 50' ' ' SER . 36.3 Cg_endo -95.25 10.31 1.66 Allowed 'Trans proline' 0 N--CA 1.453 -0.878 0 C-N-CA 122.601 2.2 . . . . 0.59999999999999998 111.484 172.31 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 1.1 mt . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 115.044 -0.98 . . . . 1.4199999999999999 109.262 -170.466 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 3' ' ' ALA . . . . . 0.546 ' HA ' ' HD2' ' A' ' 37' ' ' PHE . . . . . . . . 0 N--CA 1.462 0.174 0 CA-C-O 121.329 0.585 . . . . 1.1000000000000001 110.546 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 4' ' ' THR . . . . . 0.63 ' H ' ' HB2' ' A' ' 37' ' ' PHE . 28.5 p -107.85 -52.56 2.75 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.634 -0.712 . . . . 0.97999999999999998 111.068 -176.947 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 82.26 50.98 4.58 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.995 -0.621 . . . . 0.33000000000000002 112.797 177.164 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 6' ' ' ILE . . . . . 0.805 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.0 OUTLIER -106.68 108.24 24.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 N-CA-C 109.322 -0.621 . . . . 1.1000000000000001 109.322 173.316 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . 0.754 HG22 ' CD1' ' A' ' 49' ' ' TYR . 23.0 t -80.52 136.49 23.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-N 116.231 -0.44 . . . . 1.0800000000000001 111.217 179.673 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . 0.549 ' HD3' ' N ' ' B' ' 9' ' ' ARG . 1.1 tpp180 -131.97 126.94 35.25 Favored 'General case' 0 N--CA 1.446 -0.625 0 N-CA-C 107.61 -1.255 . . . . 2.3599999999999999 107.61 178.384 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 9' ' ' ARG . . . . . 0.549 ' N ' ' HD3' ' B' ' 8' ' ' ARG . 1.7 tpp180 -86.3 103.22 14.69 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 108.606 -0.887 . . . . 3.2000000000000002 108.606 173.858 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 10' ' ' ILE . . . . . 0.793 HG22 HD12 ' A' ' 34' ' ' LEU . 0.2 OUTLIER -10.17 -107.37 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.264 0 O-C-N 125.351 1.657 . . . . 1.0700000000000001 114.749 -177.828 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . 0.659 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 1.7 p-10 163.39 -166.38 0.01 OUTLIER 'General case' 0 CA--C 1.518 -0.286 0 N-CA-C 108.327 -0.99 . . . . 1.1799999999999999 108.327 177.441 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -66.28 -19.85 65.93 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.355 0.598 . . . . 2.3900000000000001 110.793 -179.04 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 13' ' ' LEU . . . . . 0.4 ' H ' ' CG ' ' B' ' 11' ' ' ASP . 2.9 tm? -101.59 -61.8 1.33 Allowed 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.711 -0.677 . . . . 1.1000000000000001 110.796 -179.059 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 137.96 19.5 0.55 Allowed Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.807 -0.711 . . . . 0.23000000000000001 112.116 -178.806 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 15' ' ' ARG . . . . . 0.756 ' HG2' HG23 ' A' ' 17' ' ' VAL . 2.7 mtm180 -70.22 147.65 49.54 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-O 121.244 0.545 . . . . 1.3899999999999999 110.593 177.361 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 16' ' ' VAL . . . . . 0.709 HG22 HD12 ' A' ' 46' ' ' LEU . 63.7 t -106.69 97.07 5.18 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.237 0 N-CA-C 107.644 -1.243 . . . . 1.97 107.644 166.767 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 17' ' ' VAL . . . . . 0.67 HG23 ' HG2' ' A' ' 15' ' ' ARG . 64.3 t -67.42 98.92 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 CA-C-N 115.62 -0.718 . . . . 1.0600000000000001 110.364 -171.732 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . 0.506 ' H ' ' HA ' ' A' ' 15' ' ' ARG . 6.9 mt -90.45 113.87 59.11 Favored Pre-proline 0 N--CA 1.442 -0.872 0 CA-C-N 115.181 -0.918 . . . . 1.6100000000000001 110.562 -179.624 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 19' ' ' PRO . . . . . 0.556 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 81.3 Cg_exo -50.19 147.21 16.24 Favored 'Trans proline' 0 N--CA 1.458 -0.59 0 C-N-CA 123.056 2.504 . . . . 0.33000000000000002 112.567 174.123 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 20' ' ' LYS . . . . . 0.941 ' HD3' ' H ' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -64.94 -15.63 62.36 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 115.649 -0.705 . . . . 2.3199999999999998 111.678 -178.795 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . 0.556 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 1.3 pm0 -63.13 -21.8 66.44 Favored 'General case' 0 C--O 1.237 0.439 0 N-CA-C 111.854 0.316 . . . . 1.9199999999999999 111.854 177.458 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 5.2 mp -87.61 -47.52 15.69 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 N-CA-C 108.488 -0.93 . . . . 1.24 108.488 -178.406 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 23' ' ' ARG . . . . . 0.541 ' HA ' ' HB2' ' B' ' 26' ' ' LEU . 0.0 OUTLIER -61.93 -28.28 69.42 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.262 -0.881 . . . . 1.8500000000000001 109.231 174.022 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 24' ' ' ARG . . . . . . . . . . . . . 55.0 ttp180 -65.78 -51.92 55.07 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 114.91 -1.041 . . . . 3.6899999999999999 110.988 174.639 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 18.7 m -63.65 -28.74 70.12 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-O 121.525 0.679 . . . . 1.1599999999999999 110.152 176.23 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . 0.653 ' HB3' HG13 ' B' ' 28' ' ' ILE . 1.4 mm? -64.08 -19.9 65.57 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 115.009 -0.996 . . . . 1.1100000000000001 110.678 174.091 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 27' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER 70.8 24.02 4.32 Favored 'General case' 0 C--N 1.342 0.242 0 CA-C-O 121.587 0.708 . . . . 3.77 110.154 -177.105 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 28' ' ' ILE . . . . . 0.823 HG23 ' H ' ' B' ' 29' ' ' ARG . 4.0 mt -119.25 -162.55 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.133 -0.939 . . . . 1.2 110.058 -176.889 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 29' ' ' ARG . . . . . 0.823 ' H ' HG23 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -152.99 -161.42 1.29 Allowed 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 111.618 0.229 . . . . 2.7599999999999998 111.618 -171.584 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 30' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -72.4 34.06 0.06 Allowed 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 121.858 0.837 . . . . 1.1799999999999999 111.925 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 31' ' ' GLY . . . . . 0.536 ' H ' ' C ' ' B' ' 29' ' ' ARG . . . -150.73 30.31 1.02 Allowed Glycine 0 N--CA 1.436 -1.365 0 N-CA-C 109.636 -1.385 . . . . 0.34999999999999998 109.636 172.79 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 32' ' ' ASP . . . . . 0.517 ' N ' HD11 ' A' ' 10' ' ' ILE . 6.9 t70 -85.22 128.72 58.62 Favored Pre-proline 0 CA--C 1.511 -0.523 0 CA-C-N 114.451 -0.874 . . . . 1.29 110.271 174.74 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 33' ' ' PRO . . . . . 0.696 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 10.9 Cg_endo -86.76 148.48 8.42 Favored 'Trans proline' 0 N--CA 1.433 -2.07 0 C-N-CA 122.128 1.885 . . . . 1.1000000000000001 111.469 173.195 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . 0.724 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.8 OUTLIER -137.53 148.34 45.9 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 109.273 -0.64 . . . . 1.1699999999999999 109.273 173.661 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 35' ' ' GLU . . . . . 0.648 ' O ' ' HA ' ' B' ' 46' ' ' LEU . 77.9 tt0 -104.68 111.84 24.71 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 108.11 -1.07 . . . . 1.1000000000000001 108.11 -179.535 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 36' ' ' ILE . . . . . 0.885 HG13 HD22 ' B' ' 46' ' ' LEU . 3.5 mp -86.1 109.34 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.869 0 O-C-N 124.716 1.26 . . . . 1.3200000000000001 109.108 -177.964 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 37' ' ' PHE . . . . . 0.422 ' HB2' ' HA ' ' A' ' 3' ' ' ALA . 16.5 p90 -149.82 126.77 11.16 Favored 'General case' 0 C--N 1.316 -0.88 0 CA-C-N 115.922 -0.581 . . . . 2.0299999999999998 109.954 175.415 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 38' ' ' VAL . . . . . 0.497 ' HA ' ' HA ' ' B' ' 44' ' ' VAL . 1.3 p -80.55 139.62 17.87 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.78 0 CA-C-O 121.361 0.6 . . . . 0.89000000000000001 111.16 -177.911 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 39' ' ' ASP . . . . . 0.587 ' HB2' HD11 ' B' ' 45' ' ' ILE . 7.1 t70 -74.81 -49.86 19.22 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 114.591 -1.186 . . . . 1.1399999999999999 110.472 -178.009 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 40' ' ' ARG . . . . . 0.555 ' HG3' ' HB3' ' B' ' 39' ' ' ASP . 13.8 mtp180 -132.78 -72.87 0.51 Allowed 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 112.604 0.594 . . . . 3.3700000000000001 112.604 -168.434 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -124.69 -67.65 0.9 Allowed 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.359 -0.837 . . . . 1.3200000000000001 110.986 -172.469 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 42' ' ' GLY . . . . . 0.463 ' HA3' HD13 ' A' ' 26' ' ' LEU . . . -129.75 9.56 6.08 Favored Glycine 0 N--CA 1.441 -1.028 0 CA-C-N 114.699 -1.137 . . . . 0.35999999999999999 112.142 -176.094 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 43' ' ' GLU . . . . . 0.477 ' HA ' ' O ' ' A' ' 46' ' ' LEU . 2.3 pm0 -93.13 104.74 16.91 Favored 'General case' 0 N--CA 1.446 -0.625 0 N-CA-C 109.794 -0.447 . . . . 2.0699999999999998 109.794 176.199 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 44' ' ' VAL . . . . . 0.572 HG12 HG22 ' B' ' 36' ' ' ILE . 2.0 t -89.42 134.05 29.77 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.886 0 N-CA-C 109.805 -0.443 . . . . 1.02 109.805 179.071 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 45' ' ' ILE . . . . . 0.849 HG13 HG13 ' A' ' 45' ' ' ILE . 1.6 mp -110.17 116.36 52.09 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 N-CA-C 108.095 -1.076 . . . . 0.95999999999999996 108.095 -177.908 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 46' ' ' LEU . . . . . 1.022 HD11 HD11 ' A' ' 46' ' ' LEU . 0.7 OUTLIER -109.4 116.25 31.49 Favored 'General case' 0 C--N 1.317 -0.838 0 O-C-N 123.67 0.606 . . . . 1.05 109.569 179.577 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 47' ' ' LYS . . . . . 0.609 ' HE3' ' HB3' ' B' ' 35' ' ' GLU . 0.0 OUTLIER -125.01 146.36 49.46 Favored 'General case' 0 C--N 1.315 -0.892 0 C-N-CA 119.652 -0.819 . . . . 1.3899999999999999 112.347 -177.865 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 48' ' ' LYS . . . . . 0.522 ' HG3' ' HD2' ' B' ' 51' ' ' PRO . 3.7 ptmt -45.89 -10.61 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.147 0 N-CA-C 117.812 2.523 . . . . 1.1899999999999999 117.812 -166.301 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 49' ' ' TYR . . . . . 0.696 ' HB3' ' HB2' ' B' ' 33' ' ' PRO . 23.7 t80 72.07 -51.17 0.7 Allowed 'General case' 0 N--CA 1.47 0.559 0 N-CA-C 112.955 0.724 . . . . 2.1000000000000001 112.955 172.711 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 50' ' ' SER . . . . . 0.585 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 48.3 t -51.4 -56.75 17.91 Favored Pre-proline 0 CA--C 1.535 0.383 0 C-N-CA 122.597 0.359 . . . . 1.77 111.249 -175.133 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 51' ' ' PRO . . . . . 0.585 ' HD3' ' HB3' ' B' ' 50' ' ' SER . 57.8 Cg_endo -88.3 12.35 2.84 Favored 'Trans proline' 0 C--N 1.35 0.649 0 C-N-CA 121.83 1.687 . . . . 0.59999999999999998 111.44 170.694 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 52' ' ' ILE . . . . . . . . . . . . . 1.3 mt . . . . . 0 CA--C 1.518 -0.273 0 CA-C-N 115.056 -0.975 . . . . 1.3899999999999999 108.952 -173.943 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.461 0.081 0 CA-C-O 121.545 0.688 . . . . 1.1299999999999999 111.891 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.767 ' H ' ' HB2' ' B' ' 37' ' ' PHE . 21.4 p -129.59 -57.2 1.13 Allowed 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.539 -0.755 . . . . 1.0900000000000001 110.636 -178.647 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 85.13 48.95 4.65 Favored Glycine 0 N--CA 1.441 -1.024 0 C-N-CA 120.315 -0.945 . . . . 0.32000000000000001 112.662 174.274 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.811 HG21 ' HB ' ' B' ' 36' ' ' ILE . 1.5 tp -105.49 109.09 26.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 N-CA-C 109.258 -0.645 . . . . 1.0900000000000001 109.258 173.851 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.759 ' HA ' ' O ' ' B' ' 34' ' ' LEU . 41.7 t -79.76 132.69 31.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 116.135 -0.484 . . . . 1.1299999999999999 110.715 179.284 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.491 ' HD3' ' N ' ' A' ' 9' ' ' ARG . 1.8 tpp180 -129.24 125.07 36.07 Favored 'General case' 0 N--CA 1.443 -0.781 0 N-CA-C 106.919 -1.512 . . . . 2.6099999999999999 106.919 -179.821 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ARG . . . . . 0.526 ' C ' HD12 ' A' ' 10' ' ' ILE . 0.6 OUTLIER -86.34 102.26 13.84 Favored 'General case' 0 C--N 1.315 -0.933 0 N-CA-C 108.202 -1.036 . . . . 3.4100000000000001 108.202 175.346 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.771 HG21 HD12 ' B' ' 34' ' ' LEU . 0.2 OUTLIER -5.56 -105.79 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.016 0 O-C-N 125.645 1.841 . . . . 1.0700000000000001 114.356 -176.468 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . 0.633 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 3.3 p-10 161.54 -166.45 0.0 OUTLIER 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 108.64 -0.874 . . . . 1.1299999999999999 108.64 177.28 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -68.11 -23.01 64.86 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 123.455 0.472 . . . . 2.2599999999999998 110.94 -177.84 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 2.5 tm? -100.64 -55.66 2.53 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.331 -0.395 . . . . 1.23 110.448 179.859 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.556 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 134.32 18.0 0.95 Allowed Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.449 -0.882 . . . . 0.25 113.069 -179.435 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.512 ' HG2' HG21 ' B' ' 17' ' ' VAL . 0.4 OUTLIER -76.66 156.19 32.8 Favored 'General case' 0 CA--C 1.51 -0.562 0 CA-C-N 117.625 0.712 . . . . 0.88 110.301 -179.564 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.716 HG21 HD13 ' B' ' 46' ' ' LEU . 89.8 t -111.04 98.3 6.88 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.23 0 N-CA-C 107.728 -1.212 . . . . 1.99 107.728 167.637 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.551 HG23 ' HG2' ' B' ' 15' ' ' ARG . 39.4 t -65.05 106.95 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 CA-C-N 115.249 -0.887 . . . . 1.0600000000000001 109.675 -173.702 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.446 ' HB ' ' O ' ' B' ' 14' ' ' GLY . 30.9 mm -95.82 107.88 36.88 Favored Pre-proline 0 N--CA 1.447 -0.625 0 CA-C-N 115.691 -0.686 . . . . 1.5600000000000001 110.117 -178.017 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.664 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 62.2 Cg_exo -47.44 146.06 7.85 Favored 'Trans proline' 0 N--CA 1.454 -0.821 0 C-N-CA 122.6 2.2 . . . . 0.34999999999999998 112.718 175.402 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.886 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -64.61 -14.0 55.93 Favored 'General case' 0 C--N 1.314 -0.935 0 CA-C-N 115.766 -0.652 . . . . 2.1299999999999999 111.251 179.813 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.664 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 11.5 pt-20 -63.78 -23.05 67.21 Favored 'General case' 0 C--O 1.239 0.501 0 N-CA-C 112.349 0.5 . . . . 1.3200000000000001 112.349 178.285 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.401 HD12 HG21 ' A' ' 18' ' ' ILE . 5.2 mp -87.39 -46.49 16.1 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.334 0 N-CA-C 108.096 -1.076 . . . . 1.0800000000000001 108.096 -178.635 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . 0.658 ' HA ' ' HB2' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -61.41 -27.19 68.36 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 114.941 -1.027 . . . . 2.02 109.219 172.994 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 74.9 ttt180 -63.26 -51.48 65.99 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 114.75 -1.114 . . . . 3.3999999999999999 111.116 173.315 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 28.7 m -61.69 -31.14 71.26 Favored 'General case' 0 CA--C 1.532 0.252 0 CA-C-O 121.147 0.498 . . . . 1.1499999999999999 110.636 172.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.658 ' HB2' ' HA ' ' A' ' 23' ' ' ARG . 3.2 mm? -64.92 -21.35 66.81 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.617 -0.72 . . . . 1.1599999999999999 110.71 173.855 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 2.0 mpt_? 70.39 21.96 5.48 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 123.455 0.702 . . . . 3.6800000000000002 110.943 -176.764 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.662 HG23 ' H ' ' A' ' 29' ' ' ARG . 5.3 mt -117.49 -166.5 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.786 0 CA-C-N 115.159 -0.928 . . . . 1.1000000000000001 108.932 -177.896 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.662 ' H ' HG23 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -148.5 -153.69 0.51 Allowed 'General case' 0 C--N 1.323 -0.557 0 O-C-N 122.13 -0.356 . . . . 3.0699999999999998 111.286 -175.157 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . 0.425 ' CD ' HH21 ' A' ' 23' ' ' ARG . 0.6 OUTLIER -75.72 44.66 0.3 Allowed 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 122.089 0.947 . . . . 1.23 112.188 -177.787 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.556 ' CA ' HD12 ' B' ' 10' ' ' ILE . . . -159.31 29.3 0.4 Allowed Glycine 0 N--CA 1.441 -1.006 0 CA-C-N 113.975 -1.466 . . . . 0.35999999999999999 109.547 172.466 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.589 ' O ' HG13 ' B' ' 10' ' ' ILE . 11.8 t70 -88.81 128.9 50.58 Favored Pre-proline 0 CA--C 1.514 -0.407 0 N-CA-C 109.351 -0.611 . . . . 1.26 109.351 174.549 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.683 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 3.8 Cg_endo -83.81 150.04 12.64 Favored 'Trans proline' 0 N--CA 1.435 -1.936 0 C-N-CA 122.18 1.92 . . . . 1.3 110.804 175.175 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.789 HD12 HG22 ' B' ' 10' ' ' ILE . 0.6 OUTLIER -139.68 153.75 47.34 Favored 'General case' 0 N--CA 1.43 -1.428 0 N-CA-C 109.302 -0.629 . . . . 1.21 109.302 172.023 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.888 ' HB3' ' HD2' ' A' ' 47' ' ' LYS . 33.8 tt0 -109.25 114.57 28.38 Favored 'General case' 0 C--N 1.297 -1.675 0 N-CA-C 108.392 -0.966 . . . . 1.1200000000000001 108.392 -178.316 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.849 ' HB ' HG23 ' B' ' 6' ' ' ILE . 3.2 mp -86.12 110.05 19.42 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.944 0 O-C-N 124.843 1.339 . . . . 1.1599999999999999 109.226 -178.766 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' PHE . . . . . 0.658 ' HD1' ' HA ' ' B' ' 3' ' ' ALA . 0.5 OUTLIER -149.76 125.74 10.57 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 116.211 -0.45 . . . . 2.0099999999999998 109.874 175.488 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.52 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 1.2 p -80.51 137.09 22.06 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 CA-C-O 121.191 0.52 . . . . 1.05 110.749 -179.854 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.522 ' HB3' ' HG2' ' A' ' 40' ' ' ARG . 9.9 t70 -88.65 -64.93 1.07 Allowed 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 114.617 -1.174 . . . . 1.1100000000000001 111.902 -171.459 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . 0.522 ' HG2' ' HB3' ' A' ' 39' ' ' ASP . 0.0 OUTLIER -106.58 -84.37 0.52 Allowed 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 114.899 -1.046 . . . . 2.8799999999999999 111.303 -165.759 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -111.37 -72.58 0.71 Allowed 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.12 -0.491 . . . . 1.53 110.88 -177.518 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -130.35 24.66 4.4 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.776 -0.726 . . . . 0.34000000000000002 111.638 179.276 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.539 ' HB3' HG23 ' B' ' 45' ' ' ILE . 2.3 mt-10 -97.95 113.0 24.72 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.126 -0.694 . . . . 1.97 109.126 178.465 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.52 ' HA ' ' HA ' ' A' ' 38' ' ' VAL . 1.8 t -90.4 132.95 33.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 N-CA-C 109.573 -0.529 . . . . 1.0600000000000001 109.573 178.942 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.815 HG13 HG13 ' B' ' 45' ' ' ILE . 1.6 mp -111.68 117.5 55.28 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 N-CA-C 108.575 -0.898 . . . . 1.01 108.575 -175.389 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.977 HD12 HD12 ' B' ' 46' ' ' LEU . 0.5 OUTLIER -110.13 117.09 32.79 Favored 'General case' 0 C--N 1.32 -0.706 0 O-C-N 123.676 0.61 . . . . 1.1299999999999999 109.874 179.825 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.888 ' HD2' ' HB3' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -126.44 151.9 47.12 Favored 'General case' 0 C--O 1.219 -0.55 0 C-N-CA 119.02 -1.072 . . . . 1.25 112.792 179.132 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.555 ' HA ' ' O ' ' A' ' 33' ' ' PRO . 1.9 ptmt -43.58 -16.29 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.09 0 N-CA-C 117.263 2.32 . . . . 1.0900000000000001 117.263 -168.381 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . 0.72 ' CD1' HG22 ' B' ' 7' ' ' VAL . 17.9 t80 73.22 -54.58 0.69 Allowed 'General case' 0 N--CA 1.469 0.521 0 N-CA-C 112.561 0.578 . . . . 2.1400000000000001 112.561 174.379 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.67 ' HB3' ' HD3' ' A' ' 51' ' ' PRO . 19.6 t -50.85 -49.82 77.7 Favored Pre-proline 0 CA--C 1.537 0.473 0 O-C-N 123.335 0.397 . . . . 1.95 111.387 -175.105 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.67 ' HD3' ' HB3' ' A' ' 50' ' ' SER . 86.5 Cg_endo -96.18 12.45 1.21 Allowed 'Trans proline' 0 N--CA 1.453 -0.861 0 C-N-CA 122.401 2.067 . . . . 0.59999999999999998 111.658 171.213 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 1.3 mt . . . . . 0 C--O 1.234 0.281 0 CA-C-N 115.423 -0.808 . . . . 1.4199999999999999 109.083 -173.946 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 3' ' ' ALA . . . . . 0.658 ' HA ' ' HD1' ' A' ' 37' ' ' PHE . . . . . . . . 0 N--CA 1.463 0.192 0 CA-C-O 121.512 0.672 . . . . 1.1000000000000001 110.419 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 4' ' ' THR . . . . . 0.643 ' H ' ' HB2' ' A' ' 37' ' ' PHE . 11.3 p -115.87 -46.74 2.82 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.022 -0.535 . . . . 0.97999999999999998 111.248 -178.713 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 73.01 49.72 15.54 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 120.929 -0.653 . . . . 0.33000000000000002 113.137 172.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 6' ' ' ILE . . . . . 0.849 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.0 OUTLIER -106.73 110.55 32.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 N-CA-C 109.104 -0.702 . . . . 1.1000000000000001 109.104 174.841 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . 0.72 HG22 ' CD1' ' A' ' 49' ' ' TYR . 38.9 t -80.51 134.66 26.88 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.308 0.575 . . . . 1.0800000000000001 111.389 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . 0.504 ' HB3' ' CD1' ' A' ' 36' ' ' ILE . 8.4 tpp180 -130.1 121.45 26.38 Favored 'General case' 0 N--CA 1.44 -0.948 0 N-CA-C 107.541 -1.281 . . . . 2.3599999999999999 107.541 -177.47 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 9' ' ' ARG . . . . . 0.471 ' N ' ' HD3' ' B' ' 8' ' ' ARG . 15.9 ttt180 -84.45 103.43 13.6 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 108.084 -1.08 . . . . 3.2000000000000002 108.084 173.766 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 10' ' ' ILE . . . . . 0.789 HG22 HD12 ' A' ' 34' ' ' LEU . 0.4 OUTLIER -9.2 -101.61 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.996 0 O-C-N 125.665 1.853 . . . . 1.0700000000000001 114.398 -174.707 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . 0.599 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 5.5 p-10 164.21 -154.07 0.0 OUTLIER 'General case' 0 C--O 1.219 -0.504 0 N-CA-C 108.773 -0.825 . . . . 1.1799999999999999 108.773 174.555 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -85.2 -9.18 58.1 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.047 0.451 . . . . 2.3900000000000001 110.617 -178.778 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 13' ' ' LEU . . . . . 0.441 ' HB3' ' HD2' ' B' ' 15' ' ' ARG . 3.0 tm? -109.5 -56.43 2.3 Favored 'General case' 0 N--CA 1.448 -0.537 0 CA-C-N 116.075 -0.511 . . . . 1.1000000000000001 109.935 176.496 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 14' ' ' GLY . . . . . 0.446 ' O ' ' HB ' ' A' ' 18' ' ' ILE . . . 133.16 20.85 0.89 Allowed Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.764 -0.732 . . . . 0.23000000000000001 112.689 -178.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 15' ' ' ARG . . . . . 0.551 ' HG2' HG23 ' A' ' 17' ' ' VAL . 1.5 mpt_? -78.23 154.08 31.35 Favored 'General case' 0 CA--C 1.509 -0.606 0 O-C-N 122.066 -0.667 . . . . 1.3899999999999999 110.189 179.293 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 16' ' ' VAL . . . . . 0.718 HG21 HD13 ' A' ' 46' ' ' LEU . 96.7 t -109.11 95.96 4.26 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 N-CA-C 107.475 -1.305 . . . . 1.97 107.475 168.722 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 17' ' ' VAL . . . . . 0.512 HG21 ' HG2' ' A' ' 15' ' ' ARG . 47.0 t -64.32 104.84 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.842 0 CA-C-N 114.96 -1.018 . . . . 1.0600000000000001 109.914 -173.04 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . 0.556 ' HB ' ' O ' ' A' ' 14' ' ' GLY . 26.6 mm -92.48 111.26 49.87 Favored Pre-proline 0 N--CA 1.446 -0.633 0 CA-C-N 115.647 -0.706 . . . . 1.6100000000000001 110.574 -177.463 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 19' ' ' PRO . . . . . 0.637 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 59.1 Cg_exo -48.49 142.39 17.79 Favored 'Trans proline' 0 N--CA 1.459 -0.534 0 C-N-CA 123.041 2.494 . . . . 0.33000000000000002 112.53 172.828 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 20' ' ' LYS . . . . . 0.935 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -59.44 -16.14 21.78 Favored 'General case' 0 C--O 1.211 -0.949 0 CA-C-N 115.243 -0.889 . . . . 2.3199999999999998 111.428 178.954 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . 0.637 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 10.6 pt-20 -65.5 -20.0 66.16 Favored 'General case' 0 C--O 1.234 0.284 0 N-CA-C 112.034 0.383 . . . . 1.9199999999999999 112.034 -178.226 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 22' ' ' ILE . . . . . 0.406 HD12 HG21 ' B' ' 18' ' ' ILE . 5.2 mp -87.26 -49.14 14.97 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 N-CA-C 108.433 -0.951 . . . . 1.24 108.433 179.848 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 23' ' ' ARG . . . . . 0.609 ' NE ' ' HA ' ' B' ' 29' ' ' ARG . 0.0 OUTLIER -55.33 -32.41 62.49 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-O 122.057 0.932 . . . . 1.8500000000000001 109.194 171.073 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 24' ' ' ARG . . . . . 0.461 ' N ' ' HD3' ' B' ' 23' ' ' ARG . 50.1 ttt180 -61.12 -53.72 53.52 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-N 114.021 -1.445 . . . . 3.6899999999999999 111.195 176.222 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 53.7 m -61.07 -33.52 73.46 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-O 121.275 0.559 . . . . 1.1599999999999999 110.418 173.806 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . 0.535 ' HB3' HG13 ' B' ' 28' ' ' ILE . 1.5 mm? -63.98 -20.26 65.76 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.21 -0.904 . . . . 1.1100000000000001 111.339 177.775 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 27' ' ' ARG . . . . . . . . . . . . . 6.5 mpt_? 69.79 28.38 4.37 Favored 'General case' 0 N--CA 1.471 0.6 0 CA-C-O 121.18 0.514 . . . . 3.77 110.505 -176.686 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 28' ' ' ILE . . . . . 0.855 HG23 ' H ' ' B' ' 29' ' ' ARG . 7.6 mt -122.47 -159.44 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 115.889 -0.596 . . . . 1.2 109.924 -175.583 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 29' ' ' ARG . . . . . 0.855 ' H ' HG23 ' B' ' 28' ' ' ILE . 0.1 OUTLIER -155.33 -159.9 0.98 Allowed 'General case' 0 N--CA 1.467 0.42 0 N-CA-C 112.496 0.554 . . . . 2.7599999999999998 112.496 -174.476 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 30' ' ' GLU . . . . . . . . . . . . . 38.6 mp0 -69.87 36.93 0.04 OUTLIER 'General case' 0 N--CA 1.472 0.655 0 CA-C-O 122.019 0.914 . . . . 1.1799999999999999 112.053 178.636 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 31' ' ' GLY . . . . . 0.578 ' H ' ' C ' ' B' ' 29' ' ' ARG . . . -156.46 32.97 0.59 Allowed Glycine 0 N--CA 1.431 -1.663 0 N-CA-C 109.547 -1.421 . . . . 0.34999999999999998 109.547 175.712 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 32' ' ' ASP . . . . . 0.541 ' O ' HG13 ' A' ' 10' ' ' ILE . 19.2 t0 -92.46 125.55 55.62 Favored Pre-proline 0 C--N 1.323 -0.569 0 CA-C-N 114.861 -0.669 . . . . 1.29 109.259 173.529 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 33' ' ' PRO . . . . . 0.782 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 3.5 Cg_endo -79.55 151.66 22.57 Favored 'Trans proline' 0 N--CA 1.436 -1.888 0 C-N-CA 122.216 1.944 . . . . 1.1000000000000001 110.043 174.215 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . 0.771 HD12 HG21 ' A' ' 10' ' ' ILE . 0.8 OUTLIER -140.73 149.35 42.04 Favored 'General case' 0 C--N 1.305 -1.326 0 N-CA-C 109.444 -0.576 . . . . 1.1699999999999999 109.444 172.434 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 35' ' ' GLU . . . . . 0.632 ' O ' ' HA ' ' B' ' 46' ' ' LEU . 72.1 tt0 -104.04 112.28 25.21 Favored 'General case' 0 CA--C 1.487 -1.471 0 N-CA-C 107.359 -1.348 . . . . 1.1000000000000001 107.359 -179.272 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 36' ' ' ILE . . . . . 0.879 HG13 HD23 ' B' ' 46' ' ' LEU . 2.5 mp -86.47 111.07 20.87 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.148 0 O-C-N 124.615 1.197 . . . . 1.3200000000000001 108.675 179.331 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 37' ' ' PHE . . . . . 0.767 ' HB2' ' H ' ' A' ' 4' ' ' THR . 17.9 p90 -150.29 129.28 12.59 Favored 'General case' 0 C--N 1.314 -0.96 0 N-CA-C 109.392 -0.596 . . . . 2.0299999999999998 109.392 172.613 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 38' ' ' VAL . . . . . 0.566 ' HA ' ' HA ' ' B' ' 44' ' ' VAL . 1.4 p -83.62 129.91 36.73 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.114 0 CA-C-O 121.255 0.55 . . . . 0.89000000000000001 111.539 -175.369 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 39' ' ' ASP . . . . . 0.732 ' HB3' ' HD3' ' B' ' 40' ' ' ARG . 0.5 OUTLIER -94.28 171.36 8.88 Favored 'General case' 0 N--CA 1.443 -0.777 0 N-CA-C 108.036 -1.098 . . . . 1.1399999999999999 108.036 173.634 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 40' ' ' ARG . . . . . 0.732 ' HD3' ' HB3' ' B' ' 39' ' ' ASP . 0.0 OUTLIER 41.64 -107.22 0.08 Allowed 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 113.811 1.041 . . . . 3.3700000000000001 113.811 176.902 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -108.13 -82.98 0.55 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.076 0.465 . . . . 1.3200000000000001 111.368 -174.362 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 42' ' ' GLY . . . . . . . . . . . . . . . -118.93 26.15 7.64 Favored Glycine 0 N--CA 1.444 -0.78 0 C-N-CA 120.92 -0.657 . . . . 0.35999999999999999 111.89 -175.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 43' ' ' GLU . . . . . 0.616 ' HB3' HG23 ' A' ' 45' ' ' ILE . 2.0 mt-10 -96.79 111.9 23.88 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 109.633 -0.506 . . . . 2.0699999999999998 109.633 178.082 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 44' ' ' VAL . . . . . 0.566 ' HA ' ' HA ' ' B' ' 38' ' ' VAL . 1.9 t -88.23 132.63 32.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 N-CA-C 109.575 -0.528 . . . . 1.02 109.575 178.204 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 45' ' ' ILE . . . . . 0.815 HG13 HG13 ' A' ' 45' ' ' ILE . 1.5 mp -108.97 119.36 58.39 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 N-CA-C 108.206 -1.035 . . . . 0.95999999999999996 108.206 -177.352 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 46' ' ' LEU . . . . . 0.977 HD12 HD12 ' A' ' 46' ' ' LEU . 0.7 OUTLIER -112.37 117.1 31.51 Favored 'General case' 0 C--N 1.317 -0.817 0 O-C-N 123.68 0.612 . . . . 1.05 110.008 178.217 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 47' ' ' LYS . . . . . 0.59 ' O ' ' HA ' ' B' ' 34' ' ' LEU . 0.0 OUTLIER -129.78 149.33 51.57 Favored 'General case' 0 C--O 1.215 -0.72 0 C-N-CA 119.492 -0.883 . . . . 1.3899999999999999 113.03 -179.841 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 48' ' ' LYS . . . . . 0.551 ' O ' ' HB3' ' B' ' 49' ' ' TYR . 1.7 ptmt -39.75 -21.35 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.244 0 N-CA-C 117.658 2.466 . . . . 1.1899999999999999 117.658 -168.086 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 49' ' ' TYR . . . . . 0.782 ' HB3' ' HB2' ' B' ' 33' ' ' PRO . 23.3 t80 75.1 -46.58 0.59 Allowed 'General case' 0 N--CA 1.47 0.568 0 CA-C-N 119.095 0.861 . . . . 2.1000000000000001 111.282 177.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 50' ' ' SER . . . . . 0.644 ' OG ' ' HD3' ' B' ' 51' ' ' PRO . 1.6 p -50.14 -48.38 79.64 Favored Pre-proline 0 CA--C 1.544 0.737 0 CA-C-N 115.519 -0.764 . . . . 1.77 112.395 -175.528 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 51' ' ' PRO . . . . . 0.644 ' HD3' ' OG ' ' B' ' 50' ' ' SER . 33.1 Cg_endo -103.06 14.03 0.29 Allowed 'Trans proline' 0 N--CA 1.454 -0.831 0 C-N-CA 122.976 2.45 . . . . 0.59999999999999998 111.733 170.241 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 52' ' ' ILE . . . . . . . . . . . . . 1.1 mt . . . . . 0 C--N 1.328 -0.356 0 N-CA-C 108.516 -0.92 . . . . 1.3899999999999999 108.516 -168.661 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . 0.463 ' HA ' ' HB2' ' B' ' 37' ' ' PHE . . . . . . . . 0 N--CA 1.463 0.214 0 CA-C-O 121.608 0.718 . . . . 1.1299999999999999 109.75 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 31.0 p -84.53 -31.74 24.26 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.201 -0.909 . . . . 1.0900000000000001 112.521 -169.574 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . 0.468 ' H ' ' HB3' ' B' ' 37' ' ' PHE . . . 61.01 49.19 81.35 Favored Glycine 0 N--CA 1.446 -0.66 0 C-N-CA 120.767 -0.73 . . . . 0.32000000000000001 113.074 176.567 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.84 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.6 tp -105.73 104.41 16.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 N-CA-C 109.173 -0.677 . . . . 1.0900000000000001 109.173 174.823 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.606 ' HA ' ' O ' ' B' ' 34' ' ' LEU . 38.0 t -74.25 133.04 32.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 115.719 -0.673 . . . . 1.1299999999999999 110.088 179.696 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.652 ' HB3' ' CD1' ' B' ' 36' ' ' ILE . 3.3 tpp180 -129.43 119.4 23.74 Favored 'General case' 0 N--CA 1.437 -1.077 0 N-CA-C 106.809 -1.552 . . . . 2.6099999999999999 106.809 -178.75 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' ARG . . . . . 0.52 ' HA ' ' O ' ' B' ' 32' ' ' ASP . 9.4 ttp180 -83.37 102.76 12.23 Favored 'General case' 0 C--N 1.312 -1.024 0 N-CA-C 108.553 -0.906 . . . . 3.4100000000000001 108.553 176.183 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.706 HG23 HD13 ' B' ' 34' ' ' LEU . 0.2 OUTLIER -9.62 -103.23 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 O-C-N 125.62 1.825 . . . . 1.0700000000000001 114.525 -177.108 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . 0.599 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 4.3 p-10 161.43 -162.62 0.0 OUTLIER 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 108.31 -0.996 . . . . 1.1299999999999999 108.31 176.86 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -71.27 -24.73 62.22 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.15 0.5 . . . . 2.2599999999999998 110.803 -178.109 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -95.22 -58.98 1.99 Allowed 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.112 -0.494 . . . . 1.23 110.212 178.551 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.524 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 135.64 17.72 0.83 Allowed Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.595 -0.812 . . . . 0.25 112.92 -177.998 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.632 ' HG2' HG23 ' B' ' 17' ' ' VAL . 1.4 mpt_? -74.73 153.11 38.98 Favored 'General case' 0 CA--C 1.507 -0.689 0 O-C-N 122.139 -0.624 . . . . 0.88 110.033 179.299 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.72 HG21 HD13 ' B' ' 46' ' ' LEU . 93.3 t -108.39 95.93 4.22 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.29 0 N-CA-C 107.662 -1.236 . . . . 1.99 107.662 169.239 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.618 HG23 ' HG2' ' B' ' 15' ' ' ARG . 91.0 t -64.54 99.37 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-N 115.131 -0.94 . . . . 1.0600000000000001 110.085 -174.121 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.467 ' HB ' ' O ' ' B' ' 14' ' ' GLY . 38.6 mm -87.47 112.05 45.73 Favored Pre-proline 0 N--CA 1.446 -0.659 0 CA-C-N 115.543 -0.753 . . . . 1.5600000000000001 109.854 -179.515 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.537 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 91.9 Cg_exo -50.79 140.72 37.34 Favored 'Trans proline' 0 N--CA 1.452 -0.963 0 C-N-CA 122.267 1.978 . . . . 0.34999999999999998 111.738 173.566 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.943 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -61.12 -14.95 28.12 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.675 -0.693 . . . . 2.1299999999999999 111.47 -177.992 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.537 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 11.3 pt-20 -66.77 -21.4 66.06 Favored 'General case' 0 C--O 1.237 0.442 0 N-CA-C 112.182 0.438 . . . . 1.3200000000000001 112.182 -178.685 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.2 mp -87.91 -45.27 15.98 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 107.997 -1.112 . . . . 1.0800000000000001 107.997 -179.772 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . 0.717 ' HA ' ' HB2' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -60.35 -29.37 68.86 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 115.285 -0.871 . . . . 2.02 109.18 172.448 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.464 ' HB3' ' O ' ' A' ' 21' ' ' GLU . 58.7 ttt180 -60.42 -52.6 64.52 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 114.403 -1.271 . . . . 3.3999999999999999 110.484 173.833 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 19.8 m -69.2 -21.21 63.97 Favored 'General case' 0 CA--C 1.53 0.177 0 CA-C-O 121.295 0.569 . . . . 1.1499999999999999 110.904 175.11 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.8 ' HB3' HG13 ' A' ' 28' ' ' ILE . 0.8 OUTLIER -67.55 -18.37 65.0 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.974 -0.557 . . . . 1.1599999999999999 111.2 176.418 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.455 ' HB2' ' O ' ' A' ' 26' ' ' LEU . 0.0 OUTLIER 70.51 20.46 5.89 Favored 'General case' 0 C--N 1.343 0.324 0 CA-C-O 121.299 0.571 . . . . 3.6800000000000002 110.009 -172.397 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.8 HG13 ' HB3' ' A' ' 26' ' ' LEU . 3.0 mt -119.22 -164.87 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.535 -0.757 . . . . 1.1000000000000001 109.855 -176.086 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.71 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -158.3 -156.97 0.59 Allowed 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 110.382 -0.229 . . . . 3.0699999999999998 110.382 -167.988 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -72.95 38.48 0.08 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 122.213 1.006 . . . . 1.23 111.034 176.34 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.58 ' H ' ' C ' ' A' ' 29' ' ' ARG . . . -152.55 26.17 0.85 Allowed Glycine 0 N--CA 1.435 -1.411 0 CA-C-N 113.854 -1.521 . . . . 0.35999999999999999 110.4 176.023 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.481 ' HA ' ' HD3' ' A' ' 33' ' ' PRO . 63.8 t0 -84.12 114.22 53.08 Favored Pre-proline 0 C--N 1.331 -0.205 0 CA-C-O 121.279 0.562 . . . . 1.26 109.768 175.627 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.593 ' O ' HG12 ' B' ' 7' ' ' VAL . 1.2 Cg_endo -88.97 54.76 1.95 Allowed 'Trans proline' 0 CA--C 1.507 -0.874 0 C-N-CA 124.158 3.239 . . . . 1.3 114.108 -175.188 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.588 HD13 HG21 ' B' ' 10' ' ' ILE . 1.0 OUTLIER -57.38 153.6 12.21 Favored 'General case' 0 C--N 1.297 -1.676 0 CA-C-O 122.299 1.047 . . . . 1.21 112.352 -173.768 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.811 ' HB3' ' HB3' ' A' ' 47' ' ' LYS . 33.8 tt0 -105.07 118.47 36.62 Favored 'General case' 0 CA--C 1.492 -1.259 0 CA-C-N 113.492 -1.685 . . . . 1.1200000000000001 107.505 -175.594 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.886 ' HB ' HG23 ' B' ' 6' ' ' ILE . 2.6 mp -88.28 110.16 20.72 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.014 0 O-C-N 123.847 0.717 . . . . 1.1599999999999999 109.265 179.467 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' PHE . . . . . 0.771 ' HD1' ' HA ' ' B' ' 3' ' ' ALA . 0.8 OUTLIER -150.18 124.84 9.72 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 109.785 -0.45 . . . . 2.0099999999999998 109.785 174.557 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.517 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 1.4 p -80.91 137.83 20.69 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.978 0 CA-C-O 121.053 0.454 . . . . 1.05 110.716 -179.232 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.57 ' OD2' ' HD2' ' A' ' 40' ' ' ARG . 3.6 t70 -85.4 -55.49 3.99 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.444 -0.798 . . . . 1.1100000000000001 111.514 -173.633 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . 0.57 ' HD2' ' OD2' ' A' ' 39' ' ' ASP . 0.2 OUTLIER -119.91 -91.61 0.55 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.517 -0.765 . . . . 2.8799999999999999 111.981 -169.554 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -99.01 -69.58 0.76 Allowed 'General case' 0 CA--C 1.511 -0.548 0 CA-C-O 121.345 0.593 . . . . 1.53 110.571 -176.206 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.647 ' HA3' HD13 ' B' ' 26' ' ' LEU . . . -135.54 21.74 3.58 Favored Glycine 0 N--CA 1.437 -1.261 0 CA-C-N 114.97 -1.013 . . . . 0.34000000000000002 111.696 -176.787 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.576 ' HB3' HG21 ' B' ' 45' ' ' ILE . 2.1 mt-10 -95.38 109.15 21.36 Favored 'General case' 0 N--CA 1.447 -0.602 0 N-CA-C 109.099 -0.704 . . . . 1.97 109.099 177.381 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.517 ' HA ' ' HA ' ' A' ' 38' ' ' VAL . 1.7 t -90.09 132.11 35.6 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.941 0 N-CA-C 109.214 -0.661 . . . . 1.0600000000000001 109.214 178.467 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.778 HG13 HG13 ' B' ' 45' ' ' ILE . 1.6 mp -108.21 119.55 58.0 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 N-CA-C 108.262 -1.014 . . . . 1.01 108.262 -176.104 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.917 HD12 HD12 ' B' ' 46' ' ' LEU . 6.9 mt -103.61 121.9 43.88 Favored 'General case' 0 C--N 1.322 -0.599 0 O-C-N 124.221 0.951 . . . . 1.1299999999999999 110.033 179.616 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.811 ' HB3' ' HB3' ' A' ' 35' ' ' GLU . 21.6 ttmt -126.98 123.3 36.79 Favored 'General case' 0 C--N 1.308 -1.216 0 CA-C-N 115.454 -0.793 . . . . 1.25 112.576 -168.18 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.576 ' O ' ' HD2' ' A' ' 33' ' ' PRO . 3.1 ptmt -39.0 -19.24 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.648 0 N-CA-C 116.948 2.203 . . . . 1.0900000000000001 116.948 -172.849 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . 0.651 ' CD1' HG21 ' B' ' 7' ' ' VAL . 27.1 t80 74.72 -56.02 0.64 Allowed 'General case' 0 N--CA 1.475 0.823 0 C-N-CA 123.83 0.852 . . . . 2.1400000000000001 113.001 173.414 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.667 ' HB3' ' HD3' ' A' ' 51' ' ' PRO . 48.2 t -49.62 -53.61 39.55 Favored Pre-proline 0 CA--C 1.535 0.373 0 CA-C-N 115.807 -0.633 . . . . 1.95 111.433 -175.072 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.667 ' HD3' ' HB3' ' A' ' 50' ' ' SER . 46.2 Cg_endo -95.26 14.32 1.21 Allowed 'Trans proline' 0 N--CA 1.456 -0.723 0 C-N-CA 122.27 1.98 . . . . 0.59999999999999998 111.452 170.652 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 2.6 mt . . . . . 0 C--N 1.325 -0.473 0 N-CA-C 108.587 -0.894 . . . . 1.4199999999999999 108.587 -172.433 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 3' ' ' ALA . . . . . 0.771 ' HA ' ' HD1' ' A' ' 37' ' ' PHE . . . . . . . . 0 N--CA 1.462 0.174 0 CA-C-O 121.555 0.693 . . . . 1.1000000000000001 110.169 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 4' ' ' THR . . . . . . . . . . . . . 25.0 p -82.41 -32.02 29.31 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.162 -0.926 . . . . 0.97999999999999998 112.498 -171.141 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 5' ' ' GLY . . . . . 0.405 ' H ' ' CB ' ' A' ' 37' ' ' PHE . . . 61.44 45.27 96.73 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 121.14 -0.552 . . . . 0.33000000000000002 113.128 176.728 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 6' ' ' ILE . . . . . 0.886 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.1 tp -104.17 104.74 17.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.517 0.675 . . . . 1.1000000000000001 109.556 178.066 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . 0.651 HG21 ' CD1' ' A' ' 49' ' ' TYR . 4.9 t -74.84 131.46 34.96 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.872 0 CA-C-N 115.178 -0.919 . . . . 1.0800000000000001 110.896 -179.158 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . 0.472 ' HD3' ' N ' ' B' ' 9' ' ' ARG . 0.1 OUTLIER -129.56 118.15 21.58 Favored 'General case' 0 N--CA 1.447 -0.593 0 N-CA-C 107.031 -1.47 . . . . 2.3599999999999999 107.031 177.737 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 9' ' ' ARG . . . . . 0.529 ' HA ' ' HA ' ' A' ' 33' ' ' PRO . 26.7 ttp180 -79.85 104.84 10.7 Favored 'General case' 0 N--CA 1.44 -0.969 0 C-N-CA 119.789 -0.764 . . . . 3.2000000000000002 109.001 174.527 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 10' ' ' ILE . . . . . 0.66 ' O ' ' HB3' ' B' ' 11' ' ' ASP . 0.3 OUTLIER -11.91 -102.75 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 O-C-N 125.705 1.878 . . . . 1.0700000000000001 114.644 -176.051 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . 0.66 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 2.8 p-10 160.07 -165.81 0.0 OUTLIER 'General case' 0 C--N 1.342 0.249 0 N-CA-C 107.871 -1.159 . . . . 1.1799999999999999 107.871 177.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -68.21 -30.75 69.9 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 120.967 0.413 . . . . 2.3900000000000001 110.616 -179.131 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 13' ' ' LEU . . . . . 0.512 ' HB3' ' HD2' ' B' ' 15' ' ' ARG . 3.1 tm? -85.61 -59.27 2.36 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.066 -0.515 . . . . 1.1000000000000001 110.101 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 14' ' ' GLY . . . . . 0.467 ' O ' ' HB ' ' A' ' 18' ' ' ILE . . . 131.46 16.29 1.52 Allowed Glycine 0 N--CA 1.445 -0.711 0 C-N-CA 120.327 -0.939 . . . . 0.23000000000000001 112.727 -178.112 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 15' ' ' ARG . . . . . 0.618 ' HG2' HG23 ' A' ' 17' ' ' VAL . 0.3 OUTLIER -74.8 153.3 38.81 Favored 'General case' 0 CA--C 1.507 -0.674 0 C-N-CA 119.709 -0.796 . . . . 1.3899999999999999 109.826 178.138 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 16' ' ' VAL . . . . . 0.856 HG23 HD13 ' A' ' 46' ' ' LEU . 95.9 t -108.53 98.01 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.316 0 N-CA-C 107.725 -1.213 . . . . 1.97 107.725 169.721 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 17' ' ' VAL . . . . . 0.632 HG23 ' HG2' ' A' ' 15' ' ' ARG . 57.6 t -66.69 99.58 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.877 0 CA-C-N 114.963 -1.017 . . . . 1.0600000000000001 110.14 -172.259 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . 0.524 ' HB ' ' O ' ' A' ' 14' ' ' GLY . 39.1 mm -86.92 111.7 42.23 Favored Pre-proline 0 C--N 1.323 -0.569 0 CA-C-N 115.321 -0.854 . . . . 1.6100000000000001 109.978 -179.376 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 19' ' ' PRO . . . . . 0.516 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 86.4 Cg_exo -50.61 139.85 37.77 Favored 'Trans proline' 0 N--CA 1.453 -0.909 0 C-N-CA 122.392 2.061 . . . . 0.33000000000000002 111.607 172.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 20' ' ' LYS . . . . . 0.975 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -61.07 -13.31 15.99 Favored 'General case' 0 C--N 1.313 -0.979 0 CA-C-N 115.442 -0.799 . . . . 2.3199999999999998 111.64 -178.35 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . 0.516 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 10.4 pt-20 -67.01 -22.98 65.87 Favored 'General case' 0 C--O 1.237 0.444 0 N-CA-C 112.614 0.598 . . . . 1.9199999999999999 112.614 179.751 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 4.6 mp -88.06 -43.17 15.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 N-CA-C 107.758 -1.201 . . . . 1.24 107.758 -179.672 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 23' ' ' ARG . . . . . 0.658 ' HA ' ' HB2' ' B' ' 26' ' ' LEU . 0.0 OUTLIER -60.53 -29.89 69.4 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 115.287 -0.87 . . . . 1.8500000000000001 109.298 171.503 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 24' ' ' ARG . . . . . 0.432 ' HB3' ' O ' ' B' ' 21' ' ' GLU . 23.1 ttt180 -61.66 -52.72 63.17 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 114.594 -1.184 . . . . 3.6899999999999999 110.391 174.073 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 14.4 m -66.53 -25.06 66.49 Favored 'General case' 0 N--CA 1.452 -0.366 0 CA-C-O 121.456 0.646 . . . . 1.1599999999999999 110.466 176.292 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . 0.69 ' HB3' HG13 ' B' ' 28' ' ' ILE . 0.7 OUTLIER -65.04 -19.55 66.05 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.432 -0.804 . . . . 1.1100000000000001 111.068 175.699 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 27' ' ' ARG . . . . . 0.484 ' HB2' ' O ' ' B' ' 26' ' ' LEU . 0.2 OUTLIER 70.99 19.04 5.78 Favored 'General case' 0 N--CA 1.465 0.28 0 O-C-N 123.938 0.774 . . . . 3.77 110.097 -173.265 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 28' ' ' ILE . . . . . 0.872 HG21 ' H ' ' B' ' 29' ' ' ARG . 5.6 mt -115.45 -166.61 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 115.569 -0.741 . . . . 1.2 110.037 -177.044 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 29' ' ' ARG . . . . . 0.872 ' H ' HG21 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -155.93 -157.35 0.71 Allowed 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 110.404 -0.221 . . . . 2.7599999999999998 110.404 -169.698 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 30' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -71.44 31.94 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.547 0.689 . . . . 1.1799999999999999 111.926 178.495 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 31' ' ' GLY . . . . . 0.547 ' H ' ' C ' ' B' ' 29' ' ' ARG . . . -145.73 30.24 1.69 Allowed Glycine 0 N--CA 1.438 -1.172 0 CA-C-N 115.222 -0.899 . . . . 0.34999999999999998 110.866 173.527 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 32' ' ' ASP . . . . . 0.52 ' O ' ' HA ' ' A' ' 9' ' ' ARG . 25.6 t0 -84.19 117.32 68.41 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-O 121.296 0.57 . . . . 1.29 110.301 176.881 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 33' ' ' PRO . . . . . 0.7 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 2.5 Cg_endo -87.4 66.7 3.99 Favored 'Trans proline' 0 C--O 1.206 -1.112 0 C-N-CA 123.984 3.123 . . . . 1.1000000000000001 113.793 -178.448 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . 0.706 HD13 HG23 ' A' ' 10' ' ' ILE . 0.9 OUTLIER -66.23 151.53 46.81 Favored 'General case' 0 C--N 1.284 -2.276 0 C-N-CA 118.547 -1.261 . . . . 1.1699999999999999 111.573 -174.774 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 35' ' ' GLU . . . . . 0.668 ' O ' ' HA ' ' B' ' 46' ' ' LEU . 66.1 tt0 -103.53 114.33 28.52 Favored 'General case' 0 CA--C 1.493 -1.242 0 CA-C-N 114.686 -1.143 . . . . 1.1000000000000001 108.011 -178.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 36' ' ' ILE . . . . . 0.84 ' HB ' HG23 ' A' ' 6' ' ' ILE . 2.6 mp -87.87 109.82 20.09 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.732 0 O-C-N 124.199 0.937 . . . . 1.3200000000000001 109.598 -179.04 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 37' ' ' PHE . . . . . 0.468 ' HB3' ' H ' ' A' ' 5' ' ' GLY . 15.3 p90 -150.69 125.95 10.02 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 116.111 -0.495 . . . . 2.0299999999999998 110.002 175.176 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 38' ' ' VAL . . . . . 0.56 ' HA ' ' HA ' ' B' ' 44' ' ' VAL . 0.8 OUTLIER -80.31 136.97 22.33 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 CA-C-O 121.125 0.488 . . . . 0.89000000000000001 110.895 -178.19 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 39' ' ' ASP . . . . . 0.59 ' OD1' ' HD2' ' B' ' 40' ' ' ARG . 12.2 t70 -76.86 -64.75 1.05 Allowed 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 114.699 -1.137 . . . . 1.1399999999999999 110.996 -175.213 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 40' ' ' ARG . . . . . 0.59 ' HD2' ' OD1' ' B' ' 39' ' ' ASP . 0.0 OUTLIER -117.73 -94.49 0.49 Allowed 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.682 -0.69 . . . . 3.3700000000000001 112.204 -175.162 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 26.1 t70 -90.85 -70.47 0.68 Allowed 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.993 0.425 . . . . 1.3200000000000001 111.21 -174.014 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 42' ' ' GLY . . . . . 0.564 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -134.28 24.22 3.59 Favored Glycine 0 N--CA 1.441 -0.996 0 C-N-CA 120.498 -0.858 . . . . 0.35999999999999999 112.476 -177.555 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 43' ' ' GLU . . . . . 0.636 ' HA ' ' O ' ' A' ' 46' ' ' LEU . 1.1 mt-10 -97.04 107.86 20.47 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 109.434 -0.58 . . . . 2.0699999999999998 109.434 175.956 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 44' ' ' VAL . . . . . 0.56 ' HA ' ' HA ' ' B' ' 38' ' ' VAL . 2.0 t -88.66 130.91 37.34 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 N-CA-C 109.587 -0.523 . . . . 1.02 109.587 178.18 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 45' ' ' ILE . . . . . 0.778 HG13 HG13 ' A' ' 45' ' ' ILE . 1.6 mp -106.45 121.33 58.9 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 N-CA-C 107.962 -1.125 . . . . 0.95999999999999996 107.962 -177.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 46' ' ' LEU . . . . . 0.917 HD12 HD12 ' A' ' 46' ' ' LEU . 0.7 OUTLIER -111.59 116.27 30.54 Favored 'General case' 0 C--N 1.319 -0.731 0 O-C-N 123.876 0.735 . . . . 1.05 109.782 177.779 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 47' ' ' LYS . . . . . 0.55 ' HE3' ' HB3' ' B' ' 35' ' ' GLU . 0.0 OUTLIER -131.12 140.43 49.99 Favored 'General case' 0 C--O 1.213 -0.82 0 N-CA-C 113.402 0.89 . . . . 1.3899999999999999 113.402 -178.684 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 48' ' ' LYS . . . . . 0.61 ' HE2' ' HG3' ' B' ' 51' ' ' PRO . 4.9 ptmt -38.2 -16.72 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.393 0 N-CA-C 118.747 2.869 . . . . 1.1899999999999999 118.747 -168.175 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 49' ' ' TYR . . . . . 0.7 ' HB3' ' HB2' ' B' ' 33' ' ' PRO . 39.5 t80 72.32 -51.51 0.7 Allowed 'General case' 0 N--CA 1.485 1.309 0 CA-C-N 119.241 0.928 . . . . 2.1000000000000001 113.247 176.481 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 50' ' ' SER . . . . . 0.418 ' OG ' ' HD3' ' B' ' 51' ' ' PRO . 1.4 p -51.7 -51.5 69.51 Favored Pre-proline 0 CA--C 1.541 0.613 0 CA-C-N 116.069 -0.514 . . . . 1.77 112.051 -172.581 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 51' ' ' PRO . . . . . 0.61 ' HG3' ' HE2' ' B' ' 48' ' ' LYS . 24.2 Cg_endo -95.42 16.41 0.91 Allowed 'Trans proline' 0 C--N 1.351 0.687 0 C-N-CA 122.45 2.1 . . . . 0.59999999999999998 111.582 167.735 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 52' ' ' ILE . . . . . . . . . . . . . 3.4 mt . . . . . 0 C--N 1.321 -0.641 0 N-CA-C 108.083 -1.08 . . . . 1.3899999999999999 108.083 -170.566 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . 0.414 ' HA ' ' HB2' ' B' ' 37' ' ' PHE . . . . . . . . 0 C--O 1.232 0.144 0 CA-C-O 121.865 0.841 . . . . 1.1299999999999999 112.723 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.829 ' H ' ' HB2' ' B' ' 37' ' ' PHE . 19.2 p -130.84 -54.86 1.06 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 114.792 -1.095 . . . . 1.0900000000000001 110.458 179.052 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 84.58 54.06 3.05 Favored Glycine 0 N--CA 1.446 -0.654 0 C-N-CA 120.434 -0.888 . . . . 0.32000000000000001 112.458 173.319 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.9 HG21 ' HB ' ' B' ' 36' ' ' ILE . 1.6 tp -108.84 108.96 26.6 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 N-CA-C 109.404 -0.591 . . . . 1.0900000000000001 109.404 171.235 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.762 HG21 ' CD1' ' B' ' 49' ' ' TYR . 36.5 t -83.0 135.92 23.85 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-O 120.905 0.383 . . . . 1.1299999999999999 111.286 -179.435 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.617 ' CZ ' HG22 ' A' ' 17' ' ' VAL . 5.3 tpt180 -129.63 114.79 16.47 Favored 'General case' 0 N--CA 1.446 -0.642 0 N-CA-C 107.85 -1.167 . . . . 2.6099999999999999 107.85 -176.771 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' ARG . . . . . 0.709 HH11 ' HG3' ' B' ' 33' ' ' PRO . 3.7 tpp180 -81.73 103.43 11.42 Favored 'General case' 0 CA--C 1.509 -0.618 0 N-CA-C 108.047 -1.094 . . . . 3.4100000000000001 108.047 174.19 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.656 ' O ' ' HB3' ' A' ' 11' ' ' ASP . 0.2 OUTLIER -14.5 -106.61 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.039 0 O-C-N 125.7 1.875 . . . . 1.0700000000000001 114.367 -176.295 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . 0.656 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 4.6 p-10 158.86 -169.06 0.0 OUTLIER 'General case' 0 CA--C 1.511 -0.547 0 N-CA-C 107.917 -1.142 . . . . 1.1299999999999999 107.917 175.23 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -70.61 -8.92 55.25 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.952 0.406 . . . . 2.2599999999999998 111.086 -178.686 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.438 HD13 HG12 ' B' ' 17' ' ' VAL . 1.6 tm? -107.82 -62.14 1.48 Allowed 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.763 -0.458 . . . . 1.23 109.763 175.205 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 134.36 22.34 0.71 Allowed Glycine 0 N--CA 1.445 -0.75 0 C-N-CA 120.455 -0.878 . . . . 0.25 113.264 179.288 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.541 ' HB3' ' HB3' ' B' ' 15' ' ' ARG . 1.5 mpt_? -80.99 150.44 28.91 Favored 'General case' 0 CA--C 1.51 -0.588 0 O-C-N 121.913 -0.757 . . . . 0.88 110.813 -179.885 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.596 HG23 HD13 ' B' ' 46' ' ' LEU . 70.9 t -109.91 98.78 7.49 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.284 0 N-CA-C 107.581 -1.266 . . . . 1.99 107.581 168.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.617 HG22 ' CZ ' ' A' ' 8' ' ' ARG . 61.7 t -67.25 101.66 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 CA-C-N 115.501 -0.772 . . . . 1.0600000000000001 109.577 -176.138 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.602 HG23 HD12 ' A' ' 22' ' ' ILE . 8.5 mt -93.55 111.77 53.8 Favored Pre-proline 0 C--N 1.322 -0.6 0 CA-C-N 116.022 -0.536 . . . . 1.5600000000000001 110.72 -177.836 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.655 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 95.7 Cg_exo -50.31 152.51 8.26 Favored 'Trans proline' 0 N--CA 1.458 -0.579 0 C-N-CA 122.944 2.429 . . . . 0.34999999999999998 112.893 173.963 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.769 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -67.24 -14.26 62.74 Favored 'General case' 0 C--O 1.21 -0.988 0 CA-C-N 115.668 -0.696 . . . . 2.1299999999999999 111.237 -179.851 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.655 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 15.4 pt-20 -62.65 -25.36 68.09 Favored 'General case' 0 C--O 1.238 0.495 0 CA-C-O 120.88 0.372 . . . . 1.3200000000000001 111.752 -179.322 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.602 HD12 HG23 ' A' ' 18' ' ' ILE . 5.3 mp -86.63 -47.17 16.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 108.257 -1.016 . . . . 1.0800000000000001 108.257 -177.72 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . 0.616 ' HA ' ' HB2' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -61.12 -27.19 68.2 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.172 -0.922 . . . . 2.02 109.038 174.043 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 38.8 ttp180 -64.27 -52.29 59.36 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 114.829 -1.078 . . . . 3.3999999999999999 110.564 175.088 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 21.7 m -63.93 -28.18 69.65 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-O 121.154 0.502 . . . . 1.1499999999999999 110.992 174.28 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.616 ' HB2' ' HA ' ' A' ' 23' ' ' ARG . 2.4 mm? -64.05 -19.99 65.61 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.795 -0.639 . . . . 1.1599999999999999 110.043 172.636 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER 71.44 22.26 4.27 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.01 -0.995 . . . . 3.6800000000000002 110.105 -177.609 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.658 HG23 ' H ' ' A' ' 29' ' ' ARG . 6.1 mt -121.03 -167.35 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.674 0 CA-C-N 115.155 -0.93 . . . . 1.1000000000000001 109.118 -177.424 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.658 ' H ' HG23 ' A' ' 28' ' ' ILE . 0.3 OUTLIER -146.01 -156.47 0.71 Allowed 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 118.037 0.38 . . . . 3.0699999999999998 111.943 -174.335 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . 0.418 ' H ' ' HB2' ' A' ' 29' ' ' ARG . 1.1 mp0 -72.86 48.6 0.21 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 122.197 0.998 . . . . 1.23 111.904 -179.214 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.596 ' CA ' HD13 ' B' ' 10' ' ' ILE . . . -166.14 24.9 0.15 Allowed Glycine 0 N--CA 1.443 -0.876 0 CA-C-N 113.804 -1.544 . . . . 0.35999999999999999 109.863 174.69 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.493 ' O ' HG13 ' B' ' 10' ' ' ILE . 19.8 t0 -87.67 127.63 57.54 Favored Pre-proline 0 CA--C 1.516 -0.348 0 CA-C-N 114.771 -0.715 . . . . 1.26 109.377 174.883 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.682 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 3.8 Cg_endo -82.36 154.31 16.27 Favored 'Trans proline' 0 N--CA 1.438 -1.773 0 C-N-CA 122.26 1.973 . . . . 1.3 110.676 174.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.741 ' O ' ' HA ' ' B' ' 7' ' ' VAL . 0.5 OUTLIER -142.68 149.62 39.09 Favored 'General case' 0 C--N 1.307 -1.262 0 C-N-CA 120.133 -0.627 . . . . 1.21 109.507 172.688 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.911 ' HB3' ' HD2' ' A' ' 47' ' ' LYS . 38.1 tt0 -108.55 111.1 22.77 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 108.524 -0.917 . . . . 1.1200000000000001 108.524 -176.182 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 1.041 HG13 HD22 ' A' ' 46' ' ' LEU . 2.2 mp -85.85 109.48 18.58 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.794 0 O-C-N 124.972 1.42 . . . . 1.1599999999999999 109.211 -176.239 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' PHE . . . . . 0.938 ' HD2' ' HA ' ' B' ' 3' ' ' ALA . 0.5 OUTLIER -149.37 124.72 10.23 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 115.683 -0.69 . . . . 2.0099999999999998 109.431 177.736 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.526 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 2.0 p -80.52 133.08 30.25 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.953 0 CA-C-O 121.214 0.53 . . . . 1.05 110.566 -179.221 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.548 ' HB3' ' HG2' ' A' ' 40' ' ' ARG . 27.2 t0 -81.21 -58.07 3.22 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 114.154 -1.385 . . . . 1.1100000000000001 111.453 -174.447 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . 0.555 ' HG3' ' HG3' ' A' ' 43' ' ' GLU . 1.3 ptm180 -125.6 -99.52 0.4 Allowed 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.134 -0.939 . . . . 2.8799999999999999 112.74 -166.086 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 34.7 t70 -84.11 -75.67 0.33 Allowed 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.168 0.508 . . . . 1.53 110.757 -175.735 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.475 ' HA3' HD13 ' B' ' 26' ' ' LEU . . . -135.11 24.88 3.38 Favored Glycine 0 N--CA 1.441 -0.979 0 CA-C-N 115.534 -0.757 . . . . 0.34000000000000002 111.313 178.735 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.583 ' HB3' HG23 ' B' ' 45' ' ' ILE . 2.1 mt-10 -93.6 109.91 21.53 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.048 -0.723 . . . . 1.97 109.048 178.473 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.526 ' HA ' ' HA ' ' A' ' 38' ' ' VAL . 1.5 t -90.41 130.51 39.53 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 N-CA-C 109.22 -0.659 . . . . 1.0600000000000001 109.22 178.015 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.762 HG13 HG13 ' B' ' 45' ' ' ILE . 1.5 mp -108.79 117.91 55.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 N-CA-C 108.456 -0.942 . . . . 1.01 108.456 -175.595 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 1.044 HD12 HD12 ' B' ' 46' ' ' LEU . 0.3 OUTLIER -109.7 115.16 29.35 Favored 'General case' 0 C--N 1.314 -0.939 0 N-CA-C 108.743 -0.836 . . . . 1.1299999999999999 108.743 176.936 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.911 ' HD2' ' HB3' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -123.11 151.26 42.24 Favored 'General case' 0 C--O 1.215 -0.74 0 C-N-CA 118.808 -1.157 . . . . 1.25 111.99 179.594 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.578 ' HA ' ' O ' ' A' ' 33' ' ' PRO . 2.0 ptmt -42.12 -16.78 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.93 0 N-CA-C 117.377 2.362 . . . . 1.0900000000000001 117.377 -168.058 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . 0.737 ' CD1' HG21 ' B' ' 7' ' ' VAL . 23.0 t80 73.19 -53.87 0.7 Allowed 'General case' 0 N--CA 1.473 0.676 0 CA-C-N 118.321 0.509 . . . . 2.1400000000000001 112.301 174.101 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.685 ' OG ' ' HD3' ' A' ' 51' ' ' PRO . 4.3 p -54.07 -44.42 98.36 Favored Pre-proline 0 CA--C 1.543 0.676 0 CA-C-N 116.131 -0.486 . . . . 1.95 111.804 -175.378 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.685 ' HD3' ' OG ' ' A' ' 50' ' ' SER . 94.5 Cg_endo -102.29 21.44 0.17 Allowed 'Trans proline' 0 N--CA 1.452 -0.969 0 C-N-CA 123.082 2.521 . . . . 0.59999999999999998 111.75 168.164 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.235 0.328 0 CA-C-N 115.78 -0.645 . . . . 1.4199999999999999 110.347 -176.751 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 3' ' ' ALA . . . . . 0.938 ' HA ' ' HD2' ' A' ' 37' ' ' PHE . . . . . . . . 0 N--CA 1.472 0.651 0 N-CA-C 109.147 -0.686 . . . . 1.1000000000000001 109.147 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 4' ' ' THR . . . . . 0.716 ' H ' ' HB2' ' A' ' 37' ' ' PHE . 2.1 p -152.7 -47.86 0.1 Allowed 'General case' 0 C--N 1.324 -0.52 0 O-C-N 123.671 0.607 . . . . 0.97999999999999998 109.563 174.083 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 72.53 53.1 8.93 Favored Glycine 0 N--CA 1.452 -0.254 0 CA-C-N 114.989 -1.005 . . . . 0.33000000000000002 113.134 171.256 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 6' ' ' ILE . . . . . 0.836 HG21 ' HB ' ' A' ' 36' ' ' ILE . 1.3 tp -109.13 112.18 39.37 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.801 0 N-CA-C 109.124 -0.695 . . . . 1.1000000000000001 109.124 171.895 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . 0.741 ' HA ' ' O ' ' A' ' 34' ' ' LEU . 39.7 t -84.4 136.03 23.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-O 120.94 0.4 . . . . 1.0800000000000001 110.974 -179.501 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . 0.718 ' CZ ' HG22 ' B' ' 17' ' ' VAL . 1.4 tpt180 -129.61 114.71 16.38 Favored 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 107.665 -1.235 . . . . 2.3599999999999999 107.665 -178.603 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 9' ' ' ARG . . . . . 0.488 ' HA ' ' HA ' ' A' ' 33' ' ' PRO . 0.0 OUTLIER -80.81 103.06 10.39 Favored 'General case' 0 CA--C 1.51 -0.582 0 N-CA-C 107.933 -1.136 . . . . 3.2000000000000002 107.933 173.903 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 10' ' ' ILE . . . . . 0.596 HD13 ' CA ' ' A' ' 31' ' ' GLY . 0.2 OUTLIER -13.54 -105.54 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.085 0 O-C-N 125.611 1.82 . . . . 1.0700000000000001 114.509 -176.627 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 34.8 p30 156.99 -160.71 0.0 OUTLIER 'General case' 0 CA--C 1.508 -0.637 0 C-N-CA 124.379 1.072 . . . . 1.1799999999999999 108.25 171.735 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -71.96 -8.29 53.63 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 121.085 0.469 . . . . 2.3900000000000001 110.766 -176.81 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 13' ' ' LEU . . . . . 0.446 HD12 HG12 ' A' ' 17' ' ' VAL . 2.1 tm? -114.72 -57.97 2.2 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.343 -0.39 . . . . 1.1000000000000001 109.973 -179.8 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 133.03 17.42 1.15 Allowed Glycine 0 N--CA 1.441 -0.967 0 C-N-CA 120.595 -0.812 . . . . 0.23000000000000001 113.784 179.532 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 15' ' ' ARG . . . . . 0.541 ' HB3' ' HB3' ' A' ' 15' ' ' ARG . 0.2 OUTLIER -81.5 150.52 28.22 Favored 'General case' 0 CA--C 1.507 -0.694 0 CA-C-N 118.764 1.282 . . . . 1.3899999999999999 110.962 -179.256 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 16' ' ' VAL . . . . . 0.535 HG23 HD13 ' A' ' 46' ' ' LEU . 98.2 t -108.98 100.72 11.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 CA-C-N 114.318 -1.31 . . . . 1.97 107.549 171.064 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 17' ' ' VAL . . . . . 0.718 HG22 ' CZ ' ' B' ' 8' ' ' ARG . 37.8 t -69.54 103.21 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.078 0 CA-C-N 115.832 -0.622 . . . . 1.0600000000000001 109.654 -174.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . 0.459 HD13 HD11 ' B' ' 46' ' ' LEU . 6.8 mt -91.98 112.39 54.61 Favored Pre-proline 0 N--CA 1.446 -0.647 0 CA-C-O 121.477 0.656 . . . . 1.6100000000000001 110.981 -177.768 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 19' ' ' PRO . . . . . 0.648 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 67.7 Cg_exo -49.1 142.9 19.6 Favored 'Trans proline' 0 N--CA 1.46 -0.484 0 C-N-CA 123.379 2.719 . . . . 0.33000000000000002 112.456 171.511 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 20' ' ' LYS . . . . . 0.928 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -61.36 -15.1 32.82 Favored 'General case' 0 C--O 1.211 -0.938 0 CA-C-N 115.313 -0.858 . . . . 2.3199999999999998 111.4 179.525 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . 0.648 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 10.0 pt-20 -63.37 -22.84 67.12 Favored 'General case' 0 C--O 1.238 0.486 0 N-CA-C 112.117 0.414 . . . . 1.9199999999999999 112.117 179.625 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 22' ' ' ILE . . . . . 0.405 HD12 HG23 ' B' ' 18' ' ' ILE . 5.3 mp -87.09 -47.97 15.68 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 N-CA-C 108.61 -0.885 . . . . 1.24 108.61 -179.371 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 23' ' ' ARG . . . . . 0.565 ' HA ' ' HB2' ' B' ' 26' ' ' LEU . 0.0 OUTLIER -60.06 -27.98 67.42 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.356 -0.838 . . . . 1.8500000000000001 109.27 173.234 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 24' ' ' ARG . . . . . . . . . . . . . 43.5 ttp180 -65.45 -52.76 50.83 Favored 'General case' 0 N--CA 1.446 -0.654 0 CA-C-N 114.676 -1.147 . . . . 3.6899999999999999 110.683 175.7 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 21.3 m -64.77 -26.67 68.45 Favored 'General case' 0 N--CA 1.449 -0.508 0 CA-C-O 121.355 0.597 . . . . 1.1599999999999999 110.667 175.421 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . 0.565 ' HB2' ' HA ' ' B' ' 23' ' ' ARG . 1.7 mm? -64.85 -18.97 65.61 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.46 -0.791 . . . . 1.1100000000000001 110.59 173.754 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 27' ' ' ARG . . . . . . . . . . . . . 19.6 tpt180 74.4 22.32 2.19 Favored 'General case' 0 C--N 1.34 0.166 0 O-C-N 124.136 0.897 . . . . 3.77 109.772 -178.034 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 28' ' ' ILE . . . . . 0.909 HG23 ' H ' ' B' ' 29' ' ' ARG . 6.6 mt -123.28 -163.19 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.343 -0.844 . . . . 1.2 110.287 -174.91 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 29' ' ' ARG . . . . . 0.909 ' H ' HG23 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -152.44 -159.31 0.99 Allowed 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 112.025 0.379 . . . . 2.7599999999999998 112.025 -170.392 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 30' ' ' GLU . . . . . 0.429 ' H ' ' HB2' ' B' ' 29' ' ' ARG . 0.9 OUTLIER -73.92 36.94 0.1 Allowed 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 121.849 0.833 . . . . 1.1799999999999999 111.961 -177.464 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 31' ' ' GLY . . . . . 0.539 ' CA ' HD12 ' A' ' 10' ' ' ILE . . . -153.93 30.42 0.74 Allowed Glycine 0 N--CA 1.442 -0.93 0 N-CA-C 109.757 -1.337 . . . . 0.34999999999999998 109.757 171.658 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 32' ' ' ASP . . . . . 0.51 ' N ' HD12 ' A' ' 10' ' ' ILE . 12.3 t70 -86.7 128.78 55.2 Favored Pre-proline 0 C--N 1.324 -0.543 0 CA-C-N 114.81 -0.695 . . . . 1.29 109.948 174.197 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 33' ' ' PRO . . . . . 0.729 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 10.3 Cg_endo -84.88 148.93 10.9 Favored 'Trans proline' 0 N--CA 1.435 -1.919 0 C-N-CA 122.402 2.068 . . . . 1.1000000000000001 110.785 173.474 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . 0.719 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.7 OUTLIER -137.55 148.63 46.09 Favored 'General case' 0 C--N 1.302 -1.471 0 N-CA-C 109.631 -0.507 . . . . 1.1699999999999999 109.631 173.64 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 35' ' ' GLU . . . . . 0.708 ' O ' ' HA ' ' B' ' 46' ' ' LEU . 46.8 tt0 -105.16 111.74 24.6 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 107.9 -1.148 . . . . 1.1000000000000001 107.9 -178.178 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 36' ' ' ILE . . . . . 1.106 HG13 HD23 ' B' ' 46' ' ' LEU . 3.0 mp -86.73 109.86 19.53 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.943 0 O-C-N 124.417 1.073 . . . . 1.3200000000000001 109.06 -178.604 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 37' ' ' PHE . . . . . 0.829 ' HB2' ' H ' ' A' ' 4' ' ' THR . 12.1 p90 -151.0 131.97 14.25 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 116.158 -0.474 . . . . 2.0299999999999998 109.966 174.796 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 38' ' ' VAL . . . . . 0.502 ' HA ' ' HA ' ' B' ' 44' ' ' VAL . 1.9 p -80.08 142.33 14.07 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.01 0 CA-C-O 120.949 0.404 . . . . 0.89000000000000001 110.352 -178.584 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 39' ' ' ASP . . . . . 0.444 ' HB2' ' CD1' ' B' ' 45' ' ' ILE . 25.8 t0 -92.08 -47.52 7.22 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.556 -0.747 . . . . 1.1399999999999999 111.618 -175.026 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 40' ' ' ARG . . . . . 0.544 ' HG3' ' HG3' ' B' ' 43' ' ' GLU . 0.0 OUTLIER -134.08 -100.82 0.25 Allowed 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 112.767 0.655 . . . . 3.3700000000000001 112.767 -168.12 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 25.1 t70 -83.09 -71.92 0.47 Allowed 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.422 0.63 . . . . 1.3200000000000001 110.767 -176.182 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 42' ' ' GLY . . . . . 0.444 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -139.73 25.77 2.68 Favored Glycine 0 CA--C 1.501 -0.801 0 CA-C-N 115.41 -0.814 . . . . 0.35999999999999999 111.179 178.868 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 43' ' ' GLU . . . . . 0.544 ' HG3' ' HG3' ' B' ' 40' ' ' ARG . 2.7 mt-10 -92.72 109.15 20.57 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 109.226 -0.657 . . . . 2.0699999999999998 109.226 178.629 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 44' ' ' VAL . . . . . 0.502 ' HA ' ' HA ' ' B' ' 38' ' ' VAL . 1.7 t -89.13 130.48 38.41 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 N-CA-C 109.122 -0.696 . . . . 1.02 109.122 178.09 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 45' ' ' ILE . . . . . 0.762 HG13 HG13 ' A' ' 45' ' ' ILE . 1.7 mp -108.19 118.85 56.68 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 N-CA-C 108.138 -1.06 . . . . 0.95999999999999996 108.138 -176.981 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 46' ' ' LEU . . . . . 1.106 HD23 HG13 ' B' ' 36' ' ' ILE . 0.5 OUTLIER -110.26 115.77 30.3 Favored 'General case' 0 C--N 1.317 -0.847 0 N-CA-C 108.819 -0.808 . . . . 1.05 108.819 176.648 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 47' ' ' LYS . . . . . 0.541 ' O ' ' HA ' ' B' ' 34' ' ' LEU . 0.0 OUTLIER -126.57 149.99 49.1 Favored 'General case' 0 C--N 1.317 -0.847 0 C-N-CA 119.178 -1.009 . . . . 1.3899999999999999 112.626 -177.724 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 48' ' ' LYS . . . . . 0.655 ' HE2' ' HG3' ' B' ' 51' ' ' PRO . 3.4 ptmt -41.7 -14.18 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.064 0 N-CA-C 118.007 2.595 . . . . 1.1899999999999999 118.007 -167.643 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 49' ' ' TYR . . . . . 0.762 ' CD1' HG21 ' A' ' 7' ' ' VAL . 30.9 t80 72.41 -56.62 0.65 Allowed 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 113.004 0.742 . . . . 2.1000000000000001 113.004 173.145 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 50' ' ' SER . . . . . 0.688 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 8.3 t -52.28 -52.7 60.27 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.26 -0.427 . . . . 1.77 110.778 -174.031 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 51' ' ' PRO . . . . . 0.688 ' HD3' ' HB3' ' B' ' 50' ' ' SER . 47.2 Cg_endo -92.33 14.29 1.74 Allowed 'Trans proline' 0 N--CA 1.454 -0.806 0 C-N-CA 122.155 1.903 . . . . 0.59999999999999998 111.84 170.421 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 52' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.328 -0.34 0 CA-C-N 115.52 -0.764 . . . . 1.3899999999999999 109.76 -177.184 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . 0.592 ' HA ' ' HD2' ' B' ' 37' ' ' PHE . . . . . . . . 0 C--O 1.232 0.153 0 CA-C-O 121.552 0.691 . . . . 1.1299999999999999 111.844 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.528 ' OG1' ' HA ' ' B' ' 37' ' ' PHE . 11.7 p -97.05 -45.76 6.44 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.547 -0.752 . . . . 1.0900000000000001 111.602 -179.4 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 70.51 48.93 33.78 Favored Glycine 0 N--CA 1.443 -0.866 0 C-N-CA 120.58 -0.819 . . . . 0.32000000000000001 112.919 174.155 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.791 HG21 ' HB ' ' B' ' 36' ' ' ILE . 1.0 OUTLIER -104.94 113.1 41.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 N-CA-C 108.407 -0.96 . . . . 1.0900000000000001 108.407 173.997 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.734 HG22 ' CD1' ' B' ' 49' ' ' TYR . 28.3 t -83.58 134.65 26.47 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-O 121.211 0.529 . . . . 1.1299999999999999 110.94 -178.319 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.572 ' HB3' ' CD1' ' B' ' 36' ' ' ILE . 9.0 tpp180 -131.0 119.54 22.2 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 107.818 -1.178 . . . . 2.6099999999999999 107.818 -176.583 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' ARG . . . . . 0.455 ' N ' ' HD3' ' A' ' 8' ' ' ARG . 44.8 ttp180 -79.27 108.36 12.72 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 108.613 -0.884 . . . . 3.4100000000000001 108.613 170.713 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.79 HG22 HD12 ' B' ' 34' ' ' LEU . 0.2 OUTLIER -16.19 -102.65 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 O-C-N 125.593 1.808 . . . . 1.0700000000000001 114.492 -177.724 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . 0.604 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 3.1 p-10 162.89 -160.92 0.0 OUTLIER 'General case' 0 CA--C 1.509 -0.602 0 N-CA-C 107.826 -1.176 . . . . 1.1299999999999999 107.826 175.542 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 25.0 m-20 -70.72 -22.09 62.47 Favored 'General case' 0 C--N 1.321 -0.663 0 O-C-N 123.384 0.428 . . . . 2.2599999999999998 110.812 -178.78 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.451 HD22 ' HE2' ' B' ' 20' ' ' LYS . 3.0 tm? -102.88 -61.46 1.4 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.27 -0.423 . . . . 1.23 110.305 179.682 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.521 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 144.48 16.65 0.21 Allowed Glycine 0 N--CA 1.442 -0.93 0 C-N-CA 120.768 -0.729 . . . . 0.25 112.513 -178.91 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.539 ' HB3' ' HB3' ' B' ' 15' ' ' ARG . 2.8 mpt_? -71.5 145.84 48.92 Favored 'General case' 0 CA--C 1.504 -0.793 0 CA-C-O 121.522 0.677 . . . . 0.88 110.456 -179.278 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.782 HG23 HD12 ' B' ' 46' ' ' LEU . 97.5 t -103.76 94.08 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.53 0 N-CA-C 107.146 -1.427 . . . . 1.99 107.146 168.947 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.533 ' HA ' ' HA ' ' B' ' 15' ' ' ARG . 59.7 t -67.22 97.62 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.844 0 CA-C-N 114.891 -1.049 . . . . 1.0600000000000001 110.137 -172.809 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.709 HG21 HD13 ' A' ' 22' ' ' ILE . 17.4 mt -98.54 111.23 59.59 Favored Pre-proline 0 C--N 1.326 -0.45 0 CA-C-N 115.594 -0.73 . . . . 1.5600000000000001 111.11 -175.6 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.739 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 48.6 Cg_exo -46.74 150.41 2.55 Favored 'Trans proline' 0 N--CA 1.458 -0.577 0 C-N-CA 123.183 2.588 . . . . 0.34999999999999998 113.859 175.041 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.897 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -64.49 -12.62 45.93 Favored 'General case' 0 C--O 1.207 -1.176 0 CA-C-N 115.164 -0.926 . . . . 2.1299999999999999 111.219 176.61 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.739 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 12.7 pt-20 -64.88 -22.62 67.03 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 118.436 0.562 . . . . 1.3200000000000001 111.246 176.372 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.709 HD13 HG21 ' A' ' 18' ' ' ILE . 5.1 mp -88.06 -44.31 15.72 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.404 0 N-CA-C 108.889 -0.782 . . . . 1.0800000000000001 108.889 179.167 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . 0.705 ' HG3' ' HA ' ' A' ' 20' ' ' LYS . 1.1 ppt_? -61.12 -26.25 67.54 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 122.284 1.04 . . . . 2.02 108.636 172.05 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.523 ' HB3' ' O ' ' A' ' 21' ' ' GLU . 32.0 ttt180 -64.03 -52.37 59.77 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 113.741 -1.572 . . . . 3.3999999999999999 110.628 174.914 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 40.3 m -62.73 -30.35 71.36 Favored 'General case' 0 N--CA 1.455 -0.223 0 CA-C-O 121.062 0.458 . . . . 1.1499999999999999 110.995 172.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.602 ' HB2' ' HA ' ' A' ' 23' ' ' ARG . 2.6 mm? -63.49 -18.98 64.35 Favored 'General case' 0 CA--C 1.519 -0.23 0 CA-C-N 115.952 -0.567 . . . . 1.1599999999999999 109.94 174.662 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.421 ' HB2' ' O ' ' A' ' 26' ' ' LEU . 11.3 mmt180 67.69 23.38 8.7 Favored 'General case' 0 N--CA 1.451 -0.408 0 CA-C-N 115.277 -0.874 . . . . 3.6800000000000002 109.915 -178.079 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.659 HG22 ' H ' ' A' ' 29' ' ' ARG . 11.8 mt -124.32 -167.61 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 CA-C-N 114.479 -1.237 . . . . 1.1000000000000001 108.161 -178.161 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.659 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.2 OUTLIER -142.63 -158.55 0.88 Allowed 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 118.403 0.547 . . . . 3.0699999999999998 112.116 -175.464 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . 0.43 ' H ' ' HB2' ' A' ' 29' ' ' ARG . 5.7 mp0 -72.9 47.19 0.18 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 122.221 1.01 . . . . 1.23 111.942 -179.514 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.525 ' CA ' HD13 ' B' ' 10' ' ' ILE . . . -163.08 24.91 0.2 Allowed Glycine 0 N--CA 1.445 -0.71 0 CA-C-N 113.801 -1.545 . . . . 0.35999999999999999 109.867 175.115 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.47 ' O ' HG13 ' B' ' 10' ' ' ILE . 18.1 t0 -87.97 130.81 45.07 Favored Pre-proline 0 CA--C 1.514 -0.423 0 CA-C-N 114.446 -0.877 . . . . 1.26 109.367 174.247 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.655 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 3.2 Cg_endo -82.32 153.44 16.15 Favored 'Trans proline' 0 N--CA 1.438 -1.762 0 C-N-CA 122.172 1.915 . . . . 1.3 110.634 174.668 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.828 HD12 HG22 ' B' ' 10' ' ' ILE . 0.5 OUTLIER -140.72 151.68 44.7 Favored 'General case' 0 N--CA 1.433 -1.319 0 C-N-CA 119.866 -0.734 . . . . 1.21 109.663 171.439 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.725 ' O ' ' HA ' ' A' ' 46' ' ' LEU . 86.0 tt0 -105.13 111.31 24.03 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.606 -1.257 . . . . 1.1200000000000001 107.606 -178.523 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 1.0 HG13 HD21 ' A' ' 46' ' ' LEU . 2.9 mp -87.14 109.01 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.744 0 O-C-N 124.722 1.263 . . . . 1.1599999999999999 109.116 -178.893 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' PHE . . . . . 0.647 ' HD2' ' HA ' ' B' ' 3' ' ' ALA . 1.0 OUTLIER -149.23 127.72 12.3 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 115.987 -0.551 . . . . 2.0099999999999998 109.835 176.833 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.452 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 1.3 p -81.81 132.49 31.35 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.999 0 CA-C-O 121.612 0.72 . . . . 1.05 110.657 -179.878 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.582 ' HB3' ' HG2' ' A' ' 40' ' ' ARG . 19.7 t70 -79.94 -49.89 11.22 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 114.236 -1.347 . . . . 1.1100000000000001 111.672 -173.746 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . 0.582 ' HG2' ' HB3' ' A' ' 39' ' ' ASP . 1.7 ptm180 -133.65 -96.83 0.29 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.48 -0.782 . . . . 2.8799999999999999 112.96 -167.069 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -88.6 -70.38 0.65 Allowed 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.089 0.471 . . . . 1.53 111.024 -174.311 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.419 ' O ' ' HA ' ' B' ' 47' ' ' LYS . . . -139.67 22.84 2.82 Favored Glycine 0 N--CA 1.445 -0.741 0 CA-C-N 115.596 -0.729 . . . . 0.34000000000000002 111.279 -179.344 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.538 ' HB3' HG22 ' B' ' 45' ' ' ILE . 1.7 mt-10 -95.4 113.06 24.69 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 109.483 -0.562 . . . . 1.97 109.483 179.275 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.466 ' CG1' HG23 ' A' ' 36' ' ' ILE . 1.4 t -91.15 131.26 38.77 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 N-CA-C 109.425 -0.583 . . . . 1.0600000000000001 109.425 177.182 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.811 HG13 HG13 ' B' ' 45' ' ' ILE . 1.6 mp -109.69 118.06 55.99 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 108.072 -1.084 . . . . 1.01 108.072 -176.568 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 1.022 HD13 HD11 ' B' ' 46' ' ' LEU . 0.3 OUTLIER -112.54 116.69 30.63 Favored 'General case' 0 C--N 1.315 -0.933 0 O-C-N 123.796 0.685 . . . . 1.1299999999999999 109.467 178.813 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.7 ' HD2' ' HB3' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -127.64 153.59 46.26 Favored 'General case' 0 C--O 1.215 -0.722 0 C-N-CA 118.662 -1.215 . . . . 1.25 112.216 178.56 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.641 ' HG3' ' HG2' ' A' ' 51' ' ' PRO . 1.1 ptmt -41.24 -17.42 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.026 0 N-CA-C 117.497 2.406 . . . . 1.0900000000000001 117.497 -168.88 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . 0.809 ' CD1' HG21 ' B' ' 7' ' ' VAL . 17.4 t80 75.82 -53.59 0.63 Allowed 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 112.418 0.525 . . . . 2.1400000000000001 112.418 173.379 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.667 ' HB3' ' HD3' ' A' ' 51' ' ' PRO . 8.3 t -51.57 -49.71 81.16 Favored Pre-proline 0 CA--C 1.538 0.498 0 CA-C-N 116.219 -0.446 . . . . 1.95 111.099 -177.184 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.667 ' HD3' ' HB3' ' A' ' 50' ' ' SER . 27.8 Cg_endo -93.82 9.12 2.25 Favored 'Trans proline' 0 N--CA 1.455 -0.749 0 C-N-CA 122.647 2.231 . . . . 0.59999999999999998 111.663 171.706 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.423 HG13 ' C ' ' A' ' 51' ' ' PRO . 1.1 mt . . . . . 0 CA--C 1.532 0.255 0 CA-C-N 115.439 -0.8 . . . . 1.4199999999999999 109.326 -175.038 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 3' ' ' ALA . . . . . 0.647 ' HA ' ' HD2' ' A' ' 37' ' ' PHE . . . . . . . . 0 C--O 1.233 0.208 0 CA-C-O 121.398 0.618 . . . . 1.1000000000000001 111.303 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 4' ' ' THR . . . . . 0.532 ' OG1' ' HA ' ' A' ' 37' ' ' PHE . 7.5 p -94.73 -48.14 6.18 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.909 -0.587 . . . . 0.97999999999999998 111.675 -179.174 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 72.24 48.33 25.7 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.939 -0.648 . . . . 0.33000000000000002 112.976 174.84 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 6' ' ' ILE . . . . . 0.733 HG22 ' HB ' ' A' ' 36' ' ' ILE . 0.9 OUTLIER -106.11 112.1 37.95 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 N-CA-C 108.731 -0.84 . . . . 1.1000000000000001 108.731 174.83 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . 0.809 HG21 ' CD1' ' A' ' 49' ' ' TYR . 35.2 t -83.56 136.66 22.35 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 CA-C-O 120.952 0.405 . . . . 1.0800000000000001 111.167 -178.887 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . 0.522 ' HD3' ' N ' ' B' ' 9' ' ' ARG . 1.0 OUTLIER -133.17 123.77 26.25 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 107.296 -1.372 . . . . 2.3599999999999999 107.296 179.128 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 9' ' ' ARG . . . . . 0.522 ' N ' ' HD3' ' B' ' 8' ' ' ARG . 0.1 OUTLIER -82.31 103.33 11.82 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 108.267 -1.012 . . . . 3.2000000000000002 108.267 173.219 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 10' ' ' ILE . . . . . 0.828 HG22 HD12 ' A' ' 34' ' ' LEU . 0.2 OUTLIER -10.32 -106.02 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 O-C-N 125.444 1.715 . . . . 1.0700000000000001 114.9 -176.746 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . 0.608 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 2.5 p-10 163.1 -168.29 0.01 OUTLIER 'General case' 0 CA--C 1.51 -0.575 0 N-CA-C 106.586 -1.635 . . . . 1.1799999999999999 106.586 177.174 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 52.7 m-20 -77.06 -2.87 36.28 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 118.418 0.553 . . . . 2.3900000000000001 110.995 -176.804 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 13' ' ' LEU . . . . . 0.444 HD11 HG12 ' A' ' 17' ' ' VAL . 2.1 tm? -106.56 -61.8 1.48 Allowed 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.781 -0.645 . . . . 1.1000000000000001 109.794 174.689 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 138.14 17.01 0.63 Allowed Glycine 0 N--CA 1.445 -0.722 0 CA-C-N 115.947 -0.57 . . . . 0.23000000000000001 112.093 -176.869 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 15' ' ' ARG . . . . . 0.539 ' HB3' ' HB3' ' A' ' 15' ' ' ARG . 1.6 mpt_? -70.36 143.1 52.04 Favored 'General case' 0 CA--C 1.506 -0.724 0 CA-C-O 121.536 0.684 . . . . 1.3899999999999999 110.481 -179.718 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 16' ' ' VAL . . . . . 0.698 HG23 HD11 ' A' ' 46' ' ' LEU . 81.1 t -104.69 94.34 3.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 N-CA-C 107.343 -1.354 . . . . 1.97 107.343 167.465 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 17' ' ' VAL . . . . . 0.492 HG21 ' HG2' ' A' ' 15' ' ' ARG . 40.8 t -67.13 98.49 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-N 115.188 -0.915 . . . . 1.0600000000000001 110.169 -171.1 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . 0.521 ' HB ' ' O ' ' A' ' 14' ' ' GLY . 11.4 mt -96.75 112.74 61.26 Favored Pre-proline 0 N--CA 1.447 -0.58 0 CA-C-N 115.535 -0.757 . . . . 1.6100000000000001 110.932 -177.477 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 19' ' ' PRO . . . . . 0.56 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 85.6 Cg_exo -51.67 154.31 9.54 Favored 'Trans proline' 0 N--CA 1.456 -0.68 0 C-N-CA 122.626 2.217 . . . . 0.33000000000000002 113.508 173.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 20' ' ' LYS . . . . . 0.767 ' HA ' ' HG3' ' B' ' 23' ' ' ARG . 0.0 OUTLIER -68.37 -13.37 62.24 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-N 114.828 -1.078 . . . . 2.3199999999999998 111.1 178.384 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . 0.56 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 9.8 pt-20 -66.36 -20.24 66.03 Favored 'General case' 0 C--N 1.322 -0.595 0 C-N-CA 120.327 -0.549 . . . . 1.9199999999999999 111.568 176.141 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 5.4 mp -88.56 -45.21 15.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 N-CA-C 108.863 -0.791 . . . . 1.24 108.863 177.265 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 23' ' ' ARG . . . . . 0.767 ' HG3' ' HA ' ' B' ' 20' ' ' LYS . 0.3 OUTLIER -59.92 -25.11 64.88 Favored 'General case' 0 N--CA 1.472 0.636 0 CA-C-O 121.989 0.899 . . . . 1.8500000000000001 108.789 171.996 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 24' ' ' ARG . . . . . 0.422 ' HB3' ' O ' ' B' ' 21' ' ' GLU . 35.3 ttm180 -65.17 -52.52 54.49 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 114.018 -1.446 . . . . 3.6899999999999999 110.971 174.012 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 31.7 m -63.08 -29.16 70.59 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 120.54 -0.464 . . . . 1.1599999999999999 110.906 173.756 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . 0.577 ' HB2' ' HA ' ' B' ' 23' ' ' ARG . 2.6 mm? -63.34 -20.05 65.17 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.947 -0.57 . . . . 1.1100000000000001 110.057 174.337 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 27' ' ' ARG . . . . . 0.424 ' HB2' ' O ' ' B' ' 26' ' ' LEU . 25.0 mmt180 68.11 24.72 7.62 Favored 'General case' 0 N--CA 1.453 -0.306 0 CA-C-N 115.286 -0.87 . . . . 3.77 109.904 -177.381 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 28' ' ' ILE . . . . . 0.917 HG22 ' H ' ' B' ' 29' ' ' ARG . 12.6 mt -125.17 -161.43 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 114.793 -1.094 . . . . 1.2 109.294 -177.243 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 29' ' ' ARG . . . . . 0.917 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.1 OUTLIER -149.41 -160.79 1.22 Allowed 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 112.144 0.424 . . . . 2.7599999999999998 112.144 -173.123 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 30' ' ' GLU . . . . . 0.419 ' N ' ' HD2' ' B' ' 29' ' ' ARG . 3.2 mp0 -71.12 37.82 0.05 Allowed 'General case' 0 N--CA 1.464 0.232 0 CA-C-O 121.523 0.677 . . . . 1.1799999999999999 112.55 -178.629 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 31' ' ' GLY . . . . . 0.57 ' N ' ' HD2' ' B' ' 29' ' ' ARG . . . -152.03 18.5 0.84 Allowed Glycine 0 N--CA 1.443 -0.884 0 N-CA-C 110.339 -1.104 . . . . 0.34999999999999998 110.339 173.469 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 32' ' ' ASP . . . . . 0.488 ' O ' HG13 ' A' ' 10' ' ' ILE . 18.3 t70 -78.32 129.14 75.93 Favored Pre-proline 0 C--N 1.326 -0.433 0 CA-C-N 115.054 -0.573 . . . . 1.29 109.595 174.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 33' ' ' PRO . . . . . 0.671 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 5.1 Cg_endo -82.16 150.05 15.55 Favored 'Trans proline' 0 N--CA 1.436 -1.853 0 C-N-CA 122.586 2.191 . . . . 1.1000000000000001 110.697 173.242 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . 0.79 HD12 HG22 ' A' ' 10' ' ' ILE . 0.7 OUTLIER -136.85 150.66 48.42 Favored 'General case' 0 C--N 1.306 -1.304 0 N-CA-C 109.674 -0.491 . . . . 1.1699999999999999 109.674 173.693 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 35' ' ' GLU . . . . . 0.753 ' O ' ' HA ' ' B' ' 46' ' ' LEU . 38.0 tt0 -105.31 112.92 26.21 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 107.577 -1.268 . . . . 1.1000000000000001 107.577 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 36' ' ' ILE . . . . . 0.954 HG13 HD23 ' B' ' 46' ' ' LEU . 3.3 mp -89.12 109.85 20.77 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 O-C-N 124.878 1.361 . . . . 1.3200000000000001 109.198 -178.807 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 37' ' ' PHE . . . . . 0.869 ' HE1' ' HZ2' ' B' ' 47' ' ' LYS . 2.1 p90 -149.28 131.33 15.33 Favored 'General case' 0 C--N 1.317 -0.835 0 N-CA-C 109.694 -0.484 . . . . 2.0299999999999998 109.694 175.013 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 38' ' ' VAL . . . . . 0.436 ' HA ' ' HA ' ' B' ' 44' ' ' VAL . 1.2 p -82.09 135.38 25.05 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 CA-C-O 121.367 0.603 . . . . 0.89000000000000001 110.852 179.753 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 39' ' ' ASP . . . . . 0.451 ' HB2' ' CD1' ' B' ' 45' ' ' ILE . 35.8 t70 -81.07 -50.74 9.28 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 114.354 -1.294 . . . . 1.1399999999999999 111.255 -174.675 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 40' ' ' ARG . . . . . 0.55 ' HD3' ' OE1' ' B' ' 43' ' ' GLU . 0.9 OUTLIER -134.22 -105.04 0.23 Allowed 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.908 -0.587 . . . . 3.3700000000000001 112.347 -169.937 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 24.0 t70 -78.19 -70.48 0.48 Allowed 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.086 0.47 . . . . 1.3200000000000001 111.362 -176.354 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 42' ' ' GLY . . . . . 0.406 ' O ' ' HA ' ' A' ' 47' ' ' LYS . . . -139.72 25.17 2.71 Favored Glycine 0 N--CA 1.442 -0.906 0 C-N-CA 120.449 -0.881 . . . . 0.35999999999999999 111.978 -177.933 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 43' ' ' GLU . . . . . 0.55 ' OE1' ' HD3' ' B' ' 40' ' ' ARG . 3.2 mt-10 -95.43 113.68 25.36 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.901 -0.407 . . . . 2.0699999999999998 109.901 178.083 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 44' ' ' VAL . . . . . 0.484 ' CG1' HG23 ' B' ' 36' ' ' ILE . 1.5 t -91.13 130.73 39.85 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 N-CA-C 109.602 -0.518 . . . . 1.02 109.602 176.133 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 45' ' ' ILE . . . . . 0.811 HG13 HG13 ' A' ' 45' ' ' ILE . 1.7 mp -109.41 118.13 56.03 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 N-CA-C 108.262 -1.014 . . . . 0.95999999999999996 108.262 -177.446 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 46' ' ' LEU . . . . . 1.022 HD11 HD13 ' A' ' 46' ' ' LEU . 0.3 OUTLIER -113.02 116.8 30.49 Favored 'General case' 0 C--N 1.314 -0.935 0 O-C-N 123.665 0.603 . . . . 1.05 109.571 178.916 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 47' ' ' LYS . . . . . 0.869 ' HZ2' ' HE1' ' B' ' 37' ' ' PHE . 0.0 OUTLIER -126.81 155.28 43.11 Favored 'General case' 0 C--N 1.32 -0.694 0 C-N-CA 118.85 -1.14 . . . . 1.3899999999999999 111.97 179.096 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 48' ' ' LYS . . . . . 0.541 ' HA ' ' O ' ' B' ' 33' ' ' PRO . 6.5 ptmt -49.58 -7.67 0.03 OUTLIER 'General case' 0 N--CA 1.476 0.873 0 N-CA-C 117.102 2.26 . . . . 1.1899999999999999 117.102 -166.011 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 49' ' ' TYR . . . . . 0.734 ' CD1' HG22 ' A' ' 7' ' ' VAL . 19.7 t80 73.8 -52.92 0.69 Allowed 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 112.73 0.641 . . . . 2.1000000000000001 112.73 170.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 50' ' ' SER . . . . . 0.699 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 26.9 t -50.6 -52.89 51.74 Favored Pre-proline 0 CA--C 1.541 0.628 0 CA-C-N 116.059 -0.519 . . . . 1.77 111.177 -175.48 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 51' ' ' PRO . . . . . 0.699 ' HD3' ' HB3' ' B' ' 50' ' ' SER . 59.8 Cg_endo -93.55 12.87 1.73 Allowed 'Trans proline' 0 C--N 1.352 0.754 0 C-N-CA 122.438 2.092 . . . . 0.59999999999999998 111.791 171.293 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 52' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.236 0.361 0 CA-C-N 115.323 -0.853 . . . . 1.3899999999999999 109.619 -175.734 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . 0.423 ' HA ' ' HB2' ' B' ' 37' ' ' PHE . . . . . . . . 0 N--CA 1.46 0.069 0 CA-C-O 121.466 0.651 . . . . 1.1299999999999999 111.24 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.494 ' OG1' ' HA ' ' B' ' 37' ' ' PHE . 18.2 p -87.5 -45.89 10.08 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.563 -0.744 . . . . 1.0900000000000001 111.365 -178.536 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 73.15 48.39 19.97 Favored Glycine 0 N--CA 1.444 -0.796 0 C-N-CA 120.829 -0.701 . . . . 0.32000000000000001 112.969 173.149 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.789 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.5 tp -106.46 107.4 22.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 N-CA-C 109.155 -0.683 . . . . 1.0900000000000001 109.155 174.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.687 HG21 ' CD1' ' B' ' 49' ' ' TYR . 55.7 t -76.05 136.61 24.43 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.909 0 CA-C-O 121.414 0.626 . . . . 1.1299999999999999 110.527 179.852 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.561 ' HB3' ' CD1' ' B' ' 36' ' ' ILE . 2.5 tpp180 -130.94 116.22 17.57 Favored 'General case' 0 N--CA 1.433 -1.304 0 N-CA-C 107.069 -1.456 . . . . 2.6099999999999999 107.069 -179.661 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' ARG . . . . . 0.465 ' C ' HD13 ' A' ' 10' ' ' ILE . 0.2 OUTLIER -82.48 101.68 10.85 Favored 'General case' 0 C--N 1.315 -0.931 0 N-CA-C 108.123 -1.066 . . . . 3.4100000000000001 108.123 175.63 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.938 HG22 HD12 ' B' ' 34' ' ' LEU . 0.2 OUTLIER -7.05 -105.18 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.035 0 O-C-N 125.583 1.802 . . . . 1.0700000000000001 114.681 -177.909 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . 0.456 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 47.6 p30 163.1 -151.33 0.0 OUTLIER 'General case' 0 CA--C 1.512 -0.482 0 C-N-CA 123.609 0.763 . . . . 1.1299999999999999 109.013 176.356 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -78.91 -9.75 59.6 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 123.244 0.34 . . . . 2.2599999999999998 111.288 -177.215 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -117.31 -58.06 2.08 Favored 'General case' 0 C--N 1.326 -0.454 0 O-C-N 122.237 -0.289 . . . . 1.23 110.292 -178.679 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.412 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 138.89 16.6 0.58 Allowed Glycine 0 N--CA 1.445 -0.748 0 C-N-CA 120.593 -0.813 . . . . 0.25 113.321 -177.922 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.582 ' HG2' HG23 ' B' ' 17' ' ' VAL . 0.8 OUTLIER -76.29 150.52 36.94 Favored 'General case' 0 CA--C 1.509 -0.603 0 CA-C-N 118.02 0.91 . . . . 0.88 109.837 177.406 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.693 HG22 HD11 ' B' ' 46' ' ' LEU . 54.3 t -106.73 96.87 4.98 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.29 0 N-CA-C 107.436 -1.32 . . . . 1.99 107.436 171.32 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.565 HG23 ' HG2' ' B' ' 15' ' ' ARG . 62.2 t -68.65 100.94 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.825 0 CA-C-N 115.366 -0.834 . . . . 1.0600000000000001 110.06 -173.771 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.686 HG22 HD12 ' A' ' 22' ' ' ILE . 8.0 mt -93.83 114.9 64.3 Favored Pre-proline 0 N--CA 1.446 -0.641 0 CA-C-N 115.603 -0.726 . . . . 1.5600000000000001 111.053 -177.171 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.54 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 30.9 Cg_exo -44.73 143.87 3.87 Favored 'Trans proline' 0 CA--C 1.513 -0.536 0 C-N-CA 123.403 2.736 . . . . 0.34999999999999998 113.137 171.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.817 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -59.38 -15.82 19.02 Favored 'General case' 0 C--O 1.214 -0.797 0 CA-C-N 115.258 -0.883 . . . . 2.1299999999999999 111.363 178.185 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.54 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 10.0 pt-20 -67.86 -21.06 65.19 Favored 'General case' 0 C--O 1.236 0.348 0 N-CA-C 111.63 0.233 . . . . 1.3200000000000001 111.63 -177.51 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.686 HD12 HG22 ' A' ' 18' ' ' ILE . 5.0 mp -87.68 -49.16 14.8 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.369 0 N-CA-C 107.842 -1.17 . . . . 1.0800000000000001 107.842 -179.414 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . 0.64 ' HD3' ' N ' ' A' ' 24' ' ' ARG . 0.0 OUTLIER -51.69 -34.5 38.8 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-O 121.768 0.794 . . . . 2.02 109.769 168.296 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.64 ' N ' ' HD3' ' A' ' 23' ' ' ARG . 9.3 ttm180 -60.99 -51.89 67.32 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 114.771 -1.104 . . . . 3.3999999999999999 110.943 177.506 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 27.5 m -65.19 -27.82 68.96 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-O 121.406 0.622 . . . . 1.1499999999999999 110.587 175.187 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.852 ' HB3' HG13 ' A' ' 28' ' ' ILE . 2.3 mm? -65.01 -18.99 65.77 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.405 -0.816 . . . . 1.1599999999999999 111.211 175.375 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.508 ' HB2' ' O ' ' A' ' 26' ' ' LEU . 5.7 mpt_? 71.42 14.72 6.35 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 123.437 0.695 . . . . 3.6800000000000002 111.06 -174.307 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.852 HG13 ' HB3' ' A' ' 26' ' ' LEU . 2.9 mt -109.4 -157.21 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 CA-C-N 115.773 -0.649 . . . . 1.1000000000000001 109.647 -175.71 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.685 ' H ' HG23 ' A' ' 28' ' ' ILE . 0.2 OUTLIER -161.79 -153.79 0.3 Allowed 'General case' 0 C--N 1.325 -0.494 0 C-N-CA 123.026 0.53 . . . . 3.0699999999999998 110.298 -176.211 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . 0.419 ' H ' ' HB2' ' A' ' 29' ' ' ARG . 2.8 mp0 -71.5 44.79 0.1 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 122.097 0.951 . . . . 1.23 111.516 178.039 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.549 ' CA ' HD13 ' B' ' 10' ' ' ILE . . . -161.36 33.87 0.38 Allowed Glycine 0 N--CA 1.441 -0.996 0 CA-C-N 114.331 -1.304 . . . . 0.35999999999999999 110.496 177.656 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.445 ' HA ' ' HD3' ' A' ' 33' ' ' PRO . 29.2 t0 -94.45 119.4 66.44 Favored Pre-proline 0 C--N 1.327 -0.391 0 CA-C-N 115.168 -0.516 . . . . 1.26 109.753 176.453 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.604 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 3.3 Cg_endo -88.01 63.93 3.5 Favored 'Trans proline' 0 N--CA 1.452 -0.956 0 C-N-CA 123.916 3.077 . . . . 1.3 113.957 -177.214 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.488 HD11 ' H ' ' A' ' 34' ' ' LEU . 0.9 OUTLIER -64.66 154.54 36.21 Favored 'General case' 0 C--N 1.292 -1.924 0 C-N-CA 118.328 -1.349 . . . . 1.21 111.841 -177.128 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.753 ' O ' ' HA ' ' A' ' 46' ' ' LEU . 35.0 tt0 -109.4 113.5 26.37 Favored 'General case' 0 CA--C 1.494 -1.175 0 CA-C-N 113.369 -1.741 . . . . 1.1200000000000001 108.291 -174.437 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.838 HG13 HD22 ' A' ' 46' ' ' LEU . 2.7 mp -84.4 109.49 17.74 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 O-C-N 124.143 0.902 . . . . 1.1599999999999999 109.647 -178.836 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' PHE . . . . . 0.734 ' HD1' ' HA ' ' B' ' 3' ' ' ALA . 0.6 OUTLIER -149.31 121.48 8.33 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-O 121.228 0.537 . . . . 2.0099999999999998 109.878 175.771 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.526 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 1.9 p -80.38 135.86 24.49 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.047 0 CA-C-O 121.208 0.527 . . . . 1.05 110.351 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.461 ' HB3' ' HG3' ' A' ' 40' ' ' ARG . 14.3 t70 -86.08 -40.33 15.84 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 114.99 -1.004 . . . . 1.1100000000000001 111.529 -173.261 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . 0.461 ' HG3' ' HB3' ' A' ' 39' ' ' ASP . 8.3 mtp180 -132.08 -81.44 0.5 Allowed 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 112.788 0.662 . . . . 2.8799999999999999 112.788 -163.061 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -122.19 -65.75 1.09 Allowed 'General case' 0 CA--C 1.507 -0.69 0 CA-C-O 121.581 0.705 . . . . 1.53 109.962 -176.18 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.54 ' O ' ' HA ' ' B' ' 47' ' ' LYS . . . -133.1 12.58 5.02 Favored Glycine 0 N--CA 1.438 -1.213 0 CA-C-N 114.816 -1.084 . . . . 0.34000000000000002 111.638 -178.171 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.558 ' HB3' HG23 ' B' ' 45' ' ' ILE . 0.9 OUTLIER -92.57 105.97 18.04 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 108.757 -0.831 . . . . 1.97 108.757 177.346 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.534 ' CG1' HG21 ' A' ' 36' ' ' ILE . 2.4 t -89.67 131.24 37.43 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 N-CA-C 109.29 -0.633 . . . . 1.0600000000000001 109.29 177.764 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.825 HG13 HG13 ' B' ' 45' ' ' ILE . 1.6 mp -108.85 116.07 51.02 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 N-CA-C 108.054 -1.091 . . . . 1.01 108.054 -176.028 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 1.056 HD13 HD13 ' B' ' 46' ' ' LEU . 0.7 OUTLIER -106.35 117.66 34.62 Favored 'General case' 0 C--N 1.316 -0.86 0 O-C-N 123.883 0.74 . . . . 1.1299999999999999 109.402 178.418 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.728 ' HD2' ' HB3' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -129.49 143.82 51.0 Favored 'General case' 0 C--O 1.214 -0.773 0 C-N-CA 119.265 -0.974 . . . . 1.25 112.597 178.752 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.695 ' HG3' ' HG2' ' A' ' 51' ' ' PRO . 3.0 ptmt -39.86 -12.82 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.288 0 N-CA-C 117.833 2.531 . . . . 1.0900000000000001 117.833 -169.921 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . 0.604 ' HB3' ' HB2' ' A' ' 33' ' ' PRO . 27.9 t80 70.63 -57.11 0.59 Allowed 'General case' 0 N--CA 1.478 0.952 0 N-CA-C 113.437 0.903 . . . . 2.1400000000000001 113.437 175.242 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 19.0 m -52.88 -52.64 63.05 Favored Pre-proline 0 CA--C 1.54 0.595 0 CA-C-N 115.644 -0.707 . . . . 1.95 111.951 -174.46 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.695 ' HG2' ' HG3' ' A' ' 48' ' ' LYS . 75.2 Cg_endo -90.55 10.65 2.87 Favored 'Trans proline' 0 C--N 1.35 0.618 0 C-N-CA 122.246 1.964 . . . . 0.59999999999999998 111.726 168.615 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.402 HG13 ' C ' ' A' ' 51' ' ' PRO . 1.0 OUTLIER . . . . . 0 CA--C 1.538 0.511 0 CA-C-N 115.261 -0.882 . . . . 1.4199999999999999 109.726 -175.565 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 3' ' ' ALA . . . . . 0.734 ' HA ' ' HD1' ' A' ' 37' ' ' PHE . . . . . . . . 0 N--CA 1.462 0.167 0 CA-C-O 121.615 0.721 . . . . 1.1000000000000001 110.985 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 4' ' ' THR . . . . . 0.535 ' OG1' ' HA ' ' A' ' 37' ' ' PHE . 12.5 p -80.66 -45.74 16.71 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.354 -0.839 . . . . 0.97999999999999998 111.944 -176.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 71.2 47.93 34.31 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 121.031 -0.604 . . . . 0.33000000000000002 112.911 174.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 6' ' ' ILE . . . . . 0.798 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.1 tp -105.76 107.33 22.38 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 N-CA-C 109.263 -0.643 . . . . 1.1000000000000001 109.263 175.443 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . 0.6 HG21 ' CD1' ' A' ' 49' ' ' TYR . 37.6 t -77.96 134.84 27.47 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.842 0 CA-C-N 115.627 -0.715 . . . . 1.0800000000000001 110.412 -178.838 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 1.4 tpp180 -131.04 116.63 18.04 Favored 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 107.018 -1.475 . . . . 2.3599999999999999 107.018 177.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 9' ' ' ARG . . . . . 0.434 ' C ' HD12 ' B' ' 10' ' ' ILE . 13.9 ttt180 -79.03 103.45 8.98 Favored 'General case' 0 CA--C 1.505 -0.753 0 N-CA-C 108.381 -0.97 . . . . 3.2000000000000002 108.381 174.53 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 10' ' ' ILE . . . . . 0.592 ' O ' ' HB3' ' B' ' 11' ' ' ASP . 0.3 OUTLIER -9.93 -106.15 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 O-C-N 125.895 1.997 . . . . 1.0700000000000001 114.845 -176.599 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . 0.592 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 3.2 p-10 165.58 -164.42 0.01 OUTLIER 'General case' 0 CA--C 1.514 -0.405 0 N-CA-C 107.628 -1.249 . . . . 1.1799999999999999 107.628 178.842 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 24.3 t70 -72.58 -10.63 60.02 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.012 0.434 . . . . 2.3900000000000001 111.051 -179.014 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 13' ' ' LEU . . . . . 0.402 ' H ' ' CG ' ' B' ' 11' ' ' ASP . 2.4 tm? -108.47 -62.02 1.52 Allowed 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.4 -0.364 . . . . 1.1000000000000001 110.922 -179.337 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 139.34 21.57 0.39 Allowed Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 120.799 -0.715 . . . . 0.23000000000000001 112.0 -177.246 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 15' ' ' ARG . . . . . 0.565 ' HG2' HG23 ' A' ' 17' ' ' VAL . 1.7 mpt_? -75.44 150.12 38.36 Favored 'General case' 0 CA--C 1.505 -0.771 0 CA-C-O 121.617 0.723 . . . . 1.3899999999999999 110.394 177.527 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 16' ' ' VAL . . . . . 0.794 HG22 HD11 ' A' ' 46' ' ' LEU . 61.4 t -108.18 92.74 2.17 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 N-CA-C 107.487 -1.301 . . . . 1.97 107.487 167.267 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 17' ' ' VAL . . . . . 0.582 HG23 ' HG2' ' A' ' 15' ' ' ARG . 46.8 t -67.34 98.54 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.79 0 CA-C-N 115.59 -0.732 . . . . 1.0600000000000001 109.99 -173.133 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . 0.412 ' HB ' ' O ' ' A' ' 14' ' ' GLY . 8.7 mt -92.19 112.8 56.84 Favored Pre-proline 0 N--CA 1.445 -0.677 0 CA-C-N 115.415 -0.811 . . . . 1.6100000000000001 110.819 -177.842 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 19' ' ' PRO . . . . . 0.571 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 71.0 Cg_exo -49.29 147.2 12.22 Favored 'Trans proline' 0 N--CA 1.458 -0.581 0 C-N-CA 123.23 2.62 . . . . 0.33000000000000002 112.669 173.043 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 20' ' ' LYS . . . . . 0.97 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -64.81 -14.86 60.66 Favored 'General case' 0 C--O 1.211 -0.932 0 CA-C-N 115.387 -0.824 . . . . 2.3199999999999998 111.369 -177.793 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . 0.571 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 1.1 pm0 -63.15 -23.88 67.64 Favored 'General case' 0 N--CA 1.47 0.54 0 N-CA-C 112.201 0.445 . . . . 1.9199999999999999 112.201 176.71 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 5.3 mp -87.01 -50.34 14.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 108.032 -1.099 . . . . 1.24 108.032 -178.357 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 23' ' ' ARG . . . . . 0.541 ' NE ' ' HA ' ' B' ' 29' ' ' ARG . 0.0 OUTLIER -56.08 -27.97 55.77 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.098 -0.956 . . . . 1.8500000000000001 110.061 170.497 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 24' ' ' ARG . . . . . 0.407 ' HB3' ' HA ' ' B' ' 21' ' ' GLU . 8.2 ttm180 -64.13 -53.2 53.33 Favored 'General case' 0 CA--C 1.507 -0.687 0 CA-C-N 115.23 -0.895 . . . . 3.6899999999999999 110.903 173.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 28.3 m -67.06 -22.41 65.86 Favored 'General case' 0 N--CA 1.445 -0.698 0 CA-C-O 121.614 0.721 . . . . 1.1599999999999999 110.22 178.485 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . 0.574 ' HB3' HG13 ' B' ' 28' ' ' ILE . 1.9 mm? -67.83 -18.85 64.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.08 -0.963 . . . . 1.1100000000000001 110.655 173.489 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 27' ' ' ARG . . . . . 0.442 ' HB2' ' O ' ' B' ' 26' ' ' LEU . 7.2 mpt_? 68.52 21.0 8.27 Favored 'General case' 0 C--O 1.234 0.245 0 C-N-CA 123.517 0.727 . . . . 3.77 110.475 -174.367 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 28' ' ' ILE . . . . . 0.875 HG22 ' H ' ' B' ' 29' ' ' ARG . 6.6 mt -116.91 -163.67 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.462 -0.79 . . . . 1.2 109.434 -177.669 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 29' ' ' ARG . . . . . 0.875 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -156.06 -151.38 0.33 Allowed 'General case' 0 C--N 1.32 -0.681 0 C-N-CA 122.338 0.255 . . . . 2.7599999999999998 110.723 -173.942 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 30' ' ' GLU . . . . . 0.409 ' C ' HD12 ' A' ' 10' ' ' ILE . 0.7 OUTLIER -73.43 36.74 0.09 Allowed 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 122.166 0.984 . . . . 1.1799999999999999 111.669 -179.522 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 31' ' ' GLY . . . . . 0.53 ' H ' ' C ' ' B' ' 29' ' ' ARG . . . -154.12 39.63 0.67 Allowed Glycine 0 N--CA 1.434 -1.436 0 CA-C-N 114.107 -1.406 . . . . 0.34999999999999998 110.026 175.105 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 32' ' ' ASP . . . . . 0.467 ' HA ' ' HD3' ' B' ' 33' ' ' PRO . 9.5 t0 -95.96 119.66 64.33 Favored Pre-proline 0 C--N 1.325 -0.493 0 CA-C-O 121.256 0.55 . . . . 1.29 110.049 175.147 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 33' ' ' PRO . . . . . 0.659 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 4.4 Cg_endo -87.07 76.35 2.27 Favored 'Trans proline' 0 C--O 1.205 -1.145 0 C-N-CA 123.547 2.831 . . . . 1.1000000000000001 113.268 -178.905 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . 0.938 HD12 HG22 ' A' ' 10' ' ' ILE . 0.1 OUTLIER -72.12 150.5 43.8 Favored 'General case' 0 C--N 1.284 -2.249 0 C-N-CA 117.776 -1.569 . . . . 1.1699999999999999 111.343 -178.963 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 35' ' ' GLU . . . . . 0.753 ' O ' ' HA ' ' B' ' 46' ' ' LEU . 42.7 tt0 -105.1 115.32 30.07 Favored 'General case' 0 CA--C 1.492 -1.264 0 CA-C-N 114.067 -1.424 . . . . 1.1000000000000001 107.822 -179.143 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 36' ' ' ILE . . . . . 0.903 HG13 HD23 ' B' ' 46' ' ' LEU . 3.1 mp -88.19 108.8 19.03 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 O-C-N 124.168 0.918 . . . . 1.3200000000000001 109.336 -178.443 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 37' ' ' PHE . . . . . 0.494 ' HA ' ' OG1' ' A' ' 4' ' ' THR . 12.3 p90 -149.74 126.41 11.01 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 116.159 -0.473 . . . . 2.0299999999999998 110.064 175.142 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 38' ' ' VAL . . . . . 0.508 ' HA ' ' HA ' ' B' ' 44' ' ' VAL . 0.8 OUTLIER -80.23 138.57 19.59 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-O 121.29 0.567 . . . . 0.89000000000000001 110.571 -179.561 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 39' ' ' ASP . . . . . 0.685 ' HB3' ' HG3' ' B' ' 40' ' ' ARG . 8.1 t70 -80.9 -46.13 15.69 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 114.751 -1.113 . . . . 1.1399999999999999 110.577 -177.726 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 40' ' ' ARG . . . . . 0.685 ' HG3' ' HB3' ' B' ' 39' ' ' ASP . 23.8 mtp180 -133.33 -92.53 0.35 Allowed 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.928 -0.578 . . . . 3.3700000000000001 112.34 -166.55 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 41' ' ' ASP . . . . . 0.456 ' H ' ' HB2' ' B' ' 40' ' ' ARG . 18.4 t70 -102.3 -75.59 0.6 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.314 0.578 . . . . 1.3200000000000001 110.395 -176.881 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 42' ' ' GLY . . . . . 0.512 ' O ' ' HA ' ' A' ' 47' ' ' LYS . . . -124.99 18.86 6.98 Favored Glycine 0 N--CA 1.44 -1.091 0 CA-C-N 115.376 -0.829 . . . . 0.35999999999999999 112.201 -179.341 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 43' ' ' GLU . . . . . 0.49 ' HB3' HG23 ' A' ' 45' ' ' ILE . 1.3 mt-10 -93.52 104.91 17.01 Favored 'General case' 0 CA--C 1.51 -0.595 0 N-CA-C 108.932 -0.766 . . . . 2.0699999999999998 108.932 176.533 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 44' ' ' VAL . . . . . 0.508 ' HA ' ' HA ' ' B' ' 38' ' ' VAL . 2.2 t -89.53 131.24 37.31 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 N-CA-C 109.441 -0.577 . . . . 1.02 109.441 177.194 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 45' ' ' ILE . . . . . 0.825 HG13 HG13 ' A' ' 45' ' ' ILE . 1.7 mp -108.04 117.5 53.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.463 0 N-CA-C 108.031 -1.1 . . . . 0.95999999999999996 108.031 -176.937 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 46' ' ' LEU . . . . . 1.056 HD13 HD13 ' A' ' 46' ' ' LEU . 1.6 mt -108.53 117.24 33.66 Favored 'General case' 0 C--N 1.317 -0.813 0 O-C-N 123.9 0.75 . . . . 1.05 109.776 178.391 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 47' ' ' LYS . . . . . 0.54 ' HA ' ' O ' ' A' ' 42' ' ' GLY . 0.0 OUTLIER -130.15 147.34 51.87 Favored 'General case' 0 C--O 1.214 -0.8 0 C-N-CA 119.199 -1.0 . . . . 1.3899999999999999 113.129 -179.919 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 48' ' ' LYS . . . . . 0.571 ' HG3' ' CG ' ' B' ' 51' ' ' PRO . 3.5 ptmt -44.83 -7.91 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.409 0 N-CA-C 118.065 2.617 . . . . 1.1899999999999999 118.065 -168.781 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 49' ' ' TYR . . . . . 0.687 ' CD1' HG21 ' A' ' 7' ' ' VAL . 32.5 t80 69.72 -57.5 0.55 Allowed 'General case' 0 N--CA 1.48 1.051 0 N-CA-C 113.727 1.01 . . . . 2.1000000000000001 113.727 173.506 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 50' ' ' SER . . . . . 0.657 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 9.1 t -51.24 -56.28 21.53 Favored Pre-proline 0 CA--C 1.539 0.528 0 CA-C-N 115.932 -0.576 . . . . 1.77 111.134 -173.484 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 51' ' ' PRO . . . . . 0.657 ' HD3' ' HB3' ' B' ' 50' ' ' SER . 59.1 Cg_endo -87.21 8.24 4.43 Favored 'Trans proline' 0 C--N 1.351 0.666 0 C-N-CA 122.174 1.916 . . . . 0.59999999999999998 111.968 170.396 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 52' ' ' ILE . . . . . . . . . . . . . 1.6 mt . . . . . 0 CA--C 1.534 0.341 0 CA-C-N 115.137 -0.938 . . . . 1.3899999999999999 108.863 -175.002 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . 0.434 ' HA ' ' HB2' ' B' ' 37' ' ' PHE . . . . . . . . 0 C--O 1.229 0.02 0 CA-C-O 121.583 0.706 . . . . 1.1299999999999999 111.639 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.552 ' OG1' ' HA ' ' B' ' 37' ' ' PHE . 11.8 p -81.21 -35.1 31.73 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.579 -0.737 . . . . 1.0900000000000001 111.647 -179.297 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . 0.511 ' H ' ' CB ' ' B' ' 37' ' ' PHE . . . 57.51 47.67 86.53 Favored Glycine 0 N--CA 1.445 -0.73 0 CA-C-N 115.735 -0.666 . . . . 0.32000000000000001 112.68 173.958 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.68 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.8 tp -105.9 104.06 16.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 108.807 -0.812 . . . . 1.0900000000000001 108.807 175.22 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.653 HG22 ' CG ' ' B' ' 49' ' ' TYR . 52.9 t -74.9 135.17 27.88 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.873 0 CA-C-N 115.522 -0.763 . . . . 1.1299999999999999 109.943 179.481 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.502 ' HB3' ' CD1' ' B' ' 36' ' ' ILE . 1.7 tpp180 -131.84 117.13 18.12 Favored 'General case' 0 N--CA 1.431 -1.415 0 N-CA-C 106.899 -1.519 . . . . 2.6099999999999999 106.899 -177.6 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' ARG . . . . . 0.5 ' HA ' ' O ' ' B' ' 32' ' ' ASP . 0.0 OUTLIER -78.44 101.74 7.46 Favored 'General case' 0 C--N 1.314 -0.954 0 N-CA-C 107.924 -1.139 . . . . 3.4100000000000001 107.924 174.913 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.738 HG22 HD13 ' B' ' 34' ' ' LEU . 0.2 OUTLIER -5.63 -105.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.195 0 O-C-N 125.445 1.715 . . . . 1.0700000000000001 114.587 -176.753 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . 0.608 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 2.4 p-10 165.99 -162.49 0.01 OUTLIER 'General case' 0 CA--C 1.513 -0.472 0 N-CA-C 107.935 -1.135 . . . . 1.1299999999999999 107.935 177.611 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 30.4 m-20 -76.45 -6.7 52.86 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 120.744 0.307 . . . . 2.2599999999999998 111.301 -178.255 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -114.75 -59.16 2.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.661 -0.245 . . . . 1.23 110.996 178.589 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.442 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 140.1 13.78 0.58 Allowed Glycine 0 N--CA 1.448 -0.5 0 C-N-CA 120.432 -0.889 . . . . 0.25 113.096 -178.805 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.722 ' HG2' HG23 ' B' ' 17' ' ' VAL . 0.9 OUTLIER -77.43 154.98 32.1 Favored 'General case' 0 CA--C 1.501 -0.933 0 N-CA-C 109.231 -0.655 . . . . 0.88 109.231 176.011 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.908 HG13 HD11 ' B' ' 46' ' ' LEU . 1.5 m -109.88 112.13 39.17 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.59 0 N-CA-C 107.355 -1.35 . . . . 1.99 107.355 166.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.667 HG23 ' HG2' ' B' ' 15' ' ' ARG . 59.6 t -73.16 95.94 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.427 -1.588 0 CA-C-N 114.449 -1.25 . . . . 1.0600000000000001 109.657 -174.875 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.618 HG22 HD12 ' A' ' 22' ' ' ILE . 11.0 mt -86.28 110.92 35.13 Favored Pre-proline 0 N--CA 1.446 -0.641 0 CA-C-N 115.218 -0.901 . . . . 1.5600000000000001 110.251 -179.588 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.567 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 67.5 Cg_exo -47.37 144.51 9.67 Favored 'Trans proline' 0 N--CA 1.459 -0.535 0 C-N-CA 123.115 2.544 . . . . 0.34999999999999998 112.261 173.594 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.942 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -59.95 -15.29 20.78 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.775 -0.648 . . . . 2.1299999999999999 111.706 -178.493 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.567 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 12.8 pt-20 -67.6 -19.79 65.29 Favored 'General case' 0 C--O 1.237 0.437 0 N-CA-C 112.062 0.393 . . . . 1.3200000000000001 112.062 -178.723 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.618 HD12 HG22 ' A' ' 18' ' ' ILE . 4.8 mp -87.43 -44.45 16.04 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 N-CA-C 108.125 -1.065 . . . . 1.0800000000000001 108.125 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . 0.668 ' HA ' ' HB2' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -60.68 -30.52 69.97 Favored 'General case' 0 CA--C 1.521 -0.166 0 CA-C-O 121.883 0.849 . . . . 2.02 109.093 171.208 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 63.2 ttt180 -61.33 -51.49 68.61 Favored 'General case' 0 N--CA 1.441 -0.894 0 CA-C-N 114.619 -1.173 . . . . 3.3999999999999999 110.455 176.187 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 22.7 m -66.68 -21.94 66.09 Favored 'General case' 0 CA--C 1.535 0.392 0 CA-C-O 121.527 0.679 . . . . 1.1499999999999999 110.654 174.094 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.865 ' HB3' HG13 ' A' ' 28' ' ' ILE . 2.3 mm? -71.94 -18.14 62.03 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.964 -0.562 . . . . 1.1599999999999999 110.605 174.201 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.435 ' HB2' ' O ' ' A' ' 26' ' ' LEU . 9.0 mpt_? 66.21 23.18 10.9 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-N 116.006 -0.543 . . . . 3.6800000000000002 110.625 -175.069 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.865 HG13 ' HB3' ' A' ' 26' ' ' LEU . 2.6 mt -113.92 -154.61 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 115.865 -0.607 . . . . 1.1000000000000001 109.91 -178.44 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.647 ' H ' HG23 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -162.34 -156.3 0.41 Allowed 'General case' 0 C--N 1.321 -0.653 0 C-N-CA 122.686 0.394 . . . . 3.0699999999999998 110.674 -173.951 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . 0.439 ' H ' ' HB2' ' A' ' 29' ' ' ARG . 1.8 mp0 -74.9 44.1 0.22 Allowed 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 122.132 0.968 . . . . 1.23 111.025 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.529 ' CA ' HD13 ' B' ' 10' ' ' ILE . . . -156.98 26.3 0.5 Allowed Glycine 0 N--CA 1.439 -1.137 0 CA-C-N 114.055 -1.43 . . . . 0.35999999999999999 110.999 176.757 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.428 ' HA ' ' HD3' ' A' ' 33' ' ' PRO . 9.2 t0 -85.7 122.5 73.12 Favored Pre-proline 0 C--N 1.327 -0.379 0 CA-C-O 121.108 0.48 . . . . 1.26 110.111 176.321 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.757 ' HG2' ' HG ' ' A' ' 50' ' ' SER . 3.8 Cg_endo -91.08 62.81 1.28 Allowed 'Trans proline' 0 N--CA 1.451 -0.986 0 C-N-CA 123.855 3.037 . . . . 1.3 114.253 -175.684 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.886 HD12 HG23 ' B' ' 10' ' ' ILE . 0.0 OUTLIER -61.22 153.97 24.73 Favored 'General case' 0 C--N 1.298 -1.646 0 C-N-CA 118.884 -1.127 . . . . 1.21 112.046 -178.536 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.764 ' HB3' ' HB3' ' A' ' 47' ' ' LYS . 39.4 tt0 -107.84 113.83 27.34 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 112.938 -1.937 . . . . 1.1200000000000001 107.392 -176.253 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.81 ' HB ' HG23 ' B' ' 6' ' ' ILE . 2.4 mp -86.32 107.34 16.53 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.058 0 N-CA-C 109.136 -0.69 . . . . 1.1599999999999999 109.136 -179.481 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' PHE . . . . . 0.494 ' CB ' ' H ' ' B' ' 5' ' ' GLY . 2.2 p90 -149.17 120.88 8.07 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-O 121.44 0.638 . . . . 2.0099999999999998 109.937 176.169 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.593 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 1.5 p -80.5 137.56 21.25 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.987 0 CA-C-N 115.803 -0.635 . . . . 1.05 110.555 -178.126 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.565 ' HB3' ' HG2' ' A' ' 40' ' ' ARG . 7.5 t70 -76.22 -40.91 50.95 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 114.831 -1.077 . . . . 1.1100000000000001 111.669 -171.16 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . 0.565 ' HG2' ' HB3' ' A' ' 39' ' ' ASP . 0.3 OUTLIER -150.62 -74.77 0.15 Allowed 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 112.859 0.689 . . . . 2.8799999999999999 112.859 -168.753 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -106.29 -74.16 0.66 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.171 0.51 . . . . 1.53 111.431 -175.688 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.495 ' HA3' HD11 ' B' ' 26' ' ' LEU . . . -135.82 12.74 4.21 Favored Glycine 0 N--CA 1.443 -0.866 0 CA-C-N 115.123 -0.944 . . . . 0.34000000000000002 111.891 -175.738 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.51 ' O ' HG21 ' A' ' 38' ' ' VAL . 2.5 pm0 -92.82 106.77 18.69 Favored 'General case' 0 N--CA 1.446 -0.66 0 N-CA-C 110.051 -0.352 . . . . 1.97 110.051 175.183 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.6 HG13 HG22 ' A' ' 36' ' ' ILE . 2.5 t -87.57 134.84 26.78 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 N-CA-C 109.259 -0.645 . . . . 1.0600000000000001 109.259 178.356 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.729 HG13 HG13 ' B' ' 45' ' ' ILE . 1.5 mp -110.69 118.11 56.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 N-CA-C 108.491 -0.929 . . . . 1.01 108.491 -178.077 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.939 HD13 HD13 ' B' ' 46' ' ' LEU . 6.8 mt -103.3 119.05 38.13 Favored 'General case' 0 C--N 1.32 -0.715 0 O-C-N 124.229 0.956 . . . . 1.1299999999999999 109.906 -179.541 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.764 ' HB3' ' HB3' ' A' ' 35' ' ' GLU . 16.6 ttmt -121.2 130.2 53.58 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-N 115.434 -0.803 . . . . 1.25 111.905 -170.704 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.576 ' HG3' ' HG2' ' A' ' 51' ' ' PRO . 3.2 ptmt -45.23 -12.97 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 115.937 1.828 . . . . 1.0900000000000001 115.937 -174.313 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . 0.675 ' CD1' HG22 ' B' ' 7' ' ' VAL . 34.4 t80 68.36 -56.7 0.5 Allowed 'General case' 0 N--CA 1.473 0.69 0 C-N-CA 124.623 1.169 . . . . 2.1400000000000001 114.046 174.224 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.757 ' HG ' ' HG2' ' A' ' 33' ' ' PRO . 36.1 m -53.41 -48.08 93.96 Favored Pre-proline 0 CA--C 1.542 0.636 0 CA-C-N 115.683 -0.69 . . . . 1.95 112.052 -173.691 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.576 ' HG2' ' HG3' ' A' ' 48' ' ' LYS . 60.6 Cg_endo -93.54 10.82 2.04 Favored 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 122.272 1.981 . . . . 0.59999999999999998 111.779 167.924 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.233 0.218 0 N-CA-C 108.304 -0.998 . . . . 1.4199999999999999 108.304 -171.35 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 3' ' ' ALA . . . . . 0.418 ' HA ' ' HD2' ' A' ' 37' ' ' PHE . . . . . . . . 0 N--CA 1.458 -0.074 0 CA-C-O 121.557 0.694 . . . . 1.1000000000000001 111.766 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 4' ' ' THR . . . . . 0.471 ' OG1' ' HA ' ' A' ' 37' ' ' PHE . 12.0 p -84.67 -34.94 22.91 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.63 -0.714 . . . . 0.97999999999999998 111.633 -178.221 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 5' ' ' GLY . . . . . 0.494 ' H ' ' CB ' ' A' ' 37' ' ' PHE . . . 58.43 48.07 86.15 Favored Glycine 0 N--CA 1.449 -0.487 0 CA-C-N 115.601 -0.727 . . . . 0.33000000000000002 113.052 174.655 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 6' ' ' ILE . . . . . 0.81 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.4 tp -105.23 104.34 16.78 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 N-CA-C 109.224 -0.658 . . . . 1.1000000000000001 109.224 175.817 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . 0.675 HG22 ' CD1' ' A' ' 49' ' ' TYR . 27.5 t -74.79 134.12 30.1 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.841 0 CA-C-N 115.462 -0.79 . . . . 1.0800000000000001 110.083 -179.714 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . 0.522 ' HD3' ' N ' ' B' ' 9' ' ' ARG . 0.3 OUTLIER -131.97 120.06 21.94 Favored 'General case' 0 N--CA 1.441 -0.918 0 N-CA-C 106.862 -1.532 . . . . 2.3599999999999999 106.862 179.132 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 9' ' ' ARG . . . . . 0.522 ' N ' ' HD3' ' B' ' 8' ' ' ARG . 41.9 ttp180 -78.95 103.27 8.78 Favored 'General case' 0 N--CA 1.441 -0.903 0 N-CA-C 108.667 -0.864 . . . . 3.2000000000000002 108.667 174.481 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 10' ' ' ILE . . . . . 0.886 HG23 HD12 ' A' ' 34' ' ' LEU . 0.3 OUTLIER -7.59 -100.38 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 O-C-N 125.66 1.85 . . . . 1.0700000000000001 114.189 -175.31 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . 0.58 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 13.5 p-10 161.54 -157.15 0.0 OUTLIER 'General case' 0 CA--C 1.505 -0.767 0 N-CA-C 107.889 -1.152 . . . . 1.1799999999999999 107.889 175.088 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -88.64 22.69 2.51 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 120.688 0.28 . . . . 2.3900000000000001 111.214 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 13' ' ' LEU . . . . . 0.404 ' C ' HD12 ' B' ' 13' ' ' LEU . 2.3 tm? -137.86 -55.21 0.67 Allowed 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 109.862 -0.421 . . . . 1.1000000000000001 109.862 175.564 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 14' ' ' GLY . . . . . 0.417 ' O ' ' HB ' ' A' ' 18' ' ' ILE . . . 131.97 11.85 2.0 Favored Glycine 0 N--CA 1.444 -0.8 0 C-N-CA 120.896 -0.669 . . . . 0.23000000000000001 112.491 -177.83 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 15' ' ' ARG . . . . . 0.667 ' HG2' HG23 ' A' ' 17' ' ' VAL . 0.9 OUTLIER -74.11 152.14 39.95 Favored 'General case' 0 CA--C 1.504 -0.809 0 CA-C-O 121.445 0.641 . . . . 1.3899999999999999 109.511 175.47 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 16' ' ' VAL . . . . . 0.683 HG11 HG11 ' A' ' 16' ' ' VAL . 0.2 OUTLIER -109.06 105.79 19.48 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 N-CA-C 107.697 -1.224 . . . . 1.97 107.697 167.641 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 17' ' ' VAL . . . . . 0.722 HG23 ' HG2' ' A' ' 15' ' ' ARG . 41.0 t -72.63 95.03 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.168 0 CA-C-N 114.724 -1.125 . . . . 1.0600000000000001 109.827 -173.505 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . 0.582 HG21 HD12 ' B' ' 22' ' ' ILE . 11.7 mt -87.56 112.56 49.29 Favored Pre-proline 0 N--CA 1.445 -0.724 0 CA-C-N 115.436 -0.802 . . . . 1.6100000000000001 110.503 -179.689 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 19' ' ' PRO . . . . . 0.644 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 84.9 Cg_exo -49.12 146.69 12.24 Favored 'Trans proline' 0 N--CA 1.459 -0.534 0 C-N-CA 123.045 2.497 . . . . 0.33000000000000002 112.612 173.2 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 20' ' ' LYS . . . . . 0.86 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -60.79 -15.29 28.3 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.76 -0.655 . . . . 2.3199999999999998 111.956 -179.357 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . 0.644 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 11.5 pt-20 -65.48 -21.12 66.6 Favored 'General case' 0 CA--C 1.536 0.428 0 N-CA-C 112.211 0.449 . . . . 1.9199999999999999 112.211 -179.784 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 22' ' ' ILE . . . . . 0.582 HD12 HG21 ' B' ' 18' ' ' ILE . 5.2 mp -86.76 -48.78 15.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 108.264 -1.013 . . . . 1.24 108.264 179.835 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 23' ' ' ARG . . . . . 0.587 ' HD3' ' N ' ' B' ' 24' ' ' ARG . 0.0 OUTLIER -55.89 -30.28 61.3 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 115.429 -0.805 . . . . 1.8500000000000001 109.258 170.39 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 24' ' ' ARG . . . . . 0.587 ' N ' ' HD3' ' B' ' 23' ' ' ARG . 37.2 ttt180 -62.9 -52.35 63.42 Favored 'General case' 0 N--CA 1.45 -0.444 0 CA-C-N 114.772 -1.104 . . . . 3.6899999999999999 110.858 176.427 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 51.6 m -64.22 -28.45 69.75 Favored 'General case' 0 CA--C 1.53 0.206 0 CA-C-O 121.17 0.509 . . . . 1.1599999999999999 110.811 173.629 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . 0.628 ' HB3' HG13 ' B' ' 28' ' ' ILE . 1.6 mm? -66.21 -18.78 65.56 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.755 -0.657 . . . . 1.1100000000000001 111.315 175.436 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 27' ' ' ARG . . . . . 0.46 ' HB2' ' O ' ' B' ' 26' ' ' LEU . 11.0 mpt_? 68.21 16.22 9.37 Favored 'General case' 0 N--CA 1.467 0.378 0 C-N-CA 123.192 0.597 . . . . 3.77 111.095 -174.608 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 28' ' ' ILE . . . . . 0.913 HG21 ' H ' ' B' ' 29' ' ' ARG . 7.8 mt -109.05 -160.8 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 115.825 -0.625 . . . . 1.2 109.725 -175.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 29' ' ' ARG . . . . . 0.913 ' H ' HG21 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -157.89 -153.84 0.41 Allowed 'General case' 0 C--N 1.328 -0.365 0 C-N-CA 122.386 0.275 . . . . 2.7599999999999998 110.826 -177.691 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 30' ' ' GLU . . . . . 0.437 ' H ' ' HB2' ' B' ' 29' ' ' ARG . 1.9 mp0 -70.57 40.19 0.05 Allowed 'General case' 0 N--CA 1.468 0.466 0 CA-C-O 121.537 0.684 . . . . 1.1799999999999999 112.043 178.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 31' ' ' GLY . . . . . 0.547 ' CA ' HD13 ' A' ' 10' ' ' ILE . . . -155.38 34.09 0.65 Allowed Glycine 0 N--CA 1.437 -1.234 0 CA-C-N 115.097 -0.956 . . . . 0.34999999999999998 111.106 175.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 32' ' ' ASP . . . . . 0.512 ' HB2' HG22 ' B' ' 28' ' ' ILE . 15.9 t0 -93.22 124.59 57.38 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.105 0.479 . . . . 1.29 110.706 176.534 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 33' ' ' PRO . . . . . 0.615 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 3.3 Cg_endo -87.56 75.83 2.16 Favored 'Trans proline' 0 C--O 1.206 -1.09 0 C-N-CA 124.011 3.141 . . . . 1.1000000000000001 113.68 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . 0.738 HD13 HG22 ' A' ' 10' ' ' ILE . 1.0 OUTLIER -71.47 148.79 46.48 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.021 -1.472 . . . . 1.1699999999999999 110.771 179.87 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 35' ' ' GLU . . . . . 0.674 ' O ' ' HA ' ' B' ' 46' ' ' LEU . 43.8 tt0 -103.78 110.74 22.96 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-N 114.417 -1.265 . . . . 1.1000000000000001 107.625 -179.836 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 36' ' ' ILE . . . . . 0.935 HG13 HD21 ' B' ' 46' ' ' LEU . 2.3 mp -85.94 109.27 18.38 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.731 0 O-C-N 124.048 0.842 . . . . 1.3200000000000001 109.236 -178.493 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 37' ' ' PHE . . . . . 0.552 ' HA ' ' OG1' ' A' ' 4' ' ' THR . 14.4 p90 -149.4 123.38 9.39 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 115.832 -0.622 . . . . 2.0299999999999998 109.631 175.561 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 38' ' ' VAL . . . . . 0.603 ' HA ' ' HA ' ' B' ' 44' ' ' VAL . 1.4 p -79.91 136.05 24.26 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 CA-C-O 121.424 0.63 . . . . 0.89000000000000001 110.229 -178.416 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 39' ' ' ASP . . . . . 0.578 ' OD1' ' HD3' ' B' ' 40' ' ' ARG . 12.6 t70 -69.48 -53.9 16.9 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 114.215 -1.357 . . . . 1.1399999999999999 111.244 -173.993 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 40' ' ' ARG . . . . . 0.578 ' HD3' ' OD1' ' B' ' 39' ' ' ASP . 0.0 OUTLIER -139.34 -71.22 0.4 Allowed 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 113.019 0.748 . . . . 3.3700000000000001 113.019 -174.308 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -106.48 -68.42 0.88 Allowed 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 112.089 0.403 . . . . 1.3200000000000001 112.089 -173.153 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 42' ' ' GLY . . . . . 0.439 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -140.94 12.52 2.87 Favored Glycine 0 CA--C 1.501 -0.823 0 C-N-CA 120.71 -0.757 . . . . 0.35999999999999999 111.862 -175.465 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 43' ' ' GLU . . . . . 0.59 ' HA ' ' O ' ' A' ' 46' ' ' LEU . 2.3 pm0 -93.05 104.96 17.12 Favored 'General case' 0 N--CA 1.443 -0.803 0 N-CA-C 109.568 -0.53 . . . . 2.0699999999999998 109.568 174.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 44' ' ' VAL . . . . . 0.603 ' HA ' ' HA ' ' B' ' 38' ' ' VAL . 2.1 t -87.37 131.68 34.58 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 N-CA-C 109.696 -0.483 . . . . 1.02 109.696 179.329 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 45' ' ' ILE . . . . . 0.729 HG13 HG13 ' A' ' 45' ' ' ILE . 1.7 mp -108.29 118.47 55.99 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 N-CA-C 108.414 -0.958 . . . . 0.95999999999999996 108.414 -177.592 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 46' ' ' LEU . . . . . 0.939 HD13 HD13 ' A' ' 46' ' ' LEU . 0.6 OUTLIER -109.9 117.1 32.93 Favored 'General case' 0 C--N 1.318 -0.788 0 O-C-N 123.612 0.57 . . . . 1.05 109.915 178.844 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 47' ' ' LYS . . . . . 0.601 ' HE3' ' HB3' ' B' ' 35' ' ' GLU . 0.0 OUTLIER -130.09 142.45 50.6 Favored 'General case' 0 C--N 1.318 -0.765 0 C-N-CA 119.617 -0.833 . . . . 1.3899999999999999 112.877 -178.332 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 48' ' ' LYS . . . . . 0.547 ' HE2' ' HG3' ' B' ' 51' ' ' PRO . 4.3 ptmt -43.19 -9.2 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.638 0 N-CA-C 118.112 2.634 . . . . 1.1899999999999999 118.112 -168.264 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 49' ' ' TYR . . . . . 0.653 ' CG ' HG22 ' A' ' 7' ' ' VAL . 5.9 t80 68.38 -52.75 0.55 Allowed 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 114.067 1.136 . . . . 2.1000000000000001 114.067 174.326 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 50' ' ' SER . . . . . 0.612 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 32.2 t -51.55 -57.14 15.49 Favored Pre-proline 0 CA--C 1.535 0.386 0 C-N-CA 122.417 0.287 . . . . 1.77 111.099 -173.55 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 51' ' ' PRO . . . . . 0.612 ' HD3' ' HB3' ' B' ' 50' ' ' SER . 74.8 Cg_endo -85.01 9.07 4.3 Favored 'Trans proline' 0 C--N 1.35 0.652 0 C-N-CA 122.011 1.808 . . . . 0.59999999999999998 111.159 170.174 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 52' ' ' ILE . . . . . . . . . . . . . 1.2 mt . . . . . 0 N--CA 1.449 -0.521 0 CA-C-N 114.814 -1.085 . . . . 1.3899999999999999 108.666 -171.944 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . 0.588 ' HA ' ' HD2' ' B' ' 37' ' ' PHE . . . . . . . . 0 N--CA 1.466 0.359 0 CA-C-O 121.74 0.781 . . . . 1.1299999999999999 111.33 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.788 ' H ' ' HB2' ' B' ' 37' ' ' PHE . 34.4 p -125.97 -35.73 2.44 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 115.504 -0.771 . . . . 1.0900000000000001 111.915 -173.73 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . 0.447 ' H ' ' CB ' ' B' ' 37' ' ' PHE . . . 63.96 45.14 94.79 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.902 -0.666 . . . . 0.32000000000000001 112.893 173.715 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.859 HG22 ' HB ' ' B' ' 36' ' ' ILE . 1.4 tp -104.11 105.2 18.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-O 121.354 0.597 . . . . 1.0900000000000001 109.522 177.985 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.625 HG22 ' CD1' ' B' ' 49' ' ' TYR . 54.5 t -75.02 131.73 34.53 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-N 115.655 -0.702 . . . . 1.1299999999999999 110.415 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.431 ' HG2' ' H ' ' A' ' 17' ' ' VAL . 2.9 tpp180 -127.58 114.6 17.62 Favored 'General case' 0 N--CA 1.434 -1.262 0 N-CA-C 106.522 -1.659 . . . . 2.6099999999999999 106.522 177.781 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' ARG . . . . . 0.483 ' HA ' ' O ' ' B' ' 32' ' ' ASP . 0.6 OUTLIER -78.05 101.36 6.91 Favored 'General case' 0 C--N 1.308 -1.221 0 N-CA-C 107.611 -1.255 . . . . 3.4100000000000001 107.611 174.708 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.597 ' O ' ' HB3' ' A' ' 11' ' ' ASP . 0.3 OUTLIER -7.44 -102.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.941 0 O-C-N 125.763 1.914 . . . . 1.0700000000000001 113.928 -175.385 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . 0.597 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 4.8 p-10 164.77 -159.47 0.0 OUTLIER 'General case' 0 CA--C 1.507 -0.677 0 N-CA-C 108.249 -1.019 . . . . 1.1299999999999999 108.249 175.389 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 31.2 t70 -74.57 -17.84 60.67 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.014 0.435 . . . . 2.2599999999999998 110.96 -179.173 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -103.33 -59.07 1.77 Allowed 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.186 -0.461 . . . . 1.23 110.801 179.779 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.464 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 138.46 18.76 0.54 Allowed Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.214 -0.994 . . . . 0.25 113.211 -179.039 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.735 ' HB3' ' HB3' ' B' ' 15' ' ' ARG . 0.7 OUTLIER -81.01 157.37 25.5 Favored 'General case' 0 CA--C 1.491 -1.317 0 CA-C-N 117.965 0.882 . . . . 0.88 110.031 176.034 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.833 HG23 HG23 ' B' ' 16' ' ' VAL . 17.2 m -107.81 109.81 29.6 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.201 0 N-CA-C 106.945 -1.502 . . . . 1.99 106.945 164.77 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.795 HG21 ' HG2' ' B' ' 15' ' ' ARG . 57.6 t -71.71 94.75 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.433 -1.309 0 CA-C-N 115.091 -0.959 . . . . 1.0600000000000001 109.278 -175.668 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.483 HD11 HD11 ' A' ' 46' ' ' LEU . 9.0 mt -82.37 109.79 17.9 Favored Pre-proline 0 N--CA 1.444 -0.761 0 CA-C-N 115.621 -0.718 . . . . 1.5600000000000001 110.284 179.087 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.633 ' HD3' ' O ' ' A' ' 17' ' ' VAL . 95.8 Cg_exo -51.16 151.42 12.44 Favored 'Trans proline' 0 N--CA 1.454 -0.845 0 C-N-CA 123.053 2.502 . . . . 0.34999999999999998 112.366 174.982 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.797 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -62.34 -25.14 67.74 Favored 'General case' 0 C--O 1.206 -1.194 0 CA-C-N 115.591 -0.731 . . . . 2.1299999999999999 111.763 -176.823 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.3 pm0 -55.49 -25.65 38.19 Favored 'General case' 0 C--O 1.239 0.507 0 N-CA-C 112.854 0.687 . . . . 1.3200000000000001 112.854 -178.447 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.475 HD11 HG21 ' A' ' 18' ' ' ILE . 5.1 mp -88.18 -46.95 15.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 108.404 -0.961 . . . . 1.0800000000000001 108.404 -176.574 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . 0.505 ' NE ' ' HA ' ' A' ' 29' ' ' ARG . 0.0 OUTLIER -61.02 -30.86 70.56 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 115.158 -0.928 . . . . 2.02 109.583 174.744 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 76.7 ttt180 -63.84 -52.11 61.61 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 114.269 -1.332 . . . . 3.3999999999999999 111.011 175.532 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 25.6 m -64.51 -27.99 69.35 Favored 'General case' 0 C--O 1.234 0.268 0 CA-C-O 121.137 0.494 . . . . 1.1499999999999999 110.537 175.377 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.835 ' HB3' HG13 ' A' ' 28' ' ' ILE . 0.8 OUTLIER -65.23 -18.1 65.04 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.534 -0.757 . . . . 1.1599999999999999 111.162 175.225 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.5 ' HB2' ' O ' ' A' ' 26' ' ' LEU . 10.4 mpt_? 70.45 20.28 6.03 Favored 'General case' 0 N--CA 1.466 0.34 0 C-N-CA 123.259 0.624 . . . . 3.6800000000000002 110.529 -174.109 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.835 HG13 ' HB3' ' A' ' 26' ' ' LEU . 2.7 mt -116.43 -166.06 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 115.728 -0.669 . . . . 1.1000000000000001 109.458 -176.526 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.705 ' H ' HG23 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -154.76 -155.5 0.58 Allowed 'General case' 0 C--N 1.321 -0.658 0 C-N-CA 122.267 0.227 . . . . 3.0699999999999998 110.677 -173.327 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . 0.451 ' H ' ' HB2' ' A' ' 29' ' ' ARG . 1.7 mp0 -75.11 44.32 0.24 Allowed 'General case' 0 C--N 1.332 -0.168 0 CA-C-O 122.122 0.963 . . . . 1.23 111.366 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.521 ' CA ' HD11 ' B' ' 10' ' ' ILE . . . -154.65 19.75 0.6 Allowed Glycine 0 N--CA 1.441 -1.024 0 CA-C-N 113.833 -1.531 . . . . 0.35999999999999999 110.687 175.785 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.445 ' HA ' ' HD3' ' A' ' 33' ' ' PRO . 17.7 t0 -79.65 120.23 79.47 Favored Pre-proline 0 N--CA 1.464 0.245 0 CA-C-O 121.437 0.637 . . . . 1.26 109.784 176.942 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.61 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 2.8 Cg_endo -88.98 56.35 2.09 Favored 'Trans proline' 0 N--CA 1.452 -0.946 0 C-N-CA 123.891 3.06 . . . . 1.3 114.165 -174.494 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.877 HD11 HG22 ' B' ' 10' ' ' ILE . 0.0 OUTLIER -59.28 154.44 16.45 Favored 'General case' 0 C--N 1.3 -1.545 0 C-N-CA 118.823 -1.151 . . . . 1.21 112.34 -173.478 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.81 ' HB3' ' HD2' ' A' ' 47' ' ' LYS . 42.7 tt0 -107.92 112.48 25.11 Favored 'General case' 0 CA--C 1.491 -1.31 0 CA-C-N 113.847 -1.524 . . . . 1.1200000000000001 107.909 -175.834 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.82 ' HB ' HG22 ' B' ' 6' ' ' ILE . 2.8 mt -82.65 111.05 18.47 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 O-C-N 124.424 1.078 . . . . 1.1599999999999999 109.736 -179.752 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' PHE . . . . . 0.632 ' HE1' ' HZ3' ' A' ' 47' ' ' LYS . 0.6 OUTLIER -151.11 125.88 9.68 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-O 120.98 0.419 . . . . 2.0099999999999998 110.003 173.586 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.51 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 1.1 p -80.5 138.76 19.21 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 CA-C-O 120.921 0.391 . . . . 1.05 110.798 -177.158 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.686 ' OD2' ' HD2' ' A' ' 40' ' ' ARG . 14.2 t70 -84.29 -49.42 8.77 Favored 'General case' 0 CA--C 1.513 -0.45 0 CA-C-N 115.802 -0.635 . . . . 1.1100000000000001 111.823 -173.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . 0.686 ' HD2' ' OD2' ' A' ' 39' ' ' ASP . 0.0 OUTLIER -135.81 -96.63 0.24 Allowed 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.632 -0.713 . . . . 2.8799999999999999 112.516 -165.972 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -84.85 -74.24 0.4 Allowed 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.529 0.68 . . . . 1.53 110.826 -177.03 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.57 ' HA3' HD12 ' B' ' 26' ' ' LEU . . . -138.25 26.03 2.85 Favored Glycine 0 N--CA 1.439 -1.103 0 CA-C-N 115.207 -0.906 . . . . 0.34000000000000002 110.918 -178.366 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.612 ' HB3' HG23 ' B' ' 45' ' ' ILE . 2.3 mt-10 -94.89 109.2 21.22 Favored 'General case' 0 N--CA 1.446 -0.641 0 N-CA-C 109.161 -0.681 . . . . 1.97 109.161 179.028 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.579 ' CG1' HG21 ' A' ' 36' ' ' ILE . 2.0 t -89.2 131.41 36.57 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.961 0 N-CA-C 109.268 -0.641 . . . . 1.0600000000000001 109.268 177.79 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.789 HG13 HG13 ' B' ' 45' ' ' ILE . 1.6 mp -110.44 115.96 51.14 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.223 0 N-CA-C 108.312 -0.996 . . . . 1.01 108.312 -176.397 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.943 HD12 HD12 ' B' ' 46' ' ' LEU . 0.3 OUTLIER -109.6 117.52 34.15 Favored 'General case' 0 C--N 1.315 -0.923 0 O-C-N 123.785 0.678 . . . . 1.1299999999999999 109.643 179.803 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.81 ' HD2' ' HB3' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -130.91 144.1 51.21 Favored 'General case' 0 C--O 1.215 -0.752 0 C-N-CA 118.695 -1.202 . . . . 1.25 112.844 176.303 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.62 ' HG3' ' HD2' ' A' ' 51' ' ' PRO . 1.0 OUTLIER -20.46 -25.93 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.981 0 N-CA-C 119.532 3.16 . . . . 1.0900000000000001 119.532 -179.08 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . 0.708 ' CD1' HG22 ' B' ' 7' ' ' VAL . 37.0 t80 72.87 -38.48 0.42 Allowed 'General case' 0 N--CA 1.479 1.002 0 CA-C-N 119.795 1.18 . . . . 2.1400000000000001 112.339 -179.036 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.646 ' HB3' ' HD3' ' A' ' 51' ' ' PRO . 26.3 t -52.32 -52.32 63.98 Favored Pre-proline 0 CA--C 1.542 0.667 0 CA-C-N 116.29 -0.414 . . . . 1.95 110.559 -177.741 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.646 ' HD3' ' HB3' ' A' ' 50' ' ' SER . 97.9 Cg_endo -92.21 7.93 3.02 Favored 'Trans proline' 0 C--N 1.355 0.896 0 C-N-CA 122.387 2.058 . . . . 0.59999999999999998 111.733 167.176 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.426 ' H ' ' C ' ' A' ' 49' ' ' TYR . 0.3 OUTLIER . . . . . 0 N--CA 1.467 0.394 0 CA-C-N 114.809 -1.087 . . . . 1.4199999999999999 111.515 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 3' ' ' ALA . . . . . 0.535 ' HA ' ' HD2' ' A' ' 37' ' ' PHE . . . . . . . . 0 N--CA 1.468 0.474 0 CA-C-O 121.338 0.59 . . . . 1.1000000000000001 111.51 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 4' ' ' THR . . . . . 0.532 ' H ' ' HB2' ' A' ' 37' ' ' PHE . 29.0 p -114.7 -39.75 3.69 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.939 -0.573 . . . . 0.97999999999999998 111.802 -174.608 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 67.62 45.51 76.14 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 121.107 -0.568 . . . . 0.33000000000000002 112.612 177.428 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 6' ' ' ILE . . . . . 0.82 HG22 ' HB ' ' A' ' 36' ' ' ILE . 1.3 tp -103.33 105.3 18.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.514 0.673 . . . . 1.1000000000000001 109.732 177.855 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . 0.708 HG22 ' CD1' ' A' ' 49' ' ' TYR . 24.3 t -74.93 131.57 34.8 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.838 0 CA-C-N 115.401 -0.818 . . . . 1.0800000000000001 110.899 -179.573 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . 0.502 ' HB3' ' CD1' ' A' ' 36' ' ' ILE . 1.7 tpp180 -128.72 116.04 18.92 Favored 'General case' 0 N--CA 1.435 -1.211 0 N-CA-C 106.867 -1.531 . . . . 2.3599999999999999 106.867 178.525 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 9' ' ' ARG . . . . . 0.519 ' HA ' ' HA ' ' A' ' 33' ' ' PRO . 29.2 ttp180 -78.23 102.84 7.81 Favored 'General case' 0 C--N 1.311 -1.075 0 N-CA-C 107.897 -1.149 . . . . 3.2000000000000002 107.897 173.103 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 10' ' ' ILE . . . . . 0.877 HG22 HD11 ' A' ' 34' ' ' LEU . 0.4 OUTLIER -8.57 -100.77 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 O-C-N 125.948 2.03 . . . . 1.0700000000000001 113.94 -174.645 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . 0.66 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 2.8 p-10 164.28 -161.05 0.0 OUTLIER 'General case' 0 CA--C 1.512 -0.501 0 N-CA-C 108.484 -0.932 . . . . 1.1799999999999999 108.484 175.676 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -75.09 -14.32 60.57 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.11 0.481 . . . . 2.3900000000000001 110.283 -177.237 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 13' ' ' LEU . . . . . . . . . . . . . 2.2 tm? -105.56 -61.03 1.54 Allowed 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.826 -0.625 . . . . 1.1000000000000001 110.526 179.541 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 139.84 16.16 0.52 Allowed Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.847 -0.692 . . . . 0.23000000000000001 112.357 -176.764 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 15' ' ' ARG . . . . . 0.795 ' HG2' HG21 ' A' ' 17' ' ' VAL . 2.0 mtt180 -79.74 153.87 28.93 Favored 'General case' 0 CA--C 1.501 -0.934 0 N-CA-C 109.598 -0.519 . . . . 1.3899999999999999 109.598 176.668 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 16' ' ' VAL . . . . . 0.833 HG23 HG23 ' A' ' 16' ' ' VAL . 1.1 m -110.5 111.83 37.91 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.673 0 N-CA-C 107.042 -1.466 . . . . 1.97 107.042 166.884 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 17' ' ' VAL . . . . . 0.538 HG23 ' CG ' ' A' ' 15' ' ' ARG . 62.3 t -72.71 98.62 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.165 0 CA-C-N 114.699 -1.137 . . . . 1.0600000000000001 109.668 -173.713 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . 0.464 ' HB ' ' O ' ' A' ' 14' ' ' GLY . 8.9 mt -85.88 111.73 40.0 Favored Pre-proline 0 N--CA 1.443 -0.794 0 CA-C-N 115.276 -0.875 . . . . 1.6100000000000001 110.43 179.799 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 19' ' ' PRO . . . . . 0.621 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 71.4 Cg_exo -50.24 145.4 20.72 Favored 'Trans proline' 0 N--CA 1.456 -0.721 0 C-N-CA 122.965 2.444 . . . . 0.33000000000000002 112.335 173.793 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 20' ' ' LYS . . . . . 0.929 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -61.65 -15.45 39.95 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 115.465 -0.789 . . . . 2.3199999999999998 111.696 179.827 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . 0.621 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 11.7 pt-20 -64.65 -25.78 68.1 Favored 'General case' 0 C--O 1.237 0.446 0 N-CA-C 112.035 0.383 . . . . 1.9199999999999999 112.035 -179.197 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 4.9 mp -88.65 -44.58 15.55 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.271 0 N-CA-C 107.578 -1.267 . . . . 1.24 107.578 -177.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 23' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -59.36 -31.02 68.82 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-N 115.08 -0.964 . . . . 1.8500000000000001 109.514 174.124 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 24' ' ' ARG . . . . . 0.426 HH11 ' HD2' ' B' ' 24' ' ' ARG . 22.3 ttt85 -67.7 -49.9 60.29 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 114.767 -1.106 . . . . 3.6899999999999999 110.745 177.251 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 26.2 m -65.52 -25.99 67.7 Favored 'General case' 0 CA--C 1.535 0.373 0 CA-C-O 121.412 0.625 . . . . 1.1599999999999999 110.159 176.451 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . 0.723 ' HB3' HG13 ' B' ' 28' ' ' ILE . 0.6 OUTLIER -65.91 -17.4 64.63 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.398 -0.819 . . . . 1.1100000000000001 110.805 173.038 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 27' ' ' ARG . . . . . 0.425 ' HB2' ' O ' ' B' ' 26' ' ' LEU . 8.6 mpt_? 65.97 27.02 10.86 Favored 'General case' 0 C--O 1.233 0.195 0 CA-C-O 121.458 0.647 . . . . 3.77 110.032 -173.839 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 28' ' ' ILE . . . . . 0.859 HG23 ' H ' ' B' ' 29' ' ' ARG . 5.1 mt -119.84 -167.7 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.379 -0.828 . . . . 1.2 109.683 -179.311 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 29' ' ' ARG . . . . . 0.859 ' H ' HG23 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -153.67 -155.59 0.61 Allowed 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 122.093 0.157 . . . . 2.7599999999999998 110.934 -176.041 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 30' ' ' GLU . . . . . 0.405 ' H ' ' HB2' ' B' ' 29' ' ' ARG . 1.0 OUTLIER -73.46 39.72 0.1 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 122.104 0.954 . . . . 1.1799999999999999 111.983 -178.998 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 31' ' ' GLY . . . . . 0.517 ' H ' ' C ' ' B' ' 29' ' ' ARG . . . -151.43 26.71 0.97 Allowed Glycine 0 N--CA 1.442 -0.935 0 CA-C-N 114.232 -1.349 . . . . 0.34999999999999998 110.303 172.774 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 32' ' ' ASP . . . . . 0.483 ' O ' ' HA ' ' A' ' 9' ' ' ARG . 21.9 t0 -81.7 121.14 79.3 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.183 0.516 . . . . 1.29 109.916 176.807 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 33' ' ' PRO . . . . . 0.699 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 5.2 Cg_endo -87.42 72.1 3.08 Favored 'Trans proline' 0 C--O 1.204 -1.207 0 C-N-CA 123.606 2.871 . . . . 1.1000000000000001 113.437 -177.853 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . 0.593 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.2 mp -71.27 151.85 43.84 Favored 'General case' 0 C--N 1.286 -2.184 0 C-N-CA 117.779 -1.569 . . . . 1.1699999999999999 111.386 -176.381 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 35' ' ' GLU . . . . . 0.924 ' HB3' ' HD2' ' B' ' 47' ' ' LYS . 44.1 tt0 -108.97 113.79 26.98 Favored 'General case' 0 CA--C 1.49 -1.351 0 CA-C-N 114.388 -1.278 . . . . 1.1000000000000001 107.919 -177.822 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 36' ' ' ILE . . . . . 0.859 ' HB ' HG22 ' A' ' 6' ' ' ILE . 20.5 mt -88.43 109.99 20.59 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.905 0 O-C-N 124.78 1.3 . . . . 1.3200000000000001 110.027 -176.169 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 37' ' ' PHE . . . . . 0.788 ' HB2' ' H ' ' A' ' 4' ' ' THR . 1.3 p90 -150.48 129.33 12.47 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 109.561 -0.533 . . . . 2.0299999999999998 109.561 174.777 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 38' ' ' VAL . . . . . 0.542 ' HA ' ' HA ' ' B' ' 44' ' ' VAL . 0.9 OUTLIER -79.8 142.2 14.27 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.945 0 C-N-CA 120.834 -0.346 . . . . 0.89000000000000001 110.256 -178.649 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 39' ' ' ASP . . . . . 0.492 ' OD2' ' HD2' ' B' ' 40' ' ' ARG . 38.8 t70 -87.64 -47.1 8.95 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.854 -0.612 . . . . 1.1399999999999999 111.84 -175.079 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 40' ' ' ARG . . . . . 0.492 ' HD2' ' OD2' ' B' ' 39' ' ' ASP . 0.0 OUTLIER -137.08 -100.97 0.2 Allowed 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 112.535 0.569 . . . . 3.3700000000000001 112.535 -175.736 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -76.36 -74.54 0.23 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.119 0.485 . . . . 1.3200000000000001 111.36 -174.503 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 42' ' ' GLY . . . . . 0.513 ' HA3' HD12 ' A' ' 26' ' ' LEU . . . -136.77 25.12 3.11 Favored Glycine 0 N--CA 1.444 -0.826 0 C-N-CA 120.833 -0.699 . . . . 0.35999999999999999 111.426 -178.831 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 43' ' ' GLU . . . . . 0.571 ' HB3' HG22 ' A' ' 45' ' ' ILE . 2.4 mt-10 -94.23 108.87 20.71 Favored 'General case' 0 CA--C 1.509 -0.6 0 N-CA-C 109.792 -0.448 . . . . 2.0699999999999998 109.792 179.277 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 44' ' ' VAL . . . . . 0.542 ' HA ' ' HA ' ' B' ' 38' ' ' VAL . 1.5 t -88.92 131.0 37.38 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 N-CA-C 109.55 -0.537 . . . . 1.02 109.55 177.831 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 45' ' ' ILE . . . . . 0.789 HG13 HG13 ' A' ' 45' ' ' ILE . 1.7 mp -109.29 118.9 57.67 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.197 0 N-CA-C 108.405 -0.961 . . . . 0.95999999999999996 108.405 -177.27 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 46' ' ' LEU . . . . . 0.943 HD12 HD12 ' A' ' 46' ' ' LEU . 0.5 OUTLIER -110.64 118.11 35.32 Favored 'General case' 0 C--N 1.316 -0.87 0 O-C-N 123.732 0.645 . . . . 1.05 109.862 178.486 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 47' ' ' LYS . . . . . 0.924 ' HD2' ' HB3' ' B' ' 35' ' ' GLU . 0.0 OUTLIER -129.19 148.11 51.1 Favored 'General case' 0 C--O 1.214 -0.81 0 C-N-CA 119.116 -1.034 . . . . 1.3899999999999999 112.289 177.294 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 48' ' ' LYS . . . . . 0.579 ' HG3' ' CD ' ' B' ' 51' ' ' PRO . 2.8 ptmt -45.14 -6.28 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.235 0 N-CA-C 117.895 2.554 . . . . 1.1899999999999999 117.895 -168.004 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 49' ' ' TYR . . . . . 0.699 ' HB3' ' HB2' ' B' ' 33' ' ' PRO . 24.3 t80 68.3 -36.18 0.31 Allowed 'General case' 0 N--CA 1.48 1.03 0 CA-C-N 119.372 0.987 . . . . 2.1000000000000001 113.28 176.43 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 50' ' ' SER . . . . . 0.594 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 12.4 t -53.97 -47.79 95.92 Favored Pre-proline 0 CA--C 1.542 0.667 0 C-N-CA 122.588 0.355 . . . . 1.77 110.991 -177.194 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 51' ' ' PRO . . . . . 0.594 ' HD3' ' HB3' ' B' ' 50' ' ' SER . 62.6 Cg_endo -94.56 5.52 2.52 Favored 'Trans proline' 0 C--N 1.352 0.751 0 C-N-CA 122.451 2.101 . . . . 0.59999999999999998 111.919 165.551 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 52' ' ' ILE . . . . . 0.449 HG12 ' O ' ' B' ' 49' ' ' TYR . 0.6 OUTLIER . . . . . 0 N--CA 1.465 0.293 0 CA-C-N 115.083 -0.962 . . . . 1.3899999999999999 110.595 -177.324 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . 0.815 ' HA ' ' HD2' ' B' ' 37' ' ' PHE . . . . . . . . 0 CA--C 1.519 -0.225 0 CA-C-O 121.602 0.715 . . . . 1.1299999999999999 110.802 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.467 ' OG1' ' HA ' ' B' ' 37' ' ' PHE . 15.6 p -94.08 -35.92 12.34 Favored 'General case' 0 N--CA 1.444 -0.74 0 CA-C-N 115.181 -0.918 . . . . 1.0900000000000001 112.036 -176.506 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 60.93 49.37 79.42 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.969 -0.634 . . . . 0.32000000000000001 112.799 176.317 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.856 HG22 ' HB ' ' B' ' 36' ' ' ILE . 0.9 OUTLIER -108.28 111.3 35.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 N-CA-C 109.379 -0.6 . . . . 1.0900000000000001 109.379 175.295 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.648 HG22 ' CD1' ' B' ' 49' ' ' TYR . 48.6 t -82.38 133.96 28.03 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 CA-C-O 121.303 0.573 . . . . 1.1299999999999999 111.013 -178.3 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.625 ' CZ ' HG22 ' A' ' 17' ' ' VAL . 3.9 tpt180 -126.2 107.86 10.76 Favored 'General case' 0 N--CA 1.441 -0.903 0 N-CA-C 107.074 -1.454 . . . . 2.6099999999999999 107.074 -178.545 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' ARG . . . . . 0.473 ' HA ' ' O ' ' B' ' 32' ' ' ASP . 2.0 ttt180 -78.34 102.0 7.49 Favored 'General case' 0 CA--C 1.503 -0.847 0 N-CA-C 108.02 -1.104 . . . . 3.4100000000000001 108.02 175.73 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.64 ' O ' ' HB3' ' A' ' 11' ' ' ASP . 0.2 OUTLIER -10.12 -109.25 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 O-C-N 126.036 2.085 . . . . 1.0700000000000001 114.551 -179.187 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . 0.64 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 4.2 p-10 158.81 -167.73 0.0 OUTLIER 'General case' 0 CA--C 1.513 -0.458 0 N-CA-C 107.202 -1.407 . . . . 1.1299999999999999 107.202 177.465 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -67.52 -22.78 65.42 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.013 0.435 . . . . 2.2599999999999998 110.887 -178.241 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.413 ' C ' HD12 ' A' ' 13' ' ' LEU . 2.2 tm? -95.28 -61.54 1.46 Allowed 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.081 -0.509 . . . . 1.23 109.733 177.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.584 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 132.71 21.49 0.9 Allowed Glycine 0 N--CA 1.443 -0.892 0 C-N-CA 119.898 -1.144 . . . . 0.25 114.131 178.242 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.481 ' HA ' ' HA ' ' B' ' 17' ' ' VAL . 0.9 OUTLIER -79.01 155.08 29.01 Favored 'General case' 0 CA--C 1.504 -0.814 0 CA-C-N 118.91 1.355 . . . . 0.88 110.941 179.249 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.615 HG23 HD13 ' B' ' 46' ' ' LEU . 52.9 t -111.43 101.37 12.45 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.379 0 N-CA-C 107.39 -1.337 . . . . 1.99 107.39 169.322 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.706 HG23 ' HG2' ' B' ' 15' ' ' ARG . 65.5 t -68.21 106.91 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.016 0 CA-C-N 115.038 -0.983 . . . . 1.0600000000000001 109.775 -175.767 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 31.7 mm -90.8 109.26 33.45 Favored Pre-proline 0 N--CA 1.446 -0.636 0 CA-C-N 115.79 -0.641 . . . . 1.5600000000000001 110.547 -177.895 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.57 ' HD3' ' O ' ' A' ' 17' ' ' VAL . 81.0 Cg_exo -50.37 138.04 38.63 Favored 'Trans proline' 0 N--CA 1.459 -0.521 0 C-N-CA 123.015 2.476 . . . . 0.34999999999999998 112.359 173.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.847 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -57.64 -14.21 5.12 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-N 114.947 -1.024 . . . . 2.1299999999999999 112.265 179.297 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.532 ' O ' ' HB3' ' A' ' 24' ' ' ARG . 11.9 pt-20 -67.08 -25.78 66.4 Favored 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 118.088 0.404 . . . . 1.3200000000000001 111.724 -178.256 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 4.5 mp -88.15 -42.73 15.1 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.321 0 N-CA-C 107.622 -1.251 . . . . 1.0800000000000001 107.622 -178.081 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ARG . . . . . 0.63 ' HA ' ' HB2' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -58.51 -31.78 68.21 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 114.848 -1.069 . . . . 2.02 109.145 171.936 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.532 ' HB3' ' O ' ' A' ' 21' ' ' GLU . 55.3 ttp180 -60.19 -52.85 63.56 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 114.313 -1.312 . . . . 3.3999999999999999 110.785 174.092 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 17.3 m -65.85 -27.02 67.93 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-O 121.247 0.546 . . . . 1.1499999999999999 110.961 174.699 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.687 ' HB3' HG13 ' A' ' 28' ' ' ILE . 1.3 mm? -64.68 -20.86 66.55 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.759 -0.655 . . . . 1.1599999999999999 110.638 173.879 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 8.1 tpt180 71.17 18.83 5.66 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-O 121.793 0.806 . . . . 3.6800000000000002 109.302 -176.431 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.687 HG13 ' HB3' ' A' ' 26' ' ' LEU . 3.9 mt -114.9 -167.44 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 114.894 -1.048 . . . . 1.1000000000000001 108.797 -177.926 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ARG . . . . . 0.683 ' H ' HG23 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -155.54 -149.63 0.27 Allowed 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 110.149 -0.315 . . . . 3.0699999999999998 110.149 -173.282 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 4.6 mp0 -72.58 40.15 0.08 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.471 0.653 . . . . 1.23 111.962 178.754 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.582 ' CA ' HD13 ' B' ' 10' ' ' ILE . . . -154.87 33.37 0.67 Allowed Glycine 0 N--CA 1.438 -1.189 0 N-CA-C 110.609 -0.996 . . . . 0.35999999999999999 110.609 171.592 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.512 ' HA ' ' HD3' ' A' ' 33' ' ' PRO . 45.9 t0 -90.1 116.3 66.04 Favored Pre-proline 0 C--O 1.234 0.275 0 CA-C-O 121.327 0.584 . . . . 1.26 109.602 175.742 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.534 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 1.3 Cg_endo -87.28 63.29 4.07 Favored 'Trans proline' 0 N--CA 1.454 -0.835 0 C-N-CA 123.984 3.122 . . . . 1.3 113.83 -177.064 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.539 ' HA ' ' O ' ' A' ' 47' ' ' LYS . 0.7 OUTLIER -63.87 153.79 35.72 Favored 'General case' 0 C--N 1.295 -1.785 0 C-N-CA 118.709 -1.196 . . . . 1.21 111.695 -175.636 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.897 ' HB3' ' HD2' ' A' ' 47' ' ' LYS . 34.4 tt0 -111.0 117.2 32.7 Favored 'General case' 0 CA--C 1.491 -1.29 0 CA-C-N 113.926 -1.488 . . . . 1.1200000000000001 108.987 -173.362 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.885 ' HB ' HG22 ' B' ' 6' ' ' ILE . 3.0 mp -84.19 111.59 20.28 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.828 0 O-C-N 124.534 1.146 . . . . 1.1599999999999999 109.546 -178.875 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' PHE . . . . . 0.868 ' HD2' ' HA ' ' B' ' 3' ' ' ALA . 0.3 OUTLIER -149.79 124.01 9.52 Favored 'General case' 0 C--N 1.313 -1.002 0 CA-C-O 121.13 0.491 . . . . 2.0099999999999998 109.711 172.416 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.503 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 1.4 p -80.16 137.22 21.92 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 CA-C-O 121.198 0.523 . . . . 1.05 110.143 -179.409 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.647 ' OD2' ' HD2' ' A' ' 40' ' ' ARG . 32.3 t70 -88.24 -46.07 9.54 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.256 -0.884 . . . . 1.1100000000000001 111.699 -172.877 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . 0.793 ' HG3' ' HG3' ' A' ' 43' ' ' GLU . 0.1 OUTLIER -128.19 -90.64 0.5 Allowed 'General case' 0 C--N 1.313 -1.008 0 CA-C-N 114.773 -1.103 . . . . 2.8799999999999999 112.054 -162.402 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -112.74 -66.51 1.08 Allowed 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 121.02 0.438 . . . . 1.53 111.205 -176.402 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.514 ' O ' ' HA ' ' B' ' 47' ' ' LYS . . . -130.33 13.68 5.67 Favored Glycine 0 CA--C 1.499 -0.914 0 C-N-CA 120.462 -0.875 . . . . 0.34000000000000002 111.628 -178.309 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.793 ' HG3' ' HG3' ' A' ' 40' ' ' ARG . 0.9 OUTLIER -97.04 110.54 23.06 Favored 'General case' 0 C--N 1.319 -0.732 0 N-CA-C 109.299 -0.63 . . . . 1.97 109.299 -178.794 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.567 ' CG1' HG21 ' A' ' 36' ' ' ILE . 2.3 t -90.71 133.76 31.51 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.788 0 CA-C-N 115.718 -0.674 . . . . 1.0600000000000001 109.239 177.924 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.758 HG13 HG13 ' B' ' 45' ' ' ILE . 1.7 mp -110.93 116.6 52.92 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 N-CA-C 108.644 -0.873 . . . . 1.01 108.644 -175.77 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.909 HD12 HD12 ' B' ' 46' ' ' LEU . 0.9 OUTLIER -108.08 118.36 36.54 Favored 'General case' 0 C--N 1.319 -0.76 0 O-C-N 123.764 0.665 . . . . 1.1299999999999999 109.753 179.53 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.897 ' HD2' ' HB3' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -130.08 148.73 51.96 Favored 'General case' 0 C--O 1.216 -0.689 0 C-N-CA 118.849 -1.14 . . . . 1.25 113.152 178.001 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.556 ' HE2' ' HG3' ' A' ' 51' ' ' PRO . 2.2 ptmt -35.83 -19.73 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.09 0 N-CA-C 118.044 2.609 . . . . 1.0900000000000001 118.044 -172.288 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . 0.574 ' CD1' HG22 ' B' ' 7' ' ' VAL . 22.6 t80 74.95 -54.26 0.66 Allowed 'General case' 0 N--CA 1.475 0.822 0 C-N-CA 123.455 0.702 . . . . 2.1400000000000001 112.79 177.408 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.696 ' HB3' ' HD3' ' A' ' 51' ' ' PRO . 6.8 t -52.15 -53.13 55.62 Favored Pre-proline 0 CA--C 1.541 0.601 0 CA-C-N 116.388 -0.369 . . . . 1.95 111.182 -173.675 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.696 ' HD3' ' HB3' ' A' ' 50' ' ' SER . 48.5 Cg_endo -92.98 14.39 1.6 Allowed 'Trans proline' 0 C--N 1.348 0.536 0 C-N-CA 122.376 2.051 . . . . 0.59999999999999998 111.539 170.101 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.235 0.306 0 CA-C-N 115.429 -0.805 . . . . 1.4199999999999999 109.86 -176.861 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 3' ' ' ALA . . . . . 0.868 ' HA ' ' HD2' ' A' ' 37' ' ' PHE . . . . . . . . 0 CA--C 1.517 -0.296 0 CA-C-O 121.495 0.664 . . . . 1.1000000000000001 110.979 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 4' ' ' THR . . . . . . . . . . . . . 20.4 p -91.68 -29.14 17.02 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.219 -0.901 . . . . 0.97999999999999998 112.275 -173.607 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 56.99 47.74 84.93 Favored Glycine 0 N--CA 1.45 -0.415 0 CA-C-N 115.711 -0.677 . . . . 0.33000000000000002 112.99 175.306 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 6' ' ' ILE . . . . . 0.885 HG22 ' HB ' ' A' ' 36' ' ' ILE . 1.0 OUTLIER -107.66 109.46 28.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-O 121.178 0.513 . . . . 1.1000000000000001 109.623 176.602 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 7' ' ' VAL . . . . . 0.574 HG22 ' CD1' ' A' ' 49' ' ' TYR . 14.7 t -80.52 135.38 25.39 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.996 0 CA-C-N 115.609 -0.723 . . . . 1.0800000000000001 110.783 -177.813 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . 0.613 ' CZ ' HG22 ' B' ' 17' ' ' VAL . 1.1 tpt180 -128.09 112.77 14.95 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 107.405 -1.331 . . . . 2.3599999999999999 107.405 178.696 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 9' ' ' ARG . . . . . 0.458 ' HA ' ' HA ' ' A' ' 33' ' ' PRO . 13.2 ttt180 -78.83 104.45 9.47 Favored 'General case' 0 CA--C 1.501 -0.929 0 N-CA-C 108.287 -1.005 . . . . 3.2000000000000002 108.287 174.564 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 10' ' ' ILE . . . . . 0.582 HD13 ' CA ' ' A' ' 31' ' ' GLY . 0.2 OUTLIER -15.28 -103.24 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 O-C-N 125.822 1.951 . . . . 1.0700000000000001 114.65 -177.248 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 11' ' ' ASP . . . . . 0.577 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 6.4 p-10 158.08 -161.08 0.0 OUTLIER 'General case' 0 CA--C 1.506 -0.727 0 N-CA-C 106.604 -1.628 . . . . 1.1799999999999999 106.604 174.854 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 38.4 t70 -77.04 -17.5 58.74 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.512 0.673 . . . . 2.3900000000000001 110.209 -178.151 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 13' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -96.1 -61.6 1.41 Allowed 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.575 -0.739 . . . . 1.1000000000000001 110.029 177.296 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 134.61 24.06 0.62 Allowed Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.477 -0.868 . . . . 0.23000000000000001 112.649 179.624 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 15' ' ' ARG . . . . . 0.706 ' HG2' HG23 ' A' ' 17' ' ' VAL . 56.4 mtt180 -77.82 147.28 35.28 Favored 'General case' 0 CA--C 1.51 -0.575 0 CA-C-O 121.479 0.657 . . . . 1.3899999999999999 111.175 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 16' ' ' VAL . . . . . 0.524 HG11 HD13 ' A' ' 46' ' ' LEU . 92.7 t -113.76 99.49 8.72 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.13 0 N-CA-C 107.861 -1.163 . . . . 1.97 107.861 168.335 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 17' ' ' VAL . . . . . 0.613 HG22 ' CZ ' ' B' ' 8' ' ' ARG . 60.8 t -66.41 106.33 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.847 0 CA-C-N 115.475 -0.784 . . . . 1.0600000000000001 109.847 -173.635 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 18' ' ' ILE . . . . . 0.584 ' HB ' ' O ' ' A' ' 14' ' ' GLY . 22.7 mm -89.29 109.08 28.62 Favored Pre-proline 0 C--N 1.32 -0.696 0 CA-C-N 115.587 -0.733 . . . . 1.6100000000000001 110.24 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 19' ' ' PRO . . . . . 0.583 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 93.6 Cg_exo -53.45 144.05 52.46 Favored 'Trans proline' 0 N--CA 1.454 -0.799 0 C-N-CA 122.558 2.172 . . . . 0.33000000000000002 112.22 174.773 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 20' ' ' LYS . . . . . 1.009 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -64.64 -13.71 54.99 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 115.556 -0.747 . . . . 2.3199999999999998 111.434 -179.396 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 21' ' ' GLU . . . . . 0.583 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 11.2 pt-20 -65.42 -26.32 67.92 Favored 'General case' 0 C--O 1.239 0.549 0 N-CA-C 112.688 0.625 . . . . 1.9199999999999999 112.688 179.556 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 3.9 mp -88.58 -42.09 14.52 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.252 0 N-CA-C 107.807 -1.183 . . . . 1.24 107.807 -179.214 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 23' ' ' ARG . . . . . 0.555 ' HA ' ' HB2' ' B' ' 26' ' ' LEU . 0.0 OUTLIER -57.69 -30.24 65.33 Favored 'General case' 0 N--CA 1.461 0.125 0 CA-C-N 114.927 -1.033 . . . . 1.8500000000000001 109.126 170.973 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 24' ' ' ARG . . . . . 0.524 ' HB3' ' O ' ' B' ' 21' ' ' GLU . 21.4 ttp180 -62.28 -53.17 59.06 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 114.289 -1.323 . . . . 3.6899999999999999 110.942 174.838 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 30.4 m -62.41 -32.0 72.77 Favored 'General case' 0 C--O 1.235 0.334 0 CA-C-O 121.409 0.624 . . . . 1.1599999999999999 110.557 174.278 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . 0.67 ' HB3' HG13 ' B' ' 28' ' ' ILE . 0.9 OUTLIER -64.3 -19.86 65.7 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.212 -0.903 . . . . 1.1100000000000001 110.705 176.131 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 27' ' ' ARG . . . . . 0.435 ' HD2' ' HA ' ' B' ' 27' ' ' ARG . 11.9 tpt180 68.05 22.45 8.43 Favored 'General case' 0 N--CA 1.461 0.097 0 CA-C-O 121.802 0.81 . . . . 3.77 109.906 -177.627 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 28' ' ' ILE . . . . . 0.836 HG23 ' H ' ' B' ' 29' ' ' ARG . 6.3 mt -111.92 -161.21 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.203 -0.908 . . . . 1.2 109.162 -179.306 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 29' ' ' ARG . . . . . 0.836 ' H ' HG23 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -158.68 -157.37 0.61 Allowed 'General case' 0 C--N 1.32 -0.689 0 O-C-N 122.468 -0.145 . . . . 2.7599999999999998 110.618 -173.229 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 30' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -70.31 43.48 0.06 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.975 0.893 . . . . 1.1799999999999999 111.598 176.777 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 31' ' ' GLY . . . . . 0.614 ' CA ' HD13 ' A' ' 10' ' ' ILE . . . -161.12 36.06 0.41 Allowed Glycine 0 N--CA 1.436 -1.338 0 CA-C-N 114.282 -1.326 . . . . 0.34999999999999998 110.358 174.614 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 32' ' ' ASP . . . . . 0.504 ' HA ' ' HD3' ' B' ' 33' ' ' PRO . 16.5 t0 -93.21 121.13 66.06 Favored Pre-proline 0 C--N 1.327 -0.409 0 CA-C-N 115.006 -0.597 . . . . 1.29 110.223 175.558 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 33' ' ' PRO . . . . . 0.661 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 3.9 Cg_endo -86.84 75.6 2.57 Favored 'Trans proline' 0 C--O 1.206 -1.084 0 C-N-CA 123.664 2.909 . . . . 1.1000000000000001 113.31 -179.919 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . 0.588 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 1.4 mp -71.14 150.52 45.34 Favored 'General case' 0 C--N 1.286 -2.182 0 C-N-CA 117.909 -1.516 . . . . 1.1699999999999999 111.326 -178.535 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 35' ' ' GLU . . . . . 0.745 ' HB3' ' HD2' ' B' ' 47' ' ' LYS . 45.2 tt0 -109.69 114.45 28.06 Favored 'General case' 0 CA--C 1.49 -1.343 0 CA-C-N 114.384 -1.28 . . . . 1.1000000000000001 108.326 -177.656 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 36' ' ' ILE . . . . . 0.96 HG13 HD23 ' B' ' 46' ' ' LEU . 3.0 mp -87.46 112.16 22.94 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 O-C-N 124.761 1.288 . . . . 1.3200000000000001 109.697 -177.221 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 37' ' ' PHE . . . . . 0.815 ' HD2' ' HA ' ' A' ' 3' ' ' ALA . 1.1 p90 -150.14 128.42 12.07 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 116.003 -0.544 . . . . 2.0299999999999998 109.661 172.39 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 38' ' ' VAL . . . . . 0.519 ' HA ' ' HA ' ' B' ' 44' ' ' VAL . 0.6 OUTLIER -80.67 140.19 17.03 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.982 0 CA-C-O 121.281 0.563 . . . . 0.89000000000000001 110.57 -179.636 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 39' ' ' ASP . . . . . 0.626 ' OD1' ' HD2' ' B' ' 40' ' ' ARG . 16.1 t70 -84.85 -50.74 7.29 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.16 -0.927 . . . . 1.1399999999999999 111.731 -173.249 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 40' ' ' ARG . . . . . 0.626 ' HD2' ' OD1' ' B' ' 39' ' ' ASP . 0.0 OUTLIER -134.99 -87.15 0.38 Allowed 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 112.661 0.615 . . . . 3.3700000000000001 112.661 -172.437 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -95.17 -78.81 0.44 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.025 0.44 . . . . 1.3200000000000001 110.999 -175.673 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 42' ' ' GLY . . . . . 0.454 ' HA3' HD13 ' A' ' 26' ' ' LEU . . . -125.84 16.02 6.95 Favored Glycine 0 N--CA 1.443 -0.843 0 C-N-CA 120.576 -0.821 . . . . 0.35999999999999999 112.043 -177.481 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 43' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -92.03 107.64 19.35 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.511 -0.552 . . . . 2.0699999999999998 109.511 -178.765 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 44' ' ' VAL . . . . . 0.57 ' O ' ' HA ' ' A' ' 45' ' ' ILE . 1.9 t -89.83 133.71 31.03 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.852 0 N-CA-C 109.402 -0.592 . . . . 1.02 109.402 176.441 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 45' ' ' ILE . . . . . 0.758 HG13 HG13 ' A' ' 45' ' ' ILE . 1.7 mp -110.62 119.86 60.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 N-CA-C 108.582 -0.896 . . . . 0.95999999999999996 108.582 -177.281 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 46' ' ' LEU . . . . . 0.96 HD23 HG13 ' B' ' 36' ' ' ILE . 0.6 OUTLIER -112.13 117.54 32.88 Favored 'General case' 0 C--N 1.32 -0.696 0 O-C-N 123.682 0.614 . . . . 1.05 109.936 178.333 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 47' ' ' LYS . . . . . 0.745 ' HD2' ' HB3' ' B' ' 35' ' ' GLU . 0.0 OUTLIER -130.95 152.94 49.71 Favored 'General case' 0 C--O 1.213 -0.848 0 C-N-CA 119.254 -0.978 . . . . 1.3899999999999999 113.033 177.516 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 48' ' ' LYS . . . . . 0.689 ' HE3' HD11 ' B' ' 28' ' ' ILE . 12.5 ptmt -49.87 -4.4 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.011 0 N-CA-C 117.713 2.486 . . . . 1.1899999999999999 117.713 -166.727 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 49' ' ' TYR . . . . . 0.661 ' HB3' ' HB2' ' B' ' 33' ' ' PRO . 28.7 t80 71.73 -54.53 0.67 Allowed 'General case' 0 N--CA 1.477 0.88 0 N-CA-C 113.549 0.944 . . . . 2.1000000000000001 113.549 172.027 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 50' ' ' SER . . . . . 0.664 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 9.2 t -51.55 -55.88 25.61 Favored Pre-proline 0 CA--C 1.539 0.548 0 CA-C-N 116.05 -0.523 . . . . 1.77 111.035 -173.518 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 51' ' ' PRO . . . . . 0.664 ' HD3' ' HB3' ' B' ' 50' ' ' SER . 41.3 Cg_endo -89.81 12.95 2.45 Favored 'Trans proline' 0 C--N 1.351 0.705 0 C-N-CA 122.172 1.915 . . . . 0.59999999999999998 111.514 170.698 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 52' ' ' ILE . . . . . . . . . . . . . 1.1 mt . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 115.199 -0.909 . . . . 1.3899999999999999 109.714 -176.66 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 52.6 ttm . . . . . 0 N--CA 1.478 0.945 0 CA-C-O 119.631 -0.224 . . . . 6.3300000000000001 111.037 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 19.9 mmmt 57.47 -93.25 0.04 OUTLIER 'General case' 0 CA--C 1.515 -0.395 0 O-C-N 123.617 0.573 . . . . 4.1699999999999999 110.649 -175.691 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.492 ' HA ' ' HB2' ' B' ' 37' ' ' PHE . . . 71.15 126.43 0.03 OUTLIER 'General case' 0 C--N 1.311 -1.096 0 CA-C-N 113.953 -1.476 . . . . 1.1299999999999999 113.459 172.779 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.679 ' H ' ' HB2' ' B' ' 37' ' ' PHE . 10.6 p -110.28 -48.02 3.22 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 114.968 -1.015 . . . . 1.0900000000000001 109.893 172.007 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 78.68 51.65 5.43 Favored Glycine 0 N--CA 1.446 -0.646 0 CA-C-N 115.431 -0.804 . . . . 0.32000000000000001 112.912 172.001 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.794 HG21 ' HB ' ' B' ' 36' ' ' ILE . 1.5 tp -107.99 107.17 22.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 N-CA-C 109.273 -0.64 . . . . 1.0900000000000001 109.273 172.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.745 ' HA ' ' O ' ' B' ' 34' ' ' LEU . 44.2 t -78.28 133.73 29.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-N 116.102 -0.499 . . . . 1.1299999999999999 110.565 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.558 ' HB3' ' CD1' ' B' ' 36' ' ' ILE . 0.4 OUTLIER -129.69 123.06 30.22 Favored 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 107.387 -1.338 . . . . 2.6099999999999999 107.387 -178.237 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.514 ' HA ' ' HA ' ' B' ' 33' ' ' PRO . 0.0 OUTLIER -83.82 103.02 12.76 Favored 'General case' 0 C--N 1.314 -0.947 0 N-CA-C 107.754 -1.202 . . . . 3.4100000000000001 107.754 173.246 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.786 HG23 HD12 ' B' ' 34' ' ' LEU . 0.2 OUTLIER -9.97 -102.53 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.13 0 O-C-N 125.291 1.619 . . . . 1.0700000000000001 114.595 -175.4 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . 0.524 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 27.9 p-10 163.33 -165.03 0.01 OUTLIER 'General case' 0 CA--C 1.506 -0.722 0 N-CA-C 107.86 -1.163 . . . . 1.1299999999999999 107.86 175.175 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . 0.478 ' HA ' ' HG2' ' B' ' 30' ' ' GLU . 12.8 p-10 -80.97 14.38 2.27 Favored 'General case' 0 C--N 1.318 -0.796 0 O-C-N 123.376 0.423 . . . . 2.2599999999999998 111.284 -176.648 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -129.96 -55.14 1.13 Allowed 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 109.931 -0.396 . . . . 1.23 109.931 176.799 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.545 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 135.79 7.48 1.82 Allowed Glycine 0 N--CA 1.444 -0.776 0 C-N-CA 120.606 -0.807 . . . . 0.25 113.156 -179.014 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.671 ' HG2' HG23 ' B' ' 17' ' ' VAL . 0.5 OUTLIER -77.76 156.03 30.81 Favored 'General case' 0 CA--C 1.495 -1.149 0 CA-C-N 117.813 0.806 . . . . 0.88 109.912 178.304 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 1.039 HG23 HG23 ' B' ' 16' ' ' VAL . 0.8 OUTLIER -112.2 115.09 48.89 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.86 0 N-CA-C 107.508 -1.293 . . . . 1.99 107.508 167.954 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.694 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 46.9 t -73.35 98.21 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 CA-C-N 114.801 -1.09 . . . . 1.0600000000000001 109.355 -174.281 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.503 ' HB ' ' O ' ' B' ' 14' ' ' GLY . 33.7 mm -83.96 106.97 8.98 Favored Pre-proline 0 N--CA 1.448 -0.529 0 O-C-N 123.844 0.715 . . . . 1.5600000000000001 109.907 179.849 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.694 ' HD3' ' O ' ' A' ' 17' ' ' VAL . 58.6 Cg_exo -47.1 143.86 9.56 Favored 'Trans proline' 0 N--CA 1.455 -0.784 0 C-N-CA 122.958 2.439 . . . . 0.34999999999999998 112.391 174.769 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.905 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -62.4 -15.58 49.87 Favored 'General case' 0 C--O 1.206 -1.236 0 CA-C-N 115.427 -0.806 . . . . 2.1299999999999999 110.763 -179.405 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.684 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 9.6 pt-20 -64.0 -24.07 67.57 Favored 'General case' 0 CA--C 1.532 0.278 0 N-CA-C 112.307 0.484 . . . . 1.3200000000000001 112.307 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.2 mp -87.34 -45.24 16.24 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.24 0 N-CA-C 108.2 -1.037 . . . . 1.0800000000000001 108.2 -179.303 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . 0.708 ' HA ' ' HB2' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -62.96 -26.95 69.07 Favored 'General case' 0 C--N 1.333 -0.137 0 CA-C-N 115.393 -0.822 . . . . 2.02 109.516 173.322 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 34.9 ttm180 -64.41 -49.15 72.67 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 114.94 -1.027 . . . . 3.3999999999999999 110.712 172.683 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 17.7 m -63.41 -27.41 69.28 Favored 'General case' 0 CA--C 1.532 0.265 0 CA-C-O 121.09 0.471 . . . . 1.1499999999999999 110.781 171.166 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.771 ' HB3' HG13 ' A' ' 28' ' ' ILE . 2.2 mm? -69.81 -22.13 63.33 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.038 -0.528 . . . . 1.1599999999999999 110.688 172.764 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.421 ' HB2' ' O ' ' A' ' 26' ' ' LEU . 0.0 OUTLIER 67.33 23.75 9.17 Favored 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 123.574 0.75 . . . . 3.6800000000000002 111.306 -174.218 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.771 HG13 ' HB3' ' A' ' 26' ' ' LEU . 3.6 mt -113.24 -159.68 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 116.013 -0.54 . . . . 1.1000000000000001 109.959 -176.77 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.67 ' H ' HG21 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -159.21 -159.41 0.76 Allowed 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 117.786 0.266 . . . . 3.0699999999999998 111.545 -169.208 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . 0.496 ' HG2' ' HA ' ' B' ' 12' ' ' ASP . 59.0 mp0 -70.28 32.73 0.04 OUTLIER 'General case' 0 N--CA 1.469 0.515 0 C-N-CA 123.613 0.765 . . . . 1.23 112.673 178.303 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.53 ' H ' ' C ' ' A' ' 29' ' ' ARG . . . -148.59 23.92 1.34 Allowed Glycine 0 N--CA 1.44 -1.072 0 N-CA-C 110.297 -1.121 . . . . 0.35999999999999999 110.297 173.178 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.632 ' O ' HG13 ' B' ' 10' ' ' ILE . 14.8 t0 -83.04 122.51 77.77 Favored Pre-proline 0 C--N 1.326 -0.447 0 CA-C-N 114.774 -0.713 . . . . 1.26 109.751 175.663 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.682 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 9.7 Cg_endo -85.66 149.2 9.92 Favored 'Trans proline' 0 N--CA 1.433 -2.03 0 C-N-CA 122.367 2.045 . . . . 1.3 110.522 175.753 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.787 HD13 HG22 ' B' ' 10' ' ' ILE . 0.9 OUTLIER -140.0 150.95 45.07 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 120.386 -0.526 . . . . 1.21 109.739 174.887 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.67 ' HB3' ' HB3' ' A' ' 47' ' ' LYS . 36.1 tt0 -103.48 110.27 22.24 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 107.05 -1.463 . . . . 1.1200000000000001 107.05 -178.802 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.774 ' HB ' HG21 ' B' ' 6' ' ' ILE . 2.1 mp -85.52 107.81 16.6 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.981 0 O-C-N 124.113 0.883 . . . . 1.1599999999999999 108.757 -179.218 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . 0.65 ' HB2' ' H ' ' B' ' 4' ' ' THR . 6.2 p90 -149.38 127.34 11.89 Favored 'General case' 0 C--N 1.313 -0.988 0 CA-C-N 115.875 -0.602 . . . . 2.0099999999999998 109.555 177.36 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.482 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 2.1 p -80.02 142.2 14.25 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.071 0 CA-C-N 115.941 -0.572 . . . . 1.05 110.004 -178.375 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.544 ' OD2' ' HD3' ' A' ' 40' ' ' ARG . 28.9 t70 -87.6 -43.08 12.25 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.904 -0.589 . . . . 1.1100000000000001 111.722 -175.474 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . 0.559 ' HG3' ' HG3' ' A' ' 43' ' ' GLU . 0.0 OUTLIER -138.42 -90.05 0.22 Allowed 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 112.797 0.666 . . . . 2.8799999999999999 112.797 -167.473 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 31.4 t70 -100.76 -71.91 0.69 Allowed 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.025 0.441 . . . . 1.53 110.85 -177.772 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.554 ' HA3' HD13 ' B' ' 26' ' ' LEU . . . -133.34 24.12 3.77 Favored Glycine 0 N--CA 1.445 -0.75 0 C-N-CA 120.466 -0.873 . . . . 0.34000000000000002 112.123 -178.845 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.559 ' HG3' ' HG3' ' A' ' 40' ' ' ARG . 1.5 mt-10 -98.1 109.86 22.54 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 109.081 -0.711 . . . . 1.97 109.081 176.017 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.485 ' O ' ' HA ' ' B' ' 45' ' ' ILE . 1.6 t -90.0 134.25 29.59 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.875 0 N-CA-C 109.461 -0.57 . . . . 1.0600000000000001 109.461 178.339 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.827 HG13 HG13 ' B' ' 45' ' ' ILE . 1.5 mp -109.08 122.72 64.19 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 N-CA-C 108.131 -1.063 . . . . 1.01 108.131 -177.095 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.788 HD13 HD11 ' B' ' 46' ' ' LEU . 4.9 mt -106.07 117.77 34.89 Favored 'General case' 0 C--N 1.319 -0.741 0 O-C-N 123.869 0.731 . . . . 1.1299999999999999 109.728 178.286 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.973 ' HE2' ' HB3' ' A' ' 53' ' ' SER . 15.8 ttmt -119.17 127.69 53.54 Favored 'General case' 0 C--N 1.311 -1.099 0 CA-C-N 115.73 -0.668 . . . . 1.25 111.959 -171.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.547 ' HA ' ' O ' ' A' ' 33' ' ' PRO . 3.2 ptmt -44.88 -15.03 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.451 0 N-CA-C 116.656 2.095 . . . . 1.0900000000000001 116.656 -170.758 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.706 ' CD1' HG21 ' B' ' 7' ' ' VAL . 27.1 t80 73.59 -55.9 0.66 Allowed 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 112.627 0.602 . . . . 2.1400000000000001 112.627 171.066 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.672 ' OG ' ' HD3' ' A' ' 51' ' ' PRO . 7.3 p -54.69 -41.67 91.04 Favored Pre-proline 0 CA--C 1.54 0.582 0 N-CA-C 112.439 0.533 . . . . 1.95 112.439 -174.312 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.672 ' HD3' ' OG ' ' A' ' 50' ' ' SER . 60.7 Cg_endo -103.3 14.74 0.27 Allowed 'Trans proline' 0 N--CA 1.451 -0.99 0 C-N-CA 123.063 2.509 . . . . 0.59999999999999998 111.192 168.737 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 3.0 mt 55.35 -128.72 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.444 -0.734 0 CA-C-N 115.194 -0.912 . . . . 1.4199999999999999 108.549 -168.843 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.973 ' HB3' ' HE2' ' A' ' 47' ' ' LYS . 12.4 p -107.86 2.34 23.39 Favored 'General case' 0 C--N 1.31 -1.124 0 C-N-CA 120.693 -0.403 . . . . 2.23 112.059 179.687 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . 0.427 ' O ' ' HB2' ' A' ' 55' ' ' LEU . 10.4 pt-20 174.3 -34.85 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.95 -0.568 . . . . 2.8900000000000001 112.143 -172.135 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.578 ' HG ' ' O ' ' A' ' 51' ' ' PRO . 43.6 mt . . . . . 0 C--O 1.25 1.09 0 CA-C-O 118.802 -0.618 . . . . 2.8100000000000001 110.543 -172.792 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 51.6 ttm . . . . . 0 N--CA 1.481 1.081 0 CA-C-O 119.754 -0.165 . . . . 6.71 110.655 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 2' ' ' LYS . . . . . 0.426 ' HB2' ' O ' ' A' ' 38' ' ' VAL . 21.5 mmmt 53.63 -94.45 0.04 OUTLIER 'General case' 0 CA--C 1.516 -0.361 0 O-C-N 123.58 0.55 . . . . 4.0899999999999999 111.539 -175.689 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 3' ' ' ALA . . . . . 0.516 ' HA ' ' HB2' ' A' ' 37' ' ' PHE . . . 74.02 127.24 0.04 OUTLIER 'General case' 0 C--N 1.312 -1.056 0 CA-C-N 113.853 -1.521 . . . . 1.1000000000000001 113.037 174.191 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 4' ' ' THR . . . . . 0.65 ' H ' ' HB2' ' A' ' 37' ' ' PHE . 5.4 p -110.8 -48.72 3.1 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 114.473 -1.239 . . . . 0.97999999999999998 109.661 171.473 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 78.4 51.38 5.66 Favored Glycine 0 N--CA 1.45 -0.419 0 CA-C-N 115.453 -0.794 . . . . 0.33000000000000002 112.843 172.122 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 6' ' ' ILE . . . . . 0.774 HG21 ' HB ' ' A' ' 36' ' ' ILE . 1.4 tp -107.44 106.84 21.42 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 N-CA-C 109.317 -0.623 . . . . 1.1000000000000001 109.317 173.573 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . 0.732 ' HA ' ' O ' ' A' ' 34' ' ' LEU . 25.2 t -78.1 135.2 26.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 116.124 -0.489 . . . . 1.0800000000000001 110.469 179.447 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.418 ' HD3' ' N ' ' B' ' 9' ' ' ARG . 0.8 OUTLIER -133.36 122.51 23.89 Favored 'General case' 0 N--CA 1.439 -0.999 0 N-CA-C 107.345 -1.354 . . . . 2.3599999999999999 107.345 -178.871 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 9' ' ' ARG . . . . . 0.542 ' HA ' ' HA ' ' A' ' 33' ' ' PRO . 18.3 ttp180 -81.7 104.57 12.19 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 108.596 -0.89 . . . . 3.2000000000000002 108.596 172.986 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 10' ' ' ILE . . . . . 0.787 HG22 HD13 ' A' ' 34' ' ' LEU . 0.3 OUTLIER -10.79 -101.27 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 O-C-N 125.631 1.832 . . . . 1.0700000000000001 114.234 -175.701 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . 0.652 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 2.4 p-10 162.2 -169.87 0.01 OUTLIER 'General case' 0 CA--C 1.512 -0.502 0 N-CA-C 107.672 -1.233 . . . . 1.1799999999999999 107.672 176.043 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 12' ' ' ASP . . . . . 0.496 ' HA ' ' HG2' ' A' ' 30' ' ' GLU . 3.3 p30 -78.13 7.74 5.82 Favored 'General case' 0 C--N 1.325 -0.463 0 O-C-N 123.174 0.296 . . . . 2.3900000000000001 111.251 -177.608 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 13' ' ' LEU . . . . . 0.405 ' HB3' ' HD2' ' B' ' 15' ' ' ARG . 2.4 tm? -119.03 -61.53 1.63 Allowed 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 109.8 -0.445 . . . . 1.1000000000000001 109.8 171.603 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 14' ' ' GLY . . . . . 0.503 ' O ' ' HB ' ' A' ' 18' ' ' ILE . . . 137.72 14.78 0.77 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.265 -0.969 . . . . 0.23000000000000001 113.257 -178.565 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 15' ' ' ARG . . . . . 0.687 ' HG2' HG23 ' A' ' 17' ' ' VAL . 0.3 OUTLIER -81.08 154.68 26.68 Favored 'General case' 0 CA--C 1.493 -1.23 0 CA-C-O 121.659 0.743 . . . . 1.3899999999999999 109.72 177.325 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 16' ' ' VAL . . . . . 1.039 HG23 HG23 ' A' ' 16' ' ' VAL . 3.9 m -107.7 108.52 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.219 0 N-CA-C 106.998 -1.482 . . . . 1.97 106.998 170.357 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 17' ' ' VAL . . . . . 0.671 HG23 ' HG2' ' A' ' 15' ' ' ARG . 47.3 t -70.88 96.52 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.352 0 CA-C-N 114.597 -1.183 . . . . 1.0600000000000001 109.206 -174.354 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . 0.545 ' HB ' ' O ' ' A' ' 14' ' ' GLY . 34.3 mm -85.0 108.38 15.15 Favored Pre-proline 0 N--CA 1.449 -0.519 0 CA-C-N 115.401 -0.818 . . . . 1.6100000000000001 110.299 -177.612 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . 0.678 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 58.5 Cg_exo -47.29 141.79 13.23 Favored 'Trans proline' 0 N--CA 1.456 -0.724 0 C-N-CA 122.876 2.384 . . . . 0.33000000000000002 112.702 174.78 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 20' ' ' LYS . . . . . 0.954 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -59.3 -15.15 14.27 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.444 -0.798 . . . . 2.3199999999999998 111.789 178.207 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . 0.678 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 12.9 pt-20 -64.14 -26.16 68.41 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-O 120.706 0.288 . . . . 1.9199999999999999 111.45 -179.767 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 5.3 mp -87.16 -44.1 16.05 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.354 0 N-CA-C 107.901 -1.148 . . . . 1.24 107.901 -177.284 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 23' ' ' ARG . . . . . 0.599 ' HA ' ' HB2' ' B' ' 26' ' ' LEU . 0.0 OUTLIER -63.99 -26.32 68.52 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-N 115.147 -0.933 . . . . 1.8500000000000001 109.897 174.972 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 24' ' ' ARG . . . . . . . . . . . . . 32.3 ttm180 -65.58 -50.14 66.2 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.674 -0.694 . . . . 3.6899999999999999 110.917 172.213 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 28.2 m -63.29 -21.53 66.31 Favored 'General case' 0 CA--C 1.531 0.233 0 CA-C-O 121.527 0.68 . . . . 1.1599999999999999 110.47 174.4 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.62 ' HB3' HG13 ' B' ' 28' ' ' ILE . 1.6 mm? -74.21 -20.93 60.02 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.505 -0.77 . . . . 1.1100000000000001 110.915 173.399 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 27' ' ' ARG . . . . . 0.455 ' HB2' ' O ' ' B' ' 26' ' ' LEU . 0.0 OUTLIER 67.37 28.47 7.83 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 123.33 0.652 . . . . 3.77 110.827 -173.892 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 28' ' ' ILE . . . . . 0.878 HG21 ' H ' ' B' ' 29' ' ' ARG . 5.7 mt -121.49 -163.28 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.051 -0.522 . . . . 1.2 110.399 -176.657 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 29' ' ' ARG . . . . . 0.878 ' H ' HG21 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -157.93 -158.38 0.73 Allowed 'General case' 0 N--CA 1.467 0.414 0 C-N-CA 122.046 0.138 . . . . 2.7599999999999998 111.054 -169.87 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 30' ' ' GLU . . . . . 0.478 ' HG2' ' HA ' ' A' ' 12' ' ' ASP . 58.9 mp0 -69.33 30.84 0.03 OUTLIER 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 112.95 0.722 . . . . 1.1799999999999999 112.95 178.666 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . 0.511 ' H ' ' C ' ' B' ' 29' ' ' ARG . . . -145.56 25.68 1.82 Allowed Glycine 0 N--CA 1.441 -1.006 0 N-CA-C 110.073 -1.211 . . . . 0.34999999999999998 110.073 172.503 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 32' ' ' ASP . . . . . 0.547 ' O ' HG13 ' A' ' 10' ' ' ILE . 8.6 t70 -82.0 121.5 79.09 Favored Pre-proline 0 C--N 1.324 -0.538 0 CA-C-N 114.6 -0.8 . . . . 1.29 110.224 176.002 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 33' ' ' PRO . . . . . 0.734 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 7.8 Cg_endo -83.06 147.02 12.97 Favored 'Trans proline' 0 N--CA 1.433 -2.048 0 C-N-CA 122.163 1.909 . . . . 1.1000000000000001 110.432 173.351 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . 0.786 HD12 HG23 ' A' ' 10' ' ' ILE . 1.0 OUTLIER -137.53 149.28 46.63 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 109.6 -0.519 . . . . 1.1699999999999999 109.6 173.431 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 35' ' ' GLU . . . . . 0.71 ' HB3' ' HE3' ' B' ' 47' ' ' LYS . 45.8 tt0 -101.81 111.32 23.54 Favored 'General case' 0 C--N 1.297 -1.694 0 N-CA-C 107.242 -1.392 . . . . 1.1000000000000001 107.242 178.89 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 36' ' ' ILE . . . . . 0.794 ' HB ' HG21 ' A' ' 6' ' ' ILE . 2.8 mp -85.19 108.01 16.62 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.77 0 O-C-N 124.329 1.018 . . . . 1.3200000000000001 108.831 -179.678 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 37' ' ' PHE . . . . . 0.679 ' HB2' ' H ' ' A' ' 4' ' ' THR . 7.6 p90 -150.44 127.66 11.3 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 116.003 -0.544 . . . . 2.0299999999999998 109.866 176.851 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 38' ' ' VAL . . . . . 0.523 ' HA ' ' HA ' ' B' ' 44' ' ' VAL . 1.6 p -79.94 145.23 9.53 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 CA-C-N 116.446 -0.343 . . . . 0.89000000000000001 110.562 -177.529 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 39' ' ' ASP . . . . . 0.611 ' OD2' ' HD3' ' B' ' 40' ' ' ARG . 18.2 t70 -82.58 -47.39 12.18 Favored 'General case' 0 C--N 1.326 -0.439 0 O-C-N 123.966 0.791 . . . . 1.1399999999999999 111.318 -175.569 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 40' ' ' ARG . . . . . 0.611 ' HD3' ' OD2' ' B' ' 39' ' ' ASP . 0.7 OUTLIER -144.82 -78.75 0.19 Allowed 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 113.189 0.811 . . . . 3.3700000000000001 113.189 -176.457 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -97.63 -65.45 0.96 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.039 0.447 . . . . 1.3200000000000001 111.512 -171.096 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 42' ' ' GLY . . . . . 0.486 ' HA3' ' HD2' ' A' ' 48' ' ' LYS . . . -145.9 16.97 1.77 Allowed Glycine 0 N--CA 1.442 -0.912 0 C-N-CA 120.79 -0.719 . . . . 0.35999999999999999 111.651 -178.155 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 43' ' ' GLU . . . . . 0.686 ' HA ' ' O ' ' A' ' 46' ' ' LEU . 2.3 pm0 -91.96 107.36 19.16 Favored 'General case' 0 N--CA 1.445 -0.683 0 N-CA-C 109.835 -0.431 . . . . 2.0699999999999998 109.835 176.619 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 44' ' ' VAL . . . . . 0.578 ' HB ' HD12 ' A' ' 46' ' ' LEU . 2.1 t -89.33 131.69 35.98 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 109.536 -0.542 . . . . 1.02 109.536 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 45' ' ' ILE . . . . . 0.827 HG13 HG13 ' A' ' 45' ' ' ILE . 1.6 mp -107.06 120.64 58.73 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 N-CA-C 108.065 -1.087 . . . . 0.95999999999999996 108.065 -178.302 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 46' ' ' LEU . . . . . 0.788 HD11 HD13 ' A' ' 46' ' ' LEU . 0.9 OUTLIER -109.7 116.48 31.78 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 109.442 -0.577 . . . . 1.05 109.442 177.531 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 47' ' ' LYS . . . . . 0.71 ' HE3' ' HB3' ' B' ' 35' ' ' GLU . 0.0 OUTLIER -127.71 141.81 51.5 Favored 'General case' 0 C--N 1.318 -0.774 0 C-N-CA 119.372 -0.931 . . . . 1.3899999999999999 113.083 -177.722 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 48' ' ' LYS . . . . . 0.683 ' HE2' ' HG3' ' B' ' 51' ' ' PRO . 5.2 ptmt -43.4 -12.88 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.177 0 N-CA-C 118.157 2.651 . . . . 1.1899999999999999 118.157 -166.171 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 49' ' ' TYR . . . . . 0.741 ' CD1' HG22 ' A' ' 7' ' ' VAL . 22.4 t80 71.87 -55.77 0.66 Allowed 'General case' 0 N--CA 1.475 0.809 0 N-CA-C 113.374 0.879 . . . . 2.1000000000000001 113.374 172.738 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 50' ' ' SER . . . . . 0.691 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 33.9 t -51.15 -57.02 15.35 Favored Pre-proline 0 CA--C 1.535 0.369 0 C-N-CA 122.867 0.467 . . . . 1.77 111.11 -175.186 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 51' ' ' PRO . . . . . 0.691 ' HD3' ' HB3' ' B' ' 50' ' ' SER . 48.9 Cg_endo -89.58 13.51 2.37 Favored 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 121.995 1.796 . . . . 0.59999999999999998 111.229 171.052 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 52' ' ' ILE . . . . . . . . . . . . . 3.0 mt 55.17 -133.33 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.571 0 CA-C-N 114.97 -1.014 . . . . 1.3899999999999999 108.487 -172.763 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 53' ' ' SER . . . . . 0.483 ' HA ' ' HG3' ' B' ' 47' ' ' LYS . 4.9 p -86.04 -44.81 12.0 Favored 'General case' 0 C--N 1.309 -1.169 0 CA-C-O 120.937 0.398 . . . . 2.04 110.574 178.572 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 54' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -160.18 19.76 0.15 Allowed 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.824 -0.626 . . . . 2.6200000000000001 111.591 -178.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 55' ' ' LEU . . . . . . . . . . . . . 54.4 mt . . . . . 0 C--O 1.248 0.993 0 O-C-N 123.497 0.498 . . . . 2.8700000000000001 110.601 -170.934 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 90.0 mtp . . . . . 0 N--CA 1.48 1.054 0 CA-C-O 120.877 0.37 . . . . 6.3300000000000001 110.452 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.639 ' HA ' ' CE ' ' A' ' 2' ' ' LYS . 2.2 mmpt? -128.76 -140.98 0.24 Allowed 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.371 -0.377 . . . . 4.1699999999999999 110.299 178.488 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.451 ' H ' ' HB3' ' A' ' 2' ' ' LYS . . . 67.54 102.64 0.05 OUTLIER 'General case' 0 C--N 1.327 -0.381 0 O-C-N 124.066 0.854 . . . . 1.1299999999999999 111.204 -174.593 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.408 ' OG1' ' HA ' ' B' ' 37' ' ' PHE . 17.9 p -92.29 -50.34 5.7 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.227 -0.897 . . . . 1.0900000000000001 111.756 -177.957 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 79.78 49.69 5.96 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.46 -0.876 . . . . 0.32000000000000001 113.208 175.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.742 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.1 tp -107.39 113.18 42.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 N-CA-C 109.17 -0.678 . . . . 1.0900000000000001 109.17 173.731 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.724 ' HA ' ' O ' ' B' ' 34' ' ' LEU . 39.7 t -83.43 135.52 24.65 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-O 120.922 0.391 . . . . 1.1299999999999999 110.798 -178.477 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.573 ' HB3' ' CD1' ' B' ' 36' ' ' ILE . 6.8 tpp180 -129.23 123.25 31.5 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 107.568 -1.271 . . . . 2.6099999999999999 107.568 -179.352 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.528 ' N ' ' HD3' ' A' ' 8' ' ' ARG . 4.9 tpp180 -84.43 104.44 14.44 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 108.328 -0.99 . . . . 3.4100000000000001 108.328 173.19 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.71 HG23 HD12 ' B' ' 34' ' ' LEU . 0.2 OUTLIER -12.23 -103.67 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.115 0 O-C-N 125.365 1.666 . . . . 1.0700000000000001 114.701 -176.515 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . 0.568 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 5.8 p-10 161.35 -160.27 0.0 OUTLIER 'General case' 0 CA--C 1.512 -0.485 0 N-CA-C 107.937 -1.134 . . . . 1.1299999999999999 107.937 177.019 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -72.66 -22.88 60.85 Favored 'General case' 0 C--N 1.323 -0.576 0 O-C-N 123.386 0.429 . . . . 2.2599999999999998 110.878 -178.455 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -98.42 -60.52 1.53 Allowed 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.29 -0.414 . . . . 1.23 110.233 178.287 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.453 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 136.43 18.7 0.7 Allowed Glycine 0 N--CA 1.445 -0.735 0 C-N-CA 120.073 -1.061 . . . . 0.25 113.393 -179.186 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.67 ' HG2' HG23 ' B' ' 17' ' ' VAL . 0.0 OUTLIER -79.1 153.35 30.22 Favored 'General case' 0 CA--C 1.507 -0.693 0 CA-C-N 118.028 0.914 . . . . 0.88 109.621 179.569 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.805 HG23 HD12 ' B' ' 46' ' ' LEU . 98.0 t -104.4 100.32 10.25 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.455 0 N-CA-C 107.628 -1.249 . . . . 1.99 107.628 172.353 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.756 HG23 ' HG2' ' B' ' 15' ' ' ARG . 91.0 t -68.14 98.89 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.909 0 CA-C-N 115.068 -0.969 . . . . 1.0600000000000001 110.21 -173.43 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.731 HG21 HD12 ' A' ' 22' ' ' ILE . 8.7 mt -92.25 114.02 60.96 Favored Pre-proline 0 N--CA 1.445 -0.708 0 CA-C-N 115.643 -0.708 . . . . 1.5600000000000001 110.778 -178.551 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.6 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 47.5 Cg_exo -46.08 145.89 4.89 Favored 'Trans proline' 0 N--CA 1.458 -0.599 0 C-N-CA 123.1 2.533 . . . . 0.34999999999999998 112.821 174.168 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.811 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -60.85 -16.47 41.63 Favored 'General case' 0 C--O 1.211 -0.949 0 CA-C-N 115.478 -0.783 . . . . 2.1299999999999999 111.353 179.321 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.6 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 11.1 pt-20 -66.1 -19.91 65.99 Favored 'General case' 0 C--O 1.236 0.363 0 N-CA-C 111.767 0.284 . . . . 1.3200000000000001 111.767 -178.283 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.731 HD12 HG21 ' A' ' 18' ' ' ILE . 5.0 mp -87.49 -50.8 13.48 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.635 0 N-CA-C 107.854 -1.165 . . . . 1.0800000000000001 107.854 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . 0.561 ' HA ' ' HB2' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -56.1 -31.98 63.75 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 115.492 -0.776 . . . . 2.02 110.358 171.879 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 10.2 ttt180 -63.55 -52.26 61.87 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.313 -0.858 . . . . 3.3999999999999999 110.943 174.29 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 22.5 m -66.53 -22.75 66.16 Favored 'General case' 0 C--O 1.222 -0.353 0 CA-C-O 121.182 0.515 . . . . 1.1499999999999999 110.697 175.525 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.736 ' HB3' HG13 ' A' ' 28' ' ' ILE . 2.0 mm? -65.81 -19.71 65.98 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.865 -0.607 . . . . 1.1599999999999999 110.614 173.928 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.531 ' HB2' ' O ' ' A' ' 26' ' ' LEU . 0.3 OUTLIER 72.3 21.36 3.84 Favored 'General case' 0 N--CA 1.466 0.358 0 O-C-N 124.066 0.854 . . . . 3.6800000000000002 110.371 -172.746 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.736 HG13 ' HB3' ' A' ' 26' ' ' LEU . 3.0 mt -122.18 -163.0 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.726 -0.67 . . . . 1.1000000000000001 110.175 -174.154 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.697 ' H ' HG21 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -153.18 -161.41 1.28 Allowed 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 111.481 0.178 . . . . 3.0699999999999998 111.481 -167.944 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -73.79 36.62 0.09 Allowed 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 121.961 0.886 . . . . 1.23 111.51 179.351 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.558 ' H ' ' C ' ' A' ' 29' ' ' ARG . . . -152.19 24.78 0.89 Allowed Glycine 0 N--CA 1.44 -1.099 0 CA-C-N 114.15 -1.387 . . . . 0.35999999999999999 109.894 174.026 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.597 ' O ' HG13 ' B' ' 10' ' ' ILE . 13.2 t0 -82.95 124.54 76.66 Favored Pre-proline 0 C--N 1.326 -0.436 0 CA-C-N 114.512 -0.844 . . . . 1.26 109.931 175.68 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.706 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 4.7 Cg_endo -82.94 152.5 14.5 Favored 'Trans proline' 0 N--CA 1.435 -1.939 0 C-N-CA 122.187 1.924 . . . . 1.3 110.719 173.777 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.793 HD12 HG22 ' B' ' 10' ' ' ILE . 0.6 OUTLIER -140.66 152.8 45.66 Favored 'General case' 0 C--N 1.305 -1.362 0 N-CA-C 109.14 -0.689 . . . . 1.21 109.14 171.994 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.896 ' HB3' ' HD2' ' A' ' 47' ' ' LYS . 39.4 tt0 -105.87 111.24 23.81 Favored 'General case' 0 CA--C 1.486 -1.515 0 N-CA-C 107.501 -1.296 . . . . 1.1200000000000001 107.501 -179.051 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.894 HG13 HD21 ' A' ' 46' ' ' LEU . 2.5 mp -85.17 110.21 19.09 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.98 0 O-C-N 124.648 1.217 . . . . 1.1599999999999999 108.478 -179.169 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . 0.63 ' HB2' ' H ' ' B' ' 4' ' ' THR . 1.8 p90 -150.55 124.61 9.34 Favored 'General case' 0 C--N 1.313 -1.02 0 CA-C-N 116.162 -0.472 . . . . 2.0099999999999998 109.747 175.6 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.528 HG11 ' HB3' ' B' ' 2' ' ' LYS . 1.7 p -80.83 136.34 23.4 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 CA-C-O 121.149 0.5 . . . . 1.05 110.778 -178.33 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.661 ' HB3' ' HG3' ' A' ' 40' ' ' ARG . 9.8 t70 -75.59 -45.01 40.14 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.036 -0.984 . . . . 1.1100000000000001 110.68 -175.498 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . 0.661 ' HG3' ' HB3' ' A' ' 39' ' ' ASP . 7.6 mtp180 -132.13 -73.35 0.52 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.672 -0.694 . . . . 2.8799999999999999 112.267 -165.807 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -129.67 -65.11 0.85 Allowed 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.284 -0.871 . . . . 1.53 111.09 -173.408 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.56 ' HA3' HD13 ' B' ' 26' ' ' LEU . . . -131.88 6.36 5.46 Favored Glycine 0 CA--C 1.501 -0.832 0 CA-C-N 114.838 -1.074 . . . . 0.34000000000000002 111.812 -173.852 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.562 ' HA ' ' O ' ' B' ' 46' ' ' LEU . 2.2 pm0 -93.58 105.69 17.71 Favored 'General case' 0 N--CA 1.443 -0.793 0 CA-C-O 121.009 0.433 . . . . 1.97 109.929 175.317 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.594 HG12 HG21 ' A' ' 36' ' ' ILE . 2.0 t -88.82 132.31 34.0 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.988 0 CA-C-N 115.566 -0.743 . . . . 1.0600000000000001 109.864 178.907 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.849 HG13 HG13 ' B' ' 45' ' ' ILE . 1.4 mp -110.11 115.96 51.06 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 N-CA-C 108.239 -1.023 . . . . 1.01 108.239 -177.372 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 1.022 HD11 HD11 ' B' ' 46' ' ' LEU . 0.5 OUTLIER -109.48 116.76 32.41 Favored 'General case' 0 C--N 1.319 -0.759 0 O-C-N 123.703 0.627 . . . . 1.1299999999999999 109.584 -178.871 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.896 ' HD2' ' HB3' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -122.84 150.37 42.95 Favored 'General case' 0 C--O 1.215 -0.732 0 C-N-CA 119.066 -1.054 . . . . 1.25 112.169 179.121 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.548 ' HA ' ' O ' ' A' ' 33' ' ' PRO . 1.5 ptmt -44.92 -16.45 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.24 0 N-CA-C 117.13 2.27 . . . . 1.0900000000000001 117.13 -168.188 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.754 ' CD1' HG22 ' B' ' 7' ' ' VAL . 19.9 t80 74.35 -50.36 0.68 Allowed 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 112.689 0.625 . . . . 2.1400000000000001 112.689 174.293 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.705 ' HB3' ' HD3' ' A' ' 51' ' ' PRO . 22.7 t -48.1 -50.83 52.95 Favored Pre-proline 0 CA--C 1.538 0.493 0 C-N-CA 122.585 0.354 . . . . 1.95 111.395 -177.368 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.705 ' HD3' ' HB3' ' A' ' 50' ' ' SER . 36.3 Cg_endo -95.25 10.31 1.66 Allowed 'Trans proline' 0 N--CA 1.453 -0.878 0 C-N-CA 122.601 2.2 . . . . 0.59999999999999998 111.484 172.31 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 1.1 mt 48.91 -141.78 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 115.044 -0.98 . . . . 1.4199999999999999 109.262 -170.466 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.6 ' HB3' ' HE2' ' A' ' 47' ' ' LYS . 4.2 p -104.63 76.25 1.27 Allowed 'General case' 0 N--CA 1.431 -1.416 0 N-CA-C 109.679 -0.489 . . . . 2.23 109.679 174.266 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 1.6 tp10 73.02 110.19 0.07 Allowed 'General case' 0 C--O 1.232 0.173 0 CA-C-N 115.052 -0.976 . . . . 2.8900000000000001 110.721 -175.583 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 81.8 mt . . . . . 0 C--O 1.249 1.075 0 CA-C-N 115.84 -0.618 . . . . 2.8100000000000001 110.165 176.863 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 45.1 mtp . . . . . 0 N--CA 1.484 1.266 0 CA-C-O 120.853 0.358 . . . . 6.71 110.765 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 2' ' ' LYS . . . . . 0.675 ' CE ' ' HA ' ' B' ' 2' ' ' LYS . 2.5 mmpt? -97.44 -141.62 0.29 Allowed 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.377 -0.374 . . . . 4.0899999999999999 111.873 -177.802 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 3' ' ' ALA . . . . . 0.546 ' HA ' ' HD2' ' A' ' 37' ' ' PHE . . . 72.37 116.47 0.05 Allowed 'General case' 0 C--N 1.33 -0.252 0 O-C-N 124.274 0.984 . . . . 1.1000000000000001 110.546 -169.34 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 4' ' ' THR . . . . . 0.63 ' H ' ' HB2' ' A' ' 37' ' ' PHE . 28.5 p -107.85 -52.56 2.75 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.634 -0.712 . . . . 0.97999999999999998 111.068 -176.947 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 82.26 50.98 4.58 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.995 -0.621 . . . . 0.33000000000000002 112.797 177.164 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 6' ' ' ILE . . . . . 0.805 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.0 OUTLIER -106.68 108.24 24.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 N-CA-C 109.322 -0.621 . . . . 1.1000000000000001 109.322 173.316 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . 0.754 HG22 ' CD1' ' A' ' 49' ' ' TYR . 23.0 t -80.52 136.49 23.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-N 116.231 -0.44 . . . . 1.0800000000000001 111.217 179.673 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.549 ' HD3' ' N ' ' B' ' 9' ' ' ARG . 1.1 tpp180 -131.97 126.94 35.25 Favored 'General case' 0 N--CA 1.446 -0.625 0 N-CA-C 107.61 -1.255 . . . . 2.3599999999999999 107.61 178.384 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 9' ' ' ARG . . . . . 0.549 ' N ' ' HD3' ' B' ' 8' ' ' ARG . 1.7 tpp180 -86.3 103.22 14.69 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 108.606 -0.887 . . . . 3.2000000000000002 108.606 173.858 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 10' ' ' ILE . . . . . 0.793 HG22 HD12 ' A' ' 34' ' ' LEU . 0.2 OUTLIER -10.17 -107.37 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.264 0 O-C-N 125.351 1.657 . . . . 1.0700000000000001 114.749 -177.828 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . 0.659 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 1.7 p-10 163.39 -166.38 0.01 OUTLIER 'General case' 0 CA--C 1.518 -0.286 0 N-CA-C 108.327 -0.99 . . . . 1.1799999999999999 108.327 177.441 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -66.28 -19.85 65.93 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.355 0.598 . . . . 2.3900000000000001 110.793 -179.04 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 13' ' ' LEU . . . . . 0.4 ' H ' ' CG ' ' B' ' 11' ' ' ASP . 2.9 tm? -101.59 -61.8 1.33 Allowed 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.711 -0.677 . . . . 1.1000000000000001 110.796 -179.059 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 137.96 19.5 0.55 Allowed Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.807 -0.711 . . . . 0.23000000000000001 112.116 -178.806 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 15' ' ' ARG . . . . . 0.756 ' HG2' HG23 ' A' ' 17' ' ' VAL . 2.7 mtm180 -70.22 147.65 49.54 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-O 121.244 0.545 . . . . 1.3899999999999999 110.593 177.361 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 16' ' ' VAL . . . . . 0.709 HG22 HD12 ' A' ' 46' ' ' LEU . 63.7 t -106.69 97.07 5.18 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.237 0 N-CA-C 107.644 -1.243 . . . . 1.97 107.644 166.767 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 17' ' ' VAL . . . . . 0.67 HG23 ' HG2' ' A' ' 15' ' ' ARG . 64.3 t -67.42 98.92 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 CA-C-N 115.62 -0.718 . . . . 1.0600000000000001 110.364 -171.732 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . 0.506 ' H ' ' HA ' ' A' ' 15' ' ' ARG . 6.9 mt -90.45 113.87 59.11 Favored Pre-proline 0 N--CA 1.442 -0.872 0 CA-C-N 115.181 -0.918 . . . . 1.6100000000000001 110.562 -179.624 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . 0.556 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 81.3 Cg_exo -50.19 147.21 16.24 Favored 'Trans proline' 0 N--CA 1.458 -0.59 0 C-N-CA 123.056 2.504 . . . . 0.33000000000000002 112.567 174.123 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 20' ' ' LYS . . . . . 0.941 ' HD3' ' H ' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -64.94 -15.63 62.36 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 115.649 -0.705 . . . . 2.3199999999999998 111.678 -178.795 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . 0.556 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 1.3 pm0 -63.13 -21.8 66.44 Favored 'General case' 0 C--O 1.237 0.439 0 N-CA-C 111.854 0.316 . . . . 1.9199999999999999 111.854 177.458 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 5.2 mp -87.61 -47.52 15.69 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 N-CA-C 108.488 -0.93 . . . . 1.24 108.488 -178.406 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 23' ' ' ARG . . . . . 0.541 ' HA ' ' HB2' ' B' ' 26' ' ' LEU . 0.0 OUTLIER -61.93 -28.28 69.42 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.262 -0.881 . . . . 1.8500000000000001 109.231 174.022 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 24' ' ' ARG . . . . . . . . . . . . . 55.0 ttp180 -65.78 -51.92 55.07 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 114.91 -1.041 . . . . 3.6899999999999999 110.988 174.639 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 18.7 m -63.65 -28.74 70.12 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-O 121.525 0.679 . . . . 1.1599999999999999 110.152 176.23 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.653 ' HB3' HG13 ' B' ' 28' ' ' ILE . 1.4 mm? -64.08 -19.9 65.57 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 115.009 -0.996 . . . . 1.1100000000000001 110.678 174.091 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 27' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER 70.8 24.02 4.32 Favored 'General case' 0 C--N 1.342 0.242 0 CA-C-O 121.587 0.708 . . . . 3.77 110.154 -177.105 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 28' ' ' ILE . . . . . 0.823 HG23 ' H ' ' B' ' 29' ' ' ARG . 4.0 mt -119.25 -162.55 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.133 -0.939 . . . . 1.2 110.058 -176.889 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 29' ' ' ARG . . . . . 0.823 ' H ' HG23 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -152.99 -161.42 1.29 Allowed 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 111.618 0.229 . . . . 2.7599999999999998 111.618 -171.584 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 30' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -72.4 34.06 0.06 Allowed 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 121.858 0.837 . . . . 1.1799999999999999 111.925 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . 0.536 ' H ' ' C ' ' B' ' 29' ' ' ARG . . . -150.73 30.31 1.02 Allowed Glycine 0 N--CA 1.436 -1.365 0 N-CA-C 109.636 -1.385 . . . . 0.34999999999999998 109.636 172.79 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 32' ' ' ASP . . . . . 0.517 ' N ' HD11 ' A' ' 10' ' ' ILE . 6.9 t70 -85.22 128.72 58.62 Favored Pre-proline 0 CA--C 1.511 -0.523 0 CA-C-N 114.451 -0.874 . . . . 1.29 110.271 174.74 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 33' ' ' PRO . . . . . 0.696 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 10.9 Cg_endo -86.76 148.48 8.42 Favored 'Trans proline' 0 N--CA 1.433 -2.07 0 C-N-CA 122.128 1.885 . . . . 1.1000000000000001 111.469 173.195 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . 0.724 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.8 OUTLIER -137.53 148.34 45.9 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 109.273 -0.64 . . . . 1.1699999999999999 109.273 173.661 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 35' ' ' GLU . . . . . 0.648 ' O ' ' HA ' ' B' ' 46' ' ' LEU . 77.9 tt0 -104.68 111.84 24.71 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 108.11 -1.07 . . . . 1.1000000000000001 108.11 -179.535 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 36' ' ' ILE . . . . . 0.885 HG13 HD22 ' B' ' 46' ' ' LEU . 3.5 mp -86.1 109.34 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.869 0 O-C-N 124.716 1.26 . . . . 1.3200000000000001 109.108 -177.964 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 37' ' ' PHE . . . . . 0.422 ' HB2' ' HA ' ' A' ' 3' ' ' ALA . 16.5 p90 -149.82 126.77 11.16 Favored 'General case' 0 C--N 1.316 -0.88 0 CA-C-N 115.922 -0.581 . . . . 2.0299999999999998 109.954 175.415 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 38' ' ' VAL . . . . . 0.497 ' HA ' ' HA ' ' B' ' 44' ' ' VAL . 1.3 p -80.55 139.62 17.87 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.78 0 CA-C-O 121.361 0.6 . . . . 0.89000000000000001 111.16 -177.911 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 39' ' ' ASP . . . . . 0.587 ' HB2' HD11 ' B' ' 45' ' ' ILE . 7.1 t70 -74.81 -49.86 19.22 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 114.591 -1.186 . . . . 1.1399999999999999 110.472 -178.009 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 40' ' ' ARG . . . . . 0.555 ' HG3' ' HB3' ' B' ' 39' ' ' ASP . 13.8 mtp180 -132.78 -72.87 0.51 Allowed 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 112.604 0.594 . . . . 3.3700000000000001 112.604 -168.434 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -124.69 -67.65 0.9 Allowed 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.359 -0.837 . . . . 1.3200000000000001 110.986 -172.469 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 42' ' ' GLY . . . . . 0.463 ' HA3' HD13 ' A' ' 26' ' ' LEU . . . -129.75 9.56 6.08 Favored Glycine 0 N--CA 1.441 -1.028 0 CA-C-N 114.699 -1.137 . . . . 0.35999999999999999 112.142 -176.094 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 43' ' ' GLU . . . . . 0.477 ' HA ' ' O ' ' A' ' 46' ' ' LEU . 2.3 pm0 -93.13 104.74 16.91 Favored 'General case' 0 N--CA 1.446 -0.625 0 N-CA-C 109.794 -0.447 . . . . 2.0699999999999998 109.794 176.199 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 44' ' ' VAL . . . . . 0.572 HG12 HG22 ' B' ' 36' ' ' ILE . 2.0 t -89.42 134.05 29.77 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.886 0 N-CA-C 109.805 -0.443 . . . . 1.02 109.805 179.071 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 45' ' ' ILE . . . . . 0.849 HG13 HG13 ' A' ' 45' ' ' ILE . 1.6 mp -110.17 116.36 52.09 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 N-CA-C 108.095 -1.076 . . . . 0.95999999999999996 108.095 -177.908 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 46' ' ' LEU . . . . . 1.022 HD11 HD11 ' A' ' 46' ' ' LEU . 0.7 OUTLIER -109.4 116.25 31.49 Favored 'General case' 0 C--N 1.317 -0.838 0 O-C-N 123.67 0.606 . . . . 1.05 109.569 179.577 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 47' ' ' LYS . . . . . 0.609 ' HE3' ' HB3' ' B' ' 35' ' ' GLU . 0.0 OUTLIER -125.01 146.36 49.46 Favored 'General case' 0 C--N 1.315 -0.892 0 C-N-CA 119.652 -0.819 . . . . 1.3899999999999999 112.347 -177.865 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 48' ' ' LYS . . . . . 0.522 ' HG3' ' HD2' ' B' ' 51' ' ' PRO . 3.7 ptmt -45.89 -10.61 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.147 0 N-CA-C 117.812 2.523 . . . . 1.1899999999999999 117.812 -166.301 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 49' ' ' TYR . . . . . 0.696 ' HB3' ' HB2' ' B' ' 33' ' ' PRO . 23.7 t80 72.07 -51.17 0.7 Allowed 'General case' 0 N--CA 1.47 0.559 0 N-CA-C 112.955 0.724 . . . . 2.1000000000000001 112.955 172.711 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 50' ' ' SER . . . . . 0.585 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 48.3 t -51.4 -56.75 17.91 Favored Pre-proline 0 CA--C 1.535 0.383 0 C-N-CA 122.597 0.359 . . . . 1.77 111.249 -175.133 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 51' ' ' PRO . . . . . 0.585 ' HD3' ' HB3' ' B' ' 50' ' ' SER . 57.8 Cg_endo -88.3 12.35 2.84 Favored 'Trans proline' 0 C--N 1.35 0.649 0 C-N-CA 121.83 1.687 . . . . 0.59999999999999998 111.44 170.694 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 52' ' ' ILE . . . . . . . . . . . . . 1.3 mt 50.61 -140.58 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.518 -0.273 0 CA-C-N 115.056 -0.975 . . . . 1.3899999999999999 108.952 -173.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 53' ' ' SER . . . . . 0.507 ' O ' ' HB2' ' B' ' 54' ' ' GLU . 7.9 p -109.72 76.97 1.02 Allowed 'General case' 0 N--CA 1.434 -1.249 0 N-CA-C 108.992 -0.744 . . . . 2.04 108.992 174.446 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 54' ' ' GLU . . . . . 0.507 ' HB2' ' O ' ' B' ' 53' ' ' SER . 6.1 mp0 70.84 124.33 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.356 0 O-C-N 123.899 0.749 . . . . 2.6200000000000001 110.034 -165.752 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 55' ' ' LEU . . . . . . . . . . . . . 96.5 mt . . . . . 0 C--O 1.246 0.897 0 CA-C-O 118.838 -0.601 . . . . 2.8700000000000001 110.518 177.203 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 23.0 mmt . . . . . 0 N--CA 1.48 1.033 0 N-CA-C 109.78 -0.452 . . . . 6.3300000000000001 109.78 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.407 ' HA ' ' HD2' ' A' ' 2' ' ' LYS . 13.3 mmmm 58.76 -141.3 0.7 Allowed 'General case' 0 C--O 1.235 0.338 0 CA-C-N 115.999 -0.546 . . . . 4.1699999999999999 111.372 176.13 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . 70.05 141.51 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 O-C-N 124.211 0.944 . . . . 1.1299999999999999 111.891 -176.181 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.767 ' H ' ' HB2' ' B' ' 37' ' ' PHE . 21.4 p -129.59 -57.2 1.13 Allowed 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.539 -0.755 . . . . 1.0900000000000001 110.636 -178.647 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 85.13 48.95 4.65 Favored Glycine 0 N--CA 1.441 -1.024 0 C-N-CA 120.315 -0.945 . . . . 0.32000000000000001 112.662 174.274 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.811 HG21 ' HB ' ' B' ' 36' ' ' ILE . 1.5 tp -105.49 109.09 26.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 N-CA-C 109.258 -0.645 . . . . 1.0900000000000001 109.258 173.851 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.759 ' HA ' ' O ' ' B' ' 34' ' ' LEU . 41.7 t -79.76 132.69 31.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 116.135 -0.484 . . . . 1.1299999999999999 110.715 179.284 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.491 ' HD3' ' N ' ' A' ' 9' ' ' ARG . 1.8 tpp180 -129.24 125.07 36.07 Favored 'General case' 0 N--CA 1.443 -0.781 0 N-CA-C 106.919 -1.512 . . . . 2.6099999999999999 106.919 -179.821 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.526 ' C ' HD12 ' A' ' 10' ' ' ILE . 0.6 OUTLIER -86.34 102.26 13.84 Favored 'General case' 0 C--N 1.315 -0.933 0 N-CA-C 108.202 -1.036 . . . . 3.4100000000000001 108.202 175.346 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.771 HG21 HD12 ' B' ' 34' ' ' LEU . 0.2 OUTLIER -5.56 -105.79 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.016 0 O-C-N 125.645 1.841 . . . . 1.0700000000000001 114.356 -176.468 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . 0.633 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 3.3 p-10 161.54 -166.45 0.0 OUTLIER 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 108.64 -0.874 . . . . 1.1299999999999999 108.64 177.28 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -68.11 -23.01 64.86 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 123.455 0.472 . . . . 2.2599999999999998 110.94 -177.84 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 2.5 tm? -100.64 -55.66 2.53 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.331 -0.395 . . . . 1.23 110.448 179.859 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.556 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 134.32 18.0 0.95 Allowed Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.449 -0.882 . . . . 0.25 113.069 -179.435 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.512 ' HG2' HG21 ' B' ' 17' ' ' VAL . 0.4 OUTLIER -76.66 156.19 32.8 Favored 'General case' 0 CA--C 1.51 -0.562 0 CA-C-N 117.625 0.712 . . . . 0.88 110.301 -179.564 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.716 HG21 HD13 ' B' ' 46' ' ' LEU . 89.8 t -111.04 98.3 6.88 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.23 0 N-CA-C 107.728 -1.212 . . . . 1.99 107.728 167.637 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.551 HG23 ' HG2' ' B' ' 15' ' ' ARG . 39.4 t -65.05 106.95 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 CA-C-N 115.249 -0.887 . . . . 1.0600000000000001 109.675 -173.702 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.446 ' HB ' ' O ' ' B' ' 14' ' ' GLY . 30.9 mm -95.82 107.88 36.88 Favored Pre-proline 0 N--CA 1.447 -0.625 0 CA-C-N 115.691 -0.686 . . . . 1.5600000000000001 110.117 -178.017 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.664 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 62.2 Cg_exo -47.44 146.06 7.85 Favored 'Trans proline' 0 N--CA 1.454 -0.821 0 C-N-CA 122.6 2.2 . . . . 0.34999999999999998 112.718 175.402 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.886 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -64.61 -14.0 55.93 Favored 'General case' 0 C--N 1.314 -0.935 0 CA-C-N 115.766 -0.652 . . . . 2.1299999999999999 111.251 179.813 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.664 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 11.5 pt-20 -63.78 -23.05 67.21 Favored 'General case' 0 C--O 1.239 0.501 0 N-CA-C 112.349 0.5 . . . . 1.3200000000000001 112.349 178.285 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.401 HD12 HG21 ' A' ' 18' ' ' ILE . 5.2 mp -87.39 -46.49 16.1 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.334 0 N-CA-C 108.096 -1.076 . . . . 1.0800000000000001 108.096 -178.635 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . 0.658 ' HA ' ' HB2' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -61.41 -27.19 68.36 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 114.941 -1.027 . . . . 2.02 109.219 172.994 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 74.9 ttt180 -63.26 -51.48 65.99 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 114.75 -1.114 . . . . 3.3999999999999999 111.116 173.315 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 28.7 m -61.69 -31.14 71.26 Favored 'General case' 0 CA--C 1.532 0.252 0 CA-C-O 121.147 0.498 . . . . 1.1499999999999999 110.636 172.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.658 ' HB2' ' HA ' ' A' ' 23' ' ' ARG . 3.2 mm? -64.92 -21.35 66.81 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.617 -0.72 . . . . 1.1599999999999999 110.71 173.855 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 2.0 mpt_? 70.39 21.96 5.48 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 123.455 0.702 . . . . 3.6800000000000002 110.943 -176.764 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.662 HG23 ' H ' ' A' ' 29' ' ' ARG . 5.3 mt -117.49 -166.5 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.786 0 CA-C-N 115.159 -0.928 . . . . 1.1000000000000001 108.932 -177.896 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.662 ' H ' HG23 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -148.5 -153.69 0.51 Allowed 'General case' 0 C--N 1.323 -0.557 0 O-C-N 122.13 -0.356 . . . . 3.0699999999999998 111.286 -175.157 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . 0.425 ' CD ' HH21 ' A' ' 23' ' ' ARG . 0.6 OUTLIER -75.72 44.66 0.3 Allowed 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 122.089 0.947 . . . . 1.23 112.188 -177.787 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.556 ' CA ' HD12 ' B' ' 10' ' ' ILE . . . -159.31 29.3 0.4 Allowed Glycine 0 N--CA 1.441 -1.006 0 CA-C-N 113.975 -1.466 . . . . 0.35999999999999999 109.547 172.466 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.589 ' O ' HG13 ' B' ' 10' ' ' ILE . 11.8 t70 -88.81 128.9 50.58 Favored Pre-proline 0 CA--C 1.514 -0.407 0 N-CA-C 109.351 -0.611 . . . . 1.26 109.351 174.549 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.683 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 3.8 Cg_endo -83.81 150.04 12.64 Favored 'Trans proline' 0 N--CA 1.435 -1.936 0 C-N-CA 122.18 1.92 . . . . 1.3 110.804 175.175 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.789 HD12 HG22 ' B' ' 10' ' ' ILE . 0.6 OUTLIER -139.68 153.75 47.34 Favored 'General case' 0 N--CA 1.43 -1.428 0 N-CA-C 109.302 -0.629 . . . . 1.21 109.302 172.023 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.888 ' HB3' ' HD2' ' A' ' 47' ' ' LYS . 33.8 tt0 -109.25 114.57 28.38 Favored 'General case' 0 C--N 1.297 -1.675 0 N-CA-C 108.392 -0.966 . . . . 1.1200000000000001 108.392 -178.316 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.849 ' HB ' HG23 ' B' ' 6' ' ' ILE . 3.2 mp -86.12 110.05 19.42 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.944 0 O-C-N 124.843 1.339 . . . . 1.1599999999999999 109.226 -178.766 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . 0.658 ' HD1' ' HA ' ' B' ' 3' ' ' ALA . 0.5 OUTLIER -149.76 125.74 10.57 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 116.211 -0.45 . . . . 2.0099999999999998 109.874 175.488 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.572 HG12 ' HB3' ' B' ' 2' ' ' LYS . 1.2 p -80.51 137.09 22.06 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 CA-C-O 121.191 0.52 . . . . 1.05 110.749 -179.854 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.522 ' HB3' ' HG2' ' A' ' 40' ' ' ARG . 9.9 t70 -88.65 -64.93 1.07 Allowed 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 114.617 -1.174 . . . . 1.1100000000000001 111.902 -171.459 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . 0.522 ' HG2' ' HB3' ' A' ' 39' ' ' ASP . 0.0 OUTLIER -106.58 -84.37 0.52 Allowed 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 114.899 -1.046 . . . . 2.8799999999999999 111.303 -165.759 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -111.37 -72.58 0.71 Allowed 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.12 -0.491 . . . . 1.53 110.88 -177.518 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -130.35 24.66 4.4 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.776 -0.726 . . . . 0.34000000000000002 111.638 179.276 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.539 ' HB3' HG23 ' B' ' 45' ' ' ILE . 2.3 mt-10 -97.95 113.0 24.72 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.126 -0.694 . . . . 1.97 109.126 178.465 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.52 ' HA ' ' HA ' ' A' ' 38' ' ' VAL . 1.8 t -90.4 132.95 33.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 N-CA-C 109.573 -0.529 . . . . 1.0600000000000001 109.573 178.942 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.815 HG13 HG13 ' B' ' 45' ' ' ILE . 1.6 mp -111.68 117.5 55.28 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 N-CA-C 108.575 -0.898 . . . . 1.01 108.575 -175.389 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.977 HD12 HD12 ' B' ' 46' ' ' LEU . 0.5 OUTLIER -110.13 117.09 32.79 Favored 'General case' 0 C--N 1.32 -0.706 0 O-C-N 123.676 0.61 . . . . 1.1299999999999999 109.874 179.825 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.888 ' HD2' ' HB3' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -126.44 151.9 47.12 Favored 'General case' 0 C--O 1.219 -0.55 0 C-N-CA 119.02 -1.072 . . . . 1.25 112.792 179.132 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.555 ' HA ' ' O ' ' A' ' 33' ' ' PRO . 1.9 ptmt -43.58 -16.29 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.09 0 N-CA-C 117.263 2.32 . . . . 1.0900000000000001 117.263 -168.381 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.72 ' CD1' HG22 ' B' ' 7' ' ' VAL . 17.9 t80 73.22 -54.58 0.69 Allowed 'General case' 0 N--CA 1.469 0.521 0 N-CA-C 112.561 0.578 . . . . 2.1400000000000001 112.561 174.379 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.67 ' HB3' ' HD3' ' A' ' 51' ' ' PRO . 19.6 t -50.85 -49.82 77.7 Favored Pre-proline 0 CA--C 1.537 0.473 0 O-C-N 123.335 0.397 . . . . 1.95 111.387 -175.105 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.67 ' HD3' ' HB3' ' A' ' 50' ' ' SER . 86.5 Cg_endo -96.18 12.45 1.21 Allowed 'Trans proline' 0 N--CA 1.453 -0.861 0 C-N-CA 122.401 2.067 . . . . 0.59999999999999998 111.658 171.213 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.637 HG13 HD23 ' A' ' 55' ' ' LEU . 1.3 mt 52.82 -140.47 0.02 OUTLIER 'Isoleucine or valine' 0 C--O 1.234 0.281 0 CA-C-N 115.423 -0.808 . . . . 1.4199999999999999 109.083 -173.946 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 69.3 m -102.34 5.86 40.06 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-O 121.493 0.663 . . . . 2.23 110.16 176.334 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 173.98 111.84 0.02 OUTLIER 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 114.099 -1.41 . . . . 2.8900000000000001 109.435 -173.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.637 HD23 HG13 ' A' ' 52' ' ' ILE . 0.2 OUTLIER . . . . . 0 C--O 1.25 1.085 0 CA-C-O 118.929 -0.558 . . . . 2.8100000000000001 109.907 179.666 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 26.5 mmt . . . . . 0 N--CA 1.483 1.205 0 N-CA-C 109.845 -0.428 . . . . 6.71 109.845 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 2' ' ' LYS . . . . . 0.572 ' HB3' HG12 ' A' ' 38' ' ' VAL . 21.3 mmmt 53.81 -133.76 1.72 Allowed 'General case' 0 CA--C 1.519 -0.23 0 CA-C-N 115.567 -0.742 . . . . 4.0899999999999999 112.044 -179.127 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 3' ' ' ALA . . . . . 0.658 ' HA ' ' HD1' ' A' ' 37' ' ' PHE . . . 69.07 124.47 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 O-C-N 124.145 0.903 . . . . 1.1000000000000001 110.419 -171.075 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 4' ' ' THR . . . . . 0.643 ' H ' ' HB2' ' A' ' 37' ' ' PHE . 11.3 p -115.87 -46.74 2.82 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.022 -0.535 . . . . 0.97999999999999998 111.248 -178.713 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 73.01 49.72 15.54 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 120.929 -0.653 . . . . 0.33000000000000002 113.137 172.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 6' ' ' ILE . . . . . 0.849 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.0 OUTLIER -106.73 110.55 32.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 N-CA-C 109.104 -0.702 . . . . 1.1000000000000001 109.104 174.841 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . 0.72 HG22 ' CD1' ' A' ' 49' ' ' TYR . 38.9 t -80.51 134.66 26.88 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.308 0.575 . . . . 1.0800000000000001 111.389 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.504 ' HB3' ' CD1' ' A' ' 36' ' ' ILE . 8.4 tpp180 -130.1 121.45 26.38 Favored 'General case' 0 N--CA 1.44 -0.948 0 N-CA-C 107.541 -1.281 . . . . 2.3599999999999999 107.541 -177.47 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 9' ' ' ARG . . . . . 0.471 ' N ' ' HD3' ' B' ' 8' ' ' ARG . 15.9 ttt180 -84.45 103.43 13.6 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 108.084 -1.08 . . . . 3.2000000000000002 108.084 173.766 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 10' ' ' ILE . . . . . 0.789 HG22 HD12 ' A' ' 34' ' ' LEU . 0.4 OUTLIER -9.2 -101.61 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.996 0 O-C-N 125.665 1.853 . . . . 1.0700000000000001 114.398 -174.707 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . 0.599 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 5.5 p-10 164.21 -154.07 0.0 OUTLIER 'General case' 0 C--O 1.219 -0.504 0 N-CA-C 108.773 -0.825 . . . . 1.1799999999999999 108.773 174.555 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -85.2 -9.18 58.1 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.047 0.451 . . . . 2.3900000000000001 110.617 -178.778 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 13' ' ' LEU . . . . . 0.441 ' HB3' ' HD2' ' B' ' 15' ' ' ARG . 3.0 tm? -109.5 -56.43 2.3 Favored 'General case' 0 N--CA 1.448 -0.537 0 CA-C-N 116.075 -0.511 . . . . 1.1000000000000001 109.935 176.496 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 14' ' ' GLY . . . . . 0.446 ' O ' ' HB ' ' A' ' 18' ' ' ILE . . . 133.16 20.85 0.89 Allowed Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.764 -0.732 . . . . 0.23000000000000001 112.689 -178.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 15' ' ' ARG . . . . . 0.551 ' HG2' HG23 ' A' ' 17' ' ' VAL . 1.5 mpt_? -78.23 154.08 31.35 Favored 'General case' 0 CA--C 1.509 -0.606 0 O-C-N 122.066 -0.667 . . . . 1.3899999999999999 110.189 179.293 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 16' ' ' VAL . . . . . 0.718 HG21 HD13 ' A' ' 46' ' ' LEU . 96.7 t -109.11 95.96 4.26 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 N-CA-C 107.475 -1.305 . . . . 1.97 107.475 168.722 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 17' ' ' VAL . . . . . 0.512 HG21 ' HG2' ' A' ' 15' ' ' ARG . 47.0 t -64.32 104.84 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.842 0 CA-C-N 114.96 -1.018 . . . . 1.0600000000000001 109.914 -173.04 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . 0.556 ' HB ' ' O ' ' A' ' 14' ' ' GLY . 26.6 mm -92.48 111.26 49.87 Favored Pre-proline 0 N--CA 1.446 -0.633 0 CA-C-N 115.647 -0.706 . . . . 1.6100000000000001 110.574 -177.463 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . 0.637 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 59.1 Cg_exo -48.49 142.39 17.79 Favored 'Trans proline' 0 N--CA 1.459 -0.534 0 C-N-CA 123.041 2.494 . . . . 0.33000000000000002 112.53 172.828 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 20' ' ' LYS . . . . . 0.935 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -59.44 -16.14 21.78 Favored 'General case' 0 C--O 1.211 -0.949 0 CA-C-N 115.243 -0.889 . . . . 2.3199999999999998 111.428 178.954 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . 0.637 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 10.6 pt-20 -65.5 -20.0 66.16 Favored 'General case' 0 C--O 1.234 0.284 0 N-CA-C 112.034 0.383 . . . . 1.9199999999999999 112.034 -178.226 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 22' ' ' ILE . . . . . 0.406 HD12 HG21 ' B' ' 18' ' ' ILE . 5.2 mp -87.26 -49.14 14.97 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 N-CA-C 108.433 -0.951 . . . . 1.24 108.433 179.848 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 23' ' ' ARG . . . . . 0.609 ' NE ' ' HA ' ' B' ' 29' ' ' ARG . 0.0 OUTLIER -55.33 -32.41 62.49 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-O 122.057 0.932 . . . . 1.8500000000000001 109.194 171.073 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 24' ' ' ARG . . . . . 0.461 ' N ' ' HD3' ' B' ' 23' ' ' ARG . 50.1 ttt180 -61.12 -53.72 53.52 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-N 114.021 -1.445 . . . . 3.6899999999999999 111.195 176.222 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 53.7 m -61.07 -33.52 73.46 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-O 121.275 0.559 . . . . 1.1599999999999999 110.418 173.806 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.535 ' HB3' HG13 ' B' ' 28' ' ' ILE . 1.5 mm? -63.98 -20.26 65.76 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.21 -0.904 . . . . 1.1100000000000001 111.339 177.775 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 27' ' ' ARG . . . . . . . . . . . . . 6.5 mpt_? 69.79 28.38 4.37 Favored 'General case' 0 N--CA 1.471 0.6 0 CA-C-O 121.18 0.514 . . . . 3.77 110.505 -176.686 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 28' ' ' ILE . . . . . 0.855 HG23 ' H ' ' B' ' 29' ' ' ARG . 7.6 mt -122.47 -159.44 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 115.889 -0.596 . . . . 1.2 109.924 -175.583 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 29' ' ' ARG . . . . . 0.855 ' H ' HG23 ' B' ' 28' ' ' ILE . 0.1 OUTLIER -155.33 -159.9 0.98 Allowed 'General case' 0 N--CA 1.467 0.42 0 N-CA-C 112.496 0.554 . . . . 2.7599999999999998 112.496 -174.476 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 30' ' ' GLU . . . . . . . . . . . . . 38.6 mp0 -69.87 36.93 0.04 OUTLIER 'General case' 0 N--CA 1.472 0.655 0 CA-C-O 122.019 0.914 . . . . 1.1799999999999999 112.053 178.636 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . 0.578 ' H ' ' C ' ' B' ' 29' ' ' ARG . . . -156.46 32.97 0.59 Allowed Glycine 0 N--CA 1.431 -1.663 0 N-CA-C 109.547 -1.421 . . . . 0.34999999999999998 109.547 175.712 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 32' ' ' ASP . . . . . 0.541 ' O ' HG13 ' A' ' 10' ' ' ILE . 19.2 t0 -92.46 125.55 55.62 Favored Pre-proline 0 C--N 1.323 -0.569 0 CA-C-N 114.861 -0.669 . . . . 1.29 109.259 173.529 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 33' ' ' PRO . . . . . 0.782 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 3.5 Cg_endo -79.55 151.66 22.57 Favored 'Trans proline' 0 N--CA 1.436 -1.888 0 C-N-CA 122.216 1.944 . . . . 1.1000000000000001 110.043 174.215 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . 0.771 HD12 HG21 ' A' ' 10' ' ' ILE . 0.8 OUTLIER -140.73 149.35 42.04 Favored 'General case' 0 C--N 1.305 -1.326 0 N-CA-C 109.444 -0.576 . . . . 1.1699999999999999 109.444 172.434 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 35' ' ' GLU . . . . . 0.632 ' O ' ' HA ' ' B' ' 46' ' ' LEU . 72.1 tt0 -104.04 112.28 25.21 Favored 'General case' 0 CA--C 1.487 -1.471 0 N-CA-C 107.359 -1.348 . . . . 1.1000000000000001 107.359 -179.272 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 36' ' ' ILE . . . . . 0.879 HG13 HD23 ' B' ' 46' ' ' LEU . 2.5 mp -86.47 111.07 20.87 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.148 0 O-C-N 124.615 1.197 . . . . 1.3200000000000001 108.675 179.331 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 37' ' ' PHE . . . . . 0.767 ' HB2' ' H ' ' A' ' 4' ' ' THR . 17.9 p90 -150.29 129.28 12.59 Favored 'General case' 0 C--N 1.314 -0.96 0 N-CA-C 109.392 -0.596 . . . . 2.0299999999999998 109.392 172.613 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 38' ' ' VAL . . . . . 0.566 ' HA ' ' HA ' ' B' ' 44' ' ' VAL . 1.4 p -83.62 129.91 36.73 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.114 0 CA-C-O 121.255 0.55 . . . . 0.89000000000000001 111.539 -175.369 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 39' ' ' ASP . . . . . 0.732 ' HB3' ' HD3' ' B' ' 40' ' ' ARG . 0.5 OUTLIER -94.28 171.36 8.88 Favored 'General case' 0 N--CA 1.443 -0.777 0 N-CA-C 108.036 -1.098 . . . . 1.1399999999999999 108.036 173.634 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 40' ' ' ARG . . . . . 0.732 ' HD3' ' HB3' ' B' ' 39' ' ' ASP . 0.0 OUTLIER 41.64 -107.22 0.08 Allowed 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 113.811 1.041 . . . . 3.3700000000000001 113.811 176.902 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -108.13 -82.98 0.55 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.076 0.465 . . . . 1.3200000000000001 111.368 -174.362 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 42' ' ' GLY . . . . . . . . . . . . . . . -118.93 26.15 7.64 Favored Glycine 0 N--CA 1.444 -0.78 0 C-N-CA 120.92 -0.657 . . . . 0.35999999999999999 111.89 -175.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 43' ' ' GLU . . . . . 0.616 ' HB3' HG23 ' A' ' 45' ' ' ILE . 2.0 mt-10 -96.79 111.9 23.88 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 109.633 -0.506 . . . . 2.0699999999999998 109.633 178.082 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 44' ' ' VAL . . . . . 0.566 ' HA ' ' HA ' ' B' ' 38' ' ' VAL . 1.9 t -88.23 132.63 32.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 N-CA-C 109.575 -0.528 . . . . 1.02 109.575 178.204 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 45' ' ' ILE . . . . . 0.815 HG13 HG13 ' A' ' 45' ' ' ILE . 1.5 mp -108.97 119.36 58.39 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 N-CA-C 108.206 -1.035 . . . . 0.95999999999999996 108.206 -177.352 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 46' ' ' LEU . . . . . 0.977 HD12 HD12 ' A' ' 46' ' ' LEU . 0.7 OUTLIER -112.37 117.1 31.51 Favored 'General case' 0 C--N 1.317 -0.817 0 O-C-N 123.68 0.612 . . . . 1.05 110.008 178.217 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 47' ' ' LYS . . . . . 0.59 ' O ' ' HA ' ' B' ' 34' ' ' LEU . 0.0 OUTLIER -129.78 149.33 51.57 Favored 'General case' 0 C--O 1.215 -0.72 0 C-N-CA 119.492 -0.883 . . . . 1.3899999999999999 113.03 -179.841 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 48' ' ' LYS . . . . . 0.551 ' O ' ' HB3' ' B' ' 49' ' ' TYR . 1.7 ptmt -39.75 -21.35 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.244 0 N-CA-C 117.658 2.466 . . . . 1.1899999999999999 117.658 -168.086 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 49' ' ' TYR . . . . . 0.782 ' HB3' ' HB2' ' B' ' 33' ' ' PRO . 23.3 t80 75.1 -46.58 0.59 Allowed 'General case' 0 N--CA 1.47 0.568 0 CA-C-N 119.095 0.861 . . . . 2.1000000000000001 111.282 177.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 50' ' ' SER . . . . . 0.644 ' OG ' ' HD3' ' B' ' 51' ' ' PRO . 1.6 p -50.14 -48.38 79.64 Favored Pre-proline 0 CA--C 1.544 0.737 0 CA-C-N 115.519 -0.764 . . . . 1.77 112.395 -175.528 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 51' ' ' PRO . . . . . 0.644 ' HD3' ' OG ' ' B' ' 50' ' ' SER . 33.1 Cg_endo -103.06 14.03 0.29 Allowed 'Trans proline' 0 N--CA 1.454 -0.831 0 C-N-CA 122.976 2.45 . . . . 0.59999999999999998 111.733 170.241 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 52' ' ' ILE . . . . . 0.666 HG13 HD23 ' B' ' 55' ' ' LEU . 1.1 mt 53.54 -141.93 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 N-CA-C 108.516 -0.92 . . . . 1.3899999999999999 108.516 -168.661 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 53' ' ' SER . . . . . . . . . . . . . 70.2 m -83.02 -28.18 29.82 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.509 0.671 . . . . 2.04 110.004 176.66 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 54' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -167.34 118.59 0.88 Allowed 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 114.408 -1.269 . . . . 2.6200000000000001 109.216 -176.713 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 55' ' ' LEU . . . . . 0.666 HD23 HG13 ' B' ' 52' ' ' ILE . 0.2 OUTLIER . . . . . 0 C--O 1.249 1.062 0 CA-C-O 118.673 -0.679 . . . . 2.8700000000000001 110.485 -177.068 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.48 1.075 0 N-CA-C 109.919 -0.4 . . . . 6.3300000000000001 109.919 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.708 ' HB2' HG11 ' B' ' 38' ' ' VAL . 0.0 OUTLIER -82.91 -176.6 6.4 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 109.203 -0.666 . . . . 4.1699999999999999 109.203 177.561 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.463 ' HA ' ' HB2' ' B' ' 37' ' ' PHE . . . 55.21 70.92 0.58 Allowed 'General case' 0 N--CA 1.463 0.214 0 CA-C-O 121.608 0.718 . . . . 1.1299999999999999 109.75 -171.083 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 31.0 p -84.53 -31.74 24.26 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.201 -0.909 . . . . 1.0900000000000001 112.521 -169.574 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . 0.468 ' H ' ' HB3' ' B' ' 37' ' ' PHE . . . 61.01 49.19 81.35 Favored Glycine 0 N--CA 1.446 -0.66 0 C-N-CA 120.767 -0.73 . . . . 0.32000000000000001 113.074 176.567 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.84 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.6 tp -105.73 104.41 16.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 N-CA-C 109.173 -0.677 . . . . 1.0900000000000001 109.173 174.823 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.606 ' HA ' ' O ' ' B' ' 34' ' ' LEU . 38.0 t -74.25 133.04 32.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 115.719 -0.673 . . . . 1.1299999999999999 110.088 179.696 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.652 ' HB3' ' CD1' ' B' ' 36' ' ' ILE . 3.3 tpp180 -129.43 119.4 23.74 Favored 'General case' 0 N--CA 1.437 -1.077 0 N-CA-C 106.809 -1.552 . . . . 2.6099999999999999 106.809 -178.75 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.52 ' HA ' ' O ' ' B' ' 32' ' ' ASP . 9.4 ttp180 -83.37 102.76 12.23 Favored 'General case' 0 C--N 1.312 -1.024 0 N-CA-C 108.553 -0.906 . . . . 3.4100000000000001 108.553 176.183 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.706 HG23 HD13 ' B' ' 34' ' ' LEU . 0.2 OUTLIER -9.62 -103.23 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 O-C-N 125.62 1.825 . . . . 1.0700000000000001 114.525 -177.108 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . 0.599 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 4.3 p-10 161.43 -162.62 0.0 OUTLIER 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 108.31 -0.996 . . . . 1.1299999999999999 108.31 176.86 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -71.27 -24.73 62.22 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.15 0.5 . . . . 2.2599999999999998 110.803 -178.109 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -95.22 -58.98 1.99 Allowed 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.112 -0.494 . . . . 1.23 110.212 178.551 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.524 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 135.64 17.72 0.83 Allowed Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.595 -0.812 . . . . 0.25 112.92 -177.998 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.632 ' HG2' HG23 ' B' ' 17' ' ' VAL . 1.4 mpt_? -74.73 153.11 38.98 Favored 'General case' 0 CA--C 1.507 -0.689 0 O-C-N 122.139 -0.624 . . . . 0.88 110.033 179.299 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.72 HG21 HD13 ' B' ' 46' ' ' LEU . 93.3 t -108.39 95.93 4.22 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.29 0 N-CA-C 107.662 -1.236 . . . . 1.99 107.662 169.239 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.618 HG23 ' HG2' ' B' ' 15' ' ' ARG . 91.0 t -64.54 99.37 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-N 115.131 -0.94 . . . . 1.0600000000000001 110.085 -174.121 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.467 ' HB ' ' O ' ' B' ' 14' ' ' GLY . 38.6 mm -87.47 112.05 45.73 Favored Pre-proline 0 N--CA 1.446 -0.659 0 CA-C-N 115.543 -0.753 . . . . 1.5600000000000001 109.854 -179.515 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.537 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 91.9 Cg_exo -50.79 140.72 37.34 Favored 'Trans proline' 0 N--CA 1.452 -0.963 0 C-N-CA 122.267 1.978 . . . . 0.34999999999999998 111.738 173.566 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.943 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -61.12 -14.95 28.12 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.675 -0.693 . . . . 2.1299999999999999 111.47 -177.992 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.537 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 11.3 pt-20 -66.77 -21.4 66.06 Favored 'General case' 0 C--O 1.237 0.442 0 N-CA-C 112.182 0.438 . . . . 1.3200000000000001 112.182 -178.685 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.2 mp -87.91 -45.27 15.98 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 107.997 -1.112 . . . . 1.0800000000000001 107.997 -179.772 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . 0.717 ' HA ' ' HB2' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -60.35 -29.37 68.86 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 115.285 -0.871 . . . . 2.02 109.18 172.448 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.464 ' HB3' ' O ' ' A' ' 21' ' ' GLU . 58.7 ttt180 -60.42 -52.6 64.52 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 114.403 -1.271 . . . . 3.3999999999999999 110.484 173.833 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 19.8 m -69.2 -21.21 63.97 Favored 'General case' 0 CA--C 1.53 0.177 0 CA-C-O 121.295 0.569 . . . . 1.1499999999999999 110.904 175.11 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.8 ' HB3' HG13 ' A' ' 28' ' ' ILE . 0.8 OUTLIER -67.55 -18.37 65.0 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.974 -0.557 . . . . 1.1599999999999999 111.2 176.418 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.455 ' HB2' ' O ' ' A' ' 26' ' ' LEU . 0.0 OUTLIER 70.51 20.46 5.89 Favored 'General case' 0 C--N 1.343 0.324 0 CA-C-O 121.299 0.571 . . . . 3.6800000000000002 110.009 -172.397 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.8 HG13 ' HB3' ' A' ' 26' ' ' LEU . 3.0 mt -119.22 -164.87 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.535 -0.757 . . . . 1.1000000000000001 109.855 -176.086 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.71 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -158.3 -156.97 0.59 Allowed 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 110.382 -0.229 . . . . 3.0699999999999998 110.382 -167.988 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -72.95 38.48 0.08 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 122.213 1.006 . . . . 1.23 111.034 176.34 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.58 ' H ' ' C ' ' A' ' 29' ' ' ARG . . . -152.55 26.17 0.85 Allowed Glycine 0 N--CA 1.435 -1.411 0 CA-C-N 113.854 -1.521 . . . . 0.35999999999999999 110.4 176.023 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.481 ' HA ' ' HD3' ' A' ' 33' ' ' PRO . 63.8 t0 -84.12 114.22 53.08 Favored Pre-proline 0 C--N 1.331 -0.205 0 CA-C-O 121.279 0.562 . . . . 1.26 109.768 175.627 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.593 ' O ' HG12 ' B' ' 7' ' ' VAL . 1.2 Cg_endo -88.97 54.76 1.95 Allowed 'Trans proline' 0 CA--C 1.507 -0.874 0 C-N-CA 124.158 3.239 . . . . 1.3 114.108 -175.188 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.588 HD13 HG21 ' B' ' 10' ' ' ILE . 1.0 OUTLIER -57.38 153.6 12.21 Favored 'General case' 0 C--N 1.297 -1.676 0 CA-C-O 122.299 1.047 . . . . 1.21 112.352 -173.768 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.811 ' HB3' ' HB3' ' A' ' 47' ' ' LYS . 33.8 tt0 -105.07 118.47 36.62 Favored 'General case' 0 CA--C 1.492 -1.259 0 CA-C-N 113.492 -1.685 . . . . 1.1200000000000001 107.505 -175.594 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.886 ' HB ' HG23 ' B' ' 6' ' ' ILE . 2.6 mp -88.28 110.16 20.72 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.014 0 O-C-N 123.847 0.717 . . . . 1.1599999999999999 109.265 179.467 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . 0.771 ' HD1' ' HA ' ' B' ' 3' ' ' ALA . 0.8 OUTLIER -150.18 124.84 9.72 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 109.785 -0.45 . . . . 2.0099999999999998 109.785 174.557 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.744 HG11 ' HB2' ' B' ' 2' ' ' LYS . 1.4 p -80.91 137.83 20.69 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.978 0 CA-C-O 121.053 0.454 . . . . 1.05 110.716 -179.232 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.57 ' OD2' ' HD2' ' A' ' 40' ' ' ARG . 3.6 t70 -85.4 -55.49 3.99 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.444 -0.798 . . . . 1.1100000000000001 111.514 -173.633 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . 0.57 ' HD2' ' OD2' ' A' ' 39' ' ' ASP . 0.2 OUTLIER -119.91 -91.61 0.55 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.517 -0.765 . . . . 2.8799999999999999 111.981 -169.554 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -99.01 -69.58 0.76 Allowed 'General case' 0 CA--C 1.511 -0.548 0 CA-C-O 121.345 0.593 . . . . 1.53 110.571 -176.206 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.647 ' HA3' HD13 ' B' ' 26' ' ' LEU . . . -135.54 21.74 3.58 Favored Glycine 0 N--CA 1.437 -1.261 0 CA-C-N 114.97 -1.013 . . . . 0.34000000000000002 111.696 -176.787 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.576 ' HB3' HG21 ' B' ' 45' ' ' ILE . 2.1 mt-10 -95.38 109.15 21.36 Favored 'General case' 0 N--CA 1.447 -0.602 0 N-CA-C 109.099 -0.704 . . . . 1.97 109.099 177.381 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.517 ' HA ' ' HA ' ' A' ' 38' ' ' VAL . 1.7 t -90.09 132.11 35.6 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.941 0 N-CA-C 109.214 -0.661 . . . . 1.0600000000000001 109.214 178.467 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.778 HG13 HG13 ' B' ' 45' ' ' ILE . 1.6 mp -108.21 119.55 58.0 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 N-CA-C 108.262 -1.014 . . . . 1.01 108.262 -176.104 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.917 HD12 HD12 ' B' ' 46' ' ' LEU . 6.9 mt -103.61 121.9 43.88 Favored 'General case' 0 C--N 1.322 -0.599 0 O-C-N 124.221 0.951 . . . . 1.1299999999999999 110.033 179.616 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.811 ' HB3' ' HB3' ' A' ' 35' ' ' GLU . 21.6 ttmt -126.98 123.3 36.79 Favored 'General case' 0 C--N 1.308 -1.216 0 CA-C-N 115.454 -0.793 . . . . 1.25 112.576 -168.18 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.576 ' O ' ' HD2' ' A' ' 33' ' ' PRO . 3.1 ptmt -39.0 -19.24 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.648 0 N-CA-C 116.948 2.203 . . . . 1.0900000000000001 116.948 -172.849 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.651 ' CD1' HG21 ' B' ' 7' ' ' VAL . 27.1 t80 74.72 -56.02 0.64 Allowed 'General case' 0 N--CA 1.475 0.823 0 C-N-CA 123.83 0.852 . . . . 2.1400000000000001 113.001 173.414 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.667 ' HB3' ' HD3' ' A' ' 51' ' ' PRO . 48.2 t -49.62 -53.61 39.55 Favored Pre-proline 0 CA--C 1.535 0.373 0 CA-C-N 115.807 -0.633 . . . . 1.95 111.433 -175.072 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.667 ' HD3' ' HB3' ' A' ' 50' ' ' SER . 46.2 Cg_endo -95.26 14.32 1.21 Allowed 'Trans proline' 0 N--CA 1.456 -0.723 0 C-N-CA 122.27 1.98 . . . . 0.59999999999999998 111.452 170.652 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.701 HG13 HD23 ' A' ' 55' ' ' LEU . 2.6 mt 53.96 -130.63 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 N-CA-C 108.587 -0.894 . . . . 1.4199999999999999 108.587 -172.433 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 63.1 m -91.06 -43.51 9.87 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-O 121.472 0.653 . . . . 2.23 110.126 173.789 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 29.9 tt0 -128.81 -47.88 1.25 Allowed 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 114.827 -1.079 . . . . 2.8900000000000001 110.97 -170.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.701 HD23 HG13 ' A' ' 52' ' ' ILE . 0.5 OUTLIER . . . . . 0 C--O 1.248 1.015 0 O-C-N 124.034 0.834 . . . . 2.8100000000000001 110.24 -179.057 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 22.2 mmt . . . . . 0 N--CA 1.478 0.951 0 CA-C-O 120.666 0.27 . . . . 6.71 110.355 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 2' ' ' LYS . . . . . 0.744 ' HB2' HG11 ' A' ' 38' ' ' VAL . 0.1 OUTLIER -82.07 -172.48 3.97 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 108.885 -0.783 . . . . 4.0899999999999999 108.885 172.902 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 3' ' ' ALA . . . . . 0.771 ' HA ' ' HD1' ' A' ' 37' ' ' PHE . . . 53.55 69.34 0.72 Allowed 'General case' 0 N--CA 1.462 0.174 0 CA-C-O 121.555 0.693 . . . . 1.1000000000000001 110.169 -175.472 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 4' ' ' THR . . . . . . . . . . . . . 25.0 p -82.41 -32.02 29.31 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.162 -0.926 . . . . 0.97999999999999998 112.498 -171.141 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 5' ' ' GLY . . . . . 0.405 ' H ' ' CB ' ' A' ' 37' ' ' PHE . . . 61.44 45.27 96.73 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 121.14 -0.552 . . . . 0.33000000000000002 113.128 176.728 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 6' ' ' ILE . . . . . 0.886 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.1 tp -104.17 104.74 17.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.517 0.675 . . . . 1.1000000000000001 109.556 178.066 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . 0.651 HG21 ' CD1' ' A' ' 49' ' ' TYR . 4.9 t -74.84 131.46 34.96 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.872 0 CA-C-N 115.178 -0.919 . . . . 1.0800000000000001 110.896 -179.158 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.472 ' HD3' ' N ' ' B' ' 9' ' ' ARG . 0.1 OUTLIER -129.56 118.15 21.58 Favored 'General case' 0 N--CA 1.447 -0.593 0 N-CA-C 107.031 -1.47 . . . . 2.3599999999999999 107.031 177.737 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 9' ' ' ARG . . . . . 0.529 ' HA ' ' HA ' ' A' ' 33' ' ' PRO . 26.7 ttp180 -79.85 104.84 10.7 Favored 'General case' 0 N--CA 1.44 -0.969 0 C-N-CA 119.789 -0.764 . . . . 3.2000000000000002 109.001 174.527 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 10' ' ' ILE . . . . . 0.66 ' O ' ' HB3' ' B' ' 11' ' ' ASP . 0.3 OUTLIER -11.91 -102.75 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 O-C-N 125.705 1.878 . . . . 1.0700000000000001 114.644 -176.051 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . 0.66 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 2.8 p-10 160.07 -165.81 0.0 OUTLIER 'General case' 0 C--N 1.342 0.249 0 N-CA-C 107.871 -1.159 . . . . 1.1799999999999999 107.871 177.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -68.21 -30.75 69.9 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 120.967 0.413 . . . . 2.3900000000000001 110.616 -179.131 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 13' ' ' LEU . . . . . 0.512 ' HB3' ' HD2' ' B' ' 15' ' ' ARG . 3.1 tm? -85.61 -59.27 2.36 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.066 -0.515 . . . . 1.1000000000000001 110.101 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 14' ' ' GLY . . . . . 0.467 ' O ' ' HB ' ' A' ' 18' ' ' ILE . . . 131.46 16.29 1.52 Allowed Glycine 0 N--CA 1.445 -0.711 0 C-N-CA 120.327 -0.939 . . . . 0.23000000000000001 112.727 -178.112 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 15' ' ' ARG . . . . . 0.618 ' HG2' HG23 ' A' ' 17' ' ' VAL . 0.3 OUTLIER -74.8 153.3 38.81 Favored 'General case' 0 CA--C 1.507 -0.674 0 C-N-CA 119.709 -0.796 . . . . 1.3899999999999999 109.826 178.138 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 16' ' ' VAL . . . . . 0.856 HG23 HD13 ' A' ' 46' ' ' LEU . 95.9 t -108.53 98.01 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.316 0 N-CA-C 107.725 -1.213 . . . . 1.97 107.725 169.721 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 17' ' ' VAL . . . . . 0.632 HG23 ' HG2' ' A' ' 15' ' ' ARG . 57.6 t -66.69 99.58 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.877 0 CA-C-N 114.963 -1.017 . . . . 1.0600000000000001 110.14 -172.259 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . 0.524 ' HB ' ' O ' ' A' ' 14' ' ' GLY . 39.1 mm -86.92 111.7 42.23 Favored Pre-proline 0 C--N 1.323 -0.569 0 CA-C-N 115.321 -0.854 . . . . 1.6100000000000001 109.978 -179.376 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . 0.516 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 86.4 Cg_exo -50.61 139.85 37.77 Favored 'Trans proline' 0 N--CA 1.453 -0.909 0 C-N-CA 122.392 2.061 . . . . 0.33000000000000002 111.607 172.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 20' ' ' LYS . . . . . 0.975 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -61.07 -13.31 15.99 Favored 'General case' 0 C--N 1.313 -0.979 0 CA-C-N 115.442 -0.799 . . . . 2.3199999999999998 111.64 -178.35 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . 0.516 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 10.4 pt-20 -67.01 -22.98 65.87 Favored 'General case' 0 C--O 1.237 0.444 0 N-CA-C 112.614 0.598 . . . . 1.9199999999999999 112.614 179.751 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 4.6 mp -88.06 -43.17 15.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 N-CA-C 107.758 -1.201 . . . . 1.24 107.758 -179.672 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 23' ' ' ARG . . . . . 0.658 ' HA ' ' HB2' ' B' ' 26' ' ' LEU . 0.0 OUTLIER -60.53 -29.89 69.4 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 115.287 -0.87 . . . . 1.8500000000000001 109.298 171.503 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 24' ' ' ARG . . . . . 0.432 ' HB3' ' O ' ' B' ' 21' ' ' GLU . 23.1 ttt180 -61.66 -52.72 63.17 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 114.594 -1.184 . . . . 3.6899999999999999 110.391 174.073 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 14.4 m -66.53 -25.06 66.49 Favored 'General case' 0 N--CA 1.452 -0.366 0 CA-C-O 121.456 0.646 . . . . 1.1599999999999999 110.466 176.292 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.69 ' HB3' HG13 ' B' ' 28' ' ' ILE . 0.7 OUTLIER -65.04 -19.55 66.05 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.432 -0.804 . . . . 1.1100000000000001 111.068 175.699 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 27' ' ' ARG . . . . . 0.484 ' HB2' ' O ' ' B' ' 26' ' ' LEU . 0.2 OUTLIER 70.99 19.04 5.78 Favored 'General case' 0 N--CA 1.465 0.28 0 O-C-N 123.938 0.774 . . . . 3.77 110.097 -173.265 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 28' ' ' ILE . . . . . 0.872 HG21 ' H ' ' B' ' 29' ' ' ARG . 5.6 mt -115.45 -166.61 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 115.569 -0.741 . . . . 1.2 110.037 -177.044 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 29' ' ' ARG . . . . . 0.872 ' H ' HG21 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -155.93 -157.35 0.71 Allowed 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 110.404 -0.221 . . . . 2.7599999999999998 110.404 -169.698 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 30' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -71.44 31.94 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.547 0.689 . . . . 1.1799999999999999 111.926 178.495 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . 0.547 ' H ' ' C ' ' B' ' 29' ' ' ARG . . . -145.73 30.24 1.69 Allowed Glycine 0 N--CA 1.438 -1.172 0 CA-C-N 115.222 -0.899 . . . . 0.34999999999999998 110.866 173.527 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 32' ' ' ASP . . . . . 0.52 ' O ' ' HA ' ' A' ' 9' ' ' ARG . 25.6 t0 -84.19 117.32 68.41 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-O 121.296 0.57 . . . . 1.29 110.301 176.881 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 33' ' ' PRO . . . . . 0.7 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 2.5 Cg_endo -87.4 66.7 3.99 Favored 'Trans proline' 0 C--O 1.206 -1.112 0 C-N-CA 123.984 3.123 . . . . 1.1000000000000001 113.793 -178.448 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . 0.706 HD13 HG23 ' A' ' 10' ' ' ILE . 0.9 OUTLIER -66.23 151.53 46.81 Favored 'General case' 0 C--N 1.284 -2.276 0 C-N-CA 118.547 -1.261 . . . . 1.1699999999999999 111.573 -174.774 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 35' ' ' GLU . . . . . 0.668 ' O ' ' HA ' ' B' ' 46' ' ' LEU . 66.1 tt0 -103.53 114.33 28.52 Favored 'General case' 0 CA--C 1.493 -1.242 0 CA-C-N 114.686 -1.143 . . . . 1.1000000000000001 108.011 -178.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 36' ' ' ILE . . . . . 0.84 ' HB ' HG23 ' A' ' 6' ' ' ILE . 2.6 mp -87.87 109.82 20.09 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.732 0 O-C-N 124.199 0.937 . . . . 1.3200000000000001 109.598 -179.04 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 37' ' ' PHE . . . . . 0.468 ' HB3' ' H ' ' A' ' 5' ' ' GLY . 15.3 p90 -150.69 125.95 10.02 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 116.111 -0.495 . . . . 2.0299999999999998 110.002 175.176 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 38' ' ' VAL . . . . . 0.708 HG11 ' HB2' ' A' ' 2' ' ' LYS . 0.8 OUTLIER -80.31 136.97 22.33 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 CA-C-O 121.125 0.488 . . . . 0.89000000000000001 110.895 -178.19 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 39' ' ' ASP . . . . . 0.59 ' OD1' ' HD2' ' B' ' 40' ' ' ARG . 12.2 t70 -76.86 -64.75 1.05 Allowed 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 114.699 -1.137 . . . . 1.1399999999999999 110.996 -175.213 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 40' ' ' ARG . . . . . 0.59 ' HD2' ' OD1' ' B' ' 39' ' ' ASP . 0.0 OUTLIER -117.73 -94.49 0.49 Allowed 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.682 -0.69 . . . . 3.3700000000000001 112.204 -175.162 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 26.1 t70 -90.85 -70.47 0.68 Allowed 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.993 0.425 . . . . 1.3200000000000001 111.21 -174.014 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 42' ' ' GLY . . . . . 0.564 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -134.28 24.22 3.59 Favored Glycine 0 N--CA 1.441 -0.996 0 C-N-CA 120.498 -0.858 . . . . 0.35999999999999999 112.476 -177.555 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 43' ' ' GLU . . . . . 0.636 ' HA ' ' O ' ' A' ' 46' ' ' LEU . 1.1 mt-10 -97.04 107.86 20.47 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 109.434 -0.58 . . . . 2.0699999999999998 109.434 175.956 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 44' ' ' VAL . . . . . 0.56 ' HA ' ' HA ' ' B' ' 38' ' ' VAL . 2.0 t -88.66 130.91 37.34 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 N-CA-C 109.587 -0.523 . . . . 1.02 109.587 178.18 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 45' ' ' ILE . . . . . 0.778 HG13 HG13 ' A' ' 45' ' ' ILE . 1.6 mp -106.45 121.33 58.9 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 N-CA-C 107.962 -1.125 . . . . 0.95999999999999996 107.962 -177.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 46' ' ' LEU . . . . . 0.917 HD12 HD12 ' A' ' 46' ' ' LEU . 0.7 OUTLIER -111.59 116.27 30.54 Favored 'General case' 0 C--N 1.319 -0.731 0 O-C-N 123.876 0.735 . . . . 1.05 109.782 177.779 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 47' ' ' LYS . . . . . 0.55 ' HE3' ' HB3' ' B' ' 35' ' ' GLU . 0.0 OUTLIER -131.12 140.43 49.99 Favored 'General case' 0 C--O 1.213 -0.82 0 N-CA-C 113.402 0.89 . . . . 1.3899999999999999 113.402 -178.684 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 48' ' ' LYS . . . . . 0.61 ' HE2' ' HG3' ' B' ' 51' ' ' PRO . 4.9 ptmt -38.2 -16.72 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.393 0 N-CA-C 118.747 2.869 . . . . 1.1899999999999999 118.747 -168.175 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 49' ' ' TYR . . . . . 0.7 ' HB3' ' HB2' ' B' ' 33' ' ' PRO . 39.5 t80 72.32 -51.51 0.7 Allowed 'General case' 0 N--CA 1.485 1.309 0 CA-C-N 119.241 0.928 . . . . 2.1000000000000001 113.247 176.481 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 50' ' ' SER . . . . . 0.418 ' OG ' ' HD3' ' B' ' 51' ' ' PRO . 1.4 p -51.7 -51.5 69.51 Favored Pre-proline 0 CA--C 1.541 0.613 0 CA-C-N 116.069 -0.514 . . . . 1.77 112.051 -172.581 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 51' ' ' PRO . . . . . 0.61 ' HG3' ' HE2' ' B' ' 48' ' ' LYS . 24.2 Cg_endo -95.42 16.41 0.91 Allowed 'Trans proline' 0 C--N 1.351 0.687 0 C-N-CA 122.45 2.1 . . . . 0.59999999999999998 111.582 167.735 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 52' ' ' ILE . . . . . 0.413 HG13 ' CD2' ' B' ' 55' ' ' LEU . 3.4 mt 53.2 -130.66 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 N-CA-C 108.083 -1.08 . . . . 1.3899999999999999 108.083 -170.566 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 53' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -112.97 19.53 17.19 Favored 'General case' 0 C--N 1.307 -1.277 0 C-N-CA 120.432 -0.507 . . . . 2.04 111.285 177.615 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 54' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 178.6 -55.96 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.568 -0.742 . . . . 2.6200000000000001 110.715 -175.294 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 55' ' ' LEU . . . . . 0.413 ' CD2' HG13 ' B' ' 52' ' ' ILE . 0.2 OUTLIER . . . . . 0 C--O 1.25 1.114 0 CA-C-N 115.172 -0.922 . . . . 2.8700000000000001 109.303 -175.828 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 24.7 ttt . . . . . 0 N--CA 1.48 1.032 0 CA-C-O 120.738 0.304 . . . . 6.3300000000000001 110.836 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.535 ' HB3' HG11 ' B' ' 38' ' ' VAL . 30.0 mmmt -112.26 -117.04 0.31 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.089 0.471 . . . . 4.1699999999999999 111.922 -173.941 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.414 ' HA ' ' HB2' ' B' ' 37' ' ' PHE . . . 72.53 143.29 0.06 Allowed 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 114.406 -1.27 . . . . 1.1299999999999999 112.723 179.079 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.829 ' H ' ' HB2' ' B' ' 37' ' ' PHE . 19.2 p -130.84 -54.86 1.06 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 114.792 -1.095 . . . . 1.0900000000000001 110.458 179.052 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 84.58 54.06 3.05 Favored Glycine 0 N--CA 1.446 -0.654 0 C-N-CA 120.434 -0.888 . . . . 0.32000000000000001 112.458 173.319 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.9 HG21 ' HB ' ' B' ' 36' ' ' ILE . 1.6 tp -108.84 108.96 26.6 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 N-CA-C 109.404 -0.591 . . . . 1.0900000000000001 109.404 171.235 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.762 HG21 ' CD1' ' B' ' 49' ' ' TYR . 36.5 t -83.0 135.92 23.85 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-O 120.905 0.383 . . . . 1.1299999999999999 111.286 -179.435 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.617 ' CZ ' HG22 ' A' ' 17' ' ' VAL . 5.3 tpt180 -129.63 114.79 16.47 Favored 'General case' 0 N--CA 1.446 -0.642 0 N-CA-C 107.85 -1.167 . . . . 2.6099999999999999 107.85 -176.771 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.709 HH11 ' HG3' ' B' ' 33' ' ' PRO . 3.7 tpp180 -81.73 103.43 11.42 Favored 'General case' 0 CA--C 1.509 -0.618 0 N-CA-C 108.047 -1.094 . . . . 3.4100000000000001 108.047 174.19 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.656 ' O ' ' HB3' ' A' ' 11' ' ' ASP . 0.2 OUTLIER -14.5 -106.61 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.039 0 O-C-N 125.7 1.875 . . . . 1.0700000000000001 114.367 -176.295 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . 0.656 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 4.6 p-10 158.86 -169.06 0.0 OUTLIER 'General case' 0 CA--C 1.511 -0.547 0 N-CA-C 107.917 -1.142 . . . . 1.1299999999999999 107.917 175.23 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -70.61 -8.92 55.25 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.952 0.406 . . . . 2.2599999999999998 111.086 -178.686 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.438 HD13 HG12 ' B' ' 17' ' ' VAL . 1.6 tm? -107.82 -62.14 1.48 Allowed 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.763 -0.458 . . . . 1.23 109.763 175.205 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 134.36 22.34 0.71 Allowed Glycine 0 N--CA 1.445 -0.75 0 C-N-CA 120.455 -0.878 . . . . 0.25 113.264 179.288 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.541 ' HB3' ' HB3' ' B' ' 15' ' ' ARG . 1.5 mpt_? -80.99 150.44 28.91 Favored 'General case' 0 CA--C 1.51 -0.588 0 O-C-N 121.913 -0.757 . . . . 0.88 110.813 -179.885 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.596 HG23 HD13 ' B' ' 46' ' ' LEU . 70.9 t -109.91 98.78 7.49 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.284 0 N-CA-C 107.581 -1.266 . . . . 1.99 107.581 168.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.617 HG22 ' CZ ' ' A' ' 8' ' ' ARG . 61.7 t -67.25 101.66 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 CA-C-N 115.501 -0.772 . . . . 1.0600000000000001 109.577 -176.138 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.602 HG23 HD12 ' A' ' 22' ' ' ILE . 8.5 mt -93.55 111.77 53.8 Favored Pre-proline 0 C--N 1.322 -0.6 0 CA-C-N 116.022 -0.536 . . . . 1.5600000000000001 110.72 -177.836 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.655 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 95.7 Cg_exo -50.31 152.51 8.26 Favored 'Trans proline' 0 N--CA 1.458 -0.579 0 C-N-CA 122.944 2.429 . . . . 0.34999999999999998 112.893 173.963 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.769 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -67.24 -14.26 62.74 Favored 'General case' 0 C--O 1.21 -0.988 0 CA-C-N 115.668 -0.696 . . . . 2.1299999999999999 111.237 -179.851 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.655 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 15.4 pt-20 -62.65 -25.36 68.09 Favored 'General case' 0 C--O 1.238 0.495 0 CA-C-O 120.88 0.372 . . . . 1.3200000000000001 111.752 -179.322 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.602 HD12 HG23 ' A' ' 18' ' ' ILE . 5.3 mp -86.63 -47.17 16.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 108.257 -1.016 . . . . 1.0800000000000001 108.257 -177.72 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . 0.616 ' HA ' ' HB2' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -61.12 -27.19 68.2 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.172 -0.922 . . . . 2.02 109.038 174.043 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 38.8 ttp180 -64.27 -52.29 59.36 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 114.829 -1.078 . . . . 3.3999999999999999 110.564 175.088 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' THR . . . . . 0.402 HG23 ' HZ1' ' A' ' 2' ' ' LYS . 21.7 m -63.93 -28.18 69.65 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-O 121.154 0.502 . . . . 1.1499999999999999 110.992 174.28 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.616 ' HB2' ' HA ' ' A' ' 23' ' ' ARG . 2.4 mm? -64.05 -19.99 65.61 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.795 -0.639 . . . . 1.1599999999999999 110.043 172.636 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER 71.44 22.26 4.27 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.01 -0.995 . . . . 3.6800000000000002 110.105 -177.609 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.658 HG23 ' H ' ' A' ' 29' ' ' ARG . 6.1 mt -121.03 -167.35 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.674 0 CA-C-N 115.155 -0.93 . . . . 1.1000000000000001 109.118 -177.424 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.658 ' H ' HG23 ' A' ' 28' ' ' ILE . 0.3 OUTLIER -146.01 -156.47 0.71 Allowed 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 118.037 0.38 . . . . 3.0699999999999998 111.943 -174.335 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . 0.418 ' H ' ' HB2' ' A' ' 29' ' ' ARG . 1.1 mp0 -72.86 48.6 0.21 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 122.197 0.998 . . . . 1.23 111.904 -179.214 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.596 ' CA ' HD13 ' B' ' 10' ' ' ILE . . . -166.14 24.9 0.15 Allowed Glycine 0 N--CA 1.443 -0.876 0 CA-C-N 113.804 -1.544 . . . . 0.35999999999999999 109.863 174.69 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.493 ' O ' HG13 ' B' ' 10' ' ' ILE . 19.8 t0 -87.67 127.63 57.54 Favored Pre-proline 0 CA--C 1.516 -0.348 0 CA-C-N 114.771 -0.715 . . . . 1.26 109.377 174.883 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.682 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 3.8 Cg_endo -82.36 154.31 16.27 Favored 'Trans proline' 0 N--CA 1.438 -1.773 0 C-N-CA 122.26 1.973 . . . . 1.3 110.676 174.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.741 ' O ' ' HA ' ' B' ' 7' ' ' VAL . 0.5 OUTLIER -142.68 149.62 39.09 Favored 'General case' 0 C--N 1.307 -1.262 0 C-N-CA 120.133 -0.627 . . . . 1.21 109.507 172.688 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.911 ' HB3' ' HD2' ' A' ' 47' ' ' LYS . 38.1 tt0 -108.55 111.1 22.77 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 108.524 -0.917 . . . . 1.1200000000000001 108.524 -176.182 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 1.041 HG13 HD22 ' A' ' 46' ' ' LEU . 2.2 mp -85.85 109.48 18.58 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.794 0 O-C-N 124.972 1.42 . . . . 1.1599999999999999 109.211 -176.239 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . 0.938 ' HD2' ' HA ' ' B' ' 3' ' ' ALA . 0.5 OUTLIER -149.37 124.72 10.23 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 115.683 -0.69 . . . . 2.0099999999999998 109.431 177.736 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.526 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 2.0 p -80.52 133.08 30.25 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.953 0 CA-C-O 121.214 0.53 . . . . 1.05 110.566 -179.221 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.548 ' HB3' ' HG2' ' A' ' 40' ' ' ARG . 27.2 t0 -81.21 -58.07 3.22 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 114.154 -1.385 . . . . 1.1100000000000001 111.453 -174.447 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . 0.555 ' HG3' ' HG3' ' A' ' 43' ' ' GLU . 1.3 ptm180 -125.6 -99.52 0.4 Allowed 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.134 -0.939 . . . . 2.8799999999999999 112.74 -166.086 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 34.7 t70 -84.11 -75.67 0.33 Allowed 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.168 0.508 . . . . 1.53 110.757 -175.735 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.475 ' HA3' HD13 ' B' ' 26' ' ' LEU . . . -135.11 24.88 3.38 Favored Glycine 0 N--CA 1.441 -0.979 0 CA-C-N 115.534 -0.757 . . . . 0.34000000000000002 111.313 178.735 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.583 ' HB3' HG23 ' B' ' 45' ' ' ILE . 2.1 mt-10 -93.6 109.91 21.53 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.048 -0.723 . . . . 1.97 109.048 178.473 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.526 ' HA ' ' HA ' ' A' ' 38' ' ' VAL . 1.5 t -90.41 130.51 39.53 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 N-CA-C 109.22 -0.659 . . . . 1.0600000000000001 109.22 178.015 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.762 HG13 HG13 ' B' ' 45' ' ' ILE . 1.5 mp -108.79 117.91 55.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 N-CA-C 108.456 -0.942 . . . . 1.01 108.456 -175.595 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 1.044 HD12 HD12 ' B' ' 46' ' ' LEU . 0.3 OUTLIER -109.7 115.16 29.35 Favored 'General case' 0 C--N 1.314 -0.939 0 N-CA-C 108.743 -0.836 . . . . 1.1299999999999999 108.743 176.936 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.911 ' HD2' ' HB3' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -123.11 151.26 42.24 Favored 'General case' 0 C--O 1.215 -0.74 0 C-N-CA 118.808 -1.157 . . . . 1.25 111.99 179.594 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.578 ' HA ' ' O ' ' A' ' 33' ' ' PRO . 2.0 ptmt -42.12 -16.78 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.93 0 N-CA-C 117.377 2.362 . . . . 1.0900000000000001 117.377 -168.058 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.737 ' CD1' HG21 ' B' ' 7' ' ' VAL . 23.0 t80 73.19 -53.87 0.7 Allowed 'General case' 0 N--CA 1.473 0.676 0 CA-C-N 118.321 0.509 . . . . 2.1400000000000001 112.301 174.101 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.685 ' OG ' ' HD3' ' A' ' 51' ' ' PRO . 4.3 p -54.07 -44.42 98.36 Favored Pre-proline 0 CA--C 1.543 0.676 0 CA-C-N 116.131 -0.486 . . . . 1.95 111.804 -175.378 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.685 ' HD3' ' OG ' ' A' ' 50' ' ' SER . 94.5 Cg_endo -102.29 21.44 0.17 Allowed 'Trans proline' 0 N--CA 1.452 -0.969 0 C-N-CA 123.082 2.521 . . . . 0.59999999999999998 111.75 168.164 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.445 HD12 HD23 ' A' ' 55' ' ' LEU . 0.2 OUTLIER 46.52 -148.08 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.235 0.328 0 CA-C-N 115.78 -0.645 . . . . 1.4199999999999999 110.347 -176.751 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 23.8 m -85.28 79.28 9.57 Favored 'General case' 0 N--CA 1.446 -0.657 0 C-N-CA 120.812 -0.355 . . . . 2.23 110.108 172.756 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 43.4 tt0 66.01 81.24 0.21 Allowed 'General case' 0 CA--C 1.534 0.33 0 CA-C-O 121.281 0.563 . . . . 2.8900000000000001 110.937 178.333 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.506 ' HB2' ' O ' ' A' ' 51' ' ' PRO . 0.7 OUTLIER . . . . . 0 C--O 1.251 1.14 0 CA-C-O 118.562 -0.733 . . . . 2.8100000000000001 109.489 179.037 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 25.8 ttt . . . . . 0 N--CA 1.479 0.983 0 CA-C-O 120.63 0.252 . . . . 6.71 111.139 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 2' ' ' LYS . . . . . 0.448 ' O ' ' HB2' ' B' ' 3' ' ' ALA . 30.4 mmmt -110.23 -161.87 0.77 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.617 -0.265 . . . . 4.0899999999999999 111.422 -176.53 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 3' ' ' ALA . . . . . 0.938 ' HA ' ' HD2' ' A' ' 37' ' ' PHE . . . 137.57 160.02 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 125.182 1.393 . . . . 1.1000000000000001 109.147 -163.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 4' ' ' THR . . . . . 0.716 ' H ' ' HB2' ' A' ' 37' ' ' PHE . 2.1 p -152.7 -47.86 0.1 Allowed 'General case' 0 C--N 1.324 -0.52 0 O-C-N 123.671 0.607 . . . . 0.97999999999999998 109.563 174.083 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 72.53 53.1 8.93 Favored Glycine 0 N--CA 1.452 -0.254 0 CA-C-N 114.989 -1.005 . . . . 0.33000000000000002 113.134 171.256 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 6' ' ' ILE . . . . . 0.836 HG21 ' HB ' ' A' ' 36' ' ' ILE . 1.3 tp -109.13 112.18 39.37 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.801 0 N-CA-C 109.124 -0.695 . . . . 1.1000000000000001 109.124 171.895 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . 0.741 ' HA ' ' O ' ' A' ' 34' ' ' LEU . 39.7 t -84.4 136.03 23.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-O 120.94 0.4 . . . . 1.0800000000000001 110.974 -179.501 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.718 ' CZ ' HG22 ' B' ' 17' ' ' VAL . 1.4 tpt180 -129.61 114.71 16.38 Favored 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 107.665 -1.235 . . . . 2.3599999999999999 107.665 -178.603 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 9' ' ' ARG . . . . . 0.488 ' HA ' ' HA ' ' A' ' 33' ' ' PRO . 0.0 OUTLIER -80.81 103.06 10.39 Favored 'General case' 0 CA--C 1.51 -0.582 0 N-CA-C 107.933 -1.136 . . . . 3.2000000000000002 107.933 173.903 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 10' ' ' ILE . . . . . 0.596 HD13 ' CA ' ' A' ' 31' ' ' GLY . 0.2 OUTLIER -13.54 -105.54 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.085 0 O-C-N 125.611 1.82 . . . . 1.0700000000000001 114.509 -176.627 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . . . . . . . . . 34.8 p30 156.99 -160.71 0.0 OUTLIER 'General case' 0 CA--C 1.508 -0.637 0 C-N-CA 124.379 1.072 . . . . 1.1799999999999999 108.25 171.735 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -71.96 -8.29 53.63 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 121.085 0.469 . . . . 2.3900000000000001 110.766 -176.81 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 13' ' ' LEU . . . . . 0.446 HD12 HG12 ' A' ' 17' ' ' VAL . 2.1 tm? -114.72 -57.97 2.2 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.343 -0.39 . . . . 1.1000000000000001 109.973 -179.8 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 133.03 17.42 1.15 Allowed Glycine 0 N--CA 1.441 -0.967 0 C-N-CA 120.595 -0.812 . . . . 0.23000000000000001 113.784 179.532 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 15' ' ' ARG . . . . . 0.541 ' HB3' ' HB3' ' A' ' 15' ' ' ARG . 0.2 OUTLIER -81.5 150.52 28.22 Favored 'General case' 0 CA--C 1.507 -0.694 0 CA-C-N 118.764 1.282 . . . . 1.3899999999999999 110.962 -179.256 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 16' ' ' VAL . . . . . 0.535 HG23 HD13 ' A' ' 46' ' ' LEU . 98.2 t -108.98 100.72 11.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 CA-C-N 114.318 -1.31 . . . . 1.97 107.549 171.064 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 17' ' ' VAL . . . . . 0.718 HG22 ' CZ ' ' B' ' 8' ' ' ARG . 37.8 t -69.54 103.21 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.078 0 CA-C-N 115.832 -0.622 . . . . 1.0600000000000001 109.654 -174.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . 0.459 HD13 HD11 ' B' ' 46' ' ' LEU . 6.8 mt -91.98 112.39 54.61 Favored Pre-proline 0 N--CA 1.446 -0.647 0 CA-C-O 121.477 0.656 . . . . 1.6100000000000001 110.981 -177.768 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . 0.648 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 67.7 Cg_exo -49.1 142.9 19.6 Favored 'Trans proline' 0 N--CA 1.46 -0.484 0 C-N-CA 123.379 2.719 . . . . 0.33000000000000002 112.456 171.511 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 20' ' ' LYS . . . . . 0.928 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -61.36 -15.1 32.82 Favored 'General case' 0 C--O 1.211 -0.938 0 CA-C-N 115.313 -0.858 . . . . 2.3199999999999998 111.4 179.525 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . 0.648 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 10.0 pt-20 -63.37 -22.84 67.12 Favored 'General case' 0 C--O 1.238 0.486 0 N-CA-C 112.117 0.414 . . . . 1.9199999999999999 112.117 179.625 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 22' ' ' ILE . . . . . 0.405 HD12 HG23 ' B' ' 18' ' ' ILE . 5.3 mp -87.09 -47.97 15.68 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 N-CA-C 108.61 -0.885 . . . . 1.24 108.61 -179.371 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 23' ' ' ARG . . . . . 0.565 ' HA ' ' HB2' ' B' ' 26' ' ' LEU . 0.0 OUTLIER -60.06 -27.98 67.42 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.356 -0.838 . . . . 1.8500000000000001 109.27 173.234 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 24' ' ' ARG . . . . . . . . . . . . . 43.5 ttp180 -65.45 -52.76 50.83 Favored 'General case' 0 N--CA 1.446 -0.654 0 CA-C-N 114.676 -1.147 . . . . 3.6899999999999999 110.683 175.7 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 21.3 m -64.77 -26.67 68.45 Favored 'General case' 0 N--CA 1.449 -0.508 0 CA-C-O 121.355 0.597 . . . . 1.1599999999999999 110.667 175.421 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.565 ' HB2' ' HA ' ' B' ' 23' ' ' ARG . 1.7 mm? -64.85 -18.97 65.61 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.46 -0.791 . . . . 1.1100000000000001 110.59 173.754 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 27' ' ' ARG . . . . . . . . . . . . . 19.6 tpt180 74.4 22.32 2.19 Favored 'General case' 0 C--N 1.34 0.166 0 O-C-N 124.136 0.897 . . . . 3.77 109.772 -178.034 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 28' ' ' ILE . . . . . 0.909 HG23 ' H ' ' B' ' 29' ' ' ARG . 6.6 mt -123.28 -163.19 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.343 -0.844 . . . . 1.2 110.287 -174.91 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 29' ' ' ARG . . . . . 0.909 ' H ' HG23 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -152.44 -159.31 0.99 Allowed 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 112.025 0.379 . . . . 2.7599999999999998 112.025 -170.392 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 30' ' ' GLU . . . . . 0.429 ' H ' ' HB2' ' B' ' 29' ' ' ARG . 0.9 OUTLIER -73.92 36.94 0.1 Allowed 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 121.849 0.833 . . . . 1.1799999999999999 111.961 -177.464 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . 0.539 ' CA ' HD12 ' A' ' 10' ' ' ILE . . . -153.93 30.42 0.74 Allowed Glycine 0 N--CA 1.442 -0.93 0 N-CA-C 109.757 -1.337 . . . . 0.34999999999999998 109.757 171.658 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 32' ' ' ASP . . . . . 0.51 ' N ' HD12 ' A' ' 10' ' ' ILE . 12.3 t70 -86.7 128.78 55.2 Favored Pre-proline 0 C--N 1.324 -0.543 0 CA-C-N 114.81 -0.695 . . . . 1.29 109.948 174.197 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 33' ' ' PRO . . . . . 0.729 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 10.3 Cg_endo -84.88 148.93 10.9 Favored 'Trans proline' 0 N--CA 1.435 -1.919 0 C-N-CA 122.402 2.068 . . . . 1.1000000000000001 110.785 173.474 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . 0.719 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.7 OUTLIER -137.55 148.63 46.09 Favored 'General case' 0 C--N 1.302 -1.471 0 N-CA-C 109.631 -0.507 . . . . 1.1699999999999999 109.631 173.64 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 35' ' ' GLU . . . . . 0.708 ' O ' ' HA ' ' B' ' 46' ' ' LEU . 46.8 tt0 -105.16 111.74 24.6 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 107.9 -1.148 . . . . 1.1000000000000001 107.9 -178.178 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 36' ' ' ILE . . . . . 1.106 HG13 HD23 ' B' ' 46' ' ' LEU . 3.0 mp -86.73 109.86 19.53 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.943 0 O-C-N 124.417 1.073 . . . . 1.3200000000000001 109.06 -178.604 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 37' ' ' PHE . . . . . 0.829 ' HB2' ' H ' ' A' ' 4' ' ' THR . 12.1 p90 -151.0 131.97 14.25 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 116.158 -0.474 . . . . 2.0299999999999998 109.966 174.796 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 38' ' ' VAL . . . . . 0.535 HG11 ' HB3' ' A' ' 2' ' ' LYS . 1.9 p -80.08 142.33 14.07 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.01 0 CA-C-O 120.949 0.404 . . . . 0.89000000000000001 110.352 -178.584 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 39' ' ' ASP . . . . . 0.444 ' HB2' ' CD1' ' B' ' 45' ' ' ILE . 25.8 t0 -92.08 -47.52 7.22 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.556 -0.747 . . . . 1.1399999999999999 111.618 -175.026 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 40' ' ' ARG . . . . . 0.544 ' HG3' ' HG3' ' B' ' 43' ' ' GLU . 0.0 OUTLIER -134.08 -100.82 0.25 Allowed 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 112.767 0.655 . . . . 3.3700000000000001 112.767 -168.12 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 25.1 t70 -83.09 -71.92 0.47 Allowed 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.422 0.63 . . . . 1.3200000000000001 110.767 -176.182 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 42' ' ' GLY . . . . . 0.444 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -139.73 25.77 2.68 Favored Glycine 0 CA--C 1.501 -0.801 0 CA-C-N 115.41 -0.814 . . . . 0.35999999999999999 111.179 178.868 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 43' ' ' GLU . . . . . 0.544 ' HG3' ' HG3' ' B' ' 40' ' ' ARG . 2.7 mt-10 -92.72 109.15 20.57 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 109.226 -0.657 . . . . 2.0699999999999998 109.226 178.629 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 44' ' ' VAL . . . . . 0.502 ' HA ' ' HA ' ' B' ' 38' ' ' VAL . 1.7 t -89.13 130.48 38.41 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 N-CA-C 109.122 -0.696 . . . . 1.02 109.122 178.09 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 45' ' ' ILE . . . . . 0.762 HG13 HG13 ' A' ' 45' ' ' ILE . 1.7 mp -108.19 118.85 56.68 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 N-CA-C 108.138 -1.06 . . . . 0.95999999999999996 108.138 -176.981 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 46' ' ' LEU . . . . . 1.106 HD23 HG13 ' B' ' 36' ' ' ILE . 0.5 OUTLIER -110.26 115.77 30.3 Favored 'General case' 0 C--N 1.317 -0.847 0 N-CA-C 108.819 -0.808 . . . . 1.05 108.819 176.648 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 47' ' ' LYS . . . . . 0.541 ' O ' ' HA ' ' B' ' 34' ' ' LEU . 0.0 OUTLIER -126.57 149.99 49.1 Favored 'General case' 0 C--N 1.317 -0.847 0 C-N-CA 119.178 -1.009 . . . . 1.3899999999999999 112.626 -177.724 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 48' ' ' LYS . . . . . 0.655 ' HE2' ' HG3' ' B' ' 51' ' ' PRO . 3.4 ptmt -41.7 -14.18 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.064 0 N-CA-C 118.007 2.595 . . . . 1.1899999999999999 118.007 -167.643 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 49' ' ' TYR . . . . . 0.762 ' CD1' HG21 ' A' ' 7' ' ' VAL . 30.9 t80 72.41 -56.62 0.65 Allowed 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 113.004 0.742 . . . . 2.1000000000000001 113.004 173.145 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 50' ' ' SER . . . . . 0.688 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 8.3 t -52.28 -52.7 60.27 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.26 -0.427 . . . . 1.77 110.778 -174.031 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 51' ' ' PRO . . . . . 0.688 ' HD3' ' HB3' ' B' ' 50' ' ' SER . 47.2 Cg_endo -92.33 14.29 1.74 Allowed 'Trans proline' 0 N--CA 1.454 -0.806 0 C-N-CA 122.155 1.903 . . . . 0.59999999999999998 111.84 170.421 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 52' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER 49.97 -144.99 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 115.52 -0.764 . . . . 1.3899999999999999 109.76 -177.184 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 53' ' ' SER . . . . . . . . . . . . . 17.7 m -83.8 77.97 9.79 Favored 'General case' 0 C--N 1.321 -0.646 0 C-N-CA 120.544 -0.462 . . . . 2.04 110.174 176.688 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 54' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 65.99 85.23 0.14 Allowed 'General case' 0 CA--C 1.531 0.217 0 CA-C-O 121.248 0.547 . . . . 2.6200000000000001 110.572 178.593 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 55' ' ' LEU . . . . . 0.417 HD22 ' HA ' ' B' ' 55' ' ' LEU . 0.6 OUTLIER . . . . . 0 C--O 1.249 1.026 0 CA-C-O 118.703 -0.665 . . . . 2.8700000000000001 109.498 -178.251 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 65.7 mtt . . . . . 0 N--CA 1.48 1.058 0 N-CA-C 109.227 -0.657 . . . . 6.3300000000000001 109.227 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.666 ' HA ' ' CE ' ' A' ' 2' ' ' LYS . 1.1 mmpt? -81.1 -126.32 0.02 OUTLIER 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 120.851 -0.339 . . . . 4.1699999999999999 110.368 174.064 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.592 ' HA ' ' HD2' ' B' ' 37' ' ' PHE . . . 65.96 107.03 0.04 OUTLIER 'General case' 0 C--N 1.32 -0.706 0 O-C-N 123.846 0.717 . . . . 1.1299999999999999 111.844 -179.006 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.528 ' OG1' ' HA ' ' B' ' 37' ' ' PHE . 11.7 p -97.05 -45.76 6.44 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.547 -0.752 . . . . 1.0900000000000001 111.602 -179.4 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 70.51 48.93 33.78 Favored Glycine 0 N--CA 1.443 -0.866 0 C-N-CA 120.58 -0.819 . . . . 0.32000000000000001 112.919 174.155 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.791 HG21 ' HB ' ' B' ' 36' ' ' ILE . 1.0 OUTLIER -104.94 113.1 41.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 N-CA-C 108.407 -0.96 . . . . 1.0900000000000001 108.407 173.997 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.734 HG22 ' CD1' ' B' ' 49' ' ' TYR . 28.3 t -83.58 134.65 26.47 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-O 121.211 0.529 . . . . 1.1299999999999999 110.94 -178.319 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.572 ' HB3' ' CD1' ' B' ' 36' ' ' ILE . 9.0 tpp180 -131.0 119.54 22.2 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 107.818 -1.178 . . . . 2.6099999999999999 107.818 -176.583 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.455 ' N ' ' HD3' ' A' ' 8' ' ' ARG . 44.8 ttp180 -79.27 108.36 12.72 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 108.613 -0.884 . . . . 3.4100000000000001 108.613 170.713 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.79 HG22 HD12 ' B' ' 34' ' ' LEU . 0.2 OUTLIER -16.19 -102.65 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 O-C-N 125.593 1.808 . . . . 1.0700000000000001 114.492 -177.724 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . 0.604 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 3.1 p-10 162.89 -160.92 0.0 OUTLIER 'General case' 0 CA--C 1.509 -0.602 0 N-CA-C 107.826 -1.176 . . . . 1.1299999999999999 107.826 175.542 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 25.0 m-20 -70.72 -22.09 62.47 Favored 'General case' 0 C--N 1.321 -0.663 0 O-C-N 123.384 0.428 . . . . 2.2599999999999998 110.812 -178.78 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.451 HD22 ' HE2' ' B' ' 20' ' ' LYS . 3.0 tm? -102.88 -61.46 1.4 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.27 -0.423 . . . . 1.23 110.305 179.682 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.521 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 144.48 16.65 0.21 Allowed Glycine 0 N--CA 1.442 -0.93 0 C-N-CA 120.768 -0.729 . . . . 0.25 112.513 -178.91 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.539 ' HB3' ' HB3' ' B' ' 15' ' ' ARG . 2.8 mpt_? -71.5 145.84 48.92 Favored 'General case' 0 CA--C 1.504 -0.793 0 CA-C-O 121.522 0.677 . . . . 0.88 110.456 -179.278 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.782 HG23 HD12 ' B' ' 46' ' ' LEU . 97.5 t -103.76 94.08 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.53 0 N-CA-C 107.146 -1.427 . . . . 1.99 107.146 168.947 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.533 ' HA ' ' HA ' ' B' ' 15' ' ' ARG . 59.7 t -67.22 97.62 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.844 0 CA-C-N 114.891 -1.049 . . . . 1.0600000000000001 110.137 -172.809 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.709 HG21 HD13 ' A' ' 22' ' ' ILE . 17.4 mt -98.54 111.23 59.59 Favored Pre-proline 0 C--N 1.326 -0.45 0 CA-C-N 115.594 -0.73 . . . . 1.5600000000000001 111.11 -175.6 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.739 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 48.6 Cg_exo -46.74 150.41 2.55 Favored 'Trans proline' 0 N--CA 1.458 -0.577 0 C-N-CA 123.183 2.588 . . . . 0.34999999999999998 113.859 175.041 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.897 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -64.49 -12.62 45.93 Favored 'General case' 0 C--O 1.207 -1.176 0 CA-C-N 115.164 -0.926 . . . . 2.1299999999999999 111.219 176.61 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.739 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 12.7 pt-20 -64.88 -22.62 67.03 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 118.436 0.562 . . . . 1.3200000000000001 111.246 176.372 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.709 HD13 HG21 ' A' ' 18' ' ' ILE . 5.1 mp -88.06 -44.31 15.72 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.404 0 N-CA-C 108.889 -0.782 . . . . 1.0800000000000001 108.889 179.167 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . 0.705 ' HG3' ' HA ' ' A' ' 20' ' ' LYS . 1.1 ppt_? -61.12 -26.25 67.54 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 122.284 1.04 . . . . 2.02 108.636 172.05 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.523 ' HB3' ' O ' ' A' ' 21' ' ' GLU . 32.0 ttt180 -64.03 -52.37 59.77 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 113.741 -1.572 . . . . 3.3999999999999999 110.628 174.914 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 40.3 m -62.73 -30.35 71.36 Favored 'General case' 0 N--CA 1.455 -0.223 0 CA-C-O 121.062 0.458 . . . . 1.1499999999999999 110.995 172.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.602 ' HB2' ' HA ' ' A' ' 23' ' ' ARG . 2.6 mm? -63.49 -18.98 64.35 Favored 'General case' 0 CA--C 1.519 -0.23 0 CA-C-N 115.952 -0.567 . . . . 1.1599999999999999 109.94 174.662 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.421 ' HB2' ' O ' ' A' ' 26' ' ' LEU . 11.3 mmt180 67.69 23.38 8.7 Favored 'General case' 0 N--CA 1.451 -0.408 0 CA-C-N 115.277 -0.874 . . . . 3.6800000000000002 109.915 -178.079 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.659 HG22 ' H ' ' A' ' 29' ' ' ARG . 11.8 mt -124.32 -167.61 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 CA-C-N 114.479 -1.237 . . . . 1.1000000000000001 108.161 -178.161 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.659 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.2 OUTLIER -142.63 -158.55 0.88 Allowed 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 118.403 0.547 . . . . 3.0699999999999998 112.116 -175.464 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . 0.43 ' H ' ' HB2' ' A' ' 29' ' ' ARG . 5.7 mp0 -72.9 47.19 0.18 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 122.221 1.01 . . . . 1.23 111.942 -179.514 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.525 ' CA ' HD13 ' B' ' 10' ' ' ILE . . . -163.08 24.91 0.2 Allowed Glycine 0 N--CA 1.445 -0.71 0 CA-C-N 113.801 -1.545 . . . . 0.35999999999999999 109.867 175.115 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.47 ' O ' HG13 ' B' ' 10' ' ' ILE . 18.1 t0 -87.97 130.81 45.07 Favored Pre-proline 0 CA--C 1.514 -0.423 0 CA-C-N 114.446 -0.877 . . . . 1.26 109.367 174.247 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.655 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 3.2 Cg_endo -82.32 153.44 16.15 Favored 'Trans proline' 0 N--CA 1.438 -1.762 0 C-N-CA 122.172 1.915 . . . . 1.3 110.634 174.668 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.828 HD12 HG22 ' B' ' 10' ' ' ILE . 0.5 OUTLIER -140.72 151.68 44.7 Favored 'General case' 0 N--CA 1.433 -1.319 0 C-N-CA 119.866 -0.734 . . . . 1.21 109.663 171.439 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.725 ' O ' ' HA ' ' A' ' 46' ' ' LEU . 86.0 tt0 -105.13 111.31 24.03 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.606 -1.257 . . . . 1.1200000000000001 107.606 -178.523 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 1.0 HG13 HD21 ' A' ' 46' ' ' LEU . 2.9 mp -87.14 109.01 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.744 0 O-C-N 124.722 1.263 . . . . 1.1599999999999999 109.116 -178.893 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . 0.647 ' HD2' ' HA ' ' B' ' 3' ' ' ALA . 1.0 OUTLIER -149.23 127.72 12.3 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 115.987 -0.551 . . . . 2.0099999999999998 109.835 176.833 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.463 ' CG1' ' HD3' ' B' ' 2' ' ' LYS . 1.3 p -81.81 132.49 31.35 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.999 0 CA-C-O 121.612 0.72 . . . . 1.05 110.657 -179.878 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.582 ' HB3' ' HG2' ' A' ' 40' ' ' ARG . 19.7 t70 -79.94 -49.89 11.22 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 114.236 -1.347 . . . . 1.1100000000000001 111.672 -173.746 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . 0.582 ' HG2' ' HB3' ' A' ' 39' ' ' ASP . 1.7 ptm180 -133.65 -96.83 0.29 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.48 -0.782 . . . . 2.8799999999999999 112.96 -167.069 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -88.6 -70.38 0.65 Allowed 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.089 0.471 . . . . 1.53 111.024 -174.311 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.419 ' O ' ' HA ' ' B' ' 47' ' ' LYS . . . -139.67 22.84 2.82 Favored Glycine 0 N--CA 1.445 -0.741 0 CA-C-N 115.596 -0.729 . . . . 0.34000000000000002 111.279 -179.344 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.538 ' HB3' HG22 ' B' ' 45' ' ' ILE . 1.7 mt-10 -95.4 113.06 24.69 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 109.483 -0.562 . . . . 1.97 109.483 179.275 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.466 ' CG1' HG23 ' A' ' 36' ' ' ILE . 1.4 t -91.15 131.26 38.77 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 N-CA-C 109.425 -0.583 . . . . 1.0600000000000001 109.425 177.182 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.811 HG13 HG13 ' B' ' 45' ' ' ILE . 1.6 mp -109.69 118.06 55.99 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 108.072 -1.084 . . . . 1.01 108.072 -176.568 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 1.022 HD13 HD11 ' B' ' 46' ' ' LEU . 0.3 OUTLIER -112.54 116.69 30.63 Favored 'General case' 0 C--N 1.315 -0.933 0 O-C-N 123.796 0.685 . . . . 1.1299999999999999 109.467 178.813 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.7 ' HD2' ' HB3' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -127.64 153.59 46.26 Favored 'General case' 0 C--O 1.215 -0.722 0 C-N-CA 118.662 -1.215 . . . . 1.25 112.216 178.56 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.641 ' HG3' ' HG2' ' A' ' 51' ' ' PRO . 1.1 ptmt -41.24 -17.42 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.026 0 N-CA-C 117.497 2.406 . . . . 1.0900000000000001 117.497 -168.88 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.809 ' CD1' HG21 ' B' ' 7' ' ' VAL . 17.4 t80 75.82 -53.59 0.63 Allowed 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 112.418 0.525 . . . . 2.1400000000000001 112.418 173.379 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.667 ' HB3' ' HD3' ' A' ' 51' ' ' PRO . 8.3 t -51.57 -49.71 81.16 Favored Pre-proline 0 CA--C 1.538 0.498 0 CA-C-N 116.219 -0.446 . . . . 1.95 111.099 -177.184 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.667 ' HD3' ' HB3' ' A' ' 50' ' ' SER . 27.8 Cg_endo -93.82 9.12 2.25 Favored 'Trans proline' 0 N--CA 1.455 -0.749 0 C-N-CA 122.647 2.231 . . . . 0.59999999999999998 111.663 171.706 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.423 HG13 ' C ' ' A' ' 51' ' ' PRO . 1.1 mt 53.69 -149.35 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 CA-C-N 115.439 -0.8 . . . . 1.4199999999999999 109.326 -175.038 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.409 ' O ' ' N ' ' A' ' 55' ' ' LEU . 3.6 m -78.52 89.3 4.47 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.342 -0.614 . . . . 2.23 109.342 174.388 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . 0.631 ' O ' ' HB2' ' A' ' 55' ' ' LEU . 11.9 pt-20 54.42 -64.54 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.95 0 O-C-N 124.991 1.432 . . . . 2.8900000000000001 111.865 -170.949 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.631 ' HB2' ' O ' ' A' ' 54' ' ' GLU . 0.2 OUTLIER . . . . . 0 C--O 1.249 1.066 0 C-N-CA 124.788 1.235 . . . . 2.8100000000000001 108.526 173.471 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 26.5 ttt . . . . . 0 N--CA 1.481 1.111 0 CA-C-O 120.991 0.425 . . . . 6.71 110.149 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 2' ' ' LYS . . . . . 0.814 ' HE2' ' HA ' ' B' ' 2' ' ' LYS . 1.4 mmpt? 43.87 -143.3 0.14 Allowed 'General case' 0 N--CA 1.47 0.558 0 CA-C-N 115.615 -0.72 . . . . 4.0899999999999999 112.503 -176.144 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 3' ' ' ALA . . . . . 0.647 ' HA ' ' HD2' ' A' ' 37' ' ' PHE . . . 66.01 106.82 0.04 OUTLIER 'General case' 0 C--O 1.233 0.208 0 O-C-N 123.856 0.723 . . . . 1.1000000000000001 111.303 -174.687 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 4' ' ' THR . . . . . 0.532 ' OG1' ' HA ' ' A' ' 37' ' ' PHE . 7.5 p -94.73 -48.14 6.18 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.909 -0.587 . . . . 0.97999999999999998 111.675 -179.174 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 72.24 48.33 25.7 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.939 -0.648 . . . . 0.33000000000000002 112.976 174.84 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 6' ' ' ILE . . . . . 0.733 HG22 ' HB ' ' A' ' 36' ' ' ILE . 0.9 OUTLIER -106.11 112.1 37.95 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 N-CA-C 108.731 -0.84 . . . . 1.1000000000000001 108.731 174.83 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . 0.809 HG21 ' CD1' ' A' ' 49' ' ' TYR . 35.2 t -83.56 136.66 22.35 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 CA-C-O 120.952 0.405 . . . . 1.0800000000000001 111.167 -178.887 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.522 ' HD3' ' N ' ' B' ' 9' ' ' ARG . 1.0 OUTLIER -133.17 123.77 26.25 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 107.296 -1.372 . . . . 2.3599999999999999 107.296 179.128 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 9' ' ' ARG . . . . . 0.522 ' N ' ' HD3' ' B' ' 8' ' ' ARG . 0.1 OUTLIER -82.31 103.33 11.82 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 108.267 -1.012 . . . . 3.2000000000000002 108.267 173.219 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 10' ' ' ILE . . . . . 0.828 HG22 HD12 ' A' ' 34' ' ' LEU . 0.2 OUTLIER -10.32 -106.02 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 O-C-N 125.444 1.715 . . . . 1.0700000000000001 114.9 -176.746 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . 0.608 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 2.5 p-10 163.1 -168.29 0.01 OUTLIER 'General case' 0 CA--C 1.51 -0.575 0 N-CA-C 106.586 -1.635 . . . . 1.1799999999999999 106.586 177.174 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 52.7 m-20 -77.06 -2.87 36.28 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 118.418 0.553 . . . . 2.3900000000000001 110.995 -176.804 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 13' ' ' LEU . . . . . 0.444 HD11 HG12 ' A' ' 17' ' ' VAL . 2.1 tm? -106.56 -61.8 1.48 Allowed 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.781 -0.645 . . . . 1.1000000000000001 109.794 174.689 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 138.14 17.01 0.63 Allowed Glycine 0 N--CA 1.445 -0.722 0 CA-C-N 115.947 -0.57 . . . . 0.23000000000000001 112.093 -176.869 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 15' ' ' ARG . . . . . 0.539 ' HB3' ' HB3' ' A' ' 15' ' ' ARG . 1.6 mpt_? -70.36 143.1 52.04 Favored 'General case' 0 CA--C 1.506 -0.724 0 CA-C-O 121.536 0.684 . . . . 1.3899999999999999 110.481 -179.718 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 16' ' ' VAL . . . . . 0.698 HG23 HD11 ' A' ' 46' ' ' LEU . 81.1 t -104.69 94.34 3.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 N-CA-C 107.343 -1.354 . . . . 1.97 107.343 167.465 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 17' ' ' VAL . . . . . 0.492 HG21 ' HG2' ' A' ' 15' ' ' ARG . 40.8 t -67.13 98.49 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-N 115.188 -0.915 . . . . 1.0600000000000001 110.169 -171.1 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . 0.521 ' HB ' ' O ' ' A' ' 14' ' ' GLY . 11.4 mt -96.75 112.74 61.26 Favored Pre-proline 0 N--CA 1.447 -0.58 0 CA-C-N 115.535 -0.757 . . . . 1.6100000000000001 110.932 -177.477 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . 0.56 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 85.6 Cg_exo -51.67 154.31 9.54 Favored 'Trans proline' 0 N--CA 1.456 -0.68 0 C-N-CA 122.626 2.217 . . . . 0.33000000000000002 113.508 173.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 20' ' ' LYS . . . . . 0.767 ' HA ' ' HG3' ' B' ' 23' ' ' ARG . 0.0 OUTLIER -68.37 -13.37 62.24 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-N 114.828 -1.078 . . . . 2.3199999999999998 111.1 178.384 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . 0.56 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 9.8 pt-20 -66.36 -20.24 66.03 Favored 'General case' 0 C--N 1.322 -0.595 0 C-N-CA 120.327 -0.549 . . . . 1.9199999999999999 111.568 176.141 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 5.4 mp -88.56 -45.21 15.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 N-CA-C 108.863 -0.791 . . . . 1.24 108.863 177.265 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 23' ' ' ARG . . . . . 0.767 ' HG3' ' HA ' ' B' ' 20' ' ' LYS . 0.3 OUTLIER -59.92 -25.11 64.88 Favored 'General case' 0 N--CA 1.472 0.636 0 CA-C-O 121.989 0.899 . . . . 1.8500000000000001 108.789 171.996 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 24' ' ' ARG . . . . . 0.422 ' HB3' ' O ' ' B' ' 21' ' ' GLU . 35.3 ttm180 -65.17 -52.52 54.49 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 114.018 -1.446 . . . . 3.6899999999999999 110.971 174.012 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 31.7 m -63.08 -29.16 70.59 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 120.54 -0.464 . . . . 1.1599999999999999 110.906 173.756 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.577 ' HB2' ' HA ' ' B' ' 23' ' ' ARG . 2.6 mm? -63.34 -20.05 65.17 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.947 -0.57 . . . . 1.1100000000000001 110.057 174.337 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 27' ' ' ARG . . . . . 0.424 ' HB2' ' O ' ' B' ' 26' ' ' LEU . 25.0 mmt180 68.11 24.72 7.62 Favored 'General case' 0 N--CA 1.453 -0.306 0 CA-C-N 115.286 -0.87 . . . . 3.77 109.904 -177.381 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 28' ' ' ILE . . . . . 0.917 HG22 ' H ' ' B' ' 29' ' ' ARG . 12.6 mt -125.17 -161.43 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 114.793 -1.094 . . . . 1.2 109.294 -177.243 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 29' ' ' ARG . . . . . 0.917 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.1 OUTLIER -149.41 -160.79 1.22 Allowed 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 112.144 0.424 . . . . 2.7599999999999998 112.144 -173.123 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 30' ' ' GLU . . . . . 0.419 ' N ' ' HD2' ' B' ' 29' ' ' ARG . 3.2 mp0 -71.12 37.82 0.05 Allowed 'General case' 0 N--CA 1.464 0.232 0 CA-C-O 121.523 0.677 . . . . 1.1799999999999999 112.55 -178.629 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . 0.57 ' N ' ' HD2' ' B' ' 29' ' ' ARG . . . -152.03 18.5 0.84 Allowed Glycine 0 N--CA 1.443 -0.884 0 N-CA-C 110.339 -1.104 . . . . 0.34999999999999998 110.339 173.469 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 32' ' ' ASP . . . . . 0.488 ' O ' HG13 ' A' ' 10' ' ' ILE . 18.3 t70 -78.32 129.14 75.93 Favored Pre-proline 0 C--N 1.326 -0.433 0 CA-C-N 115.054 -0.573 . . . . 1.29 109.595 174.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 33' ' ' PRO . . . . . 0.671 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 5.1 Cg_endo -82.16 150.05 15.55 Favored 'Trans proline' 0 N--CA 1.436 -1.853 0 C-N-CA 122.586 2.191 . . . . 1.1000000000000001 110.697 173.242 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . 0.79 HD12 HG22 ' A' ' 10' ' ' ILE . 0.7 OUTLIER -136.85 150.66 48.42 Favored 'General case' 0 C--N 1.306 -1.304 0 N-CA-C 109.674 -0.491 . . . . 1.1699999999999999 109.674 173.693 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 35' ' ' GLU . . . . . 0.753 ' O ' ' HA ' ' B' ' 46' ' ' LEU . 38.0 tt0 -105.31 112.92 26.21 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 107.577 -1.268 . . . . 1.1000000000000001 107.577 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 36' ' ' ILE . . . . . 0.954 HG13 HD23 ' B' ' 46' ' ' LEU . 3.3 mp -89.12 109.85 20.77 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 O-C-N 124.878 1.361 . . . . 1.3200000000000001 109.198 -178.807 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 37' ' ' PHE . . . . . 0.869 ' HE1' ' HZ2' ' B' ' 47' ' ' LYS . 2.1 p90 -149.28 131.33 15.33 Favored 'General case' 0 C--N 1.317 -0.835 0 N-CA-C 109.694 -0.484 . . . . 2.0299999999999998 109.694 175.013 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 38' ' ' VAL . . . . . 0.609 HG11 ' HB3' ' A' ' 2' ' ' LYS . 1.2 p -82.09 135.38 25.05 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 CA-C-O 121.367 0.603 . . . . 0.89000000000000001 110.852 179.753 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 39' ' ' ASP . . . . . 0.451 ' HB2' ' CD1' ' B' ' 45' ' ' ILE . 35.8 t70 -81.07 -50.74 9.28 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 114.354 -1.294 . . . . 1.1399999999999999 111.255 -174.675 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 40' ' ' ARG . . . . . 0.55 ' HD3' ' OE1' ' B' ' 43' ' ' GLU . 0.9 OUTLIER -134.22 -105.04 0.23 Allowed 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.908 -0.587 . . . . 3.3700000000000001 112.347 -169.937 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 24.0 t70 -78.19 -70.48 0.48 Allowed 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.086 0.47 . . . . 1.3200000000000001 111.362 -176.354 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 42' ' ' GLY . . . . . 0.406 ' O ' ' HA ' ' A' ' 47' ' ' LYS . . . -139.72 25.17 2.71 Favored Glycine 0 N--CA 1.442 -0.906 0 C-N-CA 120.449 -0.881 . . . . 0.35999999999999999 111.978 -177.933 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 43' ' ' GLU . . . . . 0.55 ' OE1' ' HD3' ' B' ' 40' ' ' ARG . 3.2 mt-10 -95.43 113.68 25.36 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.901 -0.407 . . . . 2.0699999999999998 109.901 178.083 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 44' ' ' VAL . . . . . 0.484 ' CG1' HG23 ' B' ' 36' ' ' ILE . 1.5 t -91.13 130.73 39.85 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 N-CA-C 109.602 -0.518 . . . . 1.02 109.602 176.133 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 45' ' ' ILE . . . . . 0.811 HG13 HG13 ' A' ' 45' ' ' ILE . 1.7 mp -109.41 118.13 56.03 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 N-CA-C 108.262 -1.014 . . . . 0.95999999999999996 108.262 -177.446 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 46' ' ' LEU . . . . . 1.022 HD11 HD13 ' A' ' 46' ' ' LEU . 0.3 OUTLIER -113.02 116.8 30.49 Favored 'General case' 0 C--N 1.314 -0.935 0 O-C-N 123.665 0.603 . . . . 1.05 109.571 178.916 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 47' ' ' LYS . . . . . 0.869 ' HZ2' ' HE1' ' B' ' 37' ' ' PHE . 0.0 OUTLIER -126.81 155.28 43.11 Favored 'General case' 0 C--N 1.32 -0.694 0 C-N-CA 118.85 -1.14 . . . . 1.3899999999999999 111.97 179.096 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 48' ' ' LYS . . . . . 0.541 ' HA ' ' O ' ' B' ' 33' ' ' PRO . 6.5 ptmt -49.58 -7.67 0.03 OUTLIER 'General case' 0 N--CA 1.476 0.873 0 N-CA-C 117.102 2.26 . . . . 1.1899999999999999 117.102 -166.011 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 49' ' ' TYR . . . . . 0.734 ' CD1' HG22 ' A' ' 7' ' ' VAL . 19.7 t80 73.8 -52.92 0.69 Allowed 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 112.73 0.641 . . . . 2.1000000000000001 112.73 170.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 50' ' ' SER . . . . . 0.699 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 26.9 t -50.6 -52.89 51.74 Favored Pre-proline 0 CA--C 1.541 0.628 0 CA-C-N 116.059 -0.519 . . . . 1.77 111.177 -175.48 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 51' ' ' PRO . . . . . 0.699 ' HD3' ' HB3' ' B' ' 50' ' ' SER . 59.8 Cg_endo -93.55 12.87 1.73 Allowed 'Trans proline' 0 C--N 1.352 0.754 0 C-N-CA 122.438 2.092 . . . . 0.59999999999999998 111.791 171.293 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 52' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER 50.15 -144.76 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.236 0.361 0 CA-C-N 115.323 -0.853 . . . . 1.3899999999999999 109.619 -175.734 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 53' ' ' SER . . . . . . . . . . . . . 1.5 m -77.2 74.69 3.77 Favored 'General case' 0 C--N 1.323 -0.586 0 C-N-CA 120.807 -0.357 . . . . 2.04 110.68 176.243 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 54' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 49.07 22.28 0.58 Allowed 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 124.322 1.049 . . . . 2.6200000000000001 112.998 179.446 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 55' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.251 1.174 0 C-N-CA 123.682 0.793 . . . . 2.8700000000000001 111.806 179.791 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 18.8 mmt . . . . . 0 N--CA 1.481 1.083 0 CA-C-O 120.876 0.37 . . . . 6.3300000000000001 110.718 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.41 ' HB3' HG12 ' B' ' 38' ' ' VAL . 25.7 mmmt -109.53 -135.02 0.35 Allowed 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.951 -0.568 . . . . 4.1699999999999999 110.297 178.441 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.423 ' HA ' ' HB2' ' B' ' 37' ' ' PHE . . . 65.6 97.15 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.464 0 O-C-N 123.98 0.8 . . . . 1.1299999999999999 111.24 -177.431 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.494 ' OG1' ' HA ' ' B' ' 37' ' ' PHE . 18.2 p -87.5 -45.89 10.08 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.563 -0.744 . . . . 1.0900000000000001 111.365 -178.536 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 73.15 48.39 19.97 Favored Glycine 0 N--CA 1.444 -0.796 0 C-N-CA 120.829 -0.701 . . . . 0.32000000000000001 112.969 173.149 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.789 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.5 tp -106.46 107.4 22.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 N-CA-C 109.155 -0.683 . . . . 1.0900000000000001 109.155 174.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.687 HG21 ' CD1' ' B' ' 49' ' ' TYR . 55.7 t -76.05 136.61 24.43 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.909 0 CA-C-O 121.414 0.626 . . . . 1.1299999999999999 110.527 179.852 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.561 ' HB3' ' CD1' ' B' ' 36' ' ' ILE . 2.5 tpp180 -130.94 116.22 17.57 Favored 'General case' 0 N--CA 1.433 -1.304 0 N-CA-C 107.069 -1.456 . . . . 2.6099999999999999 107.069 -179.661 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.465 ' C ' HD13 ' A' ' 10' ' ' ILE . 0.2 OUTLIER -82.48 101.68 10.85 Favored 'General case' 0 C--N 1.315 -0.931 0 N-CA-C 108.123 -1.066 . . . . 3.4100000000000001 108.123 175.63 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.938 HG22 HD12 ' B' ' 34' ' ' LEU . 0.2 OUTLIER -7.05 -105.18 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.035 0 O-C-N 125.583 1.802 . . . . 1.0700000000000001 114.681 -177.909 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . 0.456 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 47.6 p30 163.1 -151.33 0.0 OUTLIER 'General case' 0 CA--C 1.512 -0.482 0 C-N-CA 123.609 0.763 . . . . 1.1299999999999999 109.013 176.356 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -78.91 -9.75 59.6 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 123.244 0.34 . . . . 2.2599999999999998 111.288 -177.215 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -117.31 -58.06 2.08 Favored 'General case' 0 C--N 1.326 -0.454 0 O-C-N 122.237 -0.289 . . . . 1.23 110.292 -178.679 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.412 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 138.89 16.6 0.58 Allowed Glycine 0 N--CA 1.445 -0.748 0 C-N-CA 120.593 -0.813 . . . . 0.25 113.321 -177.922 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.582 ' HG2' HG23 ' B' ' 17' ' ' VAL . 0.8 OUTLIER -76.29 150.52 36.94 Favored 'General case' 0 CA--C 1.509 -0.603 0 CA-C-N 118.02 0.91 . . . . 0.88 109.837 177.406 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.693 HG22 HD11 ' B' ' 46' ' ' LEU . 54.3 t -106.73 96.87 4.98 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.29 0 N-CA-C 107.436 -1.32 . . . . 1.99 107.436 171.32 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.565 HG23 ' HG2' ' B' ' 15' ' ' ARG . 62.2 t -68.65 100.94 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.825 0 CA-C-N 115.366 -0.834 . . . . 1.0600000000000001 110.06 -173.771 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.686 HG22 HD12 ' A' ' 22' ' ' ILE . 8.0 mt -93.83 114.9 64.3 Favored Pre-proline 0 N--CA 1.446 -0.641 0 CA-C-N 115.603 -0.726 . . . . 1.5600000000000001 111.053 -177.171 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.54 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 30.9 Cg_exo -44.73 143.87 3.87 Favored 'Trans proline' 0 CA--C 1.513 -0.536 0 C-N-CA 123.403 2.736 . . . . 0.34999999999999998 113.137 171.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.817 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -59.38 -15.82 19.02 Favored 'General case' 0 C--O 1.214 -0.797 0 CA-C-N 115.258 -0.883 . . . . 2.1299999999999999 111.363 178.185 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.54 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 10.0 pt-20 -67.86 -21.06 65.19 Favored 'General case' 0 C--O 1.236 0.348 0 N-CA-C 111.63 0.233 . . . . 1.3200000000000001 111.63 -177.51 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.686 HD12 HG22 ' A' ' 18' ' ' ILE . 5.0 mp -87.68 -49.16 14.8 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.369 0 N-CA-C 107.842 -1.17 . . . . 1.0800000000000001 107.842 -179.414 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . 0.64 ' HD3' ' N ' ' A' ' 24' ' ' ARG . 0.0 OUTLIER -51.69 -34.5 38.8 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-O 121.768 0.794 . . . . 2.02 109.769 168.296 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.64 ' N ' ' HD3' ' A' ' 23' ' ' ARG . 9.3 ttm180 -60.99 -51.89 67.32 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 114.771 -1.104 . . . . 3.3999999999999999 110.943 177.506 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 27.5 m -65.19 -27.82 68.96 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-O 121.406 0.622 . . . . 1.1499999999999999 110.587 175.187 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.852 ' HB3' HG13 ' A' ' 28' ' ' ILE . 2.3 mm? -65.01 -18.99 65.77 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.405 -0.816 . . . . 1.1599999999999999 111.211 175.375 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.508 ' HB2' ' O ' ' A' ' 26' ' ' LEU . 5.7 mpt_? 71.42 14.72 6.35 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 123.437 0.695 . . . . 3.6800000000000002 111.06 -174.307 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.852 HG13 ' HB3' ' A' ' 26' ' ' LEU . 2.9 mt -109.4 -157.21 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 CA-C-N 115.773 -0.649 . . . . 1.1000000000000001 109.647 -175.71 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.685 ' H ' HG23 ' A' ' 28' ' ' ILE . 0.2 OUTLIER -161.79 -153.79 0.3 Allowed 'General case' 0 C--N 1.325 -0.494 0 C-N-CA 123.026 0.53 . . . . 3.0699999999999998 110.298 -176.211 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . 0.419 ' H ' ' HB2' ' A' ' 29' ' ' ARG . 2.8 mp0 -71.5 44.79 0.1 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 122.097 0.951 . . . . 1.23 111.516 178.039 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.549 ' CA ' HD13 ' B' ' 10' ' ' ILE . . . -161.36 33.87 0.38 Allowed Glycine 0 N--CA 1.441 -0.996 0 CA-C-N 114.331 -1.304 . . . . 0.35999999999999999 110.496 177.656 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.445 ' HA ' ' HD3' ' A' ' 33' ' ' PRO . 29.2 t0 -94.45 119.4 66.44 Favored Pre-proline 0 C--N 1.327 -0.391 0 CA-C-N 115.168 -0.516 . . . . 1.26 109.753 176.453 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.604 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 3.3 Cg_endo -88.01 63.93 3.5 Favored 'Trans proline' 0 N--CA 1.452 -0.956 0 C-N-CA 123.916 3.077 . . . . 1.3 113.957 -177.214 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.488 HD11 ' H ' ' A' ' 34' ' ' LEU . 0.9 OUTLIER -64.66 154.54 36.21 Favored 'General case' 0 C--N 1.292 -1.924 0 C-N-CA 118.328 -1.349 . . . . 1.21 111.841 -177.128 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.753 ' O ' ' HA ' ' A' ' 46' ' ' LEU . 35.0 tt0 -109.4 113.5 26.37 Favored 'General case' 0 CA--C 1.494 -1.175 0 CA-C-N 113.369 -1.741 . . . . 1.1200000000000001 108.291 -174.437 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.838 HG13 HD22 ' A' ' 46' ' ' LEU . 2.7 mp -84.4 109.49 17.74 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 O-C-N 124.143 0.902 . . . . 1.1599999999999999 109.647 -178.836 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . 0.734 ' HD1' ' HA ' ' B' ' 3' ' ' ALA . 0.6 OUTLIER -149.31 121.48 8.33 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-O 121.228 0.537 . . . . 2.0099999999999998 109.878 175.771 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.534 HG12 ' HB3' ' B' ' 2' ' ' LYS . 1.9 p -80.38 135.86 24.49 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.047 0 CA-C-O 121.208 0.527 . . . . 1.05 110.351 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.461 ' HB3' ' HG3' ' A' ' 40' ' ' ARG . 14.3 t70 -86.08 -40.33 15.84 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 114.99 -1.004 . . . . 1.1100000000000001 111.529 -173.261 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . 0.461 ' HG3' ' HB3' ' A' ' 39' ' ' ASP . 8.3 mtp180 -132.08 -81.44 0.5 Allowed 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 112.788 0.662 . . . . 2.8799999999999999 112.788 -163.061 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -122.19 -65.75 1.09 Allowed 'General case' 0 CA--C 1.507 -0.69 0 CA-C-O 121.581 0.705 . . . . 1.53 109.962 -176.18 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.54 ' O ' ' HA ' ' B' ' 47' ' ' LYS . . . -133.1 12.58 5.02 Favored Glycine 0 N--CA 1.438 -1.213 0 CA-C-N 114.816 -1.084 . . . . 0.34000000000000002 111.638 -178.171 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.558 ' HB3' HG23 ' B' ' 45' ' ' ILE . 0.9 OUTLIER -92.57 105.97 18.04 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 108.757 -0.831 . . . . 1.97 108.757 177.346 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.534 ' CG1' HG21 ' A' ' 36' ' ' ILE . 2.4 t -89.67 131.24 37.43 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 N-CA-C 109.29 -0.633 . . . . 1.0600000000000001 109.29 177.764 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.825 HG13 HG13 ' B' ' 45' ' ' ILE . 1.6 mp -108.85 116.07 51.02 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 N-CA-C 108.054 -1.091 . . . . 1.01 108.054 -176.028 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 1.056 HD13 HD13 ' B' ' 46' ' ' LEU . 0.7 OUTLIER -106.35 117.66 34.62 Favored 'General case' 0 C--N 1.316 -0.86 0 O-C-N 123.883 0.74 . . . . 1.1299999999999999 109.402 178.418 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.728 ' HD2' ' HB3' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -129.49 143.82 51.0 Favored 'General case' 0 C--O 1.214 -0.773 0 C-N-CA 119.265 -0.974 . . . . 1.25 112.597 178.752 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.695 ' HG3' ' HG2' ' A' ' 51' ' ' PRO . 3.0 ptmt -39.86 -12.82 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.288 0 N-CA-C 117.833 2.531 . . . . 1.0900000000000001 117.833 -169.921 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.604 ' HB3' ' HB2' ' A' ' 33' ' ' PRO . 27.9 t80 70.63 -57.11 0.59 Allowed 'General case' 0 N--CA 1.478 0.952 0 N-CA-C 113.437 0.903 . . . . 2.1400000000000001 113.437 175.242 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 19.0 m -52.88 -52.64 63.05 Favored Pre-proline 0 CA--C 1.54 0.595 0 CA-C-N 115.644 -0.707 . . . . 1.95 111.951 -174.46 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.695 ' HG2' ' HG3' ' A' ' 48' ' ' LYS . 75.2 Cg_endo -90.55 10.65 2.87 Favored 'Trans proline' 0 C--N 1.35 0.618 0 C-N-CA 122.246 1.964 . . . . 0.59999999999999998 111.726 168.615 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.402 HG13 ' C ' ' A' ' 51' ' ' PRO . 1.0 OUTLIER 55.04 -147.74 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.511 0 CA-C-N 115.261 -0.882 . . . . 1.4199999999999999 109.726 -175.565 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.592 ' HA ' ' HG3' ' A' ' 47' ' ' LYS . 34.1 m -76.91 -15.95 59.52 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-O 121.694 0.759 . . . . 2.23 110.436 179.03 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . 0.585 ' O ' ' HB2' ' A' ' 55' ' ' LEU . 31.6 tt0 169.02 -55.72 0.01 OUTLIER 'General case' 0 C--N 1.313 -1.02 0 CA-C-N 113.663 -1.608 . . . . 2.8900000000000001 106.799 -172.118 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.585 ' HB2' ' O ' ' A' ' 54' ' ' GLU . 0.2 OUTLIER . . . . . 0 C--O 1.248 1.017 0 O-C-N 125.121 1.513 . . . . 2.8100000000000001 108.936 169.604 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 23.5 mmt . . . . . 0 N--CA 1.48 1.065 0 N-CA-C 109.852 -0.425 . . . . 6.71 109.852 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 2' ' ' LYS . . . . . 0.534 ' HB3' HG12 ' A' ' 38' ' ' VAL . 24.4 mmmt -98.27 -131.63 0.22 Allowed 'General case' 0 C--N 1.326 -0.431 0 C-N-CA 121.128 -0.229 . . . . 4.0899999999999999 111.367 -179.14 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 3' ' ' ALA . . . . . 0.734 ' HA ' ' HD1' ' A' ' 37' ' ' PHE . . . 69.09 89.12 0.1 Allowed 'General case' 0 C--N 1.325 -0.46 0 O-C-N 124.057 0.848 . . . . 1.1000000000000001 110.985 -174.875 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 4' ' ' THR . . . . . 0.535 ' OG1' ' HA ' ' A' ' 37' ' ' PHE . 12.5 p -80.66 -45.74 16.71 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.354 -0.839 . . . . 0.97999999999999998 111.944 -176.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 71.2 47.93 34.31 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 121.031 -0.604 . . . . 0.33000000000000002 112.911 174.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 6' ' ' ILE . . . . . 0.798 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.1 tp -105.76 107.33 22.38 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 N-CA-C 109.263 -0.643 . . . . 1.1000000000000001 109.263 175.443 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . 0.6 HG21 ' CD1' ' A' ' 49' ' ' TYR . 37.6 t -77.96 134.84 27.47 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.842 0 CA-C-N 115.627 -0.715 . . . . 1.0800000000000001 110.412 -178.838 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 1.4 tpp180 -131.04 116.63 18.04 Favored 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 107.018 -1.475 . . . . 2.3599999999999999 107.018 177.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 9' ' ' ARG . . . . . 0.434 ' C ' HD12 ' B' ' 10' ' ' ILE . 13.9 ttt180 -79.03 103.45 8.98 Favored 'General case' 0 CA--C 1.505 -0.753 0 N-CA-C 108.381 -0.97 . . . . 3.2000000000000002 108.381 174.53 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 10' ' ' ILE . . . . . 0.592 ' O ' ' HB3' ' B' ' 11' ' ' ASP . 0.3 OUTLIER -9.93 -106.15 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 O-C-N 125.895 1.997 . . . . 1.0700000000000001 114.845 -176.599 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . 0.592 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 3.2 p-10 165.58 -164.42 0.01 OUTLIER 'General case' 0 CA--C 1.514 -0.405 0 N-CA-C 107.628 -1.249 . . . . 1.1799999999999999 107.628 178.842 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 24.3 t70 -72.58 -10.63 60.02 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.012 0.434 . . . . 2.3900000000000001 111.051 -179.014 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 13' ' ' LEU . . . . . 0.402 ' H ' ' CG ' ' B' ' 11' ' ' ASP . 2.4 tm? -108.47 -62.02 1.52 Allowed 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.4 -0.364 . . . . 1.1000000000000001 110.922 -179.337 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 139.34 21.57 0.39 Allowed Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 120.799 -0.715 . . . . 0.23000000000000001 112.0 -177.246 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 15' ' ' ARG . . . . . 0.565 ' HG2' HG23 ' A' ' 17' ' ' VAL . 1.7 mpt_? -75.44 150.12 38.36 Favored 'General case' 0 CA--C 1.505 -0.771 0 CA-C-O 121.617 0.723 . . . . 1.3899999999999999 110.394 177.527 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 16' ' ' VAL . . . . . 0.794 HG22 HD11 ' A' ' 46' ' ' LEU . 61.4 t -108.18 92.74 2.17 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 N-CA-C 107.487 -1.301 . . . . 1.97 107.487 167.267 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 17' ' ' VAL . . . . . 0.582 HG23 ' HG2' ' A' ' 15' ' ' ARG . 46.8 t -67.34 98.54 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.79 0 CA-C-N 115.59 -0.732 . . . . 1.0600000000000001 109.99 -173.133 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . 0.412 ' HB ' ' O ' ' A' ' 14' ' ' GLY . 8.7 mt -92.19 112.8 56.84 Favored Pre-proline 0 N--CA 1.445 -0.677 0 CA-C-N 115.415 -0.811 . . . . 1.6100000000000001 110.819 -177.842 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . 0.571 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 71.0 Cg_exo -49.29 147.2 12.22 Favored 'Trans proline' 0 N--CA 1.458 -0.581 0 C-N-CA 123.23 2.62 . . . . 0.33000000000000002 112.669 173.043 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 20' ' ' LYS . . . . . 0.97 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -64.81 -14.86 60.66 Favored 'General case' 0 C--O 1.211 -0.932 0 CA-C-N 115.387 -0.824 . . . . 2.3199999999999998 111.369 -177.793 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . 0.571 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 1.1 pm0 -63.15 -23.88 67.64 Favored 'General case' 0 N--CA 1.47 0.54 0 N-CA-C 112.201 0.445 . . . . 1.9199999999999999 112.201 176.71 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 5.3 mp -87.01 -50.34 14.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 108.032 -1.099 . . . . 1.24 108.032 -178.357 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 23' ' ' ARG . . . . . 0.541 ' NE ' ' HA ' ' B' ' 29' ' ' ARG . 0.0 OUTLIER -56.08 -27.97 55.77 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.098 -0.956 . . . . 1.8500000000000001 110.061 170.497 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 24' ' ' ARG . . . . . 0.407 ' HB3' ' HA ' ' B' ' 21' ' ' GLU . 8.2 ttm180 -64.13 -53.2 53.33 Favored 'General case' 0 CA--C 1.507 -0.687 0 CA-C-N 115.23 -0.895 . . . . 3.6899999999999999 110.903 173.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 28.3 m -67.06 -22.41 65.86 Favored 'General case' 0 N--CA 1.445 -0.698 0 CA-C-O 121.614 0.721 . . . . 1.1599999999999999 110.22 178.485 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.574 ' HB3' HG13 ' B' ' 28' ' ' ILE . 1.9 mm? -67.83 -18.85 64.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.08 -0.963 . . . . 1.1100000000000001 110.655 173.489 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 27' ' ' ARG . . . . . 0.442 ' HB2' ' O ' ' B' ' 26' ' ' LEU . 7.2 mpt_? 68.52 21.0 8.27 Favored 'General case' 0 C--O 1.234 0.245 0 C-N-CA 123.517 0.727 . . . . 3.77 110.475 -174.367 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 28' ' ' ILE . . . . . 0.875 HG22 ' H ' ' B' ' 29' ' ' ARG . 6.6 mt -116.91 -163.67 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.462 -0.79 . . . . 1.2 109.434 -177.669 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 29' ' ' ARG . . . . . 0.875 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -156.06 -151.38 0.33 Allowed 'General case' 0 C--N 1.32 -0.681 0 C-N-CA 122.338 0.255 . . . . 2.7599999999999998 110.723 -173.942 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 30' ' ' GLU . . . . . 0.409 ' C ' HD12 ' A' ' 10' ' ' ILE . 0.7 OUTLIER -73.43 36.74 0.09 Allowed 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 122.166 0.984 . . . . 1.1799999999999999 111.669 -179.522 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . 0.53 ' H ' ' C ' ' B' ' 29' ' ' ARG . . . -154.12 39.63 0.67 Allowed Glycine 0 N--CA 1.434 -1.436 0 CA-C-N 114.107 -1.406 . . . . 0.34999999999999998 110.026 175.105 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 32' ' ' ASP . . . . . 0.467 ' HA ' ' HD3' ' B' ' 33' ' ' PRO . 9.5 t0 -95.96 119.66 64.33 Favored Pre-proline 0 C--N 1.325 -0.493 0 CA-C-O 121.256 0.55 . . . . 1.29 110.049 175.147 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 33' ' ' PRO . . . . . 0.659 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 4.4 Cg_endo -87.07 76.35 2.27 Favored 'Trans proline' 0 C--O 1.205 -1.145 0 C-N-CA 123.547 2.831 . . . . 1.1000000000000001 113.268 -178.905 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . 0.938 HD12 HG22 ' A' ' 10' ' ' ILE . 0.1 OUTLIER -72.12 150.5 43.8 Favored 'General case' 0 C--N 1.284 -2.249 0 C-N-CA 117.776 -1.569 . . . . 1.1699999999999999 111.343 -178.963 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 35' ' ' GLU . . . . . 0.753 ' O ' ' HA ' ' B' ' 46' ' ' LEU . 42.7 tt0 -105.1 115.32 30.07 Favored 'General case' 0 CA--C 1.492 -1.264 0 CA-C-N 114.067 -1.424 . . . . 1.1000000000000001 107.822 -179.143 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 36' ' ' ILE . . . . . 0.903 HG13 HD23 ' B' ' 46' ' ' LEU . 3.1 mp -88.19 108.8 19.03 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 O-C-N 124.168 0.918 . . . . 1.3200000000000001 109.336 -178.443 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 37' ' ' PHE . . . . . 0.494 ' HA ' ' OG1' ' A' ' 4' ' ' THR . 12.3 p90 -149.74 126.41 11.01 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 116.159 -0.473 . . . . 2.0299999999999998 110.064 175.142 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 38' ' ' VAL . . . . . 0.508 ' HA ' ' HA ' ' B' ' 44' ' ' VAL . 0.8 OUTLIER -80.23 138.57 19.59 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-O 121.29 0.567 . . . . 0.89000000000000001 110.571 -179.561 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 39' ' ' ASP . . . . . 0.685 ' HB3' ' HG3' ' B' ' 40' ' ' ARG . 8.1 t70 -80.9 -46.13 15.69 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 114.751 -1.113 . . . . 1.1399999999999999 110.577 -177.726 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 40' ' ' ARG . . . . . 0.685 ' HG3' ' HB3' ' B' ' 39' ' ' ASP . 23.8 mtp180 -133.33 -92.53 0.35 Allowed 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.928 -0.578 . . . . 3.3700000000000001 112.34 -166.55 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 41' ' ' ASP . . . . . 0.456 ' H ' ' HB2' ' B' ' 40' ' ' ARG . 18.4 t70 -102.3 -75.59 0.6 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.314 0.578 . . . . 1.3200000000000001 110.395 -176.881 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 42' ' ' GLY . . . . . 0.512 ' O ' ' HA ' ' A' ' 47' ' ' LYS . . . -124.99 18.86 6.98 Favored Glycine 0 N--CA 1.44 -1.091 0 CA-C-N 115.376 -0.829 . . . . 0.35999999999999999 112.201 -179.341 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 43' ' ' GLU . . . . . 0.49 ' HB3' HG23 ' A' ' 45' ' ' ILE . 1.3 mt-10 -93.52 104.91 17.01 Favored 'General case' 0 CA--C 1.51 -0.595 0 N-CA-C 108.932 -0.766 . . . . 2.0699999999999998 108.932 176.533 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 44' ' ' VAL . . . . . 0.508 ' HA ' ' HA ' ' B' ' 38' ' ' VAL . 2.2 t -89.53 131.24 37.31 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 N-CA-C 109.441 -0.577 . . . . 1.02 109.441 177.194 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 45' ' ' ILE . . . . . 0.825 HG13 HG13 ' A' ' 45' ' ' ILE . 1.7 mp -108.04 117.5 53.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.463 0 N-CA-C 108.031 -1.1 . . . . 0.95999999999999996 108.031 -176.937 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 46' ' ' LEU . . . . . 1.056 HD13 HD13 ' A' ' 46' ' ' LEU . 1.6 mt -108.53 117.24 33.66 Favored 'General case' 0 C--N 1.317 -0.813 0 O-C-N 123.9 0.75 . . . . 1.05 109.776 178.391 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 47' ' ' LYS . . . . . 0.638 ' HG3' ' HA ' ' B' ' 53' ' ' SER . 0.0 OUTLIER -130.15 147.34 51.87 Favored 'General case' 0 C--O 1.214 -0.8 0 C-N-CA 119.199 -1.0 . . . . 1.3899999999999999 113.129 -179.919 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 48' ' ' LYS . . . . . 0.571 ' HG3' ' CG ' ' B' ' 51' ' ' PRO . 3.5 ptmt -44.83 -7.91 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.409 0 N-CA-C 118.065 2.617 . . . . 1.1899999999999999 118.065 -168.781 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 49' ' ' TYR . . . . . 0.687 ' CD1' HG21 ' A' ' 7' ' ' VAL . 32.5 t80 69.72 -57.5 0.55 Allowed 'General case' 0 N--CA 1.48 1.051 0 N-CA-C 113.727 1.01 . . . . 2.1000000000000001 113.727 173.506 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 50' ' ' SER . . . . . 0.657 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 9.1 t -51.24 -56.28 21.53 Favored Pre-proline 0 CA--C 1.539 0.528 0 CA-C-N 115.932 -0.576 . . . . 1.77 111.134 -173.484 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 51' ' ' PRO . . . . . 0.657 ' HD3' ' HB3' ' B' ' 50' ' ' SER . 59.1 Cg_endo -87.21 8.24 4.43 Favored 'Trans proline' 0 C--N 1.351 0.666 0 C-N-CA 122.174 1.916 . . . . 0.59999999999999998 111.968 170.396 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 52' ' ' ILE . . . . . . . . . . . . . 1.6 mt 56.16 -147.91 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.341 0 CA-C-N 115.137 -0.938 . . . . 1.3899999999999999 108.863 -175.002 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 53' ' ' SER . . . . . 0.638 ' HA ' ' HG3' ' B' ' 47' ' ' LYS . 61.0 m -74.73 -21.03 59.59 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.946 0.879 . . . . 2.04 109.932 -179.634 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 54' ' ' GLU . . . . . 0.522 ' O ' ' HB2' ' B' ' 55' ' ' LEU . 41.5 tt0 178.04 -54.0 0.01 OUTLIER 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 113.485 -1.689 . . . . 2.6200000000000001 106.869 -174.629 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 55' ' ' LEU . . . . . 0.522 ' HB2' ' O ' ' B' ' 54' ' ' GLU . 0.3 OUTLIER . . . . . 0 C--O 1.251 1.148 0 CA-C-N 114.535 -1.211 . . . . 2.8700000000000001 109.312 165.827 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 26.3 ptt? . . . . . 0 N--CA 1.482 1.149 0 CA-C-O 120.35 0.119 . . . . 6.3300000000000001 110.937 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.705 ' HB3' HG11 ' B' ' 38' ' ' VAL . 24.3 mmmt 51.08 -111.68 0.57 Allowed 'General case' 0 CA--C 1.517 -0.294 0 CA-C-N 116.279 -0.419 . . . . 4.1699999999999999 111.912 -176.076 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.434 ' HA ' ' HB2' ' B' ' 37' ' ' PHE . . . 58.13 89.48 0.05 Allowed 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 114.972 -1.013 . . . . 1.1299999999999999 111.639 -178.668 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.552 ' OG1' ' HA ' ' B' ' 37' ' ' PHE . 11.8 p -81.21 -35.1 31.73 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.579 -0.737 . . . . 1.0900000000000001 111.647 -179.297 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . 0.511 ' H ' ' CB ' ' B' ' 37' ' ' PHE . . . 57.51 47.67 86.53 Favored Glycine 0 N--CA 1.445 -0.73 0 CA-C-N 115.735 -0.666 . . . . 0.32000000000000001 112.68 173.958 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.68 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.8 tp -105.9 104.06 16.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 108.807 -0.812 . . . . 1.0900000000000001 108.807 175.22 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.653 HG22 ' CG ' ' B' ' 49' ' ' TYR . 52.9 t -74.9 135.17 27.88 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.873 0 CA-C-N 115.522 -0.763 . . . . 1.1299999999999999 109.943 179.481 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.502 ' HB3' ' CD1' ' B' ' 36' ' ' ILE . 1.7 tpp180 -131.84 117.13 18.12 Favored 'General case' 0 N--CA 1.431 -1.415 0 N-CA-C 106.899 -1.519 . . . . 2.6099999999999999 106.899 -177.6 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.5 ' HA ' ' O ' ' B' ' 32' ' ' ASP . 0.0 OUTLIER -78.44 101.74 7.46 Favored 'General case' 0 C--N 1.314 -0.954 0 N-CA-C 107.924 -1.139 . . . . 3.4100000000000001 107.924 174.913 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.738 HG22 HD13 ' B' ' 34' ' ' LEU . 0.2 OUTLIER -5.63 -105.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.195 0 O-C-N 125.445 1.715 . . . . 1.0700000000000001 114.587 -176.753 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . 0.608 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 2.4 p-10 165.99 -162.49 0.01 OUTLIER 'General case' 0 CA--C 1.513 -0.472 0 N-CA-C 107.935 -1.135 . . . . 1.1299999999999999 107.935 177.611 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 30.4 m-20 -76.45 -6.7 52.86 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 120.744 0.307 . . . . 2.2599999999999998 111.301 -178.255 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -114.75 -59.16 2.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.661 -0.245 . . . . 1.23 110.996 178.589 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.442 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 140.1 13.78 0.58 Allowed Glycine 0 N--CA 1.448 -0.5 0 C-N-CA 120.432 -0.889 . . . . 0.25 113.096 -178.805 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.722 ' HG2' HG23 ' B' ' 17' ' ' VAL . 0.9 OUTLIER -77.43 154.98 32.1 Favored 'General case' 0 CA--C 1.501 -0.933 0 N-CA-C 109.231 -0.655 . . . . 0.88 109.231 176.011 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.908 HG13 HD11 ' B' ' 46' ' ' LEU . 1.5 m -109.88 112.13 39.17 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.59 0 N-CA-C 107.355 -1.35 . . . . 1.99 107.355 166.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.667 HG23 ' HG2' ' B' ' 15' ' ' ARG . 59.6 t -73.16 95.94 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.427 -1.588 0 CA-C-N 114.449 -1.25 . . . . 1.0600000000000001 109.657 -174.875 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.618 HG22 HD12 ' A' ' 22' ' ' ILE . 11.0 mt -86.28 110.92 35.13 Favored Pre-proline 0 N--CA 1.446 -0.641 0 CA-C-N 115.218 -0.901 . . . . 1.5600000000000001 110.251 -179.588 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.567 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 67.5 Cg_exo -47.37 144.51 9.67 Favored 'Trans proline' 0 N--CA 1.459 -0.535 0 C-N-CA 123.115 2.544 . . . . 0.34999999999999998 112.261 173.594 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.942 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -59.95 -15.29 20.78 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.775 -0.648 . . . . 2.1299999999999999 111.706 -178.493 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.567 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 12.8 pt-20 -67.6 -19.79 65.29 Favored 'General case' 0 C--O 1.237 0.437 0 N-CA-C 112.062 0.393 . . . . 1.3200000000000001 112.062 -178.723 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.618 HD12 HG22 ' A' ' 18' ' ' ILE . 4.8 mp -87.43 -44.45 16.04 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 N-CA-C 108.125 -1.065 . . . . 1.0800000000000001 108.125 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . 0.668 ' HA ' ' HB2' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -60.68 -30.52 69.97 Favored 'General case' 0 CA--C 1.521 -0.166 0 CA-C-O 121.883 0.849 . . . . 2.02 109.093 171.208 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 63.2 ttt180 -61.33 -51.49 68.61 Favored 'General case' 0 N--CA 1.441 -0.894 0 CA-C-N 114.619 -1.173 . . . . 3.3999999999999999 110.455 176.187 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 22.7 m -66.68 -21.94 66.09 Favored 'General case' 0 CA--C 1.535 0.392 0 CA-C-O 121.527 0.679 . . . . 1.1499999999999999 110.654 174.094 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.865 ' HB3' HG13 ' A' ' 28' ' ' ILE . 2.3 mm? -71.94 -18.14 62.03 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.964 -0.562 . . . . 1.1599999999999999 110.605 174.201 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.435 ' HB2' ' O ' ' A' ' 26' ' ' LEU . 9.0 mpt_? 66.21 23.18 10.9 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-N 116.006 -0.543 . . . . 3.6800000000000002 110.625 -175.069 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.865 HG13 ' HB3' ' A' ' 26' ' ' LEU . 2.6 mt -113.92 -154.61 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 115.865 -0.607 . . . . 1.1000000000000001 109.91 -178.44 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.647 ' H ' HG23 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -162.34 -156.3 0.41 Allowed 'General case' 0 C--N 1.321 -0.653 0 C-N-CA 122.686 0.394 . . . . 3.0699999999999998 110.674 -173.951 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . 0.439 ' H ' ' HB2' ' A' ' 29' ' ' ARG . 1.8 mp0 -74.9 44.1 0.22 Allowed 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 122.132 0.968 . . . . 1.23 111.025 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.529 ' CA ' HD13 ' B' ' 10' ' ' ILE . . . -156.98 26.3 0.5 Allowed Glycine 0 N--CA 1.439 -1.137 0 CA-C-N 114.055 -1.43 . . . . 0.35999999999999999 110.999 176.757 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.428 ' HA ' ' HD3' ' A' ' 33' ' ' PRO . 9.2 t0 -85.7 122.5 73.12 Favored Pre-proline 0 C--N 1.327 -0.379 0 CA-C-O 121.108 0.48 . . . . 1.26 110.111 176.321 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.757 ' HG2' ' HG ' ' A' ' 50' ' ' SER . 3.8 Cg_endo -91.08 62.81 1.28 Allowed 'Trans proline' 0 N--CA 1.451 -0.986 0 C-N-CA 123.855 3.037 . . . . 1.3 114.253 -175.684 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.886 HD12 HG23 ' B' ' 10' ' ' ILE . 0.0 OUTLIER -61.22 153.97 24.73 Favored 'General case' 0 C--N 1.298 -1.646 0 C-N-CA 118.884 -1.127 . . . . 1.21 112.046 -178.536 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.764 ' HB3' ' HB3' ' A' ' 47' ' ' LYS . 39.4 tt0 -107.84 113.83 27.34 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 112.938 -1.937 . . . . 1.1200000000000001 107.392 -176.253 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.81 ' HB ' HG23 ' B' ' 6' ' ' ILE . 2.4 mp -86.32 107.34 16.53 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.058 0 N-CA-C 109.136 -0.69 . . . . 1.1599999999999999 109.136 -179.481 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . 0.494 ' CB ' ' H ' ' B' ' 5' ' ' GLY . 2.2 p90 -149.17 120.88 8.07 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-O 121.44 0.638 . . . . 2.0099999999999998 109.937 176.169 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.674 HG11 ' HB3' ' B' ' 2' ' ' LYS . 1.5 p -80.5 137.56 21.25 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.987 0 CA-C-N 115.803 -0.635 . . . . 1.05 110.555 -178.126 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.565 ' HB3' ' HG2' ' A' ' 40' ' ' ARG . 7.5 t70 -76.22 -40.91 50.95 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 114.831 -1.077 . . . . 1.1100000000000001 111.669 -171.16 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . 0.565 ' HG2' ' HB3' ' A' ' 39' ' ' ASP . 0.3 OUTLIER -150.62 -74.77 0.15 Allowed 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 112.859 0.689 . . . . 2.8799999999999999 112.859 -168.753 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -106.29 -74.16 0.66 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.171 0.51 . . . . 1.53 111.431 -175.688 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.495 ' HA3' HD11 ' B' ' 26' ' ' LEU . . . -135.82 12.74 4.21 Favored Glycine 0 N--CA 1.443 -0.866 0 CA-C-N 115.123 -0.944 . . . . 0.34000000000000002 111.891 -175.738 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.51 ' O ' HG21 ' A' ' 38' ' ' VAL . 2.5 pm0 -92.82 106.77 18.69 Favored 'General case' 0 N--CA 1.446 -0.66 0 N-CA-C 110.051 -0.352 . . . . 1.97 110.051 175.183 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.6 HG13 HG22 ' A' ' 36' ' ' ILE . 2.5 t -87.57 134.84 26.78 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 N-CA-C 109.259 -0.645 . . . . 1.0600000000000001 109.259 178.356 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.729 HG13 HG13 ' B' ' 45' ' ' ILE . 1.5 mp -110.69 118.11 56.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 N-CA-C 108.491 -0.929 . . . . 1.01 108.491 -178.077 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.939 HD13 HD13 ' B' ' 46' ' ' LEU . 6.8 mt -103.3 119.05 38.13 Favored 'General case' 0 C--N 1.32 -0.715 0 O-C-N 124.229 0.956 . . . . 1.1299999999999999 109.906 -179.541 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.764 ' HB3' ' HB3' ' A' ' 35' ' ' GLU . 16.6 ttmt -121.2 130.2 53.58 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-N 115.434 -0.803 . . . . 1.25 111.905 -170.704 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.576 ' HG3' ' HG2' ' A' ' 51' ' ' PRO . 3.2 ptmt -45.23 -12.97 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 115.937 1.828 . . . . 1.0900000000000001 115.937 -174.313 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.675 ' CD1' HG22 ' B' ' 7' ' ' VAL . 34.4 t80 68.36 -56.7 0.5 Allowed 'General case' 0 N--CA 1.473 0.69 0 C-N-CA 124.623 1.169 . . . . 2.1400000000000001 114.046 174.224 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.757 ' HG ' ' HG2' ' A' ' 33' ' ' PRO . 36.1 m -53.41 -48.08 93.96 Favored Pre-proline 0 CA--C 1.542 0.636 0 CA-C-N 115.683 -0.69 . . . . 1.95 112.052 -173.691 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.576 ' HG2' ' HG3' ' A' ' 48' ' ' LYS . 60.6 Cg_endo -93.54 10.82 2.04 Favored 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 122.272 1.981 . . . . 0.59999999999999998 111.779 167.924 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER 52.18 -141.43 0.02 OUTLIER 'Isoleucine or valine' 0 C--O 1.233 0.218 0 N-CA-C 108.304 -0.998 . . . . 1.4199999999999999 108.304 -171.35 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.62 ' OG ' ' HE2' ' A' ' 47' ' ' LYS . 3.0 m -106.97 113.89 27.64 Favored 'General case' 0 C--N 1.312 -1.026 0 C-N-CA 120.175 -0.61 . . . . 2.23 109.577 170.048 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . 0.424 ' CD ' HH12 ' B' ' 40' ' ' ARG . 44.9 mt-10 73.48 -31.82 0.23 Allowed 'General case' 0 N--CA 1.466 0.339 0 N-CA-C 113.055 0.761 . . . . 2.8900000000000001 113.055 175.003 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.439 HD23 ' HA ' ' A' ' 55' ' ' LEU . 0.5 OUTLIER . . . . . 0 C--O 1.248 1.009 0 C-N-CA 123.254 0.622 . . . . 2.8100000000000001 110.082 -178.164 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 26.5 ptt? . . . . . 0 N--CA 1.482 1.157 0 CA-C-O 120.359 0.123 . . . . 6.71 110.816 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 2' ' ' LYS . . . . . 0.674 ' HB3' HG11 ' A' ' 38' ' ' VAL . 28.7 mmmt 58.59 -113.97 0.72 Allowed 'General case' 0 CA--C 1.517 -0.288 0 O-C-N 123.396 0.435 . . . . 4.0899999999999999 110.479 -173.016 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 3' ' ' ALA . . . . . 0.418 ' HA ' ' HD2' ' A' ' 37' ' ' PHE . . . 58.2 91.85 0.04 OUTLIER 'General case' 0 C--N 1.318 -0.802 0 O-C-N 124.354 1.033 . . . . 1.1000000000000001 111.766 179.899 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 4' ' ' THR . . . . . 0.471 ' OG1' ' HA ' ' A' ' 37' ' ' PHE . 12.0 p -84.67 -34.94 22.91 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.63 -0.714 . . . . 0.97999999999999998 111.633 -178.221 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 5' ' ' GLY . . . . . 0.494 ' H ' ' CB ' ' A' ' 37' ' ' PHE . . . 58.43 48.07 86.15 Favored Glycine 0 N--CA 1.449 -0.487 0 CA-C-N 115.601 -0.727 . . . . 0.33000000000000002 113.052 174.655 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 6' ' ' ILE . . . . . 0.81 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.4 tp -105.23 104.34 16.78 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 N-CA-C 109.224 -0.658 . . . . 1.1000000000000001 109.224 175.817 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . 0.675 HG22 ' CD1' ' A' ' 49' ' ' TYR . 27.5 t -74.79 134.12 30.1 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.841 0 CA-C-N 115.462 -0.79 . . . . 1.0800000000000001 110.083 -179.714 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.522 ' HD3' ' N ' ' B' ' 9' ' ' ARG . 0.3 OUTLIER -131.97 120.06 21.94 Favored 'General case' 0 N--CA 1.441 -0.918 0 N-CA-C 106.862 -1.532 . . . . 2.3599999999999999 106.862 179.132 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 9' ' ' ARG . . . . . 0.522 ' N ' ' HD3' ' B' ' 8' ' ' ARG . 41.9 ttp180 -78.95 103.27 8.78 Favored 'General case' 0 N--CA 1.441 -0.903 0 N-CA-C 108.667 -0.864 . . . . 3.2000000000000002 108.667 174.481 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 10' ' ' ILE . . . . . 0.886 HG23 HD12 ' A' ' 34' ' ' LEU . 0.3 OUTLIER -7.59 -100.38 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 O-C-N 125.66 1.85 . . . . 1.0700000000000001 114.189 -175.31 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . 0.58 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 13.5 p-10 161.54 -157.15 0.0 OUTLIER 'General case' 0 CA--C 1.505 -0.767 0 N-CA-C 107.889 -1.152 . . . . 1.1799999999999999 107.889 175.088 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -88.64 22.69 2.51 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 120.688 0.28 . . . . 2.3900000000000001 111.214 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 13' ' ' LEU . . . . . 0.404 ' C ' HD12 ' B' ' 13' ' ' LEU . 2.3 tm? -137.86 -55.21 0.67 Allowed 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 109.862 -0.421 . . . . 1.1000000000000001 109.862 175.564 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 14' ' ' GLY . . . . . 0.417 ' O ' ' HB ' ' A' ' 18' ' ' ILE . . . 131.97 11.85 2.0 Favored Glycine 0 N--CA 1.444 -0.8 0 C-N-CA 120.896 -0.669 . . . . 0.23000000000000001 112.491 -177.83 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 15' ' ' ARG . . . . . 0.667 ' HG2' HG23 ' A' ' 17' ' ' VAL . 0.9 OUTLIER -74.11 152.14 39.95 Favored 'General case' 0 CA--C 1.504 -0.809 0 CA-C-O 121.445 0.641 . . . . 1.3899999999999999 109.511 175.47 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 16' ' ' VAL . . . . . 0.683 HG11 HG11 ' A' ' 16' ' ' VAL . 0.2 OUTLIER -109.06 105.79 19.48 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 N-CA-C 107.697 -1.224 . . . . 1.97 107.697 167.641 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 17' ' ' VAL . . . . . 0.722 HG23 ' HG2' ' A' ' 15' ' ' ARG . 41.0 t -72.63 95.03 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.168 0 CA-C-N 114.724 -1.125 . . . . 1.0600000000000001 109.827 -173.505 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . 0.582 HG21 HD12 ' B' ' 22' ' ' ILE . 11.7 mt -87.56 112.56 49.29 Favored Pre-proline 0 N--CA 1.445 -0.724 0 CA-C-N 115.436 -0.802 . . . . 1.6100000000000001 110.503 -179.689 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . 0.644 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 84.9 Cg_exo -49.12 146.69 12.24 Favored 'Trans proline' 0 N--CA 1.459 -0.534 0 C-N-CA 123.045 2.497 . . . . 0.33000000000000002 112.612 173.2 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 20' ' ' LYS . . . . . 0.86 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -60.79 -15.29 28.3 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.76 -0.655 . . . . 2.3199999999999998 111.956 -179.357 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . 0.644 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 11.5 pt-20 -65.48 -21.12 66.6 Favored 'General case' 0 CA--C 1.536 0.428 0 N-CA-C 112.211 0.449 . . . . 1.9199999999999999 112.211 -179.784 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 22' ' ' ILE . . . . . 0.582 HD12 HG21 ' B' ' 18' ' ' ILE . 5.2 mp -86.76 -48.78 15.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 108.264 -1.013 . . . . 1.24 108.264 179.835 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 23' ' ' ARG . . . . . 0.587 ' HD3' ' N ' ' B' ' 24' ' ' ARG . 0.0 OUTLIER -55.89 -30.28 61.3 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 115.429 -0.805 . . . . 1.8500000000000001 109.258 170.39 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 24' ' ' ARG . . . . . 0.587 ' N ' ' HD3' ' B' ' 23' ' ' ARG . 37.2 ttt180 -62.9 -52.35 63.42 Favored 'General case' 0 N--CA 1.45 -0.444 0 CA-C-N 114.772 -1.104 . . . . 3.6899999999999999 110.858 176.427 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 25' ' ' THR . . . . . 0.661 HG22 ' HZ3' ' B' ' 2' ' ' LYS . 51.6 m -64.22 -28.45 69.75 Favored 'General case' 0 CA--C 1.53 0.206 0 CA-C-O 121.17 0.509 . . . . 1.1599999999999999 110.811 173.629 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.628 ' HB3' HG13 ' B' ' 28' ' ' ILE . 1.6 mm? -66.21 -18.78 65.56 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.755 -0.657 . . . . 1.1100000000000001 111.315 175.436 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 27' ' ' ARG . . . . . 0.46 ' HB2' ' O ' ' B' ' 26' ' ' LEU . 11.0 mpt_? 68.21 16.22 9.37 Favored 'General case' 0 N--CA 1.467 0.378 0 C-N-CA 123.192 0.597 . . . . 3.77 111.095 -174.608 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 28' ' ' ILE . . . . . 0.913 HG21 ' H ' ' B' ' 29' ' ' ARG . 7.8 mt -109.05 -160.8 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 115.825 -0.625 . . . . 1.2 109.725 -175.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 29' ' ' ARG . . . . . 0.913 ' H ' HG21 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -157.89 -153.84 0.41 Allowed 'General case' 0 C--N 1.328 -0.365 0 C-N-CA 122.386 0.275 . . . . 2.7599999999999998 110.826 -177.691 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 30' ' ' GLU . . . . . 0.437 ' H ' ' HB2' ' B' ' 29' ' ' ARG . 1.9 mp0 -70.57 40.19 0.05 Allowed 'General case' 0 N--CA 1.468 0.466 0 CA-C-O 121.537 0.684 . . . . 1.1799999999999999 112.043 178.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . 0.547 ' CA ' HD13 ' A' ' 10' ' ' ILE . . . -155.38 34.09 0.65 Allowed Glycine 0 N--CA 1.437 -1.234 0 CA-C-N 115.097 -0.956 . . . . 0.34999999999999998 111.106 175.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 32' ' ' ASP . . . . . 0.512 ' HB2' HG22 ' B' ' 28' ' ' ILE . 15.9 t0 -93.22 124.59 57.38 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.105 0.479 . . . . 1.29 110.706 176.534 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 33' ' ' PRO . . . . . 0.615 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 3.3 Cg_endo -87.56 75.83 2.16 Favored 'Trans proline' 0 C--O 1.206 -1.09 0 C-N-CA 124.011 3.141 . . . . 1.1000000000000001 113.68 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . 0.738 HD13 HG22 ' A' ' 10' ' ' ILE . 1.0 OUTLIER -71.47 148.79 46.48 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.021 -1.472 . . . . 1.1699999999999999 110.771 179.87 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 35' ' ' GLU . . . . . 0.674 ' O ' ' HA ' ' B' ' 46' ' ' LEU . 43.8 tt0 -103.78 110.74 22.96 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-N 114.417 -1.265 . . . . 1.1000000000000001 107.625 -179.836 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 36' ' ' ILE . . . . . 0.935 HG13 HD21 ' B' ' 46' ' ' LEU . 2.3 mp -85.94 109.27 18.38 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.731 0 O-C-N 124.048 0.842 . . . . 1.3200000000000001 109.236 -178.493 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 37' ' ' PHE . . . . . 0.552 ' HA ' ' OG1' ' A' ' 4' ' ' THR . 14.4 p90 -149.4 123.38 9.39 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 115.832 -0.622 . . . . 2.0299999999999998 109.631 175.561 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 38' ' ' VAL . . . . . 0.705 HG11 ' HB3' ' A' ' 2' ' ' LYS . 1.4 p -79.91 136.05 24.26 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 CA-C-O 121.424 0.63 . . . . 0.89000000000000001 110.229 -178.416 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 39' ' ' ASP . . . . . 0.578 ' OD1' ' HD3' ' B' ' 40' ' ' ARG . 12.6 t70 -69.48 -53.9 16.9 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 114.215 -1.357 . . . . 1.1399999999999999 111.244 -173.993 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 40' ' ' ARG . . . . . 0.578 ' HD3' ' OD1' ' B' ' 39' ' ' ASP . 0.0 OUTLIER -139.34 -71.22 0.4 Allowed 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 113.019 0.748 . . . . 3.3700000000000001 113.019 -174.308 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -106.48 -68.42 0.88 Allowed 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 112.089 0.403 . . . . 1.3200000000000001 112.089 -173.153 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 42' ' ' GLY . . . . . 0.439 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -140.94 12.52 2.87 Favored Glycine 0 CA--C 1.501 -0.823 0 C-N-CA 120.71 -0.757 . . . . 0.35999999999999999 111.862 -175.465 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 43' ' ' GLU . . . . . 0.59 ' HA ' ' O ' ' A' ' 46' ' ' LEU . 2.3 pm0 -93.05 104.96 17.12 Favored 'General case' 0 N--CA 1.443 -0.803 0 N-CA-C 109.568 -0.53 . . . . 2.0699999999999998 109.568 174.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 44' ' ' VAL . . . . . 0.603 ' HA ' ' HA ' ' B' ' 38' ' ' VAL . 2.1 t -87.37 131.68 34.58 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 N-CA-C 109.696 -0.483 . . . . 1.02 109.696 179.329 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 45' ' ' ILE . . . . . 0.729 HG13 HG13 ' A' ' 45' ' ' ILE . 1.7 mp -108.29 118.47 55.99 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 N-CA-C 108.414 -0.958 . . . . 0.95999999999999996 108.414 -177.592 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 46' ' ' LEU . . . . . 0.939 HD13 HD13 ' A' ' 46' ' ' LEU . 0.6 OUTLIER -109.9 117.1 32.93 Favored 'General case' 0 C--N 1.318 -0.788 0 O-C-N 123.612 0.57 . . . . 1.05 109.915 178.844 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 47' ' ' LYS . . . . . 0.601 ' HE3' ' HB3' ' B' ' 35' ' ' GLU . 0.0 OUTLIER -130.09 142.45 50.6 Favored 'General case' 0 C--N 1.318 -0.765 0 C-N-CA 119.617 -0.833 . . . . 1.3899999999999999 112.877 -178.332 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 48' ' ' LYS . . . . . 0.547 ' HE2' ' HG3' ' B' ' 51' ' ' PRO . 4.3 ptmt -43.19 -9.2 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.638 0 N-CA-C 118.112 2.634 . . . . 1.1899999999999999 118.112 -168.264 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 49' ' ' TYR . . . . . 0.653 ' CG ' HG22 ' A' ' 7' ' ' VAL . 5.9 t80 68.38 -52.75 0.55 Allowed 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 114.067 1.136 . . . . 2.1000000000000001 114.067 174.326 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 50' ' ' SER . . . . . 0.612 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 32.2 t -51.55 -57.14 15.49 Favored Pre-proline 0 CA--C 1.535 0.386 0 C-N-CA 122.417 0.287 . . . . 1.77 111.099 -173.55 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 51' ' ' PRO . . . . . 0.64 ' O ' ' HB2' ' B' ' 55' ' ' LEU . 74.8 Cg_endo -85.01 9.07 4.3 Favored 'Trans proline' 0 C--N 1.35 0.652 0 C-N-CA 122.011 1.808 . . . . 0.59999999999999998 111.159 170.174 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 52' ' ' ILE . . . . . 0.45 HG13 HD22 ' B' ' 55' ' ' LEU . 1.2 mt 50.98 -138.79 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 CA-C-N 114.814 -1.085 . . . . 1.3899999999999999 108.666 -171.944 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 53' ' ' SER . . . . . 0.5 ' O ' ' HB2' ' B' ' 54' ' ' GLU . 0.1 OUTLIER -107.43 120.29 41.76 Favored 'General case' 0 N--CA 1.43 -1.455 0 N-CA-C 109.095 -0.705 . . . . 2.04 109.095 172.514 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 54' ' ' GLU . . . . . 0.5 ' HB2' ' O ' ' B' ' 53' ' ' SER . 1.8 mp0 73.41 -61.37 0.5 Allowed 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 123.821 0.848 . . . . 2.6200000000000001 111.973 -176.395 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 55' ' ' LEU . . . . . 0.64 ' HB2' ' O ' ' B' ' 51' ' ' PRO . 0.9 OUTLIER . . . . . 0 C--O 1.249 1.078 0 O-C-N 123.85 0.719 . . . . 2.8700000000000001 109.302 -172.389 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 74.1 mtm . . . . . 0 N--CA 1.478 0.96 0 N-CA-C 110.079 -0.341 . . . . 6.3300000000000001 110.079 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.588 ' HB2' HG11 ' B' ' 38' ' ' VAL . 0.0 OUTLIER -124.77 -171.25 2.31 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 116.451 -0.34 . . . . 4.1699999999999999 110.815 -174.651 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.588 ' HA ' ' HD2' ' B' ' 37' ' ' PHE . . . 64.35 113.51 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.359 0 CA-C-O 121.74 0.781 . . . . 1.1299999999999999 111.33 -173.517 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.788 ' H ' ' HB2' ' B' ' 37' ' ' PHE . 34.4 p -125.97 -35.73 2.44 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 115.504 -0.771 . . . . 1.0900000000000001 111.915 -173.73 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . 0.447 ' H ' ' CB ' ' B' ' 37' ' ' PHE . . . 63.96 45.14 94.79 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.902 -0.666 . . . . 0.32000000000000001 112.893 173.715 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.859 HG22 ' HB ' ' B' ' 36' ' ' ILE . 1.4 tp -104.11 105.2 18.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-O 121.354 0.597 . . . . 1.0900000000000001 109.522 177.985 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.625 HG22 ' CD1' ' B' ' 49' ' ' TYR . 54.5 t -75.02 131.73 34.53 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-N 115.655 -0.702 . . . . 1.1299999999999999 110.415 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.431 ' HG2' ' H ' ' A' ' 17' ' ' VAL . 2.9 tpp180 -127.58 114.6 17.62 Favored 'General case' 0 N--CA 1.434 -1.262 0 N-CA-C 106.522 -1.659 . . . . 2.6099999999999999 106.522 177.781 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.483 ' HA ' ' O ' ' B' ' 32' ' ' ASP . 0.6 OUTLIER -78.05 101.36 6.91 Favored 'General case' 0 C--N 1.308 -1.221 0 N-CA-C 107.611 -1.255 . . . . 3.4100000000000001 107.611 174.708 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.597 ' O ' ' HB3' ' A' ' 11' ' ' ASP . 0.3 OUTLIER -7.44 -102.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.941 0 O-C-N 125.763 1.914 . . . . 1.0700000000000001 113.928 -175.385 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . 0.597 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 4.8 p-10 164.77 -159.47 0.0 OUTLIER 'General case' 0 CA--C 1.507 -0.677 0 N-CA-C 108.249 -1.019 . . . . 1.1299999999999999 108.249 175.389 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 31.2 t70 -74.57 -17.84 60.67 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.014 0.435 . . . . 2.2599999999999998 110.96 -179.173 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -103.33 -59.07 1.77 Allowed 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.186 -0.461 . . . . 1.23 110.801 179.779 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.464 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 138.46 18.76 0.54 Allowed Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.214 -0.994 . . . . 0.25 113.211 -179.039 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.735 ' HB3' ' HB3' ' B' ' 15' ' ' ARG . 0.7 OUTLIER -81.01 157.37 25.5 Favored 'General case' 0 CA--C 1.491 -1.317 0 CA-C-N 117.965 0.882 . . . . 0.88 110.031 176.034 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.833 HG23 HG23 ' B' ' 16' ' ' VAL . 17.2 m -107.81 109.81 29.6 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.201 0 N-CA-C 106.945 -1.502 . . . . 1.99 106.945 164.77 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.795 HG21 ' HG2' ' B' ' 15' ' ' ARG . 57.6 t -71.71 94.75 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.433 -1.309 0 CA-C-N 115.091 -0.959 . . . . 1.0600000000000001 109.278 -175.668 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.483 HD11 HD11 ' A' ' 46' ' ' LEU . 9.0 mt -82.37 109.79 17.9 Favored Pre-proline 0 N--CA 1.444 -0.761 0 CA-C-N 115.621 -0.718 . . . . 1.5600000000000001 110.284 179.087 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.633 ' HD3' ' O ' ' A' ' 17' ' ' VAL . 95.8 Cg_exo -51.16 151.42 12.44 Favored 'Trans proline' 0 N--CA 1.454 -0.845 0 C-N-CA 123.053 2.502 . . . . 0.34999999999999998 112.366 174.982 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.797 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -62.34 -25.14 67.74 Favored 'General case' 0 C--O 1.206 -1.194 0 CA-C-N 115.591 -0.731 . . . . 2.1299999999999999 111.763 -176.823 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.3 pm0 -55.49 -25.65 38.19 Favored 'General case' 0 C--O 1.239 0.507 0 N-CA-C 112.854 0.687 . . . . 1.3200000000000001 112.854 -178.447 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.475 HD11 HG21 ' A' ' 18' ' ' ILE . 5.1 mp -88.18 -46.95 15.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 108.404 -0.961 . . . . 1.0800000000000001 108.404 -176.574 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . 0.505 ' NE ' ' HA ' ' A' ' 29' ' ' ARG . 0.0 OUTLIER -61.02 -30.86 70.56 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 115.158 -0.928 . . . . 2.02 109.583 174.744 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 76.7 ttt180 -63.84 -52.11 61.61 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 114.269 -1.332 . . . . 3.3999999999999999 111.011 175.532 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 25.6 m -64.51 -27.99 69.35 Favored 'General case' 0 C--O 1.234 0.268 0 CA-C-O 121.137 0.494 . . . . 1.1499999999999999 110.537 175.377 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.835 ' HB3' HG13 ' A' ' 28' ' ' ILE . 0.8 OUTLIER -65.23 -18.1 65.04 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.534 -0.757 . . . . 1.1599999999999999 111.162 175.225 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.5 ' HB2' ' O ' ' A' ' 26' ' ' LEU . 10.4 mpt_? 70.45 20.28 6.03 Favored 'General case' 0 N--CA 1.466 0.34 0 C-N-CA 123.259 0.624 . . . . 3.6800000000000002 110.529 -174.109 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.835 HG13 ' HB3' ' A' ' 26' ' ' LEU . 2.7 mt -116.43 -166.06 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 115.728 -0.669 . . . . 1.1000000000000001 109.458 -176.526 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.705 ' H ' HG23 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -154.76 -155.5 0.58 Allowed 'General case' 0 C--N 1.321 -0.658 0 C-N-CA 122.267 0.227 . . . . 3.0699999999999998 110.677 -173.327 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . 0.451 ' H ' ' HB2' ' A' ' 29' ' ' ARG . 1.7 mp0 -75.11 44.32 0.24 Allowed 'General case' 0 C--N 1.332 -0.168 0 CA-C-O 122.122 0.963 . . . . 1.23 111.366 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.521 ' CA ' HD11 ' B' ' 10' ' ' ILE . . . -154.65 19.75 0.6 Allowed Glycine 0 N--CA 1.441 -1.024 0 CA-C-N 113.833 -1.531 . . . . 0.35999999999999999 110.687 175.785 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.445 ' HA ' ' HD3' ' A' ' 33' ' ' PRO . 17.7 t0 -79.65 120.23 79.47 Favored Pre-proline 0 N--CA 1.464 0.245 0 CA-C-O 121.437 0.637 . . . . 1.26 109.784 176.942 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.61 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 2.8 Cg_endo -88.98 56.35 2.09 Favored 'Trans proline' 0 N--CA 1.452 -0.946 0 C-N-CA 123.891 3.06 . . . . 1.3 114.165 -174.494 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.877 HD11 HG22 ' B' ' 10' ' ' ILE . 0.0 OUTLIER -59.28 154.44 16.45 Favored 'General case' 0 C--N 1.3 -1.545 0 C-N-CA 118.823 -1.151 . . . . 1.21 112.34 -173.478 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.81 ' HB3' ' HD2' ' A' ' 47' ' ' LYS . 42.7 tt0 -107.92 112.48 25.11 Favored 'General case' 0 CA--C 1.491 -1.31 0 CA-C-N 113.847 -1.524 . . . . 1.1200000000000001 107.909 -175.834 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.82 ' HB ' HG22 ' B' ' 6' ' ' ILE . 2.8 mt -82.65 111.05 18.47 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 O-C-N 124.424 1.078 . . . . 1.1599999999999999 109.736 -179.752 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . 0.632 ' HE1' ' HZ3' ' A' ' 47' ' ' LYS . 0.6 OUTLIER -151.11 125.88 9.68 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-O 120.98 0.419 . . . . 2.0099999999999998 110.003 173.586 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.528 HG11 ' HB2' ' B' ' 2' ' ' LYS . 1.1 p -80.5 138.76 19.21 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 CA-C-O 120.921 0.391 . . . . 1.05 110.798 -177.158 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.686 ' OD2' ' HD2' ' A' ' 40' ' ' ARG . 14.2 t70 -84.29 -49.42 8.77 Favored 'General case' 0 CA--C 1.513 -0.45 0 CA-C-N 115.802 -0.635 . . . . 1.1100000000000001 111.823 -173.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . 0.686 ' HD2' ' OD2' ' A' ' 39' ' ' ASP . 0.0 OUTLIER -135.81 -96.63 0.24 Allowed 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.632 -0.713 . . . . 2.8799999999999999 112.516 -165.972 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -84.85 -74.24 0.4 Allowed 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.529 0.68 . . . . 1.53 110.826 -177.03 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.57 ' HA3' HD12 ' B' ' 26' ' ' LEU . . . -138.25 26.03 2.85 Favored Glycine 0 N--CA 1.439 -1.103 0 CA-C-N 115.207 -0.906 . . . . 0.34000000000000002 110.918 -178.366 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.612 ' HB3' HG23 ' B' ' 45' ' ' ILE . 2.3 mt-10 -94.89 109.2 21.22 Favored 'General case' 0 N--CA 1.446 -0.641 0 N-CA-C 109.161 -0.681 . . . . 1.97 109.161 179.028 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.579 ' CG1' HG21 ' A' ' 36' ' ' ILE . 2.0 t -89.2 131.41 36.57 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.961 0 N-CA-C 109.268 -0.641 . . . . 1.0600000000000001 109.268 177.79 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.789 HG13 HG13 ' B' ' 45' ' ' ILE . 1.6 mp -110.44 115.96 51.14 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.223 0 N-CA-C 108.312 -0.996 . . . . 1.01 108.312 -176.397 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.943 HD12 HD12 ' B' ' 46' ' ' LEU . 0.3 OUTLIER -109.6 117.52 34.15 Favored 'General case' 0 C--N 1.315 -0.923 0 O-C-N 123.785 0.678 . . . . 1.1299999999999999 109.643 179.803 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.81 ' HD2' ' HB3' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -130.91 144.1 51.21 Favored 'General case' 0 C--O 1.215 -0.752 0 C-N-CA 118.695 -1.202 . . . . 1.25 112.844 176.303 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.62 ' HG3' ' HD2' ' A' ' 51' ' ' PRO . 1.0 OUTLIER -20.46 -25.93 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.981 0 N-CA-C 119.532 3.16 . . . . 1.0900000000000001 119.532 -179.08 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.708 ' CD1' HG22 ' B' ' 7' ' ' VAL . 37.0 t80 72.87 -38.48 0.42 Allowed 'General case' 0 N--CA 1.479 1.002 0 CA-C-N 119.795 1.18 . . . . 2.1400000000000001 112.339 -179.036 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.646 ' HB3' ' HD3' ' A' ' 51' ' ' PRO . 26.3 t -52.32 -52.32 63.98 Favored Pre-proline 0 CA--C 1.542 0.667 0 CA-C-N 116.29 -0.414 . . . . 1.95 110.559 -177.741 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.646 ' HD3' ' HB3' ' A' ' 50' ' ' SER . 97.9 Cg_endo -92.21 7.93 3.02 Favored 'Trans proline' 0 C--N 1.355 0.896 0 C-N-CA 122.387 2.058 . . . . 0.59999999999999998 111.733 167.176 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.426 ' H ' ' C ' ' A' ' 49' ' ' TYR . 0.3 OUTLIER 47.16 -150.91 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.394 0 CA-C-N 114.809 -1.087 . . . . 1.4199999999999999 111.515 -179.953 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.414 ' O ' ' HB2' ' A' ' 54' ' ' GLU . 11.2 p -85.17 47.13 1.36 Allowed 'General case' 0 N--CA 1.443 -0.776 0 CA-C-N 115.868 -0.605 . . . . 2.23 109.799 175.054 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . 0.414 ' HB2' ' O ' ' A' ' 53' ' ' SER . 31.5 mt-10 73.85 116.76 0.05 Allowed 'General case' 0 N--CA 1.463 0.191 0 CA-C-N 115.041 -0.981 . . . . 2.8900000000000001 110.229 -175.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 4.2 mm? . . . . . 0 C--O 1.25 1.126 0 CA-C-O 118.392 -0.813 . . . . 2.8100000000000001 110.252 176.924 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 71.6 mtm . . . . . 0 N--CA 1.483 1.198 0 N-CA-C 109.693 -0.484 . . . . 6.71 109.693 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 2' ' ' LYS . . . . . 0.528 ' HB2' HG11 ' A' ' 38' ' ' VAL . 0.0 OUTLIER -141.84 -172.98 3.67 Favored 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 121.044 -0.262 . . . . 4.0899999999999999 110.34 -179.26 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 3' ' ' ALA . . . . . 0.535 ' HA ' ' HD2' ' A' ' 37' ' ' PHE . . . 61.36 105.34 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.474 0 C-N-CA 123.445 0.698 . . . . 1.1000000000000001 111.51 -173.462 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 4' ' ' THR . . . . . 0.532 ' H ' ' HB2' ' A' ' 37' ' ' PHE . 29.0 p -114.7 -39.75 3.69 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.939 -0.573 . . . . 0.97999999999999998 111.802 -174.608 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 67.62 45.51 76.14 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 121.107 -0.568 . . . . 0.33000000000000002 112.612 177.428 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 6' ' ' ILE . . . . . 0.82 HG22 ' HB ' ' A' ' 36' ' ' ILE . 1.3 tp -103.33 105.3 18.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.514 0.673 . . . . 1.1000000000000001 109.732 177.855 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . 0.708 HG22 ' CD1' ' A' ' 49' ' ' TYR . 24.3 t -74.93 131.57 34.8 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.838 0 CA-C-N 115.401 -0.818 . . . . 1.0800000000000001 110.899 -179.573 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.502 ' HB3' ' CD1' ' A' ' 36' ' ' ILE . 1.7 tpp180 -128.72 116.04 18.92 Favored 'General case' 0 N--CA 1.435 -1.211 0 N-CA-C 106.867 -1.531 . . . . 2.3599999999999999 106.867 178.525 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 9' ' ' ARG . . . . . 0.519 ' HA ' ' HA ' ' A' ' 33' ' ' PRO . 29.2 ttp180 -78.23 102.84 7.81 Favored 'General case' 0 C--N 1.311 -1.075 0 N-CA-C 107.897 -1.149 . . . . 3.2000000000000002 107.897 173.103 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 10' ' ' ILE . . . . . 0.877 HG22 HD11 ' A' ' 34' ' ' LEU . 0.4 OUTLIER -8.57 -100.77 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 O-C-N 125.948 2.03 . . . . 1.0700000000000001 113.94 -174.645 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . 0.66 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 2.8 p-10 164.28 -161.05 0.0 OUTLIER 'General case' 0 CA--C 1.512 -0.501 0 N-CA-C 108.484 -0.932 . . . . 1.1799999999999999 108.484 175.676 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -75.09 -14.32 60.57 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.11 0.481 . . . . 2.3900000000000001 110.283 -177.237 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 13' ' ' LEU . . . . . . . . . . . . . 2.2 tm? -105.56 -61.03 1.54 Allowed 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.826 -0.625 . . . . 1.1000000000000001 110.526 179.541 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 139.84 16.16 0.52 Allowed Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.847 -0.692 . . . . 0.23000000000000001 112.357 -176.764 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 15' ' ' ARG . . . . . 0.795 ' HG2' HG21 ' A' ' 17' ' ' VAL . 2.0 mtt180 -79.74 153.87 28.93 Favored 'General case' 0 CA--C 1.501 -0.934 0 N-CA-C 109.598 -0.519 . . . . 1.3899999999999999 109.598 176.668 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 16' ' ' VAL . . . . . 0.833 HG23 HG23 ' A' ' 16' ' ' VAL . 1.1 m -110.5 111.83 37.91 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.673 0 N-CA-C 107.042 -1.466 . . . . 1.97 107.042 166.884 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 17' ' ' VAL . . . . . 0.538 HG23 ' CG ' ' A' ' 15' ' ' ARG . 62.3 t -72.71 98.62 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.165 0 CA-C-N 114.699 -1.137 . . . . 1.0600000000000001 109.668 -173.713 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . 0.464 ' HB ' ' O ' ' A' ' 14' ' ' GLY . 8.9 mt -85.88 111.73 40.0 Favored Pre-proline 0 N--CA 1.443 -0.794 0 CA-C-N 115.276 -0.875 . . . . 1.6100000000000001 110.43 179.799 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . 0.621 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 71.4 Cg_exo -50.24 145.4 20.72 Favored 'Trans proline' 0 N--CA 1.456 -0.721 0 C-N-CA 122.965 2.444 . . . . 0.33000000000000002 112.335 173.793 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 20' ' ' LYS . . . . . 0.929 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -61.65 -15.45 39.95 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 115.465 -0.789 . . . . 2.3199999999999998 111.696 179.827 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . 0.621 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 11.7 pt-20 -64.65 -25.78 68.1 Favored 'General case' 0 C--O 1.237 0.446 0 N-CA-C 112.035 0.383 . . . . 1.9199999999999999 112.035 -179.197 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 4.9 mp -88.65 -44.58 15.55 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.271 0 N-CA-C 107.578 -1.267 . . . . 1.24 107.578 -177.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 23' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -59.36 -31.02 68.82 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-N 115.08 -0.964 . . . . 1.8500000000000001 109.514 174.124 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 24' ' ' ARG . . . . . 0.426 HH11 ' HD2' ' B' ' 24' ' ' ARG . 22.3 ttt85 -67.7 -49.9 60.29 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 114.767 -1.106 . . . . 3.6899999999999999 110.745 177.251 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 26.2 m -65.52 -25.99 67.7 Favored 'General case' 0 CA--C 1.535 0.373 0 CA-C-O 121.412 0.625 . . . . 1.1599999999999999 110.159 176.451 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.723 ' HB3' HG13 ' B' ' 28' ' ' ILE . 0.6 OUTLIER -65.91 -17.4 64.63 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.398 -0.819 . . . . 1.1100000000000001 110.805 173.038 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 27' ' ' ARG . . . . . 0.425 ' HB2' ' O ' ' B' ' 26' ' ' LEU . 8.6 mpt_? 65.97 27.02 10.86 Favored 'General case' 0 C--O 1.233 0.195 0 CA-C-O 121.458 0.647 . . . . 3.77 110.032 -173.839 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 28' ' ' ILE . . . . . 0.859 HG23 ' H ' ' B' ' 29' ' ' ARG . 5.1 mt -119.84 -167.7 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.379 -0.828 . . . . 1.2 109.683 -179.311 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 29' ' ' ARG . . . . . 0.859 ' H ' HG23 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -153.67 -155.59 0.61 Allowed 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 122.093 0.157 . . . . 2.7599999999999998 110.934 -176.041 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 30' ' ' GLU . . . . . 0.405 ' H ' ' HB2' ' B' ' 29' ' ' ARG . 1.0 OUTLIER -73.46 39.72 0.1 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 122.104 0.954 . . . . 1.1799999999999999 111.983 -178.998 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . 0.517 ' H ' ' C ' ' B' ' 29' ' ' ARG . . . -151.43 26.71 0.97 Allowed Glycine 0 N--CA 1.442 -0.935 0 CA-C-N 114.232 -1.349 . . . . 0.34999999999999998 110.303 172.774 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 32' ' ' ASP . . . . . 0.483 ' O ' ' HA ' ' A' ' 9' ' ' ARG . 21.9 t0 -81.7 121.14 79.3 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.183 0.516 . . . . 1.29 109.916 176.807 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 33' ' ' PRO . . . . . 0.699 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 5.2 Cg_endo -87.42 72.1 3.08 Favored 'Trans proline' 0 C--O 1.204 -1.207 0 C-N-CA 123.606 2.871 . . . . 1.1000000000000001 113.437 -177.853 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . 0.593 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.2 mp -71.27 151.85 43.84 Favored 'General case' 0 C--N 1.286 -2.184 0 C-N-CA 117.779 -1.569 . . . . 1.1699999999999999 111.386 -176.381 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 35' ' ' GLU . . . . . 0.924 ' HB3' ' HD2' ' B' ' 47' ' ' LYS . 44.1 tt0 -108.97 113.79 26.98 Favored 'General case' 0 CA--C 1.49 -1.351 0 CA-C-N 114.388 -1.278 . . . . 1.1000000000000001 107.919 -177.822 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 36' ' ' ILE . . . . . 0.859 ' HB ' HG22 ' A' ' 6' ' ' ILE . 20.5 mt -88.43 109.99 20.59 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.905 0 O-C-N 124.78 1.3 . . . . 1.3200000000000001 110.027 -176.169 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 37' ' ' PHE . . . . . 0.788 ' HB2' ' H ' ' A' ' 4' ' ' THR . 1.3 p90 -150.48 129.33 12.47 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 109.561 -0.533 . . . . 2.0299999999999998 109.561 174.777 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 38' ' ' VAL . . . . . 0.588 HG11 ' HB2' ' A' ' 2' ' ' LYS . 0.9 OUTLIER -79.8 142.2 14.27 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.945 0 C-N-CA 120.834 -0.346 . . . . 0.89000000000000001 110.256 -178.649 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 39' ' ' ASP . . . . . 0.492 ' OD2' ' HD2' ' B' ' 40' ' ' ARG . 38.8 t70 -87.64 -47.1 8.95 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.854 -0.612 . . . . 1.1399999999999999 111.84 -175.079 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 40' ' ' ARG . . . . . 0.492 ' HD2' ' OD2' ' B' ' 39' ' ' ASP . 0.0 OUTLIER -137.08 -100.97 0.2 Allowed 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 112.535 0.569 . . . . 3.3700000000000001 112.535 -175.736 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -76.36 -74.54 0.23 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.119 0.485 . . . . 1.3200000000000001 111.36 -174.503 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 42' ' ' GLY . . . . . 0.513 ' HA3' HD12 ' A' ' 26' ' ' LEU . . . -136.77 25.12 3.11 Favored Glycine 0 N--CA 1.444 -0.826 0 C-N-CA 120.833 -0.699 . . . . 0.35999999999999999 111.426 -178.831 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 43' ' ' GLU . . . . . 0.571 ' HB3' HG22 ' A' ' 45' ' ' ILE . 2.4 mt-10 -94.23 108.87 20.71 Favored 'General case' 0 CA--C 1.509 -0.6 0 N-CA-C 109.792 -0.448 . . . . 2.0699999999999998 109.792 179.277 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 44' ' ' VAL . . . . . 0.542 ' HA ' ' HA ' ' B' ' 38' ' ' VAL . 1.5 t -88.92 131.0 37.38 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 N-CA-C 109.55 -0.537 . . . . 1.02 109.55 177.831 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 45' ' ' ILE . . . . . 0.789 HG13 HG13 ' A' ' 45' ' ' ILE . 1.7 mp -109.29 118.9 57.67 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.197 0 N-CA-C 108.405 -0.961 . . . . 0.95999999999999996 108.405 -177.27 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 46' ' ' LEU . . . . . 0.943 HD12 HD12 ' A' ' 46' ' ' LEU . 0.5 OUTLIER -110.64 118.11 35.32 Favored 'General case' 0 C--N 1.316 -0.87 0 O-C-N 123.732 0.645 . . . . 1.05 109.862 178.486 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 47' ' ' LYS . . . . . 0.924 ' HD2' ' HB3' ' B' ' 35' ' ' GLU . 0.0 OUTLIER -129.19 148.11 51.1 Favored 'General case' 0 C--O 1.214 -0.81 0 C-N-CA 119.116 -1.034 . . . . 1.3899999999999999 112.289 177.294 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 48' ' ' LYS . . . . . 0.579 ' HG3' ' CD ' ' B' ' 51' ' ' PRO . 2.8 ptmt -45.14 -6.28 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.235 0 N-CA-C 117.895 2.554 . . . . 1.1899999999999999 117.895 -168.004 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 49' ' ' TYR . . . . . 0.699 ' HB3' ' HB2' ' B' ' 33' ' ' PRO . 24.3 t80 68.3 -36.18 0.31 Allowed 'General case' 0 N--CA 1.48 1.03 0 CA-C-N 119.372 0.987 . . . . 2.1000000000000001 113.28 176.43 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 50' ' ' SER . . . . . 0.594 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 12.4 t -53.97 -47.79 95.92 Favored Pre-proline 0 CA--C 1.542 0.667 0 C-N-CA 122.588 0.355 . . . . 1.77 110.991 -177.194 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 51' ' ' PRO . . . . . 0.594 ' HD3' ' HB3' ' B' ' 50' ' ' SER . 62.6 Cg_endo -94.56 5.52 2.52 Favored 'Trans proline' 0 C--N 1.352 0.751 0 C-N-CA 122.451 2.101 . . . . 0.59999999999999998 111.919 165.551 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 52' ' ' ILE . . . . . 0.449 HG12 ' O ' ' B' ' 49' ' ' TYR . 0.6 OUTLIER 49.07 -146.43 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-N 115.083 -0.962 . . . . 1.3899999999999999 110.595 -177.324 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 53' ' ' SER . . . . . 0.4 ' O ' ' HB3' ' B' ' 54' ' ' GLU . 57.2 p -84.72 36.05 0.59 Allowed 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 109.547 -0.538 . . . . 2.04 109.547 176.464 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 54' ' ' GLU . . . . . 0.4 ' HB3' ' O ' ' B' ' 53' ' ' SER . 8.9 tp10 75.97 118.42 0.05 Allowed 'General case' 0 C--N 1.341 0.201 0 C-N-CA 124.407 1.083 . . . . 2.6200000000000001 110.127 -171.858 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 55' ' ' LEU . . . . . . . . . . . . . 4.3 mm? . . . . . 0 C--O 1.247 0.933 0 CA-C-O 118.275 -0.869 . . . . 2.8700000000000001 110.737 179.852 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 64.0 mtt . . . . . 0 N--CA 1.478 0.961 0 CA-C-O 120.246 0.069 . . . . 6.3300000000000001 110.981 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.648 ' HA ' HG11 ' B' ' 38' ' ' VAL . 0.0 OUTLIER -95.7 175.49 6.51 Favored 'General case' 0 C--N 1.332 -0.178 0 C-N-CA 120.463 -0.495 . . . . 4.1699999999999999 111.849 -179.419 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.815 ' HA ' ' HD2' ' B' ' 37' ' ' PHE . . . 56.31 82.4 0.11 Allowed 'General case' 0 CA--C 1.519 -0.225 0 CA-C-N 115.325 -0.852 . . . . 1.1299999999999999 110.802 -169.232 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.467 ' OG1' ' HA ' ' B' ' 37' ' ' PHE . 15.6 p -94.08 -35.92 12.34 Favored 'General case' 0 N--CA 1.444 -0.74 0 CA-C-N 115.181 -0.918 . . . . 1.0900000000000001 112.036 -176.506 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 60.93 49.37 79.42 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.969 -0.634 . . . . 0.32000000000000001 112.799 176.317 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.856 HG22 ' HB ' ' B' ' 36' ' ' ILE . 0.9 OUTLIER -108.28 111.3 35.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 N-CA-C 109.379 -0.6 . . . . 1.0900000000000001 109.379 175.295 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.648 HG22 ' CD1' ' B' ' 49' ' ' TYR . 48.6 t -82.38 133.96 28.03 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 CA-C-O 121.303 0.573 . . . . 1.1299999999999999 111.013 -178.3 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.625 ' CZ ' HG22 ' A' ' 17' ' ' VAL . 3.9 tpt180 -126.2 107.86 10.76 Favored 'General case' 0 N--CA 1.441 -0.903 0 N-CA-C 107.074 -1.454 . . . . 2.6099999999999999 107.074 -178.545 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.473 ' HA ' ' O ' ' B' ' 32' ' ' ASP . 2.0 ttt180 -78.34 102.0 7.49 Favored 'General case' 0 CA--C 1.503 -0.847 0 N-CA-C 108.02 -1.104 . . . . 3.4100000000000001 108.02 175.73 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.64 ' O ' ' HB3' ' A' ' 11' ' ' ASP . 0.2 OUTLIER -10.12 -109.25 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 O-C-N 126.036 2.085 . . . . 1.0700000000000001 114.551 -179.187 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . 0.64 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 4.2 p-10 158.81 -167.73 0.0 OUTLIER 'General case' 0 CA--C 1.513 -0.458 0 N-CA-C 107.202 -1.407 . . . . 1.1299999999999999 107.202 177.465 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -67.52 -22.78 65.42 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.013 0.435 . . . . 2.2599999999999998 110.887 -178.241 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.413 ' C ' HD12 ' A' ' 13' ' ' LEU . 2.2 tm? -95.28 -61.54 1.46 Allowed 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.081 -0.509 . . . . 1.23 109.733 177.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.584 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 132.71 21.49 0.9 Allowed Glycine 0 N--CA 1.443 -0.892 0 C-N-CA 119.898 -1.144 . . . . 0.25 114.131 178.242 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.481 ' HA ' ' HA ' ' B' ' 17' ' ' VAL . 0.9 OUTLIER -79.01 155.08 29.01 Favored 'General case' 0 CA--C 1.504 -0.814 0 CA-C-N 118.91 1.355 . . . . 0.88 110.941 179.249 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.615 HG23 HD13 ' B' ' 46' ' ' LEU . 52.9 t -111.43 101.37 12.45 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.379 0 N-CA-C 107.39 -1.337 . . . . 1.99 107.39 169.322 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.706 HG23 ' HG2' ' B' ' 15' ' ' ARG . 65.5 t -68.21 106.91 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.016 0 CA-C-N 115.038 -0.983 . . . . 1.0600000000000001 109.775 -175.767 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 31.7 mm -90.8 109.26 33.45 Favored Pre-proline 0 N--CA 1.446 -0.636 0 CA-C-N 115.79 -0.641 . . . . 1.5600000000000001 110.547 -177.895 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.57 ' HD3' ' O ' ' A' ' 17' ' ' VAL . 81.0 Cg_exo -50.37 138.04 38.63 Favored 'Trans proline' 0 N--CA 1.459 -0.521 0 C-N-CA 123.015 2.476 . . . . 0.34999999999999998 112.359 173.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.847 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -57.64 -14.21 5.12 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-N 114.947 -1.024 . . . . 2.1299999999999999 112.265 179.297 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.532 ' O ' ' HB3' ' A' ' 24' ' ' ARG . 11.9 pt-20 -67.08 -25.78 66.4 Favored 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 118.088 0.404 . . . . 1.3200000000000001 111.724 -178.256 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 4.5 mp -88.15 -42.73 15.1 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.321 0 N-CA-C 107.622 -1.251 . . . . 1.0800000000000001 107.622 -178.081 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ARG . . . . . 0.63 ' HA ' ' HB2' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -58.51 -31.78 68.21 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 114.848 -1.069 . . . . 2.02 109.145 171.936 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.532 ' HB3' ' O ' ' A' ' 21' ' ' GLU . 55.3 ttp180 -60.19 -52.85 63.56 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 114.313 -1.312 . . . . 3.3999999999999999 110.785 174.092 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 17.3 m -65.85 -27.02 67.93 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-O 121.247 0.546 . . . . 1.1499999999999999 110.961 174.699 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.687 ' HB3' HG13 ' A' ' 28' ' ' ILE . 1.3 mm? -64.68 -20.86 66.55 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.759 -0.655 . . . . 1.1599999999999999 110.638 173.879 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 8.1 tpt180 71.17 18.83 5.66 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-O 121.793 0.806 . . . . 3.6800000000000002 109.302 -176.431 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.687 HG13 ' HB3' ' A' ' 26' ' ' LEU . 3.9 mt -114.9 -167.44 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 114.894 -1.048 . . . . 1.1000000000000001 108.797 -177.926 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ARG . . . . . 0.683 ' H ' HG23 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -155.54 -149.63 0.27 Allowed 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 110.149 -0.315 . . . . 3.0699999999999998 110.149 -173.282 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 4.6 mp0 -72.58 40.15 0.08 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.471 0.653 . . . . 1.23 111.962 178.754 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.582 ' CA ' HD13 ' B' ' 10' ' ' ILE . . . -154.87 33.37 0.67 Allowed Glycine 0 N--CA 1.438 -1.189 0 N-CA-C 110.609 -0.996 . . . . 0.35999999999999999 110.609 171.592 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.512 ' HA ' ' HD3' ' A' ' 33' ' ' PRO . 45.9 t0 -90.1 116.3 66.04 Favored Pre-proline 0 C--O 1.234 0.275 0 CA-C-O 121.327 0.584 . . . . 1.26 109.602 175.742 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.534 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 1.3 Cg_endo -87.28 63.29 4.07 Favored 'Trans proline' 0 N--CA 1.454 -0.835 0 C-N-CA 123.984 3.122 . . . . 1.3 113.83 -177.064 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.539 ' HA ' ' O ' ' A' ' 47' ' ' LYS . 0.7 OUTLIER -63.87 153.79 35.72 Favored 'General case' 0 C--N 1.295 -1.785 0 C-N-CA 118.709 -1.196 . . . . 1.21 111.695 -175.636 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.897 ' HB3' ' HD2' ' A' ' 47' ' ' LYS . 34.4 tt0 -111.0 117.2 32.7 Favored 'General case' 0 CA--C 1.491 -1.29 0 CA-C-N 113.926 -1.488 . . . . 1.1200000000000001 108.987 -173.362 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.885 ' HB ' HG22 ' B' ' 6' ' ' ILE . 3.0 mp -84.19 111.59 20.28 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.828 0 O-C-N 124.534 1.146 . . . . 1.1599999999999999 109.546 -178.875 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . 0.868 ' HD2' ' HA ' ' B' ' 3' ' ' ALA . 0.3 OUTLIER -149.79 124.01 9.52 Favored 'General case' 0 C--N 1.313 -1.002 0 CA-C-O 121.13 0.491 . . . . 2.0099999999999998 109.711 172.416 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.578 HG11 ' HA ' ' B' ' 2' ' ' LYS . 1.4 p -80.16 137.22 21.92 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 CA-C-O 121.198 0.523 . . . . 1.05 110.143 -179.409 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.647 ' OD2' ' HD2' ' A' ' 40' ' ' ARG . 32.3 t70 -88.24 -46.07 9.54 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.256 -0.884 . . . . 1.1100000000000001 111.699 -172.877 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . 0.793 ' HG3' ' HG3' ' A' ' 43' ' ' GLU . 0.1 OUTLIER -128.19 -90.64 0.5 Allowed 'General case' 0 C--N 1.313 -1.008 0 CA-C-N 114.773 -1.103 . . . . 2.8799999999999999 112.054 -162.402 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -112.74 -66.51 1.08 Allowed 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 121.02 0.438 . . . . 1.53 111.205 -176.402 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.514 ' O ' ' HA ' ' B' ' 47' ' ' LYS . . . -130.33 13.68 5.67 Favored Glycine 0 CA--C 1.499 -0.914 0 C-N-CA 120.462 -0.875 . . . . 0.34000000000000002 111.628 -178.309 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.793 ' HG3' ' HG3' ' A' ' 40' ' ' ARG . 0.9 OUTLIER -97.04 110.54 23.06 Favored 'General case' 0 C--N 1.319 -0.732 0 N-CA-C 109.299 -0.63 . . . . 1.97 109.299 -178.794 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.567 ' CG1' HG21 ' A' ' 36' ' ' ILE . 2.3 t -90.71 133.76 31.51 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.788 0 CA-C-N 115.718 -0.674 . . . . 1.0600000000000001 109.239 177.924 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.758 HG13 HG13 ' B' ' 45' ' ' ILE . 1.7 mp -110.93 116.6 52.92 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 N-CA-C 108.644 -0.873 . . . . 1.01 108.644 -175.77 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.909 HD12 HD12 ' B' ' 46' ' ' LEU . 0.9 OUTLIER -108.08 118.36 36.54 Favored 'General case' 0 C--N 1.319 -0.76 0 O-C-N 123.764 0.665 . . . . 1.1299999999999999 109.753 179.53 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.897 ' HD2' ' HB3' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -130.08 148.73 51.96 Favored 'General case' 0 C--O 1.216 -0.689 0 C-N-CA 118.849 -1.14 . . . . 1.25 113.152 178.001 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.556 ' HE2' ' HG3' ' A' ' 51' ' ' PRO . 2.2 ptmt -35.83 -19.73 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.09 0 N-CA-C 118.044 2.609 . . . . 1.0900000000000001 118.044 -172.288 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.574 ' CD1' HG22 ' B' ' 7' ' ' VAL . 22.6 t80 74.95 -54.26 0.66 Allowed 'General case' 0 N--CA 1.475 0.822 0 C-N-CA 123.455 0.702 . . . . 2.1400000000000001 112.79 177.408 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.696 ' HB3' ' HD3' ' A' ' 51' ' ' PRO . 6.8 t -52.15 -53.13 55.62 Favored Pre-proline 0 CA--C 1.541 0.601 0 CA-C-N 116.388 -0.369 . . . . 1.95 111.182 -173.675 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.696 ' HD3' ' HB3' ' A' ' 50' ' ' SER . 48.5 Cg_endo -92.98 14.39 1.6 Allowed 'Trans proline' 0 C--N 1.348 0.536 0 C-N-CA 122.376 2.051 . . . . 0.59999999999999998 111.539 170.101 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER 50.4 -145.5 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.235 0.306 0 CA-C-N 115.429 -0.805 . . . . 1.4199999999999999 109.86 -176.861 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 3.0 m -83.94 69.57 10.31 Favored 'General case' 0 C--N 1.321 -0.643 0 C-N-CA 120.968 -0.293 . . . . 2.23 111.146 178.494 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER 65.24 18.14 11.28 Favored 'General case' 0 CA--C 1.534 0.346 0 CA-C-N 115.715 -0.675 . . . . 2.8900000000000001 110.372 177.742 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 97.1 mt . . . . . 0 C--O 1.249 1.043 0 CA-C-N 115.756 -0.656 . . . . 2.8100000000000001 111.497 -179.389 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 65.9 mtt . . . . . 0 N--CA 1.485 1.323 0 CA-C-O 120.66 0.267 . . . . 6.71 111.177 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 2' ' ' LYS . . . . . 0.578 ' HA ' HG11 ' A' ' 38' ' ' VAL . 0.0 OUTLIER -114.52 -177.23 3.08 Favored 'General case' 0 C--N 1.326 -0.416 0 C-N-CA 121.066 -0.254 . . . . 4.0899999999999999 110.567 178.677 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 3' ' ' ALA . . . . . 0.868 ' HA ' ' HD2' ' A' ' 37' ' ' PHE . . . 51.78 76.34 0.18 Allowed 'General case' 0 CA--C 1.517 -0.296 0 O-C-N 123.849 0.718 . . . . 1.1000000000000001 110.979 -174.759 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 4' ' ' THR . . . . . . . . . . . . . 20.4 p -91.68 -29.14 17.02 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.219 -0.901 . . . . 0.97999999999999998 112.275 -173.607 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 56.99 47.74 84.93 Favored Glycine 0 N--CA 1.45 -0.415 0 CA-C-N 115.711 -0.677 . . . . 0.33000000000000002 112.99 175.306 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 6' ' ' ILE . . . . . 0.885 HG22 ' HB ' ' A' ' 36' ' ' ILE . 1.0 OUTLIER -107.66 109.46 28.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-O 121.178 0.513 . . . . 1.1000000000000001 109.623 176.602 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 7' ' ' VAL . . . . . 0.574 HG22 ' CD1' ' A' ' 49' ' ' TYR . 14.7 t -80.52 135.38 25.39 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.996 0 CA-C-N 115.609 -0.723 . . . . 1.0800000000000001 110.783 -177.813 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.613 ' CZ ' HG22 ' B' ' 17' ' ' VAL . 1.1 tpt180 -128.09 112.77 14.95 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 107.405 -1.331 . . . . 2.3599999999999999 107.405 178.696 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 9' ' ' ARG . . . . . 0.458 ' HA ' ' HA ' ' A' ' 33' ' ' PRO . 13.2 ttt180 -78.83 104.45 9.47 Favored 'General case' 0 CA--C 1.501 -0.929 0 N-CA-C 108.287 -1.005 . . . . 3.2000000000000002 108.287 174.564 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 10' ' ' ILE . . . . . 0.582 HD13 ' CA ' ' A' ' 31' ' ' GLY . 0.2 OUTLIER -15.28 -103.24 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 O-C-N 125.822 1.951 . . . . 1.0700000000000001 114.65 -177.248 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 11' ' ' ASP . . . . . 0.577 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 6.4 p-10 158.08 -161.08 0.0 OUTLIER 'General case' 0 CA--C 1.506 -0.727 0 N-CA-C 106.604 -1.628 . . . . 1.1799999999999999 106.604 174.854 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 38.4 t70 -77.04 -17.5 58.74 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.512 0.673 . . . . 2.3900000000000001 110.209 -178.151 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 13' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -96.1 -61.6 1.41 Allowed 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.575 -0.739 . . . . 1.1000000000000001 110.029 177.296 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 134.61 24.06 0.62 Allowed Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.477 -0.868 . . . . 0.23000000000000001 112.649 179.624 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 15' ' ' ARG . . . . . 0.706 ' HG2' HG23 ' A' ' 17' ' ' VAL . 56.4 mtt180 -77.82 147.28 35.28 Favored 'General case' 0 CA--C 1.51 -0.575 0 CA-C-O 121.479 0.657 . . . . 1.3899999999999999 111.175 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 16' ' ' VAL . . . . . 0.524 HG11 HD13 ' A' ' 46' ' ' LEU . 92.7 t -113.76 99.49 8.72 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.13 0 N-CA-C 107.861 -1.163 . . . . 1.97 107.861 168.335 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 17' ' ' VAL . . . . . 0.613 HG22 ' CZ ' ' B' ' 8' ' ' ARG . 60.8 t -66.41 106.33 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.847 0 CA-C-N 115.475 -0.784 . . . . 1.0600000000000001 109.847 -173.635 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 18' ' ' ILE . . . . . 0.584 ' HB ' ' O ' ' A' ' 14' ' ' GLY . 22.7 mm -89.29 109.08 28.62 Favored Pre-proline 0 C--N 1.32 -0.696 0 CA-C-N 115.587 -0.733 . . . . 1.6100000000000001 110.24 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . 0.583 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 93.6 Cg_exo -53.45 144.05 52.46 Favored 'Trans proline' 0 N--CA 1.454 -0.799 0 C-N-CA 122.558 2.172 . . . . 0.33000000000000002 112.22 174.773 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 20' ' ' LYS . . . . . 1.009 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -64.64 -13.71 54.99 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 115.556 -0.747 . . . . 2.3199999999999998 111.434 -179.396 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 21' ' ' GLU . . . . . 0.583 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 11.2 pt-20 -65.42 -26.32 67.92 Favored 'General case' 0 C--O 1.239 0.549 0 N-CA-C 112.688 0.625 . . . . 1.9199999999999999 112.688 179.556 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 3.9 mp -88.58 -42.09 14.52 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.252 0 N-CA-C 107.807 -1.183 . . . . 1.24 107.807 -179.214 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 23' ' ' ARG . . . . . 0.555 ' HA ' ' HB2' ' B' ' 26' ' ' LEU . 0.0 OUTLIER -57.69 -30.24 65.33 Favored 'General case' 0 N--CA 1.461 0.125 0 CA-C-N 114.927 -1.033 . . . . 1.8500000000000001 109.126 170.973 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 24' ' ' ARG . . . . . 0.524 ' HB3' ' O ' ' B' ' 21' ' ' GLU . 21.4 ttp180 -62.28 -53.17 59.06 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 114.289 -1.323 . . . . 3.6899999999999999 110.942 174.838 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 30.4 m -62.41 -32.0 72.77 Favored 'General case' 0 C--O 1.235 0.334 0 CA-C-O 121.409 0.624 . . . . 1.1599999999999999 110.557 174.278 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.67 ' HB3' HG13 ' B' ' 28' ' ' ILE . 0.9 OUTLIER -64.3 -19.86 65.7 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.212 -0.903 . . . . 1.1100000000000001 110.705 176.131 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 27' ' ' ARG . . . . . 0.435 ' HD2' ' HA ' ' B' ' 27' ' ' ARG . 11.9 tpt180 68.05 22.45 8.43 Favored 'General case' 0 N--CA 1.461 0.097 0 CA-C-O 121.802 0.81 . . . . 3.77 109.906 -177.627 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 28' ' ' ILE . . . . . 0.836 HG23 ' H ' ' B' ' 29' ' ' ARG . 6.3 mt -111.92 -161.21 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.203 -0.908 . . . . 1.2 109.162 -179.306 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 29' ' ' ARG . . . . . 0.836 ' H ' HG23 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -158.68 -157.37 0.61 Allowed 'General case' 0 C--N 1.32 -0.689 0 O-C-N 122.468 -0.145 . . . . 2.7599999999999998 110.618 -173.229 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 30' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -70.31 43.48 0.06 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.975 0.893 . . . . 1.1799999999999999 111.598 176.777 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 31' ' ' GLY . . . . . 0.614 ' CA ' HD13 ' A' ' 10' ' ' ILE . . . -161.12 36.06 0.41 Allowed Glycine 0 N--CA 1.436 -1.338 0 CA-C-N 114.282 -1.326 . . . . 0.34999999999999998 110.358 174.614 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 32' ' ' ASP . . . . . 0.504 ' HA ' ' HD3' ' B' ' 33' ' ' PRO . 16.5 t0 -93.21 121.13 66.06 Favored Pre-proline 0 C--N 1.327 -0.409 0 CA-C-N 115.006 -0.597 . . . . 1.29 110.223 175.558 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 33' ' ' PRO . . . . . 0.661 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 3.9 Cg_endo -86.84 75.6 2.57 Favored 'Trans proline' 0 C--O 1.206 -1.084 0 C-N-CA 123.664 2.909 . . . . 1.1000000000000001 113.31 -179.919 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . 0.588 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 1.4 mp -71.14 150.52 45.34 Favored 'General case' 0 C--N 1.286 -2.182 0 C-N-CA 117.909 -1.516 . . . . 1.1699999999999999 111.326 -178.535 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 35' ' ' GLU . . . . . 0.745 ' HB3' ' HD2' ' B' ' 47' ' ' LYS . 45.2 tt0 -109.69 114.45 28.06 Favored 'General case' 0 CA--C 1.49 -1.343 0 CA-C-N 114.384 -1.28 . . . . 1.1000000000000001 108.326 -177.656 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 36' ' ' ILE . . . . . 0.96 HG13 HD23 ' B' ' 46' ' ' LEU . 3.0 mp -87.46 112.16 22.94 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 O-C-N 124.761 1.288 . . . . 1.3200000000000001 109.697 -177.221 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 37' ' ' PHE . . . . . 0.815 ' HD2' ' HA ' ' A' ' 3' ' ' ALA . 1.1 p90 -150.14 128.42 12.07 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 116.003 -0.544 . . . . 2.0299999999999998 109.661 172.39 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 38' ' ' VAL . . . . . 0.648 HG11 ' HA ' ' A' ' 2' ' ' LYS . 0.6 OUTLIER -80.67 140.19 17.03 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.982 0 CA-C-O 121.281 0.563 . . . . 0.89000000000000001 110.57 -179.636 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 39' ' ' ASP . . . . . 0.626 ' OD1' ' HD2' ' B' ' 40' ' ' ARG . 16.1 t70 -84.85 -50.74 7.29 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.16 -0.927 . . . . 1.1399999999999999 111.731 -173.249 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 40' ' ' ARG . . . . . 0.626 ' HD2' ' OD1' ' B' ' 39' ' ' ASP . 0.0 OUTLIER -134.99 -87.15 0.38 Allowed 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 112.661 0.615 . . . . 3.3700000000000001 112.661 -172.437 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -95.17 -78.81 0.44 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.025 0.44 . . . . 1.3200000000000001 110.999 -175.673 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 42' ' ' GLY . . . . . 0.454 ' HA3' HD13 ' A' ' 26' ' ' LEU . . . -125.84 16.02 6.95 Favored Glycine 0 N--CA 1.443 -0.843 0 C-N-CA 120.576 -0.821 . . . . 0.35999999999999999 112.043 -177.481 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 43' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -92.03 107.64 19.35 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.511 -0.552 . . . . 2.0699999999999998 109.511 -178.765 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 44' ' ' VAL . . . . . 0.57 ' O ' ' HA ' ' A' ' 45' ' ' ILE . 1.9 t -89.83 133.71 31.03 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.852 0 N-CA-C 109.402 -0.592 . . . . 1.02 109.402 176.441 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 45' ' ' ILE . . . . . 0.758 HG13 HG13 ' A' ' 45' ' ' ILE . 1.7 mp -110.62 119.86 60.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 N-CA-C 108.582 -0.896 . . . . 0.95999999999999996 108.582 -177.281 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 46' ' ' LEU . . . . . 0.96 HD23 HG13 ' B' ' 36' ' ' ILE . 0.6 OUTLIER -112.13 117.54 32.88 Favored 'General case' 0 C--N 1.32 -0.696 0 O-C-N 123.682 0.614 . . . . 1.05 109.936 178.333 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 47' ' ' LYS . . . . . 0.745 ' HD2' ' HB3' ' B' ' 35' ' ' GLU . 0.0 OUTLIER -130.95 152.94 49.71 Favored 'General case' 0 C--O 1.213 -0.848 0 C-N-CA 119.254 -0.978 . . . . 1.3899999999999999 113.033 177.516 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 48' ' ' LYS . . . . . 0.689 ' HE3' HD11 ' B' ' 28' ' ' ILE . 12.5 ptmt -49.87 -4.4 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.011 0 N-CA-C 117.713 2.486 . . . . 1.1899999999999999 117.713 -166.727 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 49' ' ' TYR . . . . . 0.661 ' HB3' ' HB2' ' B' ' 33' ' ' PRO . 28.7 t80 71.73 -54.53 0.67 Allowed 'General case' 0 N--CA 1.477 0.88 0 N-CA-C 113.549 0.944 . . . . 2.1000000000000001 113.549 172.027 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 50' ' ' SER . . . . . 0.664 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 9.2 t -51.55 -55.88 25.61 Favored Pre-proline 0 CA--C 1.539 0.548 0 CA-C-N 116.05 -0.523 . . . . 1.77 111.035 -173.518 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 51' ' ' PRO . . . . . 0.664 ' HD3' ' HB3' ' B' ' 50' ' ' SER . 41.3 Cg_endo -89.81 12.95 2.45 Favored 'Trans proline' 0 C--N 1.351 0.705 0 C-N-CA 122.172 1.915 . . . . 0.59999999999999998 111.514 170.698 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 52' ' ' ILE . . . . . . . . . . . . . 1.1 mt 50.55 -144.57 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.199 -0.909 . . . . 1.3899999999999999 109.714 -176.66 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 53' ' ' SER . . . . . . . . . . . . . 13.8 m -81.49 62.99 5.6 Favored 'General case' 0 C--N 1.326 -0.452 0 O-C-N 122.351 -0.218 . . . . 2.04 111.155 179.427 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 54' ' ' GLU . . . . . . . . . . . . . 7.5 tm-20 66.7 21.39 10.59 Favored 'General case' 0 CA--C 1.539 0.523 0 CA-C-O 121.523 0.678 . . . . 2.6200000000000001 109.74 178.774 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 55' ' ' LEU . . . . . . . . . . . . . 95.4 mt . . . . . 0 C--O 1.251 1.149 0 CA-C-N 115.379 -0.828 . . . . 2.8700000000000001 111.211 -177.171 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 3' ' ' ALA . . . . . 0.51 ' HA ' ' HB2' ' B' ' 37' ' ' PHE . . . . . . . . 0 N--CA 1.457 -0.08 0 N-CA-C 113.459 0.911 . . . . 0.72 113.459 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.682 ' H ' ' HB2' ' B' ' 37' ' ' PHE . 10.6 p -110.28 -48.02 3.22 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 114.968 -1.015 . . . . 0.41 109.893 172.007 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 78.68 51.65 5.43 Favored Glycine 0 N--CA 1.446 -0.646 0 CA-C-N 115.431 -0.804 . . . . 0.32 112.912 172.001 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.807 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.5 tp -107.99 107.17 22.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 N-CA-C 109.273 -0.64 . . . . 0.31 109.273 172.939 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.741 ' HA ' ' O ' ' B' ' 34' ' ' LEU . 44.2 t -78.28 133.73 29.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-N 116.102 -0.499 . . . . 0.28 110.565 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.577 ' HB3' ' CD1' ' B' ' 36' ' ' ILE . 0.4 OUTLIER -129.69 123.06 30.22 Favored 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 107.387 -1.338 . . . . 1.99 107.387 -178.237 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ARG . . . . . 0.529 ' HA ' ' HA ' ' B' ' 33' ' ' PRO . 0.0 OUTLIER -83.82 103.02 12.76 Favored 'General case' 0 C--N 1.314 -0.947 0 N-CA-C 107.754 -1.202 . . . . 2.8 107.754 173.246 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.789 HG23 HD11 ' B' ' 34' ' ' LEU . 0.2 OUTLIER -9.97 -102.53 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.13 0 O-C-N 125.291 1.619 . . . . 0.33 114.595 -175.4 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ASP . . . . . 0.577 ' H ' HD13 ' A' ' 10' ' ' ILE . 27.9 p-10 163.33 -165.03 0.01 OUTLIER 'General case' 0 CA--C 1.506 -0.722 0 N-CA-C 107.86 -1.163 . . . . 1.13 107.86 175.175 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' ASP . . . . . 0.502 ' HA ' ' HG2' ' B' ' 30' ' ' GLU . 12.8 p-10 -80.97 14.38 2.27 Favored 'General case' 0 C--N 1.318 -0.796 0 O-C-N 123.376 0.423 . . . . 2.26 111.284 -176.648 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -129.96 -55.14 1.13 Allowed 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 109.931 -0.396 . . . . 0.53 109.931 176.799 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.554 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 135.79 7.48 1.82 Allowed Glycine 0 N--CA 1.444 -0.776 0 C-N-CA 120.606 -0.807 . . . . 0.22 113.156 -179.014 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.735 ' HG2' HG22 ' B' ' 17' ' ' VAL . 0.5 OUTLIER -77.76 156.03 30.81 Favored 'General case' 0 CA--C 1.495 -1.149 0 CA-C-N 117.813 0.806 . . . . 0.69 109.912 178.304 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 1.045 HG22 HG22 ' B' ' 16' ' ' VAL . 0.8 OUTLIER -112.2 115.09 48.89 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.86 0 N-CA-C 107.508 -1.293 . . . . 1.24 107.508 167.954 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.702 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 46.9 t -73.35 98.21 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 CA-C-N 114.801 -1.09 . . . . 0.28 109.355 -174.281 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.514 ' HB ' ' O ' ' B' ' 14' ' ' GLY . 33.7 mm -83.96 106.97 8.98 Favored Pre-proline 0 N--CA 1.448 -0.529 0 O-C-N 123.844 0.715 . . . . 0.77 109.907 179.849 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.715 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 58.6 Cg_exo -47.1 143.86 9.56 Favored 'Trans proline' 0 N--CA 1.455 -0.784 0 C-N-CA 122.958 2.439 . . . . 0.32 112.391 174.769 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.927 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -62.4 -15.58 49.87 Favored 'General case' 0 C--O 1.206 -1.236 0 CA-C-N 115.427 -0.806 . . . . 1.57 110.763 -179.405 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.715 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 9.6 pt-20 -64.0 -24.07 67.57 Favored 'General case' 0 CA--C 1.532 0.278 0 N-CA-C 112.307 0.484 . . . . 1.32 112.307 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.2 mp -87.34 -45.24 16.24 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.24 0 N-CA-C 108.2 -1.037 . . . . 0.35 108.2 -179.303 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ARG . . . . . 0.735 ' HA ' ' HB2' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -62.96 -26.95 69.07 Favored 'General case' 0 C--N 1.333 -0.137 0 CA-C-N 115.393 -0.822 . . . . 1.5 109.516 173.322 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 34.9 ttm180 -64.41 -49.15 72.67 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 114.94 -1.027 . . . . 2.96 110.712 172.683 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 17.7 m -63.41 -27.41 69.28 Favored 'General case' 0 CA--C 1.532 0.265 0 CA-C-O 121.09 0.471 . . . . 0.4 110.781 171.166 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.771 ' HB3' HG13 ' A' ' 28' ' ' ILE . 2.2 mm? -69.81 -22.13 63.33 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.038 -0.528 . . . . 0.36 110.688 172.764 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.416 ' HB2' ' O ' ' A' ' 26' ' ' LEU . 0.0 OUTLIER 67.33 23.75 9.17 Favored 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 123.574 0.75 . . . . 3.2 111.306 -174.218 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.771 HG13 ' HB3' ' A' ' 26' ' ' LEU . 3.6 mt -113.24 -159.68 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 116.013 -0.54 . . . . 0.48 109.959 -176.77 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.717 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -159.21 -159.41 0.76 Allowed 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 117.786 0.266 . . . . 2.4 111.545 -169.208 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 30' ' ' GLU . . . . . 0.512 ' HG2' ' HA ' ' B' ' 12' ' ' ASP . 59.0 mp0 -70.28 32.73 0.04 OUTLIER 'General case' 0 N--CA 1.469 0.515 0 C-N-CA 123.613 0.765 . . . . 1.23 112.673 178.303 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.575 ' N ' HD11 ' B' ' 10' ' ' ILE . . . -148.59 23.92 1.34 Allowed Glycine 0 N--CA 1.44 -1.072 0 N-CA-C 110.297 -1.121 . . . . 0.36 110.297 173.178 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.633 ' O ' HG13 ' B' ' 10' ' ' ILE . 14.8 t0 -83.04 122.51 77.77 Favored Pre-proline 0 C--N 1.326 -0.447 0 CA-C-N 114.774 -0.713 . . . . 1.26 109.751 175.663 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.725 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 9.7 Cg_endo -85.66 149.2 9.92 Favored 'Trans proline' 0 N--CA 1.433 -2.03 0 C-N-CA 122.367 2.045 . . . . 1.3 110.522 175.753 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.841 HD11 HG23 ' B' ' 10' ' ' ILE . 0.9 OUTLIER -140.0 150.95 45.07 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 120.386 -0.526 . . . . 0.38 109.739 174.887 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.685 ' HB3' ' HB3' ' A' ' 47' ' ' LYS . 36.1 tt0 -103.48 110.27 22.24 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 107.05 -1.463 . . . . 1.12 107.05 -178.802 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.801 ' HB ' HG23 ' B' ' 6' ' ' ILE . 2.1 mp -85.52 107.81 16.6 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.981 0 O-C-N 124.113 0.883 . . . . 0.39 108.757 -179.218 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' PHE . . . . . 0.685 ' HB2' ' H ' ' B' ' 4' ' ' THR . 6.2 p90 -149.38 127.34 11.89 Favored 'General case' 0 C--N 1.313 -0.988 0 CA-C-N 115.875 -0.602 . . . . 1.15 109.555 177.36 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.487 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 2.1 p -80.02 142.2 14.25 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.071 0 CA-C-N 115.941 -0.572 . . . . 0.17 110.004 -178.375 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.538 ' OD2' ' HD3' ' A' ' 40' ' ' ARG . 28.9 t70 -87.6 -43.08 12.25 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.904 -0.589 . . . . 1.11 111.722 -175.474 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' ARG . . . . . 0.573 ' HG3' ' HG3' ' A' ' 43' ' ' GLU . 0.0 OUTLIER -138.42 -90.05 0.22 Allowed 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 112.797 0.666 . . . . 2.29 112.797 -167.473 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 31.4 t70 -100.76 -71.91 0.69 Allowed 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.025 0.441 . . . . 1.53 110.85 -177.772 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.585 ' HA3' HD11 ' B' ' 26' ' ' LEU . . . -133.34 24.12 3.77 Favored Glycine 0 N--CA 1.445 -0.75 0 C-N-CA 120.466 -0.873 . . . . 0.32 112.123 -178.845 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.573 ' HG3' ' HG3' ' A' ' 40' ' ' ARG . 1.5 mt-10 -98.1 109.86 22.54 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 109.081 -0.711 . . . . 1.97 109.081 176.017 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.5 ' C ' HD12 ' A' ' 45' ' ' ILE . 1.6 t -90.0 134.25 29.59 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.875 0 N-CA-C 109.461 -0.57 . . . . 0.14 109.461 178.339 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.804 HG13 HG13 ' B' ' 45' ' ' ILE . 1.5 mp -109.08 122.72 64.19 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 N-CA-C 108.131 -1.063 . . . . 0.14 108.131 -177.095 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.798 HD11 HD11 ' B' ' 46' ' ' LEU . 4.9 mt -106.07 117.77 34.89 Favored 'General case' 0 C--N 1.319 -0.741 0 O-C-N 123.869 0.731 . . . . 0.23 109.728 178.286 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.685 ' HB3' ' HB3' ' A' ' 35' ' ' GLU . 15.8 ttmt -119.17 127.69 53.54 Favored 'General case' 0 C--N 1.311 -1.099 0 CA-C-N 115.73 -0.668 . . . . 0.76 111.959 -171.965 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.618 ' HA ' ' O ' ' A' ' 33' ' ' PRO . 3.2 ptmt -44.88 -15.03 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.451 0 N-CA-C 116.656 2.095 . . . . 0.32 116.656 -170.758 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 0.725 ' HB3' ' HB2' ' A' ' 33' ' ' PRO . 27.1 t80 73.59 -55.9 0.66 Allowed 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 112.627 0.602 . . . . 1.28 112.627 171.066 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.68 ' OG ' ' HD3' ' A' ' 51' ' ' PRO . 7.3 p -54.69 -41.67 91.04 Favored Pre-proline 0 CA--C 1.54 0.582 0 N-CA-C 112.439 0.533 . . . . 1.36 112.439 -174.312 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.68 ' HD3' ' OG ' ' A' ' 50' ' ' SER . 60.7 Cg_endo -103.3 14.74 0.27 Allowed 'Trans proline' 0 N--CA 1.451 -0.99 0 C-N-CA 123.063 2.509 . . . . 0.58 111.192 168.737 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 3.0 mt . . . . . 0 N--CA 1.444 -0.734 0 CA-C-N 115.194 -0.912 . . . . 0.78 108.549 -168.843 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 3' ' ' ALA . . . . . 0.531 ' HA ' ' HB2' ' A' ' 37' ' ' PHE . . . . . . . . 0 C--O 1.233 0.206 0 CA-C-O 122.058 0.932 . . . . 0.86 113.037 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 4' ' ' THR . . . . . 0.685 ' H ' ' HB2' ' A' ' 37' ' ' PHE . 5.4 p -110.8 -48.72 3.1 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 114.473 -1.239 . . . . 0.43 109.661 171.473 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 78.4 51.38 5.66 Favored Glycine 0 N--CA 1.45 -0.419 0 CA-C-N 115.453 -0.794 . . . . 0.33 112.843 172.122 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 6' ' ' ILE . . . . . 0.801 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.4 tp -107.44 106.84 21.42 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 N-CA-C 109.317 -0.623 . . . . 0.3 109.317 173.573 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 7' ' ' VAL . . . . . 0.728 ' HA ' ' O ' ' A' ' 34' ' ' LEU . 25.2 t -78.1 135.2 26.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 116.124 -0.489 . . . . 0.27 110.469 179.447 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 8' ' ' ARG . . . . . 0.413 ' HB3' HD13 ' A' ' 36' ' ' ILE . 0.8 OUTLIER -133.36 122.51 23.89 Favored 'General case' 0 N--CA 1.439 -0.999 0 N-CA-C 107.345 -1.354 . . . . 1.69 107.345 -178.871 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 9' ' ' ARG . . . . . 0.553 ' HA ' ' HA ' ' A' ' 33' ' ' PRO . 18.3 ttp180 -81.7 104.57 12.19 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 108.596 -0.89 . . . . 2.71 108.596 172.986 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 10' ' ' ILE . . . . . 0.841 HG23 HD11 ' A' ' 34' ' ' LEU . 0.3 OUTLIER -10.79 -101.27 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 O-C-N 125.631 1.832 . . . . 0.34 114.234 -175.701 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 11' ' ' ASP . . . . . 0.642 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 2.4 p-10 162.2 -169.87 0.01 OUTLIER 'General case' 0 CA--C 1.512 -0.502 0 N-CA-C 107.672 -1.233 . . . . 1.18 107.672 176.043 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 12' ' ' ASP . . . . . 0.512 ' HA ' ' HG2' ' A' ' 30' ' ' GLU . 3.3 p30 -78.13 7.74 5.82 Favored 'General case' 0 C--N 1.325 -0.463 0 O-C-N 123.174 0.296 . . . . 2.39 111.251 -177.608 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 13' ' ' LEU . . . . . 0.417 ' HB3' ' HD2' ' B' ' 15' ' ' ARG . 2.4 tm? -119.03 -61.53 1.63 Allowed 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 109.8 -0.445 . . . . 0.4 109.8 171.603 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 14' ' ' GLY . . . . . 0.514 ' O ' ' HB ' ' A' ' 18' ' ' ILE . . . 137.72 14.78 0.77 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.265 -0.969 . . . . 0.21 113.257 -178.565 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 15' ' ' ARG . . . . . 0.699 ' HG2' HG22 ' A' ' 17' ' ' VAL . 0.3 OUTLIER -81.08 154.68 26.68 Favored 'General case' 0 CA--C 1.493 -1.23 0 CA-C-O 121.659 0.743 . . . . 0.9 109.72 177.325 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 16' ' ' VAL . . . . . 1.045 HG22 HG22 ' A' ' 16' ' ' VAL . 3.9 m -107.7 108.52 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.219 0 N-CA-C 106.998 -1.482 . . . . 1.27 106.998 170.357 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 17' ' ' VAL . . . . . 0.735 HG22 ' HG2' ' A' ' 15' ' ' ARG . 47.3 t -70.88 96.52 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.352 0 CA-C-N 114.597 -1.183 . . . . 0.27 109.206 -174.354 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 18' ' ' ILE . . . . . 0.554 ' HB ' ' O ' ' A' ' 14' ' ' GLY . 34.3 mm -85.0 108.38 15.15 Favored Pre-proline 0 N--CA 1.449 -0.519 0 CA-C-N 115.401 -0.818 . . . . 0.82 110.299 -177.612 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 19' ' ' PRO . . . . . 0.715 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 58.5 Cg_exo -47.29 141.79 13.23 Favored 'Trans proline' 0 N--CA 1.456 -0.724 0 C-N-CA 122.876 2.384 . . . . 0.3 112.702 174.78 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 20' ' ' LYS . . . . . 1.015 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -59.3 -15.15 14.27 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.444 -0.798 . . . . 1.77 111.789 178.207 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 21' ' ' GLU . . . . . 0.715 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 12.9 pt-20 -64.14 -26.16 68.41 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-O 120.706 0.288 . . . . 1.92 111.45 -179.767 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 5.3 mp -87.16 -44.1 16.05 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.354 0 N-CA-C 107.901 -1.148 . . . . 0.44 107.901 -177.284 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 23' ' ' ARG . . . . . 0.628 ' HA ' ' HB2' ' B' ' 26' ' ' LEU . 0.0 OUTLIER -63.99 -26.32 68.52 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-N 115.147 -0.933 . . . . 1.4 109.897 174.972 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 24' ' ' ARG . . . . . . . . . . . . . 32.3 ttm180 -65.58 -50.14 66.2 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.674 -0.694 . . . . 3.19 110.917 172.213 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 28.2 m -63.29 -21.53 66.31 Favored 'General case' 0 CA--C 1.531 0.233 0 CA-C-O 121.527 0.68 . . . . 0.4 110.47 174.4 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 26' ' ' LEU . . . . . 0.628 ' HB2' ' HA ' ' B' ' 23' ' ' ARG . 1.6 mm? -74.21 -20.93 60.02 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.505 -0.77 . . . . 0.33 110.915 173.399 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 27' ' ' ARG . . . . . 0.455 ' HB2' ' O ' ' B' ' 26' ' ' LEU . 0.0 OUTLIER 67.37 28.47 7.83 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 123.33 0.652 . . . . 3.28 110.827 -173.892 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 28' ' ' ILE . . . . . 0.863 HG22 ' H ' ' B' ' 29' ' ' ARG . 5.7 mt -121.49 -163.28 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.051 -0.522 . . . . 0.37 110.399 -176.657 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 29' ' ' ARG . . . . . 0.863 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -157.93 -158.38 0.73 Allowed 'General case' 0 N--CA 1.467 0.414 0 C-N-CA 122.046 0.138 . . . . 2.15 111.054 -169.87 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 30' ' ' GLU . . . . . 0.502 ' HG2' ' HA ' ' A' ' 12' ' ' ASP . 58.9 mp0 -69.33 30.84 0.03 OUTLIER 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 112.95 0.722 . . . . 1.18 112.95 178.666 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 31' ' ' GLY . . . . . 0.566 ' N ' HD11 ' A' ' 10' ' ' ILE . . . -145.56 25.68 1.82 Allowed Glycine 0 N--CA 1.441 -1.006 0 N-CA-C 110.073 -1.211 . . . . 0.35 110.073 172.503 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 32' ' ' ASP . . . . . 0.545 ' O ' HG13 ' A' ' 10' ' ' ILE . 8.6 t70 -82.0 121.5 79.09 Favored Pre-proline 0 C--N 1.324 -0.538 0 CA-C-N 114.6 -0.8 . . . . 1.29 110.224 176.002 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 33' ' ' PRO . . . . . 0.784 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 7.8 Cg_endo -83.06 147.02 12.97 Favored 'Trans proline' 0 N--CA 1.433 -2.048 0 C-N-CA 122.163 1.909 . . . . 1.1 110.432 173.351 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.789 HD11 HG23 ' A' ' 10' ' ' ILE . 1.0 OUTLIER -137.53 149.28 46.63 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 109.6 -0.519 . . . . 0.44 109.6 173.431 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 35' ' ' GLU . . . . . 0.695 ' HB3' ' HE3' ' B' ' 47' ' ' LYS . 45.8 tt0 -101.81 111.32 23.54 Favored 'General case' 0 C--N 1.297 -1.694 0 N-CA-C 107.242 -1.392 . . . . 1.1 107.242 178.89 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 36' ' ' ILE . . . . . 0.807 ' HB ' HG23 ' A' ' 6' ' ' ILE . 2.8 mp -85.19 108.01 16.62 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.77 0 O-C-N 124.329 1.018 . . . . 0.62 108.831 -179.678 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 37' ' ' PHE . . . . . 0.682 ' HB2' ' H ' ' A' ' 4' ' ' THR . 7.6 p90 -150.44 127.66 11.3 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 116.003 -0.544 . . . . 1.2 109.866 176.851 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 38' ' ' VAL . . . . . 0.529 ' HA ' ' HA ' ' B' ' 44' ' ' VAL . 1.6 p -79.94 145.23 9.53 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 CA-C-N 116.446 -0.343 . . . . 0.2 110.562 -177.529 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 39' ' ' ASP . . . . . 0.618 ' OD2' ' HD3' ' B' ' 40' ' ' ARG . 18.2 t70 -82.58 -47.39 12.18 Favored 'General case' 0 C--N 1.326 -0.439 0 O-C-N 123.966 0.791 . . . . 1.14 111.318 -175.569 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 40' ' ' ARG . . . . . 0.618 ' HD3' ' OD2' ' B' ' 39' ' ' ASP . 0.7 OUTLIER -144.82 -78.75 0.19 Allowed 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 113.189 0.811 . . . . 2.71 113.189 -176.457 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -97.63 -65.45 0.96 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.039 0.447 . . . . 1.32 111.512 -171.096 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 42' ' ' GLY . . . . . 0.537 ' HA3' ' HD2' ' A' ' 48' ' ' LYS . . . -145.9 16.97 1.77 Allowed Glycine 0 N--CA 1.442 -0.912 0 C-N-CA 120.79 -0.719 . . . . 0.34 111.651 -178.155 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 43' ' ' GLU . . . . . 0.681 ' HA ' ' O ' ' A' ' 46' ' ' LEU . 2.3 pm0 -91.96 107.36 19.16 Favored 'General case' 0 N--CA 1.445 -0.683 0 N-CA-C 109.835 -0.431 . . . . 2.07 109.835 176.619 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 44' ' ' VAL . . . . . 0.596 ' HB ' HD12 ' A' ' 46' ' ' LEU . 2.1 t -89.33 131.69 35.98 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 109.536 -0.542 . . . . 0.13 109.536 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 45' ' ' ILE . . . . . 0.804 HG13 HG13 ' A' ' 45' ' ' ILE . 1.6 mp -107.06 120.64 58.73 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 N-CA-C 108.065 -1.087 . . . . 0.12 108.065 -178.302 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 46' ' ' LEU . . . . . 0.798 HD11 HD11 ' A' ' 46' ' ' LEU . 0.9 OUTLIER -109.7 116.48 31.78 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 109.442 -0.577 . . . . 0.15 109.442 177.531 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 47' ' ' LYS . . . . . 0.695 ' HE3' ' HB3' ' B' ' 35' ' ' GLU . 0.0 OUTLIER -127.71 141.81 51.5 Favored 'General case' 0 C--N 1.318 -0.774 0 C-N-CA 119.372 -0.931 . . . . 0.95 113.083 -177.722 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 48' ' ' LYS . . . . . 0.72 ' HE2' ' HG3' ' B' ' 51' ' ' PRO . 5.2 ptmt -43.4 -12.88 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.177 0 N-CA-C 118.157 2.651 . . . . 0.64 118.157 -166.171 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 49' ' ' TYR . . . . . 0.784 ' HB3' ' HB2' ' B' ' 33' ' ' PRO . 22.4 t80 71.87 -55.77 0.66 Allowed 'General case' 0 N--CA 1.475 0.809 0 N-CA-C 113.374 0.879 . . . . 1.26 113.374 172.738 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 50' ' ' SER . . . . . 0.713 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 33.9 t -51.15 -57.02 15.35 Favored Pre-proline 0 CA--C 1.535 0.369 0 C-N-CA 122.867 0.467 . . . . 1.22 111.11 -175.186 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 51' ' ' PRO . . . . . 0.72 ' HG3' ' HE2' ' B' ' 48' ' ' LYS . 48.9 Cg_endo -89.58 13.51 2.37 Favored 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 121.995 1.796 . . . . 0.56 111.229 171.052 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 52' ' ' ILE . . . . . . . . . . . . . 3.0 mt . . . . . 0 N--CA 1.448 -0.571 0 CA-C-N 114.97 -1.014 . . . . 0.73 108.487 -172.763 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 3' ' ' ALA . . . . . 0.434 ' HA ' ' HB2' ' B' ' 37' ' ' PHE . . . . . . . . 0 CA--C 1.523 -0.095 0 CA-C-O 121.54 0.686 . . . . 0.72 111.204 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.412 ' OG1' ' HA ' ' B' ' 37' ' ' PHE . 17.9 p -92.29 -50.34 5.7 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.227 -0.897 . . . . 0.41 111.756 -177.957 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 79.78 49.69 5.96 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.46 -0.876 . . . . 0.32 113.208 175.851 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.759 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.1 tp -107.39 113.18 42.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 N-CA-C 109.17 -0.678 . . . . 0.31 109.17 173.731 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.723 ' HA ' ' O ' ' B' ' 34' ' ' LEU . 39.7 t -83.43 135.52 24.65 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-O 120.922 0.391 . . . . 0.28 110.798 -178.477 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.626 ' HB3' HD11 ' B' ' 36' ' ' ILE . 6.8 tpp180 -129.23 123.25 31.5 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 107.568 -1.271 . . . . 1.99 107.568 -179.352 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ARG . . . . . 0.527 ' N ' ' HD3' ' A' ' 8' ' ' ARG . 4.9 tpp180 -84.43 104.44 14.44 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 108.328 -0.99 . . . . 2.8 108.328 173.19 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.74 HG23 HD11 ' B' ' 34' ' ' LEU . 0.2 OUTLIER -12.23 -103.67 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.115 0 O-C-N 125.365 1.666 . . . . 0.33 114.701 -176.515 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ASP . . . . . 0.568 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 5.8 p-10 161.35 -160.27 0.0 OUTLIER 'General case' 0 CA--C 1.512 -0.485 0 N-CA-C 107.937 -1.134 . . . . 1.13 107.937 177.019 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -72.66 -22.88 60.85 Favored 'General case' 0 C--N 1.323 -0.576 0 O-C-N 123.386 0.429 . . . . 2.26 110.878 -178.455 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -98.42 -60.52 1.53 Allowed 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.29 -0.414 . . . . 0.53 110.233 178.287 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.452 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 136.43 18.7 0.7 Allowed Glycine 0 N--CA 1.445 -0.735 0 C-N-CA 120.073 -1.061 . . . . 0.22 113.393 -179.186 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.706 ' HG2' HG22 ' B' ' 17' ' ' VAL . 0.0 OUTLIER -79.1 153.35 30.22 Favored 'General case' 0 CA--C 1.507 -0.693 0 CA-C-N 118.028 0.914 . . . . 0.69 109.621 179.569 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.818 HG21 HD13 ' B' ' 46' ' ' LEU . 98.0 t -104.4 100.32 10.25 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.455 0 N-CA-C 107.628 -1.249 . . . . 1.24 107.628 172.353 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.79 HG22 ' HG2' ' B' ' 15' ' ' ARG . 91.0 t -68.14 98.89 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.909 0 CA-C-N 115.068 -0.969 . . . . 0.28 110.21 -173.43 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.746 HG23 HD13 ' A' ' 22' ' ' ILE . 8.7 mt -92.25 114.02 60.96 Favored Pre-proline 0 N--CA 1.445 -0.708 0 CA-C-N 115.643 -0.708 . . . . 0.77 110.778 -178.551 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.638 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 47.5 Cg_exo -46.08 145.89 4.89 Favored 'Trans proline' 0 N--CA 1.458 -0.599 0 C-N-CA 123.1 2.533 . . . . 0.32 112.821 174.168 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.866 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -60.85 -16.47 41.63 Favored 'General case' 0 C--O 1.211 -0.949 0 CA-C-N 115.478 -0.783 . . . . 1.57 111.353 179.321 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.638 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 11.1 pt-20 -66.1 -19.91 65.99 Favored 'General case' 0 C--O 1.236 0.363 0 N-CA-C 111.767 0.284 . . . . 1.32 111.767 -178.283 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.746 HD13 HG23 ' A' ' 18' ' ' ILE . 5.0 mp -87.49 -50.8 13.48 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.635 0 N-CA-C 107.854 -1.165 . . . . 0.35 107.854 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ARG . . . . . 0.595 ' HA ' ' HB2' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -56.1 -31.98 63.75 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 115.492 -0.776 . . . . 1.5 110.358 171.879 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.42 ' HB3' ' HA ' ' A' ' 21' ' ' GLU . 10.2 ttt180 -63.55 -52.26 61.87 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.313 -0.858 . . . . 2.96 110.943 174.29 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 22.5 m -66.53 -22.75 66.16 Favored 'General case' 0 C--O 1.222 -0.353 0 CA-C-O 121.182 0.515 . . . . 0.4 110.697 175.525 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.736 ' HB3' HG13 ' A' ' 28' ' ' ILE . 2.0 mm? -65.81 -19.71 65.98 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.865 -0.607 . . . . 0.36 110.614 173.928 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.533 ' HB2' ' O ' ' A' ' 26' ' ' LEU . 0.3 OUTLIER 72.3 21.36 3.84 Favored 'General case' 0 N--CA 1.466 0.358 0 O-C-N 124.066 0.854 . . . . 3.2 110.371 -172.746 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.736 HG13 ' HB3' ' A' ' 26' ' ' LEU . 3.0 mt -122.18 -163.0 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.726 -0.67 . . . . 0.48 110.175 -174.154 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.733 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -153.18 -161.41 1.28 Allowed 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 111.481 0.178 . . . . 2.4 111.481 -167.944 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -73.79 36.62 0.09 Allowed 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 121.961 0.886 . . . . 1.23 111.51 179.351 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.575 ' N ' HD11 ' B' ' 10' ' ' ILE . . . -152.19 24.78 0.89 Allowed Glycine 0 N--CA 1.44 -1.099 0 CA-C-N 114.15 -1.387 . . . . 0.36 109.894 174.026 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.597 ' O ' HG13 ' B' ' 10' ' ' ILE . 13.2 t0 -82.95 124.54 76.66 Favored Pre-proline 0 C--N 1.326 -0.436 0 CA-C-N 114.512 -0.844 . . . . 1.26 109.931 175.68 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.75 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 4.7 Cg_endo -82.94 152.5 14.5 Favored 'Trans proline' 0 N--CA 1.435 -1.939 0 C-N-CA 122.187 1.924 . . . . 1.3 110.719 173.777 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.808 HD11 HG23 ' B' ' 10' ' ' ILE . 0.6 OUTLIER -140.66 152.8 45.66 Favored 'General case' 0 C--N 1.305 -1.362 0 N-CA-C 109.14 -0.689 . . . . 0.38 109.14 171.994 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.933 ' HB3' ' HD2' ' A' ' 47' ' ' LYS . 39.4 tt0 -105.87 111.24 23.81 Favored 'General case' 0 CA--C 1.486 -1.515 0 N-CA-C 107.501 -1.296 . . . . 1.12 107.501 -179.051 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.934 HG13 HD22 ' A' ' 46' ' ' LEU . 2.5 mp -85.17 110.21 19.09 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.98 0 O-C-N 124.648 1.217 . . . . 0.39 108.478 -179.169 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' PHE . . . . . 0.641 ' HB2' ' H ' ' B' ' 4' ' ' THR . 1.8 p90 -150.55 124.61 9.34 Favored 'General case' 0 C--N 1.313 -1.02 0 CA-C-N 116.162 -0.472 . . . . 1.15 109.747 175.6 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.533 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 1.7 p -80.83 136.34 23.4 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 CA-C-O 121.149 0.5 . . . . 0.17 110.778 -178.33 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.684 ' HB3' ' HG3' ' A' ' 40' ' ' ARG . 9.8 t70 -75.59 -45.01 40.14 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.036 -0.984 . . . . 1.11 110.68 -175.498 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' ARG . . . . . 0.684 ' HG3' ' HB3' ' A' ' 39' ' ' ASP . 7.6 mtp180 -132.13 -73.35 0.52 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.672 -0.694 . . . . 2.29 112.267 -165.807 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -129.67 -65.11 0.85 Allowed 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.284 -0.871 . . . . 1.53 111.09 -173.408 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.599 ' HA3' HD11 ' B' ' 26' ' ' LEU . . . -131.88 6.36 5.46 Favored Glycine 0 CA--C 1.501 -0.832 0 CA-C-N 114.838 -1.074 . . . . 0.32 111.812 -173.852 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.556 ' HA ' ' O ' ' B' ' 46' ' ' LEU . 2.2 pm0 -93.58 105.69 17.71 Favored 'General case' 0 N--CA 1.443 -0.793 0 CA-C-O 121.009 0.433 . . . . 1.97 109.929 175.317 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.612 HG11 HG23 ' A' ' 36' ' ' ILE . 2.0 t -88.82 132.31 34.0 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.988 0 CA-C-N 115.566 -0.743 . . . . 0.14 109.864 178.907 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.856 HG13 HG13 ' B' ' 45' ' ' ILE . 1.4 mp -110.11 115.96 51.06 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 N-CA-C 108.239 -1.023 . . . . 0.14 108.239 -177.372 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 1.041 HD11 HD11 ' B' ' 46' ' ' LEU . 0.5 OUTLIER -109.48 116.76 32.41 Favored 'General case' 0 C--N 1.319 -0.759 0 O-C-N 123.703 0.627 . . . . 0.23 109.584 -178.871 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.933 ' HD2' ' HB3' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -122.84 150.37 42.95 Favored 'General case' 0 C--O 1.215 -0.732 0 C-N-CA 119.066 -1.054 . . . . 0.76 112.169 179.121 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.62 ' HA ' ' O ' ' A' ' 33' ' ' PRO . 1.5 ptmt -44.92 -16.45 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.24 0 N-CA-C 117.13 2.27 . . . . 0.32 117.13 -168.188 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 0.765 ' CD1' HG21 ' B' ' 7' ' ' VAL . 19.9 t80 74.35 -50.36 0.68 Allowed 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 112.689 0.625 . . . . 1.28 112.689 174.293 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.71 ' HB3' ' HD3' ' A' ' 51' ' ' PRO . 22.7 t -48.1 -50.83 52.95 Favored Pre-proline 0 CA--C 1.538 0.493 0 C-N-CA 122.585 0.354 . . . . 1.36 111.395 -177.368 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.71 ' HD3' ' HB3' ' A' ' 50' ' ' SER . 36.3 Cg_endo -95.25 10.31 1.66 Allowed 'Trans proline' 0 N--CA 1.453 -0.878 0 C-N-CA 122.601 2.2 . . . . 0.58 111.484 172.31 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 1.1 mt . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 115.044 -0.98 . . . . 0.78 109.262 -170.466 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 3' ' ' ALA . . . . . 0.569 ' HA ' ' HD2' ' A' ' 37' ' ' PHE . . . . . . . . 0 N--CA 1.462 0.174 0 CA-C-O 121.329 0.585 . . . . 0.86 110.546 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 4' ' ' THR . . . . . 0.641 ' H ' ' HB2' ' A' ' 37' ' ' PHE . 28.5 p -107.85 -52.56 2.75 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.634 -0.712 . . . . 0.43 111.068 -176.947 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 82.26 50.98 4.58 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.995 -0.621 . . . . 0.33 112.797 177.164 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 6' ' ' ILE . . . . . 0.805 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.0 OUTLIER -106.68 108.24 24.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 N-CA-C 109.322 -0.621 . . . . 0.3 109.322 173.316 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 7' ' ' VAL . . . . . 0.765 HG21 ' CD1' ' A' ' 49' ' ' TYR . 23.0 t -80.52 136.49 23.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-N 116.231 -0.44 . . . . 0.27 111.217 179.673 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 8' ' ' ARG . . . . . 0.546 ' HD3' ' N ' ' B' ' 9' ' ' ARG . 1.1 tpp180 -131.97 126.94 35.25 Favored 'General case' 0 N--CA 1.446 -0.625 0 N-CA-C 107.61 -1.255 . . . . 1.69 107.61 178.384 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 9' ' ' ARG . . . . . 0.546 ' N ' ' HD3' ' B' ' 8' ' ' ARG . 1.7 tpp180 -86.3 103.22 14.69 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 108.606 -0.887 . . . . 2.71 108.606 173.858 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 10' ' ' ILE . . . . . 0.808 HG23 HD11 ' A' ' 34' ' ' LEU . 0.2 OUTLIER -10.17 -107.37 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.264 0 O-C-N 125.351 1.657 . . . . 0.34 114.749 -177.828 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 11' ' ' ASP . . . . . 0.655 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 1.7 p-10 163.39 -166.38 0.01 OUTLIER 'General case' 0 CA--C 1.518 -0.286 0 N-CA-C 108.327 -0.99 . . . . 1.18 108.327 177.441 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -66.28 -19.85 65.93 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.355 0.598 . . . . 2.39 110.793 -179.04 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 13' ' ' LEU . . . . . 0.442 ' H ' ' CG ' ' B' ' 11' ' ' ASP . 2.9 tm? -101.59 -61.8 1.33 Allowed 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.711 -0.677 . . . . 0.4 110.796 -179.059 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 137.96 19.5 0.55 Allowed Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.807 -0.711 . . . . 0.21 112.116 -178.806 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 15' ' ' ARG . . . . . 0.79 ' HG2' HG22 ' A' ' 17' ' ' VAL . 2.7 mtm180 -70.22 147.65 49.54 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-O 121.244 0.545 . . . . 0.9 110.593 177.361 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 16' ' ' VAL . . . . . 0.713 HG21 HD13 ' A' ' 46' ' ' LEU . 63.7 t -106.69 97.07 5.18 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.237 0 N-CA-C 107.644 -1.243 . . . . 1.27 107.644 166.767 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 17' ' ' VAL . . . . . 0.706 HG22 ' HG2' ' A' ' 15' ' ' ARG . 64.3 t -67.42 98.92 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 CA-C-N 115.62 -0.718 . . . . 0.27 110.364 -171.732 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 18' ' ' ILE . . . . . 0.542 ' H ' ' HA ' ' A' ' 15' ' ' ARG . 6.9 mt -90.45 113.87 59.11 Favored Pre-proline 0 N--CA 1.442 -0.872 0 CA-C-N 115.181 -0.918 . . . . 0.82 110.562 -179.624 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 19' ' ' PRO . . . . . 0.61 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 81.3 Cg_exo -50.19 147.21 16.24 Favored 'Trans proline' 0 N--CA 1.458 -0.59 0 C-N-CA 123.056 2.504 . . . . 0.3 112.567 174.123 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 20' ' ' LYS . . . . . 1.012 ' HD3' ' H ' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -64.94 -15.63 62.36 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 115.649 -0.705 . . . . 1.77 111.678 -178.795 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 21' ' ' GLU . . . . . 0.61 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 1.3 pm0 -63.13 -21.8 66.44 Favored 'General case' 0 C--O 1.237 0.439 0 N-CA-C 111.854 0.316 . . . . 1.92 111.854 177.458 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 5.2 mp -87.61 -47.52 15.69 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 N-CA-C 108.488 -0.93 . . . . 0.44 108.488 -178.406 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 23' ' ' ARG . . . . . 0.558 ' HA ' ' HB2' ' B' ' 26' ' ' LEU . 0.0 OUTLIER -61.93 -28.28 69.42 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.262 -0.881 . . . . 1.4 109.231 174.022 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 24' ' ' ARG . . . . . . . . . . . . . 55.0 ttp180 -65.78 -51.92 55.07 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 114.91 -1.041 . . . . 3.19 110.988 174.639 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 18.7 m -63.65 -28.74 70.12 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-O 121.525 0.679 . . . . 0.4 110.152 176.23 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 26' ' ' LEU . . . . . 0.656 ' HB3' HG13 ' B' ' 28' ' ' ILE . 1.4 mm? -64.08 -19.9 65.57 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 115.009 -0.996 . . . . 0.33 110.678 174.091 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 27' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER 70.8 24.02 4.32 Favored 'General case' 0 C--N 1.342 0.242 0 CA-C-O 121.587 0.708 . . . . 3.28 110.154 -177.105 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 28' ' ' ILE . . . . . 0.809 HG22 ' H ' ' B' ' 29' ' ' ARG . 4.0 mt -119.25 -162.55 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.133 -0.939 . . . . 0.37 110.058 -176.889 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 29' ' ' ARG . . . . . 0.809 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -152.99 -161.42 1.29 Allowed 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 111.618 0.229 . . . . 2.15 111.618 -171.584 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 30' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -72.4 34.06 0.06 Allowed 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 121.858 0.837 . . . . 1.18 111.925 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 31' ' ' GLY . . . . . 0.567 ' N ' HD11 ' A' ' 10' ' ' ILE . . . -150.73 30.31 1.02 Allowed Glycine 0 N--CA 1.436 -1.365 0 N-CA-C 109.636 -1.385 . . . . 0.35 109.636 172.79 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 32' ' ' ASP . . . . . 0.511 ' HB2' ' CG2' ' B' ' 28' ' ' ILE . 6.9 t70 -85.22 128.72 58.62 Favored Pre-proline 0 CA--C 1.511 -0.523 0 CA-C-N 114.451 -0.874 . . . . 1.29 110.271 174.74 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 33' ' ' PRO . . . . . 0.756 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 10.9 Cg_endo -86.76 148.48 8.42 Favored 'Trans proline' 0 N--CA 1.433 -2.07 0 C-N-CA 122.128 1.885 . . . . 1.1 111.469 173.195 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.74 HD11 HG23 ' A' ' 10' ' ' ILE . 0.8 OUTLIER -137.53 148.34 45.9 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 109.273 -0.64 . . . . 0.44 109.273 173.661 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 35' ' ' GLU . . . . . 0.659 ' O ' ' HA ' ' B' ' 46' ' ' LEU . 77.9 tt0 -104.68 111.84 24.71 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 108.11 -1.07 . . . . 1.1 108.11 -179.535 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 36' ' ' ILE . . . . . 0.899 HG13 HD22 ' B' ' 46' ' ' LEU . 3.5 mp -86.1 109.34 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.869 0 O-C-N 124.716 1.26 . . . . 0.62 109.108 -177.964 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 37' ' ' PHE . . . . . 0.434 ' HB2' ' HA ' ' A' ' 3' ' ' ALA . 16.5 p90 -149.82 126.77 11.16 Favored 'General case' 0 C--N 1.316 -0.88 0 CA-C-N 115.922 -0.581 . . . . 1.2 109.954 175.415 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 38' ' ' VAL . . . . . 0.516 ' HA ' ' HA ' ' B' ' 44' ' ' VAL . 1.3 p -80.55 139.62 17.87 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.78 0 CA-C-O 121.361 0.6 . . . . 0.2 111.16 -177.911 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 39' ' ' ASP . . . . . 0.549 ' HB3' ' HG3' ' B' ' 40' ' ' ARG . 7.1 t70 -74.81 -49.86 19.22 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 114.591 -1.186 . . . . 1.14 110.472 -178.009 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 40' ' ' ARG . . . . . 0.549 ' HG3' ' HB3' ' B' ' 39' ' ' ASP . 13.8 mtp180 -132.78 -72.87 0.51 Allowed 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 112.604 0.594 . . . . 2.71 112.604 -168.434 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -124.69 -67.65 0.9 Allowed 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.359 -0.837 . . . . 1.32 110.986 -172.469 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 42' ' ' GLY . . . . . 0.509 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -129.75 9.56 6.08 Favored Glycine 0 N--CA 1.441 -1.028 0 CA-C-N 114.699 -1.137 . . . . 0.34 112.142 -176.094 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 43' ' ' GLU . . . . . 0.48 ' HA ' ' O ' ' A' ' 46' ' ' LEU . 2.3 pm0 -93.13 104.74 16.91 Favored 'General case' 0 N--CA 1.446 -0.625 0 N-CA-C 109.794 -0.447 . . . . 2.07 109.794 176.199 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 44' ' ' VAL . . . . . 0.59 HG11 HG23 ' B' ' 36' ' ' ILE . 2.0 t -89.42 134.05 29.77 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.886 0 N-CA-C 109.805 -0.443 . . . . 0.13 109.805 179.071 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 45' ' ' ILE . . . . . 0.856 HG13 HG13 ' A' ' 45' ' ' ILE . 1.6 mp -110.17 116.36 52.09 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 N-CA-C 108.095 -1.076 . . . . 0.12 108.095 -177.908 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 46' ' ' LEU . . . . . 1.041 HD11 HD11 ' A' ' 46' ' ' LEU . 0.7 OUTLIER -109.4 116.25 31.49 Favored 'General case' 0 C--N 1.317 -0.838 0 O-C-N 123.67 0.606 . . . . 0.15 109.569 179.577 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 47' ' ' LYS . . . . . 0.588 ' HE3' ' HB3' ' B' ' 35' ' ' GLU . 0.0 OUTLIER -125.01 146.36 49.46 Favored 'General case' 0 C--N 1.315 -0.892 0 C-N-CA 119.652 -0.819 . . . . 0.95 112.347 -177.865 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 48' ' ' LYS . . . . . 0.595 ' HA ' ' O ' ' B' ' 33' ' ' PRO . 3.7 ptmt -45.89 -10.61 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.147 0 N-CA-C 117.812 2.523 . . . . 0.64 117.812 -166.301 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 49' ' ' TYR . . . . . 0.756 ' HB3' ' HB2' ' B' ' 33' ' ' PRO . 23.7 t80 72.07 -51.17 0.7 Allowed 'General case' 0 N--CA 1.47 0.559 0 N-CA-C 112.955 0.724 . . . . 1.26 112.955 172.711 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 50' ' ' SER . . . . . 0.605 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 48.3 t -51.4 -56.75 17.91 Favored Pre-proline 0 CA--C 1.535 0.383 0 C-N-CA 122.597 0.359 . . . . 1.22 111.249 -175.133 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 51' ' ' PRO . . . . . 0.605 ' HD3' ' HB3' ' B' ' 50' ' ' SER . 57.8 Cg_endo -88.3 12.35 2.84 Favored 'Trans proline' 0 C--N 1.35 0.649 0 C-N-CA 121.83 1.687 . . . . 0.56 111.44 170.694 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 52' ' ' ILE . . . . . . . . . . . . . 1.3 mt . . . . . 0 CA--C 1.518 -0.273 0 CA-C-N 115.056 -0.975 . . . . 0.73 108.952 -173.943 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.461 0.081 0 CA-C-O 121.545 0.688 . . . . 0.72 111.891 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.763 ' H ' ' HB2' ' B' ' 37' ' ' PHE . 21.4 p -129.59 -57.2 1.13 Allowed 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.539 -0.755 . . . . 0.41 110.636 -178.647 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 85.13 48.95 4.65 Favored Glycine 0 N--CA 1.441 -1.024 0 C-N-CA 120.315 -0.945 . . . . 0.32 112.662 174.274 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.806 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.5 tp -105.49 109.09 26.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 N-CA-C 109.258 -0.645 . . . . 0.31 109.258 173.851 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.757 ' HA ' ' O ' ' B' ' 34' ' ' LEU . 41.7 t -79.76 132.69 31.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 116.135 -0.484 . . . . 0.28 110.715 179.284 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.484 ' HD3' ' N ' ' A' ' 9' ' ' ARG . 1.8 tpp180 -129.24 125.07 36.07 Favored 'General case' 0 N--CA 1.443 -0.781 0 N-CA-C 106.919 -1.512 . . . . 1.99 106.919 -179.821 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ARG . . . . . 0.562 ' C ' HD12 ' A' ' 10' ' ' ILE . 0.6 OUTLIER -86.34 102.26 13.84 Favored 'General case' 0 C--N 1.315 -0.933 0 N-CA-C 108.202 -1.036 . . . . 2.8 108.202 175.346 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.831 HG23 HD11 ' B' ' 34' ' ' LEU . 0.2 OUTLIER -5.56 -105.79 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.016 0 O-C-N 125.645 1.841 . . . . 0.33 114.356 -176.468 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ASP . . . . . 0.623 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 3.3 p-10 161.54 -166.45 0.0 OUTLIER 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 108.64 -0.874 . . . . 1.13 108.64 177.28 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -68.11 -23.01 64.86 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 123.455 0.472 . . . . 2.26 110.94 -177.84 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.421 ' HB3' ' HD2' ' A' ' 15' ' ' ARG . 2.5 tm? -100.64 -55.66 2.53 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.331 -0.395 . . . . 0.53 110.448 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.56 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 134.32 18.0 0.95 Allowed Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.449 -0.882 . . . . 0.22 113.069 -179.435 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.544 ' HG2' HG22 ' B' ' 17' ' ' VAL . 0.4 OUTLIER -76.66 156.19 32.8 Favored 'General case' 0 CA--C 1.51 -0.562 0 CA-C-N 117.625 0.712 . . . . 0.69 110.301 -179.564 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.736 HG21 HD13 ' B' ' 46' ' ' LEU . 89.8 t -111.04 98.3 6.88 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.23 0 N-CA-C 107.728 -1.212 . . . . 1.24 107.728 167.637 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.58 HG22 ' HG2' ' B' ' 15' ' ' ARG . 39.4 t -65.05 106.95 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 CA-C-N 115.249 -0.887 . . . . 0.28 109.675 -173.702 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.452 ' HB ' ' O ' ' B' ' 14' ' ' GLY . 30.9 mm -95.82 107.88 36.88 Favored Pre-proline 0 N--CA 1.447 -0.625 0 CA-C-N 115.691 -0.686 . . . . 0.77 110.117 -178.017 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.699 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 62.2 Cg_exo -47.44 146.06 7.85 Favored 'Trans proline' 0 N--CA 1.454 -0.821 0 C-N-CA 122.6 2.2 . . . . 0.32 112.718 175.402 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.957 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -64.61 -14.0 55.93 Favored 'General case' 0 C--N 1.314 -0.935 0 CA-C-N 115.766 -0.652 . . . . 1.57 111.251 179.813 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.699 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 11.5 pt-20 -63.78 -23.05 67.21 Favored 'General case' 0 C--O 1.239 0.501 0 N-CA-C 112.349 0.5 . . . . 1.32 112.349 178.285 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.406 HD13 HG23 ' A' ' 18' ' ' ILE . 5.2 mp -87.39 -46.49 16.1 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.334 0 N-CA-C 108.096 -1.076 . . . . 0.35 108.096 -178.635 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ARG . . . . . 0.69 ' HA ' ' HB2' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -61.41 -27.19 68.36 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 114.941 -1.027 . . . . 1.5 109.219 172.994 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 74.9 ttt180 -63.26 -51.48 65.99 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 114.75 -1.114 . . . . 2.96 111.116 173.315 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 28.7 m -61.69 -31.14 71.26 Favored 'General case' 0 CA--C 1.532 0.252 0 CA-C-O 121.147 0.498 . . . . 0.4 110.636 172.757 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.69 ' HB2' ' HA ' ' A' ' 23' ' ' ARG . 3.2 mm? -64.92 -21.35 66.81 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.617 -0.72 . . . . 0.36 110.71 173.855 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 2.0 mpt_? 70.39 21.96 5.48 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 123.455 0.702 . . . . 3.2 110.943 -176.764 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.769 HG22 ' H ' ' A' ' 29' ' ' ARG . 5.3 mt -117.49 -166.5 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.786 0 CA-C-N 115.159 -0.928 . . . . 0.48 108.932 -177.896 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.769 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -148.5 -153.69 0.51 Allowed 'General case' 0 C--N 1.323 -0.557 0 O-C-N 122.13 -0.356 . . . . 2.4 111.286 -175.157 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 30' ' ' GLU . . . . . 0.449 ' H ' ' HB2' ' A' ' 29' ' ' ARG . 0.6 OUTLIER -75.72 44.66 0.3 Allowed 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 122.089 0.947 . . . . 1.23 112.188 -177.787 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.664 ' CA ' HD11 ' B' ' 10' ' ' ILE . . . -159.31 29.3 0.4 Allowed Glycine 0 N--CA 1.441 -1.006 0 CA-C-N 113.975 -1.466 . . . . 0.36 109.547 172.466 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.59 ' O ' HG13 ' B' ' 10' ' ' ILE . 11.8 t70 -88.81 128.9 50.58 Favored Pre-proline 0 CA--C 1.514 -0.407 0 N-CA-C 109.351 -0.611 . . . . 1.26 109.351 174.549 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.73 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 3.8 Cg_endo -83.81 150.04 12.64 Favored 'Trans proline' 0 N--CA 1.435 -1.936 0 C-N-CA 122.18 1.92 . . . . 1.3 110.804 175.175 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.803 HD11 HG23 ' B' ' 10' ' ' ILE . 0.6 OUTLIER -139.68 153.75 47.34 Favored 'General case' 0 N--CA 1.43 -1.428 0 N-CA-C 109.302 -0.629 . . . . 0.38 109.302 172.023 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.919 ' HB3' ' HD2' ' A' ' 47' ' ' LYS . 33.8 tt0 -109.25 114.57 28.38 Favored 'General case' 0 C--N 1.297 -1.675 0 N-CA-C 108.392 -0.966 . . . . 1.12 108.392 -178.316 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.878 HG13 HD22 ' A' ' 46' ' ' LEU . 3.2 mp -86.12 110.05 19.42 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.944 0 O-C-N 124.843 1.339 . . . . 0.39 109.226 -178.766 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' PHE . . . . . 0.668 ' HD1' ' HA ' ' B' ' 3' ' ' ALA . 0.5 OUTLIER -149.76 125.74 10.57 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 116.211 -0.45 . . . . 1.15 109.874 175.488 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.533 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 1.2 p -80.51 137.09 22.06 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 CA-C-O 121.191 0.52 . . . . 0.17 110.749 -179.854 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.517 ' HB3' ' HG2' ' A' ' 40' ' ' ARG . 9.9 t70 -88.65 -64.93 1.07 Allowed 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 114.617 -1.174 . . . . 1.11 111.902 -171.459 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' ARG . . . . . 0.525 ' H ' ' HG2' ' A' ' 40' ' ' ARG . 0.0 OUTLIER -106.58 -84.37 0.52 Allowed 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 114.899 -1.046 . . . . 2.29 111.303 -165.759 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -111.37 -72.58 0.71 Allowed 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.12 -0.491 . . . . 1.53 110.88 -177.518 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -130.35 24.66 4.4 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.776 -0.726 . . . . 0.32 111.638 179.276 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.555 ' HB3' HG23 ' B' ' 45' ' ' ILE . 2.3 mt-10 -97.95 113.0 24.72 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.126 -0.694 . . . . 1.97 109.126 178.465 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.533 ' HA ' ' HA ' ' A' ' 38' ' ' VAL . 1.8 t -90.4 132.95 33.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 N-CA-C 109.573 -0.529 . . . . 0.14 109.573 178.942 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.797 HG13 HG13 ' B' ' 45' ' ' ILE . 1.6 mp -111.68 117.5 55.28 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 N-CA-C 108.575 -0.898 . . . . 0.14 108.575 -175.389 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.998 HD11 HD11 ' B' ' 46' ' ' LEU . 0.5 OUTLIER -110.13 117.09 32.79 Favored 'General case' 0 C--N 1.32 -0.706 0 O-C-N 123.676 0.61 . . . . 0.23 109.874 179.825 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.919 ' HD2' ' HB3' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -126.44 151.9 47.12 Favored 'General case' 0 C--O 1.219 -0.55 0 C-N-CA 119.02 -1.072 . . . . 0.76 112.792 179.132 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.649 ' HA ' ' O ' ' A' ' 33' ' ' PRO . 1.9 ptmt -43.58 -16.29 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.09 0 N-CA-C 117.263 2.32 . . . . 0.32 117.263 -168.381 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 0.758 ' CD1' HG21 ' B' ' 7' ' ' VAL . 17.9 t80 73.22 -54.58 0.69 Allowed 'General case' 0 N--CA 1.469 0.521 0 N-CA-C 112.561 0.578 . . . . 1.28 112.561 174.379 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.687 ' HB3' ' HD3' ' A' ' 51' ' ' PRO . 19.6 t -50.85 -49.82 77.7 Favored Pre-proline 0 CA--C 1.537 0.473 0 O-C-N 123.335 0.397 . . . . 1.36 111.387 -175.105 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.687 ' HD3' ' HB3' ' A' ' 50' ' ' SER . 86.5 Cg_endo -96.18 12.45 1.21 Allowed 'Trans proline' 0 N--CA 1.453 -0.861 0 C-N-CA 122.401 2.067 . . . . 0.58 111.658 171.213 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 1.3 mt . . . . . 0 C--O 1.234 0.281 0 CA-C-N 115.423 -0.808 . . . . 0.78 109.083 -173.946 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 3' ' ' ALA . . . . . 0.668 ' HA ' ' HD1' ' A' ' 37' ' ' PHE . . . . . . . . 0 N--CA 1.463 0.192 0 CA-C-O 121.512 0.672 . . . . 0.86 110.419 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 4' ' ' THR . . . . . 0.666 ' H ' ' HB2' ' A' ' 37' ' ' PHE . 11.3 p -115.87 -46.74 2.82 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.022 -0.535 . . . . 0.43 111.248 -178.713 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 73.01 49.72 15.54 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 120.929 -0.653 . . . . 0.33 113.137 172.893 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 6' ' ' ILE . . . . . 0.856 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.0 OUTLIER -106.73 110.55 32.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 N-CA-C 109.104 -0.702 . . . . 0.3 109.104 174.841 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 7' ' ' VAL . . . . . 0.758 HG21 ' CD1' ' A' ' 49' ' ' TYR . 38.9 t -80.51 134.66 26.88 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.308 0.575 . . . . 0.27 111.389 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 8' ' ' ARG . . . . . 0.524 ' HB3' ' CD1' ' A' ' 36' ' ' ILE . 8.4 tpp180 -130.1 121.45 26.38 Favored 'General case' 0 N--CA 1.44 -0.948 0 N-CA-C 107.541 -1.281 . . . . 1.69 107.541 -177.47 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 9' ' ' ARG . . . . . 0.48 ' HA ' ' HA ' ' A' ' 33' ' ' PRO . 15.9 ttt180 -84.45 103.43 13.6 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 108.084 -1.08 . . . . 2.71 108.084 173.766 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 10' ' ' ILE . . . . . 0.803 HG23 HD11 ' A' ' 34' ' ' LEU . 0.4 OUTLIER -9.2 -101.61 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.996 0 O-C-N 125.665 1.853 . . . . 0.34 114.398 -174.707 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 11' ' ' ASP . . . . . 0.645 ' H ' HD13 ' B' ' 10' ' ' ILE . 5.5 p-10 164.21 -154.07 0.0 OUTLIER 'General case' 0 C--O 1.219 -0.504 0 N-CA-C 108.773 -0.825 . . . . 1.18 108.773 174.555 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -85.2 -9.18 58.1 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.047 0.451 . . . . 2.39 110.617 -178.778 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 13' ' ' LEU . . . . . 0.453 ' HB3' ' HD2' ' B' ' 15' ' ' ARG . 3.0 tm? -109.5 -56.43 2.3 Favored 'General case' 0 N--CA 1.448 -0.537 0 CA-C-N 116.075 -0.511 . . . . 0.4 109.935 176.496 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 14' ' ' GLY . . . . . 0.452 ' O ' ' HB ' ' A' ' 18' ' ' ILE . . . 133.16 20.85 0.89 Allowed Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.764 -0.732 . . . . 0.21 112.689 -178.972 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 15' ' ' ARG . . . . . 0.58 ' HG2' HG22 ' A' ' 17' ' ' VAL . 1.5 mpt_? -78.23 154.08 31.35 Favored 'General case' 0 CA--C 1.509 -0.606 0 O-C-N 122.066 -0.667 . . . . 0.9 110.189 179.293 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 16' ' ' VAL . . . . . 0.726 HG21 HD13 ' A' ' 46' ' ' LEU . 96.7 t -109.11 95.96 4.26 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 N-CA-C 107.475 -1.305 . . . . 1.27 107.475 168.722 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 17' ' ' VAL . . . . . 0.544 HG22 ' HG2' ' A' ' 15' ' ' ARG . 47.0 t -64.32 104.84 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.842 0 CA-C-N 114.96 -1.018 . . . . 0.27 109.914 -173.04 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 18' ' ' ILE . . . . . 0.56 ' HB ' ' O ' ' A' ' 14' ' ' GLY . 26.6 mm -92.48 111.26 49.87 Favored Pre-proline 0 N--CA 1.446 -0.633 0 CA-C-N 115.647 -0.706 . . . . 0.82 110.574 -177.463 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 19' ' ' PRO . . . . . 0.68 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 59.1 Cg_exo -48.49 142.39 17.79 Favored 'Trans proline' 0 N--CA 1.459 -0.534 0 C-N-CA 123.041 2.494 . . . . 0.3 112.53 172.828 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 20' ' ' LYS . . . . . 0.952 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -59.44 -16.14 21.78 Favored 'General case' 0 C--O 1.211 -0.949 0 CA-C-N 115.243 -0.889 . . . . 1.77 111.428 178.954 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 21' ' ' GLU . . . . . 0.68 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 10.6 pt-20 -65.5 -20.0 66.16 Favored 'General case' 0 C--O 1.234 0.284 0 N-CA-C 112.034 0.383 . . . . 1.92 112.034 -178.226 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 5.2 mp -87.26 -49.14 14.97 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 N-CA-C 108.433 -0.951 . . . . 0.44 108.433 179.848 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 23' ' ' ARG . . . . . 0.627 ' NE ' ' HA ' ' B' ' 29' ' ' ARG . 0.0 OUTLIER -55.33 -32.41 62.49 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-O 122.057 0.932 . . . . 1.4 109.194 171.073 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 24' ' ' ARG . . . . . 0.475 ' N ' ' HD3' ' B' ' 23' ' ' ARG . 50.1 ttt180 -61.12 -53.72 53.52 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-N 114.021 -1.445 . . . . 3.19 111.195 176.222 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 53.7 m -61.07 -33.52 73.46 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-O 121.275 0.559 . . . . 0.4 110.418 173.806 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 26' ' ' LEU . . . . . 0.552 ' HB2' ' HA ' ' B' ' 23' ' ' ARG . 1.5 mm? -63.98 -20.26 65.76 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.21 -0.904 . . . . 0.33 111.339 177.775 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 27' ' ' ARG . . . . . . . . . . . . . 6.5 mpt_? 69.79 28.38 4.37 Favored 'General case' 0 N--CA 1.471 0.6 0 CA-C-O 121.18 0.514 . . . . 3.28 110.505 -176.686 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 28' ' ' ILE . . . . . 0.847 HG22 ' H ' ' B' ' 29' ' ' ARG . 7.6 mt -122.47 -159.44 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 115.889 -0.596 . . . . 0.37 109.924 -175.583 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 29' ' ' ARG . . . . . 0.847 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.1 OUTLIER -155.33 -159.9 0.98 Allowed 'General case' 0 N--CA 1.467 0.42 0 N-CA-C 112.496 0.554 . . . . 2.15 112.496 -174.476 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 30' ' ' GLU . . . . . 0.422 ' H ' ' HB2' ' B' ' 29' ' ' ARG . 38.6 mp0 -69.87 36.93 0.04 OUTLIER 'General case' 0 N--CA 1.472 0.655 0 CA-C-O 122.019 0.914 . . . . 1.18 112.053 178.636 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 31' ' ' GLY . . . . . 0.608 ' CA ' HD11 ' A' ' 10' ' ' ILE . . . -156.46 32.97 0.59 Allowed Glycine 0 N--CA 1.431 -1.663 0 N-CA-C 109.547 -1.421 . . . . 0.35 109.547 175.712 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 32' ' ' ASP . . . . . 0.536 ' O ' HG13 ' A' ' 10' ' ' ILE . 19.2 t0 -92.46 125.55 55.62 Favored Pre-proline 0 C--N 1.323 -0.569 0 CA-C-N 114.861 -0.669 . . . . 1.29 109.259 173.529 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 33' ' ' PRO . . . . . 0.82 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 3.5 Cg_endo -79.55 151.66 22.57 Favored 'Trans proline' 0 N--CA 1.436 -1.888 0 C-N-CA 122.216 1.944 . . . . 1.1 110.043 174.215 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.831 HD11 HG23 ' A' ' 10' ' ' ILE . 0.8 OUTLIER -140.73 149.35 42.04 Favored 'General case' 0 C--N 1.305 -1.326 0 N-CA-C 109.444 -0.576 . . . . 0.44 109.444 172.434 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 35' ' ' GLU . . . . . 0.646 ' O ' ' HA ' ' B' ' 46' ' ' LEU . 72.1 tt0 -104.04 112.28 25.21 Favored 'General case' 0 CA--C 1.487 -1.471 0 N-CA-C 107.359 -1.348 . . . . 1.1 107.359 -179.272 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 36' ' ' ILE . . . . . 0.895 HG13 HD22 ' B' ' 46' ' ' LEU . 2.5 mp -86.47 111.07 20.87 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.148 0 O-C-N 124.615 1.197 . . . . 0.62 108.675 179.331 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 37' ' ' PHE . . . . . 0.763 ' HB2' ' H ' ' A' ' 4' ' ' THR . 17.9 p90 -150.29 129.28 12.59 Favored 'General case' 0 C--N 1.314 -0.96 0 N-CA-C 109.392 -0.596 . . . . 1.2 109.392 172.613 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 38' ' ' VAL . . . . . 0.561 ' HA ' ' HA ' ' B' ' 44' ' ' VAL . 1.4 p -83.62 129.91 36.73 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.114 0 CA-C-O 121.255 0.55 . . . . 0.2 111.539 -175.369 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 39' ' ' ASP . . . . . 0.688 ' HB3' ' HD3' ' B' ' 40' ' ' ARG . 0.5 OUTLIER -94.28 171.36 8.88 Favored 'General case' 0 N--CA 1.443 -0.777 0 N-CA-C 108.036 -1.098 . . . . 1.14 108.036 173.634 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 40' ' ' ARG . . . . . 0.688 ' HD3' ' HB3' ' B' ' 39' ' ' ASP . 0.0 OUTLIER 41.64 -107.22 0.08 Allowed 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 113.811 1.041 . . . . 2.71 113.811 176.902 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -108.13 -82.98 0.55 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.076 0.465 . . . . 1.32 111.368 -174.362 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 42' ' ' GLY . . . . . . . . . . . . . . . -118.93 26.15 7.64 Favored Glycine 0 N--CA 1.444 -0.78 0 C-N-CA 120.92 -0.657 . . . . 0.34 111.89 -175.976 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 43' ' ' GLU . . . . . 0.64 ' HB3' HG23 ' A' ' 45' ' ' ILE . 2.0 mt-10 -96.79 111.9 23.88 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 109.633 -0.506 . . . . 2.07 109.633 178.082 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 44' ' ' VAL . . . . . 0.561 ' HA ' ' HA ' ' B' ' 38' ' ' VAL . 1.9 t -88.23 132.63 32.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 N-CA-C 109.575 -0.528 . . . . 0.13 109.575 178.204 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 45' ' ' ILE . . . . . 0.797 HG13 HG13 ' A' ' 45' ' ' ILE . 1.5 mp -108.97 119.36 58.39 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 N-CA-C 108.206 -1.035 . . . . 0.12 108.206 -177.352 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 46' ' ' LEU . . . . . 0.998 HD11 HD11 ' A' ' 46' ' ' LEU . 0.7 OUTLIER -112.37 117.1 31.51 Favored 'General case' 0 C--N 1.317 -0.817 0 O-C-N 123.68 0.612 . . . . 0.15 110.008 178.217 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 47' ' ' LYS . . . . . 0.587 ' O ' ' HA ' ' B' ' 34' ' ' LEU . 0.0 OUTLIER -129.78 149.33 51.57 Favored 'General case' 0 C--O 1.215 -0.72 0 C-N-CA 119.492 -0.883 . . . . 0.95 113.03 -179.841 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 48' ' ' LYS . . . . . 0.602 ' HA ' ' O ' ' B' ' 33' ' ' PRO . 1.7 ptmt -39.75 -21.35 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.244 0 N-CA-C 117.658 2.466 . . . . 0.64 117.658 -168.086 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 49' ' ' TYR . . . . . 0.82 ' HB3' ' HB2' ' B' ' 33' ' ' PRO . 23.3 t80 75.1 -46.58 0.59 Allowed 'General case' 0 N--CA 1.47 0.568 0 CA-C-N 119.095 0.861 . . . . 1.26 111.282 177.996 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 50' ' ' SER . . . . . 0.664 ' OG ' ' HD3' ' B' ' 51' ' ' PRO . 1.6 p -50.14 -48.38 79.64 Favored Pre-proline 0 CA--C 1.544 0.737 0 CA-C-N 115.519 -0.764 . . . . 1.22 112.395 -175.528 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 51' ' ' PRO . . . . . 0.664 ' HD3' ' OG ' ' B' ' 50' ' ' SER . 33.1 Cg_endo -103.06 14.03 0.29 Allowed 'Trans proline' 0 N--CA 1.454 -0.831 0 C-N-CA 122.976 2.45 . . . . 0.56 111.733 170.241 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 52' ' ' ILE . . . . . . . . . . . . . 1.1 mt . . . . . 0 C--N 1.328 -0.356 0 N-CA-C 108.516 -0.92 . . . . 0.73 108.516 -168.661 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 3' ' ' ALA . . . . . 0.478 ' HA ' ' HB2' ' B' ' 37' ' ' PHE . . . . . . . . 0 N--CA 1.463 0.214 0 CA-C-O 121.608 0.718 . . . . 0.72 109.75 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 31.0 p -84.53 -31.74 24.26 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.201 -0.909 . . . . 0.41 112.521 -169.574 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' GLY . . . . . 0.583 ' H ' ' HB3' ' B' ' 37' ' ' PHE . . . 61.01 49.19 81.35 Favored Glycine 0 N--CA 1.446 -0.66 0 C-N-CA 120.767 -0.73 . . . . 0.32 113.074 176.567 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.85 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.6 tp -105.73 104.41 16.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 N-CA-C 109.173 -0.677 . . . . 0.31 109.173 174.823 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.615 HG21 ' CD1' ' B' ' 49' ' ' TYR . 38.0 t -74.25 133.04 32.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 115.719 -0.673 . . . . 0.28 110.088 179.696 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.667 ' HB3' ' CD1' ' B' ' 36' ' ' ILE . 3.3 tpp180 -129.43 119.4 23.74 Favored 'General case' 0 N--CA 1.437 -1.077 0 N-CA-C 106.809 -1.552 . . . . 1.99 106.809 -178.75 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' ARG . . . . . 0.53 ' HA ' ' O ' ' B' ' 32' ' ' ASP . 9.4 ttp180 -83.37 102.76 12.23 Favored 'General case' 0 C--N 1.312 -1.024 0 N-CA-C 108.553 -0.906 . . . . 2.8 108.553 176.183 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.756 HG23 HD11 ' B' ' 34' ' ' LEU . 0.2 OUTLIER -9.62 -103.23 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 O-C-N 125.62 1.825 . . . . 0.33 114.525 -177.108 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ASP . . . . . 0.603 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 4.3 p-10 161.43 -162.62 0.0 OUTLIER 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 108.31 -0.996 . . . . 1.13 108.31 176.86 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -71.27 -24.73 62.22 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.15 0.5 . . . . 2.26 110.803 -178.109 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -95.22 -58.98 1.99 Allowed 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.112 -0.494 . . . . 0.53 110.212 178.551 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.531 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 135.64 17.72 0.83 Allowed Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.595 -0.812 . . . . 0.22 112.92 -177.998 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.664 ' HG2' HG22 ' B' ' 17' ' ' VAL . 1.4 mpt_? -74.73 153.11 38.98 Favored 'General case' 0 CA--C 1.507 -0.689 0 O-C-N 122.139 -0.624 . . . . 0.69 110.033 179.299 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.749 HG21 HD13 ' B' ' 46' ' ' LEU . 93.3 t -108.39 95.93 4.22 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.29 0 N-CA-C 107.662 -1.236 . . . . 1.24 107.662 169.239 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.644 HG22 ' HG2' ' B' ' 15' ' ' ARG . 91.0 t -64.54 99.37 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-N 115.131 -0.94 . . . . 0.28 110.085 -174.121 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.473 ' HB ' ' O ' ' B' ' 14' ' ' GLY . 38.6 mm -87.47 112.05 45.73 Favored Pre-proline 0 N--CA 1.446 -0.659 0 CA-C-N 115.543 -0.753 . . . . 0.77 109.854 -179.515 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.568 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 91.9 Cg_exo -50.79 140.72 37.34 Favored 'Trans proline' 0 N--CA 1.452 -0.963 0 C-N-CA 122.267 1.978 . . . . 0.32 111.738 173.566 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.982 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -61.12 -14.95 28.12 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.675 -0.693 . . . . 1.57 111.47 -177.992 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.568 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 11.3 pt-20 -66.77 -21.4 66.06 Favored 'General case' 0 C--O 1.237 0.442 0 N-CA-C 112.182 0.438 . . . . 1.32 112.182 -178.685 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.2 mp -87.91 -45.27 15.98 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 107.997 -1.112 . . . . 0.35 107.997 -179.772 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ARG . . . . . 0.733 ' HA ' ' HB2' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -60.35 -29.37 68.86 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 115.285 -0.871 . . . . 1.5 109.18 172.448 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.473 ' HB3' ' O ' ' A' ' 21' ' ' GLU . 58.7 ttt180 -60.42 -52.6 64.52 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 114.403 -1.271 . . . . 2.96 110.484 173.833 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 19.8 m -69.2 -21.21 63.97 Favored 'General case' 0 CA--C 1.53 0.177 0 CA-C-O 121.295 0.569 . . . . 0.4 110.904 175.11 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.791 ' HB3' HG13 ' A' ' 28' ' ' ILE . 0.8 OUTLIER -67.55 -18.37 65.0 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.974 -0.557 . . . . 0.36 111.2 176.418 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.466 ' HB2' ' O ' ' A' ' 26' ' ' LEU . 0.0 OUTLIER 70.51 20.46 5.89 Favored 'General case' 0 C--N 1.343 0.324 0 CA-C-O 121.299 0.571 . . . . 3.2 110.009 -172.397 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.791 HG13 ' HB3' ' A' ' 26' ' ' LEU . 3.0 mt -119.22 -164.87 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.535 -0.757 . . . . 0.48 109.855 -176.086 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.732 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -158.3 -156.97 0.59 Allowed 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 110.382 -0.229 . . . . 2.4 110.382 -167.988 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 30' ' ' GLU . . . . . 0.404 ' C ' HD11 ' B' ' 10' ' ' ILE . 1.6 mp0 -72.95 38.48 0.08 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 122.213 1.006 . . . . 1.23 111.034 176.34 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.639 ' N ' HD11 ' B' ' 10' ' ' ILE . . . -152.55 26.17 0.85 Allowed Glycine 0 N--CA 1.435 -1.411 0 CA-C-N 113.854 -1.521 . . . . 0.36 110.4 176.023 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.495 ' HA ' ' HD3' ' A' ' 33' ' ' PRO . 63.8 t0 -84.12 114.22 53.08 Favored Pre-proline 0 C--N 1.331 -0.205 0 CA-C-O 121.279 0.562 . . . . 1.26 109.768 175.627 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.595 ' HA ' ' HA ' ' B' ' 9' ' ' ARG . 1.2 Cg_endo -88.97 54.76 1.95 Allowed 'Trans proline' 0 CA--C 1.507 -0.874 0 C-N-CA 124.158 3.239 . . . . 1.3 114.108 -175.188 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.609 HD12 ' H ' ' A' ' 34' ' ' LEU . 1.0 OUTLIER -57.38 153.6 12.21 Favored 'General case' 0 C--N 1.297 -1.676 0 CA-C-O 122.299 1.047 . . . . 0.38 112.352 -173.768 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.824 ' HB3' ' HB3' ' A' ' 47' ' ' LYS . 33.8 tt0 -105.07 118.47 36.62 Favored 'General case' 0 CA--C 1.492 -1.259 0 CA-C-N 113.492 -1.685 . . . . 1.12 107.505 -175.594 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.884 ' HB ' HG23 ' B' ' 6' ' ' ILE . 2.6 mp -88.28 110.16 20.72 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.014 0 O-C-N 123.847 0.717 . . . . 0.39 109.265 179.467 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' PHE . . . . . 0.784 ' HD1' ' HA ' ' B' ' 3' ' ' ALA . 0.8 OUTLIER -150.18 124.84 9.72 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 109.785 -0.45 . . . . 1.15 109.785 174.557 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.525 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 1.4 p -80.91 137.83 20.69 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.978 0 CA-C-O 121.053 0.454 . . . . 0.17 110.716 -179.232 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.596 ' OD2' ' HD2' ' A' ' 40' ' ' ARG . 3.6 t70 -85.4 -55.49 3.99 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.444 -0.798 . . . . 1.11 111.514 -173.633 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' ARG . . . . . 0.596 ' HD2' ' OD2' ' A' ' 39' ' ' ASP . 0.2 OUTLIER -119.91 -91.61 0.55 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.517 -0.765 . . . . 2.29 111.981 -169.554 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -99.01 -69.58 0.76 Allowed 'General case' 0 CA--C 1.511 -0.548 0 CA-C-O 121.345 0.593 . . . . 1.53 110.571 -176.206 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.729 ' HA3' HD11 ' B' ' 26' ' ' LEU . . . -135.54 21.74 3.58 Favored Glycine 0 N--CA 1.437 -1.261 0 CA-C-N 114.97 -1.013 . . . . 0.32 111.696 -176.787 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.621 ' HB3' HG23 ' B' ' 45' ' ' ILE . 2.1 mt-10 -95.38 109.15 21.36 Favored 'General case' 0 N--CA 1.447 -0.602 0 N-CA-C 109.099 -0.704 . . . . 1.97 109.099 177.381 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.528 ' CG1' HG23 ' A' ' 36' ' ' ILE . 1.7 t -90.09 132.11 35.6 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.941 0 N-CA-C 109.214 -0.661 . . . . 0.14 109.214 178.467 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.754 HG13 HG13 ' B' ' 45' ' ' ILE . 1.6 mp -108.21 119.55 58.0 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 N-CA-C 108.262 -1.014 . . . . 0.14 108.262 -176.104 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.926 HD11 HD11 ' B' ' 46' ' ' LEU . 6.9 mt -103.61 121.9 43.88 Favored 'General case' 0 C--N 1.322 -0.599 0 O-C-N 124.221 0.951 . . . . 0.23 110.033 179.616 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.824 ' HB3' ' HB3' ' A' ' 35' ' ' GLU . 21.6 ttmt -126.98 123.3 36.79 Favored 'General case' 0 C--N 1.308 -1.216 0 CA-C-N 115.454 -0.793 . . . . 0.76 112.576 -168.18 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.57 ' O ' ' HD2' ' A' ' 33' ' ' PRO . 3.1 ptmt -39.0 -19.24 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.648 0 N-CA-C 116.948 2.203 . . . . 0.32 116.948 -172.849 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 0.661 ' CD1' HG21 ' B' ' 7' ' ' VAL . 27.1 t80 74.72 -56.02 0.64 Allowed 'General case' 0 N--CA 1.475 0.823 0 C-N-CA 123.83 0.852 . . . . 1.28 113.001 173.414 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.681 ' HB3' ' HD3' ' A' ' 51' ' ' PRO . 48.2 t -49.62 -53.61 39.55 Favored Pre-proline 0 CA--C 1.535 0.373 0 CA-C-N 115.807 -0.633 . . . . 1.36 111.433 -175.072 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.681 ' HD3' ' HB3' ' A' ' 50' ' ' SER . 46.2 Cg_endo -95.26 14.32 1.21 Allowed 'Trans proline' 0 N--CA 1.456 -0.723 0 C-N-CA 122.27 1.98 . . . . 0.58 111.452 170.652 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 2.6 mt . . . . . 0 C--N 1.325 -0.473 0 N-CA-C 108.587 -0.894 . . . . 0.78 108.587 -172.433 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 3' ' ' ALA . . . . . 0.784 ' HA ' ' HD1' ' A' ' 37' ' ' PHE . . . . . . . . 0 N--CA 1.462 0.174 0 CA-C-O 121.555 0.693 . . . . 0.86 110.169 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 4' ' ' THR . . . . . . . . . . . . . 25.0 p -82.41 -32.02 29.31 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.162 -0.926 . . . . 0.43 112.498 -171.141 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 5' ' ' GLY . . . . . 0.472 ' H ' ' CB ' ' A' ' 37' ' ' PHE . . . 61.44 45.27 96.73 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 121.14 -0.552 . . . . 0.33 113.128 176.728 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 6' ' ' ILE . . . . . 0.884 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.1 tp -104.17 104.74 17.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.517 0.675 . . . . 0.3 109.556 178.066 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 7' ' ' VAL . . . . . 0.661 HG21 ' CD1' ' A' ' 49' ' ' TYR . 4.9 t -74.84 131.46 34.96 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.872 0 CA-C-N 115.178 -0.919 . . . . 0.27 110.896 -179.158 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 8' ' ' ARG . . . . . 0.474 ' HB3' ' CD1' ' A' ' 36' ' ' ILE . 0.1 OUTLIER -129.56 118.15 21.58 Favored 'General case' 0 N--CA 1.447 -0.593 0 N-CA-C 107.031 -1.47 . . . . 1.69 107.031 177.737 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 9' ' ' ARG . . . . . 0.595 ' HA ' ' HA ' ' A' ' 33' ' ' PRO . 26.7 ttp180 -79.85 104.84 10.7 Favored 'General case' 0 N--CA 1.44 -0.969 0 C-N-CA 119.789 -0.764 . . . . 2.71 109.001 174.527 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 10' ' ' ILE . . . . . 0.65 ' O ' ' HB3' ' B' ' 11' ' ' ASP . 0.3 OUTLIER -11.91 -102.75 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 O-C-N 125.705 1.878 . . . . 0.34 114.644 -176.051 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 11' ' ' ASP . . . . . 0.65 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 2.8 p-10 160.07 -165.81 0.0 OUTLIER 'General case' 0 C--N 1.342 0.249 0 N-CA-C 107.871 -1.159 . . . . 1.18 107.871 177.964 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -68.21 -30.75 69.9 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 120.967 0.413 . . . . 2.39 110.616 -179.131 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 13' ' ' LEU . . . . . 0.528 ' HB3' ' HD2' ' B' ' 15' ' ' ARG . 3.1 tm? -85.61 -59.27 2.36 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.066 -0.515 . . . . 0.4 110.101 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 14' ' ' GLY . . . . . 0.473 ' O ' ' HB ' ' A' ' 18' ' ' ILE . . . 131.46 16.29 1.52 Allowed Glycine 0 N--CA 1.445 -0.711 0 C-N-CA 120.327 -0.939 . . . . 0.21 112.727 -178.112 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 15' ' ' ARG . . . . . 0.644 ' HG2' HG22 ' A' ' 17' ' ' VAL . 0.3 OUTLIER -74.8 153.3 38.81 Favored 'General case' 0 CA--C 1.507 -0.674 0 C-N-CA 119.709 -0.796 . . . . 0.9 109.826 178.138 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 16' ' ' VAL . . . . . 0.872 HG21 HD13 ' A' ' 46' ' ' LEU . 95.9 t -108.53 98.01 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.316 0 N-CA-C 107.725 -1.213 . . . . 1.27 107.725 169.721 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 17' ' ' VAL . . . . . 0.664 HG22 ' HG2' ' A' ' 15' ' ' ARG . 57.6 t -66.69 99.58 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.877 0 CA-C-N 114.963 -1.017 . . . . 0.27 110.14 -172.259 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 18' ' ' ILE . . . . . 0.531 ' HB ' ' O ' ' A' ' 14' ' ' GLY . 39.1 mm -86.92 111.7 42.23 Favored Pre-proline 0 C--N 1.323 -0.569 0 CA-C-N 115.321 -0.854 . . . . 0.82 109.978 -179.376 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 19' ' ' PRO . . . . . 0.561 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 86.4 Cg_exo -50.61 139.85 37.77 Favored 'Trans proline' 0 N--CA 1.453 -0.909 0 C-N-CA 122.392 2.061 . . . . 0.3 111.607 172.994 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 20' ' ' LYS . . . . . 1.024 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -61.07 -13.31 15.99 Favored 'General case' 0 C--N 1.313 -0.979 0 CA-C-N 115.442 -0.799 . . . . 1.77 111.64 -178.35 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 21' ' ' GLU . . . . . 0.561 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 10.4 pt-20 -67.01 -22.98 65.87 Favored 'General case' 0 C--O 1.237 0.444 0 N-CA-C 112.614 0.598 . . . . 1.92 112.614 179.751 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 4.6 mp -88.06 -43.17 15.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 N-CA-C 107.758 -1.201 . . . . 0.44 107.758 -179.672 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 23' ' ' ARG . . . . . 0.684 ' HA ' ' HB2' ' B' ' 26' ' ' LEU . 0.0 OUTLIER -60.53 -29.89 69.4 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 115.287 -0.87 . . . . 1.4 109.298 171.503 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 24' ' ' ARG . . . . . 0.441 ' HB3' ' O ' ' B' ' 21' ' ' GLU . 23.1 ttt180 -61.66 -52.72 63.17 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 114.594 -1.184 . . . . 3.19 110.391 174.073 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 14.4 m -66.53 -25.06 66.49 Favored 'General case' 0 N--CA 1.452 -0.366 0 CA-C-O 121.456 0.646 . . . . 0.4 110.466 176.292 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 26' ' ' LEU . . . . . 0.729 HD11 ' HA3' ' A' ' 42' ' ' GLY . 0.7 OUTLIER -65.04 -19.55 66.05 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.432 -0.804 . . . . 0.33 111.068 175.699 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 27' ' ' ARG . . . . . 0.488 ' HB2' ' O ' ' B' ' 26' ' ' LEU . 0.2 OUTLIER 70.99 19.04 5.78 Favored 'General case' 0 N--CA 1.465 0.28 0 O-C-N 123.938 0.774 . . . . 3.28 110.097 -173.265 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 28' ' ' ILE . . . . . 0.892 HG22 ' H ' ' B' ' 29' ' ' ARG . 5.6 mt -115.45 -166.61 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 115.569 -0.741 . . . . 0.37 110.037 -177.044 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 29' ' ' ARG . . . . . 0.892 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -155.93 -157.35 0.71 Allowed 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 110.404 -0.221 . . . . 2.15 110.404 -169.698 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 30' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -71.44 31.94 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.547 0.689 . . . . 1.18 111.926 178.495 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 31' ' ' GLY . . . . . 0.547 ' N ' HD11 ' A' ' 10' ' ' ILE . . . -145.73 30.24 1.69 Allowed Glycine 0 N--CA 1.438 -1.172 0 CA-C-N 115.222 -0.899 . . . . 0.35 110.866 173.527 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 32' ' ' ASP . . . . . 0.53 ' O ' ' HA ' ' A' ' 9' ' ' ARG . 25.6 t0 -84.19 117.32 68.41 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-O 121.296 0.57 . . . . 1.29 110.301 176.881 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 33' ' ' PRO . . . . . 0.733 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 2.5 Cg_endo -87.4 66.7 3.99 Favored 'Trans proline' 0 C--O 1.206 -1.112 0 C-N-CA 123.984 3.123 . . . . 1.1 113.793 -178.448 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.756 HD11 HG23 ' A' ' 10' ' ' ILE . 0.9 OUTLIER -66.23 151.53 46.81 Favored 'General case' 0 C--N 1.284 -2.276 0 C-N-CA 118.547 -1.261 . . . . 0.44 111.573 -174.774 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 35' ' ' GLU . . . . . 0.682 ' O ' ' HA ' ' B' ' 46' ' ' LEU . 66.1 tt0 -103.53 114.33 28.52 Favored 'General case' 0 CA--C 1.493 -1.242 0 CA-C-N 114.686 -1.143 . . . . 1.1 108.011 -178.99 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 36' ' ' ILE . . . . . 0.85 ' HB ' HG23 ' A' ' 6' ' ' ILE . 2.6 mp -87.87 109.82 20.09 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.732 0 O-C-N 124.199 0.937 . . . . 0.62 109.598 -179.04 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 37' ' ' PHE . . . . . 0.583 ' HB3' ' H ' ' A' ' 5' ' ' GLY . 15.3 p90 -150.69 125.95 10.02 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 116.111 -0.495 . . . . 1.2 110.002 175.176 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 38' ' ' VAL . . . . . 0.573 ' HA ' ' HA ' ' B' ' 44' ' ' VAL . 0.8 OUTLIER -80.31 136.97 22.33 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 CA-C-O 121.125 0.488 . . . . 0.2 110.895 -178.19 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 39' ' ' ASP . . . . . 0.599 ' OD1' ' HD2' ' B' ' 40' ' ' ARG . 12.2 t70 -76.86 -64.75 1.05 Allowed 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 114.699 -1.137 . . . . 1.14 110.996 -175.213 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 40' ' ' ARG . . . . . 0.599 ' HD2' ' OD1' ' B' ' 39' ' ' ASP . 0.0 OUTLIER -117.73 -94.49 0.49 Allowed 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.682 -0.69 . . . . 2.71 112.204 -175.162 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 26.1 t70 -90.85 -70.47 0.68 Allowed 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.993 0.425 . . . . 1.32 111.21 -174.014 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 42' ' ' GLY . . . . . 0.623 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -134.28 24.22 3.59 Favored Glycine 0 N--CA 1.441 -0.996 0 C-N-CA 120.498 -0.858 . . . . 0.34 112.476 -177.555 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 43' ' ' GLU . . . . . 0.635 ' HA ' ' O ' ' A' ' 46' ' ' LEU . 1.1 mt-10 -97.04 107.86 20.47 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 109.434 -0.58 . . . . 2.07 109.434 175.956 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 44' ' ' VAL . . . . . 0.573 ' HA ' ' HA ' ' B' ' 38' ' ' VAL . 2.0 t -88.66 130.91 37.34 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 N-CA-C 109.587 -0.523 . . . . 0.13 109.587 178.18 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 45' ' ' ILE . . . . . 0.754 HG13 HG13 ' A' ' 45' ' ' ILE . 1.6 mp -106.45 121.33 58.9 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 N-CA-C 107.962 -1.125 . . . . 0.12 107.962 -177.994 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 46' ' ' LEU . . . . . 0.926 HD11 HD11 ' A' ' 46' ' ' LEU . 0.7 OUTLIER -111.59 116.27 30.54 Favored 'General case' 0 C--N 1.319 -0.731 0 O-C-N 123.876 0.735 . . . . 0.15 109.782 177.779 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 47' ' ' LYS . . . . . 0.544 ' HE3' ' HB3' ' B' ' 35' ' ' GLU . 0.0 OUTLIER -131.12 140.43 49.99 Favored 'General case' 0 C--O 1.213 -0.82 0 N-CA-C 113.402 0.89 . . . . 0.95 113.402 -178.684 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 48' ' ' LYS . . . . . 0.63 ' HE2' ' HG3' ' B' ' 51' ' ' PRO . 4.9 ptmt -38.2 -16.72 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.393 0 N-CA-C 118.747 2.869 . . . . 0.64 118.747 -168.175 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 49' ' ' TYR . . . . . 0.733 ' HB3' ' HB2' ' B' ' 33' ' ' PRO . 39.5 t80 72.32 -51.51 0.7 Allowed 'General case' 0 N--CA 1.485 1.309 0 CA-C-N 119.241 0.928 . . . . 1.26 113.247 176.481 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 50' ' ' SER . . . . . 0.449 ' OG ' ' HD3' ' B' ' 51' ' ' PRO . 1.4 p -51.7 -51.5 69.51 Favored Pre-proline 0 CA--C 1.541 0.613 0 CA-C-N 116.069 -0.514 . . . . 1.22 112.051 -172.581 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 51' ' ' PRO . . . . . 0.63 ' HG3' ' HE2' ' B' ' 48' ' ' LYS . 24.2 Cg_endo -95.42 16.41 0.91 Allowed 'Trans proline' 0 C--N 1.351 0.687 0 C-N-CA 122.45 2.1 . . . . 0.56 111.582 167.735 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 52' ' ' ILE . . . . . . . . . . . . . 3.4 mt . . . . . 0 C--N 1.321 -0.641 0 N-CA-C 108.083 -1.08 . . . . 0.73 108.083 -170.566 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 3' ' ' ALA . . . . . 0.422 ' HA ' ' HB2' ' B' ' 37' ' ' PHE . . . . . . . . 0 C--O 1.232 0.144 0 CA-C-O 121.865 0.841 . . . . 0.72 112.723 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.828 ' H ' ' HB2' ' B' ' 37' ' ' PHE . 19.2 p -130.84 -54.86 1.06 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 114.792 -1.095 . . . . 0.41 110.458 179.052 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 84.58 54.06 3.05 Favored Glycine 0 N--CA 1.446 -0.654 0 C-N-CA 120.434 -0.888 . . . . 0.32 112.458 173.319 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.902 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.6 tp -108.84 108.96 26.6 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 N-CA-C 109.404 -0.591 . . . . 0.31 109.404 171.235 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.757 HG21 ' CD1' ' B' ' 49' ' ' TYR . 36.5 t -83.0 135.92 23.85 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-O 120.905 0.383 . . . . 0.28 111.286 -179.435 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.528 ' HB3' HD11 ' B' ' 36' ' ' ILE . 5.3 tpt180 -129.63 114.79 16.47 Favored 'General case' 0 N--CA 1.446 -0.642 0 N-CA-C 107.85 -1.167 . . . . 1.99 107.85 -176.771 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' ARG . . . . . 0.722 HH11 ' HG3' ' B' ' 33' ' ' PRO . 3.7 tpp180 -81.73 103.43 11.42 Favored 'General case' 0 CA--C 1.509 -0.618 0 N-CA-C 108.047 -1.094 . . . . 2.8 108.047 174.19 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.662 ' O ' ' HB3' ' A' ' 11' ' ' ASP . 0.2 OUTLIER -14.5 -106.61 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.039 0 O-C-N 125.7 1.875 . . . . 0.33 114.367 -176.295 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ASP . . . . . 0.662 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 4.6 p-10 158.86 -169.06 0.0 OUTLIER 'General case' 0 CA--C 1.511 -0.547 0 N-CA-C 107.917 -1.142 . . . . 1.13 107.917 175.23 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -70.61 -8.92 55.25 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.952 0.406 . . . . 2.26 111.086 -178.686 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.403 HD12 HG13 ' B' ' 17' ' ' VAL . 1.6 tm? -107.82 -62.14 1.48 Allowed 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.763 -0.458 . . . . 0.53 109.763 175.205 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 134.36 22.34 0.71 Allowed Glycine 0 N--CA 1.445 -0.75 0 C-N-CA 120.455 -0.878 . . . . 0.22 113.264 179.288 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.566 ' HB3' ' HB3' ' B' ' 15' ' ' ARG . 1.5 mpt_? -80.99 150.44 28.91 Favored 'General case' 0 CA--C 1.51 -0.588 0 O-C-N 121.913 -0.757 . . . . 0.69 110.813 -179.885 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.597 HG21 HD13 ' B' ' 46' ' ' LEU . 70.9 t -109.91 98.78 7.49 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.284 0 N-CA-C 107.581 -1.266 . . . . 1.24 107.581 168.959 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.554 ' HA ' ' HA ' ' B' ' 15' ' ' ARG . 61.7 t -67.25 101.66 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 CA-C-N 115.501 -0.772 . . . . 0.28 109.577 -176.138 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.611 HG23 HD13 ' A' ' 22' ' ' ILE . 8.5 mt -93.55 111.77 53.8 Favored Pre-proline 0 C--N 1.322 -0.6 0 CA-C-N 116.022 -0.536 . . . . 0.77 110.72 -177.836 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.687 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 95.7 Cg_exo -50.31 152.51 8.26 Favored 'Trans proline' 0 N--CA 1.458 -0.579 0 C-N-CA 122.944 2.429 . . . . 0.32 112.893 173.963 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.825 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -67.24 -14.26 62.74 Favored 'General case' 0 C--O 1.21 -0.988 0 CA-C-N 115.668 -0.696 . . . . 1.57 111.237 -179.851 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.687 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 15.4 pt-20 -62.65 -25.36 68.09 Favored 'General case' 0 C--O 1.238 0.495 0 CA-C-O 120.88 0.372 . . . . 1.32 111.752 -179.322 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.611 HD13 HG23 ' A' ' 18' ' ' ILE . 5.3 mp -86.63 -47.17 16.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 108.257 -1.016 . . . . 0.35 108.257 -177.72 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ARG . . . . . 0.639 ' HA ' ' HB2' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -61.12 -27.19 68.2 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.172 -0.922 . . . . 1.5 109.038 174.043 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 38.8 ttp180 -64.27 -52.29 59.36 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 114.829 -1.078 . . . . 2.96 110.564 175.088 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 21.7 m -63.93 -28.18 69.65 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-O 121.154 0.502 . . . . 0.4 110.992 174.28 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.639 ' HB2' ' HA ' ' A' ' 23' ' ' ARG . 2.4 mm? -64.05 -19.99 65.61 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.795 -0.639 . . . . 0.36 110.043 172.636 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.408 HH11 ' HD3' ' A' ' 27' ' ' ARG . 0.2 OUTLIER 71.44 22.26 4.27 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.01 -0.995 . . . . 3.2 110.105 -177.609 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.782 HG22 ' H ' ' A' ' 29' ' ' ARG . 6.1 mt -121.03 -167.35 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.674 0 CA-C-N 115.155 -0.93 . . . . 0.48 109.118 -177.424 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.782 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.3 OUTLIER -146.01 -156.47 0.71 Allowed 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 118.037 0.38 . . . . 2.4 111.943 -174.335 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -72.86 48.6 0.21 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 122.197 0.998 . . . . 1.23 111.904 -179.214 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.684 ' N ' HD11 ' B' ' 10' ' ' ILE . . . -166.14 24.9 0.15 Allowed Glycine 0 N--CA 1.443 -0.876 0 CA-C-N 113.804 -1.544 . . . . 0.36 109.863 174.69 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.494 ' O ' HG13 ' B' ' 10' ' ' ILE . 19.8 t0 -87.67 127.63 57.54 Favored Pre-proline 0 CA--C 1.516 -0.348 0 CA-C-N 114.771 -0.715 . . . . 1.26 109.377 174.883 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.712 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 3.8 Cg_endo -82.36 154.31 16.27 Favored 'Trans proline' 0 N--CA 1.438 -1.773 0 C-N-CA 122.26 1.973 . . . . 1.3 110.676 174.968 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.739 ' O ' ' HA ' ' B' ' 7' ' ' VAL . 0.5 OUTLIER -142.68 149.62 39.09 Favored 'General case' 0 C--N 1.307 -1.262 0 C-N-CA 120.133 -0.627 . . . . 0.38 109.507 172.688 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.949 ' HB3' ' HD2' ' A' ' 47' ' ' LYS . 38.1 tt0 -108.55 111.1 22.77 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 108.524 -0.917 . . . . 1.12 108.524 -176.182 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 1.033 HG13 HD22 ' A' ' 46' ' ' LEU . 2.2 mp -85.85 109.48 18.58 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.794 0 O-C-N 124.972 1.42 . . . . 0.39 109.211 -176.239 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' PHE . . . . . 0.967 ' HD2' ' HA ' ' B' ' 3' ' ' ALA . 0.5 OUTLIER -149.37 124.72 10.23 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 115.683 -0.69 . . . . 1.15 109.431 177.736 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.538 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 2.0 p -80.52 133.08 30.25 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.953 0 CA-C-O 121.214 0.53 . . . . 0.17 110.566 -179.221 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.522 ' HB3' ' HG2' ' A' ' 40' ' ' ARG . 27.2 t0 -81.21 -58.07 3.22 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 114.154 -1.385 . . . . 1.11 111.453 -174.447 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' ARG . . . . . 0.567 ' HG3' ' HG3' ' A' ' 43' ' ' GLU . 1.3 ptm180 -125.6 -99.52 0.4 Allowed 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.134 -0.939 . . . . 2.29 112.74 -166.086 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 34.7 t70 -84.11 -75.67 0.33 Allowed 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.168 0.508 . . . . 1.53 110.757 -175.735 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.491 ' HA3' HD11 ' B' ' 26' ' ' LEU . . . -135.11 24.88 3.38 Favored Glycine 0 N--CA 1.441 -0.979 0 CA-C-N 115.534 -0.757 . . . . 0.32 111.313 178.735 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.633 ' HB3' HG23 ' B' ' 45' ' ' ILE . 2.1 mt-10 -93.6 109.91 21.53 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.048 -0.723 . . . . 1.97 109.048 178.473 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.538 ' HA ' ' HA ' ' A' ' 38' ' ' VAL . 1.5 t -90.41 130.51 39.53 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 N-CA-C 109.22 -0.659 . . . . 0.14 109.22 178.015 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.74 HG13 HG13 ' B' ' 45' ' ' ILE . 1.5 mp -108.79 117.91 55.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 N-CA-C 108.456 -0.942 . . . . 0.14 108.456 -175.595 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 1.049 HD11 HD11 ' B' ' 46' ' ' LEU . 0.3 OUTLIER -109.7 115.16 29.35 Favored 'General case' 0 C--N 1.314 -0.939 0 N-CA-C 108.743 -0.836 . . . . 0.23 108.743 176.936 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.949 ' HD2' ' HB3' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -123.11 151.26 42.24 Favored 'General case' 0 C--O 1.215 -0.74 0 C-N-CA 118.808 -1.157 . . . . 0.76 111.99 179.594 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.659 ' HA ' ' O ' ' A' ' 33' ' ' PRO . 2.0 ptmt -42.12 -16.78 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.93 0 N-CA-C 117.377 2.362 . . . . 0.32 117.377 -168.058 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 0.735 ' CD1' HG21 ' B' ' 7' ' ' VAL . 23.0 t80 73.19 -53.87 0.7 Allowed 'General case' 0 N--CA 1.473 0.676 0 CA-C-N 118.321 0.509 . . . . 1.28 112.301 174.101 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.7 ' OG ' ' HD3' ' A' ' 51' ' ' PRO . 4.3 p -54.07 -44.42 98.36 Favored Pre-proline 0 CA--C 1.543 0.676 0 CA-C-N 116.131 -0.486 . . . . 1.36 111.804 -175.378 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.7 ' HD3' ' OG ' ' A' ' 50' ' ' SER . 94.5 Cg_endo -102.29 21.44 0.17 Allowed 'Trans proline' 0 N--CA 1.452 -0.969 0 C-N-CA 123.082 2.521 . . . . 0.58 111.75 168.164 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.235 0.328 0 CA-C-N 115.78 -0.645 . . . . 0.78 110.347 -176.751 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 3' ' ' ALA . . . . . 0.967 ' HA ' ' HD2' ' A' ' 37' ' ' PHE . . . . . . . . 0 N--CA 1.472 0.651 0 N-CA-C 109.147 -0.686 . . . . 0.86 109.147 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 4' ' ' THR . . . . . 0.735 ' H ' ' HB2' ' A' ' 37' ' ' PHE . 2.1 p -152.7 -47.86 0.1 Allowed 'General case' 0 C--N 1.324 -0.52 0 O-C-N 123.671 0.607 . . . . 0.43 109.563 174.083 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 72.53 53.1 8.93 Favored Glycine 0 N--CA 1.452 -0.254 0 CA-C-N 114.989 -1.005 . . . . 0.33 113.134 171.256 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 6' ' ' ILE . . . . . 0.855 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.3 tp -109.13 112.18 39.37 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.801 0 N-CA-C 109.124 -0.695 . . . . 0.3 109.124 171.895 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 7' ' ' VAL . . . . . 0.739 ' HA ' ' O ' ' A' ' 34' ' ' LEU . 39.7 t -84.4 136.03 23.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-O 120.94 0.4 . . . . 0.27 110.974 -179.501 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 8' ' ' ARG . . . . . 0.573 ' CZ ' HG23 ' B' ' 17' ' ' VAL . 1.4 tpt180 -129.61 114.71 16.38 Favored 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 107.665 -1.235 . . . . 1.69 107.665 -178.603 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 9' ' ' ARG . . . . . 0.534 ' HA ' ' HA ' ' A' ' 33' ' ' PRO . 0.0 OUTLIER -80.81 103.06 10.39 Favored 'General case' 0 CA--C 1.51 -0.582 0 N-CA-C 107.933 -1.136 . . . . 2.71 107.933 173.903 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 10' ' ' ILE . . . . . 0.684 HD11 ' N ' ' A' ' 31' ' ' GLY . 0.2 OUTLIER -13.54 -105.54 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.085 0 O-C-N 125.611 1.82 . . . . 0.34 114.509 -176.627 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 11' ' ' ASP . . . . . 0.493 ' H ' HD13 ' B' ' 10' ' ' ILE . 34.8 p30 156.99 -160.71 0.0 OUTLIER 'General case' 0 CA--C 1.508 -0.637 0 C-N-CA 124.379 1.072 . . . . 1.18 108.25 171.735 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -71.96 -8.29 53.63 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 121.085 0.469 . . . . 2.39 110.766 -176.81 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 13' ' ' LEU . . . . . 0.408 HD12 HG13 ' A' ' 17' ' ' VAL . 2.1 tm? -114.72 -57.97 2.2 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.343 -0.39 . . . . 0.4 109.973 -179.8 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 133.03 17.42 1.15 Allowed Glycine 0 N--CA 1.441 -0.967 0 C-N-CA 120.595 -0.812 . . . . 0.21 113.784 179.532 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 15' ' ' ARG . . . . . 0.566 ' HB3' ' HB3' ' A' ' 15' ' ' ARG . 0.2 OUTLIER -81.5 150.52 28.22 Favored 'General case' 0 CA--C 1.507 -0.694 0 CA-C-N 118.764 1.282 . . . . 0.9 110.962 -179.256 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 16' ' ' VAL . . . . . 0.542 HG21 HD13 ' A' ' 46' ' ' LEU . 98.2 t -108.98 100.72 11.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 CA-C-N 114.318 -1.31 . . . . 1.27 107.549 171.064 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 17' ' ' VAL . . . . . 0.573 HG23 ' CZ ' ' B' ' 8' ' ' ARG . 37.8 t -69.54 103.21 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.078 0 CA-C-N 115.832 -0.622 . . . . 0.27 109.654 -174.96 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 18' ' ' ILE . . . . . 0.478 HD11 HD12 ' B' ' 46' ' ' LEU . 6.8 mt -91.98 112.39 54.61 Favored Pre-proline 0 N--CA 1.446 -0.647 0 CA-C-O 121.477 0.656 . . . . 0.82 110.981 -177.768 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 19' ' ' PRO . . . . . 0.696 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 67.7 Cg_exo -49.1 142.9 19.6 Favored 'Trans proline' 0 N--CA 1.46 -0.484 0 C-N-CA 123.379 2.719 . . . . 0.3 112.456 171.511 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 20' ' ' LYS . . . . . 0.987 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -61.36 -15.1 32.82 Favored 'General case' 0 C--O 1.211 -0.938 0 CA-C-N 115.313 -0.858 . . . . 1.77 111.4 179.525 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 21' ' ' GLU . . . . . 0.696 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 10.0 pt-20 -63.37 -22.84 67.12 Favored 'General case' 0 C--O 1.238 0.486 0 N-CA-C 112.117 0.414 . . . . 1.92 112.117 179.625 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 22' ' ' ILE . . . . . 0.402 HD13 HG23 ' B' ' 18' ' ' ILE . 5.3 mp -87.09 -47.97 15.68 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 N-CA-C 108.61 -0.885 . . . . 0.44 108.61 -179.371 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 23' ' ' ARG . . . . . 0.586 ' HA ' ' HB2' ' B' ' 26' ' ' LEU . 0.0 OUTLIER -60.06 -27.98 67.42 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.356 -0.838 . . . . 1.4 109.27 173.234 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 24' ' ' ARG . . . . . . . . . . . . . 43.5 ttp180 -65.45 -52.76 50.83 Favored 'General case' 0 N--CA 1.446 -0.654 0 CA-C-N 114.676 -1.147 . . . . 3.19 110.683 175.7 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 21.3 m -64.77 -26.67 68.45 Favored 'General case' 0 N--CA 1.449 -0.508 0 CA-C-O 121.355 0.597 . . . . 0.4 110.667 175.421 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 26' ' ' LEU . . . . . 0.586 ' HB2' ' HA ' ' B' ' 23' ' ' ARG . 1.7 mm? -64.85 -18.97 65.61 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.46 -0.791 . . . . 0.33 110.59 173.754 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 27' ' ' ARG . . . . . . . . . . . . . 19.6 tpt180 74.4 22.32 2.19 Favored 'General case' 0 C--N 1.34 0.166 0 O-C-N 124.136 0.897 . . . . 3.28 109.772 -178.034 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 28' ' ' ILE . . . . . 0.896 HG22 ' H ' ' B' ' 29' ' ' ARG . 6.6 mt -123.28 -163.19 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.343 -0.844 . . . . 0.37 110.287 -174.91 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 29' ' ' ARG . . . . . 0.896 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -152.44 -159.31 0.99 Allowed 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 112.025 0.379 . . . . 2.15 112.025 -170.392 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 30' ' ' GLU . . . . . 0.467 ' H ' ' HB2' ' B' ' 29' ' ' ARG . 0.9 OUTLIER -73.92 36.94 0.1 Allowed 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 121.849 0.833 . . . . 1.18 111.961 -177.464 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 31' ' ' GLY . . . . . 0.576 ' CA ' HD11 ' A' ' 10' ' ' ILE . . . -153.93 30.42 0.74 Allowed Glycine 0 N--CA 1.442 -0.93 0 N-CA-C 109.757 -1.337 . . . . 0.35 109.757 171.658 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 32' ' ' ASP . . . . . 0.505 ' HB2' ' CG2' ' B' ' 28' ' ' ILE . 12.3 t70 -86.7 128.78 55.2 Favored Pre-proline 0 C--N 1.324 -0.543 0 CA-C-N 114.81 -0.695 . . . . 1.29 109.948 174.197 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 33' ' ' PRO . . . . . 0.754 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 10.3 Cg_endo -84.88 148.93 10.9 Favored 'Trans proline' 0 N--CA 1.435 -1.919 0 C-N-CA 122.402 2.068 . . . . 1.1 110.785 173.474 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.717 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.7 OUTLIER -137.55 148.63 46.09 Favored 'General case' 0 C--N 1.302 -1.471 0 N-CA-C 109.631 -0.507 . . . . 0.44 109.631 173.64 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 35' ' ' GLU . . . . . 0.708 ' O ' ' HA ' ' B' ' 46' ' ' LEU . 46.8 tt0 -105.16 111.74 24.6 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 107.9 -1.148 . . . . 1.1 107.9 -178.178 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 36' ' ' ILE . . . . . 1.107 HG13 HD22 ' B' ' 46' ' ' LEU . 3.0 mp -86.73 109.86 19.53 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.943 0 O-C-N 124.417 1.073 . . . . 0.62 109.06 -178.604 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 37' ' ' PHE . . . . . 0.828 ' HB2' ' H ' ' A' ' 4' ' ' THR . 12.1 p90 -151.0 131.97 14.25 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 116.158 -0.474 . . . . 1.2 109.966 174.796 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 38' ' ' VAL . . . . . 0.514 ' HA ' ' HA ' ' B' ' 44' ' ' VAL . 1.9 p -80.08 142.33 14.07 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.01 0 CA-C-O 120.949 0.404 . . . . 0.2 110.352 -178.584 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 39' ' ' ASP . . . . . 0.458 ' HB2' ' CD1' ' B' ' 45' ' ' ILE . 25.8 t0 -92.08 -47.52 7.22 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.556 -0.747 . . . . 1.14 111.618 -175.026 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 40' ' ' ARG . . . . . 0.559 ' HG3' ' HG3' ' B' ' 43' ' ' GLU . 0.0 OUTLIER -134.08 -100.82 0.25 Allowed 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 112.767 0.655 . . . . 2.71 112.767 -168.12 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 25.1 t70 -83.09 -71.92 0.47 Allowed 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.422 0.63 . . . . 1.32 110.767 -176.182 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 42' ' ' GLY . . . . . 0.482 ' HA3' ' HD2' ' A' ' 48' ' ' LYS . . . -139.73 25.77 2.68 Favored Glycine 0 CA--C 1.501 -0.801 0 CA-C-N 115.41 -0.814 . . . . 0.34 111.179 178.868 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 43' ' ' GLU . . . . . 0.559 ' HG3' ' HG3' ' B' ' 40' ' ' ARG . 2.7 mt-10 -92.72 109.15 20.57 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 109.226 -0.657 . . . . 2.07 109.226 178.629 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 44' ' ' VAL . . . . . 0.514 ' HA ' ' HA ' ' B' ' 38' ' ' VAL . 1.7 t -89.13 130.48 38.41 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 N-CA-C 109.122 -0.696 . . . . 0.13 109.122 178.09 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 45' ' ' ILE . . . . . 0.74 HG13 HG13 ' A' ' 45' ' ' ILE . 1.7 mp -108.19 118.85 56.68 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 N-CA-C 108.138 -1.06 . . . . 0.12 108.138 -176.981 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 46' ' ' LEU . . . . . 1.107 HD22 HG13 ' B' ' 36' ' ' ILE . 0.5 OUTLIER -110.26 115.77 30.3 Favored 'General case' 0 C--N 1.317 -0.847 0 N-CA-C 108.819 -0.808 . . . . 0.15 108.819 176.648 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 47' ' ' LYS . . . . . 0.537 ' O ' ' HA ' ' B' ' 34' ' ' LEU . 0.0 OUTLIER -126.57 149.99 49.1 Favored 'General case' 0 C--N 1.317 -0.847 0 C-N-CA 119.178 -1.009 . . . . 0.95 112.626 -177.724 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 48' ' ' LYS . . . . . 0.684 ' HE2' ' HG3' ' B' ' 51' ' ' PRO . 3.4 ptmt -41.7 -14.18 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.064 0 N-CA-C 118.007 2.595 . . . . 0.64 118.007 -167.643 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 49' ' ' TYR . . . . . 0.757 ' CD1' HG21 ' A' ' 7' ' ' VAL . 30.9 t80 72.41 -56.62 0.65 Allowed 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 113.004 0.742 . . . . 1.26 113.004 173.145 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 50' ' ' SER . . . . . 0.718 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 8.3 t -52.28 -52.7 60.27 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.26 -0.427 . . . . 1.22 110.778 -174.031 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 51' ' ' PRO . . . . . 0.718 ' HD3' ' HB3' ' B' ' 50' ' ' SER . 47.2 Cg_endo -92.33 14.29 1.74 Allowed 'Trans proline' 0 N--CA 1.454 -0.806 0 C-N-CA 122.155 1.903 . . . . 0.56 111.84 170.421 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 52' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.328 -0.34 0 CA-C-N 115.52 -0.764 . . . . 0.73 109.76 -177.184 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' ALA . . . . . 0.59 ' HA ' ' HD2' ' B' ' 37' ' ' PHE . . . . . . . . 0 C--O 1.232 0.153 0 CA-C-O 121.552 0.691 . . . . 0.72 111.844 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.542 ' OG1' ' HA ' ' B' ' 37' ' ' PHE . 11.7 p -97.05 -45.76 6.44 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.547 -0.752 . . . . 0.41 111.602 -179.4 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 70.51 48.93 33.78 Favored Glycine 0 N--CA 1.443 -0.866 0 C-N-CA 120.58 -0.819 . . . . 0.32 112.919 174.155 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.783 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.0 OUTLIER -104.94 113.1 41.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 N-CA-C 108.407 -0.96 . . . . 0.31 108.407 173.997 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.755 HG21 ' CD1' ' B' ' 49' ' ' TYR . 28.3 t -83.58 134.65 26.47 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-O 121.211 0.529 . . . . 0.28 110.94 -178.319 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.593 ' HB3' ' CD1' ' B' ' 36' ' ' ILE . 9.0 tpp180 -131.0 119.54 22.2 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 107.818 -1.178 . . . . 1.99 107.818 -176.583 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' ARG . . . . . 0.452 ' N ' ' HD3' ' A' ' 8' ' ' ARG . 44.8 ttp180 -79.27 108.36 12.72 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 108.613 -0.884 . . . . 2.8 108.613 170.713 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.832 HG23 HD11 ' B' ' 34' ' ' LEU . 0.2 OUTLIER -16.19 -102.65 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 O-C-N 125.593 1.808 . . . . 0.33 114.492 -177.724 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ASP . . . . . 0.606 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 3.1 p-10 162.89 -160.92 0.0 OUTLIER 'General case' 0 CA--C 1.509 -0.602 0 N-CA-C 107.826 -1.176 . . . . 1.13 107.826 175.542 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 25.0 m-20 -70.72 -22.09 62.47 Favored 'General case' 0 C--N 1.321 -0.663 0 O-C-N 123.384 0.428 . . . . 2.26 110.812 -178.78 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.459 HD22 ' HE2' ' B' ' 20' ' ' LYS . 3.0 tm? -102.88 -61.46 1.4 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.27 -0.423 . . . . 0.53 110.305 179.682 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.524 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 144.48 16.65 0.21 Allowed Glycine 0 N--CA 1.442 -0.93 0 C-N-CA 120.768 -0.729 . . . . 0.22 112.513 -178.91 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.553 ' HB3' ' HB3' ' B' ' 15' ' ' ARG . 2.8 mpt_? -71.5 145.84 48.92 Favored 'General case' 0 CA--C 1.504 -0.793 0 CA-C-O 121.522 0.677 . . . . 0.69 110.456 -179.278 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.82 HG21 HD13 ' B' ' 46' ' ' LEU . 97.5 t -103.76 94.08 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.53 0 N-CA-C 107.146 -1.427 . . . . 1.24 107.146 168.947 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.552 ' HA ' ' HA ' ' B' ' 15' ' ' ARG . 59.7 t -67.22 97.62 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.844 0 CA-C-N 114.891 -1.049 . . . . 0.28 110.137 -172.809 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.716 HG23 HD13 ' A' ' 22' ' ' ILE . 17.4 mt -98.54 111.23 59.59 Favored Pre-proline 0 C--N 1.326 -0.45 0 CA-C-N 115.594 -0.73 . . . . 0.77 111.11 -175.6 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.783 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 48.6 Cg_exo -46.74 150.41 2.55 Favored 'Trans proline' 0 N--CA 1.458 -0.577 0 C-N-CA 123.183 2.588 . . . . 0.32 113.859 175.041 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.944 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -64.49 -12.62 45.93 Favored 'General case' 0 C--O 1.207 -1.176 0 CA-C-N 115.164 -0.926 . . . . 1.57 111.219 176.61 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.783 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 12.7 pt-20 -64.88 -22.62 67.03 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 118.436 0.562 . . . . 1.32 111.246 176.372 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.716 HD13 HG23 ' A' ' 18' ' ' ILE . 5.1 mp -88.06 -44.31 15.72 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.404 0 N-CA-C 108.889 -0.782 . . . . 0.35 108.889 179.167 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ARG . . . . . 0.72 ' HG3' ' HA ' ' A' ' 20' ' ' LYS . 1.1 ppt_? -61.12 -26.25 67.54 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 122.284 1.04 . . . . 1.5 108.636 172.05 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.534 ' HB3' ' O ' ' A' ' 21' ' ' GLU . 32.0 ttt180 -64.03 -52.37 59.77 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 113.741 -1.572 . . . . 2.96 110.628 174.914 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 40.3 m -62.73 -30.35 71.36 Favored 'General case' 0 N--CA 1.455 -0.223 0 CA-C-O 121.062 0.458 . . . . 0.4 110.995 172.928 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.616 ' HB2' ' HA ' ' A' ' 23' ' ' ARG . 2.6 mm? -63.49 -18.98 64.35 Favored 'General case' 0 CA--C 1.519 -0.23 0 CA-C-N 115.952 -0.567 . . . . 0.36 109.94 174.662 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.413 HH11 ' HD2' ' A' ' 27' ' ' ARG . 11.3 mmt180 67.69 23.38 8.7 Favored 'General case' 0 N--CA 1.451 -0.408 0 CA-C-N 115.277 -0.874 . . . . 3.2 109.915 -178.079 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.838 HG22 ' H ' ' A' ' 29' ' ' ARG . 11.8 mt -124.32 -167.61 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 CA-C-N 114.479 -1.237 . . . . 0.48 108.161 -178.161 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.838 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.2 OUTLIER -142.63 -158.55 0.88 Allowed 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 118.403 0.547 . . . . 2.4 112.116 -175.464 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 5.7 mp0 -72.9 47.19 0.18 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 122.221 1.01 . . . . 1.23 111.942 -179.514 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.661 ' N ' HD11 ' B' ' 10' ' ' ILE . . . -163.08 24.91 0.2 Allowed Glycine 0 N--CA 1.445 -0.71 0 CA-C-N 113.801 -1.545 . . . . 0.36 109.867 175.115 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.47 ' O ' HG13 ' B' ' 10' ' ' ILE . 18.1 t0 -87.97 130.81 45.07 Favored Pre-proline 0 CA--C 1.514 -0.423 0 CA-C-N 114.446 -0.877 . . . . 1.26 109.367 174.247 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.686 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 3.2 Cg_endo -82.32 153.44 16.15 Favored 'Trans proline' 0 N--CA 1.438 -1.762 0 C-N-CA 122.172 1.915 . . . . 1.3 110.634 174.668 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.846 HD11 HG23 ' B' ' 10' ' ' ILE . 0.5 OUTLIER -140.72 151.68 44.7 Favored 'General case' 0 N--CA 1.433 -1.319 0 C-N-CA 119.866 -0.734 . . . . 0.38 109.663 171.439 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.74 ' HB3' ' HD2' ' A' ' 47' ' ' LYS . 86.0 tt0 -105.13 111.31 24.03 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.606 -1.257 . . . . 1.12 107.606 -178.523 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 1.016 HG13 HD22 ' A' ' 46' ' ' LEU . 2.9 mp -87.14 109.01 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.744 0 O-C-N 124.722 1.263 . . . . 0.39 109.116 -178.893 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' PHE . . . . . 0.654 ' HD2' ' HA ' ' B' ' 3' ' ' ALA . 1.0 OUTLIER -149.23 127.72 12.3 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 115.987 -0.551 . . . . 1.15 109.835 176.833 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.463 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 1.3 p -81.81 132.49 31.35 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.999 0 CA-C-O 121.612 0.72 . . . . 0.17 110.657 -179.878 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.568 ' HB3' ' HG2' ' A' ' 40' ' ' ARG . 19.7 t70 -79.94 -49.89 11.22 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 114.236 -1.347 . . . . 1.11 111.672 -173.746 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' ARG . . . . . 0.568 ' HG2' ' HB3' ' A' ' 39' ' ' ASP . 1.7 ptm180 -133.65 -96.83 0.29 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.48 -0.782 . . . . 2.29 112.96 -167.069 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -88.6 -70.38 0.65 Allowed 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.089 0.471 . . . . 1.53 111.024 -174.311 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.432 ' O ' ' HA ' ' B' ' 47' ' ' LYS . . . -139.67 22.84 2.82 Favored Glycine 0 N--CA 1.445 -0.741 0 CA-C-N 115.596 -0.729 . . . . 0.32 111.279 -179.344 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.552 ' HB3' HG23 ' B' ' 45' ' ' ILE . 1.7 mt-10 -95.4 113.06 24.69 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 109.483 -0.562 . . . . 1.97 109.483 179.275 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.476 ' CG1' HG23 ' A' ' 36' ' ' ILE . 1.4 t -91.15 131.26 38.77 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 N-CA-C 109.425 -0.583 . . . . 0.14 109.425 177.182 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.804 HG13 HG13 ' B' ' 45' ' ' ILE . 1.6 mp -109.69 118.06 55.99 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 108.072 -1.084 . . . . 0.14 108.072 -176.568 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 1.031 HD11 HD11 ' B' ' 46' ' ' LEU . 0.3 OUTLIER -112.54 116.69 30.63 Favored 'General case' 0 C--N 1.315 -0.933 0 O-C-N 123.796 0.685 . . . . 0.23 109.467 178.813 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.74 ' HD2' ' HB3' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -127.64 153.59 46.26 Favored 'General case' 0 C--O 1.215 -0.722 0 C-N-CA 118.662 -1.215 . . . . 0.76 112.216 178.56 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.643 ' HG3' ' HG2' ' A' ' 51' ' ' PRO . 1.1 ptmt -41.24 -17.42 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.026 0 N-CA-C 117.497 2.406 . . . . 0.32 117.497 -168.88 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 0.808 ' CD1' HG21 ' B' ' 7' ' ' VAL . 17.4 t80 75.82 -53.59 0.63 Allowed 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 112.418 0.525 . . . . 1.28 112.418 173.379 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.677 ' HB3' ' HD3' ' A' ' 51' ' ' PRO . 8.3 t -51.57 -49.71 81.16 Favored Pre-proline 0 CA--C 1.538 0.498 0 CA-C-N 116.219 -0.446 . . . . 1.36 111.099 -177.184 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.677 ' HD3' ' HB3' ' A' ' 50' ' ' SER . 27.8 Cg_endo -93.82 9.12 2.25 Favored 'Trans proline' 0 N--CA 1.455 -0.749 0 C-N-CA 122.647 2.231 . . . . 0.58 111.663 171.706 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.434 HG13 ' C ' ' A' ' 51' ' ' PRO . 1.1 mt . . . . . 0 CA--C 1.532 0.255 0 CA-C-N 115.439 -0.8 . . . . 0.78 109.326 -175.038 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 3' ' ' ALA . . . . . 0.654 ' HA ' ' HD2' ' A' ' 37' ' ' PHE . . . . . . . . 0 C--O 1.233 0.208 0 CA-C-O 121.398 0.618 . . . . 0.86 111.303 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 4' ' ' THR . . . . . 0.531 ' OG1' ' HA ' ' A' ' 37' ' ' PHE . 7.5 p -94.73 -48.14 6.18 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.909 -0.587 . . . . 0.43 111.675 -179.174 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 72.24 48.33 25.7 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.939 -0.648 . . . . 0.33 112.976 174.84 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 6' ' ' ILE . . . . . 0.746 HG23 ' HB ' ' A' ' 36' ' ' ILE . 0.9 OUTLIER -106.11 112.1 37.95 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 N-CA-C 108.731 -0.84 . . . . 0.3 108.731 174.83 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 7' ' ' VAL . . . . . 0.808 HG21 ' CD1' ' A' ' 49' ' ' TYR . 35.2 t -83.56 136.66 22.35 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 CA-C-O 120.952 0.405 . . . . 0.27 111.167 -178.887 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 8' ' ' ARG . . . . . 0.514 ' HD3' ' N ' ' B' ' 9' ' ' ARG . 1.0 OUTLIER -133.17 123.77 26.25 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 107.296 -1.372 . . . . 1.69 107.296 179.128 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 9' ' ' ARG . . . . . 0.514 ' N ' ' HD3' ' B' ' 8' ' ' ARG . 0.1 OUTLIER -82.31 103.33 11.82 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 108.267 -1.012 . . . . 2.71 108.267 173.219 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 10' ' ' ILE . . . . . 0.846 HG23 HD11 ' A' ' 34' ' ' LEU . 0.2 OUTLIER -10.32 -106.02 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 O-C-N 125.444 1.715 . . . . 0.34 114.9 -176.746 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 11' ' ' ASP . . . . . 0.604 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 2.5 p-10 163.1 -168.29 0.01 OUTLIER 'General case' 0 CA--C 1.51 -0.575 0 N-CA-C 106.586 -1.635 . . . . 1.18 106.586 177.174 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 52.7 m-20 -77.06 -2.87 36.28 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 118.418 0.553 . . . . 2.39 110.995 -176.804 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 13' ' ' LEU . . . . . 0.425 ' H ' ' CG ' ' B' ' 11' ' ' ASP . 2.1 tm? -106.56 -61.8 1.48 Allowed 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.781 -0.645 . . . . 0.4 109.794 174.689 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 138.14 17.01 0.63 Allowed Glycine 0 N--CA 1.445 -0.722 0 CA-C-N 115.947 -0.57 . . . . 0.21 112.093 -176.869 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 15' ' ' ARG . . . . . 0.553 ' HB3' ' HB3' ' A' ' 15' ' ' ARG . 1.6 mpt_? -70.36 143.1 52.04 Favored 'General case' 0 CA--C 1.506 -0.724 0 CA-C-O 121.536 0.684 . . . . 0.9 110.481 -179.718 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 16' ' ' VAL . . . . . 0.715 HG21 HD13 ' A' ' 46' ' ' LEU . 81.1 t -104.69 94.34 3.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 N-CA-C 107.343 -1.354 . . . . 1.27 107.343 167.465 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 17' ' ' VAL . . . . . 0.528 HG22 ' HG2' ' A' ' 15' ' ' ARG . 40.8 t -67.13 98.49 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-N 115.188 -0.915 . . . . 0.27 110.169 -171.1 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 18' ' ' ILE . . . . . 0.524 ' HB ' ' O ' ' A' ' 14' ' ' GLY . 11.4 mt -96.75 112.74 61.26 Favored Pre-proline 0 N--CA 1.447 -0.58 0 CA-C-N 115.535 -0.757 . . . . 0.82 110.932 -177.477 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 19' ' ' PRO . . . . . 0.621 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 85.6 Cg_exo -51.67 154.31 9.54 Favored 'Trans proline' 0 N--CA 1.456 -0.68 0 C-N-CA 122.626 2.217 . . . . 0.3 113.508 173.988 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 20' ' ' LYS . . . . . 0.783 ' HA ' ' HG3' ' B' ' 23' ' ' ARG . 0.0 OUTLIER -68.37 -13.37 62.24 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-N 114.828 -1.078 . . . . 1.77 111.1 178.384 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 21' ' ' GLU . . . . . 0.621 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 9.8 pt-20 -66.36 -20.24 66.03 Favored 'General case' 0 C--N 1.322 -0.595 0 C-N-CA 120.327 -0.549 . . . . 1.92 111.568 176.141 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 22' ' ' ILE . . . . . 0.49 HD13 HG23 ' B' ' 18' ' ' ILE . 5.4 mp -88.56 -45.21 15.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 N-CA-C 108.863 -0.791 . . . . 0.44 108.863 177.265 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 23' ' ' ARG . . . . . 0.783 ' HG3' ' HA ' ' B' ' 20' ' ' LYS . 0.3 OUTLIER -59.92 -25.11 64.88 Favored 'General case' 0 N--CA 1.472 0.636 0 CA-C-O 121.989 0.899 . . . . 1.4 108.789 171.996 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 24' ' ' ARG . . . . . 0.429 ' HB3' ' O ' ' B' ' 21' ' ' GLU . 35.3 ttm180 -65.17 -52.52 54.49 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 114.018 -1.446 . . . . 3.19 110.971 174.012 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 31.7 m -63.08 -29.16 70.59 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 120.54 -0.464 . . . . 0.4 110.906 173.756 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 26' ' ' LEU . . . . . 0.581 ' HB2' ' HA ' ' B' ' 23' ' ' ARG . 2.6 mm? -63.34 -20.05 65.17 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.947 -0.57 . . . . 0.33 110.057 174.337 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 27' ' ' ARG . . . . . 0.414 ' HA ' ' HD3' ' B' ' 27' ' ' ARG . 25.0 mmt180 68.11 24.72 7.62 Favored 'General case' 0 N--CA 1.453 -0.306 0 CA-C-N 115.286 -0.87 . . . . 3.28 109.904 -177.381 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 28' ' ' ILE . . . . . 0.901 HG22 ' H ' ' B' ' 29' ' ' ARG . 12.6 mt -125.17 -161.43 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 114.793 -1.094 . . . . 0.37 109.294 -177.243 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 29' ' ' ARG . . . . . 0.901 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.1 OUTLIER -149.41 -160.79 1.22 Allowed 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 112.144 0.424 . . . . 2.15 112.144 -173.123 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 30' ' ' GLU . . . . . 0.428 ' N ' ' HD2' ' B' ' 29' ' ' ARG . 3.2 mp0 -71.12 37.82 0.05 Allowed 'General case' 0 N--CA 1.464 0.232 0 CA-C-O 121.523 0.677 . . . . 1.18 112.55 -178.629 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 31' ' ' GLY . . . . . 0.586 ' N ' HD11 ' A' ' 10' ' ' ILE . . . -152.03 18.5 0.84 Allowed Glycine 0 N--CA 1.443 -0.884 0 N-CA-C 110.339 -1.104 . . . . 0.35 110.339 173.469 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 32' ' ' ASP . . . . . 0.487 ' O ' HG13 ' A' ' 10' ' ' ILE . 18.3 t70 -78.32 129.14 75.93 Favored Pre-proline 0 C--N 1.326 -0.433 0 CA-C-N 115.054 -0.573 . . . . 1.29 109.595 174.93 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 33' ' ' PRO . . . . . 0.721 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 5.1 Cg_endo -82.16 150.05 15.55 Favored 'Trans proline' 0 N--CA 1.436 -1.853 0 C-N-CA 122.586 2.191 . . . . 1.1 110.697 173.242 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.832 HD11 HG23 ' A' ' 10' ' ' ILE . 0.7 OUTLIER -136.85 150.66 48.42 Favored 'General case' 0 C--N 1.306 -1.304 0 N-CA-C 109.674 -0.491 . . . . 0.44 109.674 173.693 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 35' ' ' GLU . . . . . 0.766 ' O ' ' HA ' ' B' ' 46' ' ' LEU . 38.0 tt0 -105.31 112.92 26.21 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 107.577 -1.268 . . . . 1.1 107.577 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 36' ' ' ILE . . . . . 0.981 HG13 HD22 ' B' ' 46' ' ' LEU . 3.3 mp -89.12 109.85 20.77 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 O-C-N 124.878 1.361 . . . . 0.62 109.198 -178.807 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 37' ' ' PHE . . . . . 0.905 ' HE1' ' HZ1' ' B' ' 47' ' ' LYS . 2.1 p90 -149.28 131.33 15.33 Favored 'General case' 0 C--N 1.317 -0.835 0 N-CA-C 109.694 -0.484 . . . . 1.2 109.694 175.013 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 38' ' ' VAL . . . . . 0.449 ' HA ' ' HA ' ' B' ' 44' ' ' VAL . 1.2 p -82.09 135.38 25.05 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 CA-C-O 121.367 0.603 . . . . 0.2 110.852 179.753 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 39' ' ' ASP . . . . . 0.465 ' HB2' ' CD1' ' B' ' 45' ' ' ILE . 35.8 t70 -81.07 -50.74 9.28 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 114.354 -1.294 . . . . 1.14 111.255 -174.675 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 40' ' ' ARG . . . . . 0.547 ' HD3' ' OE1' ' B' ' 43' ' ' GLU . 0.9 OUTLIER -134.22 -105.04 0.23 Allowed 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.908 -0.587 . . . . 2.71 112.347 -169.937 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 24.0 t70 -78.19 -70.48 0.48 Allowed 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.086 0.47 . . . . 1.32 111.362 -176.354 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 42' ' ' GLY . . . . . 0.441 ' HA3' ' HD2' ' A' ' 48' ' ' LYS . . . -139.72 25.17 2.71 Favored Glycine 0 N--CA 1.442 -0.906 0 C-N-CA 120.449 -0.881 . . . . 0.34 111.978 -177.933 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 43' ' ' GLU . . . . . 0.555 ' HB3' HG23 ' A' ' 45' ' ' ILE . 3.2 mt-10 -95.43 113.68 25.36 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.901 -0.407 . . . . 2.07 109.901 178.083 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 44' ' ' VAL . . . . . 0.502 ' CG1' HG23 ' B' ' 36' ' ' ILE . 1.5 t -91.13 130.73 39.85 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 N-CA-C 109.602 -0.518 . . . . 0.13 109.602 176.133 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 45' ' ' ILE . . . . . 0.804 HG13 HG13 ' A' ' 45' ' ' ILE . 1.7 mp -109.41 118.13 56.03 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 N-CA-C 108.262 -1.014 . . . . 0.12 108.262 -177.446 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 46' ' ' LEU . . . . . 1.031 HD11 HD11 ' A' ' 46' ' ' LEU . 0.3 OUTLIER -113.02 116.8 30.49 Favored 'General case' 0 C--N 1.314 -0.935 0 O-C-N 123.665 0.603 . . . . 0.15 109.571 178.916 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 47' ' ' LYS . . . . . 0.905 ' HZ1' ' HE1' ' B' ' 37' ' ' PHE . 0.0 OUTLIER -126.81 155.28 43.11 Favored 'General case' 0 C--N 1.32 -0.694 0 C-N-CA 118.85 -1.14 . . . . 0.95 111.97 179.096 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 48' ' ' LYS . . . . . 0.624 ' HA ' ' O ' ' B' ' 33' ' ' PRO . 6.5 ptmt -49.58 -7.67 0.03 OUTLIER 'General case' 0 N--CA 1.476 0.873 0 N-CA-C 117.102 2.26 . . . . 0.64 117.102 -166.011 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 49' ' ' TYR . . . . . 0.755 ' CD1' HG21 ' A' ' 7' ' ' VAL . 19.7 t80 73.8 -52.92 0.69 Allowed 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 112.73 0.641 . . . . 1.26 112.73 170.967 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 50' ' ' SER . . . . . 0.712 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 26.9 t -50.6 -52.89 51.74 Favored Pre-proline 0 CA--C 1.541 0.628 0 CA-C-N 116.059 -0.519 . . . . 1.22 111.177 -175.48 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 51' ' ' PRO . . . . . 0.712 ' HD3' ' HB3' ' B' ' 50' ' ' SER . 59.8 Cg_endo -93.55 12.87 1.73 Allowed 'Trans proline' 0 C--N 1.352 0.754 0 C-N-CA 122.438 2.092 . . . . 0.56 111.791 171.293 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 52' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.236 0.361 0 CA-C-N 115.323 -0.853 . . . . 0.73 109.619 -175.734 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' ALA . . . . . 0.437 ' HA ' ' HB2' ' B' ' 37' ' ' PHE . . . . . . . . 0 N--CA 1.46 0.069 0 CA-C-O 121.466 0.651 . . . . 0.72 111.24 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.5 ' OG1' ' HA ' ' B' ' 37' ' ' PHE . 18.2 p -87.5 -45.89 10.08 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.563 -0.744 . . . . 0.41 111.365 -178.536 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' GLY . . . . . 0.453 ' H ' ' HB3' ' B' ' 37' ' ' PHE . . . 73.15 48.39 19.97 Favored Glycine 0 N--CA 1.444 -0.796 0 C-N-CA 120.829 -0.701 . . . . 0.32 112.969 173.149 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.798 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.5 tp -106.46 107.4 22.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 N-CA-C 109.155 -0.683 . . . . 0.31 109.155 174.995 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.693 HG21 ' CD1' ' B' ' 49' ' ' TYR . 55.7 t -76.05 136.61 24.43 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.909 0 CA-C-O 121.414 0.626 . . . . 0.28 110.527 179.852 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.58 ' HB3' ' CD1' ' B' ' 36' ' ' ILE . 2.5 tpp180 -130.94 116.22 17.57 Favored 'General case' 0 N--CA 1.433 -1.304 0 N-CA-C 107.069 -1.456 . . . . 1.99 107.069 -179.661 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' ARG . . . . . 0.553 ' C ' HD12 ' A' ' 10' ' ' ILE . 0.2 OUTLIER -82.48 101.68 10.85 Favored 'General case' 0 C--N 1.315 -0.931 0 N-CA-C 108.123 -1.066 . . . . 2.8 108.123 175.63 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.947 HG23 HD11 ' B' ' 34' ' ' LEU . 0.2 OUTLIER -7.05 -105.18 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.035 0 O-C-N 125.583 1.802 . . . . 0.33 114.681 -177.909 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ASP . . . . . 0.511 ' H ' HD13 ' A' ' 10' ' ' ILE . 47.6 p30 163.1 -151.33 0.0 OUTLIER 'General case' 0 CA--C 1.512 -0.482 0 C-N-CA 123.609 0.763 . . . . 1.13 109.013 176.356 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -78.91 -9.75 59.6 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 123.244 0.34 . . . . 2.26 111.288 -177.215 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -117.31 -58.06 2.08 Favored 'General case' 0 C--N 1.326 -0.454 0 O-C-N 122.237 -0.289 . . . . 0.53 110.292 -178.679 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.416 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 138.89 16.6 0.58 Allowed Glycine 0 N--CA 1.445 -0.748 0 C-N-CA 120.593 -0.813 . . . . 0.22 113.321 -177.922 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.618 ' HG2' HG22 ' B' ' 17' ' ' VAL . 0.8 OUTLIER -76.29 150.52 36.94 Favored 'General case' 0 CA--C 1.509 -0.603 0 CA-C-N 118.02 0.91 . . . . 0.69 109.837 177.406 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.738 HG21 HD13 ' B' ' 46' ' ' LEU . 54.3 t -106.73 96.87 4.98 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.29 0 N-CA-C 107.436 -1.32 . . . . 1.24 107.436 171.32 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.616 HG22 ' HG2' ' B' ' 15' ' ' ARG . 62.2 t -68.65 100.94 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.825 0 CA-C-N 115.366 -0.834 . . . . 0.28 110.06 -173.771 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.706 HG23 HD13 ' A' ' 22' ' ' ILE . 8.0 mt -93.83 114.9 64.3 Favored Pre-proline 0 N--CA 1.446 -0.641 0 CA-C-N 115.603 -0.726 . . . . 0.77 111.053 -177.171 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.592 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 30.9 Cg_exo -44.73 143.87 3.87 Favored 'Trans proline' 0 CA--C 1.513 -0.536 0 C-N-CA 123.403 2.736 . . . . 0.32 113.137 171.993 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.874 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -59.38 -15.82 19.02 Favored 'General case' 0 C--O 1.214 -0.797 0 CA-C-N 115.258 -0.883 . . . . 1.57 111.363 178.185 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.592 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 10.0 pt-20 -67.86 -21.06 65.19 Favored 'General case' 0 C--O 1.236 0.348 0 N-CA-C 111.63 0.233 . . . . 1.32 111.63 -177.51 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.706 HD13 HG23 ' A' ' 18' ' ' ILE . 5.0 mp -87.68 -49.16 14.8 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.369 0 N-CA-C 107.842 -1.17 . . . . 0.35 107.842 -179.414 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ARG . . . . . 0.639 ' HD3' ' N ' ' A' ' 24' ' ' ARG . 0.0 OUTLIER -51.69 -34.5 38.8 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-O 121.768 0.794 . . . . 1.5 109.769 168.296 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.639 ' N ' ' HD3' ' A' ' 23' ' ' ARG . 9.3 ttm180 -60.99 -51.89 67.32 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 114.771 -1.104 . . . . 2.96 110.943 177.506 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 27.5 m -65.19 -27.82 68.96 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-O 121.406 0.622 . . . . 0.4 110.587 175.187 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.847 ' HB3' HG13 ' A' ' 28' ' ' ILE . 2.3 mm? -65.01 -18.99 65.77 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.405 -0.816 . . . . 0.36 111.211 175.375 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.509 ' HB2' ' O ' ' A' ' 26' ' ' LEU . 5.7 mpt_? 71.42 14.72 6.35 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 123.437 0.695 . . . . 3.2 111.06 -174.307 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.847 HG13 ' HB3' ' A' ' 26' ' ' LEU . 2.9 mt -109.4 -157.21 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 CA-C-N 115.773 -0.649 . . . . 0.48 109.647 -175.71 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.74 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.2 OUTLIER -161.79 -153.79 0.3 Allowed 'General case' 0 C--N 1.325 -0.494 0 C-N-CA 123.026 0.53 . . . . 2.4 110.298 -176.211 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -71.5 44.79 0.1 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 122.097 0.951 . . . . 1.23 111.516 178.039 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.633 ' N ' HD11 ' B' ' 10' ' ' ILE . . . -161.36 33.87 0.38 Allowed Glycine 0 N--CA 1.441 -0.996 0 CA-C-N 114.331 -1.304 . . . . 0.36 110.496 177.656 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.461 ' HA ' ' HD3' ' A' ' 33' ' ' PRO . 29.2 t0 -94.45 119.4 66.44 Favored Pre-proline 0 C--N 1.327 -0.391 0 CA-C-N 115.168 -0.516 . . . . 1.26 109.753 176.453 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.629 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 3.3 Cg_endo -88.01 63.93 3.5 Favored 'Trans proline' 0 N--CA 1.452 -0.956 0 C-N-CA 123.916 3.077 . . . . 1.3 113.957 -177.214 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.589 HD12 ' H ' ' A' ' 34' ' ' LEU . 0.9 OUTLIER -64.66 154.54 36.21 Favored 'General case' 0 C--N 1.292 -1.924 0 C-N-CA 118.328 -1.349 . . . . 0.38 111.841 -177.128 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.763 ' O ' ' HA ' ' A' ' 46' ' ' LEU . 35.0 tt0 -109.4 113.5 26.37 Favored 'General case' 0 CA--C 1.494 -1.175 0 CA-C-N 113.369 -1.741 . . . . 1.12 108.291 -174.437 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.84 HG13 HD22 ' A' ' 46' ' ' LEU . 2.7 mp -84.4 109.49 17.74 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 O-C-N 124.143 0.902 . . . . 0.39 109.647 -178.836 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' PHE . . . . . 0.746 ' HD1' ' HA ' ' B' ' 3' ' ' ALA . 0.6 OUTLIER -149.31 121.48 8.33 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-O 121.228 0.537 . . . . 1.15 109.878 175.771 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.54 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 1.9 p -80.38 135.86 24.49 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.047 0 CA-C-O 121.208 0.527 . . . . 0.17 110.351 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.481 ' HB3' ' HG3' ' A' ' 40' ' ' ARG . 14.3 t70 -86.08 -40.33 15.84 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 114.99 -1.004 . . . . 1.11 111.529 -173.261 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' ARG . . . . . 0.481 ' HG3' ' HB3' ' A' ' 39' ' ' ASP . 8.3 mtp180 -132.08 -81.44 0.5 Allowed 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 112.788 0.662 . . . . 2.29 112.788 -163.061 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -122.19 -65.75 1.09 Allowed 'General case' 0 CA--C 1.507 -0.69 0 CA-C-O 121.581 0.705 . . . . 1.53 109.962 -176.18 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.546 ' O ' ' HA ' ' B' ' 47' ' ' LYS . . . -133.1 12.58 5.02 Favored Glycine 0 N--CA 1.438 -1.213 0 CA-C-N 114.816 -1.084 . . . . 0.32 111.638 -178.171 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.589 ' HB3' HG23 ' B' ' 45' ' ' ILE . 0.9 OUTLIER -92.57 105.97 18.04 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 108.757 -0.831 . . . . 1.97 108.757 177.346 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.55 HG11 HG23 ' A' ' 36' ' ' ILE . 2.4 t -89.67 131.24 37.43 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 N-CA-C 109.29 -0.633 . . . . 0.14 109.29 177.764 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.803 HG13 HG13 ' B' ' 45' ' ' ILE . 1.6 mp -108.85 116.07 51.02 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 N-CA-C 108.054 -1.091 . . . . 0.14 108.054 -176.028 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 1.048 HD11 HD11 ' B' ' 46' ' ' LEU . 0.7 OUTLIER -106.35 117.66 34.62 Favored 'General case' 0 C--N 1.316 -0.86 0 O-C-N 123.883 0.74 . . . . 0.23 109.402 178.418 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.756 ' HD2' ' HB3' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -129.49 143.82 51.0 Favored 'General case' 0 C--O 1.214 -0.773 0 C-N-CA 119.265 -0.974 . . . . 0.76 112.597 178.752 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.706 ' HG3' ' HG2' ' A' ' 51' ' ' PRO . 3.0 ptmt -39.86 -12.82 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.288 0 N-CA-C 117.833 2.531 . . . . 0.32 117.833 -169.921 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 0.629 ' HB3' ' HB2' ' A' ' 33' ' ' PRO . 27.9 t80 70.63 -57.11 0.59 Allowed 'General case' 0 N--CA 1.478 0.952 0 N-CA-C 113.437 0.903 . . . . 1.28 113.437 175.242 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.408 ' HB2' ' HD3' ' A' ' 51' ' ' PRO . 19.0 m -52.88 -52.64 63.05 Favored Pre-proline 0 CA--C 1.54 0.595 0 CA-C-N 115.644 -0.707 . . . . 1.36 111.951 -174.46 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.706 ' HG2' ' HG3' ' A' ' 48' ' ' LYS . 75.2 Cg_endo -90.55 10.65 2.87 Favored 'Trans proline' 0 C--N 1.35 0.618 0 C-N-CA 122.246 1.964 . . . . 0.58 111.726 168.615 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.412 HG13 ' C ' ' A' ' 51' ' ' PRO . 1.0 OUTLIER . . . . . 0 CA--C 1.538 0.511 0 CA-C-N 115.261 -0.882 . . . . 0.78 109.726 -175.565 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 3' ' ' ALA . . . . . 0.746 ' HA ' ' HD1' ' A' ' 37' ' ' PHE . . . . . . . . 0 N--CA 1.462 0.167 0 CA-C-O 121.615 0.721 . . . . 0.86 110.985 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 4' ' ' THR . . . . . 0.537 ' OG1' ' HA ' ' A' ' 37' ' ' PHE . 12.5 p -80.66 -45.74 16.71 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.354 -0.839 . . . . 0.43 111.944 -176.985 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 71.2 47.93 34.31 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 121.031 -0.604 . . . . 0.33 112.911 174.975 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 6' ' ' ILE . . . . . 0.808 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.1 tp -105.76 107.33 22.38 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 N-CA-C 109.263 -0.643 . . . . 0.3 109.263 175.443 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 7' ' ' VAL . . . . . 0.605 HG21 ' CD1' ' A' ' 49' ' ' TYR . 37.6 t -77.96 134.84 27.47 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.842 0 CA-C-N 115.627 -0.715 . . . . 0.27 110.412 -178.838 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 1.4 tpp180 -131.04 116.63 18.04 Favored 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 107.018 -1.475 . . . . 1.69 107.018 177.913 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 9' ' ' ARG . . . . . 0.518 ' HA ' ' HA ' ' A' ' 33' ' ' PRO . 13.9 ttt180 -79.03 103.45 8.98 Favored 'General case' 0 CA--C 1.505 -0.753 0 N-CA-C 108.381 -0.97 . . . . 2.71 108.381 174.53 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 10' ' ' ILE . . . . . 0.633 HD11 ' N ' ' A' ' 31' ' ' GLY . 0.3 OUTLIER -9.93 -106.15 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 O-C-N 125.895 1.997 . . . . 0.34 114.845 -176.599 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 11' ' ' ASP . . . . . 0.588 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 3.2 p-10 165.58 -164.42 0.01 OUTLIER 'General case' 0 CA--C 1.514 -0.405 0 N-CA-C 107.628 -1.249 . . . . 1.18 107.628 178.842 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 24.3 t70 -72.58 -10.63 60.02 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.012 0.434 . . . . 2.39 111.051 -179.014 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 13' ' ' LEU . . . . . 0.444 ' H ' ' CG ' ' B' ' 11' ' ' ASP . 2.4 tm? -108.47 -62.02 1.52 Allowed 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.4 -0.364 . . . . 0.4 110.922 -179.337 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 139.34 21.57 0.39 Allowed Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 120.799 -0.715 . . . . 0.21 112.0 -177.246 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 15' ' ' ARG . . . . . 0.616 ' HG2' HG22 ' A' ' 17' ' ' VAL . 1.7 mpt_? -75.44 150.12 38.36 Favored 'General case' 0 CA--C 1.505 -0.771 0 CA-C-O 121.617 0.723 . . . . 0.9 110.394 177.527 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 16' ' ' VAL . . . . . 0.801 HG21 HD13 ' A' ' 46' ' ' LEU . 61.4 t -108.18 92.74 2.17 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 N-CA-C 107.487 -1.301 . . . . 1.27 107.487 167.267 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 17' ' ' VAL . . . . . 0.618 HG22 ' HG2' ' A' ' 15' ' ' ARG . 46.8 t -67.34 98.54 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.79 0 CA-C-N 115.59 -0.732 . . . . 0.27 109.99 -173.133 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 18' ' ' ILE . . . . . 0.416 ' HB ' ' O ' ' A' ' 14' ' ' GLY . 8.7 mt -92.19 112.8 56.84 Favored Pre-proline 0 N--CA 1.445 -0.677 0 CA-C-N 115.415 -0.811 . . . . 0.82 110.819 -177.842 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 19' ' ' PRO . . . . . 0.621 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 71.0 Cg_exo -49.29 147.2 12.22 Favored 'Trans proline' 0 N--CA 1.458 -0.581 0 C-N-CA 123.23 2.62 . . . . 0.3 112.669 173.043 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 20' ' ' LYS . . . . . 1.043 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -64.81 -14.86 60.66 Favored 'General case' 0 C--O 1.211 -0.932 0 CA-C-N 115.387 -0.824 . . . . 1.77 111.369 -177.793 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 21' ' ' GLU . . . . . 0.621 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 1.1 pm0 -63.15 -23.88 67.64 Favored 'General case' 0 N--CA 1.47 0.54 0 N-CA-C 112.201 0.445 . . . . 1.92 112.201 176.71 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 5.3 mp -87.01 -50.34 14.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 108.032 -1.099 . . . . 0.44 108.032 -178.357 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 23' ' ' ARG . . . . . 0.574 ' HA ' ' HB2' ' B' ' 26' ' ' LEU . 0.0 OUTLIER -56.08 -27.97 55.77 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.098 -0.956 . . . . 1.4 110.061 170.497 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 24' ' ' ARG . . . . . 0.438 ' HB3' ' HA ' ' B' ' 21' ' ' GLU . 8.2 ttm180 -64.13 -53.2 53.33 Favored 'General case' 0 CA--C 1.507 -0.687 0 CA-C-N 115.23 -0.895 . . . . 3.19 110.903 173.989 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 28.3 m -67.06 -22.41 65.86 Favored 'General case' 0 N--CA 1.445 -0.698 0 CA-C-O 121.614 0.721 . . . . 0.4 110.22 178.485 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 26' ' ' LEU . . . . . 0.574 ' HB2' ' HA ' ' B' ' 23' ' ' ARG . 1.9 mm? -67.83 -18.85 64.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.08 -0.963 . . . . 0.33 110.655 173.489 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 27' ' ' ARG . . . . . 0.439 ' HB2' ' O ' ' B' ' 26' ' ' LEU . 7.2 mpt_? 68.52 21.0 8.27 Favored 'General case' 0 C--O 1.234 0.245 0 C-N-CA 123.517 0.727 . . . . 3.28 110.475 -174.367 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 28' ' ' ILE . . . . . 0.874 HG22 ' H ' ' B' ' 29' ' ' ARG . 6.6 mt -116.91 -163.67 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.462 -0.79 . . . . 0.37 109.434 -177.669 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 29' ' ' ARG . . . . . 0.874 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -156.06 -151.38 0.33 Allowed 'General case' 0 C--N 1.32 -0.681 0 C-N-CA 122.338 0.255 . . . . 2.15 110.723 -173.942 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 30' ' ' GLU . . . . . 0.451 ' H ' ' HB2' ' B' ' 29' ' ' ARG . 0.7 OUTLIER -73.43 36.74 0.09 Allowed 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 122.166 0.984 . . . . 1.18 111.669 -179.522 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 31' ' ' GLY . . . . . 0.599 ' CA ' HD11 ' A' ' 10' ' ' ILE . . . -154.12 39.63 0.67 Allowed Glycine 0 N--CA 1.434 -1.436 0 CA-C-N 114.107 -1.406 . . . . 0.35 110.026 175.105 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 32' ' ' ASP . . . . . 0.465 ' HA ' ' HD3' ' B' ' 33' ' ' PRO . 9.5 t0 -95.96 119.66 64.33 Favored Pre-proline 0 C--N 1.325 -0.493 0 CA-C-O 121.256 0.55 . . . . 1.29 110.049 175.147 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 33' ' ' PRO . . . . . 0.702 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 4.4 Cg_endo -87.07 76.35 2.27 Favored 'Trans proline' 0 C--O 1.205 -1.145 0 C-N-CA 123.547 2.831 . . . . 1.1 113.268 -178.905 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.947 HD11 HG23 ' A' ' 10' ' ' ILE . 0.1 OUTLIER -72.12 150.5 43.8 Favored 'General case' 0 C--N 1.284 -2.249 0 C-N-CA 117.776 -1.569 . . . . 0.44 111.343 -178.963 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 35' ' ' GLU . . . . . 0.766 ' O ' ' HA ' ' B' ' 46' ' ' LEU . 42.7 tt0 -105.1 115.32 30.07 Favored 'General case' 0 CA--C 1.492 -1.264 0 CA-C-N 114.067 -1.424 . . . . 1.1 107.822 -179.143 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 36' ' ' ILE . . . . . 0.922 HG13 HD22 ' B' ' 46' ' ' LEU . 3.1 mp -88.19 108.8 19.03 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 O-C-N 124.168 0.918 . . . . 0.62 109.336 -178.443 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 37' ' ' PHE . . . . . 0.5 ' HA ' ' OG1' ' A' ' 4' ' ' THR . 12.3 p90 -149.74 126.41 11.01 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 116.159 -0.473 . . . . 1.2 110.064 175.142 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 38' ' ' VAL . . . . . 0.532 ' HA ' ' HA ' ' B' ' 44' ' ' VAL . 0.8 OUTLIER -80.23 138.57 19.59 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-O 121.29 0.567 . . . . 0.2 110.571 -179.561 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 39' ' ' ASP . . . . . 0.683 ' HB3' ' HG3' ' B' ' 40' ' ' ARG . 8.1 t70 -80.9 -46.13 15.69 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 114.751 -1.113 . . . . 1.14 110.577 -177.726 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 40' ' ' ARG . . . . . 0.683 ' HG3' ' HB3' ' B' ' 39' ' ' ASP . 23.8 mtp180 -133.33 -92.53 0.35 Allowed 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.928 -0.578 . . . . 2.71 112.34 -166.55 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 41' ' ' ASP . . . . . 0.4 ' H ' ' HB2' ' B' ' 40' ' ' ARG . 18.4 t70 -102.3 -75.59 0.6 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.314 0.578 . . . . 1.32 110.395 -176.881 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 42' ' ' GLY . . . . . 0.523 ' O ' ' HA ' ' A' ' 47' ' ' LYS . . . -124.99 18.86 6.98 Favored Glycine 0 N--CA 1.44 -1.091 0 CA-C-N 115.376 -0.829 . . . . 0.34 112.201 -179.341 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 43' ' ' GLU . . . . . 0.516 ' HB3' HG23 ' A' ' 45' ' ' ILE . 1.3 mt-10 -93.52 104.91 17.01 Favored 'General case' 0 CA--C 1.51 -0.595 0 N-CA-C 108.932 -0.766 . . . . 2.07 108.932 176.533 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 44' ' ' VAL . . . . . 0.532 ' HA ' ' HA ' ' B' ' 38' ' ' VAL . 2.2 t -89.53 131.24 37.31 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 N-CA-C 109.441 -0.577 . . . . 0.13 109.441 177.194 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 45' ' ' ILE . . . . . 0.803 HG13 HG13 ' A' ' 45' ' ' ILE . 1.7 mp -108.04 117.5 53.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.463 0 N-CA-C 108.031 -1.1 . . . . 0.12 108.031 -176.937 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 46' ' ' LEU . . . . . 1.048 HD11 HD11 ' A' ' 46' ' ' LEU . 1.6 mt -108.53 117.24 33.66 Favored 'General case' 0 C--N 1.317 -0.813 0 O-C-N 123.9 0.75 . . . . 0.15 109.776 178.391 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 47' ' ' LYS . . . . . 0.546 ' HA ' ' O ' ' A' ' 42' ' ' GLY . 0.0 OUTLIER -130.15 147.34 51.87 Favored 'General case' 0 C--O 1.214 -0.8 0 C-N-CA 119.199 -1.0 . . . . 0.95 113.129 -179.919 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 48' ' ' LYS . . . . . 0.58 ' HG3' ' CG ' ' B' ' 51' ' ' PRO . 3.5 ptmt -44.83 -7.91 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.409 0 N-CA-C 118.065 2.617 . . . . 0.64 118.065 -168.781 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 49' ' ' TYR . . . . . 0.702 ' HB3' ' HB2' ' B' ' 33' ' ' PRO . 32.5 t80 69.72 -57.5 0.55 Allowed 'General case' 0 N--CA 1.48 1.051 0 N-CA-C 113.727 1.01 . . . . 1.26 113.727 173.506 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 50' ' ' SER . . . . . 0.681 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 9.1 t -51.24 -56.28 21.53 Favored Pre-proline 0 CA--C 1.539 0.528 0 CA-C-N 115.932 -0.576 . . . . 1.22 111.134 -173.484 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 51' ' ' PRO . . . . . 0.681 ' HD3' ' HB3' ' B' ' 50' ' ' SER . 59.1 Cg_endo -87.21 8.24 4.43 Favored 'Trans proline' 0 C--N 1.351 0.666 0 C-N-CA 122.174 1.916 . . . . 0.56 111.968 170.396 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 52' ' ' ILE . . . . . . . . . . . . . 1.6 mt . . . . . 0 CA--C 1.534 0.341 0 CA-C-N 115.137 -0.938 . . . . 0.73 108.863 -175.002 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 3' ' ' ALA . . . . . 0.451 ' HA ' ' HB2' ' B' ' 37' ' ' PHE . . . . . . . . 0 C--O 1.229 0.02 0 CA-C-O 121.583 0.706 . . . . 0.72 111.639 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.552 ' OG1' ' HA ' ' B' ' 37' ' ' PHE . 11.8 p -81.21 -35.1 31.73 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.579 -0.737 . . . . 0.41 111.647 -179.297 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 5' ' ' GLY . . . . . 0.585 ' H ' ' CB ' ' B' ' 37' ' ' PHE . . . 57.51 47.67 86.53 Favored Glycine 0 N--CA 1.445 -0.73 0 CA-C-N 115.735 -0.666 . . . . 0.32 112.68 173.958 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.697 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.8 tp -105.9 104.06 16.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 108.807 -0.812 . . . . 0.31 108.807 175.22 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.676 HG21 ' CG ' ' B' ' 49' ' ' TYR . 52.9 t -74.9 135.17 27.88 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.873 0 CA-C-N 115.522 -0.763 . . . . 0.28 109.943 179.481 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.541 ' HB3' HD13 ' B' ' 36' ' ' ILE . 1.7 tpp180 -131.84 117.13 18.12 Favored 'General case' 0 N--CA 1.431 -1.415 0 N-CA-C 106.899 -1.519 . . . . 1.99 106.899 -177.6 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' ARG . . . . . 0.542 ' C ' HD12 ' A' ' 10' ' ' ILE . 0.0 OUTLIER -78.44 101.74 7.46 Favored 'General case' 0 C--N 1.314 -0.954 0 N-CA-C 107.924 -1.139 . . . . 2.8 107.924 174.913 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.806 HG23 HD11 ' B' ' 34' ' ' LEU . 0.2 OUTLIER -5.63 -105.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.195 0 O-C-N 125.445 1.715 . . . . 0.33 114.587 -176.753 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ASP . . . . . 0.604 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 2.4 p-10 165.99 -162.49 0.01 OUTLIER 'General case' 0 CA--C 1.513 -0.472 0 N-CA-C 107.935 -1.135 . . . . 1.13 107.935 177.611 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 30.4 m-20 -76.45 -6.7 52.86 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 120.744 0.307 . . . . 2.26 111.301 -178.255 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.428 ' H ' ' CG ' ' A' ' 11' ' ' ASP . 2.9 tm? -114.75 -59.16 2.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.661 -0.245 . . . . 0.53 110.996 178.589 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.449 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 140.1 13.78 0.58 Allowed Glycine 0 N--CA 1.448 -0.5 0 C-N-CA 120.432 -0.889 . . . . 0.22 113.096 -178.805 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.765 ' HG2' HG22 ' B' ' 17' ' ' VAL . 0.9 OUTLIER -77.43 154.98 32.1 Favored 'General case' 0 CA--C 1.501 -0.933 0 N-CA-C 109.231 -0.655 . . . . 0.69 109.231 176.011 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.921 HG11 HD13 ' B' ' 46' ' ' LEU . 1.5 m -109.88 112.13 39.17 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.59 0 N-CA-C 107.355 -1.35 . . . . 1.24 107.355 166.901 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.68 HG22 ' HG2' ' B' ' 15' ' ' ARG . 59.6 t -73.16 95.94 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.427 -1.588 0 CA-C-N 114.449 -1.25 . . . . 0.28 109.657 -174.875 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.611 HG23 HD13 ' A' ' 22' ' ' ILE . 11.0 mt -86.28 110.92 35.13 Favored Pre-proline 0 N--CA 1.446 -0.641 0 CA-C-N 115.218 -0.901 . . . . 0.77 110.251 -179.588 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.597 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 67.5 Cg_exo -47.37 144.51 9.67 Favored 'Trans proline' 0 N--CA 1.459 -0.535 0 C-N-CA 123.115 2.544 . . . . 0.32 112.261 173.594 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.939 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -59.95 -15.29 20.78 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.775 -0.648 . . . . 1.57 111.706 -178.493 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.597 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 12.8 pt-20 -67.6 -19.79 65.29 Favored 'General case' 0 C--O 1.237 0.437 0 N-CA-C 112.062 0.393 . . . . 1.32 112.062 -178.723 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.611 HD13 HG23 ' A' ' 18' ' ' ILE . 4.8 mp -87.43 -44.45 16.04 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 N-CA-C 108.125 -1.065 . . . . 0.35 108.125 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ARG . . . . . 0.677 ' HA ' ' HB2' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -60.68 -30.52 69.97 Favored 'General case' 0 CA--C 1.521 -0.166 0 CA-C-O 121.883 0.849 . . . . 1.5 109.093 171.208 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 63.2 ttt180 -61.33 -51.49 68.61 Favored 'General case' 0 N--CA 1.441 -0.894 0 CA-C-N 114.619 -1.173 . . . . 2.96 110.455 176.187 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 22.7 m -66.68 -21.94 66.09 Favored 'General case' 0 CA--C 1.535 0.392 0 CA-C-O 121.527 0.679 . . . . 0.4 110.654 174.094 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.864 ' HB3' HG13 ' A' ' 28' ' ' ILE . 2.3 mm? -71.94 -18.14 62.03 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.964 -0.562 . . . . 0.36 110.605 174.201 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.429 ' HB2' ' O ' ' A' ' 26' ' ' LEU . 9.0 mpt_? 66.21 23.18 10.9 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-N 116.006 -0.543 . . . . 3.2 110.625 -175.069 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.864 HG13 ' HB3' ' A' ' 26' ' ' LEU . 2.6 mt -113.92 -154.61 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 115.865 -0.607 . . . . 0.48 109.91 -178.44 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.693 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -162.34 -156.3 0.41 Allowed 'General case' 0 C--N 1.321 -0.653 0 C-N-CA 122.686 0.394 . . . . 2.4 110.674 -173.951 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 30' ' ' GLU . . . . . 0.417 ' H ' ' HB2' ' A' ' 29' ' ' ARG . 1.8 mp0 -74.9 44.1 0.22 Allowed 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 122.132 0.968 . . . . 1.23 111.025 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.706 ' N ' HD11 ' B' ' 10' ' ' ILE . . . -156.98 26.3 0.5 Allowed Glycine 0 N--CA 1.439 -1.137 0 CA-C-N 114.055 -1.43 . . . . 0.36 110.999 176.757 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.418 ' HA ' ' HD3' ' A' ' 33' ' ' PRO . 9.2 t0 -85.7 122.5 73.12 Favored Pre-proline 0 C--N 1.327 -0.379 0 CA-C-O 121.108 0.48 . . . . 1.26 110.111 176.321 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.637 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 3.8 Cg_endo -91.08 62.81 1.28 Allowed 'Trans proline' 0 N--CA 1.451 -0.986 0 C-N-CA 123.855 3.037 . . . . 1.3 114.253 -175.684 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.978 HD11 HG23 ' B' ' 10' ' ' ILE . 0.0 OUTLIER -61.22 153.97 24.73 Favored 'General case' 0 C--N 1.298 -1.646 0 C-N-CA 118.884 -1.127 . . . . 0.38 112.046 -178.536 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.77 ' HB3' ' HB3' ' A' ' 47' ' ' LYS . 39.4 tt0 -107.84 113.83 27.34 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 112.938 -1.937 . . . . 1.12 107.392 -176.253 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.811 ' HB ' HG23 ' B' ' 6' ' ' ILE . 2.4 mp -86.32 107.34 16.53 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.058 0 N-CA-C 109.136 -0.69 . . . . 0.39 109.136 -179.481 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' PHE . . . . . 0.575 ' CB ' ' H ' ' B' ' 5' ' ' GLY . 2.2 p90 -149.17 120.88 8.07 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-O 121.44 0.638 . . . . 1.15 109.937 176.169 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.597 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 1.5 p -80.5 137.56 21.25 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.987 0 CA-C-N 115.803 -0.635 . . . . 0.17 110.555 -178.126 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.554 ' HB3' ' HG2' ' A' ' 40' ' ' ARG . 7.5 t70 -76.22 -40.91 50.95 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 114.831 -1.077 . . . . 1.11 111.669 -171.16 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' ARG . . . . . 0.554 ' HG2' ' HB3' ' A' ' 39' ' ' ASP . 0.3 OUTLIER -150.62 -74.77 0.15 Allowed 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 112.859 0.689 . . . . 2.29 112.859 -168.753 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -106.29 -74.16 0.66 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.171 0.51 . . . . 1.53 111.431 -175.688 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.534 ' HA3' HD11 ' B' ' 26' ' ' LEU . . . -135.82 12.74 4.21 Favored Glycine 0 N--CA 1.443 -0.866 0 CA-C-N 115.123 -0.944 . . . . 0.32 111.891 -175.738 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.503 ' O ' HG23 ' A' ' 38' ' ' VAL . 2.5 pm0 -92.82 106.77 18.69 Favored 'General case' 0 N--CA 1.446 -0.66 0 N-CA-C 110.051 -0.352 . . . . 1.97 110.051 175.183 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.623 HG11 HG23 ' A' ' 36' ' ' ILE . 2.5 t -87.57 134.84 26.78 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 N-CA-C 109.259 -0.645 . . . . 0.14 109.259 178.356 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.709 HG13 HG13 ' B' ' 45' ' ' ILE . 1.5 mp -110.69 118.11 56.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 N-CA-C 108.491 -0.929 . . . . 0.14 108.491 -178.077 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.953 HD11 HD11 ' B' ' 46' ' ' LEU . 6.8 mt -103.3 119.05 38.13 Favored 'General case' 0 C--N 1.32 -0.715 0 O-C-N 124.229 0.956 . . . . 0.23 109.906 -179.541 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.77 ' HB3' ' HB3' ' A' ' 35' ' ' GLU . 16.6 ttmt -121.2 130.2 53.58 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-N 115.434 -0.803 . . . . 0.76 111.905 -170.704 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.613 ' HE2' ' HG3' ' A' ' 51' ' ' PRO . 3.2 ptmt -45.23 -12.97 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 115.937 1.828 . . . . 0.32 115.937 -174.313 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 0.687 ' CD1' HG21 ' B' ' 7' ' ' VAL . 34.4 t80 68.36 -56.7 0.5 Allowed 'General case' 0 N--CA 1.473 0.69 0 C-N-CA 124.623 1.169 . . . . 1.28 114.046 174.224 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.402 ' HB2' ' HD3' ' A' ' 51' ' ' PRO . 36.1 m -53.41 -48.08 93.96 Favored Pre-proline 0 CA--C 1.542 0.636 0 CA-C-N 115.683 -0.69 . . . . 1.36 112.052 -173.691 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.613 ' HG3' ' HE2' ' A' ' 48' ' ' LYS . 60.6 Cg_endo -93.54 10.82 2.04 Favored 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 122.272 1.981 . . . . 0.58 111.779 167.924 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.4 ' H ' ' C ' ' A' ' 49' ' ' TYR . 1.0 OUTLIER . . . . . 0 C--O 1.233 0.218 0 N-CA-C 108.304 -0.998 . . . . 0.78 108.304 -171.35 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 3' ' ' ALA . . . . . 0.417 ' HA ' ' HD2' ' A' ' 37' ' ' PHE . . . . . . . . 0 N--CA 1.458 -0.074 0 CA-C-O 121.557 0.694 . . . . 0.86 111.766 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 4' ' ' THR . . . . . 0.473 ' OG1' ' HA ' ' A' ' 37' ' ' PHE . 12.0 p -84.67 -34.94 22.91 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.63 -0.714 . . . . 0.43 111.633 -178.221 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 5' ' ' GLY . . . . . 0.575 ' H ' ' CB ' ' A' ' 37' ' ' PHE . . . 58.43 48.07 86.15 Favored Glycine 0 N--CA 1.449 -0.487 0 CA-C-N 115.601 -0.727 . . . . 0.33 113.052 174.655 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 6' ' ' ILE . . . . . 0.811 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.4 tp -105.23 104.34 16.78 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 N-CA-C 109.224 -0.658 . . . . 0.3 109.224 175.817 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 7' ' ' VAL . . . . . 0.687 HG21 ' CD1' ' A' ' 49' ' ' TYR . 27.5 t -74.79 134.12 30.1 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.841 0 CA-C-N 115.462 -0.79 . . . . 0.27 110.083 -179.714 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 8' ' ' ARG . . . . . 0.515 ' HD3' ' N ' ' B' ' 9' ' ' ARG . 0.3 OUTLIER -131.97 120.06 21.94 Favored 'General case' 0 N--CA 1.441 -0.918 0 N-CA-C 106.862 -1.532 . . . . 1.69 106.862 179.132 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 9' ' ' ARG . . . . . 0.548 ' HA ' ' HA ' ' A' ' 33' ' ' PRO . 41.9 ttp180 -78.95 103.27 8.78 Favored 'General case' 0 N--CA 1.441 -0.903 0 N-CA-C 108.667 -0.864 . . . . 2.71 108.667 174.481 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 10' ' ' ILE . . . . . 0.978 HG23 HD11 ' A' ' 34' ' ' LEU . 0.3 OUTLIER -7.59 -100.38 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 O-C-N 125.66 1.85 . . . . 0.34 114.189 -175.31 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 11' ' ' ASP . . . . . 0.609 ' H ' HD13 ' B' ' 10' ' ' ILE . 13.5 p-10 161.54 -157.15 0.0 OUTLIER 'General case' 0 CA--C 1.505 -0.767 0 N-CA-C 107.889 -1.152 . . . . 1.18 107.889 175.088 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -88.64 22.69 2.51 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 120.688 0.28 . . . . 2.39 111.214 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 13' ' ' LEU . . . . . 0.411 ' HB3' ' HD2' ' B' ' 15' ' ' ARG . 2.3 tm? -137.86 -55.21 0.67 Allowed 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 109.862 -0.421 . . . . 0.4 109.862 175.564 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 14' ' ' GLY . . . . . 0.427 ' O ' ' HB ' ' A' ' 18' ' ' ILE . . . 131.97 11.85 2.0 Favored Glycine 0 N--CA 1.444 -0.8 0 C-N-CA 120.896 -0.669 . . . . 0.21 112.491 -177.83 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 15' ' ' ARG . . . . . 0.68 ' HG2' HG22 ' A' ' 17' ' ' VAL . 0.9 OUTLIER -74.11 152.14 39.95 Favored 'General case' 0 CA--C 1.504 -0.809 0 CA-C-O 121.445 0.641 . . . . 0.9 109.511 175.47 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 16' ' ' VAL . . . . . 0.736 HG13 HG13 ' A' ' 16' ' ' VAL . 0.2 OUTLIER -109.06 105.79 19.48 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 N-CA-C 107.697 -1.224 . . . . 1.27 107.697 167.641 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 17' ' ' VAL . . . . . 0.765 HG22 ' HG2' ' A' ' 15' ' ' ARG . 41.0 t -72.63 95.03 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.168 0 CA-C-N 114.724 -1.125 . . . . 0.27 109.827 -173.505 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 18' ' ' ILE . . . . . 0.574 HG23 HD13 ' B' ' 22' ' ' ILE . 11.7 mt -87.56 112.56 49.29 Favored Pre-proline 0 N--CA 1.445 -0.724 0 CA-C-N 115.436 -0.802 . . . . 0.82 110.503 -179.689 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 19' ' ' PRO . . . . . 0.692 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 84.9 Cg_exo -49.12 146.69 12.24 Favored 'Trans proline' 0 N--CA 1.459 -0.534 0 C-N-CA 123.045 2.497 . . . . 0.3 112.612 173.2 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 20' ' ' LYS . . . . . 0.917 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -60.79 -15.29 28.3 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.76 -0.655 . . . . 1.77 111.956 -179.357 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 21' ' ' GLU . . . . . 0.692 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 11.5 pt-20 -65.48 -21.12 66.6 Favored 'General case' 0 CA--C 1.536 0.428 0 N-CA-C 112.211 0.449 . . . . 1.92 112.211 -179.784 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 22' ' ' ILE . . . . . 0.574 HD13 HG23 ' B' ' 18' ' ' ILE . 5.2 mp -86.76 -48.78 15.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 108.264 -1.013 . . . . 0.44 108.264 179.835 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 23' ' ' ARG . . . . . 0.602 ' HA ' ' HB2' ' B' ' 26' ' ' LEU . 0.0 OUTLIER -55.89 -30.28 61.3 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 115.429 -0.805 . . . . 1.4 109.258 170.39 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 24' ' ' ARG . . . . . 0.597 ' N ' ' HD3' ' B' ' 23' ' ' ARG . 37.2 ttt180 -62.9 -52.35 63.42 Favored 'General case' 0 N--CA 1.45 -0.444 0 CA-C-N 114.772 -1.104 . . . . 3.19 110.858 176.427 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 51.6 m -64.22 -28.45 69.75 Favored 'General case' 0 CA--C 1.53 0.206 0 CA-C-O 121.17 0.509 . . . . 0.4 110.811 173.629 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 26' ' ' LEU . . . . . 0.617 ' HB3' HG13 ' B' ' 28' ' ' ILE . 1.6 mm? -66.21 -18.78 65.56 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.755 -0.657 . . . . 0.33 111.315 175.436 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 27' ' ' ARG . . . . . 0.459 ' HB2' ' O ' ' B' ' 26' ' ' LEU . 11.0 mpt_? 68.21 16.22 9.37 Favored 'General case' 0 N--CA 1.467 0.378 0 C-N-CA 123.192 0.597 . . . . 3.28 111.095 -174.608 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 28' ' ' ILE . . . . . 0.906 HG22 ' H ' ' B' ' 29' ' ' ARG . 7.8 mt -109.05 -160.8 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 115.825 -0.625 . . . . 0.37 109.725 -175.901 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 29' ' ' ARG . . . . . 0.906 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -157.89 -153.84 0.41 Allowed 'General case' 0 C--N 1.328 -0.365 0 C-N-CA 122.386 0.275 . . . . 2.15 110.826 -177.691 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 30' ' ' GLU . . . . . 0.416 ' H ' ' HB2' ' B' ' 29' ' ' ARG . 1.9 mp0 -70.57 40.19 0.05 Allowed 'General case' 0 N--CA 1.468 0.466 0 CA-C-O 121.537 0.684 . . . . 1.18 112.043 178.981 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 31' ' ' GLY . . . . . 0.668 ' N ' HD11 ' A' ' 10' ' ' ILE . . . -155.38 34.09 0.65 Allowed Glycine 0 N--CA 1.437 -1.234 0 CA-C-N 115.097 -0.956 . . . . 0.35 111.106 175.938 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 32' ' ' ASP . . . . . 0.518 ' HB2' HG21 ' B' ' 28' ' ' ILE . 15.9 t0 -93.22 124.59 57.38 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.105 0.479 . . . . 1.29 110.706 176.534 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 33' ' ' PRO . . . . . 0.676 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 3.3 Cg_endo -87.56 75.83 2.16 Favored 'Trans proline' 0 C--O 1.206 -1.09 0 C-N-CA 124.011 3.141 . . . . 1.1 113.68 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.806 HD11 HG23 ' A' ' 10' ' ' ILE . 1.0 OUTLIER -71.47 148.79 46.48 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.021 -1.472 . . . . 0.44 110.771 179.87 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 35' ' ' GLU . . . . . 0.687 ' O ' ' HA ' ' B' ' 46' ' ' LEU . 43.8 tt0 -103.78 110.74 22.96 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-N 114.417 -1.265 . . . . 1.1 107.625 -179.836 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 36' ' ' ILE . . . . . 0.954 HG13 HD22 ' B' ' 46' ' ' LEU . 2.3 mp -85.94 109.27 18.38 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.731 0 O-C-N 124.048 0.842 . . . . 0.62 109.236 -178.493 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 37' ' ' PHE . . . . . 0.585 ' CB ' ' H ' ' A' ' 5' ' ' GLY . 14.4 p90 -149.4 123.38 9.39 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 115.832 -0.622 . . . . 1.2 109.631 175.561 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 38' ' ' VAL . . . . . 0.623 ' HA ' ' HA ' ' B' ' 44' ' ' VAL . 1.4 p -79.91 136.05 24.26 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 CA-C-O 121.424 0.63 . . . . 0.2 110.229 -178.416 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 39' ' ' ASP . . . . . 0.589 ' OD1' ' HD3' ' B' ' 40' ' ' ARG . 12.6 t70 -69.48 -53.9 16.9 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 114.215 -1.357 . . . . 1.14 111.244 -173.993 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 40' ' ' ARG . . . . . 0.589 ' HD3' ' OD1' ' B' ' 39' ' ' ASP . 0.0 OUTLIER -139.34 -71.22 0.4 Allowed 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 113.019 0.748 . . . . 2.71 113.019 -174.308 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -106.48 -68.42 0.88 Allowed 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 112.089 0.403 . . . . 1.32 112.089 -173.153 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 42' ' ' GLY . . . . . 0.458 ' HA3' ' HD2' ' A' ' 48' ' ' LYS . . . -140.94 12.52 2.87 Favored Glycine 0 CA--C 1.501 -0.823 0 C-N-CA 120.71 -0.757 . . . . 0.34 111.862 -175.465 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 43' ' ' GLU . . . . . 0.587 ' HA ' ' O ' ' A' ' 46' ' ' LEU . 2.3 pm0 -93.05 104.96 17.12 Favored 'General case' 0 N--CA 1.443 -0.803 0 N-CA-C 109.568 -0.53 . . . . 2.07 109.568 174.991 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 44' ' ' VAL . . . . . 0.623 ' HA ' ' HA ' ' B' ' 38' ' ' VAL . 2.1 t -87.37 131.68 34.58 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 N-CA-C 109.696 -0.483 . . . . 0.13 109.696 179.329 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 45' ' ' ILE . . . . . 0.709 HG13 HG13 ' A' ' 45' ' ' ILE . 1.7 mp -108.29 118.47 55.99 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 N-CA-C 108.414 -0.958 . . . . 0.12 108.414 -177.592 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 46' ' ' LEU . . . . . 0.954 HD22 HG13 ' B' ' 36' ' ' ILE . 0.6 OUTLIER -109.9 117.1 32.93 Favored 'General case' 0 C--N 1.318 -0.788 0 O-C-N 123.612 0.57 . . . . 0.15 109.915 178.844 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 47' ' ' LYS . . . . . 0.591 ' HE3' ' HB3' ' B' ' 35' ' ' GLU . 0.0 OUTLIER -130.09 142.45 50.6 Favored 'General case' 0 C--N 1.318 -0.765 0 C-N-CA 119.617 -0.833 . . . . 0.95 112.877 -178.332 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 48' ' ' LYS . . . . . 0.573 ' HE2' ' HG3' ' B' ' 51' ' ' PRO . 4.3 ptmt -43.19 -9.2 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.638 0 N-CA-C 118.112 2.634 . . . . 0.64 118.112 -168.264 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 49' ' ' TYR . . . . . 0.676 ' CG ' HG21 ' A' ' 7' ' ' VAL . 5.9 t80 68.38 -52.75 0.55 Allowed 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 114.067 1.136 . . . . 1.26 114.067 174.326 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 50' ' ' SER . . . . . 0.634 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 32.2 t -51.55 -57.14 15.49 Favored Pre-proline 0 CA--C 1.535 0.386 0 C-N-CA 122.417 0.287 . . . . 1.22 111.099 -173.55 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 51' ' ' PRO . . . . . 0.634 ' HD3' ' HB3' ' B' ' 50' ' ' SER . 74.8 Cg_endo -85.01 9.07 4.3 Favored 'Trans proline' 0 C--N 1.35 0.652 0 C-N-CA 122.011 1.808 . . . . 0.56 111.159 170.174 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 52' ' ' ILE . . . . . 0.407 ' H ' ' C ' ' B' ' 49' ' ' TYR . 1.2 mt . . . . . 0 N--CA 1.449 -0.521 0 CA-C-N 114.814 -1.085 . . . . 0.73 108.666 -171.944 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' ALA . . . . . 0.591 ' HA ' ' HD2' ' B' ' 37' ' ' PHE . . . . . . . . 0 N--CA 1.466 0.359 0 CA-C-O 121.74 0.781 . . . . 0.72 111.33 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.816 ' H ' ' HB2' ' B' ' 37' ' ' PHE . 34.4 p -125.97 -35.73 2.44 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 115.504 -0.771 . . . . 0.41 111.915 -173.73 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 5' ' ' GLY . . . . . 0.514 ' H ' ' CB ' ' B' ' 37' ' ' PHE . . . 63.96 45.14 94.79 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.902 -0.666 . . . . 0.32 112.893 173.715 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.876 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.4 tp -104.11 105.2 18.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-O 121.354 0.597 . . . . 0.31 109.522 177.985 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.63 HG21 ' CD1' ' B' ' 49' ' ' TYR . 54.5 t -75.02 131.73 34.53 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-N 115.655 -0.702 . . . . 0.28 110.415 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.426 ' HG2' ' H ' ' A' ' 17' ' ' VAL . 2.9 tpp180 -127.58 114.6 17.62 Favored 'General case' 0 N--CA 1.434 -1.262 0 N-CA-C 106.522 -1.659 . . . . 1.99 106.522 177.781 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' ARG . . . . . 0.505 ' C ' HD12 ' A' ' 10' ' ' ILE . 0.6 OUTLIER -78.05 101.36 6.91 Favored 'General case' 0 C--N 1.308 -1.221 0 N-CA-C 107.611 -1.255 . . . . 2.8 107.611 174.708 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.612 HD11 ' N ' ' B' ' 31' ' ' GLY . 0.3 OUTLIER -7.44 -102.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.941 0 O-C-N 125.763 1.914 . . . . 0.33 113.928 -175.385 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ASP . . . . . 0.599 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 4.8 p-10 164.77 -159.47 0.0 OUTLIER 'General case' 0 CA--C 1.507 -0.677 0 N-CA-C 108.249 -1.019 . . . . 1.13 108.249 175.389 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 31.2 t70 -74.57 -17.84 60.67 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.014 0.435 . . . . 2.26 110.96 -179.173 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.413 ' H ' ' CG ' ' A' ' 11' ' ' ASP . 2.8 tm? -103.33 -59.07 1.77 Allowed 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.186 -0.461 . . . . 0.53 110.801 179.779 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.464 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 138.46 18.76 0.54 Allowed Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.214 -0.994 . . . . 0.22 113.211 -179.039 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.761 ' HB3' ' HB3' ' B' ' 15' ' ' ARG . 0.7 OUTLIER -81.01 157.37 25.5 Favored 'General case' 0 CA--C 1.491 -1.317 0 CA-C-N 117.965 0.882 . . . . 0.69 110.031 176.034 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.909 HG22 HG22 ' B' ' 16' ' ' VAL . 17.2 m -107.81 109.81 29.6 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.201 0 N-CA-C 106.945 -1.502 . . . . 1.24 106.945 164.77 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.812 HG22 ' HG2' ' B' ' 15' ' ' ARG . 57.6 t -71.71 94.75 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.433 -1.309 0 CA-C-N 115.091 -0.959 . . . . 0.28 109.278 -175.668 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.488 HD11 HD12 ' A' ' 46' ' ' LEU . 9.0 mt -82.37 109.79 17.9 Favored Pre-proline 0 N--CA 1.444 -0.761 0 CA-C-N 115.621 -0.718 . . . . 0.77 110.284 179.087 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.635 ' HD3' ' O ' ' A' ' 17' ' ' VAL . 95.8 Cg_exo -51.16 151.42 12.44 Favored 'Trans proline' 0 N--CA 1.454 -0.845 0 C-N-CA 123.053 2.502 . . . . 0.32 112.366 174.982 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.855 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -62.34 -25.14 67.74 Favored 'General case' 0 C--O 1.206 -1.194 0 CA-C-N 115.591 -0.731 . . . . 1.57 111.763 -176.823 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.3 pm0 -55.49 -25.65 38.19 Favored 'General case' 0 C--O 1.239 0.507 0 N-CA-C 112.854 0.687 . . . . 1.32 112.854 -178.447 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.464 HD13 HG23 ' A' ' 18' ' ' ILE . 5.1 mp -88.18 -46.95 15.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 108.404 -0.961 . . . . 0.35 108.404 -176.574 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ARG . . . . . 0.526 ' NE ' ' HA ' ' A' ' 29' ' ' ARG . 0.0 OUTLIER -61.02 -30.86 70.56 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 115.158 -0.928 . . . . 1.5 109.583 174.744 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 76.7 ttt180 -63.84 -52.11 61.61 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 114.269 -1.332 . . . . 2.96 111.011 175.532 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 25.6 m -64.51 -27.99 69.35 Favored 'General case' 0 C--O 1.234 0.268 0 CA-C-O 121.137 0.494 . . . . 0.4 110.537 175.377 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.832 ' HB3' HG13 ' A' ' 28' ' ' ILE . 0.8 OUTLIER -65.23 -18.1 65.04 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.534 -0.757 . . . . 0.36 111.162 175.225 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.502 ' HB2' ' O ' ' A' ' 26' ' ' LEU . 10.4 mpt_? 70.45 20.28 6.03 Favored 'General case' 0 N--CA 1.466 0.34 0 C-N-CA 123.259 0.624 . . . . 3.2 110.529 -174.109 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.832 HG13 ' HB3' ' A' ' 26' ' ' LEU . 2.7 mt -116.43 -166.06 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 115.728 -0.669 . . . . 0.48 109.458 -176.526 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.717 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -154.76 -155.5 0.58 Allowed 'General case' 0 C--N 1.321 -0.658 0 C-N-CA 122.267 0.227 . . . . 2.4 110.677 -173.327 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 30' ' ' GLU . . . . . 0.412 ' H ' ' HB2' ' A' ' 29' ' ' ARG . 1.7 mp0 -75.11 44.32 0.24 Allowed 'General case' 0 C--N 1.332 -0.168 0 CA-C-O 122.122 0.963 . . . . 1.23 111.366 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.688 ' N ' HD11 ' B' ' 10' ' ' ILE . . . -154.65 19.75 0.6 Allowed Glycine 0 N--CA 1.441 -1.024 0 CA-C-N 113.833 -1.531 . . . . 0.36 110.687 175.785 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.448 ' HA ' ' HD3' ' A' ' 33' ' ' PRO . 17.7 t0 -79.65 120.23 79.47 Favored Pre-proline 0 N--CA 1.464 0.245 0 CA-C-O 121.437 0.637 . . . . 1.26 109.784 176.942 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.618 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 2.8 Cg_endo -88.98 56.35 2.09 Favored 'Trans proline' 0 N--CA 1.452 -0.946 0 C-N-CA 123.891 3.06 . . . . 1.3 114.165 -174.494 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.921 HD11 HG23 ' B' ' 10' ' ' ILE . 0.0 OUTLIER -59.28 154.44 16.45 Favored 'General case' 0 C--N 1.3 -1.545 0 C-N-CA 118.823 -1.151 . . . . 0.38 112.34 -173.478 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.85 ' HB3' ' HD2' ' A' ' 47' ' ' LYS . 42.7 tt0 -107.92 112.48 25.11 Favored 'General case' 0 CA--C 1.491 -1.31 0 CA-C-N 113.847 -1.524 . . . . 1.12 107.909 -175.834 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.836 ' HB ' HG23 ' B' ' 6' ' ' ILE . 2.8 mt -82.65 111.05 18.47 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 O-C-N 124.424 1.078 . . . . 0.39 109.736 -179.752 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' PHE . . . . . 0.544 ' HB2' ' H ' ' B' ' 4' ' ' THR . 0.6 OUTLIER -151.11 125.88 9.68 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-O 120.98 0.419 . . . . 1.15 110.003 173.586 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.511 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 1.1 p -80.5 138.76 19.21 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 CA-C-O 120.921 0.391 . . . . 0.17 110.798 -177.158 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.694 ' OD2' ' HD2' ' A' ' 40' ' ' ARG . 14.2 t70 -84.29 -49.42 8.77 Favored 'General case' 0 CA--C 1.513 -0.45 0 CA-C-N 115.802 -0.635 . . . . 1.11 111.823 -173.988 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' ARG . . . . . 0.694 ' HD2' ' OD2' ' A' ' 39' ' ' ASP . 0.0 OUTLIER -135.81 -96.63 0.24 Allowed 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.632 -0.713 . . . . 2.29 112.516 -165.972 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -84.85 -74.24 0.4 Allowed 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.529 0.68 . . . . 1.53 110.826 -177.03 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.653 ' HA3' HD11 ' B' ' 26' ' ' LEU . . . -138.25 26.03 2.85 Favored Glycine 0 N--CA 1.439 -1.103 0 CA-C-N 115.207 -0.906 . . . . 0.32 110.918 -178.366 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.636 ' HB3' HG23 ' B' ' 45' ' ' ILE . 2.3 mt-10 -94.89 109.2 21.22 Favored 'General case' 0 N--CA 1.446 -0.641 0 N-CA-C 109.161 -0.681 . . . . 1.97 109.161 179.028 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.588 ' CG1' HG23 ' A' ' 36' ' ' ILE . 2.0 t -89.2 131.41 36.57 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.961 0 N-CA-C 109.268 -0.641 . . . . 0.14 109.268 177.79 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.77 HG13 HG13 ' B' ' 45' ' ' ILE . 1.6 mp -110.44 115.96 51.14 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.223 0 N-CA-C 108.312 -0.996 . . . . 0.14 108.312 -176.397 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.952 HD11 HD11 ' B' ' 46' ' ' LEU . 0.3 OUTLIER -109.6 117.52 34.15 Favored 'General case' 0 C--N 1.315 -0.923 0 O-C-N 123.785 0.678 . . . . 0.23 109.643 179.803 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.85 ' HD2' ' HB3' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -130.91 144.1 51.21 Favored 'General case' 0 C--O 1.215 -0.752 0 C-N-CA 118.695 -1.202 . . . . 0.76 112.844 176.303 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.633 ' HG3' ' HD2' ' A' ' 51' ' ' PRO . 1.0 OUTLIER -20.46 -25.93 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.981 0 N-CA-C 119.532 3.16 . . . . 0.32 119.532 -179.08 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 0.729 ' CD1' HG21 ' B' ' 7' ' ' VAL . 37.0 t80 72.87 -38.48 0.42 Allowed 'General case' 0 N--CA 1.479 1.002 0 CA-C-N 119.795 1.18 . . . . 1.28 112.339 -179.036 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.662 ' HB3' ' HD3' ' A' ' 51' ' ' PRO . 26.3 t -52.32 -52.32 63.98 Favored Pre-proline 0 CA--C 1.542 0.667 0 CA-C-N 116.29 -0.414 . . . . 1.36 110.559 -177.741 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.662 ' HD3' ' HB3' ' A' ' 50' ' ' SER . 97.9 Cg_endo -92.21 7.93 3.02 Favored 'Trans proline' 0 C--N 1.355 0.896 0 C-N-CA 122.387 2.058 . . . . 0.58 111.733 167.176 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.499 ' H ' ' C ' ' A' ' 49' ' ' TYR . 0.3 OUTLIER . . . . . 0 N--CA 1.467 0.394 0 CA-C-N 114.809 -1.087 . . . . 0.78 111.515 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 3' ' ' ALA . . . . . 0.534 ' HA ' ' HD2' ' A' ' 37' ' ' PHE . . . . . . . . 0 N--CA 1.468 0.474 0 CA-C-O 121.338 0.59 . . . . 0.86 111.51 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 4' ' ' THR . . . . . 0.544 ' H ' ' HB2' ' A' ' 37' ' ' PHE . 29.0 p -114.7 -39.75 3.69 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.939 -0.573 . . . . 0.43 111.802 -174.608 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 5' ' ' GLY . . . . . 0.46 ' H ' ' CB ' ' A' ' 37' ' ' PHE . . . 67.62 45.51 76.14 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 121.107 -0.568 . . . . 0.33 112.612 177.428 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 6' ' ' ILE . . . . . 0.836 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.3 tp -103.33 105.3 18.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.514 0.673 . . . . 0.3 109.732 177.855 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 7' ' ' VAL . . . . . 0.729 HG21 ' CD1' ' A' ' 49' ' ' TYR . 24.3 t -74.93 131.57 34.8 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.838 0 CA-C-N 115.401 -0.818 . . . . 0.27 110.899 -179.573 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 8' ' ' ARG . . . . . 0.527 ' HB3' ' CD1' ' A' ' 36' ' ' ILE . 1.7 tpp180 -128.72 116.04 18.92 Favored 'General case' 0 N--CA 1.435 -1.211 0 N-CA-C 106.867 -1.531 . . . . 1.69 106.867 178.525 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 9' ' ' ARG . . . . . 0.604 ' HA ' ' HA ' ' A' ' 33' ' ' PRO . 29.2 ttp180 -78.23 102.84 7.81 Favored 'General case' 0 C--N 1.311 -1.075 0 N-CA-C 107.897 -1.149 . . . . 2.71 107.897 173.103 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 10' ' ' ILE . . . . . 0.921 HG23 HD11 ' A' ' 34' ' ' LEU . 0.4 OUTLIER -8.57 -100.77 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 O-C-N 125.948 2.03 . . . . 0.34 113.94 -174.645 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 11' ' ' ASP . . . . . 0.647 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 2.8 p-10 164.28 -161.05 0.0 OUTLIER 'General case' 0 CA--C 1.512 -0.501 0 N-CA-C 108.484 -0.932 . . . . 1.18 108.484 175.676 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -75.09 -14.32 60.57 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.11 0.481 . . . . 2.39 110.283 -177.237 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 13' ' ' LEU . . . . . 0.434 ' H ' ' CG ' ' B' ' 11' ' ' ASP . 2.2 tm? -105.56 -61.03 1.54 Allowed 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.826 -0.625 . . . . 0.4 110.526 179.541 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 139.84 16.16 0.52 Allowed Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.847 -0.692 . . . . 0.21 112.357 -176.764 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 15' ' ' ARG . . . . . 0.812 ' HG2' HG22 ' A' ' 17' ' ' VAL . 2.0 mtt180 -79.74 153.87 28.93 Favored 'General case' 0 CA--C 1.501 -0.934 0 N-CA-C 109.598 -0.519 . . . . 0.9 109.598 176.668 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 16' ' ' VAL . . . . . 0.909 HG22 HG22 ' A' ' 16' ' ' VAL . 1.1 m -110.5 111.83 37.91 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.673 0 N-CA-C 107.042 -1.466 . . . . 1.27 107.042 166.884 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 17' ' ' VAL . . . . . 0.536 ' O ' ' HD3' ' B' ' 19' ' ' PRO . 62.3 t -72.71 98.62 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.165 0 CA-C-N 114.699 -1.137 . . . . 0.27 109.668 -173.713 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 18' ' ' ILE . . . . . 0.464 ' HB ' ' O ' ' A' ' 14' ' ' GLY . 8.9 mt -85.88 111.73 40.0 Favored Pre-proline 0 N--CA 1.443 -0.794 0 CA-C-N 115.276 -0.875 . . . . 0.82 110.43 179.799 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 19' ' ' PRO . . . . . 0.664 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 71.4 Cg_exo -50.24 145.4 20.72 Favored 'Trans proline' 0 N--CA 1.456 -0.721 0 C-N-CA 122.965 2.444 . . . . 0.3 112.335 173.793 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 20' ' ' LYS . . . . . 1.002 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -61.65 -15.45 39.95 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 115.465 -0.789 . . . . 1.77 111.696 179.827 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 21' ' ' GLU . . . . . 0.664 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 11.7 pt-20 -64.65 -25.78 68.1 Favored 'General case' 0 C--O 1.237 0.446 0 N-CA-C 112.035 0.383 . . . . 1.92 112.035 -179.197 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 4.9 mp -88.65 -44.58 15.55 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.271 0 N-CA-C 107.578 -1.267 . . . . 0.44 107.578 -177.885 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 23' ' ' ARG . . . . . 0.422 ' HA ' ' HB2' ' B' ' 26' ' ' LEU . 0.0 OUTLIER -59.36 -31.02 68.82 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-N 115.08 -0.964 . . . . 1.4 109.514 174.124 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 24' ' ' ARG . . . . . 0.429 HH11 ' HD2' ' B' ' 24' ' ' ARG . 22.3 ttt85 -67.7 -49.9 60.29 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 114.767 -1.106 . . . . 3.19 110.745 177.251 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 26.2 m -65.52 -25.99 67.7 Favored 'General case' 0 CA--C 1.535 0.373 0 CA-C-O 121.412 0.625 . . . . 0.4 110.159 176.451 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 26' ' ' LEU . . . . . 0.717 ' HB3' HG13 ' B' ' 28' ' ' ILE . 0.6 OUTLIER -65.91 -17.4 64.63 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.398 -0.819 . . . . 0.33 110.805 173.038 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 27' ' ' ARG . . . . . 0.422 ' HB2' ' O ' ' B' ' 26' ' ' LEU . 8.6 mpt_? 65.97 27.02 10.86 Favored 'General case' 0 C--O 1.233 0.195 0 CA-C-O 121.458 0.647 . . . . 3.28 110.032 -173.839 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 28' ' ' ILE . . . . . 0.844 HG22 ' H ' ' B' ' 29' ' ' ARG . 5.1 mt -119.84 -167.7 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.379 -0.828 . . . . 0.37 109.683 -179.311 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 29' ' ' ARG . . . . . 0.844 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -153.67 -155.59 0.61 Allowed 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 122.093 0.157 . . . . 2.15 110.934 -176.041 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 30' ' ' GLU . . . . . 0.426 ' H ' ' HB2' ' B' ' 29' ' ' ARG . 1.0 OUTLIER -73.46 39.72 0.1 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 122.104 0.954 . . . . 1.18 111.983 -178.998 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 31' ' ' GLY . . . . . 0.612 ' N ' HD11 ' A' ' 10' ' ' ILE . . . -151.43 26.71 0.97 Allowed Glycine 0 N--CA 1.442 -0.935 0 CA-C-N 114.232 -1.349 . . . . 0.35 110.303 172.774 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 32' ' ' ASP . . . . . 0.501 ' O ' ' HA ' ' A' ' 9' ' ' ARG . 21.9 t0 -81.7 121.14 79.3 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.183 0.516 . . . . 1.29 109.916 176.807 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 33' ' ' PRO . . . . . 0.724 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 5.2 Cg_endo -87.42 72.1 3.08 Favored 'Trans proline' 0 C--O 1.204 -1.207 0 C-N-CA 123.606 2.871 . . . . 1.1 113.437 -177.853 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.61 ' H ' HD12 ' B' ' 34' ' ' LEU . 2.2 mp -71.27 151.85 43.84 Favored 'General case' 0 C--N 1.286 -2.184 0 C-N-CA 117.779 -1.569 . . . . 0.44 111.386 -176.381 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 35' ' ' GLU . . . . . 0.958 ' HB3' ' HD2' ' B' ' 47' ' ' LYS . 44.1 tt0 -108.97 113.79 26.98 Favored 'General case' 0 CA--C 1.49 -1.351 0 CA-C-N 114.388 -1.278 . . . . 1.1 107.919 -177.822 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 36' ' ' ILE . . . . . 0.876 ' HB ' HG23 ' A' ' 6' ' ' ILE . 20.5 mt -88.43 109.99 20.59 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.905 0 O-C-N 124.78 1.3 . . . . 0.62 110.027 -176.169 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 37' ' ' PHE . . . . . 0.816 ' HB2' ' H ' ' A' ' 4' ' ' THR . 1.3 p90 -150.48 129.33 12.47 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 109.561 -0.533 . . . . 1.2 109.561 174.777 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 38' ' ' VAL . . . . . 0.554 ' HA ' ' HA ' ' B' ' 44' ' ' VAL . 0.9 OUTLIER -79.8 142.2 14.27 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.945 0 C-N-CA 120.834 -0.346 . . . . 0.2 110.256 -178.649 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 39' ' ' ASP . . . . . 0.511 ' OD2' ' HD2' ' B' ' 40' ' ' ARG . 38.8 t70 -87.64 -47.1 8.95 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.854 -0.612 . . . . 1.14 111.84 -175.079 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 40' ' ' ARG . . . . . 0.511 ' HD2' ' OD2' ' B' ' 39' ' ' ASP . 0.0 OUTLIER -137.08 -100.97 0.2 Allowed 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 112.535 0.569 . . . . 2.71 112.535 -175.736 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -76.36 -74.54 0.23 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.119 0.485 . . . . 1.32 111.36 -174.503 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 42' ' ' GLY . . . . . 0.548 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -136.77 25.12 3.11 Favored Glycine 0 N--CA 1.444 -0.826 0 C-N-CA 120.833 -0.699 . . . . 0.34 111.426 -178.831 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 43' ' ' GLU . . . . . 0.591 ' HB3' HG23 ' A' ' 45' ' ' ILE . 2.4 mt-10 -94.23 108.87 20.71 Favored 'General case' 0 CA--C 1.509 -0.6 0 N-CA-C 109.792 -0.448 . . . . 2.07 109.792 179.277 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 44' ' ' VAL . . . . . 0.554 ' HA ' ' HA ' ' B' ' 38' ' ' VAL . 1.5 t -88.92 131.0 37.38 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 N-CA-C 109.55 -0.537 . . . . 0.13 109.55 177.831 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 45' ' ' ILE . . . . . 0.77 HG13 HG13 ' A' ' 45' ' ' ILE . 1.7 mp -109.29 118.9 57.67 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.197 0 N-CA-C 108.405 -0.961 . . . . 0.12 108.405 -177.27 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 46' ' ' LEU . . . . . 0.952 HD11 HD11 ' A' ' 46' ' ' LEU . 0.5 OUTLIER -110.64 118.11 35.32 Favored 'General case' 0 C--N 1.316 -0.87 0 O-C-N 123.732 0.645 . . . . 0.15 109.862 178.486 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 47' ' ' LYS . . . . . 0.958 ' HD2' ' HB3' ' B' ' 35' ' ' GLU . 0.0 OUTLIER -129.19 148.11 51.1 Favored 'General case' 0 C--O 1.214 -0.81 0 C-N-CA 119.116 -1.034 . . . . 0.95 112.289 177.294 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 48' ' ' LYS . . . . . 0.592 ' HG3' ' CD ' ' B' ' 51' ' ' PRO . 2.8 ptmt -45.14 -6.28 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.235 0 N-CA-C 117.895 2.554 . . . . 0.64 117.895 -168.004 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 49' ' ' TYR . . . . . 0.724 ' HB3' ' HB2' ' B' ' 33' ' ' PRO . 24.3 t80 68.3 -36.18 0.31 Allowed 'General case' 0 N--CA 1.48 1.03 0 CA-C-N 119.372 0.987 . . . . 1.26 113.28 176.43 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 50' ' ' SER . . . . . 0.614 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 12.4 t -53.97 -47.79 95.92 Favored Pre-proline 0 CA--C 1.542 0.667 0 C-N-CA 122.588 0.355 . . . . 1.22 110.991 -177.194 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 51' ' ' PRO . . . . . 0.614 ' HD3' ' HB3' ' B' ' 50' ' ' SER . 62.6 Cg_endo -94.56 5.52 2.52 Favored 'Trans proline' 0 C--N 1.352 0.751 0 C-N-CA 122.451 2.101 . . . . 0.56 111.919 165.551 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 52' ' ' ILE . . . . . 0.516 ' H ' ' C ' ' B' ' 49' ' ' TYR . 0.6 OUTLIER . . . . . 0 N--CA 1.465 0.293 0 CA-C-N 115.083 -0.962 . . . . 0.73 110.595 -177.324 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 3' ' ' ALA . . . . . 0.83 ' HA ' ' HD2' ' B' ' 37' ' ' PHE . . . . . . . . 0 CA--C 1.519 -0.225 0 CA-C-O 121.602 0.715 . . . . 0.72 110.802 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.473 ' OG1' ' HA ' ' B' ' 37' ' ' PHE . 15.6 p -94.08 -35.92 12.34 Favored 'General case' 0 N--CA 1.444 -0.74 0 CA-C-N 115.181 -0.918 . . . . 0.41 112.036 -176.506 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 60.93 49.37 79.42 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.969 -0.634 . . . . 0.32 112.799 176.317 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.876 HG23 ' HB ' ' B' ' 36' ' ' ILE . 0.9 OUTLIER -108.28 111.3 35.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 N-CA-C 109.379 -0.6 . . . . 0.31 109.379 175.295 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.665 HG21 ' CD1' ' B' ' 49' ' ' TYR . 48.6 t -82.38 133.96 28.03 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 CA-C-O 121.303 0.573 . . . . 0.28 111.013 -178.3 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.601 ' HB3' HD11 ' B' ' 36' ' ' ILE . 3.9 tpt180 -126.2 107.86 10.76 Favored 'General case' 0 N--CA 1.441 -0.903 0 N-CA-C 107.074 -1.454 . . . . 1.99 107.074 -178.545 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' ARG . . . . . 0.525 ' C ' HD12 ' A' ' 10' ' ' ILE . 2.0 ttt180 -78.34 102.0 7.49 Favored 'General case' 0 CA--C 1.503 -0.847 0 N-CA-C 108.02 -1.104 . . . . 2.8 108.02 175.73 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.706 HD11 ' CA ' ' B' ' 31' ' ' GLY . 0.2 OUTLIER -10.12 -109.25 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 O-C-N 126.036 2.085 . . . . 0.33 114.551 -179.187 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ASP . . . . . 0.63 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 4.2 p-10 158.81 -167.73 0.0 OUTLIER 'General case' 0 CA--C 1.513 -0.458 0 N-CA-C 107.202 -1.407 . . . . 1.13 107.202 177.465 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -67.52 -22.78 65.42 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.013 0.435 . . . . 2.26 110.887 -178.241 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.432 HD22 ' HA ' ' A' ' 13' ' ' LEU . 2.2 tm? -95.28 -61.54 1.46 Allowed 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.081 -0.509 . . . . 0.53 109.733 177.916 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.575 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 132.71 21.49 0.9 Allowed Glycine 0 N--CA 1.443 -0.892 0 C-N-CA 119.898 -1.144 . . . . 0.22 114.131 178.242 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.492 ' HA ' ' HA ' ' B' ' 17' ' ' VAL . 0.9 OUTLIER -79.01 155.08 29.01 Favored 'General case' 0 CA--C 1.504 -0.814 0 CA-C-N 118.91 1.355 . . . . 0.69 110.941 179.249 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.637 HG21 HD13 ' B' ' 46' ' ' LEU . 52.9 t -111.43 101.37 12.45 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.379 0 N-CA-C 107.39 -1.337 . . . . 1.24 107.39 169.322 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.709 HG22 ' HG2' ' B' ' 15' ' ' ARG . 65.5 t -68.21 106.91 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.016 0 CA-C-N 115.038 -0.983 . . . . 0.28 109.775 -175.767 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 31.7 mm -90.8 109.26 33.45 Favored Pre-proline 0 N--CA 1.446 -0.636 0 CA-C-N 115.79 -0.641 . . . . 0.77 110.547 -177.895 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.578 ' HD3' ' O ' ' A' ' 17' ' ' VAL . 81.0 Cg_exo -50.37 138.04 38.63 Favored 'Trans proline' 0 N--CA 1.459 -0.521 0 C-N-CA 123.015 2.476 . . . . 0.32 112.359 173.904 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.882 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -57.64 -14.21 5.12 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-N 114.947 -1.024 . . . . 1.57 112.265 179.297 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.541 ' O ' ' HB3' ' A' ' 24' ' ' ARG . 11.9 pt-20 -67.08 -25.78 66.4 Favored 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 118.088 0.404 . . . . 1.32 111.724 -178.256 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 4.5 mp -88.15 -42.73 15.1 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.321 0 N-CA-C 107.622 -1.251 . . . . 0.35 107.622 -178.081 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ARG . . . . . 0.657 ' HA ' ' HB2' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -58.51 -31.78 68.21 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 114.848 -1.069 . . . . 1.5 109.145 171.936 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.541 ' HB3' ' O ' ' A' ' 21' ' ' GLU . 55.3 ttp180 -60.19 -52.85 63.56 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 114.313 -1.312 . . . . 2.96 110.785 174.092 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 17.3 m -65.85 -27.02 67.93 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-O 121.247 0.546 . . . . 0.4 110.961 174.699 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.675 ' HB3' HG13 ' A' ' 28' ' ' ILE . 1.3 mm? -64.68 -20.86 66.55 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.759 -0.655 . . . . 0.36 110.638 173.879 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 8.1 tpt180 71.17 18.83 5.66 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-O 121.793 0.806 . . . . 3.2 109.302 -176.431 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.774 HG22 ' H ' ' A' ' 29' ' ' ARG . 3.9 mt -114.9 -167.44 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 114.894 -1.048 . . . . 0.48 108.797 -177.926 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ARG . . . . . 0.774 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -155.54 -149.63 0.27 Allowed 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 110.149 -0.315 . . . . 2.4 110.149 -173.282 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 4.6 mp0 -72.58 40.15 0.08 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.471 0.653 . . . . 1.23 111.962 178.754 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.665 ' CA ' HD11 ' B' ' 10' ' ' ILE . . . -154.87 33.37 0.67 Allowed Glycine 0 N--CA 1.438 -1.189 0 N-CA-C 110.609 -0.996 . . . . 0.36 110.609 171.592 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.5 ' HA ' ' HD3' ' A' ' 33' ' ' PRO . 45.9 t0 -90.1 116.3 66.04 Favored Pre-proline 0 C--O 1.234 0.275 0 CA-C-O 121.327 0.584 . . . . 1.26 109.602 175.742 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.553 ' HA ' ' HA ' ' B' ' 9' ' ' ARG . 1.3 Cg_endo -87.28 63.29 4.07 Favored 'Trans proline' 0 N--CA 1.454 -0.835 0 C-N-CA 123.984 3.122 . . . . 1.3 113.83 -177.064 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.616 HD12 ' H ' ' A' ' 34' ' ' LEU . 0.7 OUTLIER -63.87 153.79 35.72 Favored 'General case' 0 C--N 1.295 -1.785 0 C-N-CA 118.709 -1.196 . . . . 0.38 111.695 -175.636 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.925 ' HB3' ' HD2' ' A' ' 47' ' ' LYS . 34.4 tt0 -111.0 117.2 32.7 Favored 'General case' 0 CA--C 1.491 -1.29 0 CA-C-N 113.926 -1.488 . . . . 1.12 108.987 -173.362 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.905 ' HB ' HG23 ' B' ' 6' ' ' ILE . 3.0 mp -84.19 111.59 20.28 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.828 0 O-C-N 124.534 1.146 . . . . 0.39 109.546 -178.875 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' PHE . . . . . 0.876 ' HD2' ' HA ' ' B' ' 3' ' ' ALA . 0.3 OUTLIER -149.79 124.01 9.52 Favored 'General case' 0 C--N 1.313 -1.002 0 CA-C-O 121.13 0.491 . . . . 1.15 109.711 172.416 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.508 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 1.4 p -80.16 137.22 21.92 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 CA-C-O 121.198 0.523 . . . . 0.17 110.143 -179.409 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.667 ' OD2' ' HD2' ' A' ' 40' ' ' ARG . 32.3 t70 -88.24 -46.07 9.54 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.256 -0.884 . . . . 1.11 111.699 -172.877 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 40' ' ' ARG . . . . . 0.797 ' HG3' ' HG3' ' A' ' 43' ' ' GLU . 0.1 OUTLIER -128.19 -90.64 0.5 Allowed 'General case' 0 C--N 1.313 -1.008 0 CA-C-N 114.773 -1.103 . . . . 2.29 112.054 -162.402 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -112.74 -66.51 1.08 Allowed 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 121.02 0.438 . . . . 1.53 111.205 -176.402 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.563 ' HA3' HD11 ' B' ' 26' ' ' LEU . . . -130.33 13.68 5.67 Favored Glycine 0 CA--C 1.499 -0.914 0 C-N-CA 120.462 -0.875 . . . . 0.32 111.628 -178.309 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.797 ' HG3' ' HG3' ' A' ' 40' ' ' ARG . 0.9 OUTLIER -97.04 110.54 23.06 Favored 'General case' 0 C--N 1.319 -0.732 0 N-CA-C 109.299 -0.63 . . . . 1.97 109.299 -178.794 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.582 ' CG1' HG23 ' A' ' 36' ' ' ILE . 2.3 t -90.71 133.76 31.51 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.788 0 CA-C-N 115.718 -0.674 . . . . 0.14 109.239 177.924 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.736 HG13 HG13 ' B' ' 45' ' ' ILE . 1.7 mp -110.93 116.6 52.92 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 N-CA-C 108.644 -0.873 . . . . 0.14 108.644 -175.77 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.94 HD11 HD11 ' B' ' 46' ' ' LEU . 0.9 OUTLIER -108.08 118.36 36.54 Favored 'General case' 0 C--N 1.319 -0.76 0 O-C-N 123.764 0.665 . . . . 0.23 109.753 179.53 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.925 ' HD2' ' HB3' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -130.08 148.73 51.96 Favored 'General case' 0 C--O 1.216 -0.689 0 C-N-CA 118.849 -1.14 . . . . 0.76 113.152 178.001 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.596 ' HE2' ' HG3' ' A' ' 51' ' ' PRO . 2.2 ptmt -35.83 -19.73 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.09 0 N-CA-C 118.044 2.609 . . . . 0.32 118.044 -172.288 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 0.585 ' CD1' HG21 ' B' ' 7' ' ' VAL . 22.6 t80 74.95 -54.26 0.66 Allowed 'General case' 0 N--CA 1.475 0.822 0 C-N-CA 123.455 0.702 . . . . 1.28 112.79 177.408 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.713 ' HB3' ' HD3' ' A' ' 51' ' ' PRO . 6.8 t -52.15 -53.13 55.62 Favored Pre-proline 0 CA--C 1.541 0.601 0 CA-C-N 116.388 -0.369 . . . . 1.36 111.182 -173.675 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.713 ' HD3' ' HB3' ' A' ' 50' ' ' SER . 48.5 Cg_endo -92.98 14.39 1.6 Allowed 'Trans proline' 0 C--N 1.348 0.536 0 C-N-CA 122.376 2.051 . . . . 0.58 111.539 170.101 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.41 HG13 ' C ' ' A' ' 51' ' ' PRO . 0.9 OUTLIER . . . . . 0 C--O 1.235 0.306 0 CA-C-N 115.429 -0.805 . . . . 0.78 109.86 -176.861 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 3' ' ' ALA . . . . . 0.876 ' HA ' ' HD2' ' A' ' 37' ' ' PHE . . . . . . . . 0 CA--C 1.517 -0.296 0 CA-C-O 121.495 0.664 . . . . 0.86 110.979 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 4' ' ' THR . . . . . . . . . . . . . 20.4 p -91.68 -29.14 17.02 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.219 -0.901 . . . . 0.43 112.275 -173.607 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 56.99 47.74 84.93 Favored Glycine 0 N--CA 1.45 -0.415 0 CA-C-N 115.711 -0.677 . . . . 0.33 112.99 175.306 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 6' ' ' ILE . . . . . 0.905 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.0 OUTLIER -107.66 109.46 28.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-O 121.178 0.513 . . . . 0.3 109.623 176.602 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 7' ' ' VAL . . . . . 0.602 ' HA ' ' HA ' ' A' ' 35' ' ' GLU . 14.7 t -80.52 135.38 25.39 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.996 0 CA-C-N 115.609 -0.723 . . . . 0.27 110.783 -177.813 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 8' ' ' ARG . . . . . 0.526 ' CZ ' HG23 ' B' ' 17' ' ' VAL . 1.1 tpt180 -128.09 112.77 14.95 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 107.405 -1.331 . . . . 1.69 107.405 178.696 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 9' ' ' ARG . . . . . 0.553 ' HA ' ' HA ' ' A' ' 33' ' ' PRO . 13.2 ttt180 -78.83 104.45 9.47 Favored 'General case' 0 CA--C 1.501 -0.929 0 N-CA-C 108.287 -1.005 . . . . 2.71 108.287 174.564 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 10' ' ' ILE . . . . . 0.665 HD11 ' CA ' ' A' ' 31' ' ' GLY . 0.2 OUTLIER -15.28 -103.24 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 O-C-N 125.822 1.951 . . . . 0.34 114.65 -177.248 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 11' ' ' ASP . . . . . 0.575 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 6.4 p-10 158.08 -161.08 0.0 OUTLIER 'General case' 0 CA--C 1.506 -0.727 0 N-CA-C 106.604 -1.628 . . . . 1.18 106.604 174.854 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 38.4 t70 -77.04 -17.5 58.74 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.512 0.673 . . . . 2.39 110.209 -178.151 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 13' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -96.1 -61.6 1.41 Allowed 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.575 -0.739 . . . . 0.4 110.029 177.296 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 134.61 24.06 0.62 Allowed Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.477 -0.868 . . . . 0.21 112.649 179.624 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 15' ' ' ARG . . . . . 0.709 ' HG2' HG22 ' A' ' 17' ' ' VAL . 56.4 mtt180 -77.82 147.28 35.28 Favored 'General case' 0 CA--C 1.51 -0.575 0 CA-C-O 121.479 0.657 . . . . 0.9 111.175 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 16' ' ' VAL . . . . . 0.526 HG11 HD13 ' A' ' 46' ' ' LEU . 92.7 t -113.76 99.49 8.72 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.13 0 N-CA-C 107.861 -1.163 . . . . 1.27 107.861 168.335 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 17' ' ' VAL . . . . . 0.568 ' O ' ' HD3' ' B' ' 19' ' ' PRO . 60.8 t -66.41 106.33 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.847 0 CA-C-N 115.475 -0.784 . . . . 0.27 109.847 -173.635 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 18' ' ' ILE . . . . . 0.575 ' HB ' ' O ' ' A' ' 14' ' ' GLY . 22.7 mm -89.29 109.08 28.62 Favored Pre-proline 0 C--N 1.32 -0.696 0 CA-C-N 115.587 -0.733 . . . . 0.82 110.24 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 19' ' ' PRO . . . . . 0.632 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 93.6 Cg_exo -53.45 144.05 52.46 Favored 'Trans proline' 0 N--CA 1.454 -0.799 0 C-N-CA 122.558 2.172 . . . . 0.3 112.22 174.773 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 20' ' ' LYS . . . . . 0.989 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -64.64 -13.71 54.99 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 115.556 -0.747 . . . . 1.77 111.434 -179.396 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 21' ' ' GLU . . . . . 0.632 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 11.2 pt-20 -65.42 -26.32 67.92 Favored 'General case' 0 C--O 1.239 0.549 0 N-CA-C 112.688 0.625 . . . . 1.92 112.688 179.556 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 22' ' ' ILE . . . . . 0.438 ' H ' HD12 ' B' ' 22' ' ' ILE . 3.9 mp -88.58 -42.09 14.52 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.252 0 N-CA-C 107.807 -1.183 . . . . 0.44 107.807 -179.214 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 23' ' ' ARG . . . . . 0.577 ' HA ' ' HB2' ' B' ' 26' ' ' LEU . 0.0 OUTLIER -57.69 -30.24 65.33 Favored 'General case' 0 N--CA 1.461 0.125 0 CA-C-N 114.927 -1.033 . . . . 1.4 109.126 170.973 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 24' ' ' ARG . . . . . 0.535 ' HB3' ' O ' ' B' ' 21' ' ' GLU . 21.4 ttp180 -62.28 -53.17 59.06 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 114.289 -1.323 . . . . 3.19 110.942 174.838 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 30.4 m -62.41 -32.0 72.77 Favored 'General case' 0 C--O 1.235 0.334 0 CA-C-O 121.409 0.624 . . . . 0.4 110.557 174.278 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 26' ' ' LEU . . . . . 0.663 ' HB3' HG13 ' B' ' 28' ' ' ILE . 0.9 OUTLIER -64.3 -19.86 65.7 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.212 -0.903 . . . . 0.33 110.705 176.131 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 27' ' ' ARG . . . . . 0.45 ' HD2' ' HA ' ' B' ' 27' ' ' ARG . 11.9 tpt180 68.05 22.45 8.43 Favored 'General case' 0 N--CA 1.461 0.097 0 CA-C-O 121.802 0.81 . . . . 3.28 109.906 -177.627 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 28' ' ' ILE . . . . . 0.84 HG22 ' H ' ' B' ' 29' ' ' ARG . 6.3 mt -111.92 -161.21 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.203 -0.908 . . . . 0.37 109.162 -179.306 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 29' ' ' ARG . . . . . 0.84 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -158.68 -157.37 0.61 Allowed 'General case' 0 C--N 1.32 -0.689 0 O-C-N 122.468 -0.145 . . . . 2.15 110.618 -173.229 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 30' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -70.31 43.48 0.06 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.975 0.893 . . . . 1.18 111.598 176.777 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 31' ' ' GLY . . . . . 0.706 ' CA ' HD11 ' A' ' 10' ' ' ILE . . . -161.12 36.06 0.41 Allowed Glycine 0 N--CA 1.436 -1.338 0 CA-C-N 114.282 -1.326 . . . . 0.35 110.358 174.614 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 32' ' ' ASP . . . . . 0.497 ' HA ' ' HD3' ' B' ' 33' ' ' PRO . 16.5 t0 -93.21 121.13 66.06 Favored Pre-proline 0 C--N 1.327 -0.409 0 CA-C-N 115.006 -0.597 . . . . 1.29 110.223 175.558 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 33' ' ' PRO . . . . . 0.674 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 3.9 Cg_endo -86.84 75.6 2.57 Favored 'Trans proline' 0 C--O 1.206 -1.084 0 C-N-CA 123.664 2.909 . . . . 1.1 113.31 -179.919 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.699 ' H ' HD12 ' B' ' 34' ' ' LEU . 1.4 mp -71.14 150.52 45.34 Favored 'General case' 0 C--N 1.286 -2.182 0 C-N-CA 117.909 -1.516 . . . . 0.44 111.326 -178.535 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 35' ' ' GLU . . . . . 0.783 ' HB3' ' HD2' ' B' ' 47' ' ' LYS . 45.2 tt0 -109.69 114.45 28.06 Favored 'General case' 0 CA--C 1.49 -1.343 0 CA-C-N 114.384 -1.28 . . . . 1.1 108.326 -177.656 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 36' ' ' ILE . . . . . 0.986 HG13 HD22 ' B' ' 46' ' ' LEU . 3.0 mp -87.46 112.16 22.94 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 O-C-N 124.761 1.288 . . . . 0.62 109.697 -177.221 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 37' ' ' PHE . . . . . 0.83 ' HD2' ' HA ' ' A' ' 3' ' ' ALA . 1.1 p90 -150.14 128.42 12.07 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 116.003 -0.544 . . . . 1.2 109.661 172.39 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 38' ' ' VAL . . . . . 0.525 ' HA ' ' HA ' ' B' ' 44' ' ' VAL . 0.6 OUTLIER -80.67 140.19 17.03 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.982 0 CA-C-O 121.281 0.563 . . . . 0.2 110.57 -179.636 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 39' ' ' ASP . . . . . 0.631 ' OD1' ' HD2' ' B' ' 40' ' ' ARG . 16.1 t70 -84.85 -50.74 7.29 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.16 -0.927 . . . . 1.14 111.731 -173.249 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 40' ' ' ARG . . . . . 0.631 ' HD2' ' OD1' ' B' ' 39' ' ' ASP . 0.0 OUTLIER -134.99 -87.15 0.38 Allowed 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 112.661 0.615 . . . . 2.71 112.661 -172.437 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -95.17 -78.81 0.44 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.025 0.44 . . . . 1.32 110.999 -175.673 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 42' ' ' GLY . . . . . 0.479 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -125.84 16.02 6.95 Favored Glycine 0 N--CA 1.443 -0.843 0 C-N-CA 120.576 -0.821 . . . . 0.34 112.043 -177.481 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 43' ' ' GLU . . . . . 0.428 ' H ' ' HG2' ' B' ' 43' ' ' GLU . 0.0 OUTLIER -92.03 107.64 19.35 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.511 -0.552 . . . . 2.07 109.511 -178.765 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 44' ' ' VAL . . . . . 0.564 ' O ' ' HA ' ' A' ' 45' ' ' ILE . 1.9 t -89.83 133.71 31.03 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.852 0 N-CA-C 109.402 -0.592 . . . . 0.13 109.402 176.441 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 45' ' ' ILE . . . . . 0.736 HG13 HG13 ' A' ' 45' ' ' ILE . 1.7 mp -110.62 119.86 60.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 N-CA-C 108.582 -0.896 . . . . 0.12 108.582 -177.281 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 46' ' ' LEU . . . . . 0.986 HD22 HG13 ' B' ' 36' ' ' ILE . 0.6 OUTLIER -112.13 117.54 32.88 Favored 'General case' 0 C--N 1.32 -0.696 0 O-C-N 123.682 0.614 . . . . 0.15 109.936 178.333 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 47' ' ' LYS . . . . . 0.783 ' HD2' ' HB3' ' B' ' 35' ' ' GLU . 0.0 OUTLIER -130.95 152.94 49.71 Favored 'General case' 0 C--O 1.213 -0.848 0 C-N-CA 119.254 -0.978 . . . . 0.95 113.033 177.516 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 48' ' ' LYS . . . . . 0.664 ' HE3' HD11 ' B' ' 28' ' ' ILE . 12.5 ptmt -49.87 -4.4 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.011 0 N-CA-C 117.713 2.486 . . . . 0.64 117.713 -166.727 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 49' ' ' TYR . . . . . 0.674 ' HB3' ' HB2' ' B' ' 33' ' ' PRO . 28.7 t80 71.73 -54.53 0.67 Allowed 'General case' 0 N--CA 1.477 0.88 0 N-CA-C 113.549 0.944 . . . . 1.26 113.549 172.027 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 50' ' ' SER . . . . . 0.69 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 9.2 t -51.55 -55.88 25.61 Favored Pre-proline 0 CA--C 1.539 0.548 0 CA-C-N 116.05 -0.523 . . . . 1.22 111.035 -173.518 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 51' ' ' PRO . . . . . 0.69 ' HD3' ' HB3' ' B' ' 50' ' ' SER . 41.3 Cg_endo -89.81 12.95 2.45 Favored 'Trans proline' 0 C--N 1.351 0.705 0 C-N-CA 122.172 1.915 . . . . 0.56 111.514 170.698 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 52' ' ' ILE . . . . . . . . . . . . . 1.1 mt . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 115.199 -0.909 . . . . 0.73 109.714 -176.66 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 52.6 ttm . . . . . 0 N--CA 1.478 0.945 0 CA-C-O 119.631 -0.224 . . . . 5.91 111.037 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 19.9 mmmt 57.47 -93.25 0.04 OUTLIER 'General case' 0 CA--C 1.515 -0.395 0 O-C-N 123.617 0.573 . . . . 3.71 110.649 -175.691 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.51 ' HA ' ' HB2' ' B' ' 37' ' ' PHE . . . 71.15 126.43 0.03 OUTLIER 'General case' 0 C--N 1.311 -1.096 0 CA-C-N 113.953 -1.476 . . . . 0.72 113.459 172.779 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.682 ' H ' ' HB2' ' B' ' 37' ' ' PHE . 10.6 p -110.28 -48.02 3.22 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 114.968 -1.015 . . . . 0.41 109.893 172.007 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 78.68 51.65 5.43 Favored Glycine 0 N--CA 1.446 -0.646 0 CA-C-N 115.431 -0.804 . . . . 0.32 112.912 172.001 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.807 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.5 tp -107.99 107.17 22.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 N-CA-C 109.273 -0.64 . . . . 0.31 109.273 172.939 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.741 ' HA ' ' O ' ' B' ' 34' ' ' LEU . 44.2 t -78.28 133.73 29.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-N 116.102 -0.499 . . . . 0.28 110.565 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.577 ' HB3' ' CD1' ' B' ' 36' ' ' ILE . 0.4 OUTLIER -129.69 123.06 30.22 Favored 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 107.387 -1.338 . . . . 1.99 107.387 -178.237 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.529 ' HA ' ' HA ' ' B' ' 33' ' ' PRO . 0.0 OUTLIER -83.82 103.02 12.76 Favored 'General case' 0 C--N 1.314 -0.947 0 N-CA-C 107.754 -1.202 . . . . 2.8 107.754 173.246 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.789 HG23 HD11 ' B' ' 34' ' ' LEU . 0.2 OUTLIER -9.97 -102.53 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.13 0 O-C-N 125.291 1.619 . . . . 0.33 114.595 -175.4 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ASP . . . . . 0.577 ' H ' HD13 ' A' ' 10' ' ' ILE . 27.9 p-10 163.33 -165.03 0.01 OUTLIER 'General case' 0 CA--C 1.506 -0.722 0 N-CA-C 107.86 -1.163 . . . . 1.13 107.86 175.175 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ASP . . . . . 0.502 ' HA ' ' HG2' ' B' ' 30' ' ' GLU . 12.8 p-10 -80.97 14.38 2.27 Favored 'General case' 0 C--N 1.318 -0.796 0 O-C-N 123.376 0.423 . . . . 2.26 111.284 -176.648 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -129.96 -55.14 1.13 Allowed 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 109.931 -0.396 . . . . 0.53 109.931 176.799 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.554 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 135.79 7.48 1.82 Allowed Glycine 0 N--CA 1.444 -0.776 0 C-N-CA 120.606 -0.807 . . . . 0.22 113.156 -179.014 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.735 ' HG2' HG22 ' B' ' 17' ' ' VAL . 0.5 OUTLIER -77.76 156.03 30.81 Favored 'General case' 0 CA--C 1.495 -1.149 0 CA-C-N 117.813 0.806 . . . . 0.69 109.912 178.304 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 1.045 HG22 HG22 ' B' ' 16' ' ' VAL . 0.8 OUTLIER -112.2 115.09 48.89 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.86 0 N-CA-C 107.508 -1.293 . . . . 1.24 107.508 167.954 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.702 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 46.9 t -73.35 98.21 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 CA-C-N 114.801 -1.09 . . . . 0.28 109.355 -174.281 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.514 ' HB ' ' O ' ' B' ' 14' ' ' GLY . 33.7 mm -83.96 106.97 8.98 Favored Pre-proline 0 N--CA 1.448 -0.529 0 O-C-N 123.844 0.715 . . . . 0.77 109.907 179.849 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.715 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 58.6 Cg_exo -47.1 143.86 9.56 Favored 'Trans proline' 0 N--CA 1.455 -0.784 0 C-N-CA 122.958 2.439 . . . . 0.32 112.391 174.769 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.927 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -62.4 -15.58 49.87 Favored 'General case' 0 C--O 1.206 -1.236 0 CA-C-N 115.427 -0.806 . . . . 1.57 110.763 -179.405 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.715 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 9.6 pt-20 -64.0 -24.07 67.57 Favored 'General case' 0 CA--C 1.532 0.278 0 N-CA-C 112.307 0.484 . . . . 1.32 112.307 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.2 mp -87.34 -45.24 16.24 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.24 0 N-CA-C 108.2 -1.037 . . . . 0.35 108.2 -179.303 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ARG . . . . . 0.735 ' HA ' ' HB2' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -62.96 -26.95 69.07 Favored 'General case' 0 C--N 1.333 -0.137 0 CA-C-N 115.393 -0.822 . . . . 1.5 109.516 173.322 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 34.9 ttm180 -64.41 -49.15 72.67 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 114.94 -1.027 . . . . 2.96 110.712 172.683 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 17.7 m -63.41 -27.41 69.28 Favored 'General case' 0 CA--C 1.532 0.265 0 CA-C-O 121.09 0.471 . . . . 0.4 110.781 171.166 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.771 ' HB3' HG13 ' A' ' 28' ' ' ILE . 2.2 mm? -69.81 -22.13 63.33 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.038 -0.528 . . . . 0.36 110.688 172.764 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.416 ' HB2' ' O ' ' A' ' 26' ' ' LEU . 0.0 OUTLIER 67.33 23.75 9.17 Favored 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 123.574 0.75 . . . . 3.2 111.306 -174.218 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.771 HG13 ' HB3' ' A' ' 26' ' ' LEU . 3.6 mt -113.24 -159.68 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 116.013 -0.54 . . . . 0.48 109.959 -176.77 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.717 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -159.21 -159.41 0.76 Allowed 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 117.786 0.266 . . . . 2.4 111.545 -169.208 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 30' ' ' GLU . . . . . 0.512 ' HG2' ' HA ' ' B' ' 12' ' ' ASP . 59.0 mp0 -70.28 32.73 0.04 OUTLIER 'General case' 0 N--CA 1.469 0.515 0 C-N-CA 123.613 0.765 . . . . 1.23 112.673 178.303 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.575 ' N ' HD11 ' B' ' 10' ' ' ILE . . . -148.59 23.92 1.34 Allowed Glycine 0 N--CA 1.44 -1.072 0 N-CA-C 110.297 -1.121 . . . . 0.36 110.297 173.178 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.633 ' O ' HG13 ' B' ' 10' ' ' ILE . 14.8 t0 -83.04 122.51 77.77 Favored Pre-proline 0 C--N 1.326 -0.447 0 CA-C-N 114.774 -0.713 . . . . 1.26 109.751 175.663 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.725 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 9.7 Cg_endo -85.66 149.2 9.92 Favored 'Trans proline' 0 N--CA 1.433 -2.03 0 C-N-CA 122.367 2.045 . . . . 1.3 110.522 175.753 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.841 HD11 HG23 ' B' ' 10' ' ' ILE . 0.9 OUTLIER -140.0 150.95 45.07 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 120.386 -0.526 . . . . 0.38 109.739 174.887 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.685 ' HB3' ' HB3' ' A' ' 47' ' ' LYS . 36.1 tt0 -103.48 110.27 22.24 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 107.05 -1.463 . . . . 1.12 107.05 -178.802 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.801 ' HB ' HG23 ' B' ' 6' ' ' ILE . 2.1 mp -85.52 107.81 16.6 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.981 0 O-C-N 124.113 0.883 . . . . 0.39 108.757 -179.218 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' PHE . . . . . 0.685 ' HB2' ' H ' ' B' ' 4' ' ' THR . 6.2 p90 -149.38 127.34 11.89 Favored 'General case' 0 C--N 1.313 -0.988 0 CA-C-N 115.875 -0.602 . . . . 1.15 109.555 177.36 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.487 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 2.1 p -80.02 142.2 14.25 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.071 0 CA-C-N 115.941 -0.572 . . . . 0.17 110.004 -178.375 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.538 ' OD2' ' HD3' ' A' ' 40' ' ' ARG . 28.9 t70 -87.6 -43.08 12.25 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.904 -0.589 . . . . 1.11 111.722 -175.474 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' ARG . . . . . 0.573 ' HG3' ' HG3' ' A' ' 43' ' ' GLU . 0.0 OUTLIER -138.42 -90.05 0.22 Allowed 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 112.797 0.666 . . . . 2.29 112.797 -167.473 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 31.4 t70 -100.76 -71.91 0.69 Allowed 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.025 0.441 . . . . 1.53 110.85 -177.772 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.585 ' HA3' HD11 ' B' ' 26' ' ' LEU . . . -133.34 24.12 3.77 Favored Glycine 0 N--CA 1.445 -0.75 0 C-N-CA 120.466 -0.873 . . . . 0.32 112.123 -178.845 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.573 ' HG3' ' HG3' ' A' ' 40' ' ' ARG . 1.5 mt-10 -98.1 109.86 22.54 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 109.081 -0.711 . . . . 1.97 109.081 176.017 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.5 ' C ' HD12 ' A' ' 45' ' ' ILE . 1.6 t -90.0 134.25 29.59 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.875 0 N-CA-C 109.461 -0.57 . . . . 0.14 109.461 178.339 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.804 HG13 HG13 ' B' ' 45' ' ' ILE . 1.5 mp -109.08 122.72 64.19 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 N-CA-C 108.131 -1.063 . . . . 0.14 108.131 -177.095 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.798 HD11 HD11 ' B' ' 46' ' ' LEU . 4.9 mt -106.07 117.77 34.89 Favored 'General case' 0 C--N 1.319 -0.741 0 O-C-N 123.869 0.731 . . . . 0.23 109.728 178.286 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.973 ' HE2' ' HB3' ' A' ' 53' ' ' SER . 15.8 ttmt -119.17 127.69 53.54 Favored 'General case' 0 C--N 1.311 -1.099 0 CA-C-N 115.73 -0.668 . . . . 0.76 111.959 -171.965 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.618 ' HA ' ' O ' ' A' ' 33' ' ' PRO . 3.2 ptmt -44.88 -15.03 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.451 0 N-CA-C 116.656 2.095 . . . . 0.32 116.656 -170.758 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 0.725 ' HB3' ' HB2' ' A' ' 33' ' ' PRO . 27.1 t80 73.59 -55.9 0.66 Allowed 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 112.627 0.602 . . . . 1.28 112.627 171.066 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.68 ' OG ' ' HD3' ' A' ' 51' ' ' PRO . 7.3 p -54.69 -41.67 91.04 Favored Pre-proline 0 CA--C 1.54 0.582 0 N-CA-C 112.439 0.533 . . . . 1.36 112.439 -174.312 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.68 ' HD3' ' OG ' ' A' ' 50' ' ' SER . 60.7 Cg_endo -103.3 14.74 0.27 Allowed 'Trans proline' 0 N--CA 1.451 -0.99 0 C-N-CA 123.063 2.509 . . . . 0.58 111.192 168.737 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 3.0 mt 55.35 -128.72 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.444 -0.734 0 CA-C-N 115.194 -0.912 . . . . 0.78 108.549 -168.843 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.973 ' HB3' ' HE2' ' A' ' 47' ' ' LYS . 12.4 p -107.86 2.34 23.39 Favored 'General case' 0 C--N 1.31 -1.124 0 C-N-CA 120.693 -0.403 . . . . 1.96 112.059 179.687 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.427 ' O ' ' HB2' ' A' ' 55' ' ' LEU . 10.4 pt-20 174.3 -34.85 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.95 -0.568 . . . . 2.89 112.143 -172.135 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.588 ' HG ' ' O ' ' A' ' 51' ' ' PRO . 43.6 mt . . . . . 0 C--O 1.25 1.09 0 CA-C-O 118.802 -0.618 . . . . 2.65 110.543 -172.792 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 51.6 ttm . . . . . 0 N--CA 1.481 1.081 0 CA-C-O 119.754 -0.165 . . . . 6.17 110.655 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 2' ' ' LYS . . . . . 0.443 ' HB2' ' O ' ' A' ' 38' ' ' VAL . 21.5 mmmt 53.63 -94.45 0.04 OUTLIER 'General case' 0 CA--C 1.516 -0.361 0 O-C-N 123.58 0.55 . . . . 3.61 111.539 -175.689 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 3' ' ' ALA . . . . . 0.531 ' HA ' ' HB2' ' A' ' 37' ' ' PHE . . . 74.02 127.24 0.04 OUTLIER 'General case' 0 C--N 1.312 -1.056 0 CA-C-N 113.853 -1.521 . . . . 0.86 113.037 174.191 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 4' ' ' THR . . . . . 0.685 ' H ' ' HB2' ' A' ' 37' ' ' PHE . 5.4 p -110.8 -48.72 3.1 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 114.473 -1.239 . . . . 0.43 109.661 171.473 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 78.4 51.38 5.66 Favored Glycine 0 N--CA 1.45 -0.419 0 CA-C-N 115.453 -0.794 . . . . 0.33 112.843 172.122 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 6' ' ' ILE . . . . . 0.801 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.4 tp -107.44 106.84 21.42 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 N-CA-C 109.317 -0.623 . . . . 0.3 109.317 173.573 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 7' ' ' VAL . . . . . 0.728 ' HA ' ' O ' ' A' ' 34' ' ' LEU . 25.2 t -78.1 135.2 26.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 116.124 -0.489 . . . . 0.27 110.469 179.447 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.413 ' HB3' HD13 ' A' ' 36' ' ' ILE . 0.8 OUTLIER -133.36 122.51 23.89 Favored 'General case' 0 N--CA 1.439 -0.999 0 N-CA-C 107.345 -1.354 . . . . 1.69 107.345 -178.871 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 9' ' ' ARG . . . . . 0.553 ' HA ' ' HA ' ' A' ' 33' ' ' PRO . 18.3 ttp180 -81.7 104.57 12.19 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 108.596 -0.89 . . . . 2.71 108.596 172.986 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 10' ' ' ILE . . . . . 0.841 HG23 HD11 ' A' ' 34' ' ' LEU . 0.3 OUTLIER -10.79 -101.27 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 O-C-N 125.631 1.832 . . . . 0.34 114.234 -175.701 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 11' ' ' ASP . . . . . 0.642 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 2.4 p-10 162.2 -169.87 0.01 OUTLIER 'General case' 0 CA--C 1.512 -0.502 0 N-CA-C 107.672 -1.233 . . . . 1.18 107.672 176.043 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 12' ' ' ASP . . . . . 0.512 ' HA ' ' HG2' ' A' ' 30' ' ' GLU . 3.3 p30 -78.13 7.74 5.82 Favored 'General case' 0 C--N 1.325 -0.463 0 O-C-N 123.174 0.296 . . . . 2.39 111.251 -177.608 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 13' ' ' LEU . . . . . 0.417 ' HB3' ' HD2' ' B' ' 15' ' ' ARG . 2.4 tm? -119.03 -61.53 1.63 Allowed 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 109.8 -0.445 . . . . 0.4 109.8 171.603 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 14' ' ' GLY . . . . . 0.514 ' O ' ' HB ' ' A' ' 18' ' ' ILE . . . 137.72 14.78 0.77 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.265 -0.969 . . . . 0.21 113.257 -178.565 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 15' ' ' ARG . . . . . 0.699 ' HG2' HG22 ' A' ' 17' ' ' VAL . 0.3 OUTLIER -81.08 154.68 26.68 Favored 'General case' 0 CA--C 1.493 -1.23 0 CA-C-O 121.659 0.743 . . . . 0.9 109.72 177.325 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 16' ' ' VAL . . . . . 1.045 HG22 HG22 ' A' ' 16' ' ' VAL . 3.9 m -107.7 108.52 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.219 0 N-CA-C 106.998 -1.482 . . . . 1.27 106.998 170.357 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 17' ' ' VAL . . . . . 0.735 HG22 ' HG2' ' A' ' 15' ' ' ARG . 47.3 t -70.88 96.52 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.352 0 CA-C-N 114.597 -1.183 . . . . 0.27 109.206 -174.354 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 18' ' ' ILE . . . . . 0.554 ' HB ' ' O ' ' A' ' 14' ' ' GLY . 34.3 mm -85.0 108.38 15.15 Favored Pre-proline 0 N--CA 1.449 -0.519 0 CA-C-N 115.401 -0.818 . . . . 0.82 110.299 -177.612 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 19' ' ' PRO . . . . . 0.715 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 58.5 Cg_exo -47.29 141.79 13.23 Favored 'Trans proline' 0 N--CA 1.456 -0.724 0 C-N-CA 122.876 2.384 . . . . 0.3 112.702 174.78 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 20' ' ' LYS . . . . . 1.015 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -59.3 -15.15 14.27 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.444 -0.798 . . . . 1.77 111.789 178.207 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 21' ' ' GLU . . . . . 0.715 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 12.9 pt-20 -64.14 -26.16 68.41 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-O 120.706 0.288 . . . . 1.92 111.45 -179.767 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 5.3 mp -87.16 -44.1 16.05 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.354 0 N-CA-C 107.901 -1.148 . . . . 0.44 107.901 -177.284 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 23' ' ' ARG . . . . . 0.628 ' HA ' ' HB2' ' B' ' 26' ' ' LEU . 0.0 OUTLIER -63.99 -26.32 68.52 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-N 115.147 -0.933 . . . . 1.4 109.897 174.972 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 24' ' ' ARG . . . . . . . . . . . . . 32.3 ttm180 -65.58 -50.14 66.2 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.674 -0.694 . . . . 3.19 110.917 172.213 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 28.2 m -63.29 -21.53 66.31 Favored 'General case' 0 CA--C 1.531 0.233 0 CA-C-O 121.527 0.68 . . . . 0.4 110.47 174.4 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.628 ' HB2' ' HA ' ' B' ' 23' ' ' ARG . 1.6 mm? -74.21 -20.93 60.02 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.505 -0.77 . . . . 0.33 110.915 173.399 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 27' ' ' ARG . . . . . 0.455 ' HB2' ' O ' ' B' ' 26' ' ' LEU . 0.0 OUTLIER 67.37 28.47 7.83 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 123.33 0.652 . . . . 3.28 110.827 -173.892 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 28' ' ' ILE . . . . . 0.863 HG22 ' H ' ' B' ' 29' ' ' ARG . 5.7 mt -121.49 -163.28 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.051 -0.522 . . . . 0.37 110.399 -176.657 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 29' ' ' ARG . . . . . 0.863 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -157.93 -158.38 0.73 Allowed 'General case' 0 N--CA 1.467 0.414 0 C-N-CA 122.046 0.138 . . . . 2.15 111.054 -169.87 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 30' ' ' GLU . . . . . 0.502 ' HG2' ' HA ' ' A' ' 12' ' ' ASP . 58.9 mp0 -69.33 30.84 0.03 OUTLIER 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 112.95 0.722 . . . . 1.18 112.95 178.666 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 31' ' ' GLY . . . . . 0.566 ' N ' HD11 ' A' ' 10' ' ' ILE . . . -145.56 25.68 1.82 Allowed Glycine 0 N--CA 1.441 -1.006 0 N-CA-C 110.073 -1.211 . . . . 0.35 110.073 172.503 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 32' ' ' ASP . . . . . 0.545 ' O ' HG13 ' A' ' 10' ' ' ILE . 8.6 t70 -82.0 121.5 79.09 Favored Pre-proline 0 C--N 1.324 -0.538 0 CA-C-N 114.6 -0.8 . . . . 1.29 110.224 176.002 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 33' ' ' PRO . . . . . 0.784 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 7.8 Cg_endo -83.06 147.02 12.97 Favored 'Trans proline' 0 N--CA 1.433 -2.048 0 C-N-CA 122.163 1.909 . . . . 1.1 110.432 173.351 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.789 HD11 HG23 ' A' ' 10' ' ' ILE . 1.0 OUTLIER -137.53 149.28 46.63 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 109.6 -0.519 . . . . 0.44 109.6 173.431 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 35' ' ' GLU . . . . . 0.695 ' HB3' ' HE3' ' B' ' 47' ' ' LYS . 45.8 tt0 -101.81 111.32 23.54 Favored 'General case' 0 C--N 1.297 -1.694 0 N-CA-C 107.242 -1.392 . . . . 1.1 107.242 178.89 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 36' ' ' ILE . . . . . 0.807 ' HB ' HG23 ' A' ' 6' ' ' ILE . 2.8 mp -85.19 108.01 16.62 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.77 0 O-C-N 124.329 1.018 . . . . 0.62 108.831 -179.678 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 37' ' ' PHE . . . . . 0.682 ' HB2' ' H ' ' A' ' 4' ' ' THR . 7.6 p90 -150.44 127.66 11.3 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 116.003 -0.544 . . . . 1.2 109.866 176.851 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 38' ' ' VAL . . . . . 0.529 ' HA ' ' HA ' ' B' ' 44' ' ' VAL . 1.6 p -79.94 145.23 9.53 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 CA-C-N 116.446 -0.343 . . . . 0.2 110.562 -177.529 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 39' ' ' ASP . . . . . 0.618 ' OD2' ' HD3' ' B' ' 40' ' ' ARG . 18.2 t70 -82.58 -47.39 12.18 Favored 'General case' 0 C--N 1.326 -0.439 0 O-C-N 123.966 0.791 . . . . 1.14 111.318 -175.569 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 40' ' ' ARG . . . . . 0.618 ' HD3' ' OD2' ' B' ' 39' ' ' ASP . 0.7 OUTLIER -144.82 -78.75 0.19 Allowed 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 113.189 0.811 . . . . 2.71 113.189 -176.457 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -97.63 -65.45 0.96 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.039 0.447 . . . . 1.32 111.512 -171.096 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 42' ' ' GLY . . . . . 0.537 ' HA3' ' HD2' ' A' ' 48' ' ' LYS . . . -145.9 16.97 1.77 Allowed Glycine 0 N--CA 1.442 -0.912 0 C-N-CA 120.79 -0.719 . . . . 0.34 111.651 -178.155 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 43' ' ' GLU . . . . . 0.681 ' HA ' ' O ' ' A' ' 46' ' ' LEU . 2.3 pm0 -91.96 107.36 19.16 Favored 'General case' 0 N--CA 1.445 -0.683 0 N-CA-C 109.835 -0.431 . . . . 2.07 109.835 176.619 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 44' ' ' VAL . . . . . 0.596 ' HB ' HD12 ' A' ' 46' ' ' LEU . 2.1 t -89.33 131.69 35.98 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 109.536 -0.542 . . . . 0.13 109.536 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 45' ' ' ILE . . . . . 0.804 HG13 HG13 ' A' ' 45' ' ' ILE . 1.6 mp -107.06 120.64 58.73 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 N-CA-C 108.065 -1.087 . . . . 0.12 108.065 -178.302 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 46' ' ' LEU . . . . . 0.798 HD11 HD11 ' A' ' 46' ' ' LEU . 0.9 OUTLIER -109.7 116.48 31.78 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 109.442 -0.577 . . . . 0.15 109.442 177.531 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 47' ' ' LYS . . . . . 0.695 ' HE3' ' HB3' ' B' ' 35' ' ' GLU . 0.0 OUTLIER -127.71 141.81 51.5 Favored 'General case' 0 C--N 1.318 -0.774 0 C-N-CA 119.372 -0.931 . . . . 0.95 113.083 -177.722 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 48' ' ' LYS . . . . . 0.72 ' HE2' ' HG3' ' B' ' 51' ' ' PRO . 5.2 ptmt -43.4 -12.88 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.177 0 N-CA-C 118.157 2.651 . . . . 0.64 118.157 -166.171 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 49' ' ' TYR . . . . . 0.784 ' HB3' ' HB2' ' B' ' 33' ' ' PRO . 22.4 t80 71.87 -55.77 0.66 Allowed 'General case' 0 N--CA 1.475 0.809 0 N-CA-C 113.374 0.879 . . . . 1.26 113.374 172.738 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 50' ' ' SER . . . . . 0.713 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 33.9 t -51.15 -57.02 15.35 Favored Pre-proline 0 CA--C 1.535 0.369 0 C-N-CA 122.867 0.467 . . . . 1.22 111.11 -175.186 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 51' ' ' PRO . . . . . 0.72 ' HG3' ' HE2' ' B' ' 48' ' ' LYS . 48.9 Cg_endo -89.58 13.51 2.37 Favored 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 121.995 1.796 . . . . 0.56 111.229 171.052 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 52' ' ' ILE . . . . . . . . . . . . . 3.0 mt 55.17 -133.33 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.571 0 CA-C-N 114.97 -1.014 . . . . 0.73 108.487 -172.763 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 53' ' ' SER . . . . . 0.493 ' HA ' ' HG3' ' B' ' 47' ' ' LYS . 4.9 p -86.04 -44.81 12.0 Favored 'General case' 0 C--N 1.309 -1.169 0 CA-C-O 120.937 0.398 . . . . 1.86 110.574 178.572 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 54' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -160.18 19.76 0.15 Allowed 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.824 -0.626 . . . . 2.62 111.591 -178.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 55' ' ' LEU . . . . . . . . . . . . . 54.4 mt . . . . . 0 C--O 1.248 0.993 0 O-C-N 123.497 0.498 . . . . 2.64 110.601 -170.934 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 90.0 mtp . . . . . 0 N--CA 1.48 1.054 0 CA-C-O 120.877 0.37 . . . . 5.91 110.452 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.661 ' HA ' ' CE ' ' A' ' 2' ' ' LYS . 2.2 mmpt? -128.76 -140.98 0.24 Allowed 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.371 -0.377 . . . . 3.71 110.299 178.488 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.434 ' HA ' ' HB2' ' B' ' 37' ' ' PHE . . . 67.54 102.64 0.05 OUTLIER 'General case' 0 C--N 1.327 -0.381 0 O-C-N 124.066 0.854 . . . . 0.72 111.204 -174.593 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.412 ' OG1' ' HA ' ' B' ' 37' ' ' PHE . 17.9 p -92.29 -50.34 5.7 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.227 -0.897 . . . . 0.41 111.756 -177.957 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 79.78 49.69 5.96 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.46 -0.876 . . . . 0.32 113.208 175.851 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.759 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.1 tp -107.39 113.18 42.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 N-CA-C 109.17 -0.678 . . . . 0.31 109.17 173.731 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.723 ' HA ' ' O ' ' B' ' 34' ' ' LEU . 39.7 t -83.43 135.52 24.65 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-O 120.922 0.391 . . . . 0.28 110.798 -178.477 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.626 ' HB3' HD11 ' B' ' 36' ' ' ILE . 6.8 tpp180 -129.23 123.25 31.5 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 107.568 -1.271 . . . . 1.99 107.568 -179.352 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.527 ' N ' ' HD3' ' A' ' 8' ' ' ARG . 4.9 tpp180 -84.43 104.44 14.44 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 108.328 -0.99 . . . . 2.8 108.328 173.19 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.74 HG23 HD11 ' B' ' 34' ' ' LEU . 0.2 OUTLIER -12.23 -103.67 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.115 0 O-C-N 125.365 1.666 . . . . 0.33 114.701 -176.515 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ASP . . . . . 0.568 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 5.8 p-10 161.35 -160.27 0.0 OUTLIER 'General case' 0 CA--C 1.512 -0.485 0 N-CA-C 107.937 -1.134 . . . . 1.13 107.937 177.019 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -72.66 -22.88 60.85 Favored 'General case' 0 C--N 1.323 -0.576 0 O-C-N 123.386 0.429 . . . . 2.26 110.878 -178.455 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -98.42 -60.52 1.53 Allowed 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.29 -0.414 . . . . 0.53 110.233 178.287 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.452 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 136.43 18.7 0.7 Allowed Glycine 0 N--CA 1.445 -0.735 0 C-N-CA 120.073 -1.061 . . . . 0.22 113.393 -179.186 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.706 ' HG2' HG22 ' B' ' 17' ' ' VAL . 0.0 OUTLIER -79.1 153.35 30.22 Favored 'General case' 0 CA--C 1.507 -0.693 0 CA-C-N 118.028 0.914 . . . . 0.69 109.621 179.569 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.818 HG21 HD13 ' B' ' 46' ' ' LEU . 98.0 t -104.4 100.32 10.25 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.455 0 N-CA-C 107.628 -1.249 . . . . 1.24 107.628 172.353 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.79 HG22 ' HG2' ' B' ' 15' ' ' ARG . 91.0 t -68.14 98.89 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.909 0 CA-C-N 115.068 -0.969 . . . . 0.28 110.21 -173.43 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.746 HG23 HD13 ' A' ' 22' ' ' ILE . 8.7 mt -92.25 114.02 60.96 Favored Pre-proline 0 N--CA 1.445 -0.708 0 CA-C-N 115.643 -0.708 . . . . 0.77 110.778 -178.551 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.638 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 47.5 Cg_exo -46.08 145.89 4.89 Favored 'Trans proline' 0 N--CA 1.458 -0.599 0 C-N-CA 123.1 2.533 . . . . 0.32 112.821 174.168 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.866 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -60.85 -16.47 41.63 Favored 'General case' 0 C--O 1.211 -0.949 0 CA-C-N 115.478 -0.783 . . . . 1.57 111.353 179.321 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.638 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 11.1 pt-20 -66.1 -19.91 65.99 Favored 'General case' 0 C--O 1.236 0.363 0 N-CA-C 111.767 0.284 . . . . 1.32 111.767 -178.283 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.746 HD13 HG23 ' A' ' 18' ' ' ILE . 5.0 mp -87.49 -50.8 13.48 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.635 0 N-CA-C 107.854 -1.165 . . . . 0.35 107.854 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ARG . . . . . 0.595 ' HA ' ' HB2' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -56.1 -31.98 63.75 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 115.492 -0.776 . . . . 1.5 110.358 171.879 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.42 ' HB3' ' HA ' ' A' ' 21' ' ' GLU . 10.2 ttt180 -63.55 -52.26 61.87 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.313 -0.858 . . . . 2.96 110.943 174.29 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 22.5 m -66.53 -22.75 66.16 Favored 'General case' 0 C--O 1.222 -0.353 0 CA-C-O 121.182 0.515 . . . . 0.4 110.697 175.525 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.736 ' HB3' HG13 ' A' ' 28' ' ' ILE . 2.0 mm? -65.81 -19.71 65.98 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.865 -0.607 . . . . 0.36 110.614 173.928 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.533 ' HB2' ' O ' ' A' ' 26' ' ' LEU . 0.3 OUTLIER 72.3 21.36 3.84 Favored 'General case' 0 N--CA 1.466 0.358 0 O-C-N 124.066 0.854 . . . . 3.2 110.371 -172.746 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.736 HG13 ' HB3' ' A' ' 26' ' ' LEU . 3.0 mt -122.18 -163.0 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.726 -0.67 . . . . 0.48 110.175 -174.154 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.733 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -153.18 -161.41 1.28 Allowed 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 111.481 0.178 . . . . 2.4 111.481 -167.944 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -73.79 36.62 0.09 Allowed 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 121.961 0.886 . . . . 1.23 111.51 179.351 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.575 ' N ' HD11 ' B' ' 10' ' ' ILE . . . -152.19 24.78 0.89 Allowed Glycine 0 N--CA 1.44 -1.099 0 CA-C-N 114.15 -1.387 . . . . 0.36 109.894 174.026 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.597 ' O ' HG13 ' B' ' 10' ' ' ILE . 13.2 t0 -82.95 124.54 76.66 Favored Pre-proline 0 C--N 1.326 -0.436 0 CA-C-N 114.512 -0.844 . . . . 1.26 109.931 175.68 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.75 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 4.7 Cg_endo -82.94 152.5 14.5 Favored 'Trans proline' 0 N--CA 1.435 -1.939 0 C-N-CA 122.187 1.924 . . . . 1.3 110.719 173.777 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.808 HD11 HG23 ' B' ' 10' ' ' ILE . 0.6 OUTLIER -140.66 152.8 45.66 Favored 'General case' 0 C--N 1.305 -1.362 0 N-CA-C 109.14 -0.689 . . . . 0.38 109.14 171.994 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.933 ' HB3' ' HD2' ' A' ' 47' ' ' LYS . 39.4 tt0 -105.87 111.24 23.81 Favored 'General case' 0 CA--C 1.486 -1.515 0 N-CA-C 107.501 -1.296 . . . . 1.12 107.501 -179.051 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.934 HG13 HD22 ' A' ' 46' ' ' LEU . 2.5 mp -85.17 110.21 19.09 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.98 0 O-C-N 124.648 1.217 . . . . 0.39 108.478 -179.169 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' PHE . . . . . 0.641 ' HB2' ' H ' ' B' ' 4' ' ' THR . 1.8 p90 -150.55 124.61 9.34 Favored 'General case' 0 C--N 1.313 -1.02 0 CA-C-N 116.162 -0.472 . . . . 1.15 109.747 175.6 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.543 HG13 ' HB3' ' B' ' 2' ' ' LYS . 1.7 p -80.83 136.34 23.4 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 CA-C-O 121.149 0.5 . . . . 0.17 110.778 -178.33 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.684 ' HB3' ' HG3' ' A' ' 40' ' ' ARG . 9.8 t70 -75.59 -45.01 40.14 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.036 -0.984 . . . . 1.11 110.68 -175.498 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' ARG . . . . . 0.684 ' HG3' ' HB3' ' A' ' 39' ' ' ASP . 7.6 mtp180 -132.13 -73.35 0.52 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.672 -0.694 . . . . 2.29 112.267 -165.807 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -129.67 -65.11 0.85 Allowed 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.284 -0.871 . . . . 1.53 111.09 -173.408 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.599 ' HA3' HD11 ' B' ' 26' ' ' LEU . . . -131.88 6.36 5.46 Favored Glycine 0 CA--C 1.501 -0.832 0 CA-C-N 114.838 -1.074 . . . . 0.32 111.812 -173.852 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.556 ' HA ' ' O ' ' B' ' 46' ' ' LEU . 2.2 pm0 -93.58 105.69 17.71 Favored 'General case' 0 N--CA 1.443 -0.793 0 CA-C-O 121.009 0.433 . . . . 1.97 109.929 175.317 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.612 HG11 HG23 ' A' ' 36' ' ' ILE . 2.0 t -88.82 132.31 34.0 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.988 0 CA-C-N 115.566 -0.743 . . . . 0.14 109.864 178.907 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.856 HG13 HG13 ' B' ' 45' ' ' ILE . 1.4 mp -110.11 115.96 51.06 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 N-CA-C 108.239 -1.023 . . . . 0.14 108.239 -177.372 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 1.041 HD11 HD11 ' B' ' 46' ' ' LEU . 0.5 OUTLIER -109.48 116.76 32.41 Favored 'General case' 0 C--N 1.319 -0.759 0 O-C-N 123.703 0.627 . . . . 0.23 109.584 -178.871 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.933 ' HD2' ' HB3' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -122.84 150.37 42.95 Favored 'General case' 0 C--O 1.215 -0.732 0 C-N-CA 119.066 -1.054 . . . . 0.76 112.169 179.121 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.62 ' HA ' ' O ' ' A' ' 33' ' ' PRO . 1.5 ptmt -44.92 -16.45 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.24 0 N-CA-C 117.13 2.27 . . . . 0.32 117.13 -168.188 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 0.765 ' CD1' HG21 ' B' ' 7' ' ' VAL . 19.9 t80 74.35 -50.36 0.68 Allowed 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 112.689 0.625 . . . . 1.28 112.689 174.293 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.71 ' HB3' ' HD3' ' A' ' 51' ' ' PRO . 22.7 t -48.1 -50.83 52.95 Favored Pre-proline 0 CA--C 1.538 0.493 0 C-N-CA 122.585 0.354 . . . . 1.36 111.395 -177.368 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.71 ' HD3' ' HB3' ' A' ' 50' ' ' SER . 36.3 Cg_endo -95.25 10.31 1.66 Allowed 'Trans proline' 0 N--CA 1.453 -0.878 0 C-N-CA 122.601 2.2 . . . . 0.58 111.484 172.31 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 1.1 mt 48.91 -141.78 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 115.044 -0.98 . . . . 0.78 109.262 -170.466 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.614 ' HB3' ' HE2' ' A' ' 47' ' ' LYS . 4.2 p -104.63 76.25 1.27 Allowed 'General case' 0 N--CA 1.431 -1.416 0 N-CA-C 109.679 -0.489 . . . . 1.96 109.679 174.266 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 1.6 tp10 73.02 110.19 0.07 Allowed 'General case' 0 C--O 1.232 0.173 0 CA-C-N 115.052 -0.976 . . . . 2.89 110.721 -175.583 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 81.8 mt . . . . . 0 C--O 1.249 1.075 0 CA-C-N 115.84 -0.618 . . . . 2.65 110.165 176.863 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 45.1 mtp . . . . . 0 N--CA 1.484 1.266 0 CA-C-O 120.853 0.358 . . . . 6.17 110.765 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 2' ' ' LYS . . . . . 0.683 ' CE ' ' HA ' ' B' ' 2' ' ' LYS . 2.5 mmpt? -97.44 -141.62 0.29 Allowed 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.377 -0.374 . . . . 3.61 111.873 -177.802 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 3' ' ' ALA . . . . . 0.569 ' HA ' ' HD2' ' A' ' 37' ' ' PHE . . . 72.37 116.47 0.05 Allowed 'General case' 0 C--N 1.33 -0.252 0 O-C-N 124.274 0.984 . . . . 0.86 110.546 -169.34 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 4' ' ' THR . . . . . 0.641 ' H ' ' HB2' ' A' ' 37' ' ' PHE . 28.5 p -107.85 -52.56 2.75 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.634 -0.712 . . . . 0.43 111.068 -176.947 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 82.26 50.98 4.58 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.995 -0.621 . . . . 0.33 112.797 177.164 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 6' ' ' ILE . . . . . 0.805 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.0 OUTLIER -106.68 108.24 24.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 N-CA-C 109.322 -0.621 . . . . 0.3 109.322 173.316 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 7' ' ' VAL . . . . . 0.765 HG21 ' CD1' ' A' ' 49' ' ' TYR . 23.0 t -80.52 136.49 23.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-N 116.231 -0.44 . . . . 0.27 111.217 179.673 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.546 ' HD3' ' N ' ' B' ' 9' ' ' ARG . 1.1 tpp180 -131.97 126.94 35.25 Favored 'General case' 0 N--CA 1.446 -0.625 0 N-CA-C 107.61 -1.255 . . . . 1.69 107.61 178.384 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 9' ' ' ARG . . . . . 0.546 ' N ' ' HD3' ' B' ' 8' ' ' ARG . 1.7 tpp180 -86.3 103.22 14.69 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 108.606 -0.887 . . . . 2.71 108.606 173.858 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 10' ' ' ILE . . . . . 0.808 HG23 HD11 ' A' ' 34' ' ' LEU . 0.2 OUTLIER -10.17 -107.37 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.264 0 O-C-N 125.351 1.657 . . . . 0.34 114.749 -177.828 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 11' ' ' ASP . . . . . 0.655 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 1.7 p-10 163.39 -166.38 0.01 OUTLIER 'General case' 0 CA--C 1.518 -0.286 0 N-CA-C 108.327 -0.99 . . . . 1.18 108.327 177.441 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -66.28 -19.85 65.93 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.355 0.598 . . . . 2.39 110.793 -179.04 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 13' ' ' LEU . . . . . 0.442 ' H ' ' CG ' ' B' ' 11' ' ' ASP . 2.9 tm? -101.59 -61.8 1.33 Allowed 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.711 -0.677 . . . . 0.4 110.796 -179.059 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 137.96 19.5 0.55 Allowed Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.807 -0.711 . . . . 0.21 112.116 -178.806 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 15' ' ' ARG . . . . . 0.79 ' HG2' HG22 ' A' ' 17' ' ' VAL . 2.7 mtm180 -70.22 147.65 49.54 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-O 121.244 0.545 . . . . 0.9 110.593 177.361 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 16' ' ' VAL . . . . . 0.713 HG21 HD13 ' A' ' 46' ' ' LEU . 63.7 t -106.69 97.07 5.18 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.237 0 N-CA-C 107.644 -1.243 . . . . 1.27 107.644 166.767 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 17' ' ' VAL . . . . . 0.706 HG22 ' HG2' ' A' ' 15' ' ' ARG . 64.3 t -67.42 98.92 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 CA-C-N 115.62 -0.718 . . . . 0.27 110.364 -171.732 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 18' ' ' ILE . . . . . 0.542 ' H ' ' HA ' ' A' ' 15' ' ' ARG . 6.9 mt -90.45 113.87 59.11 Favored Pre-proline 0 N--CA 1.442 -0.872 0 CA-C-N 115.181 -0.918 . . . . 0.82 110.562 -179.624 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 19' ' ' PRO . . . . . 0.61 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 81.3 Cg_exo -50.19 147.21 16.24 Favored 'Trans proline' 0 N--CA 1.458 -0.59 0 C-N-CA 123.056 2.504 . . . . 0.3 112.567 174.123 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 20' ' ' LYS . . . . . 1.012 ' HD3' ' H ' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -64.94 -15.63 62.36 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 115.649 -0.705 . . . . 1.77 111.678 -178.795 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 21' ' ' GLU . . . . . 0.61 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 1.3 pm0 -63.13 -21.8 66.44 Favored 'General case' 0 C--O 1.237 0.439 0 N-CA-C 111.854 0.316 . . . . 1.92 111.854 177.458 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 5.2 mp -87.61 -47.52 15.69 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 N-CA-C 108.488 -0.93 . . . . 0.44 108.488 -178.406 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 23' ' ' ARG . . . . . 0.558 ' HA ' ' HB2' ' B' ' 26' ' ' LEU . 0.0 OUTLIER -61.93 -28.28 69.42 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.262 -0.881 . . . . 1.4 109.231 174.022 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 24' ' ' ARG . . . . . . . . . . . . . 55.0 ttp180 -65.78 -51.92 55.07 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 114.91 -1.041 . . . . 3.19 110.988 174.639 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 18.7 m -63.65 -28.74 70.12 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-O 121.525 0.679 . . . . 0.4 110.152 176.23 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.656 ' HB3' HG13 ' B' ' 28' ' ' ILE . 1.4 mm? -64.08 -19.9 65.57 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 115.009 -0.996 . . . . 0.33 110.678 174.091 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 27' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER 70.8 24.02 4.32 Favored 'General case' 0 C--N 1.342 0.242 0 CA-C-O 121.587 0.708 . . . . 3.28 110.154 -177.105 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 28' ' ' ILE . . . . . 0.809 HG22 ' H ' ' B' ' 29' ' ' ARG . 4.0 mt -119.25 -162.55 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.133 -0.939 . . . . 0.37 110.058 -176.889 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 29' ' ' ARG . . . . . 0.809 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -152.99 -161.42 1.29 Allowed 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 111.618 0.229 . . . . 2.15 111.618 -171.584 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 30' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -72.4 34.06 0.06 Allowed 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 121.858 0.837 . . . . 1.18 111.925 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 31' ' ' GLY . . . . . 0.567 ' N ' HD11 ' A' ' 10' ' ' ILE . . . -150.73 30.31 1.02 Allowed Glycine 0 N--CA 1.436 -1.365 0 N-CA-C 109.636 -1.385 . . . . 0.35 109.636 172.79 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 32' ' ' ASP . . . . . 0.511 ' HB2' ' CG2' ' B' ' 28' ' ' ILE . 6.9 t70 -85.22 128.72 58.62 Favored Pre-proline 0 CA--C 1.511 -0.523 0 CA-C-N 114.451 -0.874 . . . . 1.29 110.271 174.74 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 33' ' ' PRO . . . . . 0.756 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 10.9 Cg_endo -86.76 148.48 8.42 Favored 'Trans proline' 0 N--CA 1.433 -2.07 0 C-N-CA 122.128 1.885 . . . . 1.1 111.469 173.195 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.74 HD11 HG23 ' A' ' 10' ' ' ILE . 0.8 OUTLIER -137.53 148.34 45.9 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 109.273 -0.64 . . . . 0.44 109.273 173.661 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 35' ' ' GLU . . . . . 0.659 ' O ' ' HA ' ' B' ' 46' ' ' LEU . 77.9 tt0 -104.68 111.84 24.71 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 108.11 -1.07 . . . . 1.1 108.11 -179.535 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 36' ' ' ILE . . . . . 0.899 HG13 HD22 ' B' ' 46' ' ' LEU . 3.5 mp -86.1 109.34 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.869 0 O-C-N 124.716 1.26 . . . . 0.62 109.108 -177.964 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 37' ' ' PHE . . . . . 0.434 ' HB2' ' HA ' ' A' ' 3' ' ' ALA . 16.5 p90 -149.82 126.77 11.16 Favored 'General case' 0 C--N 1.316 -0.88 0 CA-C-N 115.922 -0.581 . . . . 1.2 109.954 175.415 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 38' ' ' VAL . . . . . 0.516 ' HA ' ' HA ' ' B' ' 44' ' ' VAL . 1.3 p -80.55 139.62 17.87 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.78 0 CA-C-O 121.361 0.6 . . . . 0.2 111.16 -177.911 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 39' ' ' ASP . . . . . 0.549 ' HB3' ' HG3' ' B' ' 40' ' ' ARG . 7.1 t70 -74.81 -49.86 19.22 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 114.591 -1.186 . . . . 1.14 110.472 -178.009 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 40' ' ' ARG . . . . . 0.549 ' HG3' ' HB3' ' B' ' 39' ' ' ASP . 13.8 mtp180 -132.78 -72.87 0.51 Allowed 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 112.604 0.594 . . . . 2.71 112.604 -168.434 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -124.69 -67.65 0.9 Allowed 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.359 -0.837 . . . . 1.32 110.986 -172.469 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 42' ' ' GLY . . . . . 0.509 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -129.75 9.56 6.08 Favored Glycine 0 N--CA 1.441 -1.028 0 CA-C-N 114.699 -1.137 . . . . 0.34 112.142 -176.094 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 43' ' ' GLU . . . . . 0.48 ' HA ' ' O ' ' A' ' 46' ' ' LEU . 2.3 pm0 -93.13 104.74 16.91 Favored 'General case' 0 N--CA 1.446 -0.625 0 N-CA-C 109.794 -0.447 . . . . 2.07 109.794 176.199 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 44' ' ' VAL . . . . . 0.59 HG11 HG23 ' B' ' 36' ' ' ILE . 2.0 t -89.42 134.05 29.77 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.886 0 N-CA-C 109.805 -0.443 . . . . 0.13 109.805 179.071 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 45' ' ' ILE . . . . . 0.856 HG13 HG13 ' A' ' 45' ' ' ILE . 1.6 mp -110.17 116.36 52.09 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 N-CA-C 108.095 -1.076 . . . . 0.12 108.095 -177.908 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 46' ' ' LEU . . . . . 1.041 HD11 HD11 ' A' ' 46' ' ' LEU . 0.7 OUTLIER -109.4 116.25 31.49 Favored 'General case' 0 C--N 1.317 -0.838 0 O-C-N 123.67 0.606 . . . . 0.15 109.569 179.577 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 47' ' ' LYS . . . . . 0.588 ' HE3' ' HB3' ' B' ' 35' ' ' GLU . 0.0 OUTLIER -125.01 146.36 49.46 Favored 'General case' 0 C--N 1.315 -0.892 0 C-N-CA 119.652 -0.819 . . . . 0.95 112.347 -177.865 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 48' ' ' LYS . . . . . 0.595 ' HA ' ' O ' ' B' ' 33' ' ' PRO . 3.7 ptmt -45.89 -10.61 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.147 0 N-CA-C 117.812 2.523 . . . . 0.64 117.812 -166.301 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 49' ' ' TYR . . . . . 0.756 ' HB3' ' HB2' ' B' ' 33' ' ' PRO . 23.7 t80 72.07 -51.17 0.7 Allowed 'General case' 0 N--CA 1.47 0.559 0 N-CA-C 112.955 0.724 . . . . 1.26 112.955 172.711 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 50' ' ' SER . . . . . 0.605 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 48.3 t -51.4 -56.75 17.91 Favored Pre-proline 0 CA--C 1.535 0.383 0 C-N-CA 122.597 0.359 . . . . 1.22 111.249 -175.133 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 51' ' ' PRO . . . . . 0.605 ' HD3' ' HB3' ' B' ' 50' ' ' SER . 57.8 Cg_endo -88.3 12.35 2.84 Favored 'Trans proline' 0 C--N 1.35 0.649 0 C-N-CA 121.83 1.687 . . . . 0.56 111.44 170.694 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 52' ' ' ILE . . . . . . . . . . . . . 1.3 mt 50.61 -140.58 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.518 -0.273 0 CA-C-N 115.056 -0.975 . . . . 0.73 108.952 -173.943 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 53' ' ' SER . . . . . 0.51 ' O ' ' HB2' ' B' ' 54' ' ' GLU . 7.9 p -109.72 76.97 1.02 Allowed 'General case' 0 N--CA 1.434 -1.249 0 N-CA-C 108.992 -0.744 . . . . 1.86 108.992 174.446 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 54' ' ' GLU . . . . . 0.51 ' HB2' ' O ' ' B' ' 53' ' ' SER . 6.1 mp0 70.84 124.33 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.356 0 O-C-N 123.899 0.749 . . . . 2.62 110.034 -165.752 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 55' ' ' LEU . . . . . . . . . . . . . 96.5 mt . . . . . 0 C--O 1.246 0.897 0 CA-C-O 118.838 -0.601 . . . . 2.64 110.518 177.203 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 23.0 mmt . . . . . 0 N--CA 1.48 1.033 0 N-CA-C 109.78 -0.452 . . . . 5.91 109.78 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 13.3 mmmm 58.76 -141.3 0.7 Allowed 'General case' 0 C--O 1.235 0.338 0 CA-C-N 115.999 -0.546 . . . . 3.71 111.372 176.13 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . 70.05 141.51 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 O-C-N 124.211 0.944 . . . . 0.72 111.891 -176.181 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.763 ' H ' ' HB2' ' B' ' 37' ' ' PHE . 21.4 p -129.59 -57.2 1.13 Allowed 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.539 -0.755 . . . . 0.41 110.636 -178.647 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 85.13 48.95 4.65 Favored Glycine 0 N--CA 1.441 -1.024 0 C-N-CA 120.315 -0.945 . . . . 0.32 112.662 174.274 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.806 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.5 tp -105.49 109.09 26.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 N-CA-C 109.258 -0.645 . . . . 0.31 109.258 173.851 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.757 ' HA ' ' O ' ' B' ' 34' ' ' LEU . 41.7 t -79.76 132.69 31.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 116.135 -0.484 . . . . 0.28 110.715 179.284 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.484 ' HD3' ' N ' ' A' ' 9' ' ' ARG . 1.8 tpp180 -129.24 125.07 36.07 Favored 'General case' 0 N--CA 1.443 -0.781 0 N-CA-C 106.919 -1.512 . . . . 1.99 106.919 -179.821 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.562 ' C ' HD12 ' A' ' 10' ' ' ILE . 0.6 OUTLIER -86.34 102.26 13.84 Favored 'General case' 0 C--N 1.315 -0.933 0 N-CA-C 108.202 -1.036 . . . . 2.8 108.202 175.346 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.831 HG23 HD11 ' B' ' 34' ' ' LEU . 0.2 OUTLIER -5.56 -105.79 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.016 0 O-C-N 125.645 1.841 . . . . 0.33 114.356 -176.468 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ASP . . . . . 0.623 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 3.3 p-10 161.54 -166.45 0.0 OUTLIER 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 108.64 -0.874 . . . . 1.13 108.64 177.28 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -68.11 -23.01 64.86 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 123.455 0.472 . . . . 2.26 110.94 -177.84 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.421 ' HB3' ' HD2' ' A' ' 15' ' ' ARG . 2.5 tm? -100.64 -55.66 2.53 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.331 -0.395 . . . . 0.53 110.448 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.56 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 134.32 18.0 0.95 Allowed Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.449 -0.882 . . . . 0.22 113.069 -179.435 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.544 ' HG2' HG22 ' B' ' 17' ' ' VAL . 0.4 OUTLIER -76.66 156.19 32.8 Favored 'General case' 0 CA--C 1.51 -0.562 0 CA-C-N 117.625 0.712 . . . . 0.69 110.301 -179.564 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.736 HG21 HD13 ' B' ' 46' ' ' LEU . 89.8 t -111.04 98.3 6.88 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.23 0 N-CA-C 107.728 -1.212 . . . . 1.24 107.728 167.637 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.58 HG22 ' HG2' ' B' ' 15' ' ' ARG . 39.4 t -65.05 106.95 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 CA-C-N 115.249 -0.887 . . . . 0.28 109.675 -173.702 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.452 ' HB ' ' O ' ' B' ' 14' ' ' GLY . 30.9 mm -95.82 107.88 36.88 Favored Pre-proline 0 N--CA 1.447 -0.625 0 CA-C-N 115.691 -0.686 . . . . 0.77 110.117 -178.017 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.699 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 62.2 Cg_exo -47.44 146.06 7.85 Favored 'Trans proline' 0 N--CA 1.454 -0.821 0 C-N-CA 122.6 2.2 . . . . 0.32 112.718 175.402 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.957 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -64.61 -14.0 55.93 Favored 'General case' 0 C--N 1.314 -0.935 0 CA-C-N 115.766 -0.652 . . . . 1.57 111.251 179.813 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.699 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 11.5 pt-20 -63.78 -23.05 67.21 Favored 'General case' 0 C--O 1.239 0.501 0 N-CA-C 112.349 0.5 . . . . 1.32 112.349 178.285 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.406 HD13 HG23 ' A' ' 18' ' ' ILE . 5.2 mp -87.39 -46.49 16.1 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.334 0 N-CA-C 108.096 -1.076 . . . . 0.35 108.096 -178.635 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ARG . . . . . 0.69 ' HA ' ' HB2' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -61.41 -27.19 68.36 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 114.941 -1.027 . . . . 1.5 109.219 172.994 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 74.9 ttt180 -63.26 -51.48 65.99 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 114.75 -1.114 . . . . 2.96 111.116 173.315 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 28.7 m -61.69 -31.14 71.26 Favored 'General case' 0 CA--C 1.532 0.252 0 CA-C-O 121.147 0.498 . . . . 0.4 110.636 172.757 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.69 ' HB2' ' HA ' ' A' ' 23' ' ' ARG . 3.2 mm? -64.92 -21.35 66.81 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.617 -0.72 . . . . 0.36 110.71 173.855 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 2.0 mpt_? 70.39 21.96 5.48 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 123.455 0.702 . . . . 3.2 110.943 -176.764 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.769 HG22 ' H ' ' A' ' 29' ' ' ARG . 5.3 mt -117.49 -166.5 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.786 0 CA-C-N 115.159 -0.928 . . . . 0.48 108.932 -177.896 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.769 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -148.5 -153.69 0.51 Allowed 'General case' 0 C--N 1.323 -0.557 0 O-C-N 122.13 -0.356 . . . . 2.4 111.286 -175.157 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 30' ' ' GLU . . . . . 0.449 ' H ' ' HB2' ' A' ' 29' ' ' ARG . 0.6 OUTLIER -75.72 44.66 0.3 Allowed 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 122.089 0.947 . . . . 1.23 112.188 -177.787 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.664 ' CA ' HD11 ' B' ' 10' ' ' ILE . . . -159.31 29.3 0.4 Allowed Glycine 0 N--CA 1.441 -1.006 0 CA-C-N 113.975 -1.466 . . . . 0.36 109.547 172.466 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.59 ' O ' HG13 ' B' ' 10' ' ' ILE . 11.8 t70 -88.81 128.9 50.58 Favored Pre-proline 0 CA--C 1.514 -0.407 0 N-CA-C 109.351 -0.611 . . . . 1.26 109.351 174.549 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.73 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 3.8 Cg_endo -83.81 150.04 12.64 Favored 'Trans proline' 0 N--CA 1.435 -1.936 0 C-N-CA 122.18 1.92 . . . . 1.3 110.804 175.175 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.803 HD11 HG23 ' B' ' 10' ' ' ILE . 0.6 OUTLIER -139.68 153.75 47.34 Favored 'General case' 0 N--CA 1.43 -1.428 0 N-CA-C 109.302 -0.629 . . . . 0.38 109.302 172.023 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.919 ' HB3' ' HD2' ' A' ' 47' ' ' LYS . 33.8 tt0 -109.25 114.57 28.38 Favored 'General case' 0 C--N 1.297 -1.675 0 N-CA-C 108.392 -0.966 . . . . 1.12 108.392 -178.316 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.878 HG13 HD22 ' A' ' 46' ' ' LEU . 3.2 mp -86.12 110.05 19.42 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.944 0 O-C-N 124.843 1.339 . . . . 0.39 109.226 -178.766 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' PHE . . . . . 0.668 ' HD1' ' HA ' ' B' ' 3' ' ' ALA . 0.5 OUTLIER -149.76 125.74 10.57 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 116.211 -0.45 . . . . 1.15 109.874 175.488 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.604 HG13 ' HB3' ' B' ' 2' ' ' LYS . 1.2 p -80.51 137.09 22.06 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 CA-C-O 121.191 0.52 . . . . 0.17 110.749 -179.854 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.517 ' HB3' ' HG2' ' A' ' 40' ' ' ARG . 9.9 t70 -88.65 -64.93 1.07 Allowed 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 114.617 -1.174 . . . . 1.11 111.902 -171.459 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' ARG . . . . . 0.525 ' H ' ' HG2' ' A' ' 40' ' ' ARG . 0.0 OUTLIER -106.58 -84.37 0.52 Allowed 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 114.899 -1.046 . . . . 2.29 111.303 -165.759 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -111.37 -72.58 0.71 Allowed 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.12 -0.491 . . . . 1.53 110.88 -177.518 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -130.35 24.66 4.4 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.776 -0.726 . . . . 0.32 111.638 179.276 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.555 ' HB3' HG23 ' B' ' 45' ' ' ILE . 2.3 mt-10 -97.95 113.0 24.72 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.126 -0.694 . . . . 1.97 109.126 178.465 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.533 ' HA ' ' HA ' ' A' ' 38' ' ' VAL . 1.8 t -90.4 132.95 33.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 N-CA-C 109.573 -0.529 . . . . 0.14 109.573 178.942 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.797 HG13 HG13 ' B' ' 45' ' ' ILE . 1.6 mp -111.68 117.5 55.28 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 N-CA-C 108.575 -0.898 . . . . 0.14 108.575 -175.389 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.998 HD11 HD11 ' B' ' 46' ' ' LEU . 0.5 OUTLIER -110.13 117.09 32.79 Favored 'General case' 0 C--N 1.32 -0.706 0 O-C-N 123.676 0.61 . . . . 0.23 109.874 179.825 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.919 ' HD2' ' HB3' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -126.44 151.9 47.12 Favored 'General case' 0 C--O 1.219 -0.55 0 C-N-CA 119.02 -1.072 . . . . 0.76 112.792 179.132 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.649 ' HA ' ' O ' ' A' ' 33' ' ' PRO . 1.9 ptmt -43.58 -16.29 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.09 0 N-CA-C 117.263 2.32 . . . . 0.32 117.263 -168.381 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 0.758 ' CD1' HG21 ' B' ' 7' ' ' VAL . 17.9 t80 73.22 -54.58 0.69 Allowed 'General case' 0 N--CA 1.469 0.521 0 N-CA-C 112.561 0.578 . . . . 1.28 112.561 174.379 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.687 ' HB3' ' HD3' ' A' ' 51' ' ' PRO . 19.6 t -50.85 -49.82 77.7 Favored Pre-proline 0 CA--C 1.537 0.473 0 O-C-N 123.335 0.397 . . . . 1.36 111.387 -175.105 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.687 ' HD3' ' HB3' ' A' ' 50' ' ' SER . 86.5 Cg_endo -96.18 12.45 1.21 Allowed 'Trans proline' 0 N--CA 1.453 -0.861 0 C-N-CA 122.401 2.067 . . . . 0.58 111.658 171.213 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.636 HG13 HD23 ' A' ' 55' ' ' LEU . 1.3 mt 52.82 -140.47 0.02 OUTLIER 'Isoleucine or valine' 0 C--O 1.234 0.281 0 CA-C-N 115.423 -0.808 . . . . 0.78 109.083 -173.946 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 69.3 m -102.34 5.86 40.06 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-O 121.493 0.663 . . . . 1.96 110.16 176.334 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 173.98 111.84 0.02 OUTLIER 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 114.099 -1.41 . . . . 2.89 109.435 -173.996 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.636 HD23 HG13 ' A' ' 52' ' ' ILE . 0.2 OUTLIER . . . . . 0 C--O 1.25 1.085 0 CA-C-O 118.929 -0.558 . . . . 2.65 109.907 179.666 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 26.5 mmt . . . . . 0 N--CA 1.483 1.205 0 N-CA-C 109.845 -0.428 . . . . 6.17 109.845 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 2' ' ' LYS . . . . . 0.604 ' HB3' HG13 ' A' ' 38' ' ' VAL . 21.3 mmmt 53.81 -133.76 1.72 Allowed 'General case' 0 CA--C 1.519 -0.23 0 CA-C-N 115.567 -0.742 . . . . 3.61 112.044 -179.127 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 3' ' ' ALA . . . . . 0.668 ' HA ' ' HD1' ' A' ' 37' ' ' PHE . . . 69.07 124.47 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 O-C-N 124.145 0.903 . . . . 0.86 110.419 -171.075 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 4' ' ' THR . . . . . 0.666 ' H ' ' HB2' ' A' ' 37' ' ' PHE . 11.3 p -115.87 -46.74 2.82 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.022 -0.535 . . . . 0.43 111.248 -178.713 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 73.01 49.72 15.54 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 120.929 -0.653 . . . . 0.33 113.137 172.893 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 6' ' ' ILE . . . . . 0.856 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.0 OUTLIER -106.73 110.55 32.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 N-CA-C 109.104 -0.702 . . . . 0.3 109.104 174.841 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 7' ' ' VAL . . . . . 0.758 HG21 ' CD1' ' A' ' 49' ' ' TYR . 38.9 t -80.51 134.66 26.88 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.308 0.575 . . . . 0.27 111.389 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.524 ' HB3' ' CD1' ' A' ' 36' ' ' ILE . 8.4 tpp180 -130.1 121.45 26.38 Favored 'General case' 0 N--CA 1.44 -0.948 0 N-CA-C 107.541 -1.281 . . . . 1.69 107.541 -177.47 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 9' ' ' ARG . . . . . 0.48 ' HA ' ' HA ' ' A' ' 33' ' ' PRO . 15.9 ttt180 -84.45 103.43 13.6 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 108.084 -1.08 . . . . 2.71 108.084 173.766 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 10' ' ' ILE . . . . . 0.803 HG23 HD11 ' A' ' 34' ' ' LEU . 0.4 OUTLIER -9.2 -101.61 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.996 0 O-C-N 125.665 1.853 . . . . 0.34 114.398 -174.707 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 11' ' ' ASP . . . . . 0.645 ' H ' HD13 ' B' ' 10' ' ' ILE . 5.5 p-10 164.21 -154.07 0.0 OUTLIER 'General case' 0 C--O 1.219 -0.504 0 N-CA-C 108.773 -0.825 . . . . 1.18 108.773 174.555 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -85.2 -9.18 58.1 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.047 0.451 . . . . 2.39 110.617 -178.778 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 13' ' ' LEU . . . . . 0.453 ' HB3' ' HD2' ' B' ' 15' ' ' ARG . 3.0 tm? -109.5 -56.43 2.3 Favored 'General case' 0 N--CA 1.448 -0.537 0 CA-C-N 116.075 -0.511 . . . . 0.4 109.935 176.496 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 14' ' ' GLY . . . . . 0.452 ' O ' ' HB ' ' A' ' 18' ' ' ILE . . . 133.16 20.85 0.89 Allowed Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.764 -0.732 . . . . 0.21 112.689 -178.972 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 15' ' ' ARG . . . . . 0.58 ' HG2' HG22 ' A' ' 17' ' ' VAL . 1.5 mpt_? -78.23 154.08 31.35 Favored 'General case' 0 CA--C 1.509 -0.606 0 O-C-N 122.066 -0.667 . . . . 0.9 110.189 179.293 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 16' ' ' VAL . . . . . 0.726 HG21 HD13 ' A' ' 46' ' ' LEU . 96.7 t -109.11 95.96 4.26 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 N-CA-C 107.475 -1.305 . . . . 1.27 107.475 168.722 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 17' ' ' VAL . . . . . 0.544 HG22 ' HG2' ' A' ' 15' ' ' ARG . 47.0 t -64.32 104.84 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.842 0 CA-C-N 114.96 -1.018 . . . . 0.27 109.914 -173.04 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 18' ' ' ILE . . . . . 0.56 ' HB ' ' O ' ' A' ' 14' ' ' GLY . 26.6 mm -92.48 111.26 49.87 Favored Pre-proline 0 N--CA 1.446 -0.633 0 CA-C-N 115.647 -0.706 . . . . 0.82 110.574 -177.463 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 19' ' ' PRO . . . . . 0.68 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 59.1 Cg_exo -48.49 142.39 17.79 Favored 'Trans proline' 0 N--CA 1.459 -0.534 0 C-N-CA 123.041 2.494 . . . . 0.3 112.53 172.828 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 20' ' ' LYS . . . . . 0.952 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -59.44 -16.14 21.78 Favored 'General case' 0 C--O 1.211 -0.949 0 CA-C-N 115.243 -0.889 . . . . 1.77 111.428 178.954 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 21' ' ' GLU . . . . . 0.68 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 10.6 pt-20 -65.5 -20.0 66.16 Favored 'General case' 0 C--O 1.234 0.284 0 N-CA-C 112.034 0.383 . . . . 1.92 112.034 -178.226 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 5.2 mp -87.26 -49.14 14.97 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 N-CA-C 108.433 -0.951 . . . . 0.44 108.433 179.848 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 23' ' ' ARG . . . . . 0.627 ' NE ' ' HA ' ' B' ' 29' ' ' ARG . 0.0 OUTLIER -55.33 -32.41 62.49 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-O 122.057 0.932 . . . . 1.4 109.194 171.073 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 24' ' ' ARG . . . . . 0.475 ' N ' ' HD3' ' B' ' 23' ' ' ARG . 50.1 ttt180 -61.12 -53.72 53.52 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-N 114.021 -1.445 . . . . 3.19 111.195 176.222 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 53.7 m -61.07 -33.52 73.46 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-O 121.275 0.559 . . . . 0.4 110.418 173.806 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.552 ' HB2' ' HA ' ' B' ' 23' ' ' ARG . 1.5 mm? -63.98 -20.26 65.76 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.21 -0.904 . . . . 0.33 111.339 177.775 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 27' ' ' ARG . . . . . . . . . . . . . 6.5 mpt_? 69.79 28.38 4.37 Favored 'General case' 0 N--CA 1.471 0.6 0 CA-C-O 121.18 0.514 . . . . 3.28 110.505 -176.686 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 28' ' ' ILE . . . . . 0.847 HG22 ' H ' ' B' ' 29' ' ' ARG . 7.6 mt -122.47 -159.44 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 115.889 -0.596 . . . . 0.37 109.924 -175.583 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 29' ' ' ARG . . . . . 0.847 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.1 OUTLIER -155.33 -159.9 0.98 Allowed 'General case' 0 N--CA 1.467 0.42 0 N-CA-C 112.496 0.554 . . . . 2.15 112.496 -174.476 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 30' ' ' GLU . . . . . 0.422 ' H ' ' HB2' ' B' ' 29' ' ' ARG . 38.6 mp0 -69.87 36.93 0.04 OUTLIER 'General case' 0 N--CA 1.472 0.655 0 CA-C-O 122.019 0.914 . . . . 1.18 112.053 178.636 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 31' ' ' GLY . . . . . 0.608 ' CA ' HD11 ' A' ' 10' ' ' ILE . . . -156.46 32.97 0.59 Allowed Glycine 0 N--CA 1.431 -1.663 0 N-CA-C 109.547 -1.421 . . . . 0.35 109.547 175.712 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 32' ' ' ASP . . . . . 0.536 ' O ' HG13 ' A' ' 10' ' ' ILE . 19.2 t0 -92.46 125.55 55.62 Favored Pre-proline 0 C--N 1.323 -0.569 0 CA-C-N 114.861 -0.669 . . . . 1.29 109.259 173.529 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 33' ' ' PRO . . . . . 0.82 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 3.5 Cg_endo -79.55 151.66 22.57 Favored 'Trans proline' 0 N--CA 1.436 -1.888 0 C-N-CA 122.216 1.944 . . . . 1.1 110.043 174.215 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.831 HD11 HG23 ' A' ' 10' ' ' ILE . 0.8 OUTLIER -140.73 149.35 42.04 Favored 'General case' 0 C--N 1.305 -1.326 0 N-CA-C 109.444 -0.576 . . . . 0.44 109.444 172.434 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 35' ' ' GLU . . . . . 0.646 ' O ' ' HA ' ' B' ' 46' ' ' LEU . 72.1 tt0 -104.04 112.28 25.21 Favored 'General case' 0 CA--C 1.487 -1.471 0 N-CA-C 107.359 -1.348 . . . . 1.1 107.359 -179.272 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 36' ' ' ILE . . . . . 0.895 HG13 HD22 ' B' ' 46' ' ' LEU . 2.5 mp -86.47 111.07 20.87 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.148 0 O-C-N 124.615 1.197 . . . . 0.62 108.675 179.331 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 37' ' ' PHE . . . . . 0.763 ' HB2' ' H ' ' A' ' 4' ' ' THR . 17.9 p90 -150.29 129.28 12.59 Favored 'General case' 0 C--N 1.314 -0.96 0 N-CA-C 109.392 -0.596 . . . . 1.2 109.392 172.613 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 38' ' ' VAL . . . . . 0.561 ' HA ' ' HA ' ' B' ' 44' ' ' VAL . 1.4 p -83.62 129.91 36.73 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.114 0 CA-C-O 121.255 0.55 . . . . 0.2 111.539 -175.369 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 39' ' ' ASP . . . . . 0.688 ' HB3' ' HD3' ' B' ' 40' ' ' ARG . 0.5 OUTLIER -94.28 171.36 8.88 Favored 'General case' 0 N--CA 1.443 -0.777 0 N-CA-C 108.036 -1.098 . . . . 1.14 108.036 173.634 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 40' ' ' ARG . . . . . 0.688 ' HD3' ' HB3' ' B' ' 39' ' ' ASP . 0.0 OUTLIER 41.64 -107.22 0.08 Allowed 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 113.811 1.041 . . . . 2.71 113.811 176.902 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -108.13 -82.98 0.55 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.076 0.465 . . . . 1.32 111.368 -174.362 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 42' ' ' GLY . . . . . . . . . . . . . . . -118.93 26.15 7.64 Favored Glycine 0 N--CA 1.444 -0.78 0 C-N-CA 120.92 -0.657 . . . . 0.34 111.89 -175.976 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 43' ' ' GLU . . . . . 0.64 ' HB3' HG23 ' A' ' 45' ' ' ILE . 2.0 mt-10 -96.79 111.9 23.88 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 109.633 -0.506 . . . . 2.07 109.633 178.082 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 44' ' ' VAL . . . . . 0.561 ' HA ' ' HA ' ' B' ' 38' ' ' VAL . 1.9 t -88.23 132.63 32.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 N-CA-C 109.575 -0.528 . . . . 0.13 109.575 178.204 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 45' ' ' ILE . . . . . 0.797 HG13 HG13 ' A' ' 45' ' ' ILE . 1.5 mp -108.97 119.36 58.39 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 N-CA-C 108.206 -1.035 . . . . 0.12 108.206 -177.352 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 46' ' ' LEU . . . . . 0.998 HD11 HD11 ' A' ' 46' ' ' LEU . 0.7 OUTLIER -112.37 117.1 31.51 Favored 'General case' 0 C--N 1.317 -0.817 0 O-C-N 123.68 0.612 . . . . 0.15 110.008 178.217 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 47' ' ' LYS . . . . . 0.587 ' O ' ' HA ' ' B' ' 34' ' ' LEU . 0.0 OUTLIER -129.78 149.33 51.57 Favored 'General case' 0 C--O 1.215 -0.72 0 C-N-CA 119.492 -0.883 . . . . 0.95 113.03 -179.841 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 48' ' ' LYS . . . . . 0.602 ' HA ' ' O ' ' B' ' 33' ' ' PRO . 1.7 ptmt -39.75 -21.35 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.244 0 N-CA-C 117.658 2.466 . . . . 0.64 117.658 -168.086 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 49' ' ' TYR . . . . . 0.82 ' HB3' ' HB2' ' B' ' 33' ' ' PRO . 23.3 t80 75.1 -46.58 0.59 Allowed 'General case' 0 N--CA 1.47 0.568 0 CA-C-N 119.095 0.861 . . . . 1.26 111.282 177.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 50' ' ' SER . . . . . 0.664 ' OG ' ' HD3' ' B' ' 51' ' ' PRO . 1.6 p -50.14 -48.38 79.64 Favored Pre-proline 0 CA--C 1.544 0.737 0 CA-C-N 115.519 -0.764 . . . . 1.22 112.395 -175.528 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 51' ' ' PRO . . . . . 0.664 ' HD3' ' OG ' ' B' ' 50' ' ' SER . 33.1 Cg_endo -103.06 14.03 0.29 Allowed 'Trans proline' 0 N--CA 1.454 -0.831 0 C-N-CA 122.976 2.45 . . . . 0.56 111.733 170.241 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 52' ' ' ILE . . . . . 0.677 HG13 HD23 ' B' ' 55' ' ' LEU . 1.1 mt 53.54 -141.93 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 N-CA-C 108.516 -0.92 . . . . 0.73 108.516 -168.661 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 53' ' ' SER . . . . . . . . . . . . . 70.2 m -83.02 -28.18 29.82 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.509 0.671 . . . . 1.86 110.004 176.66 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 54' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -167.34 118.59 0.88 Allowed 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 114.408 -1.269 . . . . 2.62 109.216 -176.713 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 55' ' ' LEU . . . . . 0.677 HD23 HG13 ' B' ' 52' ' ' ILE . 0.2 OUTLIER . . . . . 0 C--O 1.249 1.062 0 CA-C-O 118.673 -0.679 . . . . 2.64 110.485 -177.068 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.48 1.075 0 N-CA-C 109.919 -0.4 . . . . 5.91 109.919 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.733 ' HB2' HG13 ' B' ' 38' ' ' VAL . 0.0 OUTLIER -82.91 -176.6 6.4 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 109.203 -0.666 . . . . 3.71 109.203 177.561 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.478 ' HA ' ' HB2' ' B' ' 37' ' ' PHE . . . 55.21 70.92 0.58 Allowed 'General case' 0 N--CA 1.463 0.214 0 CA-C-O 121.608 0.718 . . . . 0.72 109.75 -171.083 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 31.0 p -84.53 -31.74 24.26 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.201 -0.909 . . . . 0.41 112.521 -169.574 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.583 ' H ' ' HB3' ' B' ' 37' ' ' PHE . . . 61.01 49.19 81.35 Favored Glycine 0 N--CA 1.446 -0.66 0 C-N-CA 120.767 -0.73 . . . . 0.32 113.074 176.567 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.85 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.6 tp -105.73 104.41 16.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 N-CA-C 109.173 -0.677 . . . . 0.31 109.173 174.823 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.615 HG21 ' CD1' ' B' ' 49' ' ' TYR . 38.0 t -74.25 133.04 32.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 115.719 -0.673 . . . . 0.28 110.088 179.696 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.667 ' HB3' ' CD1' ' B' ' 36' ' ' ILE . 3.3 tpp180 -129.43 119.4 23.74 Favored 'General case' 0 N--CA 1.437 -1.077 0 N-CA-C 106.809 -1.552 . . . . 1.99 106.809 -178.75 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.53 ' HA ' ' O ' ' B' ' 32' ' ' ASP . 9.4 ttp180 -83.37 102.76 12.23 Favored 'General case' 0 C--N 1.312 -1.024 0 N-CA-C 108.553 -0.906 . . . . 2.8 108.553 176.183 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.756 HG23 HD11 ' B' ' 34' ' ' LEU . 0.2 OUTLIER -9.62 -103.23 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 O-C-N 125.62 1.825 . . . . 0.33 114.525 -177.108 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ASP . . . . . 0.603 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 4.3 p-10 161.43 -162.62 0.0 OUTLIER 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 108.31 -0.996 . . . . 1.13 108.31 176.86 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -71.27 -24.73 62.22 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.15 0.5 . . . . 2.26 110.803 -178.109 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -95.22 -58.98 1.99 Allowed 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.112 -0.494 . . . . 0.53 110.212 178.551 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.531 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 135.64 17.72 0.83 Allowed Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.595 -0.812 . . . . 0.22 112.92 -177.998 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.664 ' HG2' HG22 ' B' ' 17' ' ' VAL . 1.4 mpt_? -74.73 153.11 38.98 Favored 'General case' 0 CA--C 1.507 -0.689 0 O-C-N 122.139 -0.624 . . . . 0.69 110.033 179.299 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.749 HG21 HD13 ' B' ' 46' ' ' LEU . 93.3 t -108.39 95.93 4.22 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.29 0 N-CA-C 107.662 -1.236 . . . . 1.24 107.662 169.239 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.644 HG22 ' HG2' ' B' ' 15' ' ' ARG . 91.0 t -64.54 99.37 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-N 115.131 -0.94 . . . . 0.28 110.085 -174.121 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.473 ' HB ' ' O ' ' B' ' 14' ' ' GLY . 38.6 mm -87.47 112.05 45.73 Favored Pre-proline 0 N--CA 1.446 -0.659 0 CA-C-N 115.543 -0.753 . . . . 0.77 109.854 -179.515 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.568 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 91.9 Cg_exo -50.79 140.72 37.34 Favored 'Trans proline' 0 N--CA 1.452 -0.963 0 C-N-CA 122.267 1.978 . . . . 0.32 111.738 173.566 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.982 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -61.12 -14.95 28.12 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.675 -0.693 . . . . 1.57 111.47 -177.992 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.568 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 11.3 pt-20 -66.77 -21.4 66.06 Favored 'General case' 0 C--O 1.237 0.442 0 N-CA-C 112.182 0.438 . . . . 1.32 112.182 -178.685 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.2 mp -87.91 -45.27 15.98 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 107.997 -1.112 . . . . 0.35 107.997 -179.772 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ARG . . . . . 0.733 ' HA ' ' HB2' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -60.35 -29.37 68.86 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 115.285 -0.871 . . . . 1.5 109.18 172.448 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.473 ' HB3' ' O ' ' A' ' 21' ' ' GLU . 58.7 ttt180 -60.42 -52.6 64.52 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 114.403 -1.271 . . . . 2.96 110.484 173.833 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 19.8 m -69.2 -21.21 63.97 Favored 'General case' 0 CA--C 1.53 0.177 0 CA-C-O 121.295 0.569 . . . . 0.4 110.904 175.11 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.791 ' HB3' HG13 ' A' ' 28' ' ' ILE . 0.8 OUTLIER -67.55 -18.37 65.0 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.974 -0.557 . . . . 0.36 111.2 176.418 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.466 ' HB2' ' O ' ' A' ' 26' ' ' LEU . 0.0 OUTLIER 70.51 20.46 5.89 Favored 'General case' 0 C--N 1.343 0.324 0 CA-C-O 121.299 0.571 . . . . 3.2 110.009 -172.397 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.791 HG13 ' HB3' ' A' ' 26' ' ' LEU . 3.0 mt -119.22 -164.87 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.535 -0.757 . . . . 0.48 109.855 -176.086 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.732 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -158.3 -156.97 0.59 Allowed 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 110.382 -0.229 . . . . 2.4 110.382 -167.988 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 30' ' ' GLU . . . . . 0.404 ' C ' HD11 ' B' ' 10' ' ' ILE . 1.6 mp0 -72.95 38.48 0.08 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 122.213 1.006 . . . . 1.23 111.034 176.34 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.639 ' N ' HD11 ' B' ' 10' ' ' ILE . . . -152.55 26.17 0.85 Allowed Glycine 0 N--CA 1.435 -1.411 0 CA-C-N 113.854 -1.521 . . . . 0.36 110.4 176.023 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.495 ' HA ' ' HD3' ' A' ' 33' ' ' PRO . 63.8 t0 -84.12 114.22 53.08 Favored Pre-proline 0 C--N 1.331 -0.205 0 CA-C-O 121.279 0.562 . . . . 1.26 109.768 175.627 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.595 ' HA ' ' HA ' ' B' ' 9' ' ' ARG . 1.2 Cg_endo -88.97 54.76 1.95 Allowed 'Trans proline' 0 CA--C 1.507 -0.874 0 C-N-CA 124.158 3.239 . . . . 1.3 114.108 -175.188 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.609 HD12 ' H ' ' A' ' 34' ' ' LEU . 1.0 OUTLIER -57.38 153.6 12.21 Favored 'General case' 0 C--N 1.297 -1.676 0 CA-C-O 122.299 1.047 . . . . 0.38 112.352 -173.768 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.824 ' HB3' ' HB3' ' A' ' 47' ' ' LYS . 33.8 tt0 -105.07 118.47 36.62 Favored 'General case' 0 CA--C 1.492 -1.259 0 CA-C-N 113.492 -1.685 . . . . 1.12 107.505 -175.594 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.884 ' HB ' HG23 ' B' ' 6' ' ' ILE . 2.6 mp -88.28 110.16 20.72 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.014 0 O-C-N 123.847 0.717 . . . . 0.39 109.265 179.467 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' PHE . . . . . 0.784 ' HD1' ' HA ' ' B' ' 3' ' ' ALA . 0.8 OUTLIER -150.18 124.84 9.72 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 109.785 -0.45 . . . . 1.15 109.785 174.557 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.776 HG13 ' HB2' ' B' ' 2' ' ' LYS . 1.4 p -80.91 137.83 20.69 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.978 0 CA-C-O 121.053 0.454 . . . . 0.17 110.716 -179.232 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.596 ' OD2' ' HD2' ' A' ' 40' ' ' ARG . 3.6 t70 -85.4 -55.49 3.99 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.444 -0.798 . . . . 1.11 111.514 -173.633 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' ARG . . . . . 0.596 ' HD2' ' OD2' ' A' ' 39' ' ' ASP . 0.2 OUTLIER -119.91 -91.61 0.55 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.517 -0.765 . . . . 2.29 111.981 -169.554 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -99.01 -69.58 0.76 Allowed 'General case' 0 CA--C 1.511 -0.548 0 CA-C-O 121.345 0.593 . . . . 1.53 110.571 -176.206 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.729 ' HA3' HD11 ' B' ' 26' ' ' LEU . . . -135.54 21.74 3.58 Favored Glycine 0 N--CA 1.437 -1.261 0 CA-C-N 114.97 -1.013 . . . . 0.32 111.696 -176.787 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.621 ' HB3' HG23 ' B' ' 45' ' ' ILE . 2.1 mt-10 -95.38 109.15 21.36 Favored 'General case' 0 N--CA 1.447 -0.602 0 N-CA-C 109.099 -0.704 . . . . 1.97 109.099 177.381 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.528 ' CG1' HG23 ' A' ' 36' ' ' ILE . 1.7 t -90.09 132.11 35.6 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.941 0 N-CA-C 109.214 -0.661 . . . . 0.14 109.214 178.467 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.754 HG13 HG13 ' B' ' 45' ' ' ILE . 1.6 mp -108.21 119.55 58.0 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 N-CA-C 108.262 -1.014 . . . . 0.14 108.262 -176.104 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.926 HD11 HD11 ' B' ' 46' ' ' LEU . 6.9 mt -103.61 121.9 43.88 Favored 'General case' 0 C--N 1.322 -0.599 0 O-C-N 124.221 0.951 . . . . 0.23 110.033 179.616 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.824 ' HB3' ' HB3' ' A' ' 35' ' ' GLU . 21.6 ttmt -126.98 123.3 36.79 Favored 'General case' 0 C--N 1.308 -1.216 0 CA-C-N 115.454 -0.793 . . . . 0.76 112.576 -168.18 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.57 ' O ' ' HD2' ' A' ' 33' ' ' PRO . 3.1 ptmt -39.0 -19.24 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.648 0 N-CA-C 116.948 2.203 . . . . 0.32 116.948 -172.849 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 0.661 ' CD1' HG21 ' B' ' 7' ' ' VAL . 27.1 t80 74.72 -56.02 0.64 Allowed 'General case' 0 N--CA 1.475 0.823 0 C-N-CA 123.83 0.852 . . . . 1.28 113.001 173.414 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.681 ' HB3' ' HD3' ' A' ' 51' ' ' PRO . 48.2 t -49.62 -53.61 39.55 Favored Pre-proline 0 CA--C 1.535 0.373 0 CA-C-N 115.807 -0.633 . . . . 1.36 111.433 -175.072 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.681 ' HD3' ' HB3' ' A' ' 50' ' ' SER . 46.2 Cg_endo -95.26 14.32 1.21 Allowed 'Trans proline' 0 N--CA 1.456 -0.723 0 C-N-CA 122.27 1.98 . . . . 0.58 111.452 170.652 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.67 HG13 HD23 ' A' ' 55' ' ' LEU . 2.6 mt 53.96 -130.63 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 N-CA-C 108.587 -0.894 . . . . 0.78 108.587 -172.433 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 63.1 m -91.06 -43.51 9.87 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-O 121.472 0.653 . . . . 1.96 110.126 173.789 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 29.9 tt0 -128.81 -47.88 1.25 Allowed 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 114.827 -1.079 . . . . 2.89 110.97 -170.942 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.67 HD23 HG13 ' A' ' 52' ' ' ILE . 0.5 OUTLIER . . . . . 0 C--O 1.248 1.015 0 O-C-N 124.034 0.834 . . . . 2.65 110.24 -179.057 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 22.2 mmt . . . . . 0 N--CA 1.478 0.951 0 CA-C-O 120.666 0.27 . . . . 6.17 110.355 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 2' ' ' LYS . . . . . 0.776 ' HB2' HG13 ' A' ' 38' ' ' VAL . 0.1 OUTLIER -82.07 -172.48 3.97 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 108.885 -0.783 . . . . 3.61 108.885 172.902 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 3' ' ' ALA . . . . . 0.784 ' HA ' ' HD1' ' A' ' 37' ' ' PHE . . . 53.55 69.34 0.72 Allowed 'General case' 0 N--CA 1.462 0.174 0 CA-C-O 121.555 0.693 . . . . 0.86 110.169 -175.472 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 4' ' ' THR . . . . . . . . . . . . . 25.0 p -82.41 -32.02 29.31 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.162 -0.926 . . . . 0.43 112.498 -171.141 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 5' ' ' GLY . . . . . 0.472 ' H ' ' CB ' ' A' ' 37' ' ' PHE . . . 61.44 45.27 96.73 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 121.14 -0.552 . . . . 0.33 113.128 176.728 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 6' ' ' ILE . . . . . 0.884 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.1 tp -104.17 104.74 17.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.517 0.675 . . . . 0.3 109.556 178.066 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 7' ' ' VAL . . . . . 0.661 HG21 ' CD1' ' A' ' 49' ' ' TYR . 4.9 t -74.84 131.46 34.96 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.872 0 CA-C-N 115.178 -0.919 . . . . 0.27 110.896 -179.158 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.474 ' HB3' ' CD1' ' A' ' 36' ' ' ILE . 0.1 OUTLIER -129.56 118.15 21.58 Favored 'General case' 0 N--CA 1.447 -0.593 0 N-CA-C 107.031 -1.47 . . . . 1.69 107.031 177.737 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 9' ' ' ARG . . . . . 0.595 ' HA ' ' HA ' ' A' ' 33' ' ' PRO . 26.7 ttp180 -79.85 104.84 10.7 Favored 'General case' 0 N--CA 1.44 -0.969 0 C-N-CA 119.789 -0.764 . . . . 2.71 109.001 174.527 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 10' ' ' ILE . . . . . 0.65 ' O ' ' HB3' ' B' ' 11' ' ' ASP . 0.3 OUTLIER -11.91 -102.75 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 O-C-N 125.705 1.878 . . . . 0.34 114.644 -176.051 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 11' ' ' ASP . . . . . 0.65 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 2.8 p-10 160.07 -165.81 0.0 OUTLIER 'General case' 0 C--N 1.342 0.249 0 N-CA-C 107.871 -1.159 . . . . 1.18 107.871 177.964 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -68.21 -30.75 69.9 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 120.967 0.413 . . . . 2.39 110.616 -179.131 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 13' ' ' LEU . . . . . 0.528 ' HB3' ' HD2' ' B' ' 15' ' ' ARG . 3.1 tm? -85.61 -59.27 2.36 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.066 -0.515 . . . . 0.4 110.101 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 14' ' ' GLY . . . . . 0.473 ' O ' ' HB ' ' A' ' 18' ' ' ILE . . . 131.46 16.29 1.52 Allowed Glycine 0 N--CA 1.445 -0.711 0 C-N-CA 120.327 -0.939 . . . . 0.21 112.727 -178.112 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 15' ' ' ARG . . . . . 0.644 ' HG2' HG22 ' A' ' 17' ' ' VAL . 0.3 OUTLIER -74.8 153.3 38.81 Favored 'General case' 0 CA--C 1.507 -0.674 0 C-N-CA 119.709 -0.796 . . . . 0.9 109.826 178.138 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 16' ' ' VAL . . . . . 0.872 HG21 HD13 ' A' ' 46' ' ' LEU . 95.9 t -108.53 98.01 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.316 0 N-CA-C 107.725 -1.213 . . . . 1.27 107.725 169.721 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 17' ' ' VAL . . . . . 0.664 HG22 ' HG2' ' A' ' 15' ' ' ARG . 57.6 t -66.69 99.58 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.877 0 CA-C-N 114.963 -1.017 . . . . 0.27 110.14 -172.259 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 18' ' ' ILE . . . . . 0.531 ' HB ' ' O ' ' A' ' 14' ' ' GLY . 39.1 mm -86.92 111.7 42.23 Favored Pre-proline 0 C--N 1.323 -0.569 0 CA-C-N 115.321 -0.854 . . . . 0.82 109.978 -179.376 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 19' ' ' PRO . . . . . 0.561 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 86.4 Cg_exo -50.61 139.85 37.77 Favored 'Trans proline' 0 N--CA 1.453 -0.909 0 C-N-CA 122.392 2.061 . . . . 0.3 111.607 172.994 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 20' ' ' LYS . . . . . 1.024 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -61.07 -13.31 15.99 Favored 'General case' 0 C--N 1.313 -0.979 0 CA-C-N 115.442 -0.799 . . . . 1.77 111.64 -178.35 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 21' ' ' GLU . . . . . 0.561 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 10.4 pt-20 -67.01 -22.98 65.87 Favored 'General case' 0 C--O 1.237 0.444 0 N-CA-C 112.614 0.598 . . . . 1.92 112.614 179.751 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 4.6 mp -88.06 -43.17 15.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 N-CA-C 107.758 -1.201 . . . . 0.44 107.758 -179.672 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 23' ' ' ARG . . . . . 0.684 ' HA ' ' HB2' ' B' ' 26' ' ' LEU . 0.0 OUTLIER -60.53 -29.89 69.4 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 115.287 -0.87 . . . . 1.4 109.298 171.503 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 24' ' ' ARG . . . . . 0.441 ' HB3' ' O ' ' B' ' 21' ' ' GLU . 23.1 ttt180 -61.66 -52.72 63.17 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 114.594 -1.184 . . . . 3.19 110.391 174.073 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 14.4 m -66.53 -25.06 66.49 Favored 'General case' 0 N--CA 1.452 -0.366 0 CA-C-O 121.456 0.646 . . . . 0.4 110.466 176.292 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.729 HD11 ' HA3' ' A' ' 42' ' ' GLY . 0.7 OUTLIER -65.04 -19.55 66.05 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.432 -0.804 . . . . 0.33 111.068 175.699 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 27' ' ' ARG . . . . . 0.488 ' HB2' ' O ' ' B' ' 26' ' ' LEU . 0.2 OUTLIER 70.99 19.04 5.78 Favored 'General case' 0 N--CA 1.465 0.28 0 O-C-N 123.938 0.774 . . . . 3.28 110.097 -173.265 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 28' ' ' ILE . . . . . 0.892 HG22 ' H ' ' B' ' 29' ' ' ARG . 5.6 mt -115.45 -166.61 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 115.569 -0.741 . . . . 0.37 110.037 -177.044 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 29' ' ' ARG . . . . . 0.892 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -155.93 -157.35 0.71 Allowed 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 110.404 -0.221 . . . . 2.15 110.404 -169.698 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 30' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -71.44 31.94 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.547 0.689 . . . . 1.18 111.926 178.495 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 31' ' ' GLY . . . . . 0.547 ' N ' HD11 ' A' ' 10' ' ' ILE . . . -145.73 30.24 1.69 Allowed Glycine 0 N--CA 1.438 -1.172 0 CA-C-N 115.222 -0.899 . . . . 0.35 110.866 173.527 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 32' ' ' ASP . . . . . 0.53 ' O ' ' HA ' ' A' ' 9' ' ' ARG . 25.6 t0 -84.19 117.32 68.41 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-O 121.296 0.57 . . . . 1.29 110.301 176.881 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 33' ' ' PRO . . . . . 0.733 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 2.5 Cg_endo -87.4 66.7 3.99 Favored 'Trans proline' 0 C--O 1.206 -1.112 0 C-N-CA 123.984 3.123 . . . . 1.1 113.793 -178.448 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.756 HD11 HG23 ' A' ' 10' ' ' ILE . 0.9 OUTLIER -66.23 151.53 46.81 Favored 'General case' 0 C--N 1.284 -2.276 0 C-N-CA 118.547 -1.261 . . . . 0.44 111.573 -174.774 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 35' ' ' GLU . . . . . 0.682 ' O ' ' HA ' ' B' ' 46' ' ' LEU . 66.1 tt0 -103.53 114.33 28.52 Favored 'General case' 0 CA--C 1.493 -1.242 0 CA-C-N 114.686 -1.143 . . . . 1.1 108.011 -178.99 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 36' ' ' ILE . . . . . 0.85 ' HB ' HG23 ' A' ' 6' ' ' ILE . 2.6 mp -87.87 109.82 20.09 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.732 0 O-C-N 124.199 0.937 . . . . 0.62 109.598 -179.04 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 37' ' ' PHE . . . . . 0.583 ' HB3' ' H ' ' A' ' 5' ' ' GLY . 15.3 p90 -150.69 125.95 10.02 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 116.111 -0.495 . . . . 1.2 110.002 175.176 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 38' ' ' VAL . . . . . 0.733 HG13 ' HB2' ' A' ' 2' ' ' LYS . 0.8 OUTLIER -80.31 136.97 22.33 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 CA-C-O 121.125 0.488 . . . . 0.2 110.895 -178.19 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 39' ' ' ASP . . . . . 0.599 ' OD1' ' HD2' ' B' ' 40' ' ' ARG . 12.2 t70 -76.86 -64.75 1.05 Allowed 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 114.699 -1.137 . . . . 1.14 110.996 -175.213 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 40' ' ' ARG . . . . . 0.599 ' HD2' ' OD1' ' B' ' 39' ' ' ASP . 0.0 OUTLIER -117.73 -94.49 0.49 Allowed 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.682 -0.69 . . . . 2.71 112.204 -175.162 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 26.1 t70 -90.85 -70.47 0.68 Allowed 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.993 0.425 . . . . 1.32 111.21 -174.014 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 42' ' ' GLY . . . . . 0.623 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -134.28 24.22 3.59 Favored Glycine 0 N--CA 1.441 -0.996 0 C-N-CA 120.498 -0.858 . . . . 0.34 112.476 -177.555 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 43' ' ' GLU . . . . . 0.635 ' HA ' ' O ' ' A' ' 46' ' ' LEU . 1.1 mt-10 -97.04 107.86 20.47 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 109.434 -0.58 . . . . 2.07 109.434 175.956 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 44' ' ' VAL . . . . . 0.573 ' HA ' ' HA ' ' B' ' 38' ' ' VAL . 2.0 t -88.66 130.91 37.34 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 N-CA-C 109.587 -0.523 . . . . 0.13 109.587 178.18 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 45' ' ' ILE . . . . . 0.754 HG13 HG13 ' A' ' 45' ' ' ILE . 1.6 mp -106.45 121.33 58.9 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 N-CA-C 107.962 -1.125 . . . . 0.12 107.962 -177.994 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 46' ' ' LEU . . . . . 0.926 HD11 HD11 ' A' ' 46' ' ' LEU . 0.7 OUTLIER -111.59 116.27 30.54 Favored 'General case' 0 C--N 1.319 -0.731 0 O-C-N 123.876 0.735 . . . . 0.15 109.782 177.779 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 47' ' ' LYS . . . . . 0.544 ' HE3' ' HB3' ' B' ' 35' ' ' GLU . 0.0 OUTLIER -131.12 140.43 49.99 Favored 'General case' 0 C--O 1.213 -0.82 0 N-CA-C 113.402 0.89 . . . . 0.95 113.402 -178.684 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 48' ' ' LYS . . . . . 0.63 ' HE2' ' HG3' ' B' ' 51' ' ' PRO . 4.9 ptmt -38.2 -16.72 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.393 0 N-CA-C 118.747 2.869 . . . . 0.64 118.747 -168.175 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 49' ' ' TYR . . . . . 0.733 ' HB3' ' HB2' ' B' ' 33' ' ' PRO . 39.5 t80 72.32 -51.51 0.7 Allowed 'General case' 0 N--CA 1.485 1.309 0 CA-C-N 119.241 0.928 . . . . 1.26 113.247 176.481 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 50' ' ' SER . . . . . 0.449 ' OG ' ' HD3' ' B' ' 51' ' ' PRO . 1.4 p -51.7 -51.5 69.51 Favored Pre-proline 0 CA--C 1.541 0.613 0 CA-C-N 116.069 -0.514 . . . . 1.22 112.051 -172.581 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 51' ' ' PRO . . . . . 0.63 ' HG3' ' HE2' ' B' ' 48' ' ' LYS . 24.2 Cg_endo -95.42 16.41 0.91 Allowed 'Trans proline' 0 C--N 1.351 0.687 0 C-N-CA 122.45 2.1 . . . . 0.56 111.582 167.735 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 52' ' ' ILE . . . . . 0.43 HG13 HD23 ' B' ' 55' ' ' LEU . 3.4 mt 53.2 -130.66 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 N-CA-C 108.083 -1.08 . . . . 0.73 108.083 -170.566 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 53' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -112.97 19.53 17.19 Favored 'General case' 0 C--N 1.307 -1.277 0 C-N-CA 120.432 -0.507 . . . . 1.86 111.285 177.615 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 54' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 178.6 -55.96 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.568 -0.742 . . . . 2.62 110.715 -175.294 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 55' ' ' LEU . . . . . 0.43 HD23 HG13 ' B' ' 52' ' ' ILE . 0.2 OUTLIER . . . . . 0 C--O 1.25 1.114 0 CA-C-N 115.172 -0.922 . . . . 2.64 109.303 -175.828 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 24.7 ttt . . . . . 0 N--CA 1.48 1.032 0 CA-C-O 120.738 0.304 . . . . 5.91 110.836 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.55 ' HB3' HG13 ' B' ' 38' ' ' VAL . 30.0 mmmt -112.26 -117.04 0.31 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.089 0.471 . . . . 3.71 111.922 -173.941 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.422 ' HA ' ' HB2' ' B' ' 37' ' ' PHE . . . 72.53 143.29 0.06 Allowed 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 114.406 -1.27 . . . . 0.72 112.723 179.079 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.828 ' H ' ' HB2' ' B' ' 37' ' ' PHE . 19.2 p -130.84 -54.86 1.06 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 114.792 -1.095 . . . . 0.41 110.458 179.052 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 84.58 54.06 3.05 Favored Glycine 0 N--CA 1.446 -0.654 0 C-N-CA 120.434 -0.888 . . . . 0.32 112.458 173.319 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.902 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.6 tp -108.84 108.96 26.6 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 N-CA-C 109.404 -0.591 . . . . 0.31 109.404 171.235 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.757 HG21 ' CD1' ' B' ' 49' ' ' TYR . 36.5 t -83.0 135.92 23.85 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-O 120.905 0.383 . . . . 0.28 111.286 -179.435 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.528 ' HB3' HD11 ' B' ' 36' ' ' ILE . 5.3 tpt180 -129.63 114.79 16.47 Favored 'General case' 0 N--CA 1.446 -0.642 0 N-CA-C 107.85 -1.167 . . . . 1.99 107.85 -176.771 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.722 HH11 ' HG3' ' B' ' 33' ' ' PRO . 3.7 tpp180 -81.73 103.43 11.42 Favored 'General case' 0 CA--C 1.509 -0.618 0 N-CA-C 108.047 -1.094 . . . . 2.8 108.047 174.19 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.662 ' O ' ' HB3' ' A' ' 11' ' ' ASP . 0.2 OUTLIER -14.5 -106.61 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.039 0 O-C-N 125.7 1.875 . . . . 0.33 114.367 -176.295 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ASP . . . . . 0.662 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 4.6 p-10 158.86 -169.06 0.0 OUTLIER 'General case' 0 CA--C 1.511 -0.547 0 N-CA-C 107.917 -1.142 . . . . 1.13 107.917 175.23 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -70.61 -8.92 55.25 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.952 0.406 . . . . 2.26 111.086 -178.686 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.403 HD12 HG13 ' B' ' 17' ' ' VAL . 1.6 tm? -107.82 -62.14 1.48 Allowed 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.763 -0.458 . . . . 0.53 109.763 175.205 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 134.36 22.34 0.71 Allowed Glycine 0 N--CA 1.445 -0.75 0 C-N-CA 120.455 -0.878 . . . . 0.22 113.264 179.288 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.566 ' HB3' ' HB3' ' B' ' 15' ' ' ARG . 1.5 mpt_? -80.99 150.44 28.91 Favored 'General case' 0 CA--C 1.51 -0.588 0 O-C-N 121.913 -0.757 . . . . 0.69 110.813 -179.885 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.597 HG21 HD13 ' B' ' 46' ' ' LEU . 70.9 t -109.91 98.78 7.49 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.284 0 N-CA-C 107.581 -1.266 . . . . 1.24 107.581 168.959 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.554 ' HA ' ' HA ' ' B' ' 15' ' ' ARG . 61.7 t -67.25 101.66 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 CA-C-N 115.501 -0.772 . . . . 0.28 109.577 -176.138 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.611 HG23 HD13 ' A' ' 22' ' ' ILE . 8.5 mt -93.55 111.77 53.8 Favored Pre-proline 0 C--N 1.322 -0.6 0 CA-C-N 116.022 -0.536 . . . . 0.77 110.72 -177.836 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.687 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 95.7 Cg_exo -50.31 152.51 8.26 Favored 'Trans proline' 0 N--CA 1.458 -0.579 0 C-N-CA 122.944 2.429 . . . . 0.32 112.893 173.963 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.825 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -67.24 -14.26 62.74 Favored 'General case' 0 C--O 1.21 -0.988 0 CA-C-N 115.668 -0.696 . . . . 1.57 111.237 -179.851 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.687 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 15.4 pt-20 -62.65 -25.36 68.09 Favored 'General case' 0 C--O 1.238 0.495 0 CA-C-O 120.88 0.372 . . . . 1.32 111.752 -179.322 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.611 HD13 HG23 ' A' ' 18' ' ' ILE . 5.3 mp -86.63 -47.17 16.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 108.257 -1.016 . . . . 0.35 108.257 -177.72 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ARG . . . . . 0.639 ' HA ' ' HB2' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -61.12 -27.19 68.2 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.172 -0.922 . . . . 1.5 109.038 174.043 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 38.8 ttp180 -64.27 -52.29 59.36 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 114.829 -1.078 . . . . 2.96 110.564 175.088 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 21.7 m -63.93 -28.18 69.65 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-O 121.154 0.502 . . . . 0.4 110.992 174.28 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.639 ' HB2' ' HA ' ' A' ' 23' ' ' ARG . 2.4 mm? -64.05 -19.99 65.61 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.795 -0.639 . . . . 0.36 110.043 172.636 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.408 HH11 ' HD3' ' A' ' 27' ' ' ARG . 0.2 OUTLIER 71.44 22.26 4.27 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.01 -0.995 . . . . 3.2 110.105 -177.609 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.782 HG22 ' H ' ' A' ' 29' ' ' ARG . 6.1 mt -121.03 -167.35 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.674 0 CA-C-N 115.155 -0.93 . . . . 0.48 109.118 -177.424 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.782 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.3 OUTLIER -146.01 -156.47 0.71 Allowed 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 118.037 0.38 . . . . 2.4 111.943 -174.335 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -72.86 48.6 0.21 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 122.197 0.998 . . . . 1.23 111.904 -179.214 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.684 ' N ' HD11 ' B' ' 10' ' ' ILE . . . -166.14 24.9 0.15 Allowed Glycine 0 N--CA 1.443 -0.876 0 CA-C-N 113.804 -1.544 . . . . 0.36 109.863 174.69 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.494 ' O ' HG13 ' B' ' 10' ' ' ILE . 19.8 t0 -87.67 127.63 57.54 Favored Pre-proline 0 CA--C 1.516 -0.348 0 CA-C-N 114.771 -0.715 . . . . 1.26 109.377 174.883 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.712 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 3.8 Cg_endo -82.36 154.31 16.27 Favored 'Trans proline' 0 N--CA 1.438 -1.773 0 C-N-CA 122.26 1.973 . . . . 1.3 110.676 174.968 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.739 ' O ' ' HA ' ' B' ' 7' ' ' VAL . 0.5 OUTLIER -142.68 149.62 39.09 Favored 'General case' 0 C--N 1.307 -1.262 0 C-N-CA 120.133 -0.627 . . . . 0.38 109.507 172.688 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.949 ' HB3' ' HD2' ' A' ' 47' ' ' LYS . 38.1 tt0 -108.55 111.1 22.77 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 108.524 -0.917 . . . . 1.12 108.524 -176.182 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 1.033 HG13 HD22 ' A' ' 46' ' ' LEU . 2.2 mp -85.85 109.48 18.58 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.794 0 O-C-N 124.972 1.42 . . . . 0.39 109.211 -176.239 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' PHE . . . . . 0.967 ' HD2' ' HA ' ' B' ' 3' ' ' ALA . 0.5 OUTLIER -149.37 124.72 10.23 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 115.683 -0.69 . . . . 1.15 109.431 177.736 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.538 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 2.0 p -80.52 133.08 30.25 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.953 0 CA-C-O 121.214 0.53 . . . . 0.17 110.566 -179.221 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.522 ' HB3' ' HG2' ' A' ' 40' ' ' ARG . 27.2 t0 -81.21 -58.07 3.22 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 114.154 -1.385 . . . . 1.11 111.453 -174.447 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' ARG . . . . . 0.567 ' HG3' ' HG3' ' A' ' 43' ' ' GLU . 1.3 ptm180 -125.6 -99.52 0.4 Allowed 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.134 -0.939 . . . . 2.29 112.74 -166.086 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 34.7 t70 -84.11 -75.67 0.33 Allowed 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.168 0.508 . . . . 1.53 110.757 -175.735 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.491 ' HA3' HD11 ' B' ' 26' ' ' LEU . . . -135.11 24.88 3.38 Favored Glycine 0 N--CA 1.441 -0.979 0 CA-C-N 115.534 -0.757 . . . . 0.32 111.313 178.735 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.633 ' HB3' HG23 ' B' ' 45' ' ' ILE . 2.1 mt-10 -93.6 109.91 21.53 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.048 -0.723 . . . . 1.97 109.048 178.473 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.538 ' HA ' ' HA ' ' A' ' 38' ' ' VAL . 1.5 t -90.41 130.51 39.53 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 N-CA-C 109.22 -0.659 . . . . 0.14 109.22 178.015 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.74 HG13 HG13 ' B' ' 45' ' ' ILE . 1.5 mp -108.79 117.91 55.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 N-CA-C 108.456 -0.942 . . . . 0.14 108.456 -175.595 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 1.049 HD11 HD11 ' B' ' 46' ' ' LEU . 0.3 OUTLIER -109.7 115.16 29.35 Favored 'General case' 0 C--N 1.314 -0.939 0 N-CA-C 108.743 -0.836 . . . . 0.23 108.743 176.936 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.949 ' HD2' ' HB3' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -123.11 151.26 42.24 Favored 'General case' 0 C--O 1.215 -0.74 0 C-N-CA 118.808 -1.157 . . . . 0.76 111.99 179.594 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.659 ' HA ' ' O ' ' A' ' 33' ' ' PRO . 2.0 ptmt -42.12 -16.78 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.93 0 N-CA-C 117.377 2.362 . . . . 0.32 117.377 -168.058 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 0.735 ' CD1' HG21 ' B' ' 7' ' ' VAL . 23.0 t80 73.19 -53.87 0.7 Allowed 'General case' 0 N--CA 1.473 0.676 0 CA-C-N 118.321 0.509 . . . . 1.28 112.301 174.101 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.7 ' OG ' ' HD3' ' A' ' 51' ' ' PRO . 4.3 p -54.07 -44.42 98.36 Favored Pre-proline 0 CA--C 1.543 0.676 0 CA-C-N 116.131 -0.486 . . . . 1.36 111.804 -175.378 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.7 ' HD3' ' OG ' ' A' ' 50' ' ' SER . 94.5 Cg_endo -102.29 21.44 0.17 Allowed 'Trans proline' 0 N--CA 1.452 -0.969 0 C-N-CA 123.082 2.521 . . . . 0.58 111.75 168.164 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.456 HD12 HD23 ' A' ' 55' ' ' LEU . 0.2 OUTLIER 46.52 -148.08 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.235 0.328 0 CA-C-N 115.78 -0.645 . . . . 0.78 110.347 -176.751 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 23.8 m -85.28 79.28 9.57 Favored 'General case' 0 N--CA 1.446 -0.657 0 C-N-CA 120.812 -0.355 . . . . 1.96 110.108 172.756 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 43.4 tt0 66.01 81.24 0.21 Allowed 'General case' 0 CA--C 1.534 0.33 0 CA-C-O 121.281 0.563 . . . . 2.89 110.937 178.333 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.516 ' HB2' ' O ' ' A' ' 51' ' ' PRO . 0.7 OUTLIER . . . . . 0 C--O 1.251 1.14 0 CA-C-O 118.562 -0.733 . . . . 2.65 109.489 179.037 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 25.8 ttt . . . . . 0 N--CA 1.479 0.983 0 CA-C-O 120.63 0.252 . . . . 6.17 111.139 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 2' ' ' LYS . . . . . 0.428 ' HB3' ' H ' ' B' ' 3' ' ' ALA . 30.4 mmmt -110.23 -161.87 0.77 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.617 -0.265 . . . . 3.61 111.422 -176.53 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 3' ' ' ALA . . . . . 0.967 ' HA ' ' HD2' ' A' ' 37' ' ' PHE . . . 137.57 160.02 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 125.182 1.393 . . . . 0.86 109.147 -163.96 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 4' ' ' THR . . . . . 0.735 ' H ' ' HB2' ' A' ' 37' ' ' PHE . 2.1 p -152.7 -47.86 0.1 Allowed 'General case' 0 C--N 1.324 -0.52 0 O-C-N 123.671 0.607 . . . . 0.43 109.563 174.083 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 72.53 53.1 8.93 Favored Glycine 0 N--CA 1.452 -0.254 0 CA-C-N 114.989 -1.005 . . . . 0.33 113.134 171.256 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 6' ' ' ILE . . . . . 0.855 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.3 tp -109.13 112.18 39.37 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.801 0 N-CA-C 109.124 -0.695 . . . . 0.3 109.124 171.895 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 7' ' ' VAL . . . . . 0.739 ' HA ' ' O ' ' A' ' 34' ' ' LEU . 39.7 t -84.4 136.03 23.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-O 120.94 0.4 . . . . 0.27 110.974 -179.501 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.573 ' CZ ' HG23 ' B' ' 17' ' ' VAL . 1.4 tpt180 -129.61 114.71 16.38 Favored 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 107.665 -1.235 . . . . 1.69 107.665 -178.603 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 9' ' ' ARG . . . . . 0.534 ' HA ' ' HA ' ' A' ' 33' ' ' PRO . 0.0 OUTLIER -80.81 103.06 10.39 Favored 'General case' 0 CA--C 1.51 -0.582 0 N-CA-C 107.933 -1.136 . . . . 2.71 107.933 173.903 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 10' ' ' ILE . . . . . 0.684 HD11 ' N ' ' A' ' 31' ' ' GLY . 0.2 OUTLIER -13.54 -105.54 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.085 0 O-C-N 125.611 1.82 . . . . 0.34 114.509 -176.627 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 11' ' ' ASP . . . . . 0.493 ' H ' HD13 ' B' ' 10' ' ' ILE . 34.8 p30 156.99 -160.71 0.0 OUTLIER 'General case' 0 CA--C 1.508 -0.637 0 C-N-CA 124.379 1.072 . . . . 1.18 108.25 171.735 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -71.96 -8.29 53.63 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 121.085 0.469 . . . . 2.39 110.766 -176.81 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 13' ' ' LEU . . . . . 0.408 HD12 HG13 ' A' ' 17' ' ' VAL . 2.1 tm? -114.72 -57.97 2.2 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.343 -0.39 . . . . 0.4 109.973 -179.8 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 133.03 17.42 1.15 Allowed Glycine 0 N--CA 1.441 -0.967 0 C-N-CA 120.595 -0.812 . . . . 0.21 113.784 179.532 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 15' ' ' ARG . . . . . 0.566 ' HB3' ' HB3' ' A' ' 15' ' ' ARG . 0.2 OUTLIER -81.5 150.52 28.22 Favored 'General case' 0 CA--C 1.507 -0.694 0 CA-C-N 118.764 1.282 . . . . 0.9 110.962 -179.256 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 16' ' ' VAL . . . . . 0.542 HG21 HD13 ' A' ' 46' ' ' LEU . 98.2 t -108.98 100.72 11.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 CA-C-N 114.318 -1.31 . . . . 1.27 107.549 171.064 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 17' ' ' VAL . . . . . 0.573 HG23 ' CZ ' ' B' ' 8' ' ' ARG . 37.8 t -69.54 103.21 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.078 0 CA-C-N 115.832 -0.622 . . . . 0.27 109.654 -174.96 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 18' ' ' ILE . . . . . 0.478 HD11 HD12 ' B' ' 46' ' ' LEU . 6.8 mt -91.98 112.39 54.61 Favored Pre-proline 0 N--CA 1.446 -0.647 0 CA-C-O 121.477 0.656 . . . . 0.82 110.981 -177.768 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 19' ' ' PRO . . . . . 0.696 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 67.7 Cg_exo -49.1 142.9 19.6 Favored 'Trans proline' 0 N--CA 1.46 -0.484 0 C-N-CA 123.379 2.719 . . . . 0.3 112.456 171.511 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 20' ' ' LYS . . . . . 0.987 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -61.36 -15.1 32.82 Favored 'General case' 0 C--O 1.211 -0.938 0 CA-C-N 115.313 -0.858 . . . . 1.77 111.4 179.525 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 21' ' ' GLU . . . . . 0.696 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 10.0 pt-20 -63.37 -22.84 67.12 Favored 'General case' 0 C--O 1.238 0.486 0 N-CA-C 112.117 0.414 . . . . 1.92 112.117 179.625 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 22' ' ' ILE . . . . . 0.402 HD13 HG23 ' B' ' 18' ' ' ILE . 5.3 mp -87.09 -47.97 15.68 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 N-CA-C 108.61 -0.885 . . . . 0.44 108.61 -179.371 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 23' ' ' ARG . . . . . 0.586 ' HA ' ' HB2' ' B' ' 26' ' ' LEU . 0.0 OUTLIER -60.06 -27.98 67.42 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.356 -0.838 . . . . 1.4 109.27 173.234 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 24' ' ' ARG . . . . . . . . . . . . . 43.5 ttp180 -65.45 -52.76 50.83 Favored 'General case' 0 N--CA 1.446 -0.654 0 CA-C-N 114.676 -1.147 . . . . 3.19 110.683 175.7 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 21.3 m -64.77 -26.67 68.45 Favored 'General case' 0 N--CA 1.449 -0.508 0 CA-C-O 121.355 0.597 . . . . 0.4 110.667 175.421 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.586 ' HB2' ' HA ' ' B' ' 23' ' ' ARG . 1.7 mm? -64.85 -18.97 65.61 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.46 -0.791 . . . . 0.33 110.59 173.754 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 27' ' ' ARG . . . . . . . . . . . . . 19.6 tpt180 74.4 22.32 2.19 Favored 'General case' 0 C--N 1.34 0.166 0 O-C-N 124.136 0.897 . . . . 3.28 109.772 -178.034 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 28' ' ' ILE . . . . . 0.896 HG22 ' H ' ' B' ' 29' ' ' ARG . 6.6 mt -123.28 -163.19 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.343 -0.844 . . . . 0.37 110.287 -174.91 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 29' ' ' ARG . . . . . 0.896 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -152.44 -159.31 0.99 Allowed 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 112.025 0.379 . . . . 2.15 112.025 -170.392 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 30' ' ' GLU . . . . . 0.467 ' H ' ' HB2' ' B' ' 29' ' ' ARG . 0.9 OUTLIER -73.92 36.94 0.1 Allowed 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 121.849 0.833 . . . . 1.18 111.961 -177.464 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 31' ' ' GLY . . . . . 0.576 ' CA ' HD11 ' A' ' 10' ' ' ILE . . . -153.93 30.42 0.74 Allowed Glycine 0 N--CA 1.442 -0.93 0 N-CA-C 109.757 -1.337 . . . . 0.35 109.757 171.658 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 32' ' ' ASP . . . . . 0.505 ' HB2' ' CG2' ' B' ' 28' ' ' ILE . 12.3 t70 -86.7 128.78 55.2 Favored Pre-proline 0 C--N 1.324 -0.543 0 CA-C-N 114.81 -0.695 . . . . 1.29 109.948 174.197 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 33' ' ' PRO . . . . . 0.754 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 10.3 Cg_endo -84.88 148.93 10.9 Favored 'Trans proline' 0 N--CA 1.435 -1.919 0 C-N-CA 122.402 2.068 . . . . 1.1 110.785 173.474 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.717 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.7 OUTLIER -137.55 148.63 46.09 Favored 'General case' 0 C--N 1.302 -1.471 0 N-CA-C 109.631 -0.507 . . . . 0.44 109.631 173.64 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 35' ' ' GLU . . . . . 0.708 ' O ' ' HA ' ' B' ' 46' ' ' LEU . 46.8 tt0 -105.16 111.74 24.6 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 107.9 -1.148 . . . . 1.1 107.9 -178.178 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 36' ' ' ILE . . . . . 1.107 HG13 HD22 ' B' ' 46' ' ' LEU . 3.0 mp -86.73 109.86 19.53 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.943 0 O-C-N 124.417 1.073 . . . . 0.62 109.06 -178.604 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 37' ' ' PHE . . . . . 0.828 ' HB2' ' H ' ' A' ' 4' ' ' THR . 12.1 p90 -151.0 131.97 14.25 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 116.158 -0.474 . . . . 1.2 109.966 174.796 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 38' ' ' VAL . . . . . 0.55 HG13 ' HB3' ' A' ' 2' ' ' LYS . 1.9 p -80.08 142.33 14.07 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.01 0 CA-C-O 120.949 0.404 . . . . 0.2 110.352 -178.584 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 39' ' ' ASP . . . . . 0.458 ' HB2' ' CD1' ' B' ' 45' ' ' ILE . 25.8 t0 -92.08 -47.52 7.22 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.556 -0.747 . . . . 1.14 111.618 -175.026 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 40' ' ' ARG . . . . . 0.559 ' HG3' ' HG3' ' B' ' 43' ' ' GLU . 0.0 OUTLIER -134.08 -100.82 0.25 Allowed 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 112.767 0.655 . . . . 2.71 112.767 -168.12 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 25.1 t70 -83.09 -71.92 0.47 Allowed 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.422 0.63 . . . . 1.32 110.767 -176.182 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 42' ' ' GLY . . . . . 0.482 ' HA3' ' HD2' ' A' ' 48' ' ' LYS . . . -139.73 25.77 2.68 Favored Glycine 0 CA--C 1.501 -0.801 0 CA-C-N 115.41 -0.814 . . . . 0.34 111.179 178.868 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 43' ' ' GLU . . . . . 0.559 ' HG3' ' HG3' ' B' ' 40' ' ' ARG . 2.7 mt-10 -92.72 109.15 20.57 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 109.226 -0.657 . . . . 2.07 109.226 178.629 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 44' ' ' VAL . . . . . 0.514 ' HA ' ' HA ' ' B' ' 38' ' ' VAL . 1.7 t -89.13 130.48 38.41 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 N-CA-C 109.122 -0.696 . . . . 0.13 109.122 178.09 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 45' ' ' ILE . . . . . 0.74 HG13 HG13 ' A' ' 45' ' ' ILE . 1.7 mp -108.19 118.85 56.68 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 N-CA-C 108.138 -1.06 . . . . 0.12 108.138 -176.981 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 46' ' ' LEU . . . . . 1.107 HD22 HG13 ' B' ' 36' ' ' ILE . 0.5 OUTLIER -110.26 115.77 30.3 Favored 'General case' 0 C--N 1.317 -0.847 0 N-CA-C 108.819 -0.808 . . . . 0.15 108.819 176.648 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 47' ' ' LYS . . . . . 0.537 ' O ' ' HA ' ' B' ' 34' ' ' LEU . 0.0 OUTLIER -126.57 149.99 49.1 Favored 'General case' 0 C--N 1.317 -0.847 0 C-N-CA 119.178 -1.009 . . . . 0.95 112.626 -177.724 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 48' ' ' LYS . . . . . 0.684 ' HE2' ' HG3' ' B' ' 51' ' ' PRO . 3.4 ptmt -41.7 -14.18 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.064 0 N-CA-C 118.007 2.595 . . . . 0.64 118.007 -167.643 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 49' ' ' TYR . . . . . 0.757 ' CD1' HG21 ' A' ' 7' ' ' VAL . 30.9 t80 72.41 -56.62 0.65 Allowed 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 113.004 0.742 . . . . 1.26 113.004 173.145 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 50' ' ' SER . . . . . 0.718 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 8.3 t -52.28 -52.7 60.27 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.26 -0.427 . . . . 1.22 110.778 -174.031 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 51' ' ' PRO . . . . . 0.718 ' HD3' ' HB3' ' B' ' 50' ' ' SER . 47.2 Cg_endo -92.33 14.29 1.74 Allowed 'Trans proline' 0 N--CA 1.454 -0.806 0 C-N-CA 122.155 1.903 . . . . 0.56 111.84 170.421 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 52' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER 49.97 -144.99 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 115.52 -0.764 . . . . 0.73 109.76 -177.184 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 53' ' ' SER . . . . . . . . . . . . . 17.7 m -83.8 77.97 9.79 Favored 'General case' 0 C--N 1.321 -0.646 0 C-N-CA 120.544 -0.462 . . . . 1.86 110.174 176.688 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 54' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 65.99 85.23 0.14 Allowed 'General case' 0 CA--C 1.531 0.217 0 CA-C-O 121.248 0.547 . . . . 2.62 110.572 178.593 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 55' ' ' LEU . . . . . 0.452 ' HA ' HD22 ' B' ' 55' ' ' LEU . 0.6 OUTLIER . . . . . 0 C--O 1.249 1.026 0 CA-C-O 118.703 -0.665 . . . . 2.64 109.498 -178.251 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 65.7 mtt . . . . . 0 N--CA 1.48 1.058 0 N-CA-C 109.227 -0.657 . . . . 5.91 109.227 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.69 ' HA ' ' CE ' ' A' ' 2' ' ' LYS . 1.1 mmpt? -81.1 -126.32 0.02 OUTLIER 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 120.851 -0.339 . . . . 3.71 110.368 174.064 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.59 ' HA ' ' HD2' ' B' ' 37' ' ' PHE . . . 65.96 107.03 0.04 OUTLIER 'General case' 0 C--N 1.32 -0.706 0 O-C-N 123.846 0.717 . . . . 0.72 111.844 -179.006 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.542 ' OG1' ' HA ' ' B' ' 37' ' ' PHE . 11.7 p -97.05 -45.76 6.44 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.547 -0.752 . . . . 0.41 111.602 -179.4 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 70.51 48.93 33.78 Favored Glycine 0 N--CA 1.443 -0.866 0 C-N-CA 120.58 -0.819 . . . . 0.32 112.919 174.155 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.783 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.0 OUTLIER -104.94 113.1 41.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 N-CA-C 108.407 -0.96 . . . . 0.31 108.407 173.997 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.755 HG21 ' CD1' ' B' ' 49' ' ' TYR . 28.3 t -83.58 134.65 26.47 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-O 121.211 0.529 . . . . 0.28 110.94 -178.319 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.593 ' HB3' ' CD1' ' B' ' 36' ' ' ILE . 9.0 tpp180 -131.0 119.54 22.2 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 107.818 -1.178 . . . . 1.99 107.818 -176.583 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.452 ' N ' ' HD3' ' A' ' 8' ' ' ARG . 44.8 ttp180 -79.27 108.36 12.72 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 108.613 -0.884 . . . . 2.8 108.613 170.713 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.832 HG23 HD11 ' B' ' 34' ' ' LEU . 0.2 OUTLIER -16.19 -102.65 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 O-C-N 125.593 1.808 . . . . 0.33 114.492 -177.724 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ASP . . . . . 0.606 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 3.1 p-10 162.89 -160.92 0.0 OUTLIER 'General case' 0 CA--C 1.509 -0.602 0 N-CA-C 107.826 -1.176 . . . . 1.13 107.826 175.542 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 25.0 m-20 -70.72 -22.09 62.47 Favored 'General case' 0 C--N 1.321 -0.663 0 O-C-N 123.384 0.428 . . . . 2.26 110.812 -178.78 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.459 HD22 ' HE2' ' B' ' 20' ' ' LYS . 3.0 tm? -102.88 -61.46 1.4 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.27 -0.423 . . . . 0.53 110.305 179.682 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.524 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 144.48 16.65 0.21 Allowed Glycine 0 N--CA 1.442 -0.93 0 C-N-CA 120.768 -0.729 . . . . 0.22 112.513 -178.91 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.553 ' HB3' ' HB3' ' B' ' 15' ' ' ARG . 2.8 mpt_? -71.5 145.84 48.92 Favored 'General case' 0 CA--C 1.504 -0.793 0 CA-C-O 121.522 0.677 . . . . 0.69 110.456 -179.278 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.82 HG21 HD13 ' B' ' 46' ' ' LEU . 97.5 t -103.76 94.08 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.53 0 N-CA-C 107.146 -1.427 . . . . 1.24 107.146 168.947 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.552 ' HA ' ' HA ' ' B' ' 15' ' ' ARG . 59.7 t -67.22 97.62 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.844 0 CA-C-N 114.891 -1.049 . . . . 0.28 110.137 -172.809 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.716 HG23 HD13 ' A' ' 22' ' ' ILE . 17.4 mt -98.54 111.23 59.59 Favored Pre-proline 0 C--N 1.326 -0.45 0 CA-C-N 115.594 -0.73 . . . . 0.77 111.11 -175.6 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.783 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 48.6 Cg_exo -46.74 150.41 2.55 Favored 'Trans proline' 0 N--CA 1.458 -0.577 0 C-N-CA 123.183 2.588 . . . . 0.32 113.859 175.041 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.944 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -64.49 -12.62 45.93 Favored 'General case' 0 C--O 1.207 -1.176 0 CA-C-N 115.164 -0.926 . . . . 1.57 111.219 176.61 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.783 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 12.7 pt-20 -64.88 -22.62 67.03 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 118.436 0.562 . . . . 1.32 111.246 176.372 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.716 HD13 HG23 ' A' ' 18' ' ' ILE . 5.1 mp -88.06 -44.31 15.72 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.404 0 N-CA-C 108.889 -0.782 . . . . 0.35 108.889 179.167 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ARG . . . . . 0.72 ' HG3' ' HA ' ' A' ' 20' ' ' LYS . 1.1 ppt_? -61.12 -26.25 67.54 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 122.284 1.04 . . . . 1.5 108.636 172.05 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.534 ' HB3' ' O ' ' A' ' 21' ' ' GLU . 32.0 ttt180 -64.03 -52.37 59.77 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 113.741 -1.572 . . . . 2.96 110.628 174.914 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 40.3 m -62.73 -30.35 71.36 Favored 'General case' 0 N--CA 1.455 -0.223 0 CA-C-O 121.062 0.458 . . . . 0.4 110.995 172.928 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.616 ' HB2' ' HA ' ' A' ' 23' ' ' ARG . 2.6 mm? -63.49 -18.98 64.35 Favored 'General case' 0 CA--C 1.519 -0.23 0 CA-C-N 115.952 -0.567 . . . . 0.36 109.94 174.662 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.413 HH11 ' HD2' ' A' ' 27' ' ' ARG . 11.3 mmt180 67.69 23.38 8.7 Favored 'General case' 0 N--CA 1.451 -0.408 0 CA-C-N 115.277 -0.874 . . . . 3.2 109.915 -178.079 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.838 HG22 ' H ' ' A' ' 29' ' ' ARG . 11.8 mt -124.32 -167.61 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 CA-C-N 114.479 -1.237 . . . . 0.48 108.161 -178.161 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.838 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.2 OUTLIER -142.63 -158.55 0.88 Allowed 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 118.403 0.547 . . . . 2.4 112.116 -175.464 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 5.7 mp0 -72.9 47.19 0.18 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 122.221 1.01 . . . . 1.23 111.942 -179.514 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.661 ' N ' HD11 ' B' ' 10' ' ' ILE . . . -163.08 24.91 0.2 Allowed Glycine 0 N--CA 1.445 -0.71 0 CA-C-N 113.801 -1.545 . . . . 0.36 109.867 175.115 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.47 ' O ' HG13 ' B' ' 10' ' ' ILE . 18.1 t0 -87.97 130.81 45.07 Favored Pre-proline 0 CA--C 1.514 -0.423 0 CA-C-N 114.446 -0.877 . . . . 1.26 109.367 174.247 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.686 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 3.2 Cg_endo -82.32 153.44 16.15 Favored 'Trans proline' 0 N--CA 1.438 -1.762 0 C-N-CA 122.172 1.915 . . . . 1.3 110.634 174.668 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.846 HD11 HG23 ' B' ' 10' ' ' ILE . 0.5 OUTLIER -140.72 151.68 44.7 Favored 'General case' 0 N--CA 1.433 -1.319 0 C-N-CA 119.866 -0.734 . . . . 0.38 109.663 171.439 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.74 ' HB3' ' HD2' ' A' ' 47' ' ' LYS . 86.0 tt0 -105.13 111.31 24.03 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.606 -1.257 . . . . 1.12 107.606 -178.523 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 1.016 HG13 HD22 ' A' ' 46' ' ' LEU . 2.9 mp -87.14 109.01 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.744 0 O-C-N 124.722 1.263 . . . . 0.39 109.116 -178.893 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' PHE . . . . . 0.654 ' HD2' ' HA ' ' B' ' 3' ' ' ALA . 1.0 OUTLIER -149.23 127.72 12.3 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 115.987 -0.551 . . . . 1.15 109.835 176.833 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.47 ' CG1' ' HD3' ' B' ' 2' ' ' LYS . 1.3 p -81.81 132.49 31.35 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.999 0 CA-C-O 121.612 0.72 . . . . 0.17 110.657 -179.878 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.568 ' HB3' ' HG2' ' A' ' 40' ' ' ARG . 19.7 t70 -79.94 -49.89 11.22 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 114.236 -1.347 . . . . 1.11 111.672 -173.746 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' ARG . . . . . 0.568 ' HG2' ' HB3' ' A' ' 39' ' ' ASP . 1.7 ptm180 -133.65 -96.83 0.29 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.48 -0.782 . . . . 2.29 112.96 -167.069 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -88.6 -70.38 0.65 Allowed 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.089 0.471 . . . . 1.53 111.024 -174.311 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.432 ' O ' ' HA ' ' B' ' 47' ' ' LYS . . . -139.67 22.84 2.82 Favored Glycine 0 N--CA 1.445 -0.741 0 CA-C-N 115.596 -0.729 . . . . 0.32 111.279 -179.344 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.552 ' HB3' HG23 ' B' ' 45' ' ' ILE . 1.7 mt-10 -95.4 113.06 24.69 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 109.483 -0.562 . . . . 1.97 109.483 179.275 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.476 ' CG1' HG23 ' A' ' 36' ' ' ILE . 1.4 t -91.15 131.26 38.77 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 N-CA-C 109.425 -0.583 . . . . 0.14 109.425 177.182 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.804 HG13 HG13 ' B' ' 45' ' ' ILE . 1.6 mp -109.69 118.06 55.99 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 108.072 -1.084 . . . . 0.14 108.072 -176.568 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 1.031 HD11 HD11 ' B' ' 46' ' ' LEU . 0.3 OUTLIER -112.54 116.69 30.63 Favored 'General case' 0 C--N 1.315 -0.933 0 O-C-N 123.796 0.685 . . . . 0.23 109.467 178.813 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.74 ' HD2' ' HB3' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -127.64 153.59 46.26 Favored 'General case' 0 C--O 1.215 -0.722 0 C-N-CA 118.662 -1.215 . . . . 0.76 112.216 178.56 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.643 ' HG3' ' HG2' ' A' ' 51' ' ' PRO . 1.1 ptmt -41.24 -17.42 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.026 0 N-CA-C 117.497 2.406 . . . . 0.32 117.497 -168.88 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 0.808 ' CD1' HG21 ' B' ' 7' ' ' VAL . 17.4 t80 75.82 -53.59 0.63 Allowed 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 112.418 0.525 . . . . 1.28 112.418 173.379 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.677 ' HB3' ' HD3' ' A' ' 51' ' ' PRO . 8.3 t -51.57 -49.71 81.16 Favored Pre-proline 0 CA--C 1.538 0.498 0 CA-C-N 116.219 -0.446 . . . . 1.36 111.099 -177.184 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.677 ' HD3' ' HB3' ' A' ' 50' ' ' SER . 27.8 Cg_endo -93.82 9.12 2.25 Favored 'Trans proline' 0 N--CA 1.455 -0.749 0 C-N-CA 122.647 2.231 . . . . 0.58 111.663 171.706 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.434 HG13 ' C ' ' A' ' 51' ' ' PRO . 1.1 mt 53.69 -149.35 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 CA-C-N 115.439 -0.8 . . . . 0.78 109.326 -175.038 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.433 ' O ' ' N ' ' A' ' 55' ' ' LEU . 3.6 m -78.52 89.3 4.47 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.342 -0.614 . . . . 1.96 109.342 174.388 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.627 ' O ' ' HB2' ' A' ' 55' ' ' LEU . 11.9 pt-20 54.42 -64.54 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.95 0 O-C-N 124.991 1.432 . . . . 2.89 111.865 -170.949 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.627 ' HB2' ' O ' ' A' ' 54' ' ' GLU . 0.2 OUTLIER . . . . . 0 C--O 1.249 1.066 0 C-N-CA 124.788 1.235 . . . . 2.65 108.526 173.471 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 26.5 ttt . . . . . 0 N--CA 1.481 1.111 0 CA-C-O 120.991 0.425 . . . . 6.17 110.149 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 2' ' ' LYS . . . . . 0.84 ' HE2' ' HA ' ' B' ' 2' ' ' LYS . 1.4 mmpt? 43.87 -143.3 0.14 Allowed 'General case' 0 N--CA 1.47 0.558 0 CA-C-N 115.615 -0.72 . . . . 3.61 112.503 -176.144 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 3' ' ' ALA . . . . . 0.654 ' HA ' ' HD2' ' A' ' 37' ' ' PHE . . . 66.01 106.82 0.04 OUTLIER 'General case' 0 C--O 1.233 0.208 0 O-C-N 123.856 0.723 . . . . 0.86 111.303 -174.687 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 4' ' ' THR . . . . . 0.531 ' OG1' ' HA ' ' A' ' 37' ' ' PHE . 7.5 p -94.73 -48.14 6.18 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.909 -0.587 . . . . 0.43 111.675 -179.174 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 72.24 48.33 25.7 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.939 -0.648 . . . . 0.33 112.976 174.84 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 6' ' ' ILE . . . . . 0.746 HG23 ' HB ' ' A' ' 36' ' ' ILE . 0.9 OUTLIER -106.11 112.1 37.95 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 N-CA-C 108.731 -0.84 . . . . 0.3 108.731 174.83 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 7' ' ' VAL . . . . . 0.808 HG21 ' CD1' ' A' ' 49' ' ' TYR . 35.2 t -83.56 136.66 22.35 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 CA-C-O 120.952 0.405 . . . . 0.27 111.167 -178.887 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.514 ' HD3' ' N ' ' B' ' 9' ' ' ARG . 1.0 OUTLIER -133.17 123.77 26.25 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 107.296 -1.372 . . . . 1.69 107.296 179.128 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 9' ' ' ARG . . . . . 0.514 ' N ' ' HD3' ' B' ' 8' ' ' ARG . 0.1 OUTLIER -82.31 103.33 11.82 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 108.267 -1.012 . . . . 2.71 108.267 173.219 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 10' ' ' ILE . . . . . 0.846 HG23 HD11 ' A' ' 34' ' ' LEU . 0.2 OUTLIER -10.32 -106.02 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 O-C-N 125.444 1.715 . . . . 0.34 114.9 -176.746 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 11' ' ' ASP . . . . . 0.604 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 2.5 p-10 163.1 -168.29 0.01 OUTLIER 'General case' 0 CA--C 1.51 -0.575 0 N-CA-C 106.586 -1.635 . . . . 1.18 106.586 177.174 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 52.7 m-20 -77.06 -2.87 36.28 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 118.418 0.553 . . . . 2.39 110.995 -176.804 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 13' ' ' LEU . . . . . 0.425 ' H ' ' CG ' ' B' ' 11' ' ' ASP . 2.1 tm? -106.56 -61.8 1.48 Allowed 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.781 -0.645 . . . . 0.4 109.794 174.689 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 138.14 17.01 0.63 Allowed Glycine 0 N--CA 1.445 -0.722 0 CA-C-N 115.947 -0.57 . . . . 0.21 112.093 -176.869 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 15' ' ' ARG . . . . . 0.553 ' HB3' ' HB3' ' A' ' 15' ' ' ARG . 1.6 mpt_? -70.36 143.1 52.04 Favored 'General case' 0 CA--C 1.506 -0.724 0 CA-C-O 121.536 0.684 . . . . 0.9 110.481 -179.718 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 16' ' ' VAL . . . . . 0.715 HG21 HD13 ' A' ' 46' ' ' LEU . 81.1 t -104.69 94.34 3.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 N-CA-C 107.343 -1.354 . . . . 1.27 107.343 167.465 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 17' ' ' VAL . . . . . 0.528 HG22 ' HG2' ' A' ' 15' ' ' ARG . 40.8 t -67.13 98.49 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-N 115.188 -0.915 . . . . 0.27 110.169 -171.1 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 18' ' ' ILE . . . . . 0.524 ' HB ' ' O ' ' A' ' 14' ' ' GLY . 11.4 mt -96.75 112.74 61.26 Favored Pre-proline 0 N--CA 1.447 -0.58 0 CA-C-N 115.535 -0.757 . . . . 0.82 110.932 -177.477 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 19' ' ' PRO . . . . . 0.621 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 85.6 Cg_exo -51.67 154.31 9.54 Favored 'Trans proline' 0 N--CA 1.456 -0.68 0 C-N-CA 122.626 2.217 . . . . 0.3 113.508 173.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 20' ' ' LYS . . . . . 0.783 ' HA ' ' HG3' ' B' ' 23' ' ' ARG . 0.0 OUTLIER -68.37 -13.37 62.24 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-N 114.828 -1.078 . . . . 1.77 111.1 178.384 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 21' ' ' GLU . . . . . 0.621 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 9.8 pt-20 -66.36 -20.24 66.03 Favored 'General case' 0 C--N 1.322 -0.595 0 C-N-CA 120.327 -0.549 . . . . 1.92 111.568 176.141 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 22' ' ' ILE . . . . . 0.49 HD13 HG23 ' B' ' 18' ' ' ILE . 5.4 mp -88.56 -45.21 15.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 N-CA-C 108.863 -0.791 . . . . 0.44 108.863 177.265 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 23' ' ' ARG . . . . . 0.783 ' HG3' ' HA ' ' B' ' 20' ' ' LYS . 0.3 OUTLIER -59.92 -25.11 64.88 Favored 'General case' 0 N--CA 1.472 0.636 0 CA-C-O 121.989 0.899 . . . . 1.4 108.789 171.996 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 24' ' ' ARG . . . . . 0.429 ' HB3' ' O ' ' B' ' 21' ' ' GLU . 35.3 ttm180 -65.17 -52.52 54.49 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 114.018 -1.446 . . . . 3.19 110.971 174.012 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 31.7 m -63.08 -29.16 70.59 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 120.54 -0.464 . . . . 0.4 110.906 173.756 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.581 ' HB2' ' HA ' ' B' ' 23' ' ' ARG . 2.6 mm? -63.34 -20.05 65.17 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.947 -0.57 . . . . 0.33 110.057 174.337 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 27' ' ' ARG . . . . . 0.414 ' HA ' ' HD3' ' B' ' 27' ' ' ARG . 25.0 mmt180 68.11 24.72 7.62 Favored 'General case' 0 N--CA 1.453 -0.306 0 CA-C-N 115.286 -0.87 . . . . 3.28 109.904 -177.381 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 28' ' ' ILE . . . . . 0.901 HG22 ' H ' ' B' ' 29' ' ' ARG . 12.6 mt -125.17 -161.43 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 114.793 -1.094 . . . . 0.37 109.294 -177.243 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 29' ' ' ARG . . . . . 0.901 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.1 OUTLIER -149.41 -160.79 1.22 Allowed 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 112.144 0.424 . . . . 2.15 112.144 -173.123 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 30' ' ' GLU . . . . . 0.428 ' N ' ' HD2' ' B' ' 29' ' ' ARG . 3.2 mp0 -71.12 37.82 0.05 Allowed 'General case' 0 N--CA 1.464 0.232 0 CA-C-O 121.523 0.677 . . . . 1.18 112.55 -178.629 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 31' ' ' GLY . . . . . 0.586 ' N ' HD11 ' A' ' 10' ' ' ILE . . . -152.03 18.5 0.84 Allowed Glycine 0 N--CA 1.443 -0.884 0 N-CA-C 110.339 -1.104 . . . . 0.35 110.339 173.469 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 32' ' ' ASP . . . . . 0.487 ' O ' HG13 ' A' ' 10' ' ' ILE . 18.3 t70 -78.32 129.14 75.93 Favored Pre-proline 0 C--N 1.326 -0.433 0 CA-C-N 115.054 -0.573 . . . . 1.29 109.595 174.93 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 33' ' ' PRO . . . . . 0.721 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 5.1 Cg_endo -82.16 150.05 15.55 Favored 'Trans proline' 0 N--CA 1.436 -1.853 0 C-N-CA 122.586 2.191 . . . . 1.1 110.697 173.242 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.832 HD11 HG23 ' A' ' 10' ' ' ILE . 0.7 OUTLIER -136.85 150.66 48.42 Favored 'General case' 0 C--N 1.306 -1.304 0 N-CA-C 109.674 -0.491 . . . . 0.44 109.674 173.693 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 35' ' ' GLU . . . . . 0.766 ' O ' ' HA ' ' B' ' 46' ' ' LEU . 38.0 tt0 -105.31 112.92 26.21 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 107.577 -1.268 . . . . 1.1 107.577 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 36' ' ' ILE . . . . . 0.981 HG13 HD22 ' B' ' 46' ' ' LEU . 3.3 mp -89.12 109.85 20.77 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 O-C-N 124.878 1.361 . . . . 0.62 109.198 -178.807 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 37' ' ' PHE . . . . . 0.896 ' HE1' ' HZ1' ' B' ' 47' ' ' LYS . 2.1 p90 -149.28 131.33 15.33 Favored 'General case' 0 C--N 1.317 -0.835 0 N-CA-C 109.694 -0.484 . . . . 1.2 109.694 175.013 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 38' ' ' VAL . . . . . 0.628 HG13 ' HB3' ' A' ' 2' ' ' LYS . 1.2 p -82.09 135.38 25.05 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 CA-C-O 121.367 0.603 . . . . 0.2 110.852 179.753 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 39' ' ' ASP . . . . . 0.465 ' HB2' ' CD1' ' B' ' 45' ' ' ILE . 35.8 t70 -81.07 -50.74 9.28 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 114.354 -1.294 . . . . 1.14 111.255 -174.675 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 40' ' ' ARG . . . . . 0.547 ' HD3' ' OE1' ' B' ' 43' ' ' GLU . 0.9 OUTLIER -134.22 -105.04 0.23 Allowed 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.908 -0.587 . . . . 2.71 112.347 -169.937 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 24.0 t70 -78.19 -70.48 0.48 Allowed 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.086 0.47 . . . . 1.32 111.362 -176.354 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 42' ' ' GLY . . . . . 0.441 ' HA3' ' HD2' ' A' ' 48' ' ' LYS . . . -139.72 25.17 2.71 Favored Glycine 0 N--CA 1.442 -0.906 0 C-N-CA 120.449 -0.881 . . . . 0.34 111.978 -177.933 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 43' ' ' GLU . . . . . 0.555 ' HB3' HG23 ' A' ' 45' ' ' ILE . 3.2 mt-10 -95.43 113.68 25.36 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.901 -0.407 . . . . 2.07 109.901 178.083 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 44' ' ' VAL . . . . . 0.502 ' CG1' HG23 ' B' ' 36' ' ' ILE . 1.5 t -91.13 130.73 39.85 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 N-CA-C 109.602 -0.518 . . . . 0.13 109.602 176.133 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 45' ' ' ILE . . . . . 0.804 HG13 HG13 ' A' ' 45' ' ' ILE . 1.7 mp -109.41 118.13 56.03 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 N-CA-C 108.262 -1.014 . . . . 0.12 108.262 -177.446 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 46' ' ' LEU . . . . . 1.031 HD11 HD11 ' A' ' 46' ' ' LEU . 0.3 OUTLIER -113.02 116.8 30.49 Favored 'General case' 0 C--N 1.314 -0.935 0 O-C-N 123.665 0.603 . . . . 0.15 109.571 178.916 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 47' ' ' LYS . . . . . 0.896 ' HZ1' ' HE1' ' B' ' 37' ' ' PHE . 0.0 OUTLIER -126.81 155.28 43.11 Favored 'General case' 0 C--N 1.32 -0.694 0 C-N-CA 118.85 -1.14 . . . . 0.95 111.97 179.096 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 48' ' ' LYS . . . . . 0.624 ' HA ' ' O ' ' B' ' 33' ' ' PRO . 6.5 ptmt -49.58 -7.67 0.03 OUTLIER 'General case' 0 N--CA 1.476 0.873 0 N-CA-C 117.102 2.26 . . . . 0.64 117.102 -166.011 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 49' ' ' TYR . . . . . 0.755 ' CD1' HG21 ' A' ' 7' ' ' VAL . 19.7 t80 73.8 -52.92 0.69 Allowed 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 112.73 0.641 . . . . 1.26 112.73 170.967 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 50' ' ' SER . . . . . 0.712 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 26.9 t -50.6 -52.89 51.74 Favored Pre-proline 0 CA--C 1.541 0.628 0 CA-C-N 116.059 -0.519 . . . . 1.22 111.177 -175.48 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 51' ' ' PRO . . . . . 0.712 ' HD3' ' HB3' ' B' ' 50' ' ' SER . 59.8 Cg_endo -93.55 12.87 1.73 Allowed 'Trans proline' 0 C--N 1.352 0.754 0 C-N-CA 122.438 2.092 . . . . 0.56 111.791 171.293 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 52' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER 50.15 -144.76 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.236 0.361 0 CA-C-N 115.323 -0.853 . . . . 0.73 109.619 -175.734 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 53' ' ' SER . . . . . . . . . . . . . 1.5 m -77.2 74.69 3.77 Favored 'General case' 0 C--N 1.323 -0.586 0 C-N-CA 120.807 -0.357 . . . . 1.86 110.68 176.243 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 54' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 49.07 22.28 0.58 Allowed 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 124.322 1.049 . . . . 2.62 112.998 179.446 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 55' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.251 1.174 0 C-N-CA 123.682 0.793 . . . . 2.64 111.806 179.791 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 18.8 mmt . . . . . 0 N--CA 1.481 1.083 0 CA-C-O 120.876 0.37 . . . . 5.91 110.718 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.419 ' HB3' HG13 ' B' ' 38' ' ' VAL . 25.7 mmmt -109.53 -135.02 0.35 Allowed 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.951 -0.568 . . . . 3.71 110.297 178.441 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.437 ' HA ' ' HB2' ' B' ' 37' ' ' PHE . . . 65.6 97.15 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.464 0 O-C-N 123.98 0.8 . . . . 0.72 111.24 -177.431 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.5 ' OG1' ' HA ' ' B' ' 37' ' ' PHE . 18.2 p -87.5 -45.89 10.08 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.563 -0.744 . . . . 0.41 111.365 -178.536 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.453 ' H ' ' HB3' ' B' ' 37' ' ' PHE . . . 73.15 48.39 19.97 Favored Glycine 0 N--CA 1.444 -0.796 0 C-N-CA 120.829 -0.701 . . . . 0.32 112.969 173.149 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.798 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.5 tp -106.46 107.4 22.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 N-CA-C 109.155 -0.683 . . . . 0.31 109.155 174.995 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.693 HG21 ' CD1' ' B' ' 49' ' ' TYR . 55.7 t -76.05 136.61 24.43 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.909 0 CA-C-O 121.414 0.626 . . . . 0.28 110.527 179.852 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.58 ' HB3' ' CD1' ' B' ' 36' ' ' ILE . 2.5 tpp180 -130.94 116.22 17.57 Favored 'General case' 0 N--CA 1.433 -1.304 0 N-CA-C 107.069 -1.456 . . . . 1.99 107.069 -179.661 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.553 ' C ' HD12 ' A' ' 10' ' ' ILE . 0.2 OUTLIER -82.48 101.68 10.85 Favored 'General case' 0 C--N 1.315 -0.931 0 N-CA-C 108.123 -1.066 . . . . 2.8 108.123 175.63 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.947 HG23 HD11 ' B' ' 34' ' ' LEU . 0.2 OUTLIER -7.05 -105.18 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.035 0 O-C-N 125.583 1.802 . . . . 0.33 114.681 -177.909 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ASP . . . . . 0.511 ' H ' HD13 ' A' ' 10' ' ' ILE . 47.6 p30 163.1 -151.33 0.0 OUTLIER 'General case' 0 CA--C 1.512 -0.482 0 C-N-CA 123.609 0.763 . . . . 1.13 109.013 176.356 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -78.91 -9.75 59.6 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 123.244 0.34 . . . . 2.26 111.288 -177.215 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -117.31 -58.06 2.08 Favored 'General case' 0 C--N 1.326 -0.454 0 O-C-N 122.237 -0.289 . . . . 0.53 110.292 -178.679 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.416 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 138.89 16.6 0.58 Allowed Glycine 0 N--CA 1.445 -0.748 0 C-N-CA 120.593 -0.813 . . . . 0.22 113.321 -177.922 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.618 ' HG2' HG22 ' B' ' 17' ' ' VAL . 0.8 OUTLIER -76.29 150.52 36.94 Favored 'General case' 0 CA--C 1.509 -0.603 0 CA-C-N 118.02 0.91 . . . . 0.69 109.837 177.406 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.738 HG21 HD13 ' B' ' 46' ' ' LEU . 54.3 t -106.73 96.87 4.98 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.29 0 N-CA-C 107.436 -1.32 . . . . 1.24 107.436 171.32 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.616 HG22 ' HG2' ' B' ' 15' ' ' ARG . 62.2 t -68.65 100.94 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.825 0 CA-C-N 115.366 -0.834 . . . . 0.28 110.06 -173.771 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.706 HG23 HD13 ' A' ' 22' ' ' ILE . 8.0 mt -93.83 114.9 64.3 Favored Pre-proline 0 N--CA 1.446 -0.641 0 CA-C-N 115.603 -0.726 . . . . 0.77 111.053 -177.171 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.592 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 30.9 Cg_exo -44.73 143.87 3.87 Favored 'Trans proline' 0 CA--C 1.513 -0.536 0 C-N-CA 123.403 2.736 . . . . 0.32 113.137 171.993 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.874 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -59.38 -15.82 19.02 Favored 'General case' 0 C--O 1.214 -0.797 0 CA-C-N 115.258 -0.883 . . . . 1.57 111.363 178.185 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.592 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 10.0 pt-20 -67.86 -21.06 65.19 Favored 'General case' 0 C--O 1.236 0.348 0 N-CA-C 111.63 0.233 . . . . 1.32 111.63 -177.51 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.706 HD13 HG23 ' A' ' 18' ' ' ILE . 5.0 mp -87.68 -49.16 14.8 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.369 0 N-CA-C 107.842 -1.17 . . . . 0.35 107.842 -179.414 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ARG . . . . . 0.639 ' HD3' ' N ' ' A' ' 24' ' ' ARG . 0.0 OUTLIER -51.69 -34.5 38.8 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-O 121.768 0.794 . . . . 1.5 109.769 168.296 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.639 ' N ' ' HD3' ' A' ' 23' ' ' ARG . 9.3 ttm180 -60.99 -51.89 67.32 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 114.771 -1.104 . . . . 2.96 110.943 177.506 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 27.5 m -65.19 -27.82 68.96 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-O 121.406 0.622 . . . . 0.4 110.587 175.187 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.847 ' HB3' HG13 ' A' ' 28' ' ' ILE . 2.3 mm? -65.01 -18.99 65.77 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.405 -0.816 . . . . 0.36 111.211 175.375 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.509 ' HB2' ' O ' ' A' ' 26' ' ' LEU . 5.7 mpt_? 71.42 14.72 6.35 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 123.437 0.695 . . . . 3.2 111.06 -174.307 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.847 HG13 ' HB3' ' A' ' 26' ' ' LEU . 2.9 mt -109.4 -157.21 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 CA-C-N 115.773 -0.649 . . . . 0.48 109.647 -175.71 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.74 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.2 OUTLIER -161.79 -153.79 0.3 Allowed 'General case' 0 C--N 1.325 -0.494 0 C-N-CA 123.026 0.53 . . . . 2.4 110.298 -176.211 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -71.5 44.79 0.1 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 122.097 0.951 . . . . 1.23 111.516 178.039 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.633 ' N ' HD11 ' B' ' 10' ' ' ILE . . . -161.36 33.87 0.38 Allowed Glycine 0 N--CA 1.441 -0.996 0 CA-C-N 114.331 -1.304 . . . . 0.36 110.496 177.656 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.461 ' HA ' ' HD3' ' A' ' 33' ' ' PRO . 29.2 t0 -94.45 119.4 66.44 Favored Pre-proline 0 C--N 1.327 -0.391 0 CA-C-N 115.168 -0.516 . . . . 1.26 109.753 176.453 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.629 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 3.3 Cg_endo -88.01 63.93 3.5 Favored 'Trans proline' 0 N--CA 1.452 -0.956 0 C-N-CA 123.916 3.077 . . . . 1.3 113.957 -177.214 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.589 HD12 ' H ' ' A' ' 34' ' ' LEU . 0.9 OUTLIER -64.66 154.54 36.21 Favored 'General case' 0 C--N 1.292 -1.924 0 C-N-CA 118.328 -1.349 . . . . 0.38 111.841 -177.128 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.763 ' O ' ' HA ' ' A' ' 46' ' ' LEU . 35.0 tt0 -109.4 113.5 26.37 Favored 'General case' 0 CA--C 1.494 -1.175 0 CA-C-N 113.369 -1.741 . . . . 1.12 108.291 -174.437 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.84 HG13 HD22 ' A' ' 46' ' ' LEU . 2.7 mp -84.4 109.49 17.74 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 O-C-N 124.143 0.902 . . . . 0.39 109.647 -178.836 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' PHE . . . . . 0.746 ' HD1' ' HA ' ' B' ' 3' ' ' ALA . 0.6 OUTLIER -149.31 121.48 8.33 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-O 121.228 0.537 . . . . 1.15 109.878 175.771 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.556 HG13 ' HB3' ' B' ' 2' ' ' LYS . 1.9 p -80.38 135.86 24.49 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.047 0 CA-C-O 121.208 0.527 . . . . 0.17 110.351 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.481 ' HB3' ' HG3' ' A' ' 40' ' ' ARG . 14.3 t70 -86.08 -40.33 15.84 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 114.99 -1.004 . . . . 1.11 111.529 -173.261 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' ARG . . . . . 0.481 ' HG3' ' HB3' ' A' ' 39' ' ' ASP . 8.3 mtp180 -132.08 -81.44 0.5 Allowed 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 112.788 0.662 . . . . 2.29 112.788 -163.061 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -122.19 -65.75 1.09 Allowed 'General case' 0 CA--C 1.507 -0.69 0 CA-C-O 121.581 0.705 . . . . 1.53 109.962 -176.18 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.546 ' O ' ' HA ' ' B' ' 47' ' ' LYS . . . -133.1 12.58 5.02 Favored Glycine 0 N--CA 1.438 -1.213 0 CA-C-N 114.816 -1.084 . . . . 0.32 111.638 -178.171 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.589 ' HB3' HG23 ' B' ' 45' ' ' ILE . 0.9 OUTLIER -92.57 105.97 18.04 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 108.757 -0.831 . . . . 1.97 108.757 177.346 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.55 HG11 HG23 ' A' ' 36' ' ' ILE . 2.4 t -89.67 131.24 37.43 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 N-CA-C 109.29 -0.633 . . . . 0.14 109.29 177.764 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.803 HG13 HG13 ' B' ' 45' ' ' ILE . 1.6 mp -108.85 116.07 51.02 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 N-CA-C 108.054 -1.091 . . . . 0.14 108.054 -176.028 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 1.048 HD11 HD11 ' B' ' 46' ' ' LEU . 0.7 OUTLIER -106.35 117.66 34.62 Favored 'General case' 0 C--N 1.316 -0.86 0 O-C-N 123.883 0.74 . . . . 0.23 109.402 178.418 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.756 ' HD2' ' HB3' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -129.49 143.82 51.0 Favored 'General case' 0 C--O 1.214 -0.773 0 C-N-CA 119.265 -0.974 . . . . 0.76 112.597 178.752 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.706 ' HG3' ' HG2' ' A' ' 51' ' ' PRO . 3.0 ptmt -39.86 -12.82 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.288 0 N-CA-C 117.833 2.531 . . . . 0.32 117.833 -169.921 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 0.629 ' HB3' ' HB2' ' A' ' 33' ' ' PRO . 27.9 t80 70.63 -57.11 0.59 Allowed 'General case' 0 N--CA 1.478 0.952 0 N-CA-C 113.437 0.903 . . . . 1.28 113.437 175.242 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.408 ' HB2' ' HD3' ' A' ' 51' ' ' PRO . 19.0 m -52.88 -52.64 63.05 Favored Pre-proline 0 CA--C 1.54 0.595 0 CA-C-N 115.644 -0.707 . . . . 1.36 111.951 -174.46 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.706 ' HG2' ' HG3' ' A' ' 48' ' ' LYS . 75.2 Cg_endo -90.55 10.65 2.87 Favored 'Trans proline' 0 C--N 1.35 0.618 0 C-N-CA 122.246 1.964 . . . . 0.58 111.726 168.615 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.412 HG13 ' C ' ' A' ' 51' ' ' PRO . 1.0 OUTLIER 55.04 -147.74 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.511 0 CA-C-N 115.261 -0.882 . . . . 0.78 109.726 -175.565 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.614 ' HA ' ' HG3' ' A' ' 47' ' ' LYS . 34.1 m -76.91 -15.95 59.52 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-O 121.694 0.759 . . . . 1.96 110.436 179.03 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.58 ' O ' ' HB2' ' A' ' 55' ' ' LEU . 31.6 tt0 169.02 -55.72 0.01 OUTLIER 'General case' 0 C--N 1.313 -1.02 0 CA-C-N 113.663 -1.608 . . . . 2.89 106.799 -172.118 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.58 ' HB2' ' O ' ' A' ' 54' ' ' GLU . 0.2 OUTLIER . . . . . 0 C--O 1.248 1.017 0 O-C-N 125.121 1.513 . . . . 2.65 108.936 169.604 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 23.5 mmt . . . . . 0 N--CA 1.48 1.065 0 N-CA-C 109.852 -0.425 . . . . 6.17 109.852 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 2' ' ' LYS . . . . . 0.556 ' HB3' HG13 ' A' ' 38' ' ' VAL . 24.4 mmmt -98.27 -131.63 0.22 Allowed 'General case' 0 C--N 1.326 -0.431 0 C-N-CA 121.128 -0.229 . . . . 3.61 111.367 -179.14 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 3' ' ' ALA . . . . . 0.746 ' HA ' ' HD1' ' A' ' 37' ' ' PHE . . . 69.09 89.12 0.1 Allowed 'General case' 0 C--N 1.325 -0.46 0 O-C-N 124.057 0.848 . . . . 0.86 110.985 -174.875 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 4' ' ' THR . . . . . 0.537 ' OG1' ' HA ' ' A' ' 37' ' ' PHE . 12.5 p -80.66 -45.74 16.71 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.354 -0.839 . . . . 0.43 111.944 -176.985 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 71.2 47.93 34.31 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 121.031 -0.604 . . . . 0.33 112.911 174.975 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 6' ' ' ILE . . . . . 0.808 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.1 tp -105.76 107.33 22.38 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 N-CA-C 109.263 -0.643 . . . . 0.3 109.263 175.443 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 7' ' ' VAL . . . . . 0.605 HG21 ' CD1' ' A' ' 49' ' ' TYR . 37.6 t -77.96 134.84 27.47 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.842 0 CA-C-N 115.627 -0.715 . . . . 0.27 110.412 -178.838 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 1.4 tpp180 -131.04 116.63 18.04 Favored 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 107.018 -1.475 . . . . 1.69 107.018 177.913 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 9' ' ' ARG . . . . . 0.518 ' HA ' ' HA ' ' A' ' 33' ' ' PRO . 13.9 ttt180 -79.03 103.45 8.98 Favored 'General case' 0 CA--C 1.505 -0.753 0 N-CA-C 108.381 -0.97 . . . . 2.71 108.381 174.53 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 10' ' ' ILE . . . . . 0.633 HD11 ' N ' ' A' ' 31' ' ' GLY . 0.3 OUTLIER -9.93 -106.15 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 O-C-N 125.895 1.997 . . . . 0.34 114.845 -176.599 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 11' ' ' ASP . . . . . 0.588 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 3.2 p-10 165.58 -164.42 0.01 OUTLIER 'General case' 0 CA--C 1.514 -0.405 0 N-CA-C 107.628 -1.249 . . . . 1.18 107.628 178.842 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 24.3 t70 -72.58 -10.63 60.02 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.012 0.434 . . . . 2.39 111.051 -179.014 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 13' ' ' LEU . . . . . 0.444 ' H ' ' CG ' ' B' ' 11' ' ' ASP . 2.4 tm? -108.47 -62.02 1.52 Allowed 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.4 -0.364 . . . . 0.4 110.922 -179.337 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 139.34 21.57 0.39 Allowed Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 120.799 -0.715 . . . . 0.21 112.0 -177.246 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 15' ' ' ARG . . . . . 0.616 ' HG2' HG22 ' A' ' 17' ' ' VAL . 1.7 mpt_? -75.44 150.12 38.36 Favored 'General case' 0 CA--C 1.505 -0.771 0 CA-C-O 121.617 0.723 . . . . 0.9 110.394 177.527 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 16' ' ' VAL . . . . . 0.801 HG21 HD13 ' A' ' 46' ' ' LEU . 61.4 t -108.18 92.74 2.17 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 N-CA-C 107.487 -1.301 . . . . 1.27 107.487 167.267 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 17' ' ' VAL . . . . . 0.618 HG22 ' HG2' ' A' ' 15' ' ' ARG . 46.8 t -67.34 98.54 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.79 0 CA-C-N 115.59 -0.732 . . . . 0.27 109.99 -173.133 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 18' ' ' ILE . . . . . 0.416 ' HB ' ' O ' ' A' ' 14' ' ' GLY . 8.7 mt -92.19 112.8 56.84 Favored Pre-proline 0 N--CA 1.445 -0.677 0 CA-C-N 115.415 -0.811 . . . . 0.82 110.819 -177.842 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 19' ' ' PRO . . . . . 0.621 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 71.0 Cg_exo -49.29 147.2 12.22 Favored 'Trans proline' 0 N--CA 1.458 -0.581 0 C-N-CA 123.23 2.62 . . . . 0.3 112.669 173.043 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 20' ' ' LYS . . . . . 1.043 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -64.81 -14.86 60.66 Favored 'General case' 0 C--O 1.211 -0.932 0 CA-C-N 115.387 -0.824 . . . . 1.77 111.369 -177.793 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 21' ' ' GLU . . . . . 0.621 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 1.1 pm0 -63.15 -23.88 67.64 Favored 'General case' 0 N--CA 1.47 0.54 0 N-CA-C 112.201 0.445 . . . . 1.92 112.201 176.71 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 5.3 mp -87.01 -50.34 14.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 108.032 -1.099 . . . . 0.44 108.032 -178.357 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 23' ' ' ARG . . . . . 0.574 ' HA ' ' HB2' ' B' ' 26' ' ' LEU . 0.0 OUTLIER -56.08 -27.97 55.77 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.098 -0.956 . . . . 1.4 110.061 170.497 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 24' ' ' ARG . . . . . 0.438 ' HB3' ' HA ' ' B' ' 21' ' ' GLU . 8.2 ttm180 -64.13 -53.2 53.33 Favored 'General case' 0 CA--C 1.507 -0.687 0 CA-C-N 115.23 -0.895 . . . . 3.19 110.903 173.989 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 28.3 m -67.06 -22.41 65.86 Favored 'General case' 0 N--CA 1.445 -0.698 0 CA-C-O 121.614 0.721 . . . . 0.4 110.22 178.485 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.574 ' HB2' ' HA ' ' B' ' 23' ' ' ARG . 1.9 mm? -67.83 -18.85 64.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.08 -0.963 . . . . 0.33 110.655 173.489 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 27' ' ' ARG . . . . . 0.439 ' HB2' ' O ' ' B' ' 26' ' ' LEU . 7.2 mpt_? 68.52 21.0 8.27 Favored 'General case' 0 C--O 1.234 0.245 0 C-N-CA 123.517 0.727 . . . . 3.28 110.475 -174.367 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 28' ' ' ILE . . . . . 0.874 HG22 ' H ' ' B' ' 29' ' ' ARG . 6.6 mt -116.91 -163.67 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.462 -0.79 . . . . 0.37 109.434 -177.669 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 29' ' ' ARG . . . . . 0.874 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -156.06 -151.38 0.33 Allowed 'General case' 0 C--N 1.32 -0.681 0 C-N-CA 122.338 0.255 . . . . 2.15 110.723 -173.942 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 30' ' ' GLU . . . . . 0.451 ' H ' ' HB2' ' B' ' 29' ' ' ARG . 0.7 OUTLIER -73.43 36.74 0.09 Allowed 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 122.166 0.984 . . . . 1.18 111.669 -179.522 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 31' ' ' GLY . . . . . 0.599 ' CA ' HD11 ' A' ' 10' ' ' ILE . . . -154.12 39.63 0.67 Allowed Glycine 0 N--CA 1.434 -1.436 0 CA-C-N 114.107 -1.406 . . . . 0.35 110.026 175.105 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 32' ' ' ASP . . . . . 0.465 ' HA ' ' HD3' ' B' ' 33' ' ' PRO . 9.5 t0 -95.96 119.66 64.33 Favored Pre-proline 0 C--N 1.325 -0.493 0 CA-C-O 121.256 0.55 . . . . 1.29 110.049 175.147 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 33' ' ' PRO . . . . . 0.702 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 4.4 Cg_endo -87.07 76.35 2.27 Favored 'Trans proline' 0 C--O 1.205 -1.145 0 C-N-CA 123.547 2.831 . . . . 1.1 113.268 -178.905 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.947 HD11 HG23 ' A' ' 10' ' ' ILE . 0.1 OUTLIER -72.12 150.5 43.8 Favored 'General case' 0 C--N 1.284 -2.249 0 C-N-CA 117.776 -1.569 . . . . 0.44 111.343 -178.963 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 35' ' ' GLU . . . . . 0.766 ' O ' ' HA ' ' B' ' 46' ' ' LEU . 42.7 tt0 -105.1 115.32 30.07 Favored 'General case' 0 CA--C 1.492 -1.264 0 CA-C-N 114.067 -1.424 . . . . 1.1 107.822 -179.143 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 36' ' ' ILE . . . . . 0.922 HG13 HD22 ' B' ' 46' ' ' LEU . 3.1 mp -88.19 108.8 19.03 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 O-C-N 124.168 0.918 . . . . 0.62 109.336 -178.443 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 37' ' ' PHE . . . . . 0.5 ' HA ' ' OG1' ' A' ' 4' ' ' THR . 12.3 p90 -149.74 126.41 11.01 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 116.159 -0.473 . . . . 1.2 110.064 175.142 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 38' ' ' VAL . . . . . 0.532 ' HA ' ' HA ' ' B' ' 44' ' ' VAL . 0.8 OUTLIER -80.23 138.57 19.59 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-O 121.29 0.567 . . . . 0.2 110.571 -179.561 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 39' ' ' ASP . . . . . 0.683 ' HB3' ' HG3' ' B' ' 40' ' ' ARG . 8.1 t70 -80.9 -46.13 15.69 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 114.751 -1.113 . . . . 1.14 110.577 -177.726 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 40' ' ' ARG . . . . . 0.683 ' HG3' ' HB3' ' B' ' 39' ' ' ASP . 23.8 mtp180 -133.33 -92.53 0.35 Allowed 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.928 -0.578 . . . . 2.71 112.34 -166.55 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 41' ' ' ASP . . . . . 0.4 ' H ' ' HB2' ' B' ' 40' ' ' ARG . 18.4 t70 -102.3 -75.59 0.6 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.314 0.578 . . . . 1.32 110.395 -176.881 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 42' ' ' GLY . . . . . 0.523 ' O ' ' HA ' ' A' ' 47' ' ' LYS . . . -124.99 18.86 6.98 Favored Glycine 0 N--CA 1.44 -1.091 0 CA-C-N 115.376 -0.829 . . . . 0.34 112.201 -179.341 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 43' ' ' GLU . . . . . 0.516 ' HB3' HG23 ' A' ' 45' ' ' ILE . 1.3 mt-10 -93.52 104.91 17.01 Favored 'General case' 0 CA--C 1.51 -0.595 0 N-CA-C 108.932 -0.766 . . . . 2.07 108.932 176.533 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 44' ' ' VAL . . . . . 0.532 ' HA ' ' HA ' ' B' ' 38' ' ' VAL . 2.2 t -89.53 131.24 37.31 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 N-CA-C 109.441 -0.577 . . . . 0.13 109.441 177.194 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 45' ' ' ILE . . . . . 0.803 HG13 HG13 ' A' ' 45' ' ' ILE . 1.7 mp -108.04 117.5 53.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.463 0 N-CA-C 108.031 -1.1 . . . . 0.12 108.031 -176.937 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 46' ' ' LEU . . . . . 1.048 HD11 HD11 ' A' ' 46' ' ' LEU . 1.6 mt -108.53 117.24 33.66 Favored 'General case' 0 C--N 1.317 -0.813 0 O-C-N 123.9 0.75 . . . . 0.15 109.776 178.391 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 47' ' ' LYS . . . . . 0.658 ' HG3' ' HA ' ' B' ' 53' ' ' SER . 0.0 OUTLIER -130.15 147.34 51.87 Favored 'General case' 0 C--O 1.214 -0.8 0 C-N-CA 119.199 -1.0 . . . . 0.95 113.129 -179.919 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 48' ' ' LYS . . . . . 0.58 ' HG3' ' CG ' ' B' ' 51' ' ' PRO . 3.5 ptmt -44.83 -7.91 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.409 0 N-CA-C 118.065 2.617 . . . . 0.64 118.065 -168.781 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 49' ' ' TYR . . . . . 0.702 ' HB3' ' HB2' ' B' ' 33' ' ' PRO . 32.5 t80 69.72 -57.5 0.55 Allowed 'General case' 0 N--CA 1.48 1.051 0 N-CA-C 113.727 1.01 . . . . 1.26 113.727 173.506 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 50' ' ' SER . . . . . 0.681 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 9.1 t -51.24 -56.28 21.53 Favored Pre-proline 0 CA--C 1.539 0.528 0 CA-C-N 115.932 -0.576 . . . . 1.22 111.134 -173.484 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 51' ' ' PRO . . . . . 0.681 ' HD3' ' HB3' ' B' ' 50' ' ' SER . 59.1 Cg_endo -87.21 8.24 4.43 Favored 'Trans proline' 0 C--N 1.351 0.666 0 C-N-CA 122.174 1.916 . . . . 0.56 111.968 170.396 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 52' ' ' ILE . . . . . . . . . . . . . 1.6 mt 56.16 -147.91 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.341 0 CA-C-N 115.137 -0.938 . . . . 0.73 108.863 -175.002 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 53' ' ' SER . . . . . 0.658 ' HA ' ' HG3' ' B' ' 47' ' ' LYS . 61.0 m -74.73 -21.03 59.59 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.946 0.879 . . . . 1.86 109.932 -179.634 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 54' ' ' GLU . . . . . 0.517 ' O ' ' HB2' ' B' ' 55' ' ' LEU . 41.5 tt0 178.04 -54.0 0.01 OUTLIER 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 113.485 -1.689 . . . . 2.62 106.869 -174.629 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 55' ' ' LEU . . . . . 0.517 ' HB2' ' O ' ' B' ' 54' ' ' GLU . 0.3 OUTLIER . . . . . 0 C--O 1.251 1.148 0 CA-C-N 114.535 -1.211 . . . . 2.64 109.312 165.827 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 26.3 ptt? . . . . . 0 N--CA 1.482 1.149 0 CA-C-O 120.35 0.119 . . . . 5.91 110.937 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.714 ' HB3' HG13 ' B' ' 38' ' ' VAL . 24.3 mmmt 51.08 -111.68 0.57 Allowed 'General case' 0 CA--C 1.517 -0.294 0 CA-C-N 116.279 -0.419 . . . . 3.71 111.912 -176.076 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.451 ' HA ' ' HB2' ' B' ' 37' ' ' PHE . . . 58.13 89.48 0.05 Allowed 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 114.972 -1.013 . . . . 0.72 111.639 -178.668 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.552 ' OG1' ' HA ' ' B' ' 37' ' ' PHE . 11.8 p -81.21 -35.1 31.73 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.579 -0.737 . . . . 0.41 111.647 -179.297 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.585 ' H ' ' CB ' ' B' ' 37' ' ' PHE . . . 57.51 47.67 86.53 Favored Glycine 0 N--CA 1.445 -0.73 0 CA-C-N 115.735 -0.666 . . . . 0.32 112.68 173.958 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.697 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.8 tp -105.9 104.06 16.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 108.807 -0.812 . . . . 0.31 108.807 175.22 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.676 HG21 ' CG ' ' B' ' 49' ' ' TYR . 52.9 t -74.9 135.17 27.88 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.873 0 CA-C-N 115.522 -0.763 . . . . 0.28 109.943 179.481 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.541 ' HB3' HD13 ' B' ' 36' ' ' ILE . 1.7 tpp180 -131.84 117.13 18.12 Favored 'General case' 0 N--CA 1.431 -1.415 0 N-CA-C 106.899 -1.519 . . . . 1.99 106.899 -177.6 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.542 ' C ' HD12 ' A' ' 10' ' ' ILE . 0.0 OUTLIER -78.44 101.74 7.46 Favored 'General case' 0 C--N 1.314 -0.954 0 N-CA-C 107.924 -1.139 . . . . 2.8 107.924 174.913 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.806 HG23 HD11 ' B' ' 34' ' ' LEU . 0.2 OUTLIER -5.63 -105.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.195 0 O-C-N 125.445 1.715 . . . . 0.33 114.587 -176.753 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ASP . . . . . 0.604 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 2.4 p-10 165.99 -162.49 0.01 OUTLIER 'General case' 0 CA--C 1.513 -0.472 0 N-CA-C 107.935 -1.135 . . . . 1.13 107.935 177.611 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 30.4 m-20 -76.45 -6.7 52.86 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 120.744 0.307 . . . . 2.26 111.301 -178.255 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.428 ' H ' ' CG ' ' A' ' 11' ' ' ASP . 2.9 tm? -114.75 -59.16 2.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.661 -0.245 . . . . 0.53 110.996 178.589 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.449 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 140.1 13.78 0.58 Allowed Glycine 0 N--CA 1.448 -0.5 0 C-N-CA 120.432 -0.889 . . . . 0.22 113.096 -178.805 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.765 ' HG2' HG22 ' B' ' 17' ' ' VAL . 0.9 OUTLIER -77.43 154.98 32.1 Favored 'General case' 0 CA--C 1.501 -0.933 0 N-CA-C 109.231 -0.655 . . . . 0.69 109.231 176.011 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.921 HG11 HD13 ' B' ' 46' ' ' LEU . 1.5 m -109.88 112.13 39.17 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.59 0 N-CA-C 107.355 -1.35 . . . . 1.24 107.355 166.901 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.68 HG22 ' HG2' ' B' ' 15' ' ' ARG . 59.6 t -73.16 95.94 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.427 -1.588 0 CA-C-N 114.449 -1.25 . . . . 0.28 109.657 -174.875 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.611 HG23 HD13 ' A' ' 22' ' ' ILE . 11.0 mt -86.28 110.92 35.13 Favored Pre-proline 0 N--CA 1.446 -0.641 0 CA-C-N 115.218 -0.901 . . . . 0.77 110.251 -179.588 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.597 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 67.5 Cg_exo -47.37 144.51 9.67 Favored 'Trans proline' 0 N--CA 1.459 -0.535 0 C-N-CA 123.115 2.544 . . . . 0.32 112.261 173.594 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.939 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -59.95 -15.29 20.78 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.775 -0.648 . . . . 1.57 111.706 -178.493 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.597 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 12.8 pt-20 -67.6 -19.79 65.29 Favored 'General case' 0 C--O 1.237 0.437 0 N-CA-C 112.062 0.393 . . . . 1.32 112.062 -178.723 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.611 HD13 HG23 ' A' ' 18' ' ' ILE . 4.8 mp -87.43 -44.45 16.04 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 N-CA-C 108.125 -1.065 . . . . 0.35 108.125 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ARG . . . . . 0.677 ' HA ' ' HB2' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -60.68 -30.52 69.97 Favored 'General case' 0 CA--C 1.521 -0.166 0 CA-C-O 121.883 0.849 . . . . 1.5 109.093 171.208 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 63.2 ttt180 -61.33 -51.49 68.61 Favored 'General case' 0 N--CA 1.441 -0.894 0 CA-C-N 114.619 -1.173 . . . . 2.96 110.455 176.187 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 22.7 m -66.68 -21.94 66.09 Favored 'General case' 0 CA--C 1.535 0.392 0 CA-C-O 121.527 0.679 . . . . 0.4 110.654 174.094 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.864 ' HB3' HG13 ' A' ' 28' ' ' ILE . 2.3 mm? -71.94 -18.14 62.03 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.964 -0.562 . . . . 0.36 110.605 174.201 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.429 ' HB2' ' O ' ' A' ' 26' ' ' LEU . 9.0 mpt_? 66.21 23.18 10.9 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-N 116.006 -0.543 . . . . 3.2 110.625 -175.069 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.864 HG13 ' HB3' ' A' ' 26' ' ' LEU . 2.6 mt -113.92 -154.61 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 115.865 -0.607 . . . . 0.48 109.91 -178.44 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.693 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -162.34 -156.3 0.41 Allowed 'General case' 0 C--N 1.321 -0.653 0 C-N-CA 122.686 0.394 . . . . 2.4 110.674 -173.951 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 30' ' ' GLU . . . . . 0.417 ' H ' ' HB2' ' A' ' 29' ' ' ARG . 1.8 mp0 -74.9 44.1 0.22 Allowed 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 122.132 0.968 . . . . 1.23 111.025 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.706 ' N ' HD11 ' B' ' 10' ' ' ILE . . . -156.98 26.3 0.5 Allowed Glycine 0 N--CA 1.439 -1.137 0 CA-C-N 114.055 -1.43 . . . . 0.36 110.999 176.757 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.418 ' HA ' ' HD3' ' A' ' 33' ' ' PRO . 9.2 t0 -85.7 122.5 73.12 Favored Pre-proline 0 C--N 1.327 -0.379 0 CA-C-O 121.108 0.48 . . . . 1.26 110.111 176.321 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.637 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 3.8 Cg_endo -91.08 62.81 1.28 Allowed 'Trans proline' 0 N--CA 1.451 -0.986 0 C-N-CA 123.855 3.037 . . . . 1.3 114.253 -175.684 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.978 HD11 HG23 ' B' ' 10' ' ' ILE . 0.0 OUTLIER -61.22 153.97 24.73 Favored 'General case' 0 C--N 1.298 -1.646 0 C-N-CA 118.884 -1.127 . . . . 0.38 112.046 -178.536 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.77 ' HB3' ' HB3' ' A' ' 47' ' ' LYS . 39.4 tt0 -107.84 113.83 27.34 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 112.938 -1.937 . . . . 1.12 107.392 -176.253 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.811 ' HB ' HG23 ' B' ' 6' ' ' ILE . 2.4 mp -86.32 107.34 16.53 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.058 0 N-CA-C 109.136 -0.69 . . . . 0.39 109.136 -179.481 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' PHE . . . . . 0.575 ' CB ' ' H ' ' B' ' 5' ' ' GLY . 2.2 p90 -149.17 120.88 8.07 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-O 121.44 0.638 . . . . 1.15 109.937 176.169 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.696 HG13 ' HB3' ' B' ' 2' ' ' LYS . 1.5 p -80.5 137.56 21.25 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.987 0 CA-C-N 115.803 -0.635 . . . . 0.17 110.555 -178.126 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.554 ' HB3' ' HG2' ' A' ' 40' ' ' ARG . 7.5 t70 -76.22 -40.91 50.95 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 114.831 -1.077 . . . . 1.11 111.669 -171.16 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' ARG . . . . . 0.554 ' HG2' ' HB3' ' A' ' 39' ' ' ASP . 0.3 OUTLIER -150.62 -74.77 0.15 Allowed 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 112.859 0.689 . . . . 2.29 112.859 -168.753 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -106.29 -74.16 0.66 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.171 0.51 . . . . 1.53 111.431 -175.688 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.534 ' HA3' HD11 ' B' ' 26' ' ' LEU . . . -135.82 12.74 4.21 Favored Glycine 0 N--CA 1.443 -0.866 0 CA-C-N 115.123 -0.944 . . . . 0.32 111.891 -175.738 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.503 ' O ' HG23 ' A' ' 38' ' ' VAL . 2.5 pm0 -92.82 106.77 18.69 Favored 'General case' 0 N--CA 1.446 -0.66 0 N-CA-C 110.051 -0.352 . . . . 1.97 110.051 175.183 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.623 HG11 HG23 ' A' ' 36' ' ' ILE . 2.5 t -87.57 134.84 26.78 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 N-CA-C 109.259 -0.645 . . . . 0.14 109.259 178.356 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.709 HG13 HG13 ' B' ' 45' ' ' ILE . 1.5 mp -110.69 118.11 56.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 N-CA-C 108.491 -0.929 . . . . 0.14 108.491 -178.077 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.953 HD11 HD11 ' B' ' 46' ' ' LEU . 6.8 mt -103.3 119.05 38.13 Favored 'General case' 0 C--N 1.32 -0.715 0 O-C-N 124.229 0.956 . . . . 0.23 109.906 -179.541 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.77 ' HB3' ' HB3' ' A' ' 35' ' ' GLU . 16.6 ttmt -121.2 130.2 53.58 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-N 115.434 -0.803 . . . . 0.76 111.905 -170.704 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.613 ' HE2' ' HG3' ' A' ' 51' ' ' PRO . 3.2 ptmt -45.23 -12.97 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 115.937 1.828 . . . . 0.32 115.937 -174.313 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 0.687 ' CD1' HG21 ' B' ' 7' ' ' VAL . 34.4 t80 68.36 -56.7 0.5 Allowed 'General case' 0 N--CA 1.473 0.69 0 C-N-CA 124.623 1.169 . . . . 1.28 114.046 174.224 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.402 ' HB2' ' HD3' ' A' ' 51' ' ' PRO . 36.1 m -53.41 -48.08 93.96 Favored Pre-proline 0 CA--C 1.542 0.636 0 CA-C-N 115.683 -0.69 . . . . 1.36 112.052 -173.691 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.613 ' HG3' ' HE2' ' A' ' 48' ' ' LYS . 60.6 Cg_endo -93.54 10.82 2.04 Favored 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 122.272 1.981 . . . . 0.58 111.779 167.924 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.4 ' H ' ' C ' ' A' ' 49' ' ' TYR . 1.0 OUTLIER 52.18 -141.43 0.02 OUTLIER 'Isoleucine or valine' 0 C--O 1.233 0.218 0 N-CA-C 108.304 -0.998 . . . . 0.78 108.304 -171.35 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.627 ' OG ' ' HE2' ' A' ' 47' ' ' LYS . 3.0 m -106.97 113.89 27.64 Favored 'General case' 0 C--N 1.312 -1.026 0 C-N-CA 120.175 -0.61 . . . . 1.96 109.577 170.048 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.424 ' CD ' HH12 ' B' ' 40' ' ' ARG . 44.9 mt-10 73.48 -31.82 0.23 Allowed 'General case' 0 N--CA 1.466 0.339 0 N-CA-C 113.055 0.761 . . . . 2.89 113.055 175.003 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.444 HD22 ' HA ' ' A' ' 55' ' ' LEU . 0.5 OUTLIER . . . . . 0 C--O 1.248 1.009 0 C-N-CA 123.254 0.622 . . . . 2.65 110.082 -178.164 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 26.5 ptt? . . . . . 0 N--CA 1.482 1.157 0 CA-C-O 120.359 0.123 . . . . 6.17 110.816 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 2' ' ' LYS . . . . . 0.696 ' HB3' HG13 ' A' ' 38' ' ' VAL . 28.7 mmmt 58.59 -113.97 0.72 Allowed 'General case' 0 CA--C 1.517 -0.288 0 O-C-N 123.396 0.435 . . . . 3.61 110.479 -173.016 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 3' ' ' ALA . . . . . 0.417 ' HA ' ' HD2' ' A' ' 37' ' ' PHE . . . 58.2 91.85 0.04 OUTLIER 'General case' 0 C--N 1.318 -0.802 0 O-C-N 124.354 1.033 . . . . 0.86 111.766 179.899 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 4' ' ' THR . . . . . 0.473 ' OG1' ' HA ' ' A' ' 37' ' ' PHE . 12.0 p -84.67 -34.94 22.91 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.63 -0.714 . . . . 0.43 111.633 -178.221 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 5' ' ' GLY . . . . . 0.575 ' H ' ' CB ' ' A' ' 37' ' ' PHE . . . 58.43 48.07 86.15 Favored Glycine 0 N--CA 1.449 -0.487 0 CA-C-N 115.601 -0.727 . . . . 0.33 113.052 174.655 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 6' ' ' ILE . . . . . 0.811 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.4 tp -105.23 104.34 16.78 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 N-CA-C 109.224 -0.658 . . . . 0.3 109.224 175.817 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 7' ' ' VAL . . . . . 0.687 HG21 ' CD1' ' A' ' 49' ' ' TYR . 27.5 t -74.79 134.12 30.1 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.841 0 CA-C-N 115.462 -0.79 . . . . 0.27 110.083 -179.714 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.515 ' HD3' ' N ' ' B' ' 9' ' ' ARG . 0.3 OUTLIER -131.97 120.06 21.94 Favored 'General case' 0 N--CA 1.441 -0.918 0 N-CA-C 106.862 -1.532 . . . . 1.69 106.862 179.132 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 9' ' ' ARG . . . . . 0.548 ' HA ' ' HA ' ' A' ' 33' ' ' PRO . 41.9 ttp180 -78.95 103.27 8.78 Favored 'General case' 0 N--CA 1.441 -0.903 0 N-CA-C 108.667 -0.864 . . . . 2.71 108.667 174.481 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 10' ' ' ILE . . . . . 0.978 HG23 HD11 ' A' ' 34' ' ' LEU . 0.3 OUTLIER -7.59 -100.38 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 O-C-N 125.66 1.85 . . . . 0.34 114.189 -175.31 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 11' ' ' ASP . . . . . 0.609 ' H ' HD13 ' B' ' 10' ' ' ILE . 13.5 p-10 161.54 -157.15 0.0 OUTLIER 'General case' 0 CA--C 1.505 -0.767 0 N-CA-C 107.889 -1.152 . . . . 1.18 107.889 175.088 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -88.64 22.69 2.51 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 120.688 0.28 . . . . 2.39 111.214 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 13' ' ' LEU . . . . . 0.411 ' HB3' ' HD2' ' B' ' 15' ' ' ARG . 2.3 tm? -137.86 -55.21 0.67 Allowed 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 109.862 -0.421 . . . . 0.4 109.862 175.564 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 14' ' ' GLY . . . . . 0.427 ' O ' ' HB ' ' A' ' 18' ' ' ILE . . . 131.97 11.85 2.0 Favored Glycine 0 N--CA 1.444 -0.8 0 C-N-CA 120.896 -0.669 . . . . 0.21 112.491 -177.83 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 15' ' ' ARG . . . . . 0.68 ' HG2' HG22 ' A' ' 17' ' ' VAL . 0.9 OUTLIER -74.11 152.14 39.95 Favored 'General case' 0 CA--C 1.504 -0.809 0 CA-C-O 121.445 0.641 . . . . 0.9 109.511 175.47 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 16' ' ' VAL . . . . . 0.736 HG13 HG13 ' A' ' 16' ' ' VAL . 0.2 OUTLIER -109.06 105.79 19.48 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 N-CA-C 107.697 -1.224 . . . . 1.27 107.697 167.641 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 17' ' ' VAL . . . . . 0.765 HG22 ' HG2' ' A' ' 15' ' ' ARG . 41.0 t -72.63 95.03 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.168 0 CA-C-N 114.724 -1.125 . . . . 0.27 109.827 -173.505 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 18' ' ' ILE . . . . . 0.574 HG23 HD13 ' B' ' 22' ' ' ILE . 11.7 mt -87.56 112.56 49.29 Favored Pre-proline 0 N--CA 1.445 -0.724 0 CA-C-N 115.436 -0.802 . . . . 0.82 110.503 -179.689 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 19' ' ' PRO . . . . . 0.692 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 84.9 Cg_exo -49.12 146.69 12.24 Favored 'Trans proline' 0 N--CA 1.459 -0.534 0 C-N-CA 123.045 2.497 . . . . 0.3 112.612 173.2 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 20' ' ' LYS . . . . . 0.917 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -60.79 -15.29 28.3 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.76 -0.655 . . . . 1.77 111.956 -179.357 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 21' ' ' GLU . . . . . 0.692 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 11.5 pt-20 -65.48 -21.12 66.6 Favored 'General case' 0 CA--C 1.536 0.428 0 N-CA-C 112.211 0.449 . . . . 1.92 112.211 -179.784 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 22' ' ' ILE . . . . . 0.574 HD13 HG23 ' B' ' 18' ' ' ILE . 5.2 mp -86.76 -48.78 15.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 108.264 -1.013 . . . . 0.44 108.264 179.835 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 23' ' ' ARG . . . . . 0.602 ' HA ' ' HB2' ' B' ' 26' ' ' LEU . 0.0 OUTLIER -55.89 -30.28 61.3 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 115.429 -0.805 . . . . 1.4 109.258 170.39 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 24' ' ' ARG . . . . . 0.597 ' N ' ' HD3' ' B' ' 23' ' ' ARG . 37.2 ttt180 -62.9 -52.35 63.42 Favored 'General case' 0 N--CA 1.45 -0.444 0 CA-C-N 114.772 -1.104 . . . . 3.19 110.858 176.427 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 51.6 m -64.22 -28.45 69.75 Favored 'General case' 0 CA--C 1.53 0.206 0 CA-C-O 121.17 0.509 . . . . 0.4 110.811 173.629 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.617 ' HB3' HG13 ' B' ' 28' ' ' ILE . 1.6 mm? -66.21 -18.78 65.56 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.755 -0.657 . . . . 0.33 111.315 175.436 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 27' ' ' ARG . . . . . 0.459 ' HB2' ' O ' ' B' ' 26' ' ' LEU . 11.0 mpt_? 68.21 16.22 9.37 Favored 'General case' 0 N--CA 1.467 0.378 0 C-N-CA 123.192 0.597 . . . . 3.28 111.095 -174.608 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 28' ' ' ILE . . . . . 0.906 HG22 ' H ' ' B' ' 29' ' ' ARG . 7.8 mt -109.05 -160.8 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 115.825 -0.625 . . . . 0.37 109.725 -175.901 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 29' ' ' ARG . . . . . 0.906 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -157.89 -153.84 0.41 Allowed 'General case' 0 C--N 1.328 -0.365 0 C-N-CA 122.386 0.275 . . . . 2.15 110.826 -177.691 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 30' ' ' GLU . . . . . 0.416 ' H ' ' HB2' ' B' ' 29' ' ' ARG . 1.9 mp0 -70.57 40.19 0.05 Allowed 'General case' 0 N--CA 1.468 0.466 0 CA-C-O 121.537 0.684 . . . . 1.18 112.043 178.981 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 31' ' ' GLY . . . . . 0.668 ' N ' HD11 ' A' ' 10' ' ' ILE . . . -155.38 34.09 0.65 Allowed Glycine 0 N--CA 1.437 -1.234 0 CA-C-N 115.097 -0.956 . . . . 0.35 111.106 175.938 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 32' ' ' ASP . . . . . 0.518 ' HB2' HG21 ' B' ' 28' ' ' ILE . 15.9 t0 -93.22 124.59 57.38 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.105 0.479 . . . . 1.29 110.706 176.534 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 33' ' ' PRO . . . . . 0.676 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 3.3 Cg_endo -87.56 75.83 2.16 Favored 'Trans proline' 0 C--O 1.206 -1.09 0 C-N-CA 124.011 3.141 . . . . 1.1 113.68 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.806 HD11 HG23 ' A' ' 10' ' ' ILE . 1.0 OUTLIER -71.47 148.79 46.48 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.021 -1.472 . . . . 0.44 110.771 179.87 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 35' ' ' GLU . . . . . 0.687 ' O ' ' HA ' ' B' ' 46' ' ' LEU . 43.8 tt0 -103.78 110.74 22.96 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-N 114.417 -1.265 . . . . 1.1 107.625 -179.836 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 36' ' ' ILE . . . . . 0.954 HG13 HD22 ' B' ' 46' ' ' LEU . 2.3 mp -85.94 109.27 18.38 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.731 0 O-C-N 124.048 0.842 . . . . 0.62 109.236 -178.493 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 37' ' ' PHE . . . . . 0.585 ' CB ' ' H ' ' A' ' 5' ' ' GLY . 14.4 p90 -149.4 123.38 9.39 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 115.832 -0.622 . . . . 1.2 109.631 175.561 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 38' ' ' VAL . . . . . 0.714 HG13 ' HB3' ' A' ' 2' ' ' LYS . 1.4 p -79.91 136.05 24.26 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 CA-C-O 121.424 0.63 . . . . 0.2 110.229 -178.416 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 39' ' ' ASP . . . . . 0.589 ' OD1' ' HD3' ' B' ' 40' ' ' ARG . 12.6 t70 -69.48 -53.9 16.9 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 114.215 -1.357 . . . . 1.14 111.244 -173.993 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 40' ' ' ARG . . . . . 0.589 ' HD3' ' OD1' ' B' ' 39' ' ' ASP . 0.0 OUTLIER -139.34 -71.22 0.4 Allowed 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 113.019 0.748 . . . . 2.71 113.019 -174.308 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -106.48 -68.42 0.88 Allowed 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 112.089 0.403 . . . . 1.32 112.089 -173.153 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 42' ' ' GLY . . . . . 0.458 ' HA3' ' HD2' ' A' ' 48' ' ' LYS . . . -140.94 12.52 2.87 Favored Glycine 0 CA--C 1.501 -0.823 0 C-N-CA 120.71 -0.757 . . . . 0.34 111.862 -175.465 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 43' ' ' GLU . . . . . 0.587 ' HA ' ' O ' ' A' ' 46' ' ' LEU . 2.3 pm0 -93.05 104.96 17.12 Favored 'General case' 0 N--CA 1.443 -0.803 0 N-CA-C 109.568 -0.53 . . . . 2.07 109.568 174.991 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 44' ' ' VAL . . . . . 0.623 ' HA ' ' HA ' ' B' ' 38' ' ' VAL . 2.1 t -87.37 131.68 34.58 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 N-CA-C 109.696 -0.483 . . . . 0.13 109.696 179.329 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 45' ' ' ILE . . . . . 0.709 HG13 HG13 ' A' ' 45' ' ' ILE . 1.7 mp -108.29 118.47 55.99 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 N-CA-C 108.414 -0.958 . . . . 0.12 108.414 -177.592 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 46' ' ' LEU . . . . . 0.954 HD22 HG13 ' B' ' 36' ' ' ILE . 0.6 OUTLIER -109.9 117.1 32.93 Favored 'General case' 0 C--N 1.318 -0.788 0 O-C-N 123.612 0.57 . . . . 0.15 109.915 178.844 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 47' ' ' LYS . . . . . 0.591 ' HE3' ' HB3' ' B' ' 35' ' ' GLU . 0.0 OUTLIER -130.09 142.45 50.6 Favored 'General case' 0 C--N 1.318 -0.765 0 C-N-CA 119.617 -0.833 . . . . 0.95 112.877 -178.332 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 48' ' ' LYS . . . . . 0.573 ' HE2' ' HG3' ' B' ' 51' ' ' PRO . 4.3 ptmt -43.19 -9.2 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.638 0 N-CA-C 118.112 2.634 . . . . 0.64 118.112 -168.264 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 49' ' ' TYR . . . . . 0.676 ' CG ' HG21 ' A' ' 7' ' ' VAL . 5.9 t80 68.38 -52.75 0.55 Allowed 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 114.067 1.136 . . . . 1.26 114.067 174.326 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 50' ' ' SER . . . . . 0.634 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 32.2 t -51.55 -57.14 15.49 Favored Pre-proline 0 CA--C 1.535 0.386 0 C-N-CA 122.417 0.287 . . . . 1.22 111.099 -173.55 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 51' ' ' PRO . . . . . 0.644 ' O ' ' HB2' ' B' ' 55' ' ' LEU . 74.8 Cg_endo -85.01 9.07 4.3 Favored 'Trans proline' 0 C--N 1.35 0.652 0 C-N-CA 122.011 1.808 . . . . 0.56 111.159 170.174 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 52' ' ' ILE . . . . . 0.452 HG13 HD23 ' B' ' 55' ' ' LEU . 1.2 mt 50.98 -138.79 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 CA-C-N 114.814 -1.085 . . . . 0.73 108.666 -171.944 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 53' ' ' SER . . . . . 0.5 ' O ' ' HB2' ' B' ' 54' ' ' GLU . 0.1 OUTLIER -107.43 120.29 41.76 Favored 'General case' 0 N--CA 1.43 -1.455 0 N-CA-C 109.095 -0.705 . . . . 1.86 109.095 172.514 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 54' ' ' GLU . . . . . 0.5 ' HB2' ' O ' ' B' ' 53' ' ' SER . 1.8 mp0 73.41 -61.37 0.5 Allowed 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 123.821 0.848 . . . . 2.62 111.973 -176.395 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 55' ' ' LEU . . . . . 0.644 ' HB2' ' O ' ' B' ' 51' ' ' PRO . 0.9 OUTLIER . . . . . 0 C--O 1.249 1.078 0 O-C-N 123.85 0.719 . . . . 2.64 109.302 -172.389 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 74.1 mtm . . . . . 0 N--CA 1.478 0.96 0 N-CA-C 110.079 -0.341 . . . . 5.91 110.079 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.599 ' HB2' HG13 ' B' ' 38' ' ' VAL . 0.0 OUTLIER -124.77 -171.25 2.31 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 116.451 -0.34 . . . . 3.71 110.815 -174.651 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.591 ' HA ' ' HD2' ' B' ' 37' ' ' PHE . . . 64.35 113.51 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.359 0 CA-C-O 121.74 0.781 . . . . 0.72 111.33 -173.517 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.816 ' H ' ' HB2' ' B' ' 37' ' ' PHE . 34.4 p -125.97 -35.73 2.44 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 115.504 -0.771 . . . . 0.41 111.915 -173.73 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.514 ' H ' ' CB ' ' B' ' 37' ' ' PHE . . . 63.96 45.14 94.79 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.902 -0.666 . . . . 0.32 112.893 173.715 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.876 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.4 tp -104.11 105.2 18.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-O 121.354 0.597 . . . . 0.31 109.522 177.985 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.63 HG21 ' CD1' ' B' ' 49' ' ' TYR . 54.5 t -75.02 131.73 34.53 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-N 115.655 -0.702 . . . . 0.28 110.415 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.426 ' HG2' ' H ' ' A' ' 17' ' ' VAL . 2.9 tpp180 -127.58 114.6 17.62 Favored 'General case' 0 N--CA 1.434 -1.262 0 N-CA-C 106.522 -1.659 . . . . 1.99 106.522 177.781 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.505 ' C ' HD12 ' A' ' 10' ' ' ILE . 0.6 OUTLIER -78.05 101.36 6.91 Favored 'General case' 0 C--N 1.308 -1.221 0 N-CA-C 107.611 -1.255 . . . . 2.8 107.611 174.708 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.612 HD11 ' N ' ' B' ' 31' ' ' GLY . 0.3 OUTLIER -7.44 -102.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.941 0 O-C-N 125.763 1.914 . . . . 0.33 113.928 -175.385 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ASP . . . . . 0.599 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 4.8 p-10 164.77 -159.47 0.0 OUTLIER 'General case' 0 CA--C 1.507 -0.677 0 N-CA-C 108.249 -1.019 . . . . 1.13 108.249 175.389 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 31.2 t70 -74.57 -17.84 60.67 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.014 0.435 . . . . 2.26 110.96 -179.173 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.413 ' H ' ' CG ' ' A' ' 11' ' ' ASP . 2.8 tm? -103.33 -59.07 1.77 Allowed 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.186 -0.461 . . . . 0.53 110.801 179.779 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.464 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 138.46 18.76 0.54 Allowed Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.214 -0.994 . . . . 0.22 113.211 -179.039 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.761 ' HB3' ' HB3' ' B' ' 15' ' ' ARG . 0.7 OUTLIER -81.01 157.37 25.5 Favored 'General case' 0 CA--C 1.491 -1.317 0 CA-C-N 117.965 0.882 . . . . 0.69 110.031 176.034 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.909 HG22 HG22 ' B' ' 16' ' ' VAL . 17.2 m -107.81 109.81 29.6 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.201 0 N-CA-C 106.945 -1.502 . . . . 1.24 106.945 164.77 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.812 HG22 ' HG2' ' B' ' 15' ' ' ARG . 57.6 t -71.71 94.75 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.433 -1.309 0 CA-C-N 115.091 -0.959 . . . . 0.28 109.278 -175.668 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.488 HD11 HD12 ' A' ' 46' ' ' LEU . 9.0 mt -82.37 109.79 17.9 Favored Pre-proline 0 N--CA 1.444 -0.761 0 CA-C-N 115.621 -0.718 . . . . 0.77 110.284 179.087 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.635 ' HD3' ' O ' ' A' ' 17' ' ' VAL . 95.8 Cg_exo -51.16 151.42 12.44 Favored 'Trans proline' 0 N--CA 1.454 -0.845 0 C-N-CA 123.053 2.502 . . . . 0.32 112.366 174.982 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.855 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -62.34 -25.14 67.74 Favored 'General case' 0 C--O 1.206 -1.194 0 CA-C-N 115.591 -0.731 . . . . 1.57 111.763 -176.823 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.3 pm0 -55.49 -25.65 38.19 Favored 'General case' 0 C--O 1.239 0.507 0 N-CA-C 112.854 0.687 . . . . 1.32 112.854 -178.447 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.464 HD13 HG23 ' A' ' 18' ' ' ILE . 5.1 mp -88.18 -46.95 15.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 108.404 -0.961 . . . . 0.35 108.404 -176.574 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ARG . . . . . 0.526 ' NE ' ' HA ' ' A' ' 29' ' ' ARG . 0.0 OUTLIER -61.02 -30.86 70.56 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 115.158 -0.928 . . . . 1.5 109.583 174.744 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 76.7 ttt180 -63.84 -52.11 61.61 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 114.269 -1.332 . . . . 2.96 111.011 175.532 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 25.6 m -64.51 -27.99 69.35 Favored 'General case' 0 C--O 1.234 0.268 0 CA-C-O 121.137 0.494 . . . . 0.4 110.537 175.377 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.832 ' HB3' HG13 ' A' ' 28' ' ' ILE . 0.8 OUTLIER -65.23 -18.1 65.04 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.534 -0.757 . . . . 0.36 111.162 175.225 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.502 ' HB2' ' O ' ' A' ' 26' ' ' LEU . 10.4 mpt_? 70.45 20.28 6.03 Favored 'General case' 0 N--CA 1.466 0.34 0 C-N-CA 123.259 0.624 . . . . 3.2 110.529 -174.109 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.832 HG13 ' HB3' ' A' ' 26' ' ' LEU . 2.7 mt -116.43 -166.06 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 115.728 -0.669 . . . . 0.48 109.458 -176.526 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.717 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -154.76 -155.5 0.58 Allowed 'General case' 0 C--N 1.321 -0.658 0 C-N-CA 122.267 0.227 . . . . 2.4 110.677 -173.327 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 30' ' ' GLU . . . . . 0.412 ' H ' ' HB2' ' A' ' 29' ' ' ARG . 1.7 mp0 -75.11 44.32 0.24 Allowed 'General case' 0 C--N 1.332 -0.168 0 CA-C-O 122.122 0.963 . . . . 1.23 111.366 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.688 ' N ' HD11 ' B' ' 10' ' ' ILE . . . -154.65 19.75 0.6 Allowed Glycine 0 N--CA 1.441 -1.024 0 CA-C-N 113.833 -1.531 . . . . 0.36 110.687 175.785 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.448 ' HA ' ' HD3' ' A' ' 33' ' ' PRO . 17.7 t0 -79.65 120.23 79.47 Favored Pre-proline 0 N--CA 1.464 0.245 0 CA-C-O 121.437 0.637 . . . . 1.26 109.784 176.942 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.618 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 2.8 Cg_endo -88.98 56.35 2.09 Favored 'Trans proline' 0 N--CA 1.452 -0.946 0 C-N-CA 123.891 3.06 . . . . 1.3 114.165 -174.494 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.921 HD11 HG23 ' B' ' 10' ' ' ILE . 0.0 OUTLIER -59.28 154.44 16.45 Favored 'General case' 0 C--N 1.3 -1.545 0 C-N-CA 118.823 -1.151 . . . . 0.38 112.34 -173.478 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.85 ' HB3' ' HD2' ' A' ' 47' ' ' LYS . 42.7 tt0 -107.92 112.48 25.11 Favored 'General case' 0 CA--C 1.491 -1.31 0 CA-C-N 113.847 -1.524 . . . . 1.12 107.909 -175.834 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.836 ' HB ' HG23 ' B' ' 6' ' ' ILE . 2.8 mt -82.65 111.05 18.47 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 O-C-N 124.424 1.078 . . . . 0.39 109.736 -179.752 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' PHE . . . . . 0.544 ' HB2' ' H ' ' B' ' 4' ' ' THR . 0.6 OUTLIER -151.11 125.88 9.68 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-O 120.98 0.419 . . . . 1.15 110.003 173.586 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.558 HG13 ' HB2' ' B' ' 2' ' ' LYS . 1.1 p -80.5 138.76 19.21 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 CA-C-O 120.921 0.391 . . . . 0.17 110.798 -177.158 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.694 ' OD2' ' HD2' ' A' ' 40' ' ' ARG . 14.2 t70 -84.29 -49.42 8.77 Favored 'General case' 0 CA--C 1.513 -0.45 0 CA-C-N 115.802 -0.635 . . . . 1.11 111.823 -173.988 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' ARG . . . . . 0.694 ' HD2' ' OD2' ' A' ' 39' ' ' ASP . 0.0 OUTLIER -135.81 -96.63 0.24 Allowed 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.632 -0.713 . . . . 2.29 112.516 -165.972 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -84.85 -74.24 0.4 Allowed 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.529 0.68 . . . . 1.53 110.826 -177.03 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.653 ' HA3' HD11 ' B' ' 26' ' ' LEU . . . -138.25 26.03 2.85 Favored Glycine 0 N--CA 1.439 -1.103 0 CA-C-N 115.207 -0.906 . . . . 0.32 110.918 -178.366 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.636 ' HB3' HG23 ' B' ' 45' ' ' ILE . 2.3 mt-10 -94.89 109.2 21.22 Favored 'General case' 0 N--CA 1.446 -0.641 0 N-CA-C 109.161 -0.681 . . . . 1.97 109.161 179.028 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.588 ' CG1' HG23 ' A' ' 36' ' ' ILE . 2.0 t -89.2 131.41 36.57 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.961 0 N-CA-C 109.268 -0.641 . . . . 0.14 109.268 177.79 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.77 HG13 HG13 ' B' ' 45' ' ' ILE . 1.6 mp -110.44 115.96 51.14 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.223 0 N-CA-C 108.312 -0.996 . . . . 0.14 108.312 -176.397 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.952 HD11 HD11 ' B' ' 46' ' ' LEU . 0.3 OUTLIER -109.6 117.52 34.15 Favored 'General case' 0 C--N 1.315 -0.923 0 O-C-N 123.785 0.678 . . . . 0.23 109.643 179.803 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.85 ' HD2' ' HB3' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -130.91 144.1 51.21 Favored 'General case' 0 C--O 1.215 -0.752 0 C-N-CA 118.695 -1.202 . . . . 0.76 112.844 176.303 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.633 ' HG3' ' HD2' ' A' ' 51' ' ' PRO . 1.0 OUTLIER -20.46 -25.93 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.981 0 N-CA-C 119.532 3.16 . . . . 0.32 119.532 -179.08 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 0.729 ' CD1' HG21 ' B' ' 7' ' ' VAL . 37.0 t80 72.87 -38.48 0.42 Allowed 'General case' 0 N--CA 1.479 1.002 0 CA-C-N 119.795 1.18 . . . . 1.28 112.339 -179.036 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.662 ' HB3' ' HD3' ' A' ' 51' ' ' PRO . 26.3 t -52.32 -52.32 63.98 Favored Pre-proline 0 CA--C 1.542 0.667 0 CA-C-N 116.29 -0.414 . . . . 1.36 110.559 -177.741 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.662 ' HD3' ' HB3' ' A' ' 50' ' ' SER . 97.9 Cg_endo -92.21 7.93 3.02 Favored 'Trans proline' 0 C--N 1.355 0.896 0 C-N-CA 122.387 2.058 . . . . 0.58 111.733 167.176 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.499 ' H ' ' C ' ' A' ' 49' ' ' TYR . 0.3 OUTLIER 47.16 -150.91 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.394 0 CA-C-N 114.809 -1.087 . . . . 0.78 111.515 -179.953 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.423 ' HA ' ' HZ2' ' A' ' 47' ' ' LYS . 11.2 p -85.17 47.13 1.36 Allowed 'General case' 0 N--CA 1.443 -0.776 0 CA-C-N 115.868 -0.605 . . . . 1.96 109.799 175.054 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.406 ' HB2' ' O ' ' A' ' 53' ' ' SER . 31.5 mt-10 73.85 116.76 0.05 Allowed 'General case' 0 N--CA 1.463 0.191 0 CA-C-N 115.041 -0.981 . . . . 2.89 110.229 -175.999 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 4.2 mm? . . . . . 0 C--O 1.25 1.126 0 CA-C-O 118.392 -0.813 . . . . 2.65 110.252 176.924 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 71.6 mtm . . . . . 0 N--CA 1.483 1.198 0 N-CA-C 109.693 -0.484 . . . . 6.17 109.693 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 2' ' ' LYS . . . . . 0.558 ' HB2' HG13 ' A' ' 38' ' ' VAL . 0.0 OUTLIER -141.84 -172.98 3.67 Favored 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 121.044 -0.262 . . . . 3.61 110.34 -179.26 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 3' ' ' ALA . . . . . 0.534 ' HA ' ' HD2' ' A' ' 37' ' ' PHE . . . 61.36 105.34 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.474 0 C-N-CA 123.445 0.698 . . . . 0.86 111.51 -173.462 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 4' ' ' THR . . . . . 0.544 ' H ' ' HB2' ' A' ' 37' ' ' PHE . 29.0 p -114.7 -39.75 3.69 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.939 -0.573 . . . . 0.43 111.802 -174.608 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 5' ' ' GLY . . . . . 0.46 ' H ' ' CB ' ' A' ' 37' ' ' PHE . . . 67.62 45.51 76.14 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 121.107 -0.568 . . . . 0.33 112.612 177.428 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 6' ' ' ILE . . . . . 0.836 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.3 tp -103.33 105.3 18.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.514 0.673 . . . . 0.3 109.732 177.855 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 7' ' ' VAL . . . . . 0.729 HG21 ' CD1' ' A' ' 49' ' ' TYR . 24.3 t -74.93 131.57 34.8 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.838 0 CA-C-N 115.401 -0.818 . . . . 0.27 110.899 -179.573 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.527 ' HB3' ' CD1' ' A' ' 36' ' ' ILE . 1.7 tpp180 -128.72 116.04 18.92 Favored 'General case' 0 N--CA 1.435 -1.211 0 N-CA-C 106.867 -1.531 . . . . 1.69 106.867 178.525 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 9' ' ' ARG . . . . . 0.604 ' HA ' ' HA ' ' A' ' 33' ' ' PRO . 29.2 ttp180 -78.23 102.84 7.81 Favored 'General case' 0 C--N 1.311 -1.075 0 N-CA-C 107.897 -1.149 . . . . 2.71 107.897 173.103 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 10' ' ' ILE . . . . . 0.921 HG23 HD11 ' A' ' 34' ' ' LEU . 0.4 OUTLIER -8.57 -100.77 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 O-C-N 125.948 2.03 . . . . 0.34 113.94 -174.645 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 11' ' ' ASP . . . . . 0.647 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 2.8 p-10 164.28 -161.05 0.0 OUTLIER 'General case' 0 CA--C 1.512 -0.501 0 N-CA-C 108.484 -0.932 . . . . 1.18 108.484 175.676 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -75.09 -14.32 60.57 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.11 0.481 . . . . 2.39 110.283 -177.237 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 13' ' ' LEU . . . . . 0.434 ' H ' ' CG ' ' B' ' 11' ' ' ASP . 2.2 tm? -105.56 -61.03 1.54 Allowed 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.826 -0.625 . . . . 0.4 110.526 179.541 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 139.84 16.16 0.52 Allowed Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.847 -0.692 . . . . 0.21 112.357 -176.764 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 15' ' ' ARG . . . . . 0.812 ' HG2' HG22 ' A' ' 17' ' ' VAL . 2.0 mtt180 -79.74 153.87 28.93 Favored 'General case' 0 CA--C 1.501 -0.934 0 N-CA-C 109.598 -0.519 . . . . 0.9 109.598 176.668 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 16' ' ' VAL . . . . . 0.909 HG22 HG22 ' A' ' 16' ' ' VAL . 1.1 m -110.5 111.83 37.91 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.673 0 N-CA-C 107.042 -1.466 . . . . 1.27 107.042 166.884 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 17' ' ' VAL . . . . . 0.536 ' O ' ' HD3' ' B' ' 19' ' ' PRO . 62.3 t -72.71 98.62 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.165 0 CA-C-N 114.699 -1.137 . . . . 0.27 109.668 -173.713 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 18' ' ' ILE . . . . . 0.464 ' HB ' ' O ' ' A' ' 14' ' ' GLY . 8.9 mt -85.88 111.73 40.0 Favored Pre-proline 0 N--CA 1.443 -0.794 0 CA-C-N 115.276 -0.875 . . . . 0.82 110.43 179.799 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 19' ' ' PRO . . . . . 0.664 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 71.4 Cg_exo -50.24 145.4 20.72 Favored 'Trans proline' 0 N--CA 1.456 -0.721 0 C-N-CA 122.965 2.444 . . . . 0.3 112.335 173.793 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 20' ' ' LYS . . . . . 1.002 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -61.65 -15.45 39.95 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 115.465 -0.789 . . . . 1.77 111.696 179.827 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 21' ' ' GLU . . . . . 0.664 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 11.7 pt-20 -64.65 -25.78 68.1 Favored 'General case' 0 C--O 1.237 0.446 0 N-CA-C 112.035 0.383 . . . . 1.92 112.035 -179.197 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 4.9 mp -88.65 -44.58 15.55 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.271 0 N-CA-C 107.578 -1.267 . . . . 0.44 107.578 -177.885 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 23' ' ' ARG . . . . . 0.422 ' HA ' ' HB2' ' B' ' 26' ' ' LEU . 0.0 OUTLIER -59.36 -31.02 68.82 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-N 115.08 -0.964 . . . . 1.4 109.514 174.124 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 24' ' ' ARG . . . . . 0.429 HH11 ' HD2' ' B' ' 24' ' ' ARG . 22.3 ttt85 -67.7 -49.9 60.29 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 114.767 -1.106 . . . . 3.19 110.745 177.251 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 26.2 m -65.52 -25.99 67.7 Favored 'General case' 0 CA--C 1.535 0.373 0 CA-C-O 121.412 0.625 . . . . 0.4 110.159 176.451 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.717 ' HB3' HG13 ' B' ' 28' ' ' ILE . 0.6 OUTLIER -65.91 -17.4 64.63 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.398 -0.819 . . . . 0.33 110.805 173.038 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 27' ' ' ARG . . . . . 0.422 ' HB2' ' O ' ' B' ' 26' ' ' LEU . 8.6 mpt_? 65.97 27.02 10.86 Favored 'General case' 0 C--O 1.233 0.195 0 CA-C-O 121.458 0.647 . . . . 3.28 110.032 -173.839 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 28' ' ' ILE . . . . . 0.844 HG22 ' H ' ' B' ' 29' ' ' ARG . 5.1 mt -119.84 -167.7 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.379 -0.828 . . . . 0.37 109.683 -179.311 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 29' ' ' ARG . . . . . 0.844 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -153.67 -155.59 0.61 Allowed 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 122.093 0.157 . . . . 2.15 110.934 -176.041 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 30' ' ' GLU . . . . . 0.426 ' H ' ' HB2' ' B' ' 29' ' ' ARG . 1.0 OUTLIER -73.46 39.72 0.1 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 122.104 0.954 . . . . 1.18 111.983 -178.998 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 31' ' ' GLY . . . . . 0.612 ' N ' HD11 ' A' ' 10' ' ' ILE . . . -151.43 26.71 0.97 Allowed Glycine 0 N--CA 1.442 -0.935 0 CA-C-N 114.232 -1.349 . . . . 0.35 110.303 172.774 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 32' ' ' ASP . . . . . 0.501 ' O ' ' HA ' ' A' ' 9' ' ' ARG . 21.9 t0 -81.7 121.14 79.3 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.183 0.516 . . . . 1.29 109.916 176.807 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 33' ' ' PRO . . . . . 0.724 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 5.2 Cg_endo -87.42 72.1 3.08 Favored 'Trans proline' 0 C--O 1.204 -1.207 0 C-N-CA 123.606 2.871 . . . . 1.1 113.437 -177.853 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.61 ' H ' HD12 ' B' ' 34' ' ' LEU . 2.2 mp -71.27 151.85 43.84 Favored 'General case' 0 C--N 1.286 -2.184 0 C-N-CA 117.779 -1.569 . . . . 0.44 111.386 -176.381 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 35' ' ' GLU . . . . . 0.958 ' HB3' ' HD2' ' B' ' 47' ' ' LYS . 44.1 tt0 -108.97 113.79 26.98 Favored 'General case' 0 CA--C 1.49 -1.351 0 CA-C-N 114.388 -1.278 . . . . 1.1 107.919 -177.822 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 36' ' ' ILE . . . . . 0.876 ' HB ' HG23 ' A' ' 6' ' ' ILE . 20.5 mt -88.43 109.99 20.59 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.905 0 O-C-N 124.78 1.3 . . . . 0.62 110.027 -176.169 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 37' ' ' PHE . . . . . 0.816 ' HB2' ' H ' ' A' ' 4' ' ' THR . 1.3 p90 -150.48 129.33 12.47 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 109.561 -0.533 . . . . 1.2 109.561 174.777 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 38' ' ' VAL . . . . . 0.599 HG13 ' HB2' ' A' ' 2' ' ' LYS . 0.9 OUTLIER -79.8 142.2 14.27 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.945 0 C-N-CA 120.834 -0.346 . . . . 0.2 110.256 -178.649 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 39' ' ' ASP . . . . . 0.511 ' OD2' ' HD2' ' B' ' 40' ' ' ARG . 38.8 t70 -87.64 -47.1 8.95 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.854 -0.612 . . . . 1.14 111.84 -175.079 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 40' ' ' ARG . . . . . 0.511 ' HD2' ' OD2' ' B' ' 39' ' ' ASP . 0.0 OUTLIER -137.08 -100.97 0.2 Allowed 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 112.535 0.569 . . . . 2.71 112.535 -175.736 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -76.36 -74.54 0.23 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.119 0.485 . . . . 1.32 111.36 -174.503 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 42' ' ' GLY . . . . . 0.548 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -136.77 25.12 3.11 Favored Glycine 0 N--CA 1.444 -0.826 0 C-N-CA 120.833 -0.699 . . . . 0.34 111.426 -178.831 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 43' ' ' GLU . . . . . 0.591 ' HB3' HG23 ' A' ' 45' ' ' ILE . 2.4 mt-10 -94.23 108.87 20.71 Favored 'General case' 0 CA--C 1.509 -0.6 0 N-CA-C 109.792 -0.448 . . . . 2.07 109.792 179.277 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 44' ' ' VAL . . . . . 0.554 ' HA ' ' HA ' ' B' ' 38' ' ' VAL . 1.5 t -88.92 131.0 37.38 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 N-CA-C 109.55 -0.537 . . . . 0.13 109.55 177.831 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 45' ' ' ILE . . . . . 0.77 HG13 HG13 ' A' ' 45' ' ' ILE . 1.7 mp -109.29 118.9 57.67 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.197 0 N-CA-C 108.405 -0.961 . . . . 0.12 108.405 -177.27 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 46' ' ' LEU . . . . . 0.952 HD11 HD11 ' A' ' 46' ' ' LEU . 0.5 OUTLIER -110.64 118.11 35.32 Favored 'General case' 0 C--N 1.316 -0.87 0 O-C-N 123.732 0.645 . . . . 0.15 109.862 178.486 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 47' ' ' LYS . . . . . 0.958 ' HD2' ' HB3' ' B' ' 35' ' ' GLU . 0.0 OUTLIER -129.19 148.11 51.1 Favored 'General case' 0 C--O 1.214 -0.81 0 C-N-CA 119.116 -1.034 . . . . 0.95 112.289 177.294 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 48' ' ' LYS . . . . . 0.592 ' HG3' ' CD ' ' B' ' 51' ' ' PRO . 2.8 ptmt -45.14 -6.28 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.235 0 N-CA-C 117.895 2.554 . . . . 0.64 117.895 -168.004 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 49' ' ' TYR . . . . . 0.724 ' HB3' ' HB2' ' B' ' 33' ' ' PRO . 24.3 t80 68.3 -36.18 0.31 Allowed 'General case' 0 N--CA 1.48 1.03 0 CA-C-N 119.372 0.987 . . . . 1.26 113.28 176.43 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 50' ' ' SER . . . . . 0.614 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 12.4 t -53.97 -47.79 95.92 Favored Pre-proline 0 CA--C 1.542 0.667 0 C-N-CA 122.588 0.355 . . . . 1.22 110.991 -177.194 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 51' ' ' PRO . . . . . 0.614 ' HD3' ' HB3' ' B' ' 50' ' ' SER . 62.6 Cg_endo -94.56 5.52 2.52 Favored 'Trans proline' 0 C--N 1.352 0.751 0 C-N-CA 122.451 2.101 . . . . 0.56 111.919 165.551 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 52' ' ' ILE . . . . . 0.516 ' H ' ' C ' ' B' ' 49' ' ' TYR . 0.6 OUTLIER 49.07 -146.43 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-N 115.083 -0.962 . . . . 0.73 110.595 -177.324 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 53' ' ' SER . . . . . 0.415 ' O ' ' HB3' ' B' ' 54' ' ' GLU . 57.2 p -84.72 36.05 0.59 Allowed 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 109.547 -0.538 . . . . 1.86 109.547 176.464 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 54' ' ' GLU . . . . . 0.415 ' HB3' ' O ' ' B' ' 53' ' ' SER . 8.9 tp10 75.97 118.42 0.05 Allowed 'General case' 0 C--N 1.341 0.201 0 C-N-CA 124.407 1.083 . . . . 2.62 110.127 -171.858 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 55' ' ' LEU . . . . . 0.4 ' HA ' HD13 ' B' ' 55' ' ' LEU . 4.3 mm? . . . . . 0 C--O 1.247 0.933 0 CA-C-O 118.275 -0.869 . . . . 2.64 110.737 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.402 ' HB3' HG21 ' A' ' 25' ' ' THR . 64.0 mtt . . . . . 0 N--CA 1.478 0.961 0 CA-C-O 120.246 0.069 . . . . 5.91 110.981 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.67 ' HA ' HG13 ' B' ' 38' ' ' VAL . 0.0 OUTLIER -95.7 175.49 6.51 Favored 'General case' 0 C--N 1.332 -0.178 0 C-N-CA 120.463 -0.495 . . . . 3.71 111.849 -179.419 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.83 ' HA ' ' HD2' ' B' ' 37' ' ' PHE . . . 56.31 82.4 0.11 Allowed 'General case' 0 CA--C 1.519 -0.225 0 CA-C-N 115.325 -0.852 . . . . 0.72 110.802 -169.232 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.473 ' OG1' ' HA ' ' B' ' 37' ' ' PHE . 15.6 p -94.08 -35.92 12.34 Favored 'General case' 0 N--CA 1.444 -0.74 0 CA-C-N 115.181 -0.918 . . . . 0.41 112.036 -176.506 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 60.93 49.37 79.42 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.969 -0.634 . . . . 0.32 112.799 176.317 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.876 HG23 ' HB ' ' B' ' 36' ' ' ILE . 0.9 OUTLIER -108.28 111.3 35.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 N-CA-C 109.379 -0.6 . . . . 0.31 109.379 175.295 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.665 HG21 ' CD1' ' B' ' 49' ' ' TYR . 48.6 t -82.38 133.96 28.03 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 CA-C-O 121.303 0.573 . . . . 0.28 111.013 -178.3 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.601 ' HB3' HD11 ' B' ' 36' ' ' ILE . 3.9 tpt180 -126.2 107.86 10.76 Favored 'General case' 0 N--CA 1.441 -0.903 0 N-CA-C 107.074 -1.454 . . . . 1.99 107.074 -178.545 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.525 ' C ' HD12 ' A' ' 10' ' ' ILE . 2.0 ttt180 -78.34 102.0 7.49 Favored 'General case' 0 CA--C 1.503 -0.847 0 N-CA-C 108.02 -1.104 . . . . 2.8 108.02 175.73 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.706 HD11 ' CA ' ' B' ' 31' ' ' GLY . 0.2 OUTLIER -10.12 -109.25 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 O-C-N 126.036 2.085 . . . . 0.33 114.551 -179.187 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ASP . . . . . 0.63 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 4.2 p-10 158.81 -167.73 0.0 OUTLIER 'General case' 0 CA--C 1.513 -0.458 0 N-CA-C 107.202 -1.407 . . . . 1.13 107.202 177.465 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -67.52 -22.78 65.42 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.013 0.435 . . . . 2.26 110.887 -178.241 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.432 HD22 ' HA ' ' A' ' 13' ' ' LEU . 2.2 tm? -95.28 -61.54 1.46 Allowed 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.081 -0.509 . . . . 0.53 109.733 177.916 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.575 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 132.71 21.49 0.9 Allowed Glycine 0 N--CA 1.443 -0.892 0 C-N-CA 119.898 -1.144 . . . . 0.22 114.131 178.242 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.492 ' HA ' ' HA ' ' B' ' 17' ' ' VAL . 0.9 OUTLIER -79.01 155.08 29.01 Favored 'General case' 0 CA--C 1.504 -0.814 0 CA-C-N 118.91 1.355 . . . . 0.69 110.941 179.249 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.637 HG21 HD13 ' B' ' 46' ' ' LEU . 52.9 t -111.43 101.37 12.45 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.379 0 N-CA-C 107.39 -1.337 . . . . 1.24 107.39 169.322 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.709 HG22 ' HG2' ' B' ' 15' ' ' ARG . 65.5 t -68.21 106.91 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.016 0 CA-C-N 115.038 -0.983 . . . . 0.28 109.775 -175.767 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 31.7 mm -90.8 109.26 33.45 Favored Pre-proline 0 N--CA 1.446 -0.636 0 CA-C-N 115.79 -0.641 . . . . 0.77 110.547 -177.895 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.578 ' HD3' ' O ' ' A' ' 17' ' ' VAL . 81.0 Cg_exo -50.37 138.04 38.63 Favored 'Trans proline' 0 N--CA 1.459 -0.521 0 C-N-CA 123.015 2.476 . . . . 0.32 112.359 173.904 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.882 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -57.64 -14.21 5.12 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-N 114.947 -1.024 . . . . 1.57 112.265 179.297 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.541 ' O ' ' HB3' ' A' ' 24' ' ' ARG . 11.9 pt-20 -67.08 -25.78 66.4 Favored 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 118.088 0.404 . . . . 1.32 111.724 -178.256 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 4.5 mp -88.15 -42.73 15.1 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.321 0 N-CA-C 107.622 -1.251 . . . . 0.35 107.622 -178.081 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ARG . . . . . 0.657 ' HA ' ' HB2' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -58.51 -31.78 68.21 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 114.848 -1.069 . . . . 1.5 109.145 171.936 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.541 ' HB3' ' O ' ' A' ' 21' ' ' GLU . 55.3 ttp180 -60.19 -52.85 63.56 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 114.313 -1.312 . . . . 2.96 110.785 174.092 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' THR . . . . . 0.402 HG21 ' HB3' ' A' ' 1' ' ' MET . 17.3 m -65.85 -27.02 67.93 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-O 121.247 0.546 . . . . 0.4 110.961 174.699 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.675 ' HB3' HG13 ' A' ' 28' ' ' ILE . 1.3 mm? -64.68 -20.86 66.55 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.759 -0.655 . . . . 0.36 110.638 173.879 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 8.1 tpt180 71.17 18.83 5.66 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-O 121.793 0.806 . . . . 3.2 109.302 -176.431 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.774 HG22 ' H ' ' A' ' 29' ' ' ARG . 3.9 mt -114.9 -167.44 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 114.894 -1.048 . . . . 0.48 108.797 -177.926 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ARG . . . . . 0.774 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -155.54 -149.63 0.27 Allowed 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 110.149 -0.315 . . . . 2.4 110.149 -173.282 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 4.6 mp0 -72.58 40.15 0.08 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.471 0.653 . . . . 1.23 111.962 178.754 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.665 ' CA ' HD11 ' B' ' 10' ' ' ILE . . . -154.87 33.37 0.67 Allowed Glycine 0 N--CA 1.438 -1.189 0 N-CA-C 110.609 -0.996 . . . . 0.36 110.609 171.592 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.5 ' HA ' ' HD3' ' A' ' 33' ' ' PRO . 45.9 t0 -90.1 116.3 66.04 Favored Pre-proline 0 C--O 1.234 0.275 0 CA-C-O 121.327 0.584 . . . . 1.26 109.602 175.742 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.553 ' HA ' ' HA ' ' B' ' 9' ' ' ARG . 1.3 Cg_endo -87.28 63.29 4.07 Favored 'Trans proline' 0 N--CA 1.454 -0.835 0 C-N-CA 123.984 3.122 . . . . 1.3 113.83 -177.064 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.616 HD12 ' H ' ' A' ' 34' ' ' LEU . 0.7 OUTLIER -63.87 153.79 35.72 Favored 'General case' 0 C--N 1.295 -1.785 0 C-N-CA 118.709 -1.196 . . . . 0.38 111.695 -175.636 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.925 ' HB3' ' HD2' ' A' ' 47' ' ' LYS . 34.4 tt0 -111.0 117.2 32.7 Favored 'General case' 0 CA--C 1.491 -1.29 0 CA-C-N 113.926 -1.488 . . . . 1.12 108.987 -173.362 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.905 ' HB ' HG23 ' B' ' 6' ' ' ILE . 3.0 mp -84.19 111.59 20.28 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.828 0 O-C-N 124.534 1.146 . . . . 0.39 109.546 -178.875 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' PHE . . . . . 0.876 ' HD2' ' HA ' ' B' ' 3' ' ' ALA . 0.3 OUTLIER -149.79 124.01 9.52 Favored 'General case' 0 C--N 1.313 -1.002 0 CA-C-O 121.13 0.491 . . . . 1.15 109.711 172.416 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.607 HG13 ' HA ' ' B' ' 2' ' ' LYS . 1.4 p -80.16 137.22 21.92 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 CA-C-O 121.198 0.523 . . . . 0.17 110.143 -179.409 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.667 ' OD2' ' HD2' ' A' ' 40' ' ' ARG . 32.3 t70 -88.24 -46.07 9.54 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.256 -0.884 . . . . 1.11 111.699 -172.877 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' ARG . . . . . 0.797 ' HG3' ' HG3' ' A' ' 43' ' ' GLU . 0.1 OUTLIER -128.19 -90.64 0.5 Allowed 'General case' 0 C--N 1.313 -1.008 0 CA-C-N 114.773 -1.103 . . . . 2.29 112.054 -162.402 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -112.74 -66.51 1.08 Allowed 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 121.02 0.438 . . . . 1.53 111.205 -176.402 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.563 ' HA3' HD11 ' B' ' 26' ' ' LEU . . . -130.33 13.68 5.67 Favored Glycine 0 CA--C 1.499 -0.914 0 C-N-CA 120.462 -0.875 . . . . 0.32 111.628 -178.309 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.797 ' HG3' ' HG3' ' A' ' 40' ' ' ARG . 0.9 OUTLIER -97.04 110.54 23.06 Favored 'General case' 0 C--N 1.319 -0.732 0 N-CA-C 109.299 -0.63 . . . . 1.97 109.299 -178.794 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.582 ' CG1' HG23 ' A' ' 36' ' ' ILE . 2.3 t -90.71 133.76 31.51 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.788 0 CA-C-N 115.718 -0.674 . . . . 0.14 109.239 177.924 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.736 HG13 HG13 ' B' ' 45' ' ' ILE . 1.7 mp -110.93 116.6 52.92 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 N-CA-C 108.644 -0.873 . . . . 0.14 108.644 -175.77 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.94 HD11 HD11 ' B' ' 46' ' ' LEU . 0.9 OUTLIER -108.08 118.36 36.54 Favored 'General case' 0 C--N 1.319 -0.76 0 O-C-N 123.764 0.665 . . . . 0.23 109.753 179.53 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.925 ' HD2' ' HB3' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -130.08 148.73 51.96 Favored 'General case' 0 C--O 1.216 -0.689 0 C-N-CA 118.849 -1.14 . . . . 0.76 113.152 178.001 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.596 ' HE2' ' HG3' ' A' ' 51' ' ' PRO . 2.2 ptmt -35.83 -19.73 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.09 0 N-CA-C 118.044 2.609 . . . . 0.32 118.044 -172.288 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 0.585 ' CD1' HG21 ' B' ' 7' ' ' VAL . 22.6 t80 74.95 -54.26 0.66 Allowed 'General case' 0 N--CA 1.475 0.822 0 C-N-CA 123.455 0.702 . . . . 1.28 112.79 177.408 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.713 ' HB3' ' HD3' ' A' ' 51' ' ' PRO . 6.8 t -52.15 -53.13 55.62 Favored Pre-proline 0 CA--C 1.541 0.601 0 CA-C-N 116.388 -0.369 . . . . 1.36 111.182 -173.675 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.713 ' HD3' ' HB3' ' A' ' 50' ' ' SER . 48.5 Cg_endo -92.98 14.39 1.6 Allowed 'Trans proline' 0 C--N 1.348 0.536 0 C-N-CA 122.376 2.051 . . . . 0.58 111.539 170.101 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.41 HG13 ' C ' ' A' ' 51' ' ' PRO . 0.9 OUTLIER 50.4 -145.5 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.235 0.306 0 CA-C-N 115.429 -0.805 . . . . 0.78 109.86 -176.861 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 3.0 m -83.94 69.57 10.31 Favored 'General case' 0 C--N 1.321 -0.643 0 C-N-CA 120.968 -0.293 . . . . 1.96 111.146 178.494 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER 65.24 18.14 11.28 Favored 'General case' 0 CA--C 1.534 0.346 0 CA-C-N 115.715 -0.675 . . . . 2.89 110.372 177.742 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 97.1 mt . . . . . 0 C--O 1.249 1.043 0 CA-C-N 115.756 -0.656 . . . . 2.65 111.497 -179.389 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 65.9 mtt . . . . . 0 N--CA 1.485 1.323 0 CA-C-O 120.66 0.267 . . . . 6.17 111.177 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 2' ' ' LYS . . . . . 0.607 ' HA ' HG13 ' A' ' 38' ' ' VAL . 0.0 OUTLIER -114.52 -177.23 3.08 Favored 'General case' 0 C--N 1.326 -0.416 0 C-N-CA 121.066 -0.254 . . . . 3.61 110.567 178.677 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 3' ' ' ALA . . . . . 0.876 ' HA ' ' HD2' ' A' ' 37' ' ' PHE . . . 51.78 76.34 0.18 Allowed 'General case' 0 CA--C 1.517 -0.296 0 O-C-N 123.849 0.718 . . . . 0.86 110.979 -174.759 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 4' ' ' THR . . . . . . . . . . . . . 20.4 p -91.68 -29.14 17.02 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.219 -0.901 . . . . 0.43 112.275 -173.607 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 56.99 47.74 84.93 Favored Glycine 0 N--CA 1.45 -0.415 0 CA-C-N 115.711 -0.677 . . . . 0.33 112.99 175.306 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 6' ' ' ILE . . . . . 0.905 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.0 OUTLIER -107.66 109.46 28.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-O 121.178 0.513 . . . . 0.3 109.623 176.602 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 7' ' ' VAL . . . . . 0.602 ' HA ' ' HA ' ' A' ' 35' ' ' GLU . 14.7 t -80.52 135.38 25.39 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.996 0 CA-C-N 115.609 -0.723 . . . . 0.27 110.783 -177.813 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.526 ' CZ ' HG23 ' B' ' 17' ' ' VAL . 1.1 tpt180 -128.09 112.77 14.95 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 107.405 -1.331 . . . . 1.69 107.405 178.696 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 9' ' ' ARG . . . . . 0.553 ' HA ' ' HA ' ' A' ' 33' ' ' PRO . 13.2 ttt180 -78.83 104.45 9.47 Favored 'General case' 0 CA--C 1.501 -0.929 0 N-CA-C 108.287 -1.005 . . . . 2.71 108.287 174.564 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 10' ' ' ILE . . . . . 0.665 HD11 ' CA ' ' A' ' 31' ' ' GLY . 0.2 OUTLIER -15.28 -103.24 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 O-C-N 125.822 1.951 . . . . 0.34 114.65 -177.248 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 11' ' ' ASP . . . . . 0.575 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 6.4 p-10 158.08 -161.08 0.0 OUTLIER 'General case' 0 CA--C 1.506 -0.727 0 N-CA-C 106.604 -1.628 . . . . 1.18 106.604 174.854 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 38.4 t70 -77.04 -17.5 58.74 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.512 0.673 . . . . 2.39 110.209 -178.151 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 13' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -96.1 -61.6 1.41 Allowed 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.575 -0.739 . . . . 0.4 110.029 177.296 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 134.61 24.06 0.62 Allowed Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.477 -0.868 . . . . 0.21 112.649 179.624 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 15' ' ' ARG . . . . . 0.709 ' HG2' HG22 ' A' ' 17' ' ' VAL . 56.4 mtt180 -77.82 147.28 35.28 Favored 'General case' 0 CA--C 1.51 -0.575 0 CA-C-O 121.479 0.657 . . . . 0.9 111.175 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 16' ' ' VAL . . . . . 0.526 HG11 HD13 ' A' ' 46' ' ' LEU . 92.7 t -113.76 99.49 8.72 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.13 0 N-CA-C 107.861 -1.163 . . . . 1.27 107.861 168.335 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 17' ' ' VAL . . . . . 0.568 ' O ' ' HD3' ' B' ' 19' ' ' PRO . 60.8 t -66.41 106.33 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.847 0 CA-C-N 115.475 -0.784 . . . . 0.27 109.847 -173.635 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 18' ' ' ILE . . . . . 0.575 ' HB ' ' O ' ' A' ' 14' ' ' GLY . 22.7 mm -89.29 109.08 28.62 Favored Pre-proline 0 C--N 1.32 -0.696 0 CA-C-N 115.587 -0.733 . . . . 0.82 110.24 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 19' ' ' PRO . . . . . 0.632 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 93.6 Cg_exo -53.45 144.05 52.46 Favored 'Trans proline' 0 N--CA 1.454 -0.799 0 C-N-CA 122.558 2.172 . . . . 0.3 112.22 174.773 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 20' ' ' LYS . . . . . 0.989 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -64.64 -13.71 54.99 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 115.556 -0.747 . . . . 1.77 111.434 -179.396 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 21' ' ' GLU . . . . . 0.632 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 11.2 pt-20 -65.42 -26.32 67.92 Favored 'General case' 0 C--O 1.239 0.549 0 N-CA-C 112.688 0.625 . . . . 1.92 112.688 179.556 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 22' ' ' ILE . . . . . 0.438 ' H ' HD12 ' B' ' 22' ' ' ILE . 3.9 mp -88.58 -42.09 14.52 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.252 0 N-CA-C 107.807 -1.183 . . . . 0.44 107.807 -179.214 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 23' ' ' ARG . . . . . 0.577 ' HA ' ' HB2' ' B' ' 26' ' ' LEU . 0.0 OUTLIER -57.69 -30.24 65.33 Favored 'General case' 0 N--CA 1.461 0.125 0 CA-C-N 114.927 -1.033 . . . . 1.4 109.126 170.973 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 24' ' ' ARG . . . . . 0.535 ' HB3' ' O ' ' B' ' 21' ' ' GLU . 21.4 ttp180 -62.28 -53.17 59.06 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 114.289 -1.323 . . . . 3.19 110.942 174.838 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 30.4 m -62.41 -32.0 72.77 Favored 'General case' 0 C--O 1.235 0.334 0 CA-C-O 121.409 0.624 . . . . 0.4 110.557 174.278 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.663 ' HB3' HG13 ' B' ' 28' ' ' ILE . 0.9 OUTLIER -64.3 -19.86 65.7 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.212 -0.903 . . . . 0.33 110.705 176.131 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 27' ' ' ARG . . . . . 0.45 ' HD2' ' HA ' ' B' ' 27' ' ' ARG . 11.9 tpt180 68.05 22.45 8.43 Favored 'General case' 0 N--CA 1.461 0.097 0 CA-C-O 121.802 0.81 . . . . 3.28 109.906 -177.627 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 28' ' ' ILE . . . . . 0.84 HG22 ' H ' ' B' ' 29' ' ' ARG . 6.3 mt -111.92 -161.21 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.203 -0.908 . . . . 0.37 109.162 -179.306 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 29' ' ' ARG . . . . . 0.84 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -158.68 -157.37 0.61 Allowed 'General case' 0 C--N 1.32 -0.689 0 O-C-N 122.468 -0.145 . . . . 2.15 110.618 -173.229 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 30' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -70.31 43.48 0.06 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.975 0.893 . . . . 1.18 111.598 176.777 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 31' ' ' GLY . . . . . 0.706 ' CA ' HD11 ' A' ' 10' ' ' ILE . . . -161.12 36.06 0.41 Allowed Glycine 0 N--CA 1.436 -1.338 0 CA-C-N 114.282 -1.326 . . . . 0.35 110.358 174.614 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 32' ' ' ASP . . . . . 0.497 ' HA ' ' HD3' ' B' ' 33' ' ' PRO . 16.5 t0 -93.21 121.13 66.06 Favored Pre-proline 0 C--N 1.327 -0.409 0 CA-C-N 115.006 -0.597 . . . . 1.29 110.223 175.558 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 33' ' ' PRO . . . . . 0.674 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 3.9 Cg_endo -86.84 75.6 2.57 Favored 'Trans proline' 0 C--O 1.206 -1.084 0 C-N-CA 123.664 2.909 . . . . 1.1 113.31 -179.919 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.699 ' H ' HD12 ' B' ' 34' ' ' LEU . 1.4 mp -71.14 150.52 45.34 Favored 'General case' 0 C--N 1.286 -2.182 0 C-N-CA 117.909 -1.516 . . . . 0.44 111.326 -178.535 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 35' ' ' GLU . . . . . 0.783 ' HB3' ' HD2' ' B' ' 47' ' ' LYS . 45.2 tt0 -109.69 114.45 28.06 Favored 'General case' 0 CA--C 1.49 -1.343 0 CA-C-N 114.384 -1.28 . . . . 1.1 108.326 -177.656 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 36' ' ' ILE . . . . . 0.986 HG13 HD22 ' B' ' 46' ' ' LEU . 3.0 mp -87.46 112.16 22.94 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 O-C-N 124.761 1.288 . . . . 0.62 109.697 -177.221 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 37' ' ' PHE . . . . . 0.83 ' HD2' ' HA ' ' A' ' 3' ' ' ALA . 1.1 p90 -150.14 128.42 12.07 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 116.003 -0.544 . . . . 1.2 109.661 172.39 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 38' ' ' VAL . . . . . 0.67 HG13 ' HA ' ' A' ' 2' ' ' LYS . 0.6 OUTLIER -80.67 140.19 17.03 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.982 0 CA-C-O 121.281 0.563 . . . . 0.2 110.57 -179.636 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 39' ' ' ASP . . . . . 0.631 ' OD1' ' HD2' ' B' ' 40' ' ' ARG . 16.1 t70 -84.85 -50.74 7.29 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.16 -0.927 . . . . 1.14 111.731 -173.249 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 40' ' ' ARG . . . . . 0.631 ' HD2' ' OD1' ' B' ' 39' ' ' ASP . 0.0 OUTLIER -134.99 -87.15 0.38 Allowed 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 112.661 0.615 . . . . 2.71 112.661 -172.437 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -95.17 -78.81 0.44 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.025 0.44 . . . . 1.32 110.999 -175.673 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 42' ' ' GLY . . . . . 0.479 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -125.84 16.02 6.95 Favored Glycine 0 N--CA 1.443 -0.843 0 C-N-CA 120.576 -0.821 . . . . 0.34 112.043 -177.481 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 43' ' ' GLU . . . . . 0.428 ' H ' ' HG2' ' B' ' 43' ' ' GLU . 0.0 OUTLIER -92.03 107.64 19.35 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.511 -0.552 . . . . 2.07 109.511 -178.765 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 44' ' ' VAL . . . . . 0.564 ' O ' ' HA ' ' A' ' 45' ' ' ILE . 1.9 t -89.83 133.71 31.03 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.852 0 N-CA-C 109.402 -0.592 . . . . 0.13 109.402 176.441 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 45' ' ' ILE . . . . . 0.736 HG13 HG13 ' A' ' 45' ' ' ILE . 1.7 mp -110.62 119.86 60.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 N-CA-C 108.582 -0.896 . . . . 0.12 108.582 -177.281 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 46' ' ' LEU . . . . . 0.986 HD22 HG13 ' B' ' 36' ' ' ILE . 0.6 OUTLIER -112.13 117.54 32.88 Favored 'General case' 0 C--N 1.32 -0.696 0 O-C-N 123.682 0.614 . . . . 0.15 109.936 178.333 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 47' ' ' LYS . . . . . 0.783 ' HD2' ' HB3' ' B' ' 35' ' ' GLU . 0.0 OUTLIER -130.95 152.94 49.71 Favored 'General case' 0 C--O 1.213 -0.848 0 C-N-CA 119.254 -0.978 . . . . 0.95 113.033 177.516 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 48' ' ' LYS . . . . . 0.664 ' HE3' HD11 ' B' ' 28' ' ' ILE . 12.5 ptmt -49.87 -4.4 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.011 0 N-CA-C 117.713 2.486 . . . . 0.64 117.713 -166.727 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 49' ' ' TYR . . . . . 0.674 ' HB3' ' HB2' ' B' ' 33' ' ' PRO . 28.7 t80 71.73 -54.53 0.67 Allowed 'General case' 0 N--CA 1.477 0.88 0 N-CA-C 113.549 0.944 . . . . 1.26 113.549 172.027 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 50' ' ' SER . . . . . 0.69 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 9.2 t -51.55 -55.88 25.61 Favored Pre-proline 0 CA--C 1.539 0.548 0 CA-C-N 116.05 -0.523 . . . . 1.22 111.035 -173.518 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 51' ' ' PRO . . . . . 0.69 ' HD3' ' HB3' ' B' ' 50' ' ' SER . 41.3 Cg_endo -89.81 12.95 2.45 Favored 'Trans proline' 0 C--N 1.351 0.705 0 C-N-CA 122.172 1.915 . . . . 0.56 111.514 170.698 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 52' ' ' ILE . . . . . . . . . . . . . 1.1 mt 50.55 -144.57 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.199 -0.909 . . . . 0.73 109.714 -176.66 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 53' ' ' SER . . . . . 0.402 ' HA ' ' HG3' ' B' ' 47' ' ' LYS . 13.8 m -81.49 62.99 5.6 Favored 'General case' 0 C--N 1.326 -0.452 0 O-C-N 122.351 -0.218 . . . . 1.86 111.155 179.427 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 54' ' ' GLU . . . . . . . . . . . . . 7.5 tm-20 66.7 21.39 10.59 Favored 'General case' 0 CA--C 1.539 0.523 0 CA-C-O 121.523 0.678 . . . . 2.62 109.74 178.774 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 55' ' ' LEU . . . . . . . . . . . . . 95.4 mt . . . . . 0 C--O 1.251 1.149 0 CA-C-N 115.379 -0.828 . . . . 2.64 111.211 -177.171 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . 0.51 ' HA ' ' HB2' ' B' ' 37' ' ' PHE . . . . . . . . 0 N--CA 1.457 -0.08 0 N-CA-C 113.459 0.911 . . . . 0.72 113.459 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.682 ' H ' ' HB2' ' B' ' 37' ' ' PHE . 10.6 p -110.28 -48.02 3.22 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 114.968 -1.015 . . . . 0.41 109.893 172.007 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 78.68 51.65 5.43 Favored Glycine 0 N--CA 1.446 -0.646 0 CA-C-N 115.431 -0.804 . . . . 0.32 112.912 172.001 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.807 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.5 tp -107.99 107.17 22.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 N-CA-C 109.273 -0.64 . . . . 0.31 109.273 172.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.741 ' HA ' ' O ' ' B' ' 34' ' ' LEU . 44.2 t -78.28 133.73 29.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-N 116.102 -0.499 . . . . 0.28 110.565 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.577 ' HB3' ' CD1' ' B' ' 36' ' ' ILE . 0.4 OUTLIER -129.69 123.06 30.22 Favored 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 107.387 -1.338 . . . . 1.99 107.387 -178.237 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ARG . . . . . 0.529 ' HA ' ' HA ' ' B' ' 33' ' ' PRO . 0.0 OUTLIER -83.82 103.02 12.76 Favored 'General case' 0 C--N 1.314 -0.947 0 N-CA-C 107.754 -1.202 . . . . 2.8 107.754 173.246 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.789 HG23 HD11 ' B' ' 34' ' ' LEU . 0.2 OUTLIER -9.97 -102.53 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.13 0 O-C-N 125.291 1.619 . . . . 0.33 114.595 -175.4 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . 0.577 ' H ' HD13 ' A' ' 10' ' ' ILE . 27.9 p-10 163.33 -165.03 0.01 OUTLIER 'General case' 0 CA--C 1.506 -0.722 0 N-CA-C 107.86 -1.163 . . . . 1.13 107.86 175.175 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . 0.502 ' HA ' ' HG2' ' B' ' 30' ' ' GLU . 12.8 p-10 -80.97 14.38 2.27 Favored 'General case' 0 C--N 1.318 -0.796 0 O-C-N 123.376 0.423 . . . . 2.26 111.284 -176.648 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -129.96 -55.14 1.13 Allowed 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 109.931 -0.396 . . . . 0.53 109.931 176.799 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.554 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 135.79 7.48 1.82 Allowed Glycine 0 N--CA 1.444 -0.776 0 C-N-CA 120.606 -0.807 . . . . 0.22 113.156 -179.014 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.735 ' HG2' HG22 ' B' ' 17' ' ' VAL . 0.5 OUTLIER -77.76 156.03 30.81 Favored 'General case' 0 CA--C 1.495 -1.149 0 CA-C-N 117.813 0.806 . . . . 0.69 109.912 178.304 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 1.045 HG22 HG22 ' B' ' 16' ' ' VAL . 0.8 OUTLIER -112.2 115.09 48.89 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.86 0 N-CA-C 107.508 -1.293 . . . . 1.24 107.508 167.954 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.702 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 46.9 t -73.35 98.21 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 CA-C-N 114.801 -1.09 . . . . 0.28 109.355 -174.281 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.514 ' HB ' ' O ' ' B' ' 14' ' ' GLY . 33.7 mm -83.96 106.97 8.98 Favored Pre-proline 0 N--CA 1.448 -0.529 0 O-C-N 123.844 0.715 . . . . 0.77 109.907 179.849 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.715 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 58.6 Cg_exo -47.1 143.86 9.56 Favored 'Trans proline' 0 N--CA 1.455 -0.784 0 C-N-CA 122.958 2.439 . . . . 0.32 112.391 174.769 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.927 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -62.4 -15.58 49.87 Favored 'General case' 0 C--O 1.206 -1.236 0 CA-C-N 115.427 -0.806 . . . . 1.57 110.763 -179.405 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.715 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 9.6 pt-20 -64.0 -24.07 67.57 Favored 'General case' 0 CA--C 1.532 0.278 0 N-CA-C 112.307 0.484 . . . . 1.32 112.307 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.2 mp -87.34 -45.24 16.24 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.24 0 N-CA-C 108.2 -1.037 . . . . 0.35 108.2 -179.303 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . 0.735 ' HA ' ' HB2' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -62.96 -26.95 69.07 Favored 'General case' 0 C--N 1.333 -0.137 0 CA-C-N 115.393 -0.822 . . . . 1.5 109.516 173.322 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 34.9 ttm180 -64.41 -49.15 72.67 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 114.94 -1.027 . . . . 2.96 110.712 172.683 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 17.7 m -63.41 -27.41 69.28 Favored 'General case' 0 CA--C 1.532 0.265 0 CA-C-O 121.09 0.471 . . . . 0.4 110.781 171.166 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.771 ' HB3' HG13 ' A' ' 28' ' ' ILE . 2.2 mm? -69.81 -22.13 63.33 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.038 -0.528 . . . . 0.36 110.688 172.764 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.416 ' HB2' ' O ' ' A' ' 26' ' ' LEU . 0.0 OUTLIER 67.33 23.75 9.17 Favored 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 123.574 0.75 . . . . 3.2 111.306 -174.218 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.771 HG13 ' HB3' ' A' ' 26' ' ' LEU . 3.6 mt -113.24 -159.68 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 116.013 -0.54 . . . . 0.48 109.959 -176.77 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.717 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -159.21 -159.41 0.76 Allowed 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 117.786 0.266 . . . . 2.4 111.545 -169.208 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . 0.512 ' HG2' ' HA ' ' B' ' 12' ' ' ASP . 59.0 mp0 -70.28 32.73 0.04 OUTLIER 'General case' 0 N--CA 1.469 0.515 0 C-N-CA 123.613 0.765 . . . . 1.23 112.673 178.303 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.575 ' N ' HD11 ' B' ' 10' ' ' ILE . . . -148.59 23.92 1.34 Allowed Glycine 0 N--CA 1.44 -1.072 0 N-CA-C 110.297 -1.121 . . . . 0.36 110.297 173.178 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.633 ' O ' HG13 ' B' ' 10' ' ' ILE . 14.8 t0 -83.04 122.51 77.77 Favored Pre-proline 0 C--N 1.326 -0.447 0 CA-C-N 114.774 -0.713 . . . . 1.26 109.751 175.663 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.725 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 9.7 Cg_endo -85.66 149.2 9.92 Favored 'Trans proline' 0 N--CA 1.433 -2.03 0 C-N-CA 122.367 2.045 . . . . 1.3 110.522 175.753 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.841 HD11 HG23 ' B' ' 10' ' ' ILE . 0.9 OUTLIER -140.0 150.95 45.07 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 120.386 -0.526 . . . . 0.38 109.739 174.887 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.685 ' HB3' ' HB3' ' A' ' 47' ' ' LYS . 36.1 tt0 -103.48 110.27 22.24 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 107.05 -1.463 . . . . 1.12 107.05 -178.802 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.801 ' HB ' HG23 ' B' ' 6' ' ' ILE . 2.1 mp -85.52 107.81 16.6 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.981 0 O-C-N 124.113 0.883 . . . . 0.39 108.757 -179.218 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' PHE . . . . . 0.685 ' HB2' ' H ' ' B' ' 4' ' ' THR . 6.2 p90 -149.38 127.34 11.89 Favored 'General case' 0 C--N 1.313 -0.988 0 CA-C-N 115.875 -0.602 . . . . 1.15 109.555 177.36 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.487 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 2.1 p -80.02 142.2 14.25 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.071 0 CA-C-N 115.941 -0.572 . . . . 0.17 110.004 -178.375 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.538 ' OD2' ' HD3' ' A' ' 40' ' ' ARG . 28.9 t70 -87.6 -43.08 12.25 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.904 -0.589 . . . . 1.11 111.722 -175.474 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . 0.573 ' HG3' ' HG3' ' A' ' 43' ' ' GLU . 0.0 OUTLIER -138.42 -90.05 0.22 Allowed 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 112.797 0.666 . . . . 2.29 112.797 -167.473 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 31.4 t70 -100.76 -71.91 0.69 Allowed 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.025 0.441 . . . . 1.53 110.85 -177.772 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.585 ' HA3' HD11 ' B' ' 26' ' ' LEU . . . -133.34 24.12 3.77 Favored Glycine 0 N--CA 1.445 -0.75 0 C-N-CA 120.466 -0.873 . . . . 0.32 112.123 -178.845 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.573 ' HG3' ' HG3' ' A' ' 40' ' ' ARG . 1.5 mt-10 -98.1 109.86 22.54 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 109.081 -0.711 . . . . 1.97 109.081 176.017 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.5 ' C ' HD12 ' A' ' 45' ' ' ILE . 1.6 t -90.0 134.25 29.59 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.875 0 N-CA-C 109.461 -0.57 . . . . 0.14 109.461 178.339 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.804 HG13 HG13 ' B' ' 45' ' ' ILE . 1.5 mp -109.08 122.72 64.19 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 N-CA-C 108.131 -1.063 . . . . 0.14 108.131 -177.095 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.798 HD11 HD11 ' B' ' 46' ' ' LEU . 4.9 mt -106.07 117.77 34.89 Favored 'General case' 0 C--N 1.319 -0.741 0 O-C-N 123.869 0.731 . . . . 0.23 109.728 178.286 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.685 ' HB3' ' HB3' ' A' ' 35' ' ' GLU . 15.8 ttmt -119.17 127.69 53.54 Favored 'General case' 0 C--N 1.311 -1.099 0 CA-C-N 115.73 -0.668 . . . . 0.76 111.959 -171.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.618 ' HA ' ' O ' ' A' ' 33' ' ' PRO . 3.2 ptmt -44.88 -15.03 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.451 0 N-CA-C 116.656 2.095 . . . . 0.32 116.656 -170.758 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 0.725 ' HB3' ' HB2' ' A' ' 33' ' ' PRO . 27.1 t80 73.59 -55.9 0.66 Allowed 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 112.627 0.602 . . . . 1.28 112.627 171.066 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.68 ' OG ' ' HD3' ' A' ' 51' ' ' PRO . 7.3 p -54.69 -41.67 91.04 Favored Pre-proline 0 CA--C 1.54 0.582 0 N-CA-C 112.439 0.533 . . . . 1.36 112.439 -174.312 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.68 ' HD3' ' OG ' ' A' ' 50' ' ' SER . 60.7 Cg_endo -103.3 14.74 0.27 Allowed 'Trans proline' 0 N--CA 1.451 -0.99 0 C-N-CA 123.063 2.509 . . . . 0.58 111.192 168.737 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 3.0 mt . . . . . 0 N--CA 1.444 -0.734 0 CA-C-N 115.194 -0.912 . . . . 0.78 108.549 -168.843 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 3' ' ' ALA . . . . . 0.531 ' HA ' ' HB2' ' A' ' 37' ' ' PHE . . . . . . . . 0 C--O 1.233 0.206 0 CA-C-O 122.058 0.932 . . . . 0.86 113.037 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 4' ' ' THR . . . . . 0.685 ' H ' ' HB2' ' A' ' 37' ' ' PHE . 5.4 p -110.8 -48.72 3.1 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 114.473 -1.239 . . . . 0.43 109.661 171.473 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 78.4 51.38 5.66 Favored Glycine 0 N--CA 1.45 -0.419 0 CA-C-N 115.453 -0.794 . . . . 0.33 112.843 172.122 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 6' ' ' ILE . . . . . 0.801 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.4 tp -107.44 106.84 21.42 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 N-CA-C 109.317 -0.623 . . . . 0.3 109.317 173.573 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . 0.728 ' HA ' ' O ' ' A' ' 34' ' ' LEU . 25.2 t -78.1 135.2 26.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 116.124 -0.489 . . . . 0.27 110.469 179.447 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . 0.413 ' HB3' HD13 ' A' ' 36' ' ' ILE . 0.8 OUTLIER -133.36 122.51 23.89 Favored 'General case' 0 N--CA 1.439 -0.999 0 N-CA-C 107.345 -1.354 . . . . 1.69 107.345 -178.871 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 9' ' ' ARG . . . . . 0.553 ' HA ' ' HA ' ' A' ' 33' ' ' PRO . 18.3 ttp180 -81.7 104.57 12.19 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 108.596 -0.89 . . . . 2.71 108.596 172.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 10' ' ' ILE . . . . . 0.841 HG23 HD11 ' A' ' 34' ' ' LEU . 0.3 OUTLIER -10.79 -101.27 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 O-C-N 125.631 1.832 . . . . 0.34 114.234 -175.701 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . 0.642 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 2.4 p-10 162.2 -169.87 0.01 OUTLIER 'General case' 0 CA--C 1.512 -0.502 0 N-CA-C 107.672 -1.233 . . . . 1.18 107.672 176.043 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 12' ' ' ASP . . . . . 0.512 ' HA ' ' HG2' ' A' ' 30' ' ' GLU . 3.3 p30 -78.13 7.74 5.82 Favored 'General case' 0 C--N 1.325 -0.463 0 O-C-N 123.174 0.296 . . . . 2.39 111.251 -177.608 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 13' ' ' LEU . . . . . 0.417 ' HB3' ' HD2' ' B' ' 15' ' ' ARG . 2.4 tm? -119.03 -61.53 1.63 Allowed 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 109.8 -0.445 . . . . 0.4 109.8 171.603 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 14' ' ' GLY . . . . . 0.514 ' O ' ' HB ' ' A' ' 18' ' ' ILE . . . 137.72 14.78 0.77 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.265 -0.969 . . . . 0.21 113.257 -178.565 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 15' ' ' ARG . . . . . 0.699 ' HG2' HG22 ' A' ' 17' ' ' VAL . 0.3 OUTLIER -81.08 154.68 26.68 Favored 'General case' 0 CA--C 1.493 -1.23 0 CA-C-O 121.659 0.743 . . . . 0.9 109.72 177.325 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 16' ' ' VAL . . . . . 1.045 HG22 HG22 ' A' ' 16' ' ' VAL . 3.9 m -107.7 108.52 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.219 0 N-CA-C 106.998 -1.482 . . . . 1.27 106.998 170.357 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 17' ' ' VAL . . . . . 0.735 HG22 ' HG2' ' A' ' 15' ' ' ARG . 47.3 t -70.88 96.52 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.352 0 CA-C-N 114.597 -1.183 . . . . 0.27 109.206 -174.354 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . 0.554 ' HB ' ' O ' ' A' ' 14' ' ' GLY . 34.3 mm -85.0 108.38 15.15 Favored Pre-proline 0 N--CA 1.449 -0.519 0 CA-C-N 115.401 -0.818 . . . . 0.82 110.299 -177.612 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 19' ' ' PRO . . . . . 0.715 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 58.5 Cg_exo -47.29 141.79 13.23 Favored 'Trans proline' 0 N--CA 1.456 -0.724 0 C-N-CA 122.876 2.384 . . . . 0.3 112.702 174.78 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 20' ' ' LYS . . . . . 1.015 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -59.3 -15.15 14.27 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.444 -0.798 . . . . 1.77 111.789 178.207 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . 0.715 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 12.9 pt-20 -64.14 -26.16 68.41 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-O 120.706 0.288 . . . . 1.92 111.45 -179.767 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 5.3 mp -87.16 -44.1 16.05 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.354 0 N-CA-C 107.901 -1.148 . . . . 0.44 107.901 -177.284 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 23' ' ' ARG . . . . . 0.628 ' HA ' ' HB2' ' B' ' 26' ' ' LEU . 0.0 OUTLIER -63.99 -26.32 68.52 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-N 115.147 -0.933 . . . . 1.4 109.897 174.972 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 24' ' ' ARG . . . . . . . . . . . . . 32.3 ttm180 -65.58 -50.14 66.2 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.674 -0.694 . . . . 3.19 110.917 172.213 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 28.2 m -63.29 -21.53 66.31 Favored 'General case' 0 CA--C 1.531 0.233 0 CA-C-O 121.527 0.68 . . . . 0.4 110.47 174.4 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . 0.628 ' HB2' ' HA ' ' B' ' 23' ' ' ARG . 1.6 mm? -74.21 -20.93 60.02 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.505 -0.77 . . . . 0.33 110.915 173.399 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 27' ' ' ARG . . . . . 0.455 ' HB2' ' O ' ' B' ' 26' ' ' LEU . 0.0 OUTLIER 67.37 28.47 7.83 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 123.33 0.652 . . . . 3.28 110.827 -173.892 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 28' ' ' ILE . . . . . 0.863 HG22 ' H ' ' B' ' 29' ' ' ARG . 5.7 mt -121.49 -163.28 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.051 -0.522 . . . . 0.37 110.399 -176.657 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 29' ' ' ARG . . . . . 0.863 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -157.93 -158.38 0.73 Allowed 'General case' 0 N--CA 1.467 0.414 0 C-N-CA 122.046 0.138 . . . . 2.15 111.054 -169.87 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 30' ' ' GLU . . . . . 0.502 ' HG2' ' HA ' ' A' ' 12' ' ' ASP . 58.9 mp0 -69.33 30.84 0.03 OUTLIER 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 112.95 0.722 . . . . 1.18 112.95 178.666 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 31' ' ' GLY . . . . . 0.566 ' N ' HD11 ' A' ' 10' ' ' ILE . . . -145.56 25.68 1.82 Allowed Glycine 0 N--CA 1.441 -1.006 0 N-CA-C 110.073 -1.211 . . . . 0.35 110.073 172.503 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 32' ' ' ASP . . . . . 0.545 ' O ' HG13 ' A' ' 10' ' ' ILE . 8.6 t70 -82.0 121.5 79.09 Favored Pre-proline 0 C--N 1.324 -0.538 0 CA-C-N 114.6 -0.8 . . . . 1.29 110.224 176.002 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 33' ' ' PRO . . . . . 0.784 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 7.8 Cg_endo -83.06 147.02 12.97 Favored 'Trans proline' 0 N--CA 1.433 -2.048 0 C-N-CA 122.163 1.909 . . . . 1.1 110.432 173.351 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.789 HD11 HG23 ' A' ' 10' ' ' ILE . 1.0 OUTLIER -137.53 149.28 46.63 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 109.6 -0.519 . . . . 0.44 109.6 173.431 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 35' ' ' GLU . . . . . 0.695 ' HB3' ' HE3' ' B' ' 47' ' ' LYS . 45.8 tt0 -101.81 111.32 23.54 Favored 'General case' 0 C--N 1.297 -1.694 0 N-CA-C 107.242 -1.392 . . . . 1.1 107.242 178.89 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 36' ' ' ILE . . . . . 0.807 ' HB ' HG23 ' A' ' 6' ' ' ILE . 2.8 mp -85.19 108.01 16.62 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.77 0 O-C-N 124.329 1.018 . . . . 0.62 108.831 -179.678 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 37' ' ' PHE . . . . . 0.682 ' HB2' ' H ' ' A' ' 4' ' ' THR . 7.6 p90 -150.44 127.66 11.3 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 116.003 -0.544 . . . . 1.2 109.866 176.851 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 38' ' ' VAL . . . . . 0.529 ' HA ' ' HA ' ' B' ' 44' ' ' VAL . 1.6 p -79.94 145.23 9.53 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 CA-C-N 116.446 -0.343 . . . . 0.2 110.562 -177.529 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 39' ' ' ASP . . . . . 0.618 ' OD2' ' HD3' ' B' ' 40' ' ' ARG . 18.2 t70 -82.58 -47.39 12.18 Favored 'General case' 0 C--N 1.326 -0.439 0 O-C-N 123.966 0.791 . . . . 1.14 111.318 -175.569 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 40' ' ' ARG . . . . . 0.618 ' HD3' ' OD2' ' B' ' 39' ' ' ASP . 0.7 OUTLIER -144.82 -78.75 0.19 Allowed 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 113.189 0.811 . . . . 2.71 113.189 -176.457 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -97.63 -65.45 0.96 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.039 0.447 . . . . 1.32 111.512 -171.096 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 42' ' ' GLY . . . . . 0.537 ' HA3' ' HD2' ' A' ' 48' ' ' LYS . . . -145.9 16.97 1.77 Allowed Glycine 0 N--CA 1.442 -0.912 0 C-N-CA 120.79 -0.719 . . . . 0.34 111.651 -178.155 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 43' ' ' GLU . . . . . 0.681 ' HA ' ' O ' ' A' ' 46' ' ' LEU . 2.3 pm0 -91.96 107.36 19.16 Favored 'General case' 0 N--CA 1.445 -0.683 0 N-CA-C 109.835 -0.431 . . . . 2.07 109.835 176.619 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 44' ' ' VAL . . . . . 0.596 ' HB ' HD12 ' A' ' 46' ' ' LEU . 2.1 t -89.33 131.69 35.98 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 109.536 -0.542 . . . . 0.13 109.536 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 45' ' ' ILE . . . . . 0.804 HG13 HG13 ' A' ' 45' ' ' ILE . 1.6 mp -107.06 120.64 58.73 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 N-CA-C 108.065 -1.087 . . . . 0.12 108.065 -178.302 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 46' ' ' LEU . . . . . 0.798 HD11 HD11 ' A' ' 46' ' ' LEU . 0.9 OUTLIER -109.7 116.48 31.78 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 109.442 -0.577 . . . . 0.15 109.442 177.531 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 47' ' ' LYS . . . . . 0.695 ' HE3' ' HB3' ' B' ' 35' ' ' GLU . 0.0 OUTLIER -127.71 141.81 51.5 Favored 'General case' 0 C--N 1.318 -0.774 0 C-N-CA 119.372 -0.931 . . . . 0.95 113.083 -177.722 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 48' ' ' LYS . . . . . 0.72 ' HE2' ' HG3' ' B' ' 51' ' ' PRO . 5.2 ptmt -43.4 -12.88 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.177 0 N-CA-C 118.157 2.651 . . . . 0.64 118.157 -166.171 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 49' ' ' TYR . . . . . 0.784 ' HB3' ' HB2' ' B' ' 33' ' ' PRO . 22.4 t80 71.87 -55.77 0.66 Allowed 'General case' 0 N--CA 1.475 0.809 0 N-CA-C 113.374 0.879 . . . . 1.26 113.374 172.738 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 50' ' ' SER . . . . . 0.713 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 33.9 t -51.15 -57.02 15.35 Favored Pre-proline 0 CA--C 1.535 0.369 0 C-N-CA 122.867 0.467 . . . . 1.22 111.11 -175.186 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 51' ' ' PRO . . . . . 0.72 ' HG3' ' HE2' ' B' ' 48' ' ' LYS . 48.9 Cg_endo -89.58 13.51 2.37 Favored 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 121.995 1.796 . . . . 0.56 111.229 171.052 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 52' ' ' ILE . . . . . . . . . . . . . 3.0 mt . . . . . 0 N--CA 1.448 -0.571 0 CA-C-N 114.97 -1.014 . . . . 0.73 108.487 -172.763 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . 0.434 ' HA ' ' HB2' ' B' ' 37' ' ' PHE . . . . . . . . 0 CA--C 1.523 -0.095 0 CA-C-O 121.54 0.686 . . . . 0.72 111.204 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.412 ' OG1' ' HA ' ' B' ' 37' ' ' PHE . 17.9 p -92.29 -50.34 5.7 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.227 -0.897 . . . . 0.41 111.756 -177.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 79.78 49.69 5.96 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.46 -0.876 . . . . 0.32 113.208 175.851 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.759 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.1 tp -107.39 113.18 42.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 N-CA-C 109.17 -0.678 . . . . 0.31 109.17 173.731 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.723 ' HA ' ' O ' ' B' ' 34' ' ' LEU . 39.7 t -83.43 135.52 24.65 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-O 120.922 0.391 . . . . 0.28 110.798 -178.477 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.626 ' HB3' HD11 ' B' ' 36' ' ' ILE . 6.8 tpp180 -129.23 123.25 31.5 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 107.568 -1.271 . . . . 1.99 107.568 -179.352 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ARG . . . . . 0.527 ' N ' ' HD3' ' A' ' 8' ' ' ARG . 4.9 tpp180 -84.43 104.44 14.44 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 108.328 -0.99 . . . . 2.8 108.328 173.19 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.74 HG23 HD11 ' B' ' 34' ' ' LEU . 0.2 OUTLIER -12.23 -103.67 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.115 0 O-C-N 125.365 1.666 . . . . 0.33 114.701 -176.515 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . 0.568 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 5.8 p-10 161.35 -160.27 0.0 OUTLIER 'General case' 0 CA--C 1.512 -0.485 0 N-CA-C 107.937 -1.134 . . . . 1.13 107.937 177.019 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -72.66 -22.88 60.85 Favored 'General case' 0 C--N 1.323 -0.576 0 O-C-N 123.386 0.429 . . . . 2.26 110.878 -178.455 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -98.42 -60.52 1.53 Allowed 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.29 -0.414 . . . . 0.53 110.233 178.287 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.452 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 136.43 18.7 0.7 Allowed Glycine 0 N--CA 1.445 -0.735 0 C-N-CA 120.073 -1.061 . . . . 0.22 113.393 -179.186 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.706 ' HG2' HG22 ' B' ' 17' ' ' VAL . 0.0 OUTLIER -79.1 153.35 30.22 Favored 'General case' 0 CA--C 1.507 -0.693 0 CA-C-N 118.028 0.914 . . . . 0.69 109.621 179.569 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.818 HG21 HD13 ' B' ' 46' ' ' LEU . 98.0 t -104.4 100.32 10.25 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.455 0 N-CA-C 107.628 -1.249 . . . . 1.24 107.628 172.353 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.79 HG22 ' HG2' ' B' ' 15' ' ' ARG . 91.0 t -68.14 98.89 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.909 0 CA-C-N 115.068 -0.969 . . . . 0.28 110.21 -173.43 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.746 HG23 HD13 ' A' ' 22' ' ' ILE . 8.7 mt -92.25 114.02 60.96 Favored Pre-proline 0 N--CA 1.445 -0.708 0 CA-C-N 115.643 -0.708 . . . . 0.77 110.778 -178.551 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.638 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 47.5 Cg_exo -46.08 145.89 4.89 Favored 'Trans proline' 0 N--CA 1.458 -0.599 0 C-N-CA 123.1 2.533 . . . . 0.32 112.821 174.168 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.866 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -60.85 -16.47 41.63 Favored 'General case' 0 C--O 1.211 -0.949 0 CA-C-N 115.478 -0.783 . . . . 1.57 111.353 179.321 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.638 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 11.1 pt-20 -66.1 -19.91 65.99 Favored 'General case' 0 C--O 1.236 0.363 0 N-CA-C 111.767 0.284 . . . . 1.32 111.767 -178.283 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.746 HD13 HG23 ' A' ' 18' ' ' ILE . 5.0 mp -87.49 -50.8 13.48 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.635 0 N-CA-C 107.854 -1.165 . . . . 0.35 107.854 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . 0.595 ' HA ' ' HB2' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -56.1 -31.98 63.75 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 115.492 -0.776 . . . . 1.5 110.358 171.879 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.42 ' HB3' ' HA ' ' A' ' 21' ' ' GLU . 10.2 ttt180 -63.55 -52.26 61.87 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.313 -0.858 . . . . 2.96 110.943 174.29 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 22.5 m -66.53 -22.75 66.16 Favored 'General case' 0 C--O 1.222 -0.353 0 CA-C-O 121.182 0.515 . . . . 0.4 110.697 175.525 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.736 ' HB3' HG13 ' A' ' 28' ' ' ILE . 2.0 mm? -65.81 -19.71 65.98 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.865 -0.607 . . . . 0.36 110.614 173.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.533 ' HB2' ' O ' ' A' ' 26' ' ' LEU . 0.3 OUTLIER 72.3 21.36 3.84 Favored 'General case' 0 N--CA 1.466 0.358 0 O-C-N 124.066 0.854 . . . . 3.2 110.371 -172.746 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.736 HG13 ' HB3' ' A' ' 26' ' ' LEU . 3.0 mt -122.18 -163.0 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.726 -0.67 . . . . 0.48 110.175 -174.154 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.733 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -153.18 -161.41 1.28 Allowed 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 111.481 0.178 . . . . 2.4 111.481 -167.944 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -73.79 36.62 0.09 Allowed 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 121.961 0.886 . . . . 1.23 111.51 179.351 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.575 ' N ' HD11 ' B' ' 10' ' ' ILE . . . -152.19 24.78 0.89 Allowed Glycine 0 N--CA 1.44 -1.099 0 CA-C-N 114.15 -1.387 . . . . 0.36 109.894 174.026 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.597 ' O ' HG13 ' B' ' 10' ' ' ILE . 13.2 t0 -82.95 124.54 76.66 Favored Pre-proline 0 C--N 1.326 -0.436 0 CA-C-N 114.512 -0.844 . . . . 1.26 109.931 175.68 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.75 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 4.7 Cg_endo -82.94 152.5 14.5 Favored 'Trans proline' 0 N--CA 1.435 -1.939 0 C-N-CA 122.187 1.924 . . . . 1.3 110.719 173.777 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.808 HD11 HG23 ' B' ' 10' ' ' ILE . 0.6 OUTLIER -140.66 152.8 45.66 Favored 'General case' 0 C--N 1.305 -1.362 0 N-CA-C 109.14 -0.689 . . . . 0.38 109.14 171.994 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.933 ' HB3' ' HD2' ' A' ' 47' ' ' LYS . 39.4 tt0 -105.87 111.24 23.81 Favored 'General case' 0 CA--C 1.486 -1.515 0 N-CA-C 107.501 -1.296 . . . . 1.12 107.501 -179.051 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.934 HG13 HD22 ' A' ' 46' ' ' LEU . 2.5 mp -85.17 110.21 19.09 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.98 0 O-C-N 124.648 1.217 . . . . 0.39 108.478 -179.169 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' PHE . . . . . 0.641 ' HB2' ' H ' ' B' ' 4' ' ' THR . 1.8 p90 -150.55 124.61 9.34 Favored 'General case' 0 C--N 1.313 -1.02 0 CA-C-N 116.162 -0.472 . . . . 1.15 109.747 175.6 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.533 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 1.7 p -80.83 136.34 23.4 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 CA-C-O 121.149 0.5 . . . . 0.17 110.778 -178.33 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.684 ' HB3' ' HG3' ' A' ' 40' ' ' ARG . 9.8 t70 -75.59 -45.01 40.14 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.036 -0.984 . . . . 1.11 110.68 -175.498 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . 0.684 ' HG3' ' HB3' ' A' ' 39' ' ' ASP . 7.6 mtp180 -132.13 -73.35 0.52 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.672 -0.694 . . . . 2.29 112.267 -165.807 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -129.67 -65.11 0.85 Allowed 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.284 -0.871 . . . . 1.53 111.09 -173.408 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.599 ' HA3' HD11 ' B' ' 26' ' ' LEU . . . -131.88 6.36 5.46 Favored Glycine 0 CA--C 1.501 -0.832 0 CA-C-N 114.838 -1.074 . . . . 0.32 111.812 -173.852 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.556 ' HA ' ' O ' ' B' ' 46' ' ' LEU . 2.2 pm0 -93.58 105.69 17.71 Favored 'General case' 0 N--CA 1.443 -0.793 0 CA-C-O 121.009 0.433 . . . . 1.97 109.929 175.317 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.612 HG11 HG23 ' A' ' 36' ' ' ILE . 2.0 t -88.82 132.31 34.0 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.988 0 CA-C-N 115.566 -0.743 . . . . 0.14 109.864 178.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.856 HG13 HG13 ' B' ' 45' ' ' ILE . 1.4 mp -110.11 115.96 51.06 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 N-CA-C 108.239 -1.023 . . . . 0.14 108.239 -177.372 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 1.041 HD11 HD11 ' B' ' 46' ' ' LEU . 0.5 OUTLIER -109.48 116.76 32.41 Favored 'General case' 0 C--N 1.319 -0.759 0 O-C-N 123.703 0.627 . . . . 0.23 109.584 -178.871 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.933 ' HD2' ' HB3' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -122.84 150.37 42.95 Favored 'General case' 0 C--O 1.215 -0.732 0 C-N-CA 119.066 -1.054 . . . . 0.76 112.169 179.121 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.62 ' HA ' ' O ' ' A' ' 33' ' ' PRO . 1.5 ptmt -44.92 -16.45 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.24 0 N-CA-C 117.13 2.27 . . . . 0.32 117.13 -168.188 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 0.765 ' CD1' HG21 ' B' ' 7' ' ' VAL . 19.9 t80 74.35 -50.36 0.68 Allowed 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 112.689 0.625 . . . . 1.28 112.689 174.293 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.71 ' HB3' ' HD3' ' A' ' 51' ' ' PRO . 22.7 t -48.1 -50.83 52.95 Favored Pre-proline 0 CA--C 1.538 0.493 0 C-N-CA 122.585 0.354 . . . . 1.36 111.395 -177.368 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.71 ' HD3' ' HB3' ' A' ' 50' ' ' SER . 36.3 Cg_endo -95.25 10.31 1.66 Allowed 'Trans proline' 0 N--CA 1.453 -0.878 0 C-N-CA 122.601 2.2 . . . . 0.58 111.484 172.31 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 1.1 mt . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 115.044 -0.98 . . . . 0.78 109.262 -170.466 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 3' ' ' ALA . . . . . 0.569 ' HA ' ' HD2' ' A' ' 37' ' ' PHE . . . . . . . . 0 N--CA 1.462 0.174 0 CA-C-O 121.329 0.585 . . . . 0.86 110.546 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 4' ' ' THR . . . . . 0.641 ' H ' ' HB2' ' A' ' 37' ' ' PHE . 28.5 p -107.85 -52.56 2.75 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.634 -0.712 . . . . 0.43 111.068 -176.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 82.26 50.98 4.58 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.995 -0.621 . . . . 0.33 112.797 177.164 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 6' ' ' ILE . . . . . 0.805 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.0 OUTLIER -106.68 108.24 24.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 N-CA-C 109.322 -0.621 . . . . 0.3 109.322 173.316 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . 0.765 HG21 ' CD1' ' A' ' 49' ' ' TYR . 23.0 t -80.52 136.49 23.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-N 116.231 -0.44 . . . . 0.27 111.217 179.673 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . 0.546 ' HD3' ' N ' ' B' ' 9' ' ' ARG . 1.1 tpp180 -131.97 126.94 35.25 Favored 'General case' 0 N--CA 1.446 -0.625 0 N-CA-C 107.61 -1.255 . . . . 1.69 107.61 178.384 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 9' ' ' ARG . . . . . 0.546 ' N ' ' HD3' ' B' ' 8' ' ' ARG . 1.7 tpp180 -86.3 103.22 14.69 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 108.606 -0.887 . . . . 2.71 108.606 173.858 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 10' ' ' ILE . . . . . 0.808 HG23 HD11 ' A' ' 34' ' ' LEU . 0.2 OUTLIER -10.17 -107.37 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.264 0 O-C-N 125.351 1.657 . . . . 0.34 114.749 -177.828 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . 0.655 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 1.7 p-10 163.39 -166.38 0.01 OUTLIER 'General case' 0 CA--C 1.518 -0.286 0 N-CA-C 108.327 -0.99 . . . . 1.18 108.327 177.441 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -66.28 -19.85 65.93 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.355 0.598 . . . . 2.39 110.793 -179.04 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 13' ' ' LEU . . . . . 0.442 ' H ' ' CG ' ' B' ' 11' ' ' ASP . 2.9 tm? -101.59 -61.8 1.33 Allowed 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.711 -0.677 . . . . 0.4 110.796 -179.059 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 137.96 19.5 0.55 Allowed Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.807 -0.711 . . . . 0.21 112.116 -178.806 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 15' ' ' ARG . . . . . 0.79 ' HG2' HG22 ' A' ' 17' ' ' VAL . 2.7 mtm180 -70.22 147.65 49.54 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-O 121.244 0.545 . . . . 0.9 110.593 177.361 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 16' ' ' VAL . . . . . 0.713 HG21 HD13 ' A' ' 46' ' ' LEU . 63.7 t -106.69 97.07 5.18 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.237 0 N-CA-C 107.644 -1.243 . . . . 1.27 107.644 166.767 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 17' ' ' VAL . . . . . 0.706 HG22 ' HG2' ' A' ' 15' ' ' ARG . 64.3 t -67.42 98.92 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 CA-C-N 115.62 -0.718 . . . . 0.27 110.364 -171.732 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . 0.542 ' H ' ' HA ' ' A' ' 15' ' ' ARG . 6.9 mt -90.45 113.87 59.11 Favored Pre-proline 0 N--CA 1.442 -0.872 0 CA-C-N 115.181 -0.918 . . . . 0.82 110.562 -179.624 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 19' ' ' PRO . . . . . 0.61 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 81.3 Cg_exo -50.19 147.21 16.24 Favored 'Trans proline' 0 N--CA 1.458 -0.59 0 C-N-CA 123.056 2.504 . . . . 0.3 112.567 174.123 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 20' ' ' LYS . . . . . 1.012 ' HD3' ' H ' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -64.94 -15.63 62.36 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 115.649 -0.705 . . . . 1.77 111.678 -178.795 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . 0.61 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 1.3 pm0 -63.13 -21.8 66.44 Favored 'General case' 0 C--O 1.237 0.439 0 N-CA-C 111.854 0.316 . . . . 1.92 111.854 177.458 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 5.2 mp -87.61 -47.52 15.69 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 N-CA-C 108.488 -0.93 . . . . 0.44 108.488 -178.406 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 23' ' ' ARG . . . . . 0.558 ' HA ' ' HB2' ' B' ' 26' ' ' LEU . 0.0 OUTLIER -61.93 -28.28 69.42 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.262 -0.881 . . . . 1.4 109.231 174.022 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 24' ' ' ARG . . . . . . . . . . . . . 55.0 ttp180 -65.78 -51.92 55.07 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 114.91 -1.041 . . . . 3.19 110.988 174.639 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 18.7 m -63.65 -28.74 70.12 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-O 121.525 0.679 . . . . 0.4 110.152 176.23 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . 0.656 ' HB3' HG13 ' B' ' 28' ' ' ILE . 1.4 mm? -64.08 -19.9 65.57 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 115.009 -0.996 . . . . 0.33 110.678 174.091 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 27' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER 70.8 24.02 4.32 Favored 'General case' 0 C--N 1.342 0.242 0 CA-C-O 121.587 0.708 . . . . 3.28 110.154 -177.105 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 28' ' ' ILE . . . . . 0.809 HG22 ' H ' ' B' ' 29' ' ' ARG . 4.0 mt -119.25 -162.55 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.133 -0.939 . . . . 0.37 110.058 -176.889 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 29' ' ' ARG . . . . . 0.809 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -152.99 -161.42 1.29 Allowed 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 111.618 0.229 . . . . 2.15 111.618 -171.584 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 30' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -72.4 34.06 0.06 Allowed 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 121.858 0.837 . . . . 1.18 111.925 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 31' ' ' GLY . . . . . 0.567 ' N ' HD11 ' A' ' 10' ' ' ILE . . . -150.73 30.31 1.02 Allowed Glycine 0 N--CA 1.436 -1.365 0 N-CA-C 109.636 -1.385 . . . . 0.35 109.636 172.79 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 32' ' ' ASP . . . . . 0.511 ' HB2' ' CG2' ' B' ' 28' ' ' ILE . 6.9 t70 -85.22 128.72 58.62 Favored Pre-proline 0 CA--C 1.511 -0.523 0 CA-C-N 114.451 -0.874 . . . . 1.29 110.271 174.74 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 33' ' ' PRO . . . . . 0.756 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 10.9 Cg_endo -86.76 148.48 8.42 Favored 'Trans proline' 0 N--CA 1.433 -2.07 0 C-N-CA 122.128 1.885 . . . . 1.1 111.469 173.195 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.74 HD11 HG23 ' A' ' 10' ' ' ILE . 0.8 OUTLIER -137.53 148.34 45.9 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 109.273 -0.64 . . . . 0.44 109.273 173.661 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 35' ' ' GLU . . . . . 0.659 ' O ' ' HA ' ' B' ' 46' ' ' LEU . 77.9 tt0 -104.68 111.84 24.71 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 108.11 -1.07 . . . . 1.1 108.11 -179.535 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 36' ' ' ILE . . . . . 0.899 HG13 HD22 ' B' ' 46' ' ' LEU . 3.5 mp -86.1 109.34 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.869 0 O-C-N 124.716 1.26 . . . . 0.62 109.108 -177.964 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 37' ' ' PHE . . . . . 0.434 ' HB2' ' HA ' ' A' ' 3' ' ' ALA . 16.5 p90 -149.82 126.77 11.16 Favored 'General case' 0 C--N 1.316 -0.88 0 CA-C-N 115.922 -0.581 . . . . 1.2 109.954 175.415 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 38' ' ' VAL . . . . . 0.516 ' HA ' ' HA ' ' B' ' 44' ' ' VAL . 1.3 p -80.55 139.62 17.87 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.78 0 CA-C-O 121.361 0.6 . . . . 0.2 111.16 -177.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 39' ' ' ASP . . . . . 0.549 ' HB3' ' HG3' ' B' ' 40' ' ' ARG . 7.1 t70 -74.81 -49.86 19.22 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 114.591 -1.186 . . . . 1.14 110.472 -178.009 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 40' ' ' ARG . . . . . 0.549 ' HG3' ' HB3' ' B' ' 39' ' ' ASP . 13.8 mtp180 -132.78 -72.87 0.51 Allowed 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 112.604 0.594 . . . . 2.71 112.604 -168.434 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -124.69 -67.65 0.9 Allowed 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.359 -0.837 . . . . 1.32 110.986 -172.469 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 42' ' ' GLY . . . . . 0.509 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -129.75 9.56 6.08 Favored Glycine 0 N--CA 1.441 -1.028 0 CA-C-N 114.699 -1.137 . . . . 0.34 112.142 -176.094 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 43' ' ' GLU . . . . . 0.48 ' HA ' ' O ' ' A' ' 46' ' ' LEU . 2.3 pm0 -93.13 104.74 16.91 Favored 'General case' 0 N--CA 1.446 -0.625 0 N-CA-C 109.794 -0.447 . . . . 2.07 109.794 176.199 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 44' ' ' VAL . . . . . 0.59 HG11 HG23 ' B' ' 36' ' ' ILE . 2.0 t -89.42 134.05 29.77 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.886 0 N-CA-C 109.805 -0.443 . . . . 0.13 109.805 179.071 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 45' ' ' ILE . . . . . 0.856 HG13 HG13 ' A' ' 45' ' ' ILE . 1.6 mp -110.17 116.36 52.09 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 N-CA-C 108.095 -1.076 . . . . 0.12 108.095 -177.908 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 46' ' ' LEU . . . . . 1.041 HD11 HD11 ' A' ' 46' ' ' LEU . 0.7 OUTLIER -109.4 116.25 31.49 Favored 'General case' 0 C--N 1.317 -0.838 0 O-C-N 123.67 0.606 . . . . 0.15 109.569 179.577 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 47' ' ' LYS . . . . . 0.588 ' HE3' ' HB3' ' B' ' 35' ' ' GLU . 0.0 OUTLIER -125.01 146.36 49.46 Favored 'General case' 0 C--N 1.315 -0.892 0 C-N-CA 119.652 -0.819 . . . . 0.95 112.347 -177.865 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 48' ' ' LYS . . . . . 0.595 ' HA ' ' O ' ' B' ' 33' ' ' PRO . 3.7 ptmt -45.89 -10.61 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.147 0 N-CA-C 117.812 2.523 . . . . 0.64 117.812 -166.301 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 49' ' ' TYR . . . . . 0.756 ' HB3' ' HB2' ' B' ' 33' ' ' PRO . 23.7 t80 72.07 -51.17 0.7 Allowed 'General case' 0 N--CA 1.47 0.559 0 N-CA-C 112.955 0.724 . . . . 1.26 112.955 172.711 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 50' ' ' SER . . . . . 0.605 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 48.3 t -51.4 -56.75 17.91 Favored Pre-proline 0 CA--C 1.535 0.383 0 C-N-CA 122.597 0.359 . . . . 1.22 111.249 -175.133 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 51' ' ' PRO . . . . . 0.605 ' HD3' ' HB3' ' B' ' 50' ' ' SER . 57.8 Cg_endo -88.3 12.35 2.84 Favored 'Trans proline' 0 C--N 1.35 0.649 0 C-N-CA 121.83 1.687 . . . . 0.56 111.44 170.694 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 52' ' ' ILE . . . . . . . . . . . . . 1.3 mt . . . . . 0 CA--C 1.518 -0.273 0 CA-C-N 115.056 -0.975 . . . . 0.73 108.952 -173.943 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.461 0.081 0 CA-C-O 121.545 0.688 . . . . 0.72 111.891 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.763 ' H ' ' HB2' ' B' ' 37' ' ' PHE . 21.4 p -129.59 -57.2 1.13 Allowed 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.539 -0.755 . . . . 0.41 110.636 -178.647 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 85.13 48.95 4.65 Favored Glycine 0 N--CA 1.441 -1.024 0 C-N-CA 120.315 -0.945 . . . . 0.32 112.662 174.274 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.806 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.5 tp -105.49 109.09 26.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 N-CA-C 109.258 -0.645 . . . . 0.31 109.258 173.851 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.757 ' HA ' ' O ' ' B' ' 34' ' ' LEU . 41.7 t -79.76 132.69 31.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 116.135 -0.484 . . . . 0.28 110.715 179.284 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.484 ' HD3' ' N ' ' A' ' 9' ' ' ARG . 1.8 tpp180 -129.24 125.07 36.07 Favored 'General case' 0 N--CA 1.443 -0.781 0 N-CA-C 106.919 -1.512 . . . . 1.99 106.919 -179.821 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ARG . . . . . 0.562 ' C ' HD12 ' A' ' 10' ' ' ILE . 0.6 OUTLIER -86.34 102.26 13.84 Favored 'General case' 0 C--N 1.315 -0.933 0 N-CA-C 108.202 -1.036 . . . . 2.8 108.202 175.346 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.831 HG23 HD11 ' B' ' 34' ' ' LEU . 0.2 OUTLIER -5.56 -105.79 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.016 0 O-C-N 125.645 1.841 . . . . 0.33 114.356 -176.468 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . 0.623 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 3.3 p-10 161.54 -166.45 0.0 OUTLIER 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 108.64 -0.874 . . . . 1.13 108.64 177.28 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -68.11 -23.01 64.86 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 123.455 0.472 . . . . 2.26 110.94 -177.84 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.421 ' HB3' ' HD2' ' A' ' 15' ' ' ARG . 2.5 tm? -100.64 -55.66 2.53 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.331 -0.395 . . . . 0.53 110.448 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.56 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 134.32 18.0 0.95 Allowed Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.449 -0.882 . . . . 0.22 113.069 -179.435 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.544 ' HG2' HG22 ' B' ' 17' ' ' VAL . 0.4 OUTLIER -76.66 156.19 32.8 Favored 'General case' 0 CA--C 1.51 -0.562 0 CA-C-N 117.625 0.712 . . . . 0.69 110.301 -179.564 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.736 HG21 HD13 ' B' ' 46' ' ' LEU . 89.8 t -111.04 98.3 6.88 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.23 0 N-CA-C 107.728 -1.212 . . . . 1.24 107.728 167.637 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.58 HG22 ' HG2' ' B' ' 15' ' ' ARG . 39.4 t -65.05 106.95 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 CA-C-N 115.249 -0.887 . . . . 0.28 109.675 -173.702 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.452 ' HB ' ' O ' ' B' ' 14' ' ' GLY . 30.9 mm -95.82 107.88 36.88 Favored Pre-proline 0 N--CA 1.447 -0.625 0 CA-C-N 115.691 -0.686 . . . . 0.77 110.117 -178.017 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.699 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 62.2 Cg_exo -47.44 146.06 7.85 Favored 'Trans proline' 0 N--CA 1.454 -0.821 0 C-N-CA 122.6 2.2 . . . . 0.32 112.718 175.402 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.957 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -64.61 -14.0 55.93 Favored 'General case' 0 C--N 1.314 -0.935 0 CA-C-N 115.766 -0.652 . . . . 1.57 111.251 179.813 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.699 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 11.5 pt-20 -63.78 -23.05 67.21 Favored 'General case' 0 C--O 1.239 0.501 0 N-CA-C 112.349 0.5 . . . . 1.32 112.349 178.285 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.406 HD13 HG23 ' A' ' 18' ' ' ILE . 5.2 mp -87.39 -46.49 16.1 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.334 0 N-CA-C 108.096 -1.076 . . . . 0.35 108.096 -178.635 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . 0.69 ' HA ' ' HB2' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -61.41 -27.19 68.36 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 114.941 -1.027 . . . . 1.5 109.219 172.994 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 74.9 ttt180 -63.26 -51.48 65.99 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 114.75 -1.114 . . . . 2.96 111.116 173.315 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 28.7 m -61.69 -31.14 71.26 Favored 'General case' 0 CA--C 1.532 0.252 0 CA-C-O 121.147 0.498 . . . . 0.4 110.636 172.757 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.69 ' HB2' ' HA ' ' A' ' 23' ' ' ARG . 3.2 mm? -64.92 -21.35 66.81 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.617 -0.72 . . . . 0.36 110.71 173.855 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 2.0 mpt_? 70.39 21.96 5.48 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 123.455 0.702 . . . . 3.2 110.943 -176.764 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.769 HG22 ' H ' ' A' ' 29' ' ' ARG . 5.3 mt -117.49 -166.5 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.786 0 CA-C-N 115.159 -0.928 . . . . 0.48 108.932 -177.896 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.769 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -148.5 -153.69 0.51 Allowed 'General case' 0 C--N 1.323 -0.557 0 O-C-N 122.13 -0.356 . . . . 2.4 111.286 -175.157 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . 0.449 ' H ' ' HB2' ' A' ' 29' ' ' ARG . 0.6 OUTLIER -75.72 44.66 0.3 Allowed 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 122.089 0.947 . . . . 1.23 112.188 -177.787 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.664 ' CA ' HD11 ' B' ' 10' ' ' ILE . . . -159.31 29.3 0.4 Allowed Glycine 0 N--CA 1.441 -1.006 0 CA-C-N 113.975 -1.466 . . . . 0.36 109.547 172.466 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.59 ' O ' HG13 ' B' ' 10' ' ' ILE . 11.8 t70 -88.81 128.9 50.58 Favored Pre-proline 0 CA--C 1.514 -0.407 0 N-CA-C 109.351 -0.611 . . . . 1.26 109.351 174.549 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.73 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 3.8 Cg_endo -83.81 150.04 12.64 Favored 'Trans proline' 0 N--CA 1.435 -1.936 0 C-N-CA 122.18 1.92 . . . . 1.3 110.804 175.175 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.803 HD11 HG23 ' B' ' 10' ' ' ILE . 0.6 OUTLIER -139.68 153.75 47.34 Favored 'General case' 0 N--CA 1.43 -1.428 0 N-CA-C 109.302 -0.629 . . . . 0.38 109.302 172.023 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.919 ' HB3' ' HD2' ' A' ' 47' ' ' LYS . 33.8 tt0 -109.25 114.57 28.38 Favored 'General case' 0 C--N 1.297 -1.675 0 N-CA-C 108.392 -0.966 . . . . 1.12 108.392 -178.316 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.878 HG13 HD22 ' A' ' 46' ' ' LEU . 3.2 mp -86.12 110.05 19.42 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.944 0 O-C-N 124.843 1.339 . . . . 0.39 109.226 -178.766 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' PHE . . . . . 0.668 ' HD1' ' HA ' ' B' ' 3' ' ' ALA . 0.5 OUTLIER -149.76 125.74 10.57 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 116.211 -0.45 . . . . 1.15 109.874 175.488 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.533 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 1.2 p -80.51 137.09 22.06 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 CA-C-O 121.191 0.52 . . . . 0.17 110.749 -179.854 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.517 ' HB3' ' HG2' ' A' ' 40' ' ' ARG . 9.9 t70 -88.65 -64.93 1.07 Allowed 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 114.617 -1.174 . . . . 1.11 111.902 -171.459 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . 0.525 ' H ' ' HG2' ' A' ' 40' ' ' ARG . 0.0 OUTLIER -106.58 -84.37 0.52 Allowed 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 114.899 -1.046 . . . . 2.29 111.303 -165.759 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -111.37 -72.58 0.71 Allowed 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.12 -0.491 . . . . 1.53 110.88 -177.518 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -130.35 24.66 4.4 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.776 -0.726 . . . . 0.32 111.638 179.276 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.555 ' HB3' HG23 ' B' ' 45' ' ' ILE . 2.3 mt-10 -97.95 113.0 24.72 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.126 -0.694 . . . . 1.97 109.126 178.465 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.533 ' HA ' ' HA ' ' A' ' 38' ' ' VAL . 1.8 t -90.4 132.95 33.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 N-CA-C 109.573 -0.529 . . . . 0.14 109.573 178.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.797 HG13 HG13 ' B' ' 45' ' ' ILE . 1.6 mp -111.68 117.5 55.28 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 N-CA-C 108.575 -0.898 . . . . 0.14 108.575 -175.389 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.998 HD11 HD11 ' B' ' 46' ' ' LEU . 0.5 OUTLIER -110.13 117.09 32.79 Favored 'General case' 0 C--N 1.32 -0.706 0 O-C-N 123.676 0.61 . . . . 0.23 109.874 179.825 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.919 ' HD2' ' HB3' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -126.44 151.9 47.12 Favored 'General case' 0 C--O 1.219 -0.55 0 C-N-CA 119.02 -1.072 . . . . 0.76 112.792 179.132 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.649 ' HA ' ' O ' ' A' ' 33' ' ' PRO . 1.9 ptmt -43.58 -16.29 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.09 0 N-CA-C 117.263 2.32 . . . . 0.32 117.263 -168.381 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 0.758 ' CD1' HG21 ' B' ' 7' ' ' VAL . 17.9 t80 73.22 -54.58 0.69 Allowed 'General case' 0 N--CA 1.469 0.521 0 N-CA-C 112.561 0.578 . . . . 1.28 112.561 174.379 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.687 ' HB3' ' HD3' ' A' ' 51' ' ' PRO . 19.6 t -50.85 -49.82 77.7 Favored Pre-proline 0 CA--C 1.537 0.473 0 O-C-N 123.335 0.397 . . . . 1.36 111.387 -175.105 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.687 ' HD3' ' HB3' ' A' ' 50' ' ' SER . 86.5 Cg_endo -96.18 12.45 1.21 Allowed 'Trans proline' 0 N--CA 1.453 -0.861 0 C-N-CA 122.401 2.067 . . . . 0.58 111.658 171.213 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 1.3 mt . . . . . 0 C--O 1.234 0.281 0 CA-C-N 115.423 -0.808 . . . . 0.78 109.083 -173.946 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 3' ' ' ALA . . . . . 0.668 ' HA ' ' HD1' ' A' ' 37' ' ' PHE . . . . . . . . 0 N--CA 1.463 0.192 0 CA-C-O 121.512 0.672 . . . . 0.86 110.419 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 4' ' ' THR . . . . . 0.666 ' H ' ' HB2' ' A' ' 37' ' ' PHE . 11.3 p -115.87 -46.74 2.82 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.022 -0.535 . . . . 0.43 111.248 -178.713 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 73.01 49.72 15.54 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 120.929 -0.653 . . . . 0.33 113.137 172.893 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 6' ' ' ILE . . . . . 0.856 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.0 OUTLIER -106.73 110.55 32.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 N-CA-C 109.104 -0.702 . . . . 0.3 109.104 174.841 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . 0.758 HG21 ' CD1' ' A' ' 49' ' ' TYR . 38.9 t -80.51 134.66 26.88 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.308 0.575 . . . . 0.27 111.389 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . 0.524 ' HB3' ' CD1' ' A' ' 36' ' ' ILE . 8.4 tpp180 -130.1 121.45 26.38 Favored 'General case' 0 N--CA 1.44 -0.948 0 N-CA-C 107.541 -1.281 . . . . 1.69 107.541 -177.47 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 9' ' ' ARG . . . . . 0.48 ' HA ' ' HA ' ' A' ' 33' ' ' PRO . 15.9 ttt180 -84.45 103.43 13.6 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 108.084 -1.08 . . . . 2.71 108.084 173.766 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 10' ' ' ILE . . . . . 0.803 HG23 HD11 ' A' ' 34' ' ' LEU . 0.4 OUTLIER -9.2 -101.61 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.996 0 O-C-N 125.665 1.853 . . . . 0.34 114.398 -174.707 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . 0.645 ' H ' HD13 ' B' ' 10' ' ' ILE . 5.5 p-10 164.21 -154.07 0.0 OUTLIER 'General case' 0 C--O 1.219 -0.504 0 N-CA-C 108.773 -0.825 . . . . 1.18 108.773 174.555 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -85.2 -9.18 58.1 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.047 0.451 . . . . 2.39 110.617 -178.778 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 13' ' ' LEU . . . . . 0.453 ' HB3' ' HD2' ' B' ' 15' ' ' ARG . 3.0 tm? -109.5 -56.43 2.3 Favored 'General case' 0 N--CA 1.448 -0.537 0 CA-C-N 116.075 -0.511 . . . . 0.4 109.935 176.496 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 14' ' ' GLY . . . . . 0.452 ' O ' ' HB ' ' A' ' 18' ' ' ILE . . . 133.16 20.85 0.89 Allowed Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.764 -0.732 . . . . 0.21 112.689 -178.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 15' ' ' ARG . . . . . 0.58 ' HG2' HG22 ' A' ' 17' ' ' VAL . 1.5 mpt_? -78.23 154.08 31.35 Favored 'General case' 0 CA--C 1.509 -0.606 0 O-C-N 122.066 -0.667 . . . . 0.9 110.189 179.293 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 16' ' ' VAL . . . . . 0.726 HG21 HD13 ' A' ' 46' ' ' LEU . 96.7 t -109.11 95.96 4.26 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 N-CA-C 107.475 -1.305 . . . . 1.27 107.475 168.722 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 17' ' ' VAL . . . . . 0.544 HG22 ' HG2' ' A' ' 15' ' ' ARG . 47.0 t -64.32 104.84 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.842 0 CA-C-N 114.96 -1.018 . . . . 0.27 109.914 -173.04 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . 0.56 ' HB ' ' O ' ' A' ' 14' ' ' GLY . 26.6 mm -92.48 111.26 49.87 Favored Pre-proline 0 N--CA 1.446 -0.633 0 CA-C-N 115.647 -0.706 . . . . 0.82 110.574 -177.463 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 19' ' ' PRO . . . . . 0.68 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 59.1 Cg_exo -48.49 142.39 17.79 Favored 'Trans proline' 0 N--CA 1.459 -0.534 0 C-N-CA 123.041 2.494 . . . . 0.3 112.53 172.828 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 20' ' ' LYS . . . . . 0.952 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -59.44 -16.14 21.78 Favored 'General case' 0 C--O 1.211 -0.949 0 CA-C-N 115.243 -0.889 . . . . 1.77 111.428 178.954 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . 0.68 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 10.6 pt-20 -65.5 -20.0 66.16 Favored 'General case' 0 C--O 1.234 0.284 0 N-CA-C 112.034 0.383 . . . . 1.92 112.034 -178.226 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 5.2 mp -87.26 -49.14 14.97 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 N-CA-C 108.433 -0.951 . . . . 0.44 108.433 179.848 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 23' ' ' ARG . . . . . 0.627 ' NE ' ' HA ' ' B' ' 29' ' ' ARG . 0.0 OUTLIER -55.33 -32.41 62.49 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-O 122.057 0.932 . . . . 1.4 109.194 171.073 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 24' ' ' ARG . . . . . 0.475 ' N ' ' HD3' ' B' ' 23' ' ' ARG . 50.1 ttt180 -61.12 -53.72 53.52 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-N 114.021 -1.445 . . . . 3.19 111.195 176.222 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 53.7 m -61.07 -33.52 73.46 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-O 121.275 0.559 . . . . 0.4 110.418 173.806 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . 0.552 ' HB2' ' HA ' ' B' ' 23' ' ' ARG . 1.5 mm? -63.98 -20.26 65.76 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.21 -0.904 . . . . 0.33 111.339 177.775 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 27' ' ' ARG . . . . . . . . . . . . . 6.5 mpt_? 69.79 28.38 4.37 Favored 'General case' 0 N--CA 1.471 0.6 0 CA-C-O 121.18 0.514 . . . . 3.28 110.505 -176.686 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 28' ' ' ILE . . . . . 0.847 HG22 ' H ' ' B' ' 29' ' ' ARG . 7.6 mt -122.47 -159.44 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 115.889 -0.596 . . . . 0.37 109.924 -175.583 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 29' ' ' ARG . . . . . 0.847 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.1 OUTLIER -155.33 -159.9 0.98 Allowed 'General case' 0 N--CA 1.467 0.42 0 N-CA-C 112.496 0.554 . . . . 2.15 112.496 -174.476 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 30' ' ' GLU . . . . . 0.422 ' H ' ' HB2' ' B' ' 29' ' ' ARG . 38.6 mp0 -69.87 36.93 0.04 OUTLIER 'General case' 0 N--CA 1.472 0.655 0 CA-C-O 122.019 0.914 . . . . 1.18 112.053 178.636 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 31' ' ' GLY . . . . . 0.608 ' CA ' HD11 ' A' ' 10' ' ' ILE . . . -156.46 32.97 0.59 Allowed Glycine 0 N--CA 1.431 -1.663 0 N-CA-C 109.547 -1.421 . . . . 0.35 109.547 175.712 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 32' ' ' ASP . . . . . 0.536 ' O ' HG13 ' A' ' 10' ' ' ILE . 19.2 t0 -92.46 125.55 55.62 Favored Pre-proline 0 C--N 1.323 -0.569 0 CA-C-N 114.861 -0.669 . . . . 1.29 109.259 173.529 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 33' ' ' PRO . . . . . 0.82 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 3.5 Cg_endo -79.55 151.66 22.57 Favored 'Trans proline' 0 N--CA 1.436 -1.888 0 C-N-CA 122.216 1.944 . . . . 1.1 110.043 174.215 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.831 HD11 HG23 ' A' ' 10' ' ' ILE . 0.8 OUTLIER -140.73 149.35 42.04 Favored 'General case' 0 C--N 1.305 -1.326 0 N-CA-C 109.444 -0.576 . . . . 0.44 109.444 172.434 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 35' ' ' GLU . . . . . 0.646 ' O ' ' HA ' ' B' ' 46' ' ' LEU . 72.1 tt0 -104.04 112.28 25.21 Favored 'General case' 0 CA--C 1.487 -1.471 0 N-CA-C 107.359 -1.348 . . . . 1.1 107.359 -179.272 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 36' ' ' ILE . . . . . 0.895 HG13 HD22 ' B' ' 46' ' ' LEU . 2.5 mp -86.47 111.07 20.87 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.148 0 O-C-N 124.615 1.197 . . . . 0.62 108.675 179.331 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 37' ' ' PHE . . . . . 0.763 ' HB2' ' H ' ' A' ' 4' ' ' THR . 17.9 p90 -150.29 129.28 12.59 Favored 'General case' 0 C--N 1.314 -0.96 0 N-CA-C 109.392 -0.596 . . . . 1.2 109.392 172.613 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 38' ' ' VAL . . . . . 0.561 ' HA ' ' HA ' ' B' ' 44' ' ' VAL . 1.4 p -83.62 129.91 36.73 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.114 0 CA-C-O 121.255 0.55 . . . . 0.2 111.539 -175.369 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 39' ' ' ASP . . . . . 0.688 ' HB3' ' HD3' ' B' ' 40' ' ' ARG . 0.5 OUTLIER -94.28 171.36 8.88 Favored 'General case' 0 N--CA 1.443 -0.777 0 N-CA-C 108.036 -1.098 . . . . 1.14 108.036 173.634 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 40' ' ' ARG . . . . . 0.688 ' HD3' ' HB3' ' B' ' 39' ' ' ASP . 0.0 OUTLIER 41.64 -107.22 0.08 Allowed 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 113.811 1.041 . . . . 2.71 113.811 176.902 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -108.13 -82.98 0.55 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.076 0.465 . . . . 1.32 111.368 -174.362 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 42' ' ' GLY . . . . . . . . . . . . . . . -118.93 26.15 7.64 Favored Glycine 0 N--CA 1.444 -0.78 0 C-N-CA 120.92 -0.657 . . . . 0.34 111.89 -175.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 43' ' ' GLU . . . . . 0.64 ' HB3' HG23 ' A' ' 45' ' ' ILE . 2.0 mt-10 -96.79 111.9 23.88 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 109.633 -0.506 . . . . 2.07 109.633 178.082 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 44' ' ' VAL . . . . . 0.561 ' HA ' ' HA ' ' B' ' 38' ' ' VAL . 1.9 t -88.23 132.63 32.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 N-CA-C 109.575 -0.528 . . . . 0.13 109.575 178.204 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 45' ' ' ILE . . . . . 0.797 HG13 HG13 ' A' ' 45' ' ' ILE . 1.5 mp -108.97 119.36 58.39 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 N-CA-C 108.206 -1.035 . . . . 0.12 108.206 -177.352 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 46' ' ' LEU . . . . . 0.998 HD11 HD11 ' A' ' 46' ' ' LEU . 0.7 OUTLIER -112.37 117.1 31.51 Favored 'General case' 0 C--N 1.317 -0.817 0 O-C-N 123.68 0.612 . . . . 0.15 110.008 178.217 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 47' ' ' LYS . . . . . 0.587 ' O ' ' HA ' ' B' ' 34' ' ' LEU . 0.0 OUTLIER -129.78 149.33 51.57 Favored 'General case' 0 C--O 1.215 -0.72 0 C-N-CA 119.492 -0.883 . . . . 0.95 113.03 -179.841 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 48' ' ' LYS . . . . . 0.602 ' HA ' ' O ' ' B' ' 33' ' ' PRO . 1.7 ptmt -39.75 -21.35 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.244 0 N-CA-C 117.658 2.466 . . . . 0.64 117.658 -168.086 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 49' ' ' TYR . . . . . 0.82 ' HB3' ' HB2' ' B' ' 33' ' ' PRO . 23.3 t80 75.1 -46.58 0.59 Allowed 'General case' 0 N--CA 1.47 0.568 0 CA-C-N 119.095 0.861 . . . . 1.26 111.282 177.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 50' ' ' SER . . . . . 0.664 ' OG ' ' HD3' ' B' ' 51' ' ' PRO . 1.6 p -50.14 -48.38 79.64 Favored Pre-proline 0 CA--C 1.544 0.737 0 CA-C-N 115.519 -0.764 . . . . 1.22 112.395 -175.528 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 51' ' ' PRO . . . . . 0.664 ' HD3' ' OG ' ' B' ' 50' ' ' SER . 33.1 Cg_endo -103.06 14.03 0.29 Allowed 'Trans proline' 0 N--CA 1.454 -0.831 0 C-N-CA 122.976 2.45 . . . . 0.56 111.733 170.241 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 52' ' ' ILE . . . . . . . . . . . . . 1.1 mt . . . . . 0 C--N 1.328 -0.356 0 N-CA-C 108.516 -0.92 . . . . 0.73 108.516 -168.661 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . 0.478 ' HA ' ' HB2' ' B' ' 37' ' ' PHE . . . . . . . . 0 N--CA 1.463 0.214 0 CA-C-O 121.608 0.718 . . . . 0.72 109.75 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 31.0 p -84.53 -31.74 24.26 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.201 -0.909 . . . . 0.41 112.521 -169.574 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . 0.583 ' H ' ' HB3' ' B' ' 37' ' ' PHE . . . 61.01 49.19 81.35 Favored Glycine 0 N--CA 1.446 -0.66 0 C-N-CA 120.767 -0.73 . . . . 0.32 113.074 176.567 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.85 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.6 tp -105.73 104.41 16.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 N-CA-C 109.173 -0.677 . . . . 0.31 109.173 174.823 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.615 HG21 ' CD1' ' B' ' 49' ' ' TYR . 38.0 t -74.25 133.04 32.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 115.719 -0.673 . . . . 0.28 110.088 179.696 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.667 ' HB3' ' CD1' ' B' ' 36' ' ' ILE . 3.3 tpp180 -129.43 119.4 23.74 Favored 'General case' 0 N--CA 1.437 -1.077 0 N-CA-C 106.809 -1.552 . . . . 1.99 106.809 -178.75 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' ARG . . . . . 0.53 ' HA ' ' O ' ' B' ' 32' ' ' ASP . 9.4 ttp180 -83.37 102.76 12.23 Favored 'General case' 0 C--N 1.312 -1.024 0 N-CA-C 108.553 -0.906 . . . . 2.8 108.553 176.183 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.756 HG23 HD11 ' B' ' 34' ' ' LEU . 0.2 OUTLIER -9.62 -103.23 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 O-C-N 125.62 1.825 . . . . 0.33 114.525 -177.108 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . 0.603 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 4.3 p-10 161.43 -162.62 0.0 OUTLIER 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 108.31 -0.996 . . . . 1.13 108.31 176.86 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -71.27 -24.73 62.22 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.15 0.5 . . . . 2.26 110.803 -178.109 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -95.22 -58.98 1.99 Allowed 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.112 -0.494 . . . . 0.53 110.212 178.551 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.531 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 135.64 17.72 0.83 Allowed Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.595 -0.812 . . . . 0.22 112.92 -177.998 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.664 ' HG2' HG22 ' B' ' 17' ' ' VAL . 1.4 mpt_? -74.73 153.11 38.98 Favored 'General case' 0 CA--C 1.507 -0.689 0 O-C-N 122.139 -0.624 . . . . 0.69 110.033 179.299 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.749 HG21 HD13 ' B' ' 46' ' ' LEU . 93.3 t -108.39 95.93 4.22 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.29 0 N-CA-C 107.662 -1.236 . . . . 1.24 107.662 169.239 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.644 HG22 ' HG2' ' B' ' 15' ' ' ARG . 91.0 t -64.54 99.37 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-N 115.131 -0.94 . . . . 0.28 110.085 -174.121 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.473 ' HB ' ' O ' ' B' ' 14' ' ' GLY . 38.6 mm -87.47 112.05 45.73 Favored Pre-proline 0 N--CA 1.446 -0.659 0 CA-C-N 115.543 -0.753 . . . . 0.77 109.854 -179.515 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.568 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 91.9 Cg_exo -50.79 140.72 37.34 Favored 'Trans proline' 0 N--CA 1.452 -0.963 0 C-N-CA 122.267 1.978 . . . . 0.32 111.738 173.566 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.982 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -61.12 -14.95 28.12 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.675 -0.693 . . . . 1.57 111.47 -177.992 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.568 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 11.3 pt-20 -66.77 -21.4 66.06 Favored 'General case' 0 C--O 1.237 0.442 0 N-CA-C 112.182 0.438 . . . . 1.32 112.182 -178.685 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.2 mp -87.91 -45.27 15.98 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 107.997 -1.112 . . . . 0.35 107.997 -179.772 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . 0.733 ' HA ' ' HB2' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -60.35 -29.37 68.86 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 115.285 -0.871 . . . . 1.5 109.18 172.448 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.473 ' HB3' ' O ' ' A' ' 21' ' ' GLU . 58.7 ttt180 -60.42 -52.6 64.52 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 114.403 -1.271 . . . . 2.96 110.484 173.833 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 19.8 m -69.2 -21.21 63.97 Favored 'General case' 0 CA--C 1.53 0.177 0 CA-C-O 121.295 0.569 . . . . 0.4 110.904 175.11 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.791 ' HB3' HG13 ' A' ' 28' ' ' ILE . 0.8 OUTLIER -67.55 -18.37 65.0 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.974 -0.557 . . . . 0.36 111.2 176.418 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.466 ' HB2' ' O ' ' A' ' 26' ' ' LEU . 0.0 OUTLIER 70.51 20.46 5.89 Favored 'General case' 0 C--N 1.343 0.324 0 CA-C-O 121.299 0.571 . . . . 3.2 110.009 -172.397 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.791 HG13 ' HB3' ' A' ' 26' ' ' LEU . 3.0 mt -119.22 -164.87 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.535 -0.757 . . . . 0.48 109.855 -176.086 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.732 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -158.3 -156.97 0.59 Allowed 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 110.382 -0.229 . . . . 2.4 110.382 -167.988 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . 0.404 ' C ' HD11 ' B' ' 10' ' ' ILE . 1.6 mp0 -72.95 38.48 0.08 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 122.213 1.006 . . . . 1.23 111.034 176.34 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.639 ' N ' HD11 ' B' ' 10' ' ' ILE . . . -152.55 26.17 0.85 Allowed Glycine 0 N--CA 1.435 -1.411 0 CA-C-N 113.854 -1.521 . . . . 0.36 110.4 176.023 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.495 ' HA ' ' HD3' ' A' ' 33' ' ' PRO . 63.8 t0 -84.12 114.22 53.08 Favored Pre-proline 0 C--N 1.331 -0.205 0 CA-C-O 121.279 0.562 . . . . 1.26 109.768 175.627 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.595 ' HA ' ' HA ' ' B' ' 9' ' ' ARG . 1.2 Cg_endo -88.97 54.76 1.95 Allowed 'Trans proline' 0 CA--C 1.507 -0.874 0 C-N-CA 124.158 3.239 . . . . 1.3 114.108 -175.188 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.609 HD12 ' H ' ' A' ' 34' ' ' LEU . 1.0 OUTLIER -57.38 153.6 12.21 Favored 'General case' 0 C--N 1.297 -1.676 0 CA-C-O 122.299 1.047 . . . . 0.38 112.352 -173.768 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.824 ' HB3' ' HB3' ' A' ' 47' ' ' LYS . 33.8 tt0 -105.07 118.47 36.62 Favored 'General case' 0 CA--C 1.492 -1.259 0 CA-C-N 113.492 -1.685 . . . . 1.12 107.505 -175.594 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.884 ' HB ' HG23 ' B' ' 6' ' ' ILE . 2.6 mp -88.28 110.16 20.72 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.014 0 O-C-N 123.847 0.717 . . . . 0.39 109.265 179.467 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' PHE . . . . . 0.784 ' HD1' ' HA ' ' B' ' 3' ' ' ALA . 0.8 OUTLIER -150.18 124.84 9.72 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 109.785 -0.45 . . . . 1.15 109.785 174.557 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.525 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 1.4 p -80.91 137.83 20.69 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.978 0 CA-C-O 121.053 0.454 . . . . 0.17 110.716 -179.232 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.596 ' OD2' ' HD2' ' A' ' 40' ' ' ARG . 3.6 t70 -85.4 -55.49 3.99 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.444 -0.798 . . . . 1.11 111.514 -173.633 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . 0.596 ' HD2' ' OD2' ' A' ' 39' ' ' ASP . 0.2 OUTLIER -119.91 -91.61 0.55 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.517 -0.765 . . . . 2.29 111.981 -169.554 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -99.01 -69.58 0.76 Allowed 'General case' 0 CA--C 1.511 -0.548 0 CA-C-O 121.345 0.593 . . . . 1.53 110.571 -176.206 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.729 ' HA3' HD11 ' B' ' 26' ' ' LEU . . . -135.54 21.74 3.58 Favored Glycine 0 N--CA 1.437 -1.261 0 CA-C-N 114.97 -1.013 . . . . 0.32 111.696 -176.787 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.621 ' HB3' HG23 ' B' ' 45' ' ' ILE . 2.1 mt-10 -95.38 109.15 21.36 Favored 'General case' 0 N--CA 1.447 -0.602 0 N-CA-C 109.099 -0.704 . . . . 1.97 109.099 177.381 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.528 ' CG1' HG23 ' A' ' 36' ' ' ILE . 1.7 t -90.09 132.11 35.6 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.941 0 N-CA-C 109.214 -0.661 . . . . 0.14 109.214 178.467 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.754 HG13 HG13 ' B' ' 45' ' ' ILE . 1.6 mp -108.21 119.55 58.0 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 N-CA-C 108.262 -1.014 . . . . 0.14 108.262 -176.104 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.926 HD11 HD11 ' B' ' 46' ' ' LEU . 6.9 mt -103.61 121.9 43.88 Favored 'General case' 0 C--N 1.322 -0.599 0 O-C-N 124.221 0.951 . . . . 0.23 110.033 179.616 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.824 ' HB3' ' HB3' ' A' ' 35' ' ' GLU . 21.6 ttmt -126.98 123.3 36.79 Favored 'General case' 0 C--N 1.308 -1.216 0 CA-C-N 115.454 -0.793 . . . . 0.76 112.576 -168.18 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.57 ' O ' ' HD2' ' A' ' 33' ' ' PRO . 3.1 ptmt -39.0 -19.24 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.648 0 N-CA-C 116.948 2.203 . . . . 0.32 116.948 -172.849 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 0.661 ' CD1' HG21 ' B' ' 7' ' ' VAL . 27.1 t80 74.72 -56.02 0.64 Allowed 'General case' 0 N--CA 1.475 0.823 0 C-N-CA 123.83 0.852 . . . . 1.28 113.001 173.414 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.681 ' HB3' ' HD3' ' A' ' 51' ' ' PRO . 48.2 t -49.62 -53.61 39.55 Favored Pre-proline 0 CA--C 1.535 0.373 0 CA-C-N 115.807 -0.633 . . . . 1.36 111.433 -175.072 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.681 ' HD3' ' HB3' ' A' ' 50' ' ' SER . 46.2 Cg_endo -95.26 14.32 1.21 Allowed 'Trans proline' 0 N--CA 1.456 -0.723 0 C-N-CA 122.27 1.98 . . . . 0.58 111.452 170.652 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 2.6 mt . . . . . 0 C--N 1.325 -0.473 0 N-CA-C 108.587 -0.894 . . . . 0.78 108.587 -172.433 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 3' ' ' ALA . . . . . 0.784 ' HA ' ' HD1' ' A' ' 37' ' ' PHE . . . . . . . . 0 N--CA 1.462 0.174 0 CA-C-O 121.555 0.693 . . . . 0.86 110.169 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 4' ' ' THR . . . . . . . . . . . . . 25.0 p -82.41 -32.02 29.31 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.162 -0.926 . . . . 0.43 112.498 -171.141 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 5' ' ' GLY . . . . . 0.472 ' H ' ' CB ' ' A' ' 37' ' ' PHE . . . 61.44 45.27 96.73 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 121.14 -0.552 . . . . 0.33 113.128 176.728 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 6' ' ' ILE . . . . . 0.884 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.1 tp -104.17 104.74 17.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.517 0.675 . . . . 0.3 109.556 178.066 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . 0.661 HG21 ' CD1' ' A' ' 49' ' ' TYR . 4.9 t -74.84 131.46 34.96 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.872 0 CA-C-N 115.178 -0.919 . . . . 0.27 110.896 -179.158 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . 0.474 ' HB3' ' CD1' ' A' ' 36' ' ' ILE . 0.1 OUTLIER -129.56 118.15 21.58 Favored 'General case' 0 N--CA 1.447 -0.593 0 N-CA-C 107.031 -1.47 . . . . 1.69 107.031 177.737 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 9' ' ' ARG . . . . . 0.595 ' HA ' ' HA ' ' A' ' 33' ' ' PRO . 26.7 ttp180 -79.85 104.84 10.7 Favored 'General case' 0 N--CA 1.44 -0.969 0 C-N-CA 119.789 -0.764 . . . . 2.71 109.001 174.527 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 10' ' ' ILE . . . . . 0.65 ' O ' ' HB3' ' B' ' 11' ' ' ASP . 0.3 OUTLIER -11.91 -102.75 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 O-C-N 125.705 1.878 . . . . 0.34 114.644 -176.051 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . 0.65 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 2.8 p-10 160.07 -165.81 0.0 OUTLIER 'General case' 0 C--N 1.342 0.249 0 N-CA-C 107.871 -1.159 . . . . 1.18 107.871 177.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -68.21 -30.75 69.9 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 120.967 0.413 . . . . 2.39 110.616 -179.131 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 13' ' ' LEU . . . . . 0.528 ' HB3' ' HD2' ' B' ' 15' ' ' ARG . 3.1 tm? -85.61 -59.27 2.36 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.066 -0.515 . . . . 0.4 110.101 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 14' ' ' GLY . . . . . 0.473 ' O ' ' HB ' ' A' ' 18' ' ' ILE . . . 131.46 16.29 1.52 Allowed Glycine 0 N--CA 1.445 -0.711 0 C-N-CA 120.327 -0.939 . . . . 0.21 112.727 -178.112 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 15' ' ' ARG . . . . . 0.644 ' HG2' HG22 ' A' ' 17' ' ' VAL . 0.3 OUTLIER -74.8 153.3 38.81 Favored 'General case' 0 CA--C 1.507 -0.674 0 C-N-CA 119.709 -0.796 . . . . 0.9 109.826 178.138 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 16' ' ' VAL . . . . . 0.872 HG21 HD13 ' A' ' 46' ' ' LEU . 95.9 t -108.53 98.01 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.316 0 N-CA-C 107.725 -1.213 . . . . 1.27 107.725 169.721 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 17' ' ' VAL . . . . . 0.664 HG22 ' HG2' ' A' ' 15' ' ' ARG . 57.6 t -66.69 99.58 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.877 0 CA-C-N 114.963 -1.017 . . . . 0.27 110.14 -172.259 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . 0.531 ' HB ' ' O ' ' A' ' 14' ' ' GLY . 39.1 mm -86.92 111.7 42.23 Favored Pre-proline 0 C--N 1.323 -0.569 0 CA-C-N 115.321 -0.854 . . . . 0.82 109.978 -179.376 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 19' ' ' PRO . . . . . 0.561 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 86.4 Cg_exo -50.61 139.85 37.77 Favored 'Trans proline' 0 N--CA 1.453 -0.909 0 C-N-CA 122.392 2.061 . . . . 0.3 111.607 172.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 20' ' ' LYS . . . . . 1.024 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -61.07 -13.31 15.99 Favored 'General case' 0 C--N 1.313 -0.979 0 CA-C-N 115.442 -0.799 . . . . 1.77 111.64 -178.35 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . 0.561 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 10.4 pt-20 -67.01 -22.98 65.87 Favored 'General case' 0 C--O 1.237 0.444 0 N-CA-C 112.614 0.598 . . . . 1.92 112.614 179.751 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 4.6 mp -88.06 -43.17 15.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 N-CA-C 107.758 -1.201 . . . . 0.44 107.758 -179.672 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 23' ' ' ARG . . . . . 0.684 ' HA ' ' HB2' ' B' ' 26' ' ' LEU . 0.0 OUTLIER -60.53 -29.89 69.4 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 115.287 -0.87 . . . . 1.4 109.298 171.503 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 24' ' ' ARG . . . . . 0.441 ' HB3' ' O ' ' B' ' 21' ' ' GLU . 23.1 ttt180 -61.66 -52.72 63.17 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 114.594 -1.184 . . . . 3.19 110.391 174.073 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 14.4 m -66.53 -25.06 66.49 Favored 'General case' 0 N--CA 1.452 -0.366 0 CA-C-O 121.456 0.646 . . . . 0.4 110.466 176.292 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . 0.729 HD11 ' HA3' ' A' ' 42' ' ' GLY . 0.7 OUTLIER -65.04 -19.55 66.05 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.432 -0.804 . . . . 0.33 111.068 175.699 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 27' ' ' ARG . . . . . 0.488 ' HB2' ' O ' ' B' ' 26' ' ' LEU . 0.2 OUTLIER 70.99 19.04 5.78 Favored 'General case' 0 N--CA 1.465 0.28 0 O-C-N 123.938 0.774 . . . . 3.28 110.097 -173.265 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 28' ' ' ILE . . . . . 0.892 HG22 ' H ' ' B' ' 29' ' ' ARG . 5.6 mt -115.45 -166.61 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 115.569 -0.741 . . . . 0.37 110.037 -177.044 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 29' ' ' ARG . . . . . 0.892 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -155.93 -157.35 0.71 Allowed 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 110.404 -0.221 . . . . 2.15 110.404 -169.698 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 30' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -71.44 31.94 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.547 0.689 . . . . 1.18 111.926 178.495 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 31' ' ' GLY . . . . . 0.547 ' N ' HD11 ' A' ' 10' ' ' ILE . . . -145.73 30.24 1.69 Allowed Glycine 0 N--CA 1.438 -1.172 0 CA-C-N 115.222 -0.899 . . . . 0.35 110.866 173.527 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 32' ' ' ASP . . . . . 0.53 ' O ' ' HA ' ' A' ' 9' ' ' ARG . 25.6 t0 -84.19 117.32 68.41 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-O 121.296 0.57 . . . . 1.29 110.301 176.881 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 33' ' ' PRO . . . . . 0.733 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 2.5 Cg_endo -87.4 66.7 3.99 Favored 'Trans proline' 0 C--O 1.206 -1.112 0 C-N-CA 123.984 3.123 . . . . 1.1 113.793 -178.448 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.756 HD11 HG23 ' A' ' 10' ' ' ILE . 0.9 OUTLIER -66.23 151.53 46.81 Favored 'General case' 0 C--N 1.284 -2.276 0 C-N-CA 118.547 -1.261 . . . . 0.44 111.573 -174.774 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 35' ' ' GLU . . . . . 0.682 ' O ' ' HA ' ' B' ' 46' ' ' LEU . 66.1 tt0 -103.53 114.33 28.52 Favored 'General case' 0 CA--C 1.493 -1.242 0 CA-C-N 114.686 -1.143 . . . . 1.1 108.011 -178.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 36' ' ' ILE . . . . . 0.85 ' HB ' HG23 ' A' ' 6' ' ' ILE . 2.6 mp -87.87 109.82 20.09 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.732 0 O-C-N 124.199 0.937 . . . . 0.62 109.598 -179.04 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 37' ' ' PHE . . . . . 0.583 ' HB3' ' H ' ' A' ' 5' ' ' GLY . 15.3 p90 -150.69 125.95 10.02 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 116.111 -0.495 . . . . 1.2 110.002 175.176 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 38' ' ' VAL . . . . . 0.573 ' HA ' ' HA ' ' B' ' 44' ' ' VAL . 0.8 OUTLIER -80.31 136.97 22.33 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 CA-C-O 121.125 0.488 . . . . 0.2 110.895 -178.19 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 39' ' ' ASP . . . . . 0.599 ' OD1' ' HD2' ' B' ' 40' ' ' ARG . 12.2 t70 -76.86 -64.75 1.05 Allowed 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 114.699 -1.137 . . . . 1.14 110.996 -175.213 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 40' ' ' ARG . . . . . 0.599 ' HD2' ' OD1' ' B' ' 39' ' ' ASP . 0.0 OUTLIER -117.73 -94.49 0.49 Allowed 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.682 -0.69 . . . . 2.71 112.204 -175.162 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 26.1 t70 -90.85 -70.47 0.68 Allowed 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.993 0.425 . . . . 1.32 111.21 -174.014 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 42' ' ' GLY . . . . . 0.623 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -134.28 24.22 3.59 Favored Glycine 0 N--CA 1.441 -0.996 0 C-N-CA 120.498 -0.858 . . . . 0.34 112.476 -177.555 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 43' ' ' GLU . . . . . 0.635 ' HA ' ' O ' ' A' ' 46' ' ' LEU . 1.1 mt-10 -97.04 107.86 20.47 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 109.434 -0.58 . . . . 2.07 109.434 175.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 44' ' ' VAL . . . . . 0.573 ' HA ' ' HA ' ' B' ' 38' ' ' VAL . 2.0 t -88.66 130.91 37.34 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 N-CA-C 109.587 -0.523 . . . . 0.13 109.587 178.18 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 45' ' ' ILE . . . . . 0.754 HG13 HG13 ' A' ' 45' ' ' ILE . 1.6 mp -106.45 121.33 58.9 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 N-CA-C 107.962 -1.125 . . . . 0.12 107.962 -177.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 46' ' ' LEU . . . . . 0.926 HD11 HD11 ' A' ' 46' ' ' LEU . 0.7 OUTLIER -111.59 116.27 30.54 Favored 'General case' 0 C--N 1.319 -0.731 0 O-C-N 123.876 0.735 . . . . 0.15 109.782 177.779 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 47' ' ' LYS . . . . . 0.544 ' HE3' ' HB3' ' B' ' 35' ' ' GLU . 0.0 OUTLIER -131.12 140.43 49.99 Favored 'General case' 0 C--O 1.213 -0.82 0 N-CA-C 113.402 0.89 . . . . 0.95 113.402 -178.684 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 48' ' ' LYS . . . . . 0.63 ' HE2' ' HG3' ' B' ' 51' ' ' PRO . 4.9 ptmt -38.2 -16.72 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.393 0 N-CA-C 118.747 2.869 . . . . 0.64 118.747 -168.175 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 49' ' ' TYR . . . . . 0.733 ' HB3' ' HB2' ' B' ' 33' ' ' PRO . 39.5 t80 72.32 -51.51 0.7 Allowed 'General case' 0 N--CA 1.485 1.309 0 CA-C-N 119.241 0.928 . . . . 1.26 113.247 176.481 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 50' ' ' SER . . . . . 0.449 ' OG ' ' HD3' ' B' ' 51' ' ' PRO . 1.4 p -51.7 -51.5 69.51 Favored Pre-proline 0 CA--C 1.541 0.613 0 CA-C-N 116.069 -0.514 . . . . 1.22 112.051 -172.581 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 51' ' ' PRO . . . . . 0.63 ' HG3' ' HE2' ' B' ' 48' ' ' LYS . 24.2 Cg_endo -95.42 16.41 0.91 Allowed 'Trans proline' 0 C--N 1.351 0.687 0 C-N-CA 122.45 2.1 . . . . 0.56 111.582 167.735 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 52' ' ' ILE . . . . . . . . . . . . . 3.4 mt . . . . . 0 C--N 1.321 -0.641 0 N-CA-C 108.083 -1.08 . . . . 0.73 108.083 -170.566 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . 0.422 ' HA ' ' HB2' ' B' ' 37' ' ' PHE . . . . . . . . 0 C--O 1.232 0.144 0 CA-C-O 121.865 0.841 . . . . 0.72 112.723 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.828 ' H ' ' HB2' ' B' ' 37' ' ' PHE . 19.2 p -130.84 -54.86 1.06 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 114.792 -1.095 . . . . 0.41 110.458 179.052 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 84.58 54.06 3.05 Favored Glycine 0 N--CA 1.446 -0.654 0 C-N-CA 120.434 -0.888 . . . . 0.32 112.458 173.319 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.902 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.6 tp -108.84 108.96 26.6 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 N-CA-C 109.404 -0.591 . . . . 0.31 109.404 171.235 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.757 HG21 ' CD1' ' B' ' 49' ' ' TYR . 36.5 t -83.0 135.92 23.85 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-O 120.905 0.383 . . . . 0.28 111.286 -179.435 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.528 ' HB3' HD11 ' B' ' 36' ' ' ILE . 5.3 tpt180 -129.63 114.79 16.47 Favored 'General case' 0 N--CA 1.446 -0.642 0 N-CA-C 107.85 -1.167 . . . . 1.99 107.85 -176.771 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' ARG . . . . . 0.722 HH11 ' HG3' ' B' ' 33' ' ' PRO . 3.7 tpp180 -81.73 103.43 11.42 Favored 'General case' 0 CA--C 1.509 -0.618 0 N-CA-C 108.047 -1.094 . . . . 2.8 108.047 174.19 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.662 ' O ' ' HB3' ' A' ' 11' ' ' ASP . 0.2 OUTLIER -14.5 -106.61 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.039 0 O-C-N 125.7 1.875 . . . . 0.33 114.367 -176.295 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . 0.662 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 4.6 p-10 158.86 -169.06 0.0 OUTLIER 'General case' 0 CA--C 1.511 -0.547 0 N-CA-C 107.917 -1.142 . . . . 1.13 107.917 175.23 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -70.61 -8.92 55.25 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.952 0.406 . . . . 2.26 111.086 -178.686 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.403 HD12 HG13 ' B' ' 17' ' ' VAL . 1.6 tm? -107.82 -62.14 1.48 Allowed 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.763 -0.458 . . . . 0.53 109.763 175.205 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 134.36 22.34 0.71 Allowed Glycine 0 N--CA 1.445 -0.75 0 C-N-CA 120.455 -0.878 . . . . 0.22 113.264 179.288 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.566 ' HB3' ' HB3' ' B' ' 15' ' ' ARG . 1.5 mpt_? -80.99 150.44 28.91 Favored 'General case' 0 CA--C 1.51 -0.588 0 O-C-N 121.913 -0.757 . . . . 0.69 110.813 -179.885 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.597 HG21 HD13 ' B' ' 46' ' ' LEU . 70.9 t -109.91 98.78 7.49 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.284 0 N-CA-C 107.581 -1.266 . . . . 1.24 107.581 168.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.554 ' HA ' ' HA ' ' B' ' 15' ' ' ARG . 61.7 t -67.25 101.66 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 CA-C-N 115.501 -0.772 . . . . 0.28 109.577 -176.138 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.611 HG23 HD13 ' A' ' 22' ' ' ILE . 8.5 mt -93.55 111.77 53.8 Favored Pre-proline 0 C--N 1.322 -0.6 0 CA-C-N 116.022 -0.536 . . . . 0.77 110.72 -177.836 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.687 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 95.7 Cg_exo -50.31 152.51 8.26 Favored 'Trans proline' 0 N--CA 1.458 -0.579 0 C-N-CA 122.944 2.429 . . . . 0.32 112.893 173.963 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.825 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -67.24 -14.26 62.74 Favored 'General case' 0 C--O 1.21 -0.988 0 CA-C-N 115.668 -0.696 . . . . 1.57 111.237 -179.851 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.687 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 15.4 pt-20 -62.65 -25.36 68.09 Favored 'General case' 0 C--O 1.238 0.495 0 CA-C-O 120.88 0.372 . . . . 1.32 111.752 -179.322 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.611 HD13 HG23 ' A' ' 18' ' ' ILE . 5.3 mp -86.63 -47.17 16.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 108.257 -1.016 . . . . 0.35 108.257 -177.72 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . 0.639 ' HA ' ' HB2' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -61.12 -27.19 68.2 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.172 -0.922 . . . . 1.5 109.038 174.043 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 38.8 ttp180 -64.27 -52.29 59.36 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 114.829 -1.078 . . . . 2.96 110.564 175.088 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 21.7 m -63.93 -28.18 69.65 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-O 121.154 0.502 . . . . 0.4 110.992 174.28 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.639 ' HB2' ' HA ' ' A' ' 23' ' ' ARG . 2.4 mm? -64.05 -19.99 65.61 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.795 -0.639 . . . . 0.36 110.043 172.636 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.408 HH11 ' HD3' ' A' ' 27' ' ' ARG . 0.2 OUTLIER 71.44 22.26 4.27 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.01 -0.995 . . . . 3.2 110.105 -177.609 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.782 HG22 ' H ' ' A' ' 29' ' ' ARG . 6.1 mt -121.03 -167.35 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.674 0 CA-C-N 115.155 -0.93 . . . . 0.48 109.118 -177.424 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.782 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.3 OUTLIER -146.01 -156.47 0.71 Allowed 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 118.037 0.38 . . . . 2.4 111.943 -174.335 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -72.86 48.6 0.21 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 122.197 0.998 . . . . 1.23 111.904 -179.214 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.684 ' N ' HD11 ' B' ' 10' ' ' ILE . . . -166.14 24.9 0.15 Allowed Glycine 0 N--CA 1.443 -0.876 0 CA-C-N 113.804 -1.544 . . . . 0.36 109.863 174.69 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.494 ' O ' HG13 ' B' ' 10' ' ' ILE . 19.8 t0 -87.67 127.63 57.54 Favored Pre-proline 0 CA--C 1.516 -0.348 0 CA-C-N 114.771 -0.715 . . . . 1.26 109.377 174.883 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.712 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 3.8 Cg_endo -82.36 154.31 16.27 Favored 'Trans proline' 0 N--CA 1.438 -1.773 0 C-N-CA 122.26 1.973 . . . . 1.3 110.676 174.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.739 ' O ' ' HA ' ' B' ' 7' ' ' VAL . 0.5 OUTLIER -142.68 149.62 39.09 Favored 'General case' 0 C--N 1.307 -1.262 0 C-N-CA 120.133 -0.627 . . . . 0.38 109.507 172.688 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.949 ' HB3' ' HD2' ' A' ' 47' ' ' LYS . 38.1 tt0 -108.55 111.1 22.77 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 108.524 -0.917 . . . . 1.12 108.524 -176.182 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 1.033 HG13 HD22 ' A' ' 46' ' ' LEU . 2.2 mp -85.85 109.48 18.58 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.794 0 O-C-N 124.972 1.42 . . . . 0.39 109.211 -176.239 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' PHE . . . . . 0.967 ' HD2' ' HA ' ' B' ' 3' ' ' ALA . 0.5 OUTLIER -149.37 124.72 10.23 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 115.683 -0.69 . . . . 1.15 109.431 177.736 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.538 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 2.0 p -80.52 133.08 30.25 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.953 0 CA-C-O 121.214 0.53 . . . . 0.17 110.566 -179.221 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.522 ' HB3' ' HG2' ' A' ' 40' ' ' ARG . 27.2 t0 -81.21 -58.07 3.22 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 114.154 -1.385 . . . . 1.11 111.453 -174.447 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . 0.567 ' HG3' ' HG3' ' A' ' 43' ' ' GLU . 1.3 ptm180 -125.6 -99.52 0.4 Allowed 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.134 -0.939 . . . . 2.29 112.74 -166.086 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 34.7 t70 -84.11 -75.67 0.33 Allowed 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.168 0.508 . . . . 1.53 110.757 -175.735 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.491 ' HA3' HD11 ' B' ' 26' ' ' LEU . . . -135.11 24.88 3.38 Favored Glycine 0 N--CA 1.441 -0.979 0 CA-C-N 115.534 -0.757 . . . . 0.32 111.313 178.735 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.633 ' HB3' HG23 ' B' ' 45' ' ' ILE . 2.1 mt-10 -93.6 109.91 21.53 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.048 -0.723 . . . . 1.97 109.048 178.473 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.538 ' HA ' ' HA ' ' A' ' 38' ' ' VAL . 1.5 t -90.41 130.51 39.53 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 N-CA-C 109.22 -0.659 . . . . 0.14 109.22 178.015 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.74 HG13 HG13 ' B' ' 45' ' ' ILE . 1.5 mp -108.79 117.91 55.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 N-CA-C 108.456 -0.942 . . . . 0.14 108.456 -175.595 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 1.049 HD11 HD11 ' B' ' 46' ' ' LEU . 0.3 OUTLIER -109.7 115.16 29.35 Favored 'General case' 0 C--N 1.314 -0.939 0 N-CA-C 108.743 -0.836 . . . . 0.23 108.743 176.936 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.949 ' HD2' ' HB3' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -123.11 151.26 42.24 Favored 'General case' 0 C--O 1.215 -0.74 0 C-N-CA 118.808 -1.157 . . . . 0.76 111.99 179.594 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.659 ' HA ' ' O ' ' A' ' 33' ' ' PRO . 2.0 ptmt -42.12 -16.78 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.93 0 N-CA-C 117.377 2.362 . . . . 0.32 117.377 -168.058 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 0.735 ' CD1' HG21 ' B' ' 7' ' ' VAL . 23.0 t80 73.19 -53.87 0.7 Allowed 'General case' 0 N--CA 1.473 0.676 0 CA-C-N 118.321 0.509 . . . . 1.28 112.301 174.101 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.7 ' OG ' ' HD3' ' A' ' 51' ' ' PRO . 4.3 p -54.07 -44.42 98.36 Favored Pre-proline 0 CA--C 1.543 0.676 0 CA-C-N 116.131 -0.486 . . . . 1.36 111.804 -175.378 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.7 ' HD3' ' OG ' ' A' ' 50' ' ' SER . 94.5 Cg_endo -102.29 21.44 0.17 Allowed 'Trans proline' 0 N--CA 1.452 -0.969 0 C-N-CA 123.082 2.521 . . . . 0.58 111.75 168.164 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.235 0.328 0 CA-C-N 115.78 -0.645 . . . . 0.78 110.347 -176.751 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 3' ' ' ALA . . . . . 0.967 ' HA ' ' HD2' ' A' ' 37' ' ' PHE . . . . . . . . 0 N--CA 1.472 0.651 0 N-CA-C 109.147 -0.686 . . . . 0.86 109.147 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 4' ' ' THR . . . . . 0.735 ' H ' ' HB2' ' A' ' 37' ' ' PHE . 2.1 p -152.7 -47.86 0.1 Allowed 'General case' 0 C--N 1.324 -0.52 0 O-C-N 123.671 0.607 . . . . 0.43 109.563 174.083 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 72.53 53.1 8.93 Favored Glycine 0 N--CA 1.452 -0.254 0 CA-C-N 114.989 -1.005 . . . . 0.33 113.134 171.256 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 6' ' ' ILE . . . . . 0.855 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.3 tp -109.13 112.18 39.37 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.801 0 N-CA-C 109.124 -0.695 . . . . 0.3 109.124 171.895 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . 0.739 ' HA ' ' O ' ' A' ' 34' ' ' LEU . 39.7 t -84.4 136.03 23.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-O 120.94 0.4 . . . . 0.27 110.974 -179.501 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . 0.573 ' CZ ' HG23 ' B' ' 17' ' ' VAL . 1.4 tpt180 -129.61 114.71 16.38 Favored 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 107.665 -1.235 . . . . 1.69 107.665 -178.603 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 9' ' ' ARG . . . . . 0.534 ' HA ' ' HA ' ' A' ' 33' ' ' PRO . 0.0 OUTLIER -80.81 103.06 10.39 Favored 'General case' 0 CA--C 1.51 -0.582 0 N-CA-C 107.933 -1.136 . . . . 2.71 107.933 173.903 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 10' ' ' ILE . . . . . 0.684 HD11 ' N ' ' A' ' 31' ' ' GLY . 0.2 OUTLIER -13.54 -105.54 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.085 0 O-C-N 125.611 1.82 . . . . 0.34 114.509 -176.627 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . 0.493 ' H ' HD13 ' B' ' 10' ' ' ILE . 34.8 p30 156.99 -160.71 0.0 OUTLIER 'General case' 0 CA--C 1.508 -0.637 0 C-N-CA 124.379 1.072 . . . . 1.18 108.25 171.735 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -71.96 -8.29 53.63 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 121.085 0.469 . . . . 2.39 110.766 -176.81 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 13' ' ' LEU . . . . . 0.408 HD12 HG13 ' A' ' 17' ' ' VAL . 2.1 tm? -114.72 -57.97 2.2 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.343 -0.39 . . . . 0.4 109.973 -179.8 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 133.03 17.42 1.15 Allowed Glycine 0 N--CA 1.441 -0.967 0 C-N-CA 120.595 -0.812 . . . . 0.21 113.784 179.532 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 15' ' ' ARG . . . . . 0.566 ' HB3' ' HB3' ' A' ' 15' ' ' ARG . 0.2 OUTLIER -81.5 150.52 28.22 Favored 'General case' 0 CA--C 1.507 -0.694 0 CA-C-N 118.764 1.282 . . . . 0.9 110.962 -179.256 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 16' ' ' VAL . . . . . 0.542 HG21 HD13 ' A' ' 46' ' ' LEU . 98.2 t -108.98 100.72 11.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 CA-C-N 114.318 -1.31 . . . . 1.27 107.549 171.064 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 17' ' ' VAL . . . . . 0.573 HG23 ' CZ ' ' B' ' 8' ' ' ARG . 37.8 t -69.54 103.21 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.078 0 CA-C-N 115.832 -0.622 . . . . 0.27 109.654 -174.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . 0.478 HD11 HD12 ' B' ' 46' ' ' LEU . 6.8 mt -91.98 112.39 54.61 Favored Pre-proline 0 N--CA 1.446 -0.647 0 CA-C-O 121.477 0.656 . . . . 0.82 110.981 -177.768 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 19' ' ' PRO . . . . . 0.696 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 67.7 Cg_exo -49.1 142.9 19.6 Favored 'Trans proline' 0 N--CA 1.46 -0.484 0 C-N-CA 123.379 2.719 . . . . 0.3 112.456 171.511 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 20' ' ' LYS . . . . . 0.987 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -61.36 -15.1 32.82 Favored 'General case' 0 C--O 1.211 -0.938 0 CA-C-N 115.313 -0.858 . . . . 1.77 111.4 179.525 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . 0.696 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 10.0 pt-20 -63.37 -22.84 67.12 Favored 'General case' 0 C--O 1.238 0.486 0 N-CA-C 112.117 0.414 . . . . 1.92 112.117 179.625 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 22' ' ' ILE . . . . . 0.402 HD13 HG23 ' B' ' 18' ' ' ILE . 5.3 mp -87.09 -47.97 15.68 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 N-CA-C 108.61 -0.885 . . . . 0.44 108.61 -179.371 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 23' ' ' ARG . . . . . 0.586 ' HA ' ' HB2' ' B' ' 26' ' ' LEU . 0.0 OUTLIER -60.06 -27.98 67.42 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.356 -0.838 . . . . 1.4 109.27 173.234 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 24' ' ' ARG . . . . . . . . . . . . . 43.5 ttp180 -65.45 -52.76 50.83 Favored 'General case' 0 N--CA 1.446 -0.654 0 CA-C-N 114.676 -1.147 . . . . 3.19 110.683 175.7 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 21.3 m -64.77 -26.67 68.45 Favored 'General case' 0 N--CA 1.449 -0.508 0 CA-C-O 121.355 0.597 . . . . 0.4 110.667 175.421 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . 0.586 ' HB2' ' HA ' ' B' ' 23' ' ' ARG . 1.7 mm? -64.85 -18.97 65.61 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.46 -0.791 . . . . 0.33 110.59 173.754 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 27' ' ' ARG . . . . . . . . . . . . . 19.6 tpt180 74.4 22.32 2.19 Favored 'General case' 0 C--N 1.34 0.166 0 O-C-N 124.136 0.897 . . . . 3.28 109.772 -178.034 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 28' ' ' ILE . . . . . 0.896 HG22 ' H ' ' B' ' 29' ' ' ARG . 6.6 mt -123.28 -163.19 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.343 -0.844 . . . . 0.37 110.287 -174.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 29' ' ' ARG . . . . . 0.896 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -152.44 -159.31 0.99 Allowed 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 112.025 0.379 . . . . 2.15 112.025 -170.392 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 30' ' ' GLU . . . . . 0.467 ' H ' ' HB2' ' B' ' 29' ' ' ARG . 0.9 OUTLIER -73.92 36.94 0.1 Allowed 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 121.849 0.833 . . . . 1.18 111.961 -177.464 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 31' ' ' GLY . . . . . 0.576 ' CA ' HD11 ' A' ' 10' ' ' ILE . . . -153.93 30.42 0.74 Allowed Glycine 0 N--CA 1.442 -0.93 0 N-CA-C 109.757 -1.337 . . . . 0.35 109.757 171.658 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 32' ' ' ASP . . . . . 0.505 ' HB2' ' CG2' ' B' ' 28' ' ' ILE . 12.3 t70 -86.7 128.78 55.2 Favored Pre-proline 0 C--N 1.324 -0.543 0 CA-C-N 114.81 -0.695 . . . . 1.29 109.948 174.197 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 33' ' ' PRO . . . . . 0.754 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 10.3 Cg_endo -84.88 148.93 10.9 Favored 'Trans proline' 0 N--CA 1.435 -1.919 0 C-N-CA 122.402 2.068 . . . . 1.1 110.785 173.474 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.717 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.7 OUTLIER -137.55 148.63 46.09 Favored 'General case' 0 C--N 1.302 -1.471 0 N-CA-C 109.631 -0.507 . . . . 0.44 109.631 173.64 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 35' ' ' GLU . . . . . 0.708 ' O ' ' HA ' ' B' ' 46' ' ' LEU . 46.8 tt0 -105.16 111.74 24.6 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 107.9 -1.148 . . . . 1.1 107.9 -178.178 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 36' ' ' ILE . . . . . 1.107 HG13 HD22 ' B' ' 46' ' ' LEU . 3.0 mp -86.73 109.86 19.53 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.943 0 O-C-N 124.417 1.073 . . . . 0.62 109.06 -178.604 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 37' ' ' PHE . . . . . 0.828 ' HB2' ' H ' ' A' ' 4' ' ' THR . 12.1 p90 -151.0 131.97 14.25 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 116.158 -0.474 . . . . 1.2 109.966 174.796 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 38' ' ' VAL . . . . . 0.514 ' HA ' ' HA ' ' B' ' 44' ' ' VAL . 1.9 p -80.08 142.33 14.07 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.01 0 CA-C-O 120.949 0.404 . . . . 0.2 110.352 -178.584 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 39' ' ' ASP . . . . . 0.458 ' HB2' ' CD1' ' B' ' 45' ' ' ILE . 25.8 t0 -92.08 -47.52 7.22 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.556 -0.747 . . . . 1.14 111.618 -175.026 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 40' ' ' ARG . . . . . 0.559 ' HG3' ' HG3' ' B' ' 43' ' ' GLU . 0.0 OUTLIER -134.08 -100.82 0.25 Allowed 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 112.767 0.655 . . . . 2.71 112.767 -168.12 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 25.1 t70 -83.09 -71.92 0.47 Allowed 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.422 0.63 . . . . 1.32 110.767 -176.182 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 42' ' ' GLY . . . . . 0.482 ' HA3' ' HD2' ' A' ' 48' ' ' LYS . . . -139.73 25.77 2.68 Favored Glycine 0 CA--C 1.501 -0.801 0 CA-C-N 115.41 -0.814 . . . . 0.34 111.179 178.868 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 43' ' ' GLU . . . . . 0.559 ' HG3' ' HG3' ' B' ' 40' ' ' ARG . 2.7 mt-10 -92.72 109.15 20.57 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 109.226 -0.657 . . . . 2.07 109.226 178.629 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 44' ' ' VAL . . . . . 0.514 ' HA ' ' HA ' ' B' ' 38' ' ' VAL . 1.7 t -89.13 130.48 38.41 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 N-CA-C 109.122 -0.696 . . . . 0.13 109.122 178.09 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 45' ' ' ILE . . . . . 0.74 HG13 HG13 ' A' ' 45' ' ' ILE . 1.7 mp -108.19 118.85 56.68 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 N-CA-C 108.138 -1.06 . . . . 0.12 108.138 -176.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 46' ' ' LEU . . . . . 1.107 HD22 HG13 ' B' ' 36' ' ' ILE . 0.5 OUTLIER -110.26 115.77 30.3 Favored 'General case' 0 C--N 1.317 -0.847 0 N-CA-C 108.819 -0.808 . . . . 0.15 108.819 176.648 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 47' ' ' LYS . . . . . 0.537 ' O ' ' HA ' ' B' ' 34' ' ' LEU . 0.0 OUTLIER -126.57 149.99 49.1 Favored 'General case' 0 C--N 1.317 -0.847 0 C-N-CA 119.178 -1.009 . . . . 0.95 112.626 -177.724 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 48' ' ' LYS . . . . . 0.684 ' HE2' ' HG3' ' B' ' 51' ' ' PRO . 3.4 ptmt -41.7 -14.18 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.064 0 N-CA-C 118.007 2.595 . . . . 0.64 118.007 -167.643 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 49' ' ' TYR . . . . . 0.757 ' CD1' HG21 ' A' ' 7' ' ' VAL . 30.9 t80 72.41 -56.62 0.65 Allowed 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 113.004 0.742 . . . . 1.26 113.004 173.145 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 50' ' ' SER . . . . . 0.718 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 8.3 t -52.28 -52.7 60.27 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.26 -0.427 . . . . 1.22 110.778 -174.031 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 51' ' ' PRO . . . . . 0.718 ' HD3' ' HB3' ' B' ' 50' ' ' SER . 47.2 Cg_endo -92.33 14.29 1.74 Allowed 'Trans proline' 0 N--CA 1.454 -0.806 0 C-N-CA 122.155 1.903 . . . . 0.56 111.84 170.421 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 52' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.328 -0.34 0 CA-C-N 115.52 -0.764 . . . . 0.73 109.76 -177.184 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . 0.59 ' HA ' ' HD2' ' B' ' 37' ' ' PHE . . . . . . . . 0 C--O 1.232 0.153 0 CA-C-O 121.552 0.691 . . . . 0.72 111.844 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.542 ' OG1' ' HA ' ' B' ' 37' ' ' PHE . 11.7 p -97.05 -45.76 6.44 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.547 -0.752 . . . . 0.41 111.602 -179.4 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 70.51 48.93 33.78 Favored Glycine 0 N--CA 1.443 -0.866 0 C-N-CA 120.58 -0.819 . . . . 0.32 112.919 174.155 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.783 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.0 OUTLIER -104.94 113.1 41.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 N-CA-C 108.407 -0.96 . . . . 0.31 108.407 173.997 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.755 HG21 ' CD1' ' B' ' 49' ' ' TYR . 28.3 t -83.58 134.65 26.47 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-O 121.211 0.529 . . . . 0.28 110.94 -178.319 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.593 ' HB3' ' CD1' ' B' ' 36' ' ' ILE . 9.0 tpp180 -131.0 119.54 22.2 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 107.818 -1.178 . . . . 1.99 107.818 -176.583 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' ARG . . . . . 0.452 ' N ' ' HD3' ' A' ' 8' ' ' ARG . 44.8 ttp180 -79.27 108.36 12.72 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 108.613 -0.884 . . . . 2.8 108.613 170.713 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.832 HG23 HD11 ' B' ' 34' ' ' LEU . 0.2 OUTLIER -16.19 -102.65 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 O-C-N 125.593 1.808 . . . . 0.33 114.492 -177.724 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . 0.606 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 3.1 p-10 162.89 -160.92 0.0 OUTLIER 'General case' 0 CA--C 1.509 -0.602 0 N-CA-C 107.826 -1.176 . . . . 1.13 107.826 175.542 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 25.0 m-20 -70.72 -22.09 62.47 Favored 'General case' 0 C--N 1.321 -0.663 0 O-C-N 123.384 0.428 . . . . 2.26 110.812 -178.78 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.459 HD22 ' HE2' ' B' ' 20' ' ' LYS . 3.0 tm? -102.88 -61.46 1.4 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.27 -0.423 . . . . 0.53 110.305 179.682 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.524 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 144.48 16.65 0.21 Allowed Glycine 0 N--CA 1.442 -0.93 0 C-N-CA 120.768 -0.729 . . . . 0.22 112.513 -178.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.553 ' HB3' ' HB3' ' B' ' 15' ' ' ARG . 2.8 mpt_? -71.5 145.84 48.92 Favored 'General case' 0 CA--C 1.504 -0.793 0 CA-C-O 121.522 0.677 . . . . 0.69 110.456 -179.278 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.82 HG21 HD13 ' B' ' 46' ' ' LEU . 97.5 t -103.76 94.08 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.53 0 N-CA-C 107.146 -1.427 . . . . 1.24 107.146 168.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.552 ' HA ' ' HA ' ' B' ' 15' ' ' ARG . 59.7 t -67.22 97.62 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.844 0 CA-C-N 114.891 -1.049 . . . . 0.28 110.137 -172.809 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.716 HG23 HD13 ' A' ' 22' ' ' ILE . 17.4 mt -98.54 111.23 59.59 Favored Pre-proline 0 C--N 1.326 -0.45 0 CA-C-N 115.594 -0.73 . . . . 0.77 111.11 -175.6 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.783 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 48.6 Cg_exo -46.74 150.41 2.55 Favored 'Trans proline' 0 N--CA 1.458 -0.577 0 C-N-CA 123.183 2.588 . . . . 0.32 113.859 175.041 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.944 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -64.49 -12.62 45.93 Favored 'General case' 0 C--O 1.207 -1.176 0 CA-C-N 115.164 -0.926 . . . . 1.57 111.219 176.61 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.783 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 12.7 pt-20 -64.88 -22.62 67.03 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 118.436 0.562 . . . . 1.32 111.246 176.372 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.716 HD13 HG23 ' A' ' 18' ' ' ILE . 5.1 mp -88.06 -44.31 15.72 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.404 0 N-CA-C 108.889 -0.782 . . . . 0.35 108.889 179.167 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . 0.72 ' HG3' ' HA ' ' A' ' 20' ' ' LYS . 1.1 ppt_? -61.12 -26.25 67.54 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 122.284 1.04 . . . . 1.5 108.636 172.05 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.534 ' HB3' ' O ' ' A' ' 21' ' ' GLU . 32.0 ttt180 -64.03 -52.37 59.77 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 113.741 -1.572 . . . . 2.96 110.628 174.914 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 40.3 m -62.73 -30.35 71.36 Favored 'General case' 0 N--CA 1.455 -0.223 0 CA-C-O 121.062 0.458 . . . . 0.4 110.995 172.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.616 ' HB2' ' HA ' ' A' ' 23' ' ' ARG . 2.6 mm? -63.49 -18.98 64.35 Favored 'General case' 0 CA--C 1.519 -0.23 0 CA-C-N 115.952 -0.567 . . . . 0.36 109.94 174.662 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.413 HH11 ' HD2' ' A' ' 27' ' ' ARG . 11.3 mmt180 67.69 23.38 8.7 Favored 'General case' 0 N--CA 1.451 -0.408 0 CA-C-N 115.277 -0.874 . . . . 3.2 109.915 -178.079 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.838 HG22 ' H ' ' A' ' 29' ' ' ARG . 11.8 mt -124.32 -167.61 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 CA-C-N 114.479 -1.237 . . . . 0.48 108.161 -178.161 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.838 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.2 OUTLIER -142.63 -158.55 0.88 Allowed 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 118.403 0.547 . . . . 2.4 112.116 -175.464 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 5.7 mp0 -72.9 47.19 0.18 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 122.221 1.01 . . . . 1.23 111.942 -179.514 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.661 ' N ' HD11 ' B' ' 10' ' ' ILE . . . -163.08 24.91 0.2 Allowed Glycine 0 N--CA 1.445 -0.71 0 CA-C-N 113.801 -1.545 . . . . 0.36 109.867 175.115 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.47 ' O ' HG13 ' B' ' 10' ' ' ILE . 18.1 t0 -87.97 130.81 45.07 Favored Pre-proline 0 CA--C 1.514 -0.423 0 CA-C-N 114.446 -0.877 . . . . 1.26 109.367 174.247 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.686 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 3.2 Cg_endo -82.32 153.44 16.15 Favored 'Trans proline' 0 N--CA 1.438 -1.762 0 C-N-CA 122.172 1.915 . . . . 1.3 110.634 174.668 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.846 HD11 HG23 ' B' ' 10' ' ' ILE . 0.5 OUTLIER -140.72 151.68 44.7 Favored 'General case' 0 N--CA 1.433 -1.319 0 C-N-CA 119.866 -0.734 . . . . 0.38 109.663 171.439 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.74 ' HB3' ' HD2' ' A' ' 47' ' ' LYS . 86.0 tt0 -105.13 111.31 24.03 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.606 -1.257 . . . . 1.12 107.606 -178.523 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 1.016 HG13 HD22 ' A' ' 46' ' ' LEU . 2.9 mp -87.14 109.01 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.744 0 O-C-N 124.722 1.263 . . . . 0.39 109.116 -178.893 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' PHE . . . . . 0.654 ' HD2' ' HA ' ' B' ' 3' ' ' ALA . 1.0 OUTLIER -149.23 127.72 12.3 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 115.987 -0.551 . . . . 1.15 109.835 176.833 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.463 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 1.3 p -81.81 132.49 31.35 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.999 0 CA-C-O 121.612 0.72 . . . . 0.17 110.657 -179.878 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.568 ' HB3' ' HG2' ' A' ' 40' ' ' ARG . 19.7 t70 -79.94 -49.89 11.22 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 114.236 -1.347 . . . . 1.11 111.672 -173.746 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . 0.568 ' HG2' ' HB3' ' A' ' 39' ' ' ASP . 1.7 ptm180 -133.65 -96.83 0.29 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.48 -0.782 . . . . 2.29 112.96 -167.069 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -88.6 -70.38 0.65 Allowed 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.089 0.471 . . . . 1.53 111.024 -174.311 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.432 ' O ' ' HA ' ' B' ' 47' ' ' LYS . . . -139.67 22.84 2.82 Favored Glycine 0 N--CA 1.445 -0.741 0 CA-C-N 115.596 -0.729 . . . . 0.32 111.279 -179.344 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.552 ' HB3' HG23 ' B' ' 45' ' ' ILE . 1.7 mt-10 -95.4 113.06 24.69 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 109.483 -0.562 . . . . 1.97 109.483 179.275 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.476 ' CG1' HG23 ' A' ' 36' ' ' ILE . 1.4 t -91.15 131.26 38.77 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 N-CA-C 109.425 -0.583 . . . . 0.14 109.425 177.182 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.804 HG13 HG13 ' B' ' 45' ' ' ILE . 1.6 mp -109.69 118.06 55.99 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 108.072 -1.084 . . . . 0.14 108.072 -176.568 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 1.031 HD11 HD11 ' B' ' 46' ' ' LEU . 0.3 OUTLIER -112.54 116.69 30.63 Favored 'General case' 0 C--N 1.315 -0.933 0 O-C-N 123.796 0.685 . . . . 0.23 109.467 178.813 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.74 ' HD2' ' HB3' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -127.64 153.59 46.26 Favored 'General case' 0 C--O 1.215 -0.722 0 C-N-CA 118.662 -1.215 . . . . 0.76 112.216 178.56 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.643 ' HG3' ' HG2' ' A' ' 51' ' ' PRO . 1.1 ptmt -41.24 -17.42 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.026 0 N-CA-C 117.497 2.406 . . . . 0.32 117.497 -168.88 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 0.808 ' CD1' HG21 ' B' ' 7' ' ' VAL . 17.4 t80 75.82 -53.59 0.63 Allowed 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 112.418 0.525 . . . . 1.28 112.418 173.379 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.677 ' HB3' ' HD3' ' A' ' 51' ' ' PRO . 8.3 t -51.57 -49.71 81.16 Favored Pre-proline 0 CA--C 1.538 0.498 0 CA-C-N 116.219 -0.446 . . . . 1.36 111.099 -177.184 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.677 ' HD3' ' HB3' ' A' ' 50' ' ' SER . 27.8 Cg_endo -93.82 9.12 2.25 Favored 'Trans proline' 0 N--CA 1.455 -0.749 0 C-N-CA 122.647 2.231 . . . . 0.58 111.663 171.706 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.434 HG13 ' C ' ' A' ' 51' ' ' PRO . 1.1 mt . . . . . 0 CA--C 1.532 0.255 0 CA-C-N 115.439 -0.8 . . . . 0.78 109.326 -175.038 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 3' ' ' ALA . . . . . 0.654 ' HA ' ' HD2' ' A' ' 37' ' ' PHE . . . . . . . . 0 C--O 1.233 0.208 0 CA-C-O 121.398 0.618 . . . . 0.86 111.303 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 4' ' ' THR . . . . . 0.531 ' OG1' ' HA ' ' A' ' 37' ' ' PHE . 7.5 p -94.73 -48.14 6.18 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.909 -0.587 . . . . 0.43 111.675 -179.174 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 72.24 48.33 25.7 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.939 -0.648 . . . . 0.33 112.976 174.84 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 6' ' ' ILE . . . . . 0.746 HG23 ' HB ' ' A' ' 36' ' ' ILE . 0.9 OUTLIER -106.11 112.1 37.95 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 N-CA-C 108.731 -0.84 . . . . 0.3 108.731 174.83 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . 0.808 HG21 ' CD1' ' A' ' 49' ' ' TYR . 35.2 t -83.56 136.66 22.35 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 CA-C-O 120.952 0.405 . . . . 0.27 111.167 -178.887 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . 0.514 ' HD3' ' N ' ' B' ' 9' ' ' ARG . 1.0 OUTLIER -133.17 123.77 26.25 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 107.296 -1.372 . . . . 1.69 107.296 179.128 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 9' ' ' ARG . . . . . 0.514 ' N ' ' HD3' ' B' ' 8' ' ' ARG . 0.1 OUTLIER -82.31 103.33 11.82 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 108.267 -1.012 . . . . 2.71 108.267 173.219 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 10' ' ' ILE . . . . . 0.846 HG23 HD11 ' A' ' 34' ' ' LEU . 0.2 OUTLIER -10.32 -106.02 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 O-C-N 125.444 1.715 . . . . 0.34 114.9 -176.746 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . 0.604 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 2.5 p-10 163.1 -168.29 0.01 OUTLIER 'General case' 0 CA--C 1.51 -0.575 0 N-CA-C 106.586 -1.635 . . . . 1.18 106.586 177.174 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 52.7 m-20 -77.06 -2.87 36.28 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 118.418 0.553 . . . . 2.39 110.995 -176.804 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 13' ' ' LEU . . . . . 0.425 ' H ' ' CG ' ' B' ' 11' ' ' ASP . 2.1 tm? -106.56 -61.8 1.48 Allowed 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.781 -0.645 . . . . 0.4 109.794 174.689 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 138.14 17.01 0.63 Allowed Glycine 0 N--CA 1.445 -0.722 0 CA-C-N 115.947 -0.57 . . . . 0.21 112.093 -176.869 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 15' ' ' ARG . . . . . 0.553 ' HB3' ' HB3' ' A' ' 15' ' ' ARG . 1.6 mpt_? -70.36 143.1 52.04 Favored 'General case' 0 CA--C 1.506 -0.724 0 CA-C-O 121.536 0.684 . . . . 0.9 110.481 -179.718 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 16' ' ' VAL . . . . . 0.715 HG21 HD13 ' A' ' 46' ' ' LEU . 81.1 t -104.69 94.34 3.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 N-CA-C 107.343 -1.354 . . . . 1.27 107.343 167.465 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 17' ' ' VAL . . . . . 0.528 HG22 ' HG2' ' A' ' 15' ' ' ARG . 40.8 t -67.13 98.49 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-N 115.188 -0.915 . . . . 0.27 110.169 -171.1 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . 0.524 ' HB ' ' O ' ' A' ' 14' ' ' GLY . 11.4 mt -96.75 112.74 61.26 Favored Pre-proline 0 N--CA 1.447 -0.58 0 CA-C-N 115.535 -0.757 . . . . 0.82 110.932 -177.477 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 19' ' ' PRO . . . . . 0.621 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 85.6 Cg_exo -51.67 154.31 9.54 Favored 'Trans proline' 0 N--CA 1.456 -0.68 0 C-N-CA 122.626 2.217 . . . . 0.3 113.508 173.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 20' ' ' LYS . . . . . 0.783 ' HA ' ' HG3' ' B' ' 23' ' ' ARG . 0.0 OUTLIER -68.37 -13.37 62.24 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-N 114.828 -1.078 . . . . 1.77 111.1 178.384 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . 0.621 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 9.8 pt-20 -66.36 -20.24 66.03 Favored 'General case' 0 C--N 1.322 -0.595 0 C-N-CA 120.327 -0.549 . . . . 1.92 111.568 176.141 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 22' ' ' ILE . . . . . 0.49 HD13 HG23 ' B' ' 18' ' ' ILE . 5.4 mp -88.56 -45.21 15.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 N-CA-C 108.863 -0.791 . . . . 0.44 108.863 177.265 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 23' ' ' ARG . . . . . 0.783 ' HG3' ' HA ' ' B' ' 20' ' ' LYS . 0.3 OUTLIER -59.92 -25.11 64.88 Favored 'General case' 0 N--CA 1.472 0.636 0 CA-C-O 121.989 0.899 . . . . 1.4 108.789 171.996 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 24' ' ' ARG . . . . . 0.429 ' HB3' ' O ' ' B' ' 21' ' ' GLU . 35.3 ttm180 -65.17 -52.52 54.49 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 114.018 -1.446 . . . . 3.19 110.971 174.012 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 31.7 m -63.08 -29.16 70.59 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 120.54 -0.464 . . . . 0.4 110.906 173.756 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . 0.581 ' HB2' ' HA ' ' B' ' 23' ' ' ARG . 2.6 mm? -63.34 -20.05 65.17 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.947 -0.57 . . . . 0.33 110.057 174.337 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 27' ' ' ARG . . . . . 0.414 ' HA ' ' HD3' ' B' ' 27' ' ' ARG . 25.0 mmt180 68.11 24.72 7.62 Favored 'General case' 0 N--CA 1.453 -0.306 0 CA-C-N 115.286 -0.87 . . . . 3.28 109.904 -177.381 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 28' ' ' ILE . . . . . 0.901 HG22 ' H ' ' B' ' 29' ' ' ARG . 12.6 mt -125.17 -161.43 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 114.793 -1.094 . . . . 0.37 109.294 -177.243 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 29' ' ' ARG . . . . . 0.901 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.1 OUTLIER -149.41 -160.79 1.22 Allowed 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 112.144 0.424 . . . . 2.15 112.144 -173.123 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 30' ' ' GLU . . . . . 0.428 ' N ' ' HD2' ' B' ' 29' ' ' ARG . 3.2 mp0 -71.12 37.82 0.05 Allowed 'General case' 0 N--CA 1.464 0.232 0 CA-C-O 121.523 0.677 . . . . 1.18 112.55 -178.629 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 31' ' ' GLY . . . . . 0.586 ' N ' HD11 ' A' ' 10' ' ' ILE . . . -152.03 18.5 0.84 Allowed Glycine 0 N--CA 1.443 -0.884 0 N-CA-C 110.339 -1.104 . . . . 0.35 110.339 173.469 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 32' ' ' ASP . . . . . 0.487 ' O ' HG13 ' A' ' 10' ' ' ILE . 18.3 t70 -78.32 129.14 75.93 Favored Pre-proline 0 C--N 1.326 -0.433 0 CA-C-N 115.054 -0.573 . . . . 1.29 109.595 174.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 33' ' ' PRO . . . . . 0.721 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 5.1 Cg_endo -82.16 150.05 15.55 Favored 'Trans proline' 0 N--CA 1.436 -1.853 0 C-N-CA 122.586 2.191 . . . . 1.1 110.697 173.242 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.832 HD11 HG23 ' A' ' 10' ' ' ILE . 0.7 OUTLIER -136.85 150.66 48.42 Favored 'General case' 0 C--N 1.306 -1.304 0 N-CA-C 109.674 -0.491 . . . . 0.44 109.674 173.693 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 35' ' ' GLU . . . . . 0.766 ' O ' ' HA ' ' B' ' 46' ' ' LEU . 38.0 tt0 -105.31 112.92 26.21 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 107.577 -1.268 . . . . 1.1 107.577 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 36' ' ' ILE . . . . . 0.981 HG13 HD22 ' B' ' 46' ' ' LEU . 3.3 mp -89.12 109.85 20.77 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 O-C-N 124.878 1.361 . . . . 0.62 109.198 -178.807 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 37' ' ' PHE . . . . . 0.905 ' HE1' ' HZ1' ' B' ' 47' ' ' LYS . 2.1 p90 -149.28 131.33 15.33 Favored 'General case' 0 C--N 1.317 -0.835 0 N-CA-C 109.694 -0.484 . . . . 1.2 109.694 175.013 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 38' ' ' VAL . . . . . 0.449 ' HA ' ' HA ' ' B' ' 44' ' ' VAL . 1.2 p -82.09 135.38 25.05 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 CA-C-O 121.367 0.603 . . . . 0.2 110.852 179.753 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 39' ' ' ASP . . . . . 0.465 ' HB2' ' CD1' ' B' ' 45' ' ' ILE . 35.8 t70 -81.07 -50.74 9.28 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 114.354 -1.294 . . . . 1.14 111.255 -174.675 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 40' ' ' ARG . . . . . 0.547 ' HD3' ' OE1' ' B' ' 43' ' ' GLU . 0.9 OUTLIER -134.22 -105.04 0.23 Allowed 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.908 -0.587 . . . . 2.71 112.347 -169.937 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 24.0 t70 -78.19 -70.48 0.48 Allowed 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.086 0.47 . . . . 1.32 111.362 -176.354 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 42' ' ' GLY . . . . . 0.441 ' HA3' ' HD2' ' A' ' 48' ' ' LYS . . . -139.72 25.17 2.71 Favored Glycine 0 N--CA 1.442 -0.906 0 C-N-CA 120.449 -0.881 . . . . 0.34 111.978 -177.933 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 43' ' ' GLU . . . . . 0.555 ' HB3' HG23 ' A' ' 45' ' ' ILE . 3.2 mt-10 -95.43 113.68 25.36 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.901 -0.407 . . . . 2.07 109.901 178.083 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 44' ' ' VAL . . . . . 0.502 ' CG1' HG23 ' B' ' 36' ' ' ILE . 1.5 t -91.13 130.73 39.85 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 N-CA-C 109.602 -0.518 . . . . 0.13 109.602 176.133 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 45' ' ' ILE . . . . . 0.804 HG13 HG13 ' A' ' 45' ' ' ILE . 1.7 mp -109.41 118.13 56.03 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 N-CA-C 108.262 -1.014 . . . . 0.12 108.262 -177.446 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 46' ' ' LEU . . . . . 1.031 HD11 HD11 ' A' ' 46' ' ' LEU . 0.3 OUTLIER -113.02 116.8 30.49 Favored 'General case' 0 C--N 1.314 -0.935 0 O-C-N 123.665 0.603 . . . . 0.15 109.571 178.916 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 47' ' ' LYS . . . . . 0.905 ' HZ1' ' HE1' ' B' ' 37' ' ' PHE . 0.0 OUTLIER -126.81 155.28 43.11 Favored 'General case' 0 C--N 1.32 -0.694 0 C-N-CA 118.85 -1.14 . . . . 0.95 111.97 179.096 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 48' ' ' LYS . . . . . 0.624 ' HA ' ' O ' ' B' ' 33' ' ' PRO . 6.5 ptmt -49.58 -7.67 0.03 OUTLIER 'General case' 0 N--CA 1.476 0.873 0 N-CA-C 117.102 2.26 . . . . 0.64 117.102 -166.011 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 49' ' ' TYR . . . . . 0.755 ' CD1' HG21 ' A' ' 7' ' ' VAL . 19.7 t80 73.8 -52.92 0.69 Allowed 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 112.73 0.641 . . . . 1.26 112.73 170.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 50' ' ' SER . . . . . 0.712 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 26.9 t -50.6 -52.89 51.74 Favored Pre-proline 0 CA--C 1.541 0.628 0 CA-C-N 116.059 -0.519 . . . . 1.22 111.177 -175.48 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 51' ' ' PRO . . . . . 0.712 ' HD3' ' HB3' ' B' ' 50' ' ' SER . 59.8 Cg_endo -93.55 12.87 1.73 Allowed 'Trans proline' 0 C--N 1.352 0.754 0 C-N-CA 122.438 2.092 . . . . 0.56 111.791 171.293 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 52' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.236 0.361 0 CA-C-N 115.323 -0.853 . . . . 0.73 109.619 -175.734 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . 0.437 ' HA ' ' HB2' ' B' ' 37' ' ' PHE . . . . . . . . 0 N--CA 1.46 0.069 0 CA-C-O 121.466 0.651 . . . . 0.72 111.24 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.5 ' OG1' ' HA ' ' B' ' 37' ' ' PHE . 18.2 p -87.5 -45.89 10.08 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.563 -0.744 . . . . 0.41 111.365 -178.536 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . 0.453 ' H ' ' HB3' ' B' ' 37' ' ' PHE . . . 73.15 48.39 19.97 Favored Glycine 0 N--CA 1.444 -0.796 0 C-N-CA 120.829 -0.701 . . . . 0.32 112.969 173.149 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.798 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.5 tp -106.46 107.4 22.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 N-CA-C 109.155 -0.683 . . . . 0.31 109.155 174.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.693 HG21 ' CD1' ' B' ' 49' ' ' TYR . 55.7 t -76.05 136.61 24.43 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.909 0 CA-C-O 121.414 0.626 . . . . 0.28 110.527 179.852 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.58 ' HB3' ' CD1' ' B' ' 36' ' ' ILE . 2.5 tpp180 -130.94 116.22 17.57 Favored 'General case' 0 N--CA 1.433 -1.304 0 N-CA-C 107.069 -1.456 . . . . 1.99 107.069 -179.661 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' ARG . . . . . 0.553 ' C ' HD12 ' A' ' 10' ' ' ILE . 0.2 OUTLIER -82.48 101.68 10.85 Favored 'General case' 0 C--N 1.315 -0.931 0 N-CA-C 108.123 -1.066 . . . . 2.8 108.123 175.63 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.947 HG23 HD11 ' B' ' 34' ' ' LEU . 0.2 OUTLIER -7.05 -105.18 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.035 0 O-C-N 125.583 1.802 . . . . 0.33 114.681 -177.909 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . 0.511 ' H ' HD13 ' A' ' 10' ' ' ILE . 47.6 p30 163.1 -151.33 0.0 OUTLIER 'General case' 0 CA--C 1.512 -0.482 0 C-N-CA 123.609 0.763 . . . . 1.13 109.013 176.356 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -78.91 -9.75 59.6 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 123.244 0.34 . . . . 2.26 111.288 -177.215 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -117.31 -58.06 2.08 Favored 'General case' 0 C--N 1.326 -0.454 0 O-C-N 122.237 -0.289 . . . . 0.53 110.292 -178.679 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.416 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 138.89 16.6 0.58 Allowed Glycine 0 N--CA 1.445 -0.748 0 C-N-CA 120.593 -0.813 . . . . 0.22 113.321 -177.922 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.618 ' HG2' HG22 ' B' ' 17' ' ' VAL . 0.8 OUTLIER -76.29 150.52 36.94 Favored 'General case' 0 CA--C 1.509 -0.603 0 CA-C-N 118.02 0.91 . . . . 0.69 109.837 177.406 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.738 HG21 HD13 ' B' ' 46' ' ' LEU . 54.3 t -106.73 96.87 4.98 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.29 0 N-CA-C 107.436 -1.32 . . . . 1.24 107.436 171.32 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.616 HG22 ' HG2' ' B' ' 15' ' ' ARG . 62.2 t -68.65 100.94 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.825 0 CA-C-N 115.366 -0.834 . . . . 0.28 110.06 -173.771 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.706 HG23 HD13 ' A' ' 22' ' ' ILE . 8.0 mt -93.83 114.9 64.3 Favored Pre-proline 0 N--CA 1.446 -0.641 0 CA-C-N 115.603 -0.726 . . . . 0.77 111.053 -177.171 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.592 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 30.9 Cg_exo -44.73 143.87 3.87 Favored 'Trans proline' 0 CA--C 1.513 -0.536 0 C-N-CA 123.403 2.736 . . . . 0.32 113.137 171.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.874 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -59.38 -15.82 19.02 Favored 'General case' 0 C--O 1.214 -0.797 0 CA-C-N 115.258 -0.883 . . . . 1.57 111.363 178.185 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.592 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 10.0 pt-20 -67.86 -21.06 65.19 Favored 'General case' 0 C--O 1.236 0.348 0 N-CA-C 111.63 0.233 . . . . 1.32 111.63 -177.51 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.706 HD13 HG23 ' A' ' 18' ' ' ILE . 5.0 mp -87.68 -49.16 14.8 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.369 0 N-CA-C 107.842 -1.17 . . . . 0.35 107.842 -179.414 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . 0.639 ' HD3' ' N ' ' A' ' 24' ' ' ARG . 0.0 OUTLIER -51.69 -34.5 38.8 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-O 121.768 0.794 . . . . 1.5 109.769 168.296 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.639 ' N ' ' HD3' ' A' ' 23' ' ' ARG . 9.3 ttm180 -60.99 -51.89 67.32 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 114.771 -1.104 . . . . 2.96 110.943 177.506 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 27.5 m -65.19 -27.82 68.96 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-O 121.406 0.622 . . . . 0.4 110.587 175.187 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.847 ' HB3' HG13 ' A' ' 28' ' ' ILE . 2.3 mm? -65.01 -18.99 65.77 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.405 -0.816 . . . . 0.36 111.211 175.375 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.509 ' HB2' ' O ' ' A' ' 26' ' ' LEU . 5.7 mpt_? 71.42 14.72 6.35 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 123.437 0.695 . . . . 3.2 111.06 -174.307 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.847 HG13 ' HB3' ' A' ' 26' ' ' LEU . 2.9 mt -109.4 -157.21 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 CA-C-N 115.773 -0.649 . . . . 0.48 109.647 -175.71 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.74 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.2 OUTLIER -161.79 -153.79 0.3 Allowed 'General case' 0 C--N 1.325 -0.494 0 C-N-CA 123.026 0.53 . . . . 2.4 110.298 -176.211 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -71.5 44.79 0.1 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 122.097 0.951 . . . . 1.23 111.516 178.039 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.633 ' N ' HD11 ' B' ' 10' ' ' ILE . . . -161.36 33.87 0.38 Allowed Glycine 0 N--CA 1.441 -0.996 0 CA-C-N 114.331 -1.304 . . . . 0.36 110.496 177.656 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.461 ' HA ' ' HD3' ' A' ' 33' ' ' PRO . 29.2 t0 -94.45 119.4 66.44 Favored Pre-proline 0 C--N 1.327 -0.391 0 CA-C-N 115.168 -0.516 . . . . 1.26 109.753 176.453 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.629 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 3.3 Cg_endo -88.01 63.93 3.5 Favored 'Trans proline' 0 N--CA 1.452 -0.956 0 C-N-CA 123.916 3.077 . . . . 1.3 113.957 -177.214 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.589 HD12 ' H ' ' A' ' 34' ' ' LEU . 0.9 OUTLIER -64.66 154.54 36.21 Favored 'General case' 0 C--N 1.292 -1.924 0 C-N-CA 118.328 -1.349 . . . . 0.38 111.841 -177.128 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.763 ' O ' ' HA ' ' A' ' 46' ' ' LEU . 35.0 tt0 -109.4 113.5 26.37 Favored 'General case' 0 CA--C 1.494 -1.175 0 CA-C-N 113.369 -1.741 . . . . 1.12 108.291 -174.437 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.84 HG13 HD22 ' A' ' 46' ' ' LEU . 2.7 mp -84.4 109.49 17.74 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 O-C-N 124.143 0.902 . . . . 0.39 109.647 -178.836 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' PHE . . . . . 0.746 ' HD1' ' HA ' ' B' ' 3' ' ' ALA . 0.6 OUTLIER -149.31 121.48 8.33 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-O 121.228 0.537 . . . . 1.15 109.878 175.771 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.54 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 1.9 p -80.38 135.86 24.49 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.047 0 CA-C-O 121.208 0.527 . . . . 0.17 110.351 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.481 ' HB3' ' HG3' ' A' ' 40' ' ' ARG . 14.3 t70 -86.08 -40.33 15.84 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 114.99 -1.004 . . . . 1.11 111.529 -173.261 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . 0.481 ' HG3' ' HB3' ' A' ' 39' ' ' ASP . 8.3 mtp180 -132.08 -81.44 0.5 Allowed 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 112.788 0.662 . . . . 2.29 112.788 -163.061 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -122.19 -65.75 1.09 Allowed 'General case' 0 CA--C 1.507 -0.69 0 CA-C-O 121.581 0.705 . . . . 1.53 109.962 -176.18 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.546 ' O ' ' HA ' ' B' ' 47' ' ' LYS . . . -133.1 12.58 5.02 Favored Glycine 0 N--CA 1.438 -1.213 0 CA-C-N 114.816 -1.084 . . . . 0.32 111.638 -178.171 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.589 ' HB3' HG23 ' B' ' 45' ' ' ILE . 0.9 OUTLIER -92.57 105.97 18.04 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 108.757 -0.831 . . . . 1.97 108.757 177.346 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.55 HG11 HG23 ' A' ' 36' ' ' ILE . 2.4 t -89.67 131.24 37.43 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 N-CA-C 109.29 -0.633 . . . . 0.14 109.29 177.764 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.803 HG13 HG13 ' B' ' 45' ' ' ILE . 1.6 mp -108.85 116.07 51.02 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 N-CA-C 108.054 -1.091 . . . . 0.14 108.054 -176.028 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 1.048 HD11 HD11 ' B' ' 46' ' ' LEU . 0.7 OUTLIER -106.35 117.66 34.62 Favored 'General case' 0 C--N 1.316 -0.86 0 O-C-N 123.883 0.74 . . . . 0.23 109.402 178.418 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.756 ' HD2' ' HB3' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -129.49 143.82 51.0 Favored 'General case' 0 C--O 1.214 -0.773 0 C-N-CA 119.265 -0.974 . . . . 0.76 112.597 178.752 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.706 ' HG3' ' HG2' ' A' ' 51' ' ' PRO . 3.0 ptmt -39.86 -12.82 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.288 0 N-CA-C 117.833 2.531 . . . . 0.32 117.833 -169.921 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 0.629 ' HB3' ' HB2' ' A' ' 33' ' ' PRO . 27.9 t80 70.63 -57.11 0.59 Allowed 'General case' 0 N--CA 1.478 0.952 0 N-CA-C 113.437 0.903 . . . . 1.28 113.437 175.242 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.408 ' HB2' ' HD3' ' A' ' 51' ' ' PRO . 19.0 m -52.88 -52.64 63.05 Favored Pre-proline 0 CA--C 1.54 0.595 0 CA-C-N 115.644 -0.707 . . . . 1.36 111.951 -174.46 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.706 ' HG2' ' HG3' ' A' ' 48' ' ' LYS . 75.2 Cg_endo -90.55 10.65 2.87 Favored 'Trans proline' 0 C--N 1.35 0.618 0 C-N-CA 122.246 1.964 . . . . 0.58 111.726 168.615 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.412 HG13 ' C ' ' A' ' 51' ' ' PRO . 1.0 OUTLIER . . . . . 0 CA--C 1.538 0.511 0 CA-C-N 115.261 -0.882 . . . . 0.78 109.726 -175.565 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 3' ' ' ALA . . . . . 0.746 ' HA ' ' HD1' ' A' ' 37' ' ' PHE . . . . . . . . 0 N--CA 1.462 0.167 0 CA-C-O 121.615 0.721 . . . . 0.86 110.985 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 4' ' ' THR . . . . . 0.537 ' OG1' ' HA ' ' A' ' 37' ' ' PHE . 12.5 p -80.66 -45.74 16.71 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.354 -0.839 . . . . 0.43 111.944 -176.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 71.2 47.93 34.31 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 121.031 -0.604 . . . . 0.33 112.911 174.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 6' ' ' ILE . . . . . 0.808 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.1 tp -105.76 107.33 22.38 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 N-CA-C 109.263 -0.643 . . . . 0.3 109.263 175.443 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . 0.605 HG21 ' CD1' ' A' ' 49' ' ' TYR . 37.6 t -77.96 134.84 27.47 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.842 0 CA-C-N 115.627 -0.715 . . . . 0.27 110.412 -178.838 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 1.4 tpp180 -131.04 116.63 18.04 Favored 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 107.018 -1.475 . . . . 1.69 107.018 177.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 9' ' ' ARG . . . . . 0.518 ' HA ' ' HA ' ' A' ' 33' ' ' PRO . 13.9 ttt180 -79.03 103.45 8.98 Favored 'General case' 0 CA--C 1.505 -0.753 0 N-CA-C 108.381 -0.97 . . . . 2.71 108.381 174.53 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 10' ' ' ILE . . . . . 0.633 HD11 ' N ' ' A' ' 31' ' ' GLY . 0.3 OUTLIER -9.93 -106.15 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 O-C-N 125.895 1.997 . . . . 0.34 114.845 -176.599 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . 0.588 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 3.2 p-10 165.58 -164.42 0.01 OUTLIER 'General case' 0 CA--C 1.514 -0.405 0 N-CA-C 107.628 -1.249 . . . . 1.18 107.628 178.842 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 24.3 t70 -72.58 -10.63 60.02 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.012 0.434 . . . . 2.39 111.051 -179.014 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 13' ' ' LEU . . . . . 0.444 ' H ' ' CG ' ' B' ' 11' ' ' ASP . 2.4 tm? -108.47 -62.02 1.52 Allowed 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.4 -0.364 . . . . 0.4 110.922 -179.337 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 139.34 21.57 0.39 Allowed Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 120.799 -0.715 . . . . 0.21 112.0 -177.246 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 15' ' ' ARG . . . . . 0.616 ' HG2' HG22 ' A' ' 17' ' ' VAL . 1.7 mpt_? -75.44 150.12 38.36 Favored 'General case' 0 CA--C 1.505 -0.771 0 CA-C-O 121.617 0.723 . . . . 0.9 110.394 177.527 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 16' ' ' VAL . . . . . 0.801 HG21 HD13 ' A' ' 46' ' ' LEU . 61.4 t -108.18 92.74 2.17 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 N-CA-C 107.487 -1.301 . . . . 1.27 107.487 167.267 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 17' ' ' VAL . . . . . 0.618 HG22 ' HG2' ' A' ' 15' ' ' ARG . 46.8 t -67.34 98.54 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.79 0 CA-C-N 115.59 -0.732 . . . . 0.27 109.99 -173.133 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . 0.416 ' HB ' ' O ' ' A' ' 14' ' ' GLY . 8.7 mt -92.19 112.8 56.84 Favored Pre-proline 0 N--CA 1.445 -0.677 0 CA-C-N 115.415 -0.811 . . . . 0.82 110.819 -177.842 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 19' ' ' PRO . . . . . 0.621 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 71.0 Cg_exo -49.29 147.2 12.22 Favored 'Trans proline' 0 N--CA 1.458 -0.581 0 C-N-CA 123.23 2.62 . . . . 0.3 112.669 173.043 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 20' ' ' LYS . . . . . 1.043 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -64.81 -14.86 60.66 Favored 'General case' 0 C--O 1.211 -0.932 0 CA-C-N 115.387 -0.824 . . . . 1.77 111.369 -177.793 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . 0.621 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 1.1 pm0 -63.15 -23.88 67.64 Favored 'General case' 0 N--CA 1.47 0.54 0 N-CA-C 112.201 0.445 . . . . 1.92 112.201 176.71 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 5.3 mp -87.01 -50.34 14.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 108.032 -1.099 . . . . 0.44 108.032 -178.357 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 23' ' ' ARG . . . . . 0.574 ' HA ' ' HB2' ' B' ' 26' ' ' LEU . 0.0 OUTLIER -56.08 -27.97 55.77 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.098 -0.956 . . . . 1.4 110.061 170.497 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 24' ' ' ARG . . . . . 0.438 ' HB3' ' HA ' ' B' ' 21' ' ' GLU . 8.2 ttm180 -64.13 -53.2 53.33 Favored 'General case' 0 CA--C 1.507 -0.687 0 CA-C-N 115.23 -0.895 . . . . 3.19 110.903 173.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 28.3 m -67.06 -22.41 65.86 Favored 'General case' 0 N--CA 1.445 -0.698 0 CA-C-O 121.614 0.721 . . . . 0.4 110.22 178.485 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . 0.574 ' HB2' ' HA ' ' B' ' 23' ' ' ARG . 1.9 mm? -67.83 -18.85 64.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.08 -0.963 . . . . 0.33 110.655 173.489 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 27' ' ' ARG . . . . . 0.439 ' HB2' ' O ' ' B' ' 26' ' ' LEU . 7.2 mpt_? 68.52 21.0 8.27 Favored 'General case' 0 C--O 1.234 0.245 0 C-N-CA 123.517 0.727 . . . . 3.28 110.475 -174.367 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 28' ' ' ILE . . . . . 0.874 HG22 ' H ' ' B' ' 29' ' ' ARG . 6.6 mt -116.91 -163.67 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.462 -0.79 . . . . 0.37 109.434 -177.669 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 29' ' ' ARG . . . . . 0.874 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -156.06 -151.38 0.33 Allowed 'General case' 0 C--N 1.32 -0.681 0 C-N-CA 122.338 0.255 . . . . 2.15 110.723 -173.942 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 30' ' ' GLU . . . . . 0.451 ' H ' ' HB2' ' B' ' 29' ' ' ARG . 0.7 OUTLIER -73.43 36.74 0.09 Allowed 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 122.166 0.984 . . . . 1.18 111.669 -179.522 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 31' ' ' GLY . . . . . 0.599 ' CA ' HD11 ' A' ' 10' ' ' ILE . . . -154.12 39.63 0.67 Allowed Glycine 0 N--CA 1.434 -1.436 0 CA-C-N 114.107 -1.406 . . . . 0.35 110.026 175.105 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 32' ' ' ASP . . . . . 0.465 ' HA ' ' HD3' ' B' ' 33' ' ' PRO . 9.5 t0 -95.96 119.66 64.33 Favored Pre-proline 0 C--N 1.325 -0.493 0 CA-C-O 121.256 0.55 . . . . 1.29 110.049 175.147 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 33' ' ' PRO . . . . . 0.702 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 4.4 Cg_endo -87.07 76.35 2.27 Favored 'Trans proline' 0 C--O 1.205 -1.145 0 C-N-CA 123.547 2.831 . . . . 1.1 113.268 -178.905 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.947 HD11 HG23 ' A' ' 10' ' ' ILE . 0.1 OUTLIER -72.12 150.5 43.8 Favored 'General case' 0 C--N 1.284 -2.249 0 C-N-CA 117.776 -1.569 . . . . 0.44 111.343 -178.963 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 35' ' ' GLU . . . . . 0.766 ' O ' ' HA ' ' B' ' 46' ' ' LEU . 42.7 tt0 -105.1 115.32 30.07 Favored 'General case' 0 CA--C 1.492 -1.264 0 CA-C-N 114.067 -1.424 . . . . 1.1 107.822 -179.143 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 36' ' ' ILE . . . . . 0.922 HG13 HD22 ' B' ' 46' ' ' LEU . 3.1 mp -88.19 108.8 19.03 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 O-C-N 124.168 0.918 . . . . 0.62 109.336 -178.443 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 37' ' ' PHE . . . . . 0.5 ' HA ' ' OG1' ' A' ' 4' ' ' THR . 12.3 p90 -149.74 126.41 11.01 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 116.159 -0.473 . . . . 1.2 110.064 175.142 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 38' ' ' VAL . . . . . 0.532 ' HA ' ' HA ' ' B' ' 44' ' ' VAL . 0.8 OUTLIER -80.23 138.57 19.59 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-O 121.29 0.567 . . . . 0.2 110.571 -179.561 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 39' ' ' ASP . . . . . 0.683 ' HB3' ' HG3' ' B' ' 40' ' ' ARG . 8.1 t70 -80.9 -46.13 15.69 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 114.751 -1.113 . . . . 1.14 110.577 -177.726 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 40' ' ' ARG . . . . . 0.683 ' HG3' ' HB3' ' B' ' 39' ' ' ASP . 23.8 mtp180 -133.33 -92.53 0.35 Allowed 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.928 -0.578 . . . . 2.71 112.34 -166.55 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 41' ' ' ASP . . . . . 0.4 ' H ' ' HB2' ' B' ' 40' ' ' ARG . 18.4 t70 -102.3 -75.59 0.6 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.314 0.578 . . . . 1.32 110.395 -176.881 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 42' ' ' GLY . . . . . 0.523 ' O ' ' HA ' ' A' ' 47' ' ' LYS . . . -124.99 18.86 6.98 Favored Glycine 0 N--CA 1.44 -1.091 0 CA-C-N 115.376 -0.829 . . . . 0.34 112.201 -179.341 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 43' ' ' GLU . . . . . 0.516 ' HB3' HG23 ' A' ' 45' ' ' ILE . 1.3 mt-10 -93.52 104.91 17.01 Favored 'General case' 0 CA--C 1.51 -0.595 0 N-CA-C 108.932 -0.766 . . . . 2.07 108.932 176.533 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 44' ' ' VAL . . . . . 0.532 ' HA ' ' HA ' ' B' ' 38' ' ' VAL . 2.2 t -89.53 131.24 37.31 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 N-CA-C 109.441 -0.577 . . . . 0.13 109.441 177.194 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 45' ' ' ILE . . . . . 0.803 HG13 HG13 ' A' ' 45' ' ' ILE . 1.7 mp -108.04 117.5 53.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.463 0 N-CA-C 108.031 -1.1 . . . . 0.12 108.031 -176.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 46' ' ' LEU . . . . . 1.048 HD11 HD11 ' A' ' 46' ' ' LEU . 1.6 mt -108.53 117.24 33.66 Favored 'General case' 0 C--N 1.317 -0.813 0 O-C-N 123.9 0.75 . . . . 0.15 109.776 178.391 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 47' ' ' LYS . . . . . 0.546 ' HA ' ' O ' ' A' ' 42' ' ' GLY . 0.0 OUTLIER -130.15 147.34 51.87 Favored 'General case' 0 C--O 1.214 -0.8 0 C-N-CA 119.199 -1.0 . . . . 0.95 113.129 -179.919 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 48' ' ' LYS . . . . . 0.58 ' HG3' ' CG ' ' B' ' 51' ' ' PRO . 3.5 ptmt -44.83 -7.91 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.409 0 N-CA-C 118.065 2.617 . . . . 0.64 118.065 -168.781 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 49' ' ' TYR . . . . . 0.702 ' HB3' ' HB2' ' B' ' 33' ' ' PRO . 32.5 t80 69.72 -57.5 0.55 Allowed 'General case' 0 N--CA 1.48 1.051 0 N-CA-C 113.727 1.01 . . . . 1.26 113.727 173.506 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 50' ' ' SER . . . . . 0.681 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 9.1 t -51.24 -56.28 21.53 Favored Pre-proline 0 CA--C 1.539 0.528 0 CA-C-N 115.932 -0.576 . . . . 1.22 111.134 -173.484 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 51' ' ' PRO . . . . . 0.681 ' HD3' ' HB3' ' B' ' 50' ' ' SER . 59.1 Cg_endo -87.21 8.24 4.43 Favored 'Trans proline' 0 C--N 1.351 0.666 0 C-N-CA 122.174 1.916 . . . . 0.56 111.968 170.396 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 52' ' ' ILE . . . . . . . . . . . . . 1.6 mt . . . . . 0 CA--C 1.534 0.341 0 CA-C-N 115.137 -0.938 . . . . 0.73 108.863 -175.002 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . 0.451 ' HA ' ' HB2' ' B' ' 37' ' ' PHE . . . . . . . . 0 C--O 1.229 0.02 0 CA-C-O 121.583 0.706 . . . . 0.72 111.639 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.552 ' OG1' ' HA ' ' B' ' 37' ' ' PHE . 11.8 p -81.21 -35.1 31.73 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.579 -0.737 . . . . 0.41 111.647 -179.297 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . 0.585 ' H ' ' CB ' ' B' ' 37' ' ' PHE . . . 57.51 47.67 86.53 Favored Glycine 0 N--CA 1.445 -0.73 0 CA-C-N 115.735 -0.666 . . . . 0.32 112.68 173.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.697 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.8 tp -105.9 104.06 16.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 108.807 -0.812 . . . . 0.31 108.807 175.22 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.676 HG21 ' CG ' ' B' ' 49' ' ' TYR . 52.9 t -74.9 135.17 27.88 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.873 0 CA-C-N 115.522 -0.763 . . . . 0.28 109.943 179.481 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.541 ' HB3' HD13 ' B' ' 36' ' ' ILE . 1.7 tpp180 -131.84 117.13 18.12 Favored 'General case' 0 N--CA 1.431 -1.415 0 N-CA-C 106.899 -1.519 . . . . 1.99 106.899 -177.6 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' ARG . . . . . 0.542 ' C ' HD12 ' A' ' 10' ' ' ILE . 0.0 OUTLIER -78.44 101.74 7.46 Favored 'General case' 0 C--N 1.314 -0.954 0 N-CA-C 107.924 -1.139 . . . . 2.8 107.924 174.913 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.806 HG23 HD11 ' B' ' 34' ' ' LEU . 0.2 OUTLIER -5.63 -105.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.195 0 O-C-N 125.445 1.715 . . . . 0.33 114.587 -176.753 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . 0.604 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 2.4 p-10 165.99 -162.49 0.01 OUTLIER 'General case' 0 CA--C 1.513 -0.472 0 N-CA-C 107.935 -1.135 . . . . 1.13 107.935 177.611 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 30.4 m-20 -76.45 -6.7 52.86 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 120.744 0.307 . . . . 2.26 111.301 -178.255 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.428 ' H ' ' CG ' ' A' ' 11' ' ' ASP . 2.9 tm? -114.75 -59.16 2.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.661 -0.245 . . . . 0.53 110.996 178.589 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.449 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 140.1 13.78 0.58 Allowed Glycine 0 N--CA 1.448 -0.5 0 C-N-CA 120.432 -0.889 . . . . 0.22 113.096 -178.805 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.765 ' HG2' HG22 ' B' ' 17' ' ' VAL . 0.9 OUTLIER -77.43 154.98 32.1 Favored 'General case' 0 CA--C 1.501 -0.933 0 N-CA-C 109.231 -0.655 . . . . 0.69 109.231 176.011 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.921 HG11 HD13 ' B' ' 46' ' ' LEU . 1.5 m -109.88 112.13 39.17 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.59 0 N-CA-C 107.355 -1.35 . . . . 1.24 107.355 166.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.68 HG22 ' HG2' ' B' ' 15' ' ' ARG . 59.6 t -73.16 95.94 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.427 -1.588 0 CA-C-N 114.449 -1.25 . . . . 0.28 109.657 -174.875 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.611 HG23 HD13 ' A' ' 22' ' ' ILE . 11.0 mt -86.28 110.92 35.13 Favored Pre-proline 0 N--CA 1.446 -0.641 0 CA-C-N 115.218 -0.901 . . . . 0.77 110.251 -179.588 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.597 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 67.5 Cg_exo -47.37 144.51 9.67 Favored 'Trans proline' 0 N--CA 1.459 -0.535 0 C-N-CA 123.115 2.544 . . . . 0.32 112.261 173.594 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.939 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -59.95 -15.29 20.78 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.775 -0.648 . . . . 1.57 111.706 -178.493 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.597 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 12.8 pt-20 -67.6 -19.79 65.29 Favored 'General case' 0 C--O 1.237 0.437 0 N-CA-C 112.062 0.393 . . . . 1.32 112.062 -178.723 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.611 HD13 HG23 ' A' ' 18' ' ' ILE . 4.8 mp -87.43 -44.45 16.04 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 N-CA-C 108.125 -1.065 . . . . 0.35 108.125 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . 0.677 ' HA ' ' HB2' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -60.68 -30.52 69.97 Favored 'General case' 0 CA--C 1.521 -0.166 0 CA-C-O 121.883 0.849 . . . . 1.5 109.093 171.208 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 63.2 ttt180 -61.33 -51.49 68.61 Favored 'General case' 0 N--CA 1.441 -0.894 0 CA-C-N 114.619 -1.173 . . . . 2.96 110.455 176.187 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 22.7 m -66.68 -21.94 66.09 Favored 'General case' 0 CA--C 1.535 0.392 0 CA-C-O 121.527 0.679 . . . . 0.4 110.654 174.094 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.864 ' HB3' HG13 ' A' ' 28' ' ' ILE . 2.3 mm? -71.94 -18.14 62.03 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.964 -0.562 . . . . 0.36 110.605 174.201 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.429 ' HB2' ' O ' ' A' ' 26' ' ' LEU . 9.0 mpt_? 66.21 23.18 10.9 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-N 116.006 -0.543 . . . . 3.2 110.625 -175.069 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.864 HG13 ' HB3' ' A' ' 26' ' ' LEU . 2.6 mt -113.92 -154.61 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 115.865 -0.607 . . . . 0.48 109.91 -178.44 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.693 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -162.34 -156.3 0.41 Allowed 'General case' 0 C--N 1.321 -0.653 0 C-N-CA 122.686 0.394 . . . . 2.4 110.674 -173.951 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . 0.417 ' H ' ' HB2' ' A' ' 29' ' ' ARG . 1.8 mp0 -74.9 44.1 0.22 Allowed 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 122.132 0.968 . . . . 1.23 111.025 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.706 ' N ' HD11 ' B' ' 10' ' ' ILE . . . -156.98 26.3 0.5 Allowed Glycine 0 N--CA 1.439 -1.137 0 CA-C-N 114.055 -1.43 . . . . 0.36 110.999 176.757 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.418 ' HA ' ' HD3' ' A' ' 33' ' ' PRO . 9.2 t0 -85.7 122.5 73.12 Favored Pre-proline 0 C--N 1.327 -0.379 0 CA-C-O 121.108 0.48 . . . . 1.26 110.111 176.321 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.637 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 3.8 Cg_endo -91.08 62.81 1.28 Allowed 'Trans proline' 0 N--CA 1.451 -0.986 0 C-N-CA 123.855 3.037 . . . . 1.3 114.253 -175.684 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.978 HD11 HG23 ' B' ' 10' ' ' ILE . 0.0 OUTLIER -61.22 153.97 24.73 Favored 'General case' 0 C--N 1.298 -1.646 0 C-N-CA 118.884 -1.127 . . . . 0.38 112.046 -178.536 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.77 ' HB3' ' HB3' ' A' ' 47' ' ' LYS . 39.4 tt0 -107.84 113.83 27.34 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 112.938 -1.937 . . . . 1.12 107.392 -176.253 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.811 ' HB ' HG23 ' B' ' 6' ' ' ILE . 2.4 mp -86.32 107.34 16.53 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.058 0 N-CA-C 109.136 -0.69 . . . . 0.39 109.136 -179.481 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' PHE . . . . . 0.575 ' CB ' ' H ' ' B' ' 5' ' ' GLY . 2.2 p90 -149.17 120.88 8.07 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-O 121.44 0.638 . . . . 1.15 109.937 176.169 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.597 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 1.5 p -80.5 137.56 21.25 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.987 0 CA-C-N 115.803 -0.635 . . . . 0.17 110.555 -178.126 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.554 ' HB3' ' HG2' ' A' ' 40' ' ' ARG . 7.5 t70 -76.22 -40.91 50.95 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 114.831 -1.077 . . . . 1.11 111.669 -171.16 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . 0.554 ' HG2' ' HB3' ' A' ' 39' ' ' ASP . 0.3 OUTLIER -150.62 -74.77 0.15 Allowed 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 112.859 0.689 . . . . 2.29 112.859 -168.753 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -106.29 -74.16 0.66 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.171 0.51 . . . . 1.53 111.431 -175.688 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.534 ' HA3' HD11 ' B' ' 26' ' ' LEU . . . -135.82 12.74 4.21 Favored Glycine 0 N--CA 1.443 -0.866 0 CA-C-N 115.123 -0.944 . . . . 0.32 111.891 -175.738 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.503 ' O ' HG23 ' A' ' 38' ' ' VAL . 2.5 pm0 -92.82 106.77 18.69 Favored 'General case' 0 N--CA 1.446 -0.66 0 N-CA-C 110.051 -0.352 . . . . 1.97 110.051 175.183 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.623 HG11 HG23 ' A' ' 36' ' ' ILE . 2.5 t -87.57 134.84 26.78 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 N-CA-C 109.259 -0.645 . . . . 0.14 109.259 178.356 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.709 HG13 HG13 ' B' ' 45' ' ' ILE . 1.5 mp -110.69 118.11 56.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 N-CA-C 108.491 -0.929 . . . . 0.14 108.491 -178.077 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.953 HD11 HD11 ' B' ' 46' ' ' LEU . 6.8 mt -103.3 119.05 38.13 Favored 'General case' 0 C--N 1.32 -0.715 0 O-C-N 124.229 0.956 . . . . 0.23 109.906 -179.541 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.77 ' HB3' ' HB3' ' A' ' 35' ' ' GLU . 16.6 ttmt -121.2 130.2 53.58 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-N 115.434 -0.803 . . . . 0.76 111.905 -170.704 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.613 ' HE2' ' HG3' ' A' ' 51' ' ' PRO . 3.2 ptmt -45.23 -12.97 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 115.937 1.828 . . . . 0.32 115.937 -174.313 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 0.687 ' CD1' HG21 ' B' ' 7' ' ' VAL . 34.4 t80 68.36 -56.7 0.5 Allowed 'General case' 0 N--CA 1.473 0.69 0 C-N-CA 124.623 1.169 . . . . 1.28 114.046 174.224 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.402 ' HB2' ' HD3' ' A' ' 51' ' ' PRO . 36.1 m -53.41 -48.08 93.96 Favored Pre-proline 0 CA--C 1.542 0.636 0 CA-C-N 115.683 -0.69 . . . . 1.36 112.052 -173.691 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.613 ' HG3' ' HE2' ' A' ' 48' ' ' LYS . 60.6 Cg_endo -93.54 10.82 2.04 Favored 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 122.272 1.981 . . . . 0.58 111.779 167.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.4 ' H ' ' C ' ' A' ' 49' ' ' TYR . 1.0 OUTLIER . . . . . 0 C--O 1.233 0.218 0 N-CA-C 108.304 -0.998 . . . . 0.78 108.304 -171.35 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 3' ' ' ALA . . . . . 0.417 ' HA ' ' HD2' ' A' ' 37' ' ' PHE . . . . . . . . 0 N--CA 1.458 -0.074 0 CA-C-O 121.557 0.694 . . . . 0.86 111.766 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 4' ' ' THR . . . . . 0.473 ' OG1' ' HA ' ' A' ' 37' ' ' PHE . 12.0 p -84.67 -34.94 22.91 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.63 -0.714 . . . . 0.43 111.633 -178.221 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 5' ' ' GLY . . . . . 0.575 ' H ' ' CB ' ' A' ' 37' ' ' PHE . . . 58.43 48.07 86.15 Favored Glycine 0 N--CA 1.449 -0.487 0 CA-C-N 115.601 -0.727 . . . . 0.33 113.052 174.655 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 6' ' ' ILE . . . . . 0.811 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.4 tp -105.23 104.34 16.78 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 N-CA-C 109.224 -0.658 . . . . 0.3 109.224 175.817 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . 0.687 HG21 ' CD1' ' A' ' 49' ' ' TYR . 27.5 t -74.79 134.12 30.1 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.841 0 CA-C-N 115.462 -0.79 . . . . 0.27 110.083 -179.714 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . 0.515 ' HD3' ' N ' ' B' ' 9' ' ' ARG . 0.3 OUTLIER -131.97 120.06 21.94 Favored 'General case' 0 N--CA 1.441 -0.918 0 N-CA-C 106.862 -1.532 . . . . 1.69 106.862 179.132 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 9' ' ' ARG . . . . . 0.548 ' HA ' ' HA ' ' A' ' 33' ' ' PRO . 41.9 ttp180 -78.95 103.27 8.78 Favored 'General case' 0 N--CA 1.441 -0.903 0 N-CA-C 108.667 -0.864 . . . . 2.71 108.667 174.481 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 10' ' ' ILE . . . . . 0.978 HG23 HD11 ' A' ' 34' ' ' LEU . 0.3 OUTLIER -7.59 -100.38 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 O-C-N 125.66 1.85 . . . . 0.34 114.189 -175.31 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . 0.609 ' H ' HD13 ' B' ' 10' ' ' ILE . 13.5 p-10 161.54 -157.15 0.0 OUTLIER 'General case' 0 CA--C 1.505 -0.767 0 N-CA-C 107.889 -1.152 . . . . 1.18 107.889 175.088 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -88.64 22.69 2.51 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 120.688 0.28 . . . . 2.39 111.214 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 13' ' ' LEU . . . . . 0.411 ' HB3' ' HD2' ' B' ' 15' ' ' ARG . 2.3 tm? -137.86 -55.21 0.67 Allowed 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 109.862 -0.421 . . . . 0.4 109.862 175.564 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 14' ' ' GLY . . . . . 0.427 ' O ' ' HB ' ' A' ' 18' ' ' ILE . . . 131.97 11.85 2.0 Favored Glycine 0 N--CA 1.444 -0.8 0 C-N-CA 120.896 -0.669 . . . . 0.21 112.491 -177.83 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 15' ' ' ARG . . . . . 0.68 ' HG2' HG22 ' A' ' 17' ' ' VAL . 0.9 OUTLIER -74.11 152.14 39.95 Favored 'General case' 0 CA--C 1.504 -0.809 0 CA-C-O 121.445 0.641 . . . . 0.9 109.511 175.47 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 16' ' ' VAL . . . . . 0.736 HG13 HG13 ' A' ' 16' ' ' VAL . 0.2 OUTLIER -109.06 105.79 19.48 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 N-CA-C 107.697 -1.224 . . . . 1.27 107.697 167.641 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 17' ' ' VAL . . . . . 0.765 HG22 ' HG2' ' A' ' 15' ' ' ARG . 41.0 t -72.63 95.03 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.168 0 CA-C-N 114.724 -1.125 . . . . 0.27 109.827 -173.505 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . 0.574 HG23 HD13 ' B' ' 22' ' ' ILE . 11.7 mt -87.56 112.56 49.29 Favored Pre-proline 0 N--CA 1.445 -0.724 0 CA-C-N 115.436 -0.802 . . . . 0.82 110.503 -179.689 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 19' ' ' PRO . . . . . 0.692 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 84.9 Cg_exo -49.12 146.69 12.24 Favored 'Trans proline' 0 N--CA 1.459 -0.534 0 C-N-CA 123.045 2.497 . . . . 0.3 112.612 173.2 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 20' ' ' LYS . . . . . 0.917 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -60.79 -15.29 28.3 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.76 -0.655 . . . . 1.77 111.956 -179.357 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . 0.692 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 11.5 pt-20 -65.48 -21.12 66.6 Favored 'General case' 0 CA--C 1.536 0.428 0 N-CA-C 112.211 0.449 . . . . 1.92 112.211 -179.784 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 22' ' ' ILE . . . . . 0.574 HD13 HG23 ' B' ' 18' ' ' ILE . 5.2 mp -86.76 -48.78 15.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 108.264 -1.013 . . . . 0.44 108.264 179.835 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 23' ' ' ARG . . . . . 0.602 ' HA ' ' HB2' ' B' ' 26' ' ' LEU . 0.0 OUTLIER -55.89 -30.28 61.3 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 115.429 -0.805 . . . . 1.4 109.258 170.39 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 24' ' ' ARG . . . . . 0.597 ' N ' ' HD3' ' B' ' 23' ' ' ARG . 37.2 ttt180 -62.9 -52.35 63.42 Favored 'General case' 0 N--CA 1.45 -0.444 0 CA-C-N 114.772 -1.104 . . . . 3.19 110.858 176.427 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 51.6 m -64.22 -28.45 69.75 Favored 'General case' 0 CA--C 1.53 0.206 0 CA-C-O 121.17 0.509 . . . . 0.4 110.811 173.629 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . 0.617 ' HB3' HG13 ' B' ' 28' ' ' ILE . 1.6 mm? -66.21 -18.78 65.56 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.755 -0.657 . . . . 0.33 111.315 175.436 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 27' ' ' ARG . . . . . 0.459 ' HB2' ' O ' ' B' ' 26' ' ' LEU . 11.0 mpt_? 68.21 16.22 9.37 Favored 'General case' 0 N--CA 1.467 0.378 0 C-N-CA 123.192 0.597 . . . . 3.28 111.095 -174.608 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 28' ' ' ILE . . . . . 0.906 HG22 ' H ' ' B' ' 29' ' ' ARG . 7.8 mt -109.05 -160.8 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 115.825 -0.625 . . . . 0.37 109.725 -175.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 29' ' ' ARG . . . . . 0.906 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -157.89 -153.84 0.41 Allowed 'General case' 0 C--N 1.328 -0.365 0 C-N-CA 122.386 0.275 . . . . 2.15 110.826 -177.691 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 30' ' ' GLU . . . . . 0.416 ' H ' ' HB2' ' B' ' 29' ' ' ARG . 1.9 mp0 -70.57 40.19 0.05 Allowed 'General case' 0 N--CA 1.468 0.466 0 CA-C-O 121.537 0.684 . . . . 1.18 112.043 178.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 31' ' ' GLY . . . . . 0.668 ' N ' HD11 ' A' ' 10' ' ' ILE . . . -155.38 34.09 0.65 Allowed Glycine 0 N--CA 1.437 -1.234 0 CA-C-N 115.097 -0.956 . . . . 0.35 111.106 175.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 32' ' ' ASP . . . . . 0.518 ' HB2' HG21 ' B' ' 28' ' ' ILE . 15.9 t0 -93.22 124.59 57.38 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.105 0.479 . . . . 1.29 110.706 176.534 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 33' ' ' PRO . . . . . 0.676 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 3.3 Cg_endo -87.56 75.83 2.16 Favored 'Trans proline' 0 C--O 1.206 -1.09 0 C-N-CA 124.011 3.141 . . . . 1.1 113.68 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.806 HD11 HG23 ' A' ' 10' ' ' ILE . 1.0 OUTLIER -71.47 148.79 46.48 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.021 -1.472 . . . . 0.44 110.771 179.87 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 35' ' ' GLU . . . . . 0.687 ' O ' ' HA ' ' B' ' 46' ' ' LEU . 43.8 tt0 -103.78 110.74 22.96 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-N 114.417 -1.265 . . . . 1.1 107.625 -179.836 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 36' ' ' ILE . . . . . 0.954 HG13 HD22 ' B' ' 46' ' ' LEU . 2.3 mp -85.94 109.27 18.38 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.731 0 O-C-N 124.048 0.842 . . . . 0.62 109.236 -178.493 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 37' ' ' PHE . . . . . 0.585 ' CB ' ' H ' ' A' ' 5' ' ' GLY . 14.4 p90 -149.4 123.38 9.39 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 115.832 -0.622 . . . . 1.2 109.631 175.561 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 38' ' ' VAL . . . . . 0.623 ' HA ' ' HA ' ' B' ' 44' ' ' VAL . 1.4 p -79.91 136.05 24.26 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 CA-C-O 121.424 0.63 . . . . 0.2 110.229 -178.416 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 39' ' ' ASP . . . . . 0.589 ' OD1' ' HD3' ' B' ' 40' ' ' ARG . 12.6 t70 -69.48 -53.9 16.9 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 114.215 -1.357 . . . . 1.14 111.244 -173.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 40' ' ' ARG . . . . . 0.589 ' HD3' ' OD1' ' B' ' 39' ' ' ASP . 0.0 OUTLIER -139.34 -71.22 0.4 Allowed 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 113.019 0.748 . . . . 2.71 113.019 -174.308 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -106.48 -68.42 0.88 Allowed 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 112.089 0.403 . . . . 1.32 112.089 -173.153 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 42' ' ' GLY . . . . . 0.458 ' HA3' ' HD2' ' A' ' 48' ' ' LYS . . . -140.94 12.52 2.87 Favored Glycine 0 CA--C 1.501 -0.823 0 C-N-CA 120.71 -0.757 . . . . 0.34 111.862 -175.465 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 43' ' ' GLU . . . . . 0.587 ' HA ' ' O ' ' A' ' 46' ' ' LEU . 2.3 pm0 -93.05 104.96 17.12 Favored 'General case' 0 N--CA 1.443 -0.803 0 N-CA-C 109.568 -0.53 . . . . 2.07 109.568 174.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 44' ' ' VAL . . . . . 0.623 ' HA ' ' HA ' ' B' ' 38' ' ' VAL . 2.1 t -87.37 131.68 34.58 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 N-CA-C 109.696 -0.483 . . . . 0.13 109.696 179.329 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 45' ' ' ILE . . . . . 0.709 HG13 HG13 ' A' ' 45' ' ' ILE . 1.7 mp -108.29 118.47 55.99 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 N-CA-C 108.414 -0.958 . . . . 0.12 108.414 -177.592 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 46' ' ' LEU . . . . . 0.954 HD22 HG13 ' B' ' 36' ' ' ILE . 0.6 OUTLIER -109.9 117.1 32.93 Favored 'General case' 0 C--N 1.318 -0.788 0 O-C-N 123.612 0.57 . . . . 0.15 109.915 178.844 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 47' ' ' LYS . . . . . 0.591 ' HE3' ' HB3' ' B' ' 35' ' ' GLU . 0.0 OUTLIER -130.09 142.45 50.6 Favored 'General case' 0 C--N 1.318 -0.765 0 C-N-CA 119.617 -0.833 . . . . 0.95 112.877 -178.332 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 48' ' ' LYS . . . . . 0.573 ' HE2' ' HG3' ' B' ' 51' ' ' PRO . 4.3 ptmt -43.19 -9.2 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.638 0 N-CA-C 118.112 2.634 . . . . 0.64 118.112 -168.264 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 49' ' ' TYR . . . . . 0.676 ' CG ' HG21 ' A' ' 7' ' ' VAL . 5.9 t80 68.38 -52.75 0.55 Allowed 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 114.067 1.136 . . . . 1.26 114.067 174.326 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 50' ' ' SER . . . . . 0.634 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 32.2 t -51.55 -57.14 15.49 Favored Pre-proline 0 CA--C 1.535 0.386 0 C-N-CA 122.417 0.287 . . . . 1.22 111.099 -173.55 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 51' ' ' PRO . . . . . 0.634 ' HD3' ' HB3' ' B' ' 50' ' ' SER . 74.8 Cg_endo -85.01 9.07 4.3 Favored 'Trans proline' 0 C--N 1.35 0.652 0 C-N-CA 122.011 1.808 . . . . 0.56 111.159 170.174 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 52' ' ' ILE . . . . . 0.407 ' H ' ' C ' ' B' ' 49' ' ' TYR . 1.2 mt . . . . . 0 N--CA 1.449 -0.521 0 CA-C-N 114.814 -1.085 . . . . 0.73 108.666 -171.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . 0.591 ' HA ' ' HD2' ' B' ' 37' ' ' PHE . . . . . . . . 0 N--CA 1.466 0.359 0 CA-C-O 121.74 0.781 . . . . 0.72 111.33 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.816 ' H ' ' HB2' ' B' ' 37' ' ' PHE . 34.4 p -125.97 -35.73 2.44 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 115.504 -0.771 . . . . 0.41 111.915 -173.73 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . 0.514 ' H ' ' CB ' ' B' ' 37' ' ' PHE . . . 63.96 45.14 94.79 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.902 -0.666 . . . . 0.32 112.893 173.715 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.876 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.4 tp -104.11 105.2 18.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-O 121.354 0.597 . . . . 0.31 109.522 177.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.63 HG21 ' CD1' ' B' ' 49' ' ' TYR . 54.5 t -75.02 131.73 34.53 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-N 115.655 -0.702 . . . . 0.28 110.415 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.426 ' HG2' ' H ' ' A' ' 17' ' ' VAL . 2.9 tpp180 -127.58 114.6 17.62 Favored 'General case' 0 N--CA 1.434 -1.262 0 N-CA-C 106.522 -1.659 . . . . 1.99 106.522 177.781 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' ARG . . . . . 0.505 ' C ' HD12 ' A' ' 10' ' ' ILE . 0.6 OUTLIER -78.05 101.36 6.91 Favored 'General case' 0 C--N 1.308 -1.221 0 N-CA-C 107.611 -1.255 . . . . 2.8 107.611 174.708 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.612 HD11 ' N ' ' B' ' 31' ' ' GLY . 0.3 OUTLIER -7.44 -102.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.941 0 O-C-N 125.763 1.914 . . . . 0.33 113.928 -175.385 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . 0.599 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 4.8 p-10 164.77 -159.47 0.0 OUTLIER 'General case' 0 CA--C 1.507 -0.677 0 N-CA-C 108.249 -1.019 . . . . 1.13 108.249 175.389 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 31.2 t70 -74.57 -17.84 60.67 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.014 0.435 . . . . 2.26 110.96 -179.173 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.413 ' H ' ' CG ' ' A' ' 11' ' ' ASP . 2.8 tm? -103.33 -59.07 1.77 Allowed 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.186 -0.461 . . . . 0.53 110.801 179.779 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.464 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 138.46 18.76 0.54 Allowed Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.214 -0.994 . . . . 0.22 113.211 -179.039 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.761 ' HB3' ' HB3' ' B' ' 15' ' ' ARG . 0.7 OUTLIER -81.01 157.37 25.5 Favored 'General case' 0 CA--C 1.491 -1.317 0 CA-C-N 117.965 0.882 . . . . 0.69 110.031 176.034 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.909 HG22 HG22 ' B' ' 16' ' ' VAL . 17.2 m -107.81 109.81 29.6 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.201 0 N-CA-C 106.945 -1.502 . . . . 1.24 106.945 164.77 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.812 HG22 ' HG2' ' B' ' 15' ' ' ARG . 57.6 t -71.71 94.75 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.433 -1.309 0 CA-C-N 115.091 -0.959 . . . . 0.28 109.278 -175.668 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.488 HD11 HD12 ' A' ' 46' ' ' LEU . 9.0 mt -82.37 109.79 17.9 Favored Pre-proline 0 N--CA 1.444 -0.761 0 CA-C-N 115.621 -0.718 . . . . 0.77 110.284 179.087 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.635 ' HD3' ' O ' ' A' ' 17' ' ' VAL . 95.8 Cg_exo -51.16 151.42 12.44 Favored 'Trans proline' 0 N--CA 1.454 -0.845 0 C-N-CA 123.053 2.502 . . . . 0.32 112.366 174.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.855 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -62.34 -25.14 67.74 Favored 'General case' 0 C--O 1.206 -1.194 0 CA-C-N 115.591 -0.731 . . . . 1.57 111.763 -176.823 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.3 pm0 -55.49 -25.65 38.19 Favored 'General case' 0 C--O 1.239 0.507 0 N-CA-C 112.854 0.687 . . . . 1.32 112.854 -178.447 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.464 HD13 HG23 ' A' ' 18' ' ' ILE . 5.1 mp -88.18 -46.95 15.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 108.404 -0.961 . . . . 0.35 108.404 -176.574 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . 0.526 ' NE ' ' HA ' ' A' ' 29' ' ' ARG . 0.0 OUTLIER -61.02 -30.86 70.56 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 115.158 -0.928 . . . . 1.5 109.583 174.744 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 76.7 ttt180 -63.84 -52.11 61.61 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 114.269 -1.332 . . . . 2.96 111.011 175.532 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 25.6 m -64.51 -27.99 69.35 Favored 'General case' 0 C--O 1.234 0.268 0 CA-C-O 121.137 0.494 . . . . 0.4 110.537 175.377 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.832 ' HB3' HG13 ' A' ' 28' ' ' ILE . 0.8 OUTLIER -65.23 -18.1 65.04 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.534 -0.757 . . . . 0.36 111.162 175.225 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.502 ' HB2' ' O ' ' A' ' 26' ' ' LEU . 10.4 mpt_? 70.45 20.28 6.03 Favored 'General case' 0 N--CA 1.466 0.34 0 C-N-CA 123.259 0.624 . . . . 3.2 110.529 -174.109 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.832 HG13 ' HB3' ' A' ' 26' ' ' LEU . 2.7 mt -116.43 -166.06 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 115.728 -0.669 . . . . 0.48 109.458 -176.526 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.717 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -154.76 -155.5 0.58 Allowed 'General case' 0 C--N 1.321 -0.658 0 C-N-CA 122.267 0.227 . . . . 2.4 110.677 -173.327 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . 0.412 ' H ' ' HB2' ' A' ' 29' ' ' ARG . 1.7 mp0 -75.11 44.32 0.24 Allowed 'General case' 0 C--N 1.332 -0.168 0 CA-C-O 122.122 0.963 . . . . 1.23 111.366 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.688 ' N ' HD11 ' B' ' 10' ' ' ILE . . . -154.65 19.75 0.6 Allowed Glycine 0 N--CA 1.441 -1.024 0 CA-C-N 113.833 -1.531 . . . . 0.36 110.687 175.785 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.448 ' HA ' ' HD3' ' A' ' 33' ' ' PRO . 17.7 t0 -79.65 120.23 79.47 Favored Pre-proline 0 N--CA 1.464 0.245 0 CA-C-O 121.437 0.637 . . . . 1.26 109.784 176.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.618 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 2.8 Cg_endo -88.98 56.35 2.09 Favored 'Trans proline' 0 N--CA 1.452 -0.946 0 C-N-CA 123.891 3.06 . . . . 1.3 114.165 -174.494 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.921 HD11 HG23 ' B' ' 10' ' ' ILE . 0.0 OUTLIER -59.28 154.44 16.45 Favored 'General case' 0 C--N 1.3 -1.545 0 C-N-CA 118.823 -1.151 . . . . 0.38 112.34 -173.478 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.85 ' HB3' ' HD2' ' A' ' 47' ' ' LYS . 42.7 tt0 -107.92 112.48 25.11 Favored 'General case' 0 CA--C 1.491 -1.31 0 CA-C-N 113.847 -1.524 . . . . 1.12 107.909 -175.834 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.836 ' HB ' HG23 ' B' ' 6' ' ' ILE . 2.8 mt -82.65 111.05 18.47 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 O-C-N 124.424 1.078 . . . . 0.39 109.736 -179.752 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' PHE . . . . . 0.544 ' HB2' ' H ' ' B' ' 4' ' ' THR . 0.6 OUTLIER -151.11 125.88 9.68 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-O 120.98 0.419 . . . . 1.15 110.003 173.586 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.511 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 1.1 p -80.5 138.76 19.21 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 CA-C-O 120.921 0.391 . . . . 0.17 110.798 -177.158 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.694 ' OD2' ' HD2' ' A' ' 40' ' ' ARG . 14.2 t70 -84.29 -49.42 8.77 Favored 'General case' 0 CA--C 1.513 -0.45 0 CA-C-N 115.802 -0.635 . . . . 1.11 111.823 -173.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . 0.694 ' HD2' ' OD2' ' A' ' 39' ' ' ASP . 0.0 OUTLIER -135.81 -96.63 0.24 Allowed 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.632 -0.713 . . . . 2.29 112.516 -165.972 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -84.85 -74.24 0.4 Allowed 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.529 0.68 . . . . 1.53 110.826 -177.03 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.653 ' HA3' HD11 ' B' ' 26' ' ' LEU . . . -138.25 26.03 2.85 Favored Glycine 0 N--CA 1.439 -1.103 0 CA-C-N 115.207 -0.906 . . . . 0.32 110.918 -178.366 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.636 ' HB3' HG23 ' B' ' 45' ' ' ILE . 2.3 mt-10 -94.89 109.2 21.22 Favored 'General case' 0 N--CA 1.446 -0.641 0 N-CA-C 109.161 -0.681 . . . . 1.97 109.161 179.028 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.588 ' CG1' HG23 ' A' ' 36' ' ' ILE . 2.0 t -89.2 131.41 36.57 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.961 0 N-CA-C 109.268 -0.641 . . . . 0.14 109.268 177.79 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.77 HG13 HG13 ' B' ' 45' ' ' ILE . 1.6 mp -110.44 115.96 51.14 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.223 0 N-CA-C 108.312 -0.996 . . . . 0.14 108.312 -176.397 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.952 HD11 HD11 ' B' ' 46' ' ' LEU . 0.3 OUTLIER -109.6 117.52 34.15 Favored 'General case' 0 C--N 1.315 -0.923 0 O-C-N 123.785 0.678 . . . . 0.23 109.643 179.803 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.85 ' HD2' ' HB3' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -130.91 144.1 51.21 Favored 'General case' 0 C--O 1.215 -0.752 0 C-N-CA 118.695 -1.202 . . . . 0.76 112.844 176.303 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.633 ' HG3' ' HD2' ' A' ' 51' ' ' PRO . 1.0 OUTLIER -20.46 -25.93 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.981 0 N-CA-C 119.532 3.16 . . . . 0.32 119.532 -179.08 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 0.729 ' CD1' HG21 ' B' ' 7' ' ' VAL . 37.0 t80 72.87 -38.48 0.42 Allowed 'General case' 0 N--CA 1.479 1.002 0 CA-C-N 119.795 1.18 . . . . 1.28 112.339 -179.036 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.662 ' HB3' ' HD3' ' A' ' 51' ' ' PRO . 26.3 t -52.32 -52.32 63.98 Favored Pre-proline 0 CA--C 1.542 0.667 0 CA-C-N 116.29 -0.414 . . . . 1.36 110.559 -177.741 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.662 ' HD3' ' HB3' ' A' ' 50' ' ' SER . 97.9 Cg_endo -92.21 7.93 3.02 Favored 'Trans proline' 0 C--N 1.355 0.896 0 C-N-CA 122.387 2.058 . . . . 0.58 111.733 167.176 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.499 ' H ' ' C ' ' A' ' 49' ' ' TYR . 0.3 OUTLIER . . . . . 0 N--CA 1.467 0.394 0 CA-C-N 114.809 -1.087 . . . . 0.78 111.515 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 3' ' ' ALA . . . . . 0.534 ' HA ' ' HD2' ' A' ' 37' ' ' PHE . . . . . . . . 0 N--CA 1.468 0.474 0 CA-C-O 121.338 0.59 . . . . 0.86 111.51 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 4' ' ' THR . . . . . 0.544 ' H ' ' HB2' ' A' ' 37' ' ' PHE . 29.0 p -114.7 -39.75 3.69 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.939 -0.573 . . . . 0.43 111.802 -174.608 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 5' ' ' GLY . . . . . 0.46 ' H ' ' CB ' ' A' ' 37' ' ' PHE . . . 67.62 45.51 76.14 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 121.107 -0.568 . . . . 0.33 112.612 177.428 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 6' ' ' ILE . . . . . 0.836 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.3 tp -103.33 105.3 18.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.514 0.673 . . . . 0.3 109.732 177.855 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . 0.729 HG21 ' CD1' ' A' ' 49' ' ' TYR . 24.3 t -74.93 131.57 34.8 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.838 0 CA-C-N 115.401 -0.818 . . . . 0.27 110.899 -179.573 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . 0.527 ' HB3' ' CD1' ' A' ' 36' ' ' ILE . 1.7 tpp180 -128.72 116.04 18.92 Favored 'General case' 0 N--CA 1.435 -1.211 0 N-CA-C 106.867 -1.531 . . . . 1.69 106.867 178.525 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 9' ' ' ARG . . . . . 0.604 ' HA ' ' HA ' ' A' ' 33' ' ' PRO . 29.2 ttp180 -78.23 102.84 7.81 Favored 'General case' 0 C--N 1.311 -1.075 0 N-CA-C 107.897 -1.149 . . . . 2.71 107.897 173.103 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 10' ' ' ILE . . . . . 0.921 HG23 HD11 ' A' ' 34' ' ' LEU . 0.4 OUTLIER -8.57 -100.77 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 O-C-N 125.948 2.03 . . . . 0.34 113.94 -174.645 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . 0.647 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 2.8 p-10 164.28 -161.05 0.0 OUTLIER 'General case' 0 CA--C 1.512 -0.501 0 N-CA-C 108.484 -0.932 . . . . 1.18 108.484 175.676 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -75.09 -14.32 60.57 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.11 0.481 . . . . 2.39 110.283 -177.237 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 13' ' ' LEU . . . . . 0.434 ' H ' ' CG ' ' B' ' 11' ' ' ASP . 2.2 tm? -105.56 -61.03 1.54 Allowed 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.826 -0.625 . . . . 0.4 110.526 179.541 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 139.84 16.16 0.52 Allowed Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.847 -0.692 . . . . 0.21 112.357 -176.764 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 15' ' ' ARG . . . . . 0.812 ' HG2' HG22 ' A' ' 17' ' ' VAL . 2.0 mtt180 -79.74 153.87 28.93 Favored 'General case' 0 CA--C 1.501 -0.934 0 N-CA-C 109.598 -0.519 . . . . 0.9 109.598 176.668 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 16' ' ' VAL . . . . . 0.909 HG22 HG22 ' A' ' 16' ' ' VAL . 1.1 m -110.5 111.83 37.91 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.673 0 N-CA-C 107.042 -1.466 . . . . 1.27 107.042 166.884 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 17' ' ' VAL . . . . . 0.536 ' O ' ' HD3' ' B' ' 19' ' ' PRO . 62.3 t -72.71 98.62 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.165 0 CA-C-N 114.699 -1.137 . . . . 0.27 109.668 -173.713 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . 0.464 ' HB ' ' O ' ' A' ' 14' ' ' GLY . 8.9 mt -85.88 111.73 40.0 Favored Pre-proline 0 N--CA 1.443 -0.794 0 CA-C-N 115.276 -0.875 . . . . 0.82 110.43 179.799 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 19' ' ' PRO . . . . . 0.664 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 71.4 Cg_exo -50.24 145.4 20.72 Favored 'Trans proline' 0 N--CA 1.456 -0.721 0 C-N-CA 122.965 2.444 . . . . 0.3 112.335 173.793 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 20' ' ' LYS . . . . . 1.002 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -61.65 -15.45 39.95 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 115.465 -0.789 . . . . 1.77 111.696 179.827 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . 0.664 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 11.7 pt-20 -64.65 -25.78 68.1 Favored 'General case' 0 C--O 1.237 0.446 0 N-CA-C 112.035 0.383 . . . . 1.92 112.035 -179.197 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 4.9 mp -88.65 -44.58 15.55 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.271 0 N-CA-C 107.578 -1.267 . . . . 0.44 107.578 -177.885 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 23' ' ' ARG . . . . . 0.422 ' HA ' ' HB2' ' B' ' 26' ' ' LEU . 0.0 OUTLIER -59.36 -31.02 68.82 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-N 115.08 -0.964 . . . . 1.4 109.514 174.124 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 24' ' ' ARG . . . . . 0.429 HH11 ' HD2' ' B' ' 24' ' ' ARG . 22.3 ttt85 -67.7 -49.9 60.29 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 114.767 -1.106 . . . . 3.19 110.745 177.251 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 26.2 m -65.52 -25.99 67.7 Favored 'General case' 0 CA--C 1.535 0.373 0 CA-C-O 121.412 0.625 . . . . 0.4 110.159 176.451 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . 0.717 ' HB3' HG13 ' B' ' 28' ' ' ILE . 0.6 OUTLIER -65.91 -17.4 64.63 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.398 -0.819 . . . . 0.33 110.805 173.038 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 27' ' ' ARG . . . . . 0.422 ' HB2' ' O ' ' B' ' 26' ' ' LEU . 8.6 mpt_? 65.97 27.02 10.86 Favored 'General case' 0 C--O 1.233 0.195 0 CA-C-O 121.458 0.647 . . . . 3.28 110.032 -173.839 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 28' ' ' ILE . . . . . 0.844 HG22 ' H ' ' B' ' 29' ' ' ARG . 5.1 mt -119.84 -167.7 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.379 -0.828 . . . . 0.37 109.683 -179.311 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 29' ' ' ARG . . . . . 0.844 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -153.67 -155.59 0.61 Allowed 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 122.093 0.157 . . . . 2.15 110.934 -176.041 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 30' ' ' GLU . . . . . 0.426 ' H ' ' HB2' ' B' ' 29' ' ' ARG . 1.0 OUTLIER -73.46 39.72 0.1 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 122.104 0.954 . . . . 1.18 111.983 -178.998 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 31' ' ' GLY . . . . . 0.612 ' N ' HD11 ' A' ' 10' ' ' ILE . . . -151.43 26.71 0.97 Allowed Glycine 0 N--CA 1.442 -0.935 0 CA-C-N 114.232 -1.349 . . . . 0.35 110.303 172.774 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 32' ' ' ASP . . . . . 0.501 ' O ' ' HA ' ' A' ' 9' ' ' ARG . 21.9 t0 -81.7 121.14 79.3 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.183 0.516 . . . . 1.29 109.916 176.807 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 33' ' ' PRO . . . . . 0.724 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 5.2 Cg_endo -87.42 72.1 3.08 Favored 'Trans proline' 0 C--O 1.204 -1.207 0 C-N-CA 123.606 2.871 . . . . 1.1 113.437 -177.853 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.61 ' H ' HD12 ' B' ' 34' ' ' LEU . 2.2 mp -71.27 151.85 43.84 Favored 'General case' 0 C--N 1.286 -2.184 0 C-N-CA 117.779 -1.569 . . . . 0.44 111.386 -176.381 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 35' ' ' GLU . . . . . 0.958 ' HB3' ' HD2' ' B' ' 47' ' ' LYS . 44.1 tt0 -108.97 113.79 26.98 Favored 'General case' 0 CA--C 1.49 -1.351 0 CA-C-N 114.388 -1.278 . . . . 1.1 107.919 -177.822 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 36' ' ' ILE . . . . . 0.876 ' HB ' HG23 ' A' ' 6' ' ' ILE . 20.5 mt -88.43 109.99 20.59 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.905 0 O-C-N 124.78 1.3 . . . . 0.62 110.027 -176.169 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 37' ' ' PHE . . . . . 0.816 ' HB2' ' H ' ' A' ' 4' ' ' THR . 1.3 p90 -150.48 129.33 12.47 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 109.561 -0.533 . . . . 1.2 109.561 174.777 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 38' ' ' VAL . . . . . 0.554 ' HA ' ' HA ' ' B' ' 44' ' ' VAL . 0.9 OUTLIER -79.8 142.2 14.27 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.945 0 C-N-CA 120.834 -0.346 . . . . 0.2 110.256 -178.649 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 39' ' ' ASP . . . . . 0.511 ' OD2' ' HD2' ' B' ' 40' ' ' ARG . 38.8 t70 -87.64 -47.1 8.95 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.854 -0.612 . . . . 1.14 111.84 -175.079 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 40' ' ' ARG . . . . . 0.511 ' HD2' ' OD2' ' B' ' 39' ' ' ASP . 0.0 OUTLIER -137.08 -100.97 0.2 Allowed 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 112.535 0.569 . . . . 2.71 112.535 -175.736 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -76.36 -74.54 0.23 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.119 0.485 . . . . 1.32 111.36 -174.503 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 42' ' ' GLY . . . . . 0.548 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -136.77 25.12 3.11 Favored Glycine 0 N--CA 1.444 -0.826 0 C-N-CA 120.833 -0.699 . . . . 0.34 111.426 -178.831 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 43' ' ' GLU . . . . . 0.591 ' HB3' HG23 ' A' ' 45' ' ' ILE . 2.4 mt-10 -94.23 108.87 20.71 Favored 'General case' 0 CA--C 1.509 -0.6 0 N-CA-C 109.792 -0.448 . . . . 2.07 109.792 179.277 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 44' ' ' VAL . . . . . 0.554 ' HA ' ' HA ' ' B' ' 38' ' ' VAL . 1.5 t -88.92 131.0 37.38 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 N-CA-C 109.55 -0.537 . . . . 0.13 109.55 177.831 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 45' ' ' ILE . . . . . 0.77 HG13 HG13 ' A' ' 45' ' ' ILE . 1.7 mp -109.29 118.9 57.67 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.197 0 N-CA-C 108.405 -0.961 . . . . 0.12 108.405 -177.27 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 46' ' ' LEU . . . . . 0.952 HD11 HD11 ' A' ' 46' ' ' LEU . 0.5 OUTLIER -110.64 118.11 35.32 Favored 'General case' 0 C--N 1.316 -0.87 0 O-C-N 123.732 0.645 . . . . 0.15 109.862 178.486 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 47' ' ' LYS . . . . . 0.958 ' HD2' ' HB3' ' B' ' 35' ' ' GLU . 0.0 OUTLIER -129.19 148.11 51.1 Favored 'General case' 0 C--O 1.214 -0.81 0 C-N-CA 119.116 -1.034 . . . . 0.95 112.289 177.294 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 48' ' ' LYS . . . . . 0.592 ' HG3' ' CD ' ' B' ' 51' ' ' PRO . 2.8 ptmt -45.14 -6.28 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.235 0 N-CA-C 117.895 2.554 . . . . 0.64 117.895 -168.004 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 49' ' ' TYR . . . . . 0.724 ' HB3' ' HB2' ' B' ' 33' ' ' PRO . 24.3 t80 68.3 -36.18 0.31 Allowed 'General case' 0 N--CA 1.48 1.03 0 CA-C-N 119.372 0.987 . . . . 1.26 113.28 176.43 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 50' ' ' SER . . . . . 0.614 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 12.4 t -53.97 -47.79 95.92 Favored Pre-proline 0 CA--C 1.542 0.667 0 C-N-CA 122.588 0.355 . . . . 1.22 110.991 -177.194 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 51' ' ' PRO . . . . . 0.614 ' HD3' ' HB3' ' B' ' 50' ' ' SER . 62.6 Cg_endo -94.56 5.52 2.52 Favored 'Trans proline' 0 C--N 1.352 0.751 0 C-N-CA 122.451 2.101 . . . . 0.56 111.919 165.551 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 52' ' ' ILE . . . . . 0.516 ' H ' ' C ' ' B' ' 49' ' ' TYR . 0.6 OUTLIER . . . . . 0 N--CA 1.465 0.293 0 CA-C-N 115.083 -0.962 . . . . 0.73 110.595 -177.324 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . 0.83 ' HA ' ' HD2' ' B' ' 37' ' ' PHE . . . . . . . . 0 CA--C 1.519 -0.225 0 CA-C-O 121.602 0.715 . . . . 0.72 110.802 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.473 ' OG1' ' HA ' ' B' ' 37' ' ' PHE . 15.6 p -94.08 -35.92 12.34 Favored 'General case' 0 N--CA 1.444 -0.74 0 CA-C-N 115.181 -0.918 . . . . 0.41 112.036 -176.506 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 60.93 49.37 79.42 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.969 -0.634 . . . . 0.32 112.799 176.317 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.876 HG23 ' HB ' ' B' ' 36' ' ' ILE . 0.9 OUTLIER -108.28 111.3 35.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 N-CA-C 109.379 -0.6 . . . . 0.31 109.379 175.295 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.665 HG21 ' CD1' ' B' ' 49' ' ' TYR . 48.6 t -82.38 133.96 28.03 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 CA-C-O 121.303 0.573 . . . . 0.28 111.013 -178.3 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.601 ' HB3' HD11 ' B' ' 36' ' ' ILE . 3.9 tpt180 -126.2 107.86 10.76 Favored 'General case' 0 N--CA 1.441 -0.903 0 N-CA-C 107.074 -1.454 . . . . 1.99 107.074 -178.545 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' ARG . . . . . 0.525 ' C ' HD12 ' A' ' 10' ' ' ILE . 2.0 ttt180 -78.34 102.0 7.49 Favored 'General case' 0 CA--C 1.503 -0.847 0 N-CA-C 108.02 -1.104 . . . . 2.8 108.02 175.73 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.706 HD11 ' CA ' ' B' ' 31' ' ' GLY . 0.2 OUTLIER -10.12 -109.25 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 O-C-N 126.036 2.085 . . . . 0.33 114.551 -179.187 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . 0.63 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 4.2 p-10 158.81 -167.73 0.0 OUTLIER 'General case' 0 CA--C 1.513 -0.458 0 N-CA-C 107.202 -1.407 . . . . 1.13 107.202 177.465 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -67.52 -22.78 65.42 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.013 0.435 . . . . 2.26 110.887 -178.241 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.432 HD22 ' HA ' ' A' ' 13' ' ' LEU . 2.2 tm? -95.28 -61.54 1.46 Allowed 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.081 -0.509 . . . . 0.53 109.733 177.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.575 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 132.71 21.49 0.9 Allowed Glycine 0 N--CA 1.443 -0.892 0 C-N-CA 119.898 -1.144 . . . . 0.22 114.131 178.242 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.492 ' HA ' ' HA ' ' B' ' 17' ' ' VAL . 0.9 OUTLIER -79.01 155.08 29.01 Favored 'General case' 0 CA--C 1.504 -0.814 0 CA-C-N 118.91 1.355 . . . . 0.69 110.941 179.249 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.637 HG21 HD13 ' B' ' 46' ' ' LEU . 52.9 t -111.43 101.37 12.45 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.379 0 N-CA-C 107.39 -1.337 . . . . 1.24 107.39 169.322 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.709 HG22 ' HG2' ' B' ' 15' ' ' ARG . 65.5 t -68.21 106.91 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.016 0 CA-C-N 115.038 -0.983 . . . . 0.28 109.775 -175.767 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 31.7 mm -90.8 109.26 33.45 Favored Pre-proline 0 N--CA 1.446 -0.636 0 CA-C-N 115.79 -0.641 . . . . 0.77 110.547 -177.895 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.578 ' HD3' ' O ' ' A' ' 17' ' ' VAL . 81.0 Cg_exo -50.37 138.04 38.63 Favored 'Trans proline' 0 N--CA 1.459 -0.521 0 C-N-CA 123.015 2.476 . . . . 0.32 112.359 173.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.882 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -57.64 -14.21 5.12 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-N 114.947 -1.024 . . . . 1.57 112.265 179.297 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.541 ' O ' ' HB3' ' A' ' 24' ' ' ARG . 11.9 pt-20 -67.08 -25.78 66.4 Favored 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 118.088 0.404 . . . . 1.32 111.724 -178.256 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 4.5 mp -88.15 -42.73 15.1 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.321 0 N-CA-C 107.622 -1.251 . . . . 0.35 107.622 -178.081 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ARG . . . . . 0.657 ' HA ' ' HB2' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -58.51 -31.78 68.21 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 114.848 -1.069 . . . . 1.5 109.145 171.936 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.541 ' HB3' ' O ' ' A' ' 21' ' ' GLU . 55.3 ttp180 -60.19 -52.85 63.56 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 114.313 -1.312 . . . . 2.96 110.785 174.092 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 17.3 m -65.85 -27.02 67.93 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-O 121.247 0.546 . . . . 0.4 110.961 174.699 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.675 ' HB3' HG13 ' A' ' 28' ' ' ILE . 1.3 mm? -64.68 -20.86 66.55 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.759 -0.655 . . . . 0.36 110.638 173.879 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 8.1 tpt180 71.17 18.83 5.66 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-O 121.793 0.806 . . . . 3.2 109.302 -176.431 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.774 HG22 ' H ' ' A' ' 29' ' ' ARG . 3.9 mt -114.9 -167.44 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 114.894 -1.048 . . . . 0.48 108.797 -177.926 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ARG . . . . . 0.774 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -155.54 -149.63 0.27 Allowed 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 110.149 -0.315 . . . . 2.4 110.149 -173.282 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 4.6 mp0 -72.58 40.15 0.08 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.471 0.653 . . . . 1.23 111.962 178.754 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.665 ' CA ' HD11 ' B' ' 10' ' ' ILE . . . -154.87 33.37 0.67 Allowed Glycine 0 N--CA 1.438 -1.189 0 N-CA-C 110.609 -0.996 . . . . 0.36 110.609 171.592 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.5 ' HA ' ' HD3' ' A' ' 33' ' ' PRO . 45.9 t0 -90.1 116.3 66.04 Favored Pre-proline 0 C--O 1.234 0.275 0 CA-C-O 121.327 0.584 . . . . 1.26 109.602 175.742 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.553 ' HA ' ' HA ' ' B' ' 9' ' ' ARG . 1.3 Cg_endo -87.28 63.29 4.07 Favored 'Trans proline' 0 N--CA 1.454 -0.835 0 C-N-CA 123.984 3.122 . . . . 1.3 113.83 -177.064 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.616 HD12 ' H ' ' A' ' 34' ' ' LEU . 0.7 OUTLIER -63.87 153.79 35.72 Favored 'General case' 0 C--N 1.295 -1.785 0 C-N-CA 118.709 -1.196 . . . . 0.38 111.695 -175.636 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.925 ' HB3' ' HD2' ' A' ' 47' ' ' LYS . 34.4 tt0 -111.0 117.2 32.7 Favored 'General case' 0 CA--C 1.491 -1.29 0 CA-C-N 113.926 -1.488 . . . . 1.12 108.987 -173.362 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.905 ' HB ' HG23 ' B' ' 6' ' ' ILE . 3.0 mp -84.19 111.59 20.28 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.828 0 O-C-N 124.534 1.146 . . . . 0.39 109.546 -178.875 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' PHE . . . . . 0.876 ' HD2' ' HA ' ' B' ' 3' ' ' ALA . 0.3 OUTLIER -149.79 124.01 9.52 Favored 'General case' 0 C--N 1.313 -1.002 0 CA-C-O 121.13 0.491 . . . . 1.15 109.711 172.416 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.508 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 1.4 p -80.16 137.22 21.92 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 CA-C-O 121.198 0.523 . . . . 0.17 110.143 -179.409 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.667 ' OD2' ' HD2' ' A' ' 40' ' ' ARG . 32.3 t70 -88.24 -46.07 9.54 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.256 -0.884 . . . . 1.11 111.699 -172.877 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . 0.797 ' HG3' ' HG3' ' A' ' 43' ' ' GLU . 0.1 OUTLIER -128.19 -90.64 0.5 Allowed 'General case' 0 C--N 1.313 -1.008 0 CA-C-N 114.773 -1.103 . . . . 2.29 112.054 -162.402 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -112.74 -66.51 1.08 Allowed 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 121.02 0.438 . . . . 1.53 111.205 -176.402 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.563 ' HA3' HD11 ' B' ' 26' ' ' LEU . . . -130.33 13.68 5.67 Favored Glycine 0 CA--C 1.499 -0.914 0 C-N-CA 120.462 -0.875 . . . . 0.32 111.628 -178.309 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.797 ' HG3' ' HG3' ' A' ' 40' ' ' ARG . 0.9 OUTLIER -97.04 110.54 23.06 Favored 'General case' 0 C--N 1.319 -0.732 0 N-CA-C 109.299 -0.63 . . . . 1.97 109.299 -178.794 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.582 ' CG1' HG23 ' A' ' 36' ' ' ILE . 2.3 t -90.71 133.76 31.51 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.788 0 CA-C-N 115.718 -0.674 . . . . 0.14 109.239 177.924 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.736 HG13 HG13 ' B' ' 45' ' ' ILE . 1.7 mp -110.93 116.6 52.92 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 N-CA-C 108.644 -0.873 . . . . 0.14 108.644 -175.77 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.94 HD11 HD11 ' B' ' 46' ' ' LEU . 0.9 OUTLIER -108.08 118.36 36.54 Favored 'General case' 0 C--N 1.319 -0.76 0 O-C-N 123.764 0.665 . . . . 0.23 109.753 179.53 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.925 ' HD2' ' HB3' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -130.08 148.73 51.96 Favored 'General case' 0 C--O 1.216 -0.689 0 C-N-CA 118.849 -1.14 . . . . 0.76 113.152 178.001 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.596 ' HE2' ' HG3' ' A' ' 51' ' ' PRO . 2.2 ptmt -35.83 -19.73 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.09 0 N-CA-C 118.044 2.609 . . . . 0.32 118.044 -172.288 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 0.585 ' CD1' HG21 ' B' ' 7' ' ' VAL . 22.6 t80 74.95 -54.26 0.66 Allowed 'General case' 0 N--CA 1.475 0.822 0 C-N-CA 123.455 0.702 . . . . 1.28 112.79 177.408 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.713 ' HB3' ' HD3' ' A' ' 51' ' ' PRO . 6.8 t -52.15 -53.13 55.62 Favored Pre-proline 0 CA--C 1.541 0.601 0 CA-C-N 116.388 -0.369 . . . . 1.36 111.182 -173.675 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.713 ' HD3' ' HB3' ' A' ' 50' ' ' SER . 48.5 Cg_endo -92.98 14.39 1.6 Allowed 'Trans proline' 0 C--N 1.348 0.536 0 C-N-CA 122.376 2.051 . . . . 0.58 111.539 170.101 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.41 HG13 ' C ' ' A' ' 51' ' ' PRO . 0.9 OUTLIER . . . . . 0 C--O 1.235 0.306 0 CA-C-N 115.429 -0.805 . . . . 0.78 109.86 -176.861 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 3' ' ' ALA . . . . . 0.876 ' HA ' ' HD2' ' A' ' 37' ' ' PHE . . . . . . . . 0 CA--C 1.517 -0.296 0 CA-C-O 121.495 0.664 . . . . 0.86 110.979 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 4' ' ' THR . . . . . . . . . . . . . 20.4 p -91.68 -29.14 17.02 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.219 -0.901 . . . . 0.43 112.275 -173.607 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 56.99 47.74 84.93 Favored Glycine 0 N--CA 1.45 -0.415 0 CA-C-N 115.711 -0.677 . . . . 0.33 112.99 175.306 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 6' ' ' ILE . . . . . 0.905 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.0 OUTLIER -107.66 109.46 28.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-O 121.178 0.513 . . . . 0.3 109.623 176.602 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 7' ' ' VAL . . . . . 0.602 ' HA ' ' HA ' ' A' ' 35' ' ' GLU . 14.7 t -80.52 135.38 25.39 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.996 0 CA-C-N 115.609 -0.723 . . . . 0.27 110.783 -177.813 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . 0.526 ' CZ ' HG23 ' B' ' 17' ' ' VAL . 1.1 tpt180 -128.09 112.77 14.95 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 107.405 -1.331 . . . . 1.69 107.405 178.696 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 9' ' ' ARG . . . . . 0.553 ' HA ' ' HA ' ' A' ' 33' ' ' PRO . 13.2 ttt180 -78.83 104.45 9.47 Favored 'General case' 0 CA--C 1.501 -0.929 0 N-CA-C 108.287 -1.005 . . . . 2.71 108.287 174.564 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 10' ' ' ILE . . . . . 0.665 HD11 ' CA ' ' A' ' 31' ' ' GLY . 0.2 OUTLIER -15.28 -103.24 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 O-C-N 125.822 1.951 . . . . 0.34 114.65 -177.248 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 11' ' ' ASP . . . . . 0.575 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 6.4 p-10 158.08 -161.08 0.0 OUTLIER 'General case' 0 CA--C 1.506 -0.727 0 N-CA-C 106.604 -1.628 . . . . 1.18 106.604 174.854 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 38.4 t70 -77.04 -17.5 58.74 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.512 0.673 . . . . 2.39 110.209 -178.151 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 13' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -96.1 -61.6 1.41 Allowed 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.575 -0.739 . . . . 0.4 110.029 177.296 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 134.61 24.06 0.62 Allowed Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.477 -0.868 . . . . 0.21 112.649 179.624 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 15' ' ' ARG . . . . . 0.709 ' HG2' HG22 ' A' ' 17' ' ' VAL . 56.4 mtt180 -77.82 147.28 35.28 Favored 'General case' 0 CA--C 1.51 -0.575 0 CA-C-O 121.479 0.657 . . . . 0.9 111.175 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 16' ' ' VAL . . . . . 0.526 HG11 HD13 ' A' ' 46' ' ' LEU . 92.7 t -113.76 99.49 8.72 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.13 0 N-CA-C 107.861 -1.163 . . . . 1.27 107.861 168.335 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 17' ' ' VAL . . . . . 0.568 ' O ' ' HD3' ' B' ' 19' ' ' PRO . 60.8 t -66.41 106.33 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.847 0 CA-C-N 115.475 -0.784 . . . . 0.27 109.847 -173.635 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 18' ' ' ILE . . . . . 0.575 ' HB ' ' O ' ' A' ' 14' ' ' GLY . 22.7 mm -89.29 109.08 28.62 Favored Pre-proline 0 C--N 1.32 -0.696 0 CA-C-N 115.587 -0.733 . . . . 0.82 110.24 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 19' ' ' PRO . . . . . 0.632 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 93.6 Cg_exo -53.45 144.05 52.46 Favored 'Trans proline' 0 N--CA 1.454 -0.799 0 C-N-CA 122.558 2.172 . . . . 0.3 112.22 174.773 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 20' ' ' LYS . . . . . 0.989 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -64.64 -13.71 54.99 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 115.556 -0.747 . . . . 1.77 111.434 -179.396 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 21' ' ' GLU . . . . . 0.632 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 11.2 pt-20 -65.42 -26.32 67.92 Favored 'General case' 0 C--O 1.239 0.549 0 N-CA-C 112.688 0.625 . . . . 1.92 112.688 179.556 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 22' ' ' ILE . . . . . 0.438 ' H ' HD12 ' B' ' 22' ' ' ILE . 3.9 mp -88.58 -42.09 14.52 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.252 0 N-CA-C 107.807 -1.183 . . . . 0.44 107.807 -179.214 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 23' ' ' ARG . . . . . 0.577 ' HA ' ' HB2' ' B' ' 26' ' ' LEU . 0.0 OUTLIER -57.69 -30.24 65.33 Favored 'General case' 0 N--CA 1.461 0.125 0 CA-C-N 114.927 -1.033 . . . . 1.4 109.126 170.973 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 24' ' ' ARG . . . . . 0.535 ' HB3' ' O ' ' B' ' 21' ' ' GLU . 21.4 ttp180 -62.28 -53.17 59.06 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 114.289 -1.323 . . . . 3.19 110.942 174.838 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 30.4 m -62.41 -32.0 72.77 Favored 'General case' 0 C--O 1.235 0.334 0 CA-C-O 121.409 0.624 . . . . 0.4 110.557 174.278 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . 0.663 ' HB3' HG13 ' B' ' 28' ' ' ILE . 0.9 OUTLIER -64.3 -19.86 65.7 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.212 -0.903 . . . . 0.33 110.705 176.131 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 27' ' ' ARG . . . . . 0.45 ' HD2' ' HA ' ' B' ' 27' ' ' ARG . 11.9 tpt180 68.05 22.45 8.43 Favored 'General case' 0 N--CA 1.461 0.097 0 CA-C-O 121.802 0.81 . . . . 3.28 109.906 -177.627 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 28' ' ' ILE . . . . . 0.84 HG22 ' H ' ' B' ' 29' ' ' ARG . 6.3 mt -111.92 -161.21 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.203 -0.908 . . . . 0.37 109.162 -179.306 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 29' ' ' ARG . . . . . 0.84 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -158.68 -157.37 0.61 Allowed 'General case' 0 C--N 1.32 -0.689 0 O-C-N 122.468 -0.145 . . . . 2.15 110.618 -173.229 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 30' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -70.31 43.48 0.06 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.975 0.893 . . . . 1.18 111.598 176.777 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 31' ' ' GLY . . . . . 0.706 ' CA ' HD11 ' A' ' 10' ' ' ILE . . . -161.12 36.06 0.41 Allowed Glycine 0 N--CA 1.436 -1.338 0 CA-C-N 114.282 -1.326 . . . . 0.35 110.358 174.614 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 32' ' ' ASP . . . . . 0.497 ' HA ' ' HD3' ' B' ' 33' ' ' PRO . 16.5 t0 -93.21 121.13 66.06 Favored Pre-proline 0 C--N 1.327 -0.409 0 CA-C-N 115.006 -0.597 . . . . 1.29 110.223 175.558 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 33' ' ' PRO . . . . . 0.674 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 3.9 Cg_endo -86.84 75.6 2.57 Favored 'Trans proline' 0 C--O 1.206 -1.084 0 C-N-CA 123.664 2.909 . . . . 1.1 113.31 -179.919 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.699 ' H ' HD12 ' B' ' 34' ' ' LEU . 1.4 mp -71.14 150.52 45.34 Favored 'General case' 0 C--N 1.286 -2.182 0 C-N-CA 117.909 -1.516 . . . . 0.44 111.326 -178.535 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 35' ' ' GLU . . . . . 0.783 ' HB3' ' HD2' ' B' ' 47' ' ' LYS . 45.2 tt0 -109.69 114.45 28.06 Favored 'General case' 0 CA--C 1.49 -1.343 0 CA-C-N 114.384 -1.28 . . . . 1.1 108.326 -177.656 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 36' ' ' ILE . . . . . 0.986 HG13 HD22 ' B' ' 46' ' ' LEU . 3.0 mp -87.46 112.16 22.94 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 O-C-N 124.761 1.288 . . . . 0.62 109.697 -177.221 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 37' ' ' PHE . . . . . 0.83 ' HD2' ' HA ' ' A' ' 3' ' ' ALA . 1.1 p90 -150.14 128.42 12.07 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 116.003 -0.544 . . . . 1.2 109.661 172.39 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 38' ' ' VAL . . . . . 0.525 ' HA ' ' HA ' ' B' ' 44' ' ' VAL . 0.6 OUTLIER -80.67 140.19 17.03 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.982 0 CA-C-O 121.281 0.563 . . . . 0.2 110.57 -179.636 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 39' ' ' ASP . . . . . 0.631 ' OD1' ' HD2' ' B' ' 40' ' ' ARG . 16.1 t70 -84.85 -50.74 7.29 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.16 -0.927 . . . . 1.14 111.731 -173.249 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 40' ' ' ARG . . . . . 0.631 ' HD2' ' OD1' ' B' ' 39' ' ' ASP . 0.0 OUTLIER -134.99 -87.15 0.38 Allowed 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 112.661 0.615 . . . . 2.71 112.661 -172.437 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -95.17 -78.81 0.44 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.025 0.44 . . . . 1.32 110.999 -175.673 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 42' ' ' GLY . . . . . 0.479 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -125.84 16.02 6.95 Favored Glycine 0 N--CA 1.443 -0.843 0 C-N-CA 120.576 -0.821 . . . . 0.34 112.043 -177.481 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 43' ' ' GLU . . . . . 0.428 ' H ' ' HG2' ' B' ' 43' ' ' GLU . 0.0 OUTLIER -92.03 107.64 19.35 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.511 -0.552 . . . . 2.07 109.511 -178.765 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 44' ' ' VAL . . . . . 0.564 ' O ' ' HA ' ' A' ' 45' ' ' ILE . 1.9 t -89.83 133.71 31.03 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.852 0 N-CA-C 109.402 -0.592 . . . . 0.13 109.402 176.441 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 45' ' ' ILE . . . . . 0.736 HG13 HG13 ' A' ' 45' ' ' ILE . 1.7 mp -110.62 119.86 60.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 N-CA-C 108.582 -0.896 . . . . 0.12 108.582 -177.281 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 46' ' ' LEU . . . . . 0.986 HD22 HG13 ' B' ' 36' ' ' ILE . 0.6 OUTLIER -112.13 117.54 32.88 Favored 'General case' 0 C--N 1.32 -0.696 0 O-C-N 123.682 0.614 . . . . 0.15 109.936 178.333 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 47' ' ' LYS . . . . . 0.783 ' HD2' ' HB3' ' B' ' 35' ' ' GLU . 0.0 OUTLIER -130.95 152.94 49.71 Favored 'General case' 0 C--O 1.213 -0.848 0 C-N-CA 119.254 -0.978 . . . . 0.95 113.033 177.516 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 48' ' ' LYS . . . . . 0.664 ' HE3' HD11 ' B' ' 28' ' ' ILE . 12.5 ptmt -49.87 -4.4 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.011 0 N-CA-C 117.713 2.486 . . . . 0.64 117.713 -166.727 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 49' ' ' TYR . . . . . 0.674 ' HB3' ' HB2' ' B' ' 33' ' ' PRO . 28.7 t80 71.73 -54.53 0.67 Allowed 'General case' 0 N--CA 1.477 0.88 0 N-CA-C 113.549 0.944 . . . . 1.26 113.549 172.027 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 50' ' ' SER . . . . . 0.69 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 9.2 t -51.55 -55.88 25.61 Favored Pre-proline 0 CA--C 1.539 0.548 0 CA-C-N 116.05 -0.523 . . . . 1.22 111.035 -173.518 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 51' ' ' PRO . . . . . 0.69 ' HD3' ' HB3' ' B' ' 50' ' ' SER . 41.3 Cg_endo -89.81 12.95 2.45 Favored 'Trans proline' 0 C--N 1.351 0.705 0 C-N-CA 122.172 1.915 . . . . 0.56 111.514 170.698 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 52' ' ' ILE . . . . . . . . . . . . . 1.1 mt . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 115.199 -0.909 . . . . 0.73 109.714 -176.66 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 52.6 ttm . . . . . 0 N--CA 1.478 0.945 0 CA-C-O 119.631 -0.224 . . . . 5.91 111.037 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 19.9 mmmt 57.47 -93.25 0.04 OUTLIER 'General case' 0 CA--C 1.515 -0.395 0 O-C-N 123.617 0.573 . . . . 3.71 110.649 -175.691 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.51 ' HA ' ' HB2' ' B' ' 37' ' ' PHE . . . 71.15 126.43 0.03 OUTLIER 'General case' 0 C--N 1.311 -1.096 0 CA-C-N 113.953 -1.476 . . . . 0.72 113.459 172.779 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.682 ' H ' ' HB2' ' B' ' 37' ' ' PHE . 10.6 p -110.28 -48.02 3.22 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 114.968 -1.015 . . . . 0.41 109.893 172.007 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 78.68 51.65 5.43 Favored Glycine 0 N--CA 1.446 -0.646 0 CA-C-N 115.431 -0.804 . . . . 0.32 112.912 172.001 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.807 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.5 tp -107.99 107.17 22.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 N-CA-C 109.273 -0.64 . . . . 0.31 109.273 172.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.741 ' HA ' ' O ' ' B' ' 34' ' ' LEU . 44.2 t -78.28 133.73 29.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-N 116.102 -0.499 . . . . 0.28 110.565 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.577 ' HB3' ' CD1' ' B' ' 36' ' ' ILE . 0.4 OUTLIER -129.69 123.06 30.22 Favored 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 107.387 -1.338 . . . . 1.99 107.387 -178.237 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.529 ' HA ' ' HA ' ' B' ' 33' ' ' PRO . 0.0 OUTLIER -83.82 103.02 12.76 Favored 'General case' 0 C--N 1.314 -0.947 0 N-CA-C 107.754 -1.202 . . . . 2.8 107.754 173.246 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.789 HG23 HD11 ' B' ' 34' ' ' LEU . 0.2 OUTLIER -9.97 -102.53 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.13 0 O-C-N 125.291 1.619 . . . . 0.33 114.595 -175.4 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . 0.577 ' H ' HD13 ' A' ' 10' ' ' ILE . 27.9 p-10 163.33 -165.03 0.01 OUTLIER 'General case' 0 CA--C 1.506 -0.722 0 N-CA-C 107.86 -1.163 . . . . 1.13 107.86 175.175 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . 0.502 ' HA ' ' HG2' ' B' ' 30' ' ' GLU . 12.8 p-10 -80.97 14.38 2.27 Favored 'General case' 0 C--N 1.318 -0.796 0 O-C-N 123.376 0.423 . . . . 2.26 111.284 -176.648 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -129.96 -55.14 1.13 Allowed 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 109.931 -0.396 . . . . 0.53 109.931 176.799 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.554 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 135.79 7.48 1.82 Allowed Glycine 0 N--CA 1.444 -0.776 0 C-N-CA 120.606 -0.807 . . . . 0.22 113.156 -179.014 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.735 ' HG2' HG22 ' B' ' 17' ' ' VAL . 0.5 OUTLIER -77.76 156.03 30.81 Favored 'General case' 0 CA--C 1.495 -1.149 0 CA-C-N 117.813 0.806 . . . . 0.69 109.912 178.304 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 1.045 HG22 HG22 ' B' ' 16' ' ' VAL . 0.8 OUTLIER -112.2 115.09 48.89 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.86 0 N-CA-C 107.508 -1.293 . . . . 1.24 107.508 167.954 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.702 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 46.9 t -73.35 98.21 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 CA-C-N 114.801 -1.09 . . . . 0.28 109.355 -174.281 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.514 ' HB ' ' O ' ' B' ' 14' ' ' GLY . 33.7 mm -83.96 106.97 8.98 Favored Pre-proline 0 N--CA 1.448 -0.529 0 O-C-N 123.844 0.715 . . . . 0.77 109.907 179.849 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.715 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 58.6 Cg_exo -47.1 143.86 9.56 Favored 'Trans proline' 0 N--CA 1.455 -0.784 0 C-N-CA 122.958 2.439 . . . . 0.32 112.391 174.769 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.927 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -62.4 -15.58 49.87 Favored 'General case' 0 C--O 1.206 -1.236 0 CA-C-N 115.427 -0.806 . . . . 1.57 110.763 -179.405 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.715 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 9.6 pt-20 -64.0 -24.07 67.57 Favored 'General case' 0 CA--C 1.532 0.278 0 N-CA-C 112.307 0.484 . . . . 1.32 112.307 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.2 mp -87.34 -45.24 16.24 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.24 0 N-CA-C 108.2 -1.037 . . . . 0.35 108.2 -179.303 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . 0.735 ' HA ' ' HB2' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -62.96 -26.95 69.07 Favored 'General case' 0 C--N 1.333 -0.137 0 CA-C-N 115.393 -0.822 . . . . 1.5 109.516 173.322 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 34.9 ttm180 -64.41 -49.15 72.67 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 114.94 -1.027 . . . . 2.96 110.712 172.683 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 17.7 m -63.41 -27.41 69.28 Favored 'General case' 0 CA--C 1.532 0.265 0 CA-C-O 121.09 0.471 . . . . 0.4 110.781 171.166 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.771 ' HB3' HG13 ' A' ' 28' ' ' ILE . 2.2 mm? -69.81 -22.13 63.33 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.038 -0.528 . . . . 0.36 110.688 172.764 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.416 ' HB2' ' O ' ' A' ' 26' ' ' LEU . 0.0 OUTLIER 67.33 23.75 9.17 Favored 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 123.574 0.75 . . . . 3.2 111.306 -174.218 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.771 HG13 ' HB3' ' A' ' 26' ' ' LEU . 3.6 mt -113.24 -159.68 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 116.013 -0.54 . . . . 0.48 109.959 -176.77 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.717 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -159.21 -159.41 0.76 Allowed 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 117.786 0.266 . . . . 2.4 111.545 -169.208 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . 0.512 ' HG2' ' HA ' ' B' ' 12' ' ' ASP . 59.0 mp0 -70.28 32.73 0.04 OUTLIER 'General case' 0 N--CA 1.469 0.515 0 C-N-CA 123.613 0.765 . . . . 1.23 112.673 178.303 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.575 ' N ' HD11 ' B' ' 10' ' ' ILE . . . -148.59 23.92 1.34 Allowed Glycine 0 N--CA 1.44 -1.072 0 N-CA-C 110.297 -1.121 . . . . 0.36 110.297 173.178 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.633 ' O ' HG13 ' B' ' 10' ' ' ILE . 14.8 t0 -83.04 122.51 77.77 Favored Pre-proline 0 C--N 1.326 -0.447 0 CA-C-N 114.774 -0.713 . . . . 1.26 109.751 175.663 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.725 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 9.7 Cg_endo -85.66 149.2 9.92 Favored 'Trans proline' 0 N--CA 1.433 -2.03 0 C-N-CA 122.367 2.045 . . . . 1.3 110.522 175.753 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.841 HD11 HG23 ' B' ' 10' ' ' ILE . 0.9 OUTLIER -140.0 150.95 45.07 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 120.386 -0.526 . . . . 0.38 109.739 174.887 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.685 ' HB3' ' HB3' ' A' ' 47' ' ' LYS . 36.1 tt0 -103.48 110.27 22.24 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 107.05 -1.463 . . . . 1.12 107.05 -178.802 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.801 ' HB ' HG23 ' B' ' 6' ' ' ILE . 2.1 mp -85.52 107.81 16.6 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.981 0 O-C-N 124.113 0.883 . . . . 0.39 108.757 -179.218 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . 0.685 ' HB2' ' H ' ' B' ' 4' ' ' THR . 6.2 p90 -149.38 127.34 11.89 Favored 'General case' 0 C--N 1.313 -0.988 0 CA-C-N 115.875 -0.602 . . . . 1.15 109.555 177.36 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.487 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 2.1 p -80.02 142.2 14.25 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.071 0 CA-C-N 115.941 -0.572 . . . . 0.17 110.004 -178.375 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.538 ' OD2' ' HD3' ' A' ' 40' ' ' ARG . 28.9 t70 -87.6 -43.08 12.25 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.904 -0.589 . . . . 1.11 111.722 -175.474 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . 0.573 ' HG3' ' HG3' ' A' ' 43' ' ' GLU . 0.0 OUTLIER -138.42 -90.05 0.22 Allowed 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 112.797 0.666 . . . . 2.29 112.797 -167.473 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 31.4 t70 -100.76 -71.91 0.69 Allowed 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.025 0.441 . . . . 1.53 110.85 -177.772 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.585 ' HA3' HD11 ' B' ' 26' ' ' LEU . . . -133.34 24.12 3.77 Favored Glycine 0 N--CA 1.445 -0.75 0 C-N-CA 120.466 -0.873 . . . . 0.32 112.123 -178.845 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.573 ' HG3' ' HG3' ' A' ' 40' ' ' ARG . 1.5 mt-10 -98.1 109.86 22.54 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 109.081 -0.711 . . . . 1.97 109.081 176.017 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.5 ' C ' HD12 ' A' ' 45' ' ' ILE . 1.6 t -90.0 134.25 29.59 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.875 0 N-CA-C 109.461 -0.57 . . . . 0.14 109.461 178.339 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.804 HG13 HG13 ' B' ' 45' ' ' ILE . 1.5 mp -109.08 122.72 64.19 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 N-CA-C 108.131 -1.063 . . . . 0.14 108.131 -177.095 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.798 HD11 HD11 ' B' ' 46' ' ' LEU . 4.9 mt -106.07 117.77 34.89 Favored 'General case' 0 C--N 1.319 -0.741 0 O-C-N 123.869 0.731 . . . . 0.23 109.728 178.286 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.973 ' HE2' ' HB3' ' A' ' 53' ' ' SER . 15.8 ttmt -119.17 127.69 53.54 Favored 'General case' 0 C--N 1.311 -1.099 0 CA-C-N 115.73 -0.668 . . . . 0.76 111.959 -171.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.618 ' HA ' ' O ' ' A' ' 33' ' ' PRO . 3.2 ptmt -44.88 -15.03 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.451 0 N-CA-C 116.656 2.095 . . . . 0.32 116.656 -170.758 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 0.725 ' HB3' ' HB2' ' A' ' 33' ' ' PRO . 27.1 t80 73.59 -55.9 0.66 Allowed 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 112.627 0.602 . . . . 1.28 112.627 171.066 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.68 ' OG ' ' HD3' ' A' ' 51' ' ' PRO . 7.3 p -54.69 -41.67 91.04 Favored Pre-proline 0 CA--C 1.54 0.582 0 N-CA-C 112.439 0.533 . . . . 1.36 112.439 -174.312 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.68 ' HD3' ' OG ' ' A' ' 50' ' ' SER . 60.7 Cg_endo -103.3 14.74 0.27 Allowed 'Trans proline' 0 N--CA 1.451 -0.99 0 C-N-CA 123.063 2.509 . . . . 0.58 111.192 168.737 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 3.0 mt 55.35 -128.72 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.444 -0.734 0 CA-C-N 115.194 -0.912 . . . . 0.78 108.549 -168.843 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.973 ' HB3' ' HE2' ' A' ' 47' ' ' LYS . 12.4 p -107.86 2.34 23.39 Favored 'General case' 0 C--N 1.31 -1.124 0 C-N-CA 120.693 -0.403 . . . . 1.96 112.059 179.687 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.427 ' O ' ' HB2' ' A' ' 55' ' ' LEU . 10.4 pt-20 174.3 -34.85 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.95 -0.568 . . . . 2.89 112.143 -172.135 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.588 ' HG ' ' O ' ' A' ' 51' ' ' PRO . 43.6 mt . . . . . 0 C--O 1.25 1.09 0 CA-C-O 118.802 -0.618 . . . . 2.65 110.543 -172.792 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 51.6 ttm . . . . . 0 N--CA 1.481 1.081 0 CA-C-O 119.754 -0.165 . . . . 6.17 110.655 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 2' ' ' LYS . . . . . 0.443 ' HB2' ' O ' ' A' ' 38' ' ' VAL . 21.5 mmmt 53.63 -94.45 0.04 OUTLIER 'General case' 0 CA--C 1.516 -0.361 0 O-C-N 123.58 0.55 . . . . 3.61 111.539 -175.689 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 3' ' ' ALA . . . . . 0.531 ' HA ' ' HB2' ' A' ' 37' ' ' PHE . . . 74.02 127.24 0.04 OUTLIER 'General case' 0 C--N 1.312 -1.056 0 CA-C-N 113.853 -1.521 . . . . 0.86 113.037 174.191 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 4' ' ' THR . . . . . 0.685 ' H ' ' HB2' ' A' ' 37' ' ' PHE . 5.4 p -110.8 -48.72 3.1 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 114.473 -1.239 . . . . 0.43 109.661 171.473 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 78.4 51.38 5.66 Favored Glycine 0 N--CA 1.45 -0.419 0 CA-C-N 115.453 -0.794 . . . . 0.33 112.843 172.122 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 6' ' ' ILE . . . . . 0.801 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.4 tp -107.44 106.84 21.42 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 N-CA-C 109.317 -0.623 . . . . 0.3 109.317 173.573 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . 0.728 ' HA ' ' O ' ' A' ' 34' ' ' LEU . 25.2 t -78.1 135.2 26.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 116.124 -0.489 . . . . 0.27 110.469 179.447 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.413 ' HB3' HD13 ' A' ' 36' ' ' ILE . 0.8 OUTLIER -133.36 122.51 23.89 Favored 'General case' 0 N--CA 1.439 -0.999 0 N-CA-C 107.345 -1.354 . . . . 1.69 107.345 -178.871 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 9' ' ' ARG . . . . . 0.553 ' HA ' ' HA ' ' A' ' 33' ' ' PRO . 18.3 ttp180 -81.7 104.57 12.19 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 108.596 -0.89 . . . . 2.71 108.596 172.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 10' ' ' ILE . . . . . 0.841 HG23 HD11 ' A' ' 34' ' ' LEU . 0.3 OUTLIER -10.79 -101.27 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 O-C-N 125.631 1.832 . . . . 0.34 114.234 -175.701 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . 0.642 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 2.4 p-10 162.2 -169.87 0.01 OUTLIER 'General case' 0 CA--C 1.512 -0.502 0 N-CA-C 107.672 -1.233 . . . . 1.18 107.672 176.043 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 12' ' ' ASP . . . . . 0.512 ' HA ' ' HG2' ' A' ' 30' ' ' GLU . 3.3 p30 -78.13 7.74 5.82 Favored 'General case' 0 C--N 1.325 -0.463 0 O-C-N 123.174 0.296 . . . . 2.39 111.251 -177.608 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 13' ' ' LEU . . . . . 0.417 ' HB3' ' HD2' ' B' ' 15' ' ' ARG . 2.4 tm? -119.03 -61.53 1.63 Allowed 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 109.8 -0.445 . . . . 0.4 109.8 171.603 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 14' ' ' GLY . . . . . 0.514 ' O ' ' HB ' ' A' ' 18' ' ' ILE . . . 137.72 14.78 0.77 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.265 -0.969 . . . . 0.21 113.257 -178.565 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 15' ' ' ARG . . . . . 0.699 ' HG2' HG22 ' A' ' 17' ' ' VAL . 0.3 OUTLIER -81.08 154.68 26.68 Favored 'General case' 0 CA--C 1.493 -1.23 0 CA-C-O 121.659 0.743 . . . . 0.9 109.72 177.325 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 16' ' ' VAL . . . . . 1.045 HG22 HG22 ' A' ' 16' ' ' VAL . 3.9 m -107.7 108.52 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.219 0 N-CA-C 106.998 -1.482 . . . . 1.27 106.998 170.357 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 17' ' ' VAL . . . . . 0.735 HG22 ' HG2' ' A' ' 15' ' ' ARG . 47.3 t -70.88 96.52 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.352 0 CA-C-N 114.597 -1.183 . . . . 0.27 109.206 -174.354 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . 0.554 ' HB ' ' O ' ' A' ' 14' ' ' GLY . 34.3 mm -85.0 108.38 15.15 Favored Pre-proline 0 N--CA 1.449 -0.519 0 CA-C-N 115.401 -0.818 . . . . 0.82 110.299 -177.612 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . 0.715 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 58.5 Cg_exo -47.29 141.79 13.23 Favored 'Trans proline' 0 N--CA 1.456 -0.724 0 C-N-CA 122.876 2.384 . . . . 0.3 112.702 174.78 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 20' ' ' LYS . . . . . 1.015 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -59.3 -15.15 14.27 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.444 -0.798 . . . . 1.77 111.789 178.207 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . 0.715 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 12.9 pt-20 -64.14 -26.16 68.41 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-O 120.706 0.288 . . . . 1.92 111.45 -179.767 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 5.3 mp -87.16 -44.1 16.05 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.354 0 N-CA-C 107.901 -1.148 . . . . 0.44 107.901 -177.284 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 23' ' ' ARG . . . . . 0.628 ' HA ' ' HB2' ' B' ' 26' ' ' LEU . 0.0 OUTLIER -63.99 -26.32 68.52 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-N 115.147 -0.933 . . . . 1.4 109.897 174.972 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 24' ' ' ARG . . . . . . . . . . . . . 32.3 ttm180 -65.58 -50.14 66.2 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.674 -0.694 . . . . 3.19 110.917 172.213 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 28.2 m -63.29 -21.53 66.31 Favored 'General case' 0 CA--C 1.531 0.233 0 CA-C-O 121.527 0.68 . . . . 0.4 110.47 174.4 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.628 ' HB2' ' HA ' ' B' ' 23' ' ' ARG . 1.6 mm? -74.21 -20.93 60.02 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.505 -0.77 . . . . 0.33 110.915 173.399 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 27' ' ' ARG . . . . . 0.455 ' HB2' ' O ' ' B' ' 26' ' ' LEU . 0.0 OUTLIER 67.37 28.47 7.83 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 123.33 0.652 . . . . 3.28 110.827 -173.892 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 28' ' ' ILE . . . . . 0.863 HG22 ' H ' ' B' ' 29' ' ' ARG . 5.7 mt -121.49 -163.28 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.051 -0.522 . . . . 0.37 110.399 -176.657 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 29' ' ' ARG . . . . . 0.863 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -157.93 -158.38 0.73 Allowed 'General case' 0 N--CA 1.467 0.414 0 C-N-CA 122.046 0.138 . . . . 2.15 111.054 -169.87 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 30' ' ' GLU . . . . . 0.502 ' HG2' ' HA ' ' A' ' 12' ' ' ASP . 58.9 mp0 -69.33 30.84 0.03 OUTLIER 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 112.95 0.722 . . . . 1.18 112.95 178.666 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . 0.566 ' N ' HD11 ' A' ' 10' ' ' ILE . . . -145.56 25.68 1.82 Allowed Glycine 0 N--CA 1.441 -1.006 0 N-CA-C 110.073 -1.211 . . . . 0.35 110.073 172.503 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 32' ' ' ASP . . . . . 0.545 ' O ' HG13 ' A' ' 10' ' ' ILE . 8.6 t70 -82.0 121.5 79.09 Favored Pre-proline 0 C--N 1.324 -0.538 0 CA-C-N 114.6 -0.8 . . . . 1.29 110.224 176.002 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 33' ' ' PRO . . . . . 0.784 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 7.8 Cg_endo -83.06 147.02 12.97 Favored 'Trans proline' 0 N--CA 1.433 -2.048 0 C-N-CA 122.163 1.909 . . . . 1.1 110.432 173.351 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.789 HD11 HG23 ' A' ' 10' ' ' ILE . 1.0 OUTLIER -137.53 149.28 46.63 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 109.6 -0.519 . . . . 0.44 109.6 173.431 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 35' ' ' GLU . . . . . 0.695 ' HB3' ' HE3' ' B' ' 47' ' ' LYS . 45.8 tt0 -101.81 111.32 23.54 Favored 'General case' 0 C--N 1.297 -1.694 0 N-CA-C 107.242 -1.392 . . . . 1.1 107.242 178.89 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 36' ' ' ILE . . . . . 0.807 ' HB ' HG23 ' A' ' 6' ' ' ILE . 2.8 mp -85.19 108.01 16.62 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.77 0 O-C-N 124.329 1.018 . . . . 0.62 108.831 -179.678 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 37' ' ' PHE . . . . . 0.682 ' HB2' ' H ' ' A' ' 4' ' ' THR . 7.6 p90 -150.44 127.66 11.3 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 116.003 -0.544 . . . . 1.2 109.866 176.851 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 38' ' ' VAL . . . . . 0.529 ' HA ' ' HA ' ' B' ' 44' ' ' VAL . 1.6 p -79.94 145.23 9.53 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 CA-C-N 116.446 -0.343 . . . . 0.2 110.562 -177.529 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 39' ' ' ASP . . . . . 0.618 ' OD2' ' HD3' ' B' ' 40' ' ' ARG . 18.2 t70 -82.58 -47.39 12.18 Favored 'General case' 0 C--N 1.326 -0.439 0 O-C-N 123.966 0.791 . . . . 1.14 111.318 -175.569 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 40' ' ' ARG . . . . . 0.618 ' HD3' ' OD2' ' B' ' 39' ' ' ASP . 0.7 OUTLIER -144.82 -78.75 0.19 Allowed 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 113.189 0.811 . . . . 2.71 113.189 -176.457 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -97.63 -65.45 0.96 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.039 0.447 . . . . 1.32 111.512 -171.096 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 42' ' ' GLY . . . . . 0.537 ' HA3' ' HD2' ' A' ' 48' ' ' LYS . . . -145.9 16.97 1.77 Allowed Glycine 0 N--CA 1.442 -0.912 0 C-N-CA 120.79 -0.719 . . . . 0.34 111.651 -178.155 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 43' ' ' GLU . . . . . 0.681 ' HA ' ' O ' ' A' ' 46' ' ' LEU . 2.3 pm0 -91.96 107.36 19.16 Favored 'General case' 0 N--CA 1.445 -0.683 0 N-CA-C 109.835 -0.431 . . . . 2.07 109.835 176.619 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 44' ' ' VAL . . . . . 0.596 ' HB ' HD12 ' A' ' 46' ' ' LEU . 2.1 t -89.33 131.69 35.98 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 109.536 -0.542 . . . . 0.13 109.536 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 45' ' ' ILE . . . . . 0.804 HG13 HG13 ' A' ' 45' ' ' ILE . 1.6 mp -107.06 120.64 58.73 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 N-CA-C 108.065 -1.087 . . . . 0.12 108.065 -178.302 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 46' ' ' LEU . . . . . 0.798 HD11 HD11 ' A' ' 46' ' ' LEU . 0.9 OUTLIER -109.7 116.48 31.78 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 109.442 -0.577 . . . . 0.15 109.442 177.531 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 47' ' ' LYS . . . . . 0.695 ' HE3' ' HB3' ' B' ' 35' ' ' GLU . 0.0 OUTLIER -127.71 141.81 51.5 Favored 'General case' 0 C--N 1.318 -0.774 0 C-N-CA 119.372 -0.931 . . . . 0.95 113.083 -177.722 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 48' ' ' LYS . . . . . 0.72 ' HE2' ' HG3' ' B' ' 51' ' ' PRO . 5.2 ptmt -43.4 -12.88 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.177 0 N-CA-C 118.157 2.651 . . . . 0.64 118.157 -166.171 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 49' ' ' TYR . . . . . 0.784 ' HB3' ' HB2' ' B' ' 33' ' ' PRO . 22.4 t80 71.87 -55.77 0.66 Allowed 'General case' 0 N--CA 1.475 0.809 0 N-CA-C 113.374 0.879 . . . . 1.26 113.374 172.738 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 50' ' ' SER . . . . . 0.713 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 33.9 t -51.15 -57.02 15.35 Favored Pre-proline 0 CA--C 1.535 0.369 0 C-N-CA 122.867 0.467 . . . . 1.22 111.11 -175.186 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 51' ' ' PRO . . . . . 0.72 ' HG3' ' HE2' ' B' ' 48' ' ' LYS . 48.9 Cg_endo -89.58 13.51 2.37 Favored 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 121.995 1.796 . . . . 0.56 111.229 171.052 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 52' ' ' ILE . . . . . . . . . . . . . 3.0 mt 55.17 -133.33 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.571 0 CA-C-N 114.97 -1.014 . . . . 0.73 108.487 -172.763 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 53' ' ' SER . . . . . 0.493 ' HA ' ' HG3' ' B' ' 47' ' ' LYS . 4.9 p -86.04 -44.81 12.0 Favored 'General case' 0 C--N 1.309 -1.169 0 CA-C-O 120.937 0.398 . . . . 1.86 110.574 178.572 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 54' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -160.18 19.76 0.15 Allowed 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.824 -0.626 . . . . 2.62 111.591 -178.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 55' ' ' LEU . . . . . . . . . . . . . 54.4 mt . . . . . 0 C--O 1.248 0.993 0 O-C-N 123.497 0.498 . . . . 2.64 110.601 -170.934 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 90.0 mtp . . . . . 0 N--CA 1.48 1.054 0 CA-C-O 120.877 0.37 . . . . 5.91 110.452 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.661 ' HA ' ' CE ' ' A' ' 2' ' ' LYS . 2.2 mmpt? -128.76 -140.98 0.24 Allowed 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.371 -0.377 . . . . 3.71 110.299 178.488 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.434 ' HA ' ' HB2' ' B' ' 37' ' ' PHE . . . 67.54 102.64 0.05 OUTLIER 'General case' 0 C--N 1.327 -0.381 0 O-C-N 124.066 0.854 . . . . 0.72 111.204 -174.593 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.412 ' OG1' ' HA ' ' B' ' 37' ' ' PHE . 17.9 p -92.29 -50.34 5.7 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.227 -0.897 . . . . 0.41 111.756 -177.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 79.78 49.69 5.96 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.46 -0.876 . . . . 0.32 113.208 175.851 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.759 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.1 tp -107.39 113.18 42.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 N-CA-C 109.17 -0.678 . . . . 0.31 109.17 173.731 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.723 ' HA ' ' O ' ' B' ' 34' ' ' LEU . 39.7 t -83.43 135.52 24.65 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-O 120.922 0.391 . . . . 0.28 110.798 -178.477 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.626 ' HB3' HD11 ' B' ' 36' ' ' ILE . 6.8 tpp180 -129.23 123.25 31.5 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 107.568 -1.271 . . . . 1.99 107.568 -179.352 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.527 ' N ' ' HD3' ' A' ' 8' ' ' ARG . 4.9 tpp180 -84.43 104.44 14.44 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 108.328 -0.99 . . . . 2.8 108.328 173.19 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.74 HG23 HD11 ' B' ' 34' ' ' LEU . 0.2 OUTLIER -12.23 -103.67 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.115 0 O-C-N 125.365 1.666 . . . . 0.33 114.701 -176.515 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . 0.568 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 5.8 p-10 161.35 -160.27 0.0 OUTLIER 'General case' 0 CA--C 1.512 -0.485 0 N-CA-C 107.937 -1.134 . . . . 1.13 107.937 177.019 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -72.66 -22.88 60.85 Favored 'General case' 0 C--N 1.323 -0.576 0 O-C-N 123.386 0.429 . . . . 2.26 110.878 -178.455 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -98.42 -60.52 1.53 Allowed 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.29 -0.414 . . . . 0.53 110.233 178.287 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.452 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 136.43 18.7 0.7 Allowed Glycine 0 N--CA 1.445 -0.735 0 C-N-CA 120.073 -1.061 . . . . 0.22 113.393 -179.186 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.706 ' HG2' HG22 ' B' ' 17' ' ' VAL . 0.0 OUTLIER -79.1 153.35 30.22 Favored 'General case' 0 CA--C 1.507 -0.693 0 CA-C-N 118.028 0.914 . . . . 0.69 109.621 179.569 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.818 HG21 HD13 ' B' ' 46' ' ' LEU . 98.0 t -104.4 100.32 10.25 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.455 0 N-CA-C 107.628 -1.249 . . . . 1.24 107.628 172.353 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.79 HG22 ' HG2' ' B' ' 15' ' ' ARG . 91.0 t -68.14 98.89 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.909 0 CA-C-N 115.068 -0.969 . . . . 0.28 110.21 -173.43 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.746 HG23 HD13 ' A' ' 22' ' ' ILE . 8.7 mt -92.25 114.02 60.96 Favored Pre-proline 0 N--CA 1.445 -0.708 0 CA-C-N 115.643 -0.708 . . . . 0.77 110.778 -178.551 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.638 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 47.5 Cg_exo -46.08 145.89 4.89 Favored 'Trans proline' 0 N--CA 1.458 -0.599 0 C-N-CA 123.1 2.533 . . . . 0.32 112.821 174.168 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.866 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -60.85 -16.47 41.63 Favored 'General case' 0 C--O 1.211 -0.949 0 CA-C-N 115.478 -0.783 . . . . 1.57 111.353 179.321 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.638 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 11.1 pt-20 -66.1 -19.91 65.99 Favored 'General case' 0 C--O 1.236 0.363 0 N-CA-C 111.767 0.284 . . . . 1.32 111.767 -178.283 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.746 HD13 HG23 ' A' ' 18' ' ' ILE . 5.0 mp -87.49 -50.8 13.48 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.635 0 N-CA-C 107.854 -1.165 . . . . 0.35 107.854 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . 0.595 ' HA ' ' HB2' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -56.1 -31.98 63.75 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 115.492 -0.776 . . . . 1.5 110.358 171.879 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.42 ' HB3' ' HA ' ' A' ' 21' ' ' GLU . 10.2 ttt180 -63.55 -52.26 61.87 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.313 -0.858 . . . . 2.96 110.943 174.29 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 22.5 m -66.53 -22.75 66.16 Favored 'General case' 0 C--O 1.222 -0.353 0 CA-C-O 121.182 0.515 . . . . 0.4 110.697 175.525 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.736 ' HB3' HG13 ' A' ' 28' ' ' ILE . 2.0 mm? -65.81 -19.71 65.98 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.865 -0.607 . . . . 0.36 110.614 173.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.533 ' HB2' ' O ' ' A' ' 26' ' ' LEU . 0.3 OUTLIER 72.3 21.36 3.84 Favored 'General case' 0 N--CA 1.466 0.358 0 O-C-N 124.066 0.854 . . . . 3.2 110.371 -172.746 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.736 HG13 ' HB3' ' A' ' 26' ' ' LEU . 3.0 mt -122.18 -163.0 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.726 -0.67 . . . . 0.48 110.175 -174.154 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.733 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -153.18 -161.41 1.28 Allowed 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 111.481 0.178 . . . . 2.4 111.481 -167.944 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -73.79 36.62 0.09 Allowed 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 121.961 0.886 . . . . 1.23 111.51 179.351 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.575 ' N ' HD11 ' B' ' 10' ' ' ILE . . . -152.19 24.78 0.89 Allowed Glycine 0 N--CA 1.44 -1.099 0 CA-C-N 114.15 -1.387 . . . . 0.36 109.894 174.026 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.597 ' O ' HG13 ' B' ' 10' ' ' ILE . 13.2 t0 -82.95 124.54 76.66 Favored Pre-proline 0 C--N 1.326 -0.436 0 CA-C-N 114.512 -0.844 . . . . 1.26 109.931 175.68 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.75 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 4.7 Cg_endo -82.94 152.5 14.5 Favored 'Trans proline' 0 N--CA 1.435 -1.939 0 C-N-CA 122.187 1.924 . . . . 1.3 110.719 173.777 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.808 HD11 HG23 ' B' ' 10' ' ' ILE . 0.6 OUTLIER -140.66 152.8 45.66 Favored 'General case' 0 C--N 1.305 -1.362 0 N-CA-C 109.14 -0.689 . . . . 0.38 109.14 171.994 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.933 ' HB3' ' HD2' ' A' ' 47' ' ' LYS . 39.4 tt0 -105.87 111.24 23.81 Favored 'General case' 0 CA--C 1.486 -1.515 0 N-CA-C 107.501 -1.296 . . . . 1.12 107.501 -179.051 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.934 HG13 HD22 ' A' ' 46' ' ' LEU . 2.5 mp -85.17 110.21 19.09 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.98 0 O-C-N 124.648 1.217 . . . . 0.39 108.478 -179.169 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . 0.641 ' HB2' ' H ' ' B' ' 4' ' ' THR . 1.8 p90 -150.55 124.61 9.34 Favored 'General case' 0 C--N 1.313 -1.02 0 CA-C-N 116.162 -0.472 . . . . 1.15 109.747 175.6 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.543 HG13 ' HB3' ' B' ' 2' ' ' LYS . 1.7 p -80.83 136.34 23.4 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 CA-C-O 121.149 0.5 . . . . 0.17 110.778 -178.33 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.684 ' HB3' ' HG3' ' A' ' 40' ' ' ARG . 9.8 t70 -75.59 -45.01 40.14 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.036 -0.984 . . . . 1.11 110.68 -175.498 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . 0.684 ' HG3' ' HB3' ' A' ' 39' ' ' ASP . 7.6 mtp180 -132.13 -73.35 0.52 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.672 -0.694 . . . . 2.29 112.267 -165.807 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -129.67 -65.11 0.85 Allowed 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.284 -0.871 . . . . 1.53 111.09 -173.408 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.599 ' HA3' HD11 ' B' ' 26' ' ' LEU . . . -131.88 6.36 5.46 Favored Glycine 0 CA--C 1.501 -0.832 0 CA-C-N 114.838 -1.074 . . . . 0.32 111.812 -173.852 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.556 ' HA ' ' O ' ' B' ' 46' ' ' LEU . 2.2 pm0 -93.58 105.69 17.71 Favored 'General case' 0 N--CA 1.443 -0.793 0 CA-C-O 121.009 0.433 . . . . 1.97 109.929 175.317 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.612 HG11 HG23 ' A' ' 36' ' ' ILE . 2.0 t -88.82 132.31 34.0 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.988 0 CA-C-N 115.566 -0.743 . . . . 0.14 109.864 178.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.856 HG13 HG13 ' B' ' 45' ' ' ILE . 1.4 mp -110.11 115.96 51.06 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 N-CA-C 108.239 -1.023 . . . . 0.14 108.239 -177.372 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 1.041 HD11 HD11 ' B' ' 46' ' ' LEU . 0.5 OUTLIER -109.48 116.76 32.41 Favored 'General case' 0 C--N 1.319 -0.759 0 O-C-N 123.703 0.627 . . . . 0.23 109.584 -178.871 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.933 ' HD2' ' HB3' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -122.84 150.37 42.95 Favored 'General case' 0 C--O 1.215 -0.732 0 C-N-CA 119.066 -1.054 . . . . 0.76 112.169 179.121 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.62 ' HA ' ' O ' ' A' ' 33' ' ' PRO . 1.5 ptmt -44.92 -16.45 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.24 0 N-CA-C 117.13 2.27 . . . . 0.32 117.13 -168.188 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 0.765 ' CD1' HG21 ' B' ' 7' ' ' VAL . 19.9 t80 74.35 -50.36 0.68 Allowed 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 112.689 0.625 . . . . 1.28 112.689 174.293 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.71 ' HB3' ' HD3' ' A' ' 51' ' ' PRO . 22.7 t -48.1 -50.83 52.95 Favored Pre-proline 0 CA--C 1.538 0.493 0 C-N-CA 122.585 0.354 . . . . 1.36 111.395 -177.368 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.71 ' HD3' ' HB3' ' A' ' 50' ' ' SER . 36.3 Cg_endo -95.25 10.31 1.66 Allowed 'Trans proline' 0 N--CA 1.453 -0.878 0 C-N-CA 122.601 2.2 . . . . 0.58 111.484 172.31 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 1.1 mt 48.91 -141.78 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 115.044 -0.98 . . . . 0.78 109.262 -170.466 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.614 ' HB3' ' HE2' ' A' ' 47' ' ' LYS . 4.2 p -104.63 76.25 1.27 Allowed 'General case' 0 N--CA 1.431 -1.416 0 N-CA-C 109.679 -0.489 . . . . 1.96 109.679 174.266 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 1.6 tp10 73.02 110.19 0.07 Allowed 'General case' 0 C--O 1.232 0.173 0 CA-C-N 115.052 -0.976 . . . . 2.89 110.721 -175.583 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 81.8 mt . . . . . 0 C--O 1.249 1.075 0 CA-C-N 115.84 -0.618 . . . . 2.65 110.165 176.863 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 45.1 mtp . . . . . 0 N--CA 1.484 1.266 0 CA-C-O 120.853 0.358 . . . . 6.17 110.765 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 2' ' ' LYS . . . . . 0.683 ' CE ' ' HA ' ' B' ' 2' ' ' LYS . 2.5 mmpt? -97.44 -141.62 0.29 Allowed 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.377 -0.374 . . . . 3.61 111.873 -177.802 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 3' ' ' ALA . . . . . 0.569 ' HA ' ' HD2' ' A' ' 37' ' ' PHE . . . 72.37 116.47 0.05 Allowed 'General case' 0 C--N 1.33 -0.252 0 O-C-N 124.274 0.984 . . . . 0.86 110.546 -169.34 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 4' ' ' THR . . . . . 0.641 ' H ' ' HB2' ' A' ' 37' ' ' PHE . 28.5 p -107.85 -52.56 2.75 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.634 -0.712 . . . . 0.43 111.068 -176.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 82.26 50.98 4.58 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.995 -0.621 . . . . 0.33 112.797 177.164 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 6' ' ' ILE . . . . . 0.805 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.0 OUTLIER -106.68 108.24 24.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 N-CA-C 109.322 -0.621 . . . . 0.3 109.322 173.316 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . 0.765 HG21 ' CD1' ' A' ' 49' ' ' TYR . 23.0 t -80.52 136.49 23.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-N 116.231 -0.44 . . . . 0.27 111.217 179.673 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.546 ' HD3' ' N ' ' B' ' 9' ' ' ARG . 1.1 tpp180 -131.97 126.94 35.25 Favored 'General case' 0 N--CA 1.446 -0.625 0 N-CA-C 107.61 -1.255 . . . . 1.69 107.61 178.384 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 9' ' ' ARG . . . . . 0.546 ' N ' ' HD3' ' B' ' 8' ' ' ARG . 1.7 tpp180 -86.3 103.22 14.69 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 108.606 -0.887 . . . . 2.71 108.606 173.858 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 10' ' ' ILE . . . . . 0.808 HG23 HD11 ' A' ' 34' ' ' LEU . 0.2 OUTLIER -10.17 -107.37 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.264 0 O-C-N 125.351 1.657 . . . . 0.34 114.749 -177.828 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . 0.655 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 1.7 p-10 163.39 -166.38 0.01 OUTLIER 'General case' 0 CA--C 1.518 -0.286 0 N-CA-C 108.327 -0.99 . . . . 1.18 108.327 177.441 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -66.28 -19.85 65.93 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.355 0.598 . . . . 2.39 110.793 -179.04 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 13' ' ' LEU . . . . . 0.442 ' H ' ' CG ' ' B' ' 11' ' ' ASP . 2.9 tm? -101.59 -61.8 1.33 Allowed 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.711 -0.677 . . . . 0.4 110.796 -179.059 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 137.96 19.5 0.55 Allowed Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.807 -0.711 . . . . 0.21 112.116 -178.806 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 15' ' ' ARG . . . . . 0.79 ' HG2' HG22 ' A' ' 17' ' ' VAL . 2.7 mtm180 -70.22 147.65 49.54 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-O 121.244 0.545 . . . . 0.9 110.593 177.361 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 16' ' ' VAL . . . . . 0.713 HG21 HD13 ' A' ' 46' ' ' LEU . 63.7 t -106.69 97.07 5.18 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.237 0 N-CA-C 107.644 -1.243 . . . . 1.27 107.644 166.767 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 17' ' ' VAL . . . . . 0.706 HG22 ' HG2' ' A' ' 15' ' ' ARG . 64.3 t -67.42 98.92 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 CA-C-N 115.62 -0.718 . . . . 0.27 110.364 -171.732 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . 0.542 ' H ' ' HA ' ' A' ' 15' ' ' ARG . 6.9 mt -90.45 113.87 59.11 Favored Pre-proline 0 N--CA 1.442 -0.872 0 CA-C-N 115.181 -0.918 . . . . 0.82 110.562 -179.624 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . 0.61 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 81.3 Cg_exo -50.19 147.21 16.24 Favored 'Trans proline' 0 N--CA 1.458 -0.59 0 C-N-CA 123.056 2.504 . . . . 0.3 112.567 174.123 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 20' ' ' LYS . . . . . 1.012 ' HD3' ' H ' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -64.94 -15.63 62.36 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 115.649 -0.705 . . . . 1.77 111.678 -178.795 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . 0.61 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 1.3 pm0 -63.13 -21.8 66.44 Favored 'General case' 0 C--O 1.237 0.439 0 N-CA-C 111.854 0.316 . . . . 1.92 111.854 177.458 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 5.2 mp -87.61 -47.52 15.69 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 N-CA-C 108.488 -0.93 . . . . 0.44 108.488 -178.406 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 23' ' ' ARG . . . . . 0.558 ' HA ' ' HB2' ' B' ' 26' ' ' LEU . 0.0 OUTLIER -61.93 -28.28 69.42 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.262 -0.881 . . . . 1.4 109.231 174.022 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 24' ' ' ARG . . . . . . . . . . . . . 55.0 ttp180 -65.78 -51.92 55.07 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 114.91 -1.041 . . . . 3.19 110.988 174.639 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 18.7 m -63.65 -28.74 70.12 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-O 121.525 0.679 . . . . 0.4 110.152 176.23 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.656 ' HB3' HG13 ' B' ' 28' ' ' ILE . 1.4 mm? -64.08 -19.9 65.57 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 115.009 -0.996 . . . . 0.33 110.678 174.091 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 27' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER 70.8 24.02 4.32 Favored 'General case' 0 C--N 1.342 0.242 0 CA-C-O 121.587 0.708 . . . . 3.28 110.154 -177.105 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 28' ' ' ILE . . . . . 0.809 HG22 ' H ' ' B' ' 29' ' ' ARG . 4.0 mt -119.25 -162.55 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.133 -0.939 . . . . 0.37 110.058 -176.889 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 29' ' ' ARG . . . . . 0.809 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -152.99 -161.42 1.29 Allowed 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 111.618 0.229 . . . . 2.15 111.618 -171.584 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 30' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -72.4 34.06 0.06 Allowed 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 121.858 0.837 . . . . 1.18 111.925 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . 0.567 ' N ' HD11 ' A' ' 10' ' ' ILE . . . -150.73 30.31 1.02 Allowed Glycine 0 N--CA 1.436 -1.365 0 N-CA-C 109.636 -1.385 . . . . 0.35 109.636 172.79 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 32' ' ' ASP . . . . . 0.511 ' HB2' ' CG2' ' B' ' 28' ' ' ILE . 6.9 t70 -85.22 128.72 58.62 Favored Pre-proline 0 CA--C 1.511 -0.523 0 CA-C-N 114.451 -0.874 . . . . 1.29 110.271 174.74 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 33' ' ' PRO . . . . . 0.756 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 10.9 Cg_endo -86.76 148.48 8.42 Favored 'Trans proline' 0 N--CA 1.433 -2.07 0 C-N-CA 122.128 1.885 . . . . 1.1 111.469 173.195 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.74 HD11 HG23 ' A' ' 10' ' ' ILE . 0.8 OUTLIER -137.53 148.34 45.9 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 109.273 -0.64 . . . . 0.44 109.273 173.661 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 35' ' ' GLU . . . . . 0.659 ' O ' ' HA ' ' B' ' 46' ' ' LEU . 77.9 tt0 -104.68 111.84 24.71 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 108.11 -1.07 . . . . 1.1 108.11 -179.535 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 36' ' ' ILE . . . . . 0.899 HG13 HD22 ' B' ' 46' ' ' LEU . 3.5 mp -86.1 109.34 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.869 0 O-C-N 124.716 1.26 . . . . 0.62 109.108 -177.964 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 37' ' ' PHE . . . . . 0.434 ' HB2' ' HA ' ' A' ' 3' ' ' ALA . 16.5 p90 -149.82 126.77 11.16 Favored 'General case' 0 C--N 1.316 -0.88 0 CA-C-N 115.922 -0.581 . . . . 1.2 109.954 175.415 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 38' ' ' VAL . . . . . 0.516 ' HA ' ' HA ' ' B' ' 44' ' ' VAL . 1.3 p -80.55 139.62 17.87 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.78 0 CA-C-O 121.361 0.6 . . . . 0.2 111.16 -177.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 39' ' ' ASP . . . . . 0.549 ' HB3' ' HG3' ' B' ' 40' ' ' ARG . 7.1 t70 -74.81 -49.86 19.22 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 114.591 -1.186 . . . . 1.14 110.472 -178.009 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 40' ' ' ARG . . . . . 0.549 ' HG3' ' HB3' ' B' ' 39' ' ' ASP . 13.8 mtp180 -132.78 -72.87 0.51 Allowed 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 112.604 0.594 . . . . 2.71 112.604 -168.434 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -124.69 -67.65 0.9 Allowed 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.359 -0.837 . . . . 1.32 110.986 -172.469 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 42' ' ' GLY . . . . . 0.509 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -129.75 9.56 6.08 Favored Glycine 0 N--CA 1.441 -1.028 0 CA-C-N 114.699 -1.137 . . . . 0.34 112.142 -176.094 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 43' ' ' GLU . . . . . 0.48 ' HA ' ' O ' ' A' ' 46' ' ' LEU . 2.3 pm0 -93.13 104.74 16.91 Favored 'General case' 0 N--CA 1.446 -0.625 0 N-CA-C 109.794 -0.447 . . . . 2.07 109.794 176.199 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 44' ' ' VAL . . . . . 0.59 HG11 HG23 ' B' ' 36' ' ' ILE . 2.0 t -89.42 134.05 29.77 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.886 0 N-CA-C 109.805 -0.443 . . . . 0.13 109.805 179.071 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 45' ' ' ILE . . . . . 0.856 HG13 HG13 ' A' ' 45' ' ' ILE . 1.6 mp -110.17 116.36 52.09 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 N-CA-C 108.095 -1.076 . . . . 0.12 108.095 -177.908 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 46' ' ' LEU . . . . . 1.041 HD11 HD11 ' A' ' 46' ' ' LEU . 0.7 OUTLIER -109.4 116.25 31.49 Favored 'General case' 0 C--N 1.317 -0.838 0 O-C-N 123.67 0.606 . . . . 0.15 109.569 179.577 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 47' ' ' LYS . . . . . 0.588 ' HE3' ' HB3' ' B' ' 35' ' ' GLU . 0.0 OUTLIER -125.01 146.36 49.46 Favored 'General case' 0 C--N 1.315 -0.892 0 C-N-CA 119.652 -0.819 . . . . 0.95 112.347 -177.865 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 48' ' ' LYS . . . . . 0.595 ' HA ' ' O ' ' B' ' 33' ' ' PRO . 3.7 ptmt -45.89 -10.61 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.147 0 N-CA-C 117.812 2.523 . . . . 0.64 117.812 -166.301 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 49' ' ' TYR . . . . . 0.756 ' HB3' ' HB2' ' B' ' 33' ' ' PRO . 23.7 t80 72.07 -51.17 0.7 Allowed 'General case' 0 N--CA 1.47 0.559 0 N-CA-C 112.955 0.724 . . . . 1.26 112.955 172.711 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 50' ' ' SER . . . . . 0.605 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 48.3 t -51.4 -56.75 17.91 Favored Pre-proline 0 CA--C 1.535 0.383 0 C-N-CA 122.597 0.359 . . . . 1.22 111.249 -175.133 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 51' ' ' PRO . . . . . 0.605 ' HD3' ' HB3' ' B' ' 50' ' ' SER . 57.8 Cg_endo -88.3 12.35 2.84 Favored 'Trans proline' 0 C--N 1.35 0.649 0 C-N-CA 121.83 1.687 . . . . 0.56 111.44 170.694 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 52' ' ' ILE . . . . . . . . . . . . . 1.3 mt 50.61 -140.58 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.518 -0.273 0 CA-C-N 115.056 -0.975 . . . . 0.73 108.952 -173.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 53' ' ' SER . . . . . 0.51 ' O ' ' HB2' ' B' ' 54' ' ' GLU . 7.9 p -109.72 76.97 1.02 Allowed 'General case' 0 N--CA 1.434 -1.249 0 N-CA-C 108.992 -0.744 . . . . 1.86 108.992 174.446 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 54' ' ' GLU . . . . . 0.51 ' HB2' ' O ' ' B' ' 53' ' ' SER . 6.1 mp0 70.84 124.33 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.356 0 O-C-N 123.899 0.749 . . . . 2.62 110.034 -165.752 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 55' ' ' LEU . . . . . . . . . . . . . 96.5 mt . . . . . 0 C--O 1.246 0.897 0 CA-C-O 118.838 -0.601 . . . . 2.64 110.518 177.203 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 23.0 mmt . . . . . 0 N--CA 1.48 1.033 0 N-CA-C 109.78 -0.452 . . . . 5.91 109.78 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 13.3 mmmm 58.76 -141.3 0.7 Allowed 'General case' 0 C--O 1.235 0.338 0 CA-C-N 115.999 -0.546 . . . . 3.71 111.372 176.13 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . 70.05 141.51 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 O-C-N 124.211 0.944 . . . . 0.72 111.891 -176.181 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.763 ' H ' ' HB2' ' B' ' 37' ' ' PHE . 21.4 p -129.59 -57.2 1.13 Allowed 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.539 -0.755 . . . . 0.41 110.636 -178.647 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 85.13 48.95 4.65 Favored Glycine 0 N--CA 1.441 -1.024 0 C-N-CA 120.315 -0.945 . . . . 0.32 112.662 174.274 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.806 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.5 tp -105.49 109.09 26.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 N-CA-C 109.258 -0.645 . . . . 0.31 109.258 173.851 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.757 ' HA ' ' O ' ' B' ' 34' ' ' LEU . 41.7 t -79.76 132.69 31.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 116.135 -0.484 . . . . 0.28 110.715 179.284 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.484 ' HD3' ' N ' ' A' ' 9' ' ' ARG . 1.8 tpp180 -129.24 125.07 36.07 Favored 'General case' 0 N--CA 1.443 -0.781 0 N-CA-C 106.919 -1.512 . . . . 1.99 106.919 -179.821 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.562 ' C ' HD12 ' A' ' 10' ' ' ILE . 0.6 OUTLIER -86.34 102.26 13.84 Favored 'General case' 0 C--N 1.315 -0.933 0 N-CA-C 108.202 -1.036 . . . . 2.8 108.202 175.346 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.831 HG23 HD11 ' B' ' 34' ' ' LEU . 0.2 OUTLIER -5.56 -105.79 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.016 0 O-C-N 125.645 1.841 . . . . 0.33 114.356 -176.468 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . 0.623 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 3.3 p-10 161.54 -166.45 0.0 OUTLIER 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 108.64 -0.874 . . . . 1.13 108.64 177.28 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -68.11 -23.01 64.86 Favored 'General case' 0 C--N 1.324 -0.502 0 O-C-N 123.455 0.472 . . . . 2.26 110.94 -177.84 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.421 ' HB3' ' HD2' ' A' ' 15' ' ' ARG . 2.5 tm? -100.64 -55.66 2.53 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.331 -0.395 . . . . 0.53 110.448 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.56 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 134.32 18.0 0.95 Allowed Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.449 -0.882 . . . . 0.22 113.069 -179.435 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.544 ' HG2' HG22 ' B' ' 17' ' ' VAL . 0.4 OUTLIER -76.66 156.19 32.8 Favored 'General case' 0 CA--C 1.51 -0.562 0 CA-C-N 117.625 0.712 . . . . 0.69 110.301 -179.564 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.736 HG21 HD13 ' B' ' 46' ' ' LEU . 89.8 t -111.04 98.3 6.88 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.23 0 N-CA-C 107.728 -1.212 . . . . 1.24 107.728 167.637 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.58 HG22 ' HG2' ' B' ' 15' ' ' ARG . 39.4 t -65.05 106.95 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 CA-C-N 115.249 -0.887 . . . . 0.28 109.675 -173.702 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.452 ' HB ' ' O ' ' B' ' 14' ' ' GLY . 30.9 mm -95.82 107.88 36.88 Favored Pre-proline 0 N--CA 1.447 -0.625 0 CA-C-N 115.691 -0.686 . . . . 0.77 110.117 -178.017 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.699 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 62.2 Cg_exo -47.44 146.06 7.85 Favored 'Trans proline' 0 N--CA 1.454 -0.821 0 C-N-CA 122.6 2.2 . . . . 0.32 112.718 175.402 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.957 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -64.61 -14.0 55.93 Favored 'General case' 0 C--N 1.314 -0.935 0 CA-C-N 115.766 -0.652 . . . . 1.57 111.251 179.813 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.699 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 11.5 pt-20 -63.78 -23.05 67.21 Favored 'General case' 0 C--O 1.239 0.501 0 N-CA-C 112.349 0.5 . . . . 1.32 112.349 178.285 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.406 HD13 HG23 ' A' ' 18' ' ' ILE . 5.2 mp -87.39 -46.49 16.1 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.334 0 N-CA-C 108.096 -1.076 . . . . 0.35 108.096 -178.635 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . 0.69 ' HA ' ' HB2' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -61.41 -27.19 68.36 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 114.941 -1.027 . . . . 1.5 109.219 172.994 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 74.9 ttt180 -63.26 -51.48 65.99 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 114.75 -1.114 . . . . 2.96 111.116 173.315 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 28.7 m -61.69 -31.14 71.26 Favored 'General case' 0 CA--C 1.532 0.252 0 CA-C-O 121.147 0.498 . . . . 0.4 110.636 172.757 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.69 ' HB2' ' HA ' ' A' ' 23' ' ' ARG . 3.2 mm? -64.92 -21.35 66.81 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.617 -0.72 . . . . 0.36 110.71 173.855 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 2.0 mpt_? 70.39 21.96 5.48 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 123.455 0.702 . . . . 3.2 110.943 -176.764 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.769 HG22 ' H ' ' A' ' 29' ' ' ARG . 5.3 mt -117.49 -166.5 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.786 0 CA-C-N 115.159 -0.928 . . . . 0.48 108.932 -177.896 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.769 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -148.5 -153.69 0.51 Allowed 'General case' 0 C--N 1.323 -0.557 0 O-C-N 122.13 -0.356 . . . . 2.4 111.286 -175.157 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . 0.449 ' H ' ' HB2' ' A' ' 29' ' ' ARG . 0.6 OUTLIER -75.72 44.66 0.3 Allowed 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 122.089 0.947 . . . . 1.23 112.188 -177.787 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.664 ' CA ' HD11 ' B' ' 10' ' ' ILE . . . -159.31 29.3 0.4 Allowed Glycine 0 N--CA 1.441 -1.006 0 CA-C-N 113.975 -1.466 . . . . 0.36 109.547 172.466 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.59 ' O ' HG13 ' B' ' 10' ' ' ILE . 11.8 t70 -88.81 128.9 50.58 Favored Pre-proline 0 CA--C 1.514 -0.407 0 N-CA-C 109.351 -0.611 . . . . 1.26 109.351 174.549 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.73 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 3.8 Cg_endo -83.81 150.04 12.64 Favored 'Trans proline' 0 N--CA 1.435 -1.936 0 C-N-CA 122.18 1.92 . . . . 1.3 110.804 175.175 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.803 HD11 HG23 ' B' ' 10' ' ' ILE . 0.6 OUTLIER -139.68 153.75 47.34 Favored 'General case' 0 N--CA 1.43 -1.428 0 N-CA-C 109.302 -0.629 . . . . 0.38 109.302 172.023 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.919 ' HB3' ' HD2' ' A' ' 47' ' ' LYS . 33.8 tt0 -109.25 114.57 28.38 Favored 'General case' 0 C--N 1.297 -1.675 0 N-CA-C 108.392 -0.966 . . . . 1.12 108.392 -178.316 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.878 HG13 HD22 ' A' ' 46' ' ' LEU . 3.2 mp -86.12 110.05 19.42 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.944 0 O-C-N 124.843 1.339 . . . . 0.39 109.226 -178.766 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . 0.668 ' HD1' ' HA ' ' B' ' 3' ' ' ALA . 0.5 OUTLIER -149.76 125.74 10.57 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 116.211 -0.45 . . . . 1.15 109.874 175.488 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.604 HG13 ' HB3' ' B' ' 2' ' ' LYS . 1.2 p -80.51 137.09 22.06 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 CA-C-O 121.191 0.52 . . . . 0.17 110.749 -179.854 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.517 ' HB3' ' HG2' ' A' ' 40' ' ' ARG . 9.9 t70 -88.65 -64.93 1.07 Allowed 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 114.617 -1.174 . . . . 1.11 111.902 -171.459 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . 0.525 ' H ' ' HG2' ' A' ' 40' ' ' ARG . 0.0 OUTLIER -106.58 -84.37 0.52 Allowed 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 114.899 -1.046 . . . . 2.29 111.303 -165.759 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -111.37 -72.58 0.71 Allowed 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.12 -0.491 . . . . 1.53 110.88 -177.518 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -130.35 24.66 4.4 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.776 -0.726 . . . . 0.32 111.638 179.276 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.555 ' HB3' HG23 ' B' ' 45' ' ' ILE . 2.3 mt-10 -97.95 113.0 24.72 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.126 -0.694 . . . . 1.97 109.126 178.465 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.533 ' HA ' ' HA ' ' A' ' 38' ' ' VAL . 1.8 t -90.4 132.95 33.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 N-CA-C 109.573 -0.529 . . . . 0.14 109.573 178.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.797 HG13 HG13 ' B' ' 45' ' ' ILE . 1.6 mp -111.68 117.5 55.28 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 N-CA-C 108.575 -0.898 . . . . 0.14 108.575 -175.389 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.998 HD11 HD11 ' B' ' 46' ' ' LEU . 0.5 OUTLIER -110.13 117.09 32.79 Favored 'General case' 0 C--N 1.32 -0.706 0 O-C-N 123.676 0.61 . . . . 0.23 109.874 179.825 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.919 ' HD2' ' HB3' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -126.44 151.9 47.12 Favored 'General case' 0 C--O 1.219 -0.55 0 C-N-CA 119.02 -1.072 . . . . 0.76 112.792 179.132 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.649 ' HA ' ' O ' ' A' ' 33' ' ' PRO . 1.9 ptmt -43.58 -16.29 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.09 0 N-CA-C 117.263 2.32 . . . . 0.32 117.263 -168.381 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 0.758 ' CD1' HG21 ' B' ' 7' ' ' VAL . 17.9 t80 73.22 -54.58 0.69 Allowed 'General case' 0 N--CA 1.469 0.521 0 N-CA-C 112.561 0.578 . . . . 1.28 112.561 174.379 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.687 ' HB3' ' HD3' ' A' ' 51' ' ' PRO . 19.6 t -50.85 -49.82 77.7 Favored Pre-proline 0 CA--C 1.537 0.473 0 O-C-N 123.335 0.397 . . . . 1.36 111.387 -175.105 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.687 ' HD3' ' HB3' ' A' ' 50' ' ' SER . 86.5 Cg_endo -96.18 12.45 1.21 Allowed 'Trans proline' 0 N--CA 1.453 -0.861 0 C-N-CA 122.401 2.067 . . . . 0.58 111.658 171.213 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.636 HG13 HD23 ' A' ' 55' ' ' LEU . 1.3 mt 52.82 -140.47 0.02 OUTLIER 'Isoleucine or valine' 0 C--O 1.234 0.281 0 CA-C-N 115.423 -0.808 . . . . 0.78 109.083 -173.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 69.3 m -102.34 5.86 40.06 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-O 121.493 0.663 . . . . 1.96 110.16 176.334 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 173.98 111.84 0.02 OUTLIER 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 114.099 -1.41 . . . . 2.89 109.435 -173.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.636 HD23 HG13 ' A' ' 52' ' ' ILE . 0.2 OUTLIER . . . . . 0 C--O 1.25 1.085 0 CA-C-O 118.929 -0.558 . . . . 2.65 109.907 179.666 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 26.5 mmt . . . . . 0 N--CA 1.483 1.205 0 N-CA-C 109.845 -0.428 . . . . 6.17 109.845 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 2' ' ' LYS . . . . . 0.604 ' HB3' HG13 ' A' ' 38' ' ' VAL . 21.3 mmmt 53.81 -133.76 1.72 Allowed 'General case' 0 CA--C 1.519 -0.23 0 CA-C-N 115.567 -0.742 . . . . 3.61 112.044 -179.127 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 3' ' ' ALA . . . . . 0.668 ' HA ' ' HD1' ' A' ' 37' ' ' PHE . . . 69.07 124.47 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 O-C-N 124.145 0.903 . . . . 0.86 110.419 -171.075 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 4' ' ' THR . . . . . 0.666 ' H ' ' HB2' ' A' ' 37' ' ' PHE . 11.3 p -115.87 -46.74 2.82 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.022 -0.535 . . . . 0.43 111.248 -178.713 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 73.01 49.72 15.54 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 120.929 -0.653 . . . . 0.33 113.137 172.893 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 6' ' ' ILE . . . . . 0.856 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.0 OUTLIER -106.73 110.55 32.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 N-CA-C 109.104 -0.702 . . . . 0.3 109.104 174.841 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . 0.758 HG21 ' CD1' ' A' ' 49' ' ' TYR . 38.9 t -80.51 134.66 26.88 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.308 0.575 . . . . 0.27 111.389 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.524 ' HB3' ' CD1' ' A' ' 36' ' ' ILE . 8.4 tpp180 -130.1 121.45 26.38 Favored 'General case' 0 N--CA 1.44 -0.948 0 N-CA-C 107.541 -1.281 . . . . 1.69 107.541 -177.47 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 9' ' ' ARG . . . . . 0.48 ' HA ' ' HA ' ' A' ' 33' ' ' PRO . 15.9 ttt180 -84.45 103.43 13.6 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 108.084 -1.08 . . . . 2.71 108.084 173.766 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 10' ' ' ILE . . . . . 0.803 HG23 HD11 ' A' ' 34' ' ' LEU . 0.4 OUTLIER -9.2 -101.61 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.996 0 O-C-N 125.665 1.853 . . . . 0.34 114.398 -174.707 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . 0.645 ' H ' HD13 ' B' ' 10' ' ' ILE . 5.5 p-10 164.21 -154.07 0.0 OUTLIER 'General case' 0 C--O 1.219 -0.504 0 N-CA-C 108.773 -0.825 . . . . 1.18 108.773 174.555 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -85.2 -9.18 58.1 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.047 0.451 . . . . 2.39 110.617 -178.778 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 13' ' ' LEU . . . . . 0.453 ' HB3' ' HD2' ' B' ' 15' ' ' ARG . 3.0 tm? -109.5 -56.43 2.3 Favored 'General case' 0 N--CA 1.448 -0.537 0 CA-C-N 116.075 -0.511 . . . . 0.4 109.935 176.496 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 14' ' ' GLY . . . . . 0.452 ' O ' ' HB ' ' A' ' 18' ' ' ILE . . . 133.16 20.85 0.89 Allowed Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.764 -0.732 . . . . 0.21 112.689 -178.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 15' ' ' ARG . . . . . 0.58 ' HG2' HG22 ' A' ' 17' ' ' VAL . 1.5 mpt_? -78.23 154.08 31.35 Favored 'General case' 0 CA--C 1.509 -0.606 0 O-C-N 122.066 -0.667 . . . . 0.9 110.189 179.293 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 16' ' ' VAL . . . . . 0.726 HG21 HD13 ' A' ' 46' ' ' LEU . 96.7 t -109.11 95.96 4.26 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 N-CA-C 107.475 -1.305 . . . . 1.27 107.475 168.722 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 17' ' ' VAL . . . . . 0.544 HG22 ' HG2' ' A' ' 15' ' ' ARG . 47.0 t -64.32 104.84 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.842 0 CA-C-N 114.96 -1.018 . . . . 0.27 109.914 -173.04 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . 0.56 ' HB ' ' O ' ' A' ' 14' ' ' GLY . 26.6 mm -92.48 111.26 49.87 Favored Pre-proline 0 N--CA 1.446 -0.633 0 CA-C-N 115.647 -0.706 . . . . 0.82 110.574 -177.463 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . 0.68 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 59.1 Cg_exo -48.49 142.39 17.79 Favored 'Trans proline' 0 N--CA 1.459 -0.534 0 C-N-CA 123.041 2.494 . . . . 0.3 112.53 172.828 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 20' ' ' LYS . . . . . 0.952 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -59.44 -16.14 21.78 Favored 'General case' 0 C--O 1.211 -0.949 0 CA-C-N 115.243 -0.889 . . . . 1.77 111.428 178.954 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . 0.68 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 10.6 pt-20 -65.5 -20.0 66.16 Favored 'General case' 0 C--O 1.234 0.284 0 N-CA-C 112.034 0.383 . . . . 1.92 112.034 -178.226 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 5.2 mp -87.26 -49.14 14.97 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 N-CA-C 108.433 -0.951 . . . . 0.44 108.433 179.848 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 23' ' ' ARG . . . . . 0.627 ' NE ' ' HA ' ' B' ' 29' ' ' ARG . 0.0 OUTLIER -55.33 -32.41 62.49 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-O 122.057 0.932 . . . . 1.4 109.194 171.073 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 24' ' ' ARG . . . . . 0.475 ' N ' ' HD3' ' B' ' 23' ' ' ARG . 50.1 ttt180 -61.12 -53.72 53.52 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-N 114.021 -1.445 . . . . 3.19 111.195 176.222 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 53.7 m -61.07 -33.52 73.46 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-O 121.275 0.559 . . . . 0.4 110.418 173.806 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.552 ' HB2' ' HA ' ' B' ' 23' ' ' ARG . 1.5 mm? -63.98 -20.26 65.76 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.21 -0.904 . . . . 0.33 111.339 177.775 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 27' ' ' ARG . . . . . . . . . . . . . 6.5 mpt_? 69.79 28.38 4.37 Favored 'General case' 0 N--CA 1.471 0.6 0 CA-C-O 121.18 0.514 . . . . 3.28 110.505 -176.686 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 28' ' ' ILE . . . . . 0.847 HG22 ' H ' ' B' ' 29' ' ' ARG . 7.6 mt -122.47 -159.44 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 115.889 -0.596 . . . . 0.37 109.924 -175.583 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 29' ' ' ARG . . . . . 0.847 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.1 OUTLIER -155.33 -159.9 0.98 Allowed 'General case' 0 N--CA 1.467 0.42 0 N-CA-C 112.496 0.554 . . . . 2.15 112.496 -174.476 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 30' ' ' GLU . . . . . 0.422 ' H ' ' HB2' ' B' ' 29' ' ' ARG . 38.6 mp0 -69.87 36.93 0.04 OUTLIER 'General case' 0 N--CA 1.472 0.655 0 CA-C-O 122.019 0.914 . . . . 1.18 112.053 178.636 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . 0.608 ' CA ' HD11 ' A' ' 10' ' ' ILE . . . -156.46 32.97 0.59 Allowed Glycine 0 N--CA 1.431 -1.663 0 N-CA-C 109.547 -1.421 . . . . 0.35 109.547 175.712 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 32' ' ' ASP . . . . . 0.536 ' O ' HG13 ' A' ' 10' ' ' ILE . 19.2 t0 -92.46 125.55 55.62 Favored Pre-proline 0 C--N 1.323 -0.569 0 CA-C-N 114.861 -0.669 . . . . 1.29 109.259 173.529 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 33' ' ' PRO . . . . . 0.82 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 3.5 Cg_endo -79.55 151.66 22.57 Favored 'Trans proline' 0 N--CA 1.436 -1.888 0 C-N-CA 122.216 1.944 . . . . 1.1 110.043 174.215 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.831 HD11 HG23 ' A' ' 10' ' ' ILE . 0.8 OUTLIER -140.73 149.35 42.04 Favored 'General case' 0 C--N 1.305 -1.326 0 N-CA-C 109.444 -0.576 . . . . 0.44 109.444 172.434 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 35' ' ' GLU . . . . . 0.646 ' O ' ' HA ' ' B' ' 46' ' ' LEU . 72.1 tt0 -104.04 112.28 25.21 Favored 'General case' 0 CA--C 1.487 -1.471 0 N-CA-C 107.359 -1.348 . . . . 1.1 107.359 -179.272 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 36' ' ' ILE . . . . . 0.895 HG13 HD22 ' B' ' 46' ' ' LEU . 2.5 mp -86.47 111.07 20.87 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.148 0 O-C-N 124.615 1.197 . . . . 0.62 108.675 179.331 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 37' ' ' PHE . . . . . 0.763 ' HB2' ' H ' ' A' ' 4' ' ' THR . 17.9 p90 -150.29 129.28 12.59 Favored 'General case' 0 C--N 1.314 -0.96 0 N-CA-C 109.392 -0.596 . . . . 1.2 109.392 172.613 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 38' ' ' VAL . . . . . 0.561 ' HA ' ' HA ' ' B' ' 44' ' ' VAL . 1.4 p -83.62 129.91 36.73 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.114 0 CA-C-O 121.255 0.55 . . . . 0.2 111.539 -175.369 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 39' ' ' ASP . . . . . 0.688 ' HB3' ' HD3' ' B' ' 40' ' ' ARG . 0.5 OUTLIER -94.28 171.36 8.88 Favored 'General case' 0 N--CA 1.443 -0.777 0 N-CA-C 108.036 -1.098 . . . . 1.14 108.036 173.634 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 40' ' ' ARG . . . . . 0.688 ' HD3' ' HB3' ' B' ' 39' ' ' ASP . 0.0 OUTLIER 41.64 -107.22 0.08 Allowed 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 113.811 1.041 . . . . 2.71 113.811 176.902 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -108.13 -82.98 0.55 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.076 0.465 . . . . 1.32 111.368 -174.362 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 42' ' ' GLY . . . . . . . . . . . . . . . -118.93 26.15 7.64 Favored Glycine 0 N--CA 1.444 -0.78 0 C-N-CA 120.92 -0.657 . . . . 0.34 111.89 -175.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 43' ' ' GLU . . . . . 0.64 ' HB3' HG23 ' A' ' 45' ' ' ILE . 2.0 mt-10 -96.79 111.9 23.88 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 109.633 -0.506 . . . . 2.07 109.633 178.082 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 44' ' ' VAL . . . . . 0.561 ' HA ' ' HA ' ' B' ' 38' ' ' VAL . 1.9 t -88.23 132.63 32.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 N-CA-C 109.575 -0.528 . . . . 0.13 109.575 178.204 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 45' ' ' ILE . . . . . 0.797 HG13 HG13 ' A' ' 45' ' ' ILE . 1.5 mp -108.97 119.36 58.39 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 N-CA-C 108.206 -1.035 . . . . 0.12 108.206 -177.352 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 46' ' ' LEU . . . . . 0.998 HD11 HD11 ' A' ' 46' ' ' LEU . 0.7 OUTLIER -112.37 117.1 31.51 Favored 'General case' 0 C--N 1.317 -0.817 0 O-C-N 123.68 0.612 . . . . 0.15 110.008 178.217 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 47' ' ' LYS . . . . . 0.587 ' O ' ' HA ' ' B' ' 34' ' ' LEU . 0.0 OUTLIER -129.78 149.33 51.57 Favored 'General case' 0 C--O 1.215 -0.72 0 C-N-CA 119.492 -0.883 . . . . 0.95 113.03 -179.841 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 48' ' ' LYS . . . . . 0.602 ' HA ' ' O ' ' B' ' 33' ' ' PRO . 1.7 ptmt -39.75 -21.35 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.244 0 N-CA-C 117.658 2.466 . . . . 0.64 117.658 -168.086 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 49' ' ' TYR . . . . . 0.82 ' HB3' ' HB2' ' B' ' 33' ' ' PRO . 23.3 t80 75.1 -46.58 0.59 Allowed 'General case' 0 N--CA 1.47 0.568 0 CA-C-N 119.095 0.861 . . . . 1.26 111.282 177.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 50' ' ' SER . . . . . 0.664 ' OG ' ' HD3' ' B' ' 51' ' ' PRO . 1.6 p -50.14 -48.38 79.64 Favored Pre-proline 0 CA--C 1.544 0.737 0 CA-C-N 115.519 -0.764 . . . . 1.22 112.395 -175.528 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 51' ' ' PRO . . . . . 0.664 ' HD3' ' OG ' ' B' ' 50' ' ' SER . 33.1 Cg_endo -103.06 14.03 0.29 Allowed 'Trans proline' 0 N--CA 1.454 -0.831 0 C-N-CA 122.976 2.45 . . . . 0.56 111.733 170.241 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 52' ' ' ILE . . . . . 0.677 HG13 HD23 ' B' ' 55' ' ' LEU . 1.1 mt 53.54 -141.93 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 N-CA-C 108.516 -0.92 . . . . 0.73 108.516 -168.661 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 53' ' ' SER . . . . . . . . . . . . . 70.2 m -83.02 -28.18 29.82 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.509 0.671 . . . . 1.86 110.004 176.66 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 54' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -167.34 118.59 0.88 Allowed 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 114.408 -1.269 . . . . 2.62 109.216 -176.713 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 55' ' ' LEU . . . . . 0.677 HD23 HG13 ' B' ' 52' ' ' ILE . 0.2 OUTLIER . . . . . 0 C--O 1.249 1.062 0 CA-C-O 118.673 -0.679 . . . . 2.64 110.485 -177.068 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.48 1.075 0 N-CA-C 109.919 -0.4 . . . . 5.91 109.919 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.733 ' HB2' HG13 ' B' ' 38' ' ' VAL . 0.0 OUTLIER -82.91 -176.6 6.4 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 109.203 -0.666 . . . . 3.71 109.203 177.561 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.478 ' HA ' ' HB2' ' B' ' 37' ' ' PHE . . . 55.21 70.92 0.58 Allowed 'General case' 0 N--CA 1.463 0.214 0 CA-C-O 121.608 0.718 . . . . 0.72 109.75 -171.083 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 31.0 p -84.53 -31.74 24.26 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.201 -0.909 . . . . 0.41 112.521 -169.574 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.583 ' H ' ' HB3' ' B' ' 37' ' ' PHE . . . 61.01 49.19 81.35 Favored Glycine 0 N--CA 1.446 -0.66 0 C-N-CA 120.767 -0.73 . . . . 0.32 113.074 176.567 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.85 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.6 tp -105.73 104.41 16.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 N-CA-C 109.173 -0.677 . . . . 0.31 109.173 174.823 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.615 HG21 ' CD1' ' B' ' 49' ' ' TYR . 38.0 t -74.25 133.04 32.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 115.719 -0.673 . . . . 0.28 110.088 179.696 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.667 ' HB3' ' CD1' ' B' ' 36' ' ' ILE . 3.3 tpp180 -129.43 119.4 23.74 Favored 'General case' 0 N--CA 1.437 -1.077 0 N-CA-C 106.809 -1.552 . . . . 1.99 106.809 -178.75 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.53 ' HA ' ' O ' ' B' ' 32' ' ' ASP . 9.4 ttp180 -83.37 102.76 12.23 Favored 'General case' 0 C--N 1.312 -1.024 0 N-CA-C 108.553 -0.906 . . . . 2.8 108.553 176.183 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.756 HG23 HD11 ' B' ' 34' ' ' LEU . 0.2 OUTLIER -9.62 -103.23 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 O-C-N 125.62 1.825 . . . . 0.33 114.525 -177.108 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . 0.603 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 4.3 p-10 161.43 -162.62 0.0 OUTLIER 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 108.31 -0.996 . . . . 1.13 108.31 176.86 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -71.27 -24.73 62.22 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.15 0.5 . . . . 2.26 110.803 -178.109 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -95.22 -58.98 1.99 Allowed 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.112 -0.494 . . . . 0.53 110.212 178.551 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.531 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 135.64 17.72 0.83 Allowed Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.595 -0.812 . . . . 0.22 112.92 -177.998 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.664 ' HG2' HG22 ' B' ' 17' ' ' VAL . 1.4 mpt_? -74.73 153.11 38.98 Favored 'General case' 0 CA--C 1.507 -0.689 0 O-C-N 122.139 -0.624 . . . . 0.69 110.033 179.299 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.749 HG21 HD13 ' B' ' 46' ' ' LEU . 93.3 t -108.39 95.93 4.22 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.29 0 N-CA-C 107.662 -1.236 . . . . 1.24 107.662 169.239 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.644 HG22 ' HG2' ' B' ' 15' ' ' ARG . 91.0 t -64.54 99.37 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-N 115.131 -0.94 . . . . 0.28 110.085 -174.121 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.473 ' HB ' ' O ' ' B' ' 14' ' ' GLY . 38.6 mm -87.47 112.05 45.73 Favored Pre-proline 0 N--CA 1.446 -0.659 0 CA-C-N 115.543 -0.753 . . . . 0.77 109.854 -179.515 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.568 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 91.9 Cg_exo -50.79 140.72 37.34 Favored 'Trans proline' 0 N--CA 1.452 -0.963 0 C-N-CA 122.267 1.978 . . . . 0.32 111.738 173.566 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.982 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -61.12 -14.95 28.12 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.675 -0.693 . . . . 1.57 111.47 -177.992 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.568 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 11.3 pt-20 -66.77 -21.4 66.06 Favored 'General case' 0 C--O 1.237 0.442 0 N-CA-C 112.182 0.438 . . . . 1.32 112.182 -178.685 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 5.2 mp -87.91 -45.27 15.98 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 107.997 -1.112 . . . . 0.35 107.997 -179.772 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . 0.733 ' HA ' ' HB2' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -60.35 -29.37 68.86 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 115.285 -0.871 . . . . 1.5 109.18 172.448 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.473 ' HB3' ' O ' ' A' ' 21' ' ' GLU . 58.7 ttt180 -60.42 -52.6 64.52 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 114.403 -1.271 . . . . 2.96 110.484 173.833 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 19.8 m -69.2 -21.21 63.97 Favored 'General case' 0 CA--C 1.53 0.177 0 CA-C-O 121.295 0.569 . . . . 0.4 110.904 175.11 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.791 ' HB3' HG13 ' A' ' 28' ' ' ILE . 0.8 OUTLIER -67.55 -18.37 65.0 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.974 -0.557 . . . . 0.36 111.2 176.418 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.466 ' HB2' ' O ' ' A' ' 26' ' ' LEU . 0.0 OUTLIER 70.51 20.46 5.89 Favored 'General case' 0 C--N 1.343 0.324 0 CA-C-O 121.299 0.571 . . . . 3.2 110.009 -172.397 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.791 HG13 ' HB3' ' A' ' 26' ' ' LEU . 3.0 mt -119.22 -164.87 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.535 -0.757 . . . . 0.48 109.855 -176.086 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.732 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -158.3 -156.97 0.59 Allowed 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 110.382 -0.229 . . . . 2.4 110.382 -167.988 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . 0.404 ' C ' HD11 ' B' ' 10' ' ' ILE . 1.6 mp0 -72.95 38.48 0.08 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 122.213 1.006 . . . . 1.23 111.034 176.34 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.639 ' N ' HD11 ' B' ' 10' ' ' ILE . . . -152.55 26.17 0.85 Allowed Glycine 0 N--CA 1.435 -1.411 0 CA-C-N 113.854 -1.521 . . . . 0.36 110.4 176.023 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.495 ' HA ' ' HD3' ' A' ' 33' ' ' PRO . 63.8 t0 -84.12 114.22 53.08 Favored Pre-proline 0 C--N 1.331 -0.205 0 CA-C-O 121.279 0.562 . . . . 1.26 109.768 175.627 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.595 ' HA ' ' HA ' ' B' ' 9' ' ' ARG . 1.2 Cg_endo -88.97 54.76 1.95 Allowed 'Trans proline' 0 CA--C 1.507 -0.874 0 C-N-CA 124.158 3.239 . . . . 1.3 114.108 -175.188 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.609 HD12 ' H ' ' A' ' 34' ' ' LEU . 1.0 OUTLIER -57.38 153.6 12.21 Favored 'General case' 0 C--N 1.297 -1.676 0 CA-C-O 122.299 1.047 . . . . 0.38 112.352 -173.768 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.824 ' HB3' ' HB3' ' A' ' 47' ' ' LYS . 33.8 tt0 -105.07 118.47 36.62 Favored 'General case' 0 CA--C 1.492 -1.259 0 CA-C-N 113.492 -1.685 . . . . 1.12 107.505 -175.594 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.884 ' HB ' HG23 ' B' ' 6' ' ' ILE . 2.6 mp -88.28 110.16 20.72 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.014 0 O-C-N 123.847 0.717 . . . . 0.39 109.265 179.467 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . 0.784 ' HD1' ' HA ' ' B' ' 3' ' ' ALA . 0.8 OUTLIER -150.18 124.84 9.72 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 109.785 -0.45 . . . . 1.15 109.785 174.557 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.776 HG13 ' HB2' ' B' ' 2' ' ' LYS . 1.4 p -80.91 137.83 20.69 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.978 0 CA-C-O 121.053 0.454 . . . . 0.17 110.716 -179.232 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.596 ' OD2' ' HD2' ' A' ' 40' ' ' ARG . 3.6 t70 -85.4 -55.49 3.99 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.444 -0.798 . . . . 1.11 111.514 -173.633 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . 0.596 ' HD2' ' OD2' ' A' ' 39' ' ' ASP . 0.2 OUTLIER -119.91 -91.61 0.55 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.517 -0.765 . . . . 2.29 111.981 -169.554 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -99.01 -69.58 0.76 Allowed 'General case' 0 CA--C 1.511 -0.548 0 CA-C-O 121.345 0.593 . . . . 1.53 110.571 -176.206 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.729 ' HA3' HD11 ' B' ' 26' ' ' LEU . . . -135.54 21.74 3.58 Favored Glycine 0 N--CA 1.437 -1.261 0 CA-C-N 114.97 -1.013 . . . . 0.32 111.696 -176.787 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.621 ' HB3' HG23 ' B' ' 45' ' ' ILE . 2.1 mt-10 -95.38 109.15 21.36 Favored 'General case' 0 N--CA 1.447 -0.602 0 N-CA-C 109.099 -0.704 . . . . 1.97 109.099 177.381 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.528 ' CG1' HG23 ' A' ' 36' ' ' ILE . 1.7 t -90.09 132.11 35.6 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.941 0 N-CA-C 109.214 -0.661 . . . . 0.14 109.214 178.467 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.754 HG13 HG13 ' B' ' 45' ' ' ILE . 1.6 mp -108.21 119.55 58.0 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 N-CA-C 108.262 -1.014 . . . . 0.14 108.262 -176.104 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.926 HD11 HD11 ' B' ' 46' ' ' LEU . 6.9 mt -103.61 121.9 43.88 Favored 'General case' 0 C--N 1.322 -0.599 0 O-C-N 124.221 0.951 . . . . 0.23 110.033 179.616 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.824 ' HB3' ' HB3' ' A' ' 35' ' ' GLU . 21.6 ttmt -126.98 123.3 36.79 Favored 'General case' 0 C--N 1.308 -1.216 0 CA-C-N 115.454 -0.793 . . . . 0.76 112.576 -168.18 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.57 ' O ' ' HD2' ' A' ' 33' ' ' PRO . 3.1 ptmt -39.0 -19.24 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.648 0 N-CA-C 116.948 2.203 . . . . 0.32 116.948 -172.849 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 0.661 ' CD1' HG21 ' B' ' 7' ' ' VAL . 27.1 t80 74.72 -56.02 0.64 Allowed 'General case' 0 N--CA 1.475 0.823 0 C-N-CA 123.83 0.852 . . . . 1.28 113.001 173.414 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.681 ' HB3' ' HD3' ' A' ' 51' ' ' PRO . 48.2 t -49.62 -53.61 39.55 Favored Pre-proline 0 CA--C 1.535 0.373 0 CA-C-N 115.807 -0.633 . . . . 1.36 111.433 -175.072 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.681 ' HD3' ' HB3' ' A' ' 50' ' ' SER . 46.2 Cg_endo -95.26 14.32 1.21 Allowed 'Trans proline' 0 N--CA 1.456 -0.723 0 C-N-CA 122.27 1.98 . . . . 0.58 111.452 170.652 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.67 HG13 HD23 ' A' ' 55' ' ' LEU . 2.6 mt 53.96 -130.63 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 N-CA-C 108.587 -0.894 . . . . 0.78 108.587 -172.433 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 63.1 m -91.06 -43.51 9.87 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-O 121.472 0.653 . . . . 1.96 110.126 173.789 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 29.9 tt0 -128.81 -47.88 1.25 Allowed 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 114.827 -1.079 . . . . 2.89 110.97 -170.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.67 HD23 HG13 ' A' ' 52' ' ' ILE . 0.5 OUTLIER . . . . . 0 C--O 1.248 1.015 0 O-C-N 124.034 0.834 . . . . 2.65 110.24 -179.057 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 22.2 mmt . . . . . 0 N--CA 1.478 0.951 0 CA-C-O 120.666 0.27 . . . . 6.17 110.355 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 2' ' ' LYS . . . . . 0.776 ' HB2' HG13 ' A' ' 38' ' ' VAL . 0.1 OUTLIER -82.07 -172.48 3.97 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 108.885 -0.783 . . . . 3.61 108.885 172.902 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 3' ' ' ALA . . . . . 0.784 ' HA ' ' HD1' ' A' ' 37' ' ' PHE . . . 53.55 69.34 0.72 Allowed 'General case' 0 N--CA 1.462 0.174 0 CA-C-O 121.555 0.693 . . . . 0.86 110.169 -175.472 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 4' ' ' THR . . . . . . . . . . . . . 25.0 p -82.41 -32.02 29.31 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.162 -0.926 . . . . 0.43 112.498 -171.141 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 5' ' ' GLY . . . . . 0.472 ' H ' ' CB ' ' A' ' 37' ' ' PHE . . . 61.44 45.27 96.73 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 121.14 -0.552 . . . . 0.33 113.128 176.728 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 6' ' ' ILE . . . . . 0.884 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.1 tp -104.17 104.74 17.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.517 0.675 . . . . 0.3 109.556 178.066 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . 0.661 HG21 ' CD1' ' A' ' 49' ' ' TYR . 4.9 t -74.84 131.46 34.96 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.872 0 CA-C-N 115.178 -0.919 . . . . 0.27 110.896 -179.158 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.474 ' HB3' ' CD1' ' A' ' 36' ' ' ILE . 0.1 OUTLIER -129.56 118.15 21.58 Favored 'General case' 0 N--CA 1.447 -0.593 0 N-CA-C 107.031 -1.47 . . . . 1.69 107.031 177.737 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 9' ' ' ARG . . . . . 0.595 ' HA ' ' HA ' ' A' ' 33' ' ' PRO . 26.7 ttp180 -79.85 104.84 10.7 Favored 'General case' 0 N--CA 1.44 -0.969 0 C-N-CA 119.789 -0.764 . . . . 2.71 109.001 174.527 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 10' ' ' ILE . . . . . 0.65 ' O ' ' HB3' ' B' ' 11' ' ' ASP . 0.3 OUTLIER -11.91 -102.75 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 O-C-N 125.705 1.878 . . . . 0.34 114.644 -176.051 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . 0.65 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 2.8 p-10 160.07 -165.81 0.0 OUTLIER 'General case' 0 C--N 1.342 0.249 0 N-CA-C 107.871 -1.159 . . . . 1.18 107.871 177.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -68.21 -30.75 69.9 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 120.967 0.413 . . . . 2.39 110.616 -179.131 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 13' ' ' LEU . . . . . 0.528 ' HB3' ' HD2' ' B' ' 15' ' ' ARG . 3.1 tm? -85.61 -59.27 2.36 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.066 -0.515 . . . . 0.4 110.101 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 14' ' ' GLY . . . . . 0.473 ' O ' ' HB ' ' A' ' 18' ' ' ILE . . . 131.46 16.29 1.52 Allowed Glycine 0 N--CA 1.445 -0.711 0 C-N-CA 120.327 -0.939 . . . . 0.21 112.727 -178.112 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 15' ' ' ARG . . . . . 0.644 ' HG2' HG22 ' A' ' 17' ' ' VAL . 0.3 OUTLIER -74.8 153.3 38.81 Favored 'General case' 0 CA--C 1.507 -0.674 0 C-N-CA 119.709 -0.796 . . . . 0.9 109.826 178.138 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 16' ' ' VAL . . . . . 0.872 HG21 HD13 ' A' ' 46' ' ' LEU . 95.9 t -108.53 98.01 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.316 0 N-CA-C 107.725 -1.213 . . . . 1.27 107.725 169.721 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 17' ' ' VAL . . . . . 0.664 HG22 ' HG2' ' A' ' 15' ' ' ARG . 57.6 t -66.69 99.58 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.877 0 CA-C-N 114.963 -1.017 . . . . 0.27 110.14 -172.259 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . 0.531 ' HB ' ' O ' ' A' ' 14' ' ' GLY . 39.1 mm -86.92 111.7 42.23 Favored Pre-proline 0 C--N 1.323 -0.569 0 CA-C-N 115.321 -0.854 . . . . 0.82 109.978 -179.376 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . 0.561 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 86.4 Cg_exo -50.61 139.85 37.77 Favored 'Trans proline' 0 N--CA 1.453 -0.909 0 C-N-CA 122.392 2.061 . . . . 0.3 111.607 172.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 20' ' ' LYS . . . . . 1.024 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -61.07 -13.31 15.99 Favored 'General case' 0 C--N 1.313 -0.979 0 CA-C-N 115.442 -0.799 . . . . 1.77 111.64 -178.35 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . 0.561 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 10.4 pt-20 -67.01 -22.98 65.87 Favored 'General case' 0 C--O 1.237 0.444 0 N-CA-C 112.614 0.598 . . . . 1.92 112.614 179.751 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 4.6 mp -88.06 -43.17 15.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 N-CA-C 107.758 -1.201 . . . . 0.44 107.758 -179.672 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 23' ' ' ARG . . . . . 0.684 ' HA ' ' HB2' ' B' ' 26' ' ' LEU . 0.0 OUTLIER -60.53 -29.89 69.4 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 115.287 -0.87 . . . . 1.4 109.298 171.503 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 24' ' ' ARG . . . . . 0.441 ' HB3' ' O ' ' B' ' 21' ' ' GLU . 23.1 ttt180 -61.66 -52.72 63.17 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 114.594 -1.184 . . . . 3.19 110.391 174.073 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 14.4 m -66.53 -25.06 66.49 Favored 'General case' 0 N--CA 1.452 -0.366 0 CA-C-O 121.456 0.646 . . . . 0.4 110.466 176.292 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.729 HD11 ' HA3' ' A' ' 42' ' ' GLY . 0.7 OUTLIER -65.04 -19.55 66.05 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.432 -0.804 . . . . 0.33 111.068 175.699 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 27' ' ' ARG . . . . . 0.488 ' HB2' ' O ' ' B' ' 26' ' ' LEU . 0.2 OUTLIER 70.99 19.04 5.78 Favored 'General case' 0 N--CA 1.465 0.28 0 O-C-N 123.938 0.774 . . . . 3.28 110.097 -173.265 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 28' ' ' ILE . . . . . 0.892 HG22 ' H ' ' B' ' 29' ' ' ARG . 5.6 mt -115.45 -166.61 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 115.569 -0.741 . . . . 0.37 110.037 -177.044 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 29' ' ' ARG . . . . . 0.892 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -155.93 -157.35 0.71 Allowed 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 110.404 -0.221 . . . . 2.15 110.404 -169.698 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 30' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -71.44 31.94 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.547 0.689 . . . . 1.18 111.926 178.495 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . 0.547 ' N ' HD11 ' A' ' 10' ' ' ILE . . . -145.73 30.24 1.69 Allowed Glycine 0 N--CA 1.438 -1.172 0 CA-C-N 115.222 -0.899 . . . . 0.35 110.866 173.527 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 32' ' ' ASP . . . . . 0.53 ' O ' ' HA ' ' A' ' 9' ' ' ARG . 25.6 t0 -84.19 117.32 68.41 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-O 121.296 0.57 . . . . 1.29 110.301 176.881 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 33' ' ' PRO . . . . . 0.733 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 2.5 Cg_endo -87.4 66.7 3.99 Favored 'Trans proline' 0 C--O 1.206 -1.112 0 C-N-CA 123.984 3.123 . . . . 1.1 113.793 -178.448 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.756 HD11 HG23 ' A' ' 10' ' ' ILE . 0.9 OUTLIER -66.23 151.53 46.81 Favored 'General case' 0 C--N 1.284 -2.276 0 C-N-CA 118.547 -1.261 . . . . 0.44 111.573 -174.774 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 35' ' ' GLU . . . . . 0.682 ' O ' ' HA ' ' B' ' 46' ' ' LEU . 66.1 tt0 -103.53 114.33 28.52 Favored 'General case' 0 CA--C 1.493 -1.242 0 CA-C-N 114.686 -1.143 . . . . 1.1 108.011 -178.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 36' ' ' ILE . . . . . 0.85 ' HB ' HG23 ' A' ' 6' ' ' ILE . 2.6 mp -87.87 109.82 20.09 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.732 0 O-C-N 124.199 0.937 . . . . 0.62 109.598 -179.04 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 37' ' ' PHE . . . . . 0.583 ' HB3' ' H ' ' A' ' 5' ' ' GLY . 15.3 p90 -150.69 125.95 10.02 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 116.111 -0.495 . . . . 1.2 110.002 175.176 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 38' ' ' VAL . . . . . 0.733 HG13 ' HB2' ' A' ' 2' ' ' LYS . 0.8 OUTLIER -80.31 136.97 22.33 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 CA-C-O 121.125 0.488 . . . . 0.2 110.895 -178.19 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 39' ' ' ASP . . . . . 0.599 ' OD1' ' HD2' ' B' ' 40' ' ' ARG . 12.2 t70 -76.86 -64.75 1.05 Allowed 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 114.699 -1.137 . . . . 1.14 110.996 -175.213 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 40' ' ' ARG . . . . . 0.599 ' HD2' ' OD1' ' B' ' 39' ' ' ASP . 0.0 OUTLIER -117.73 -94.49 0.49 Allowed 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.682 -0.69 . . . . 2.71 112.204 -175.162 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 26.1 t70 -90.85 -70.47 0.68 Allowed 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.993 0.425 . . . . 1.32 111.21 -174.014 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 42' ' ' GLY . . . . . 0.623 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -134.28 24.22 3.59 Favored Glycine 0 N--CA 1.441 -0.996 0 C-N-CA 120.498 -0.858 . . . . 0.34 112.476 -177.555 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 43' ' ' GLU . . . . . 0.635 ' HA ' ' O ' ' A' ' 46' ' ' LEU . 1.1 mt-10 -97.04 107.86 20.47 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 109.434 -0.58 . . . . 2.07 109.434 175.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 44' ' ' VAL . . . . . 0.573 ' HA ' ' HA ' ' B' ' 38' ' ' VAL . 2.0 t -88.66 130.91 37.34 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 N-CA-C 109.587 -0.523 . . . . 0.13 109.587 178.18 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 45' ' ' ILE . . . . . 0.754 HG13 HG13 ' A' ' 45' ' ' ILE . 1.6 mp -106.45 121.33 58.9 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 N-CA-C 107.962 -1.125 . . . . 0.12 107.962 -177.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 46' ' ' LEU . . . . . 0.926 HD11 HD11 ' A' ' 46' ' ' LEU . 0.7 OUTLIER -111.59 116.27 30.54 Favored 'General case' 0 C--N 1.319 -0.731 0 O-C-N 123.876 0.735 . . . . 0.15 109.782 177.779 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 47' ' ' LYS . . . . . 0.544 ' HE3' ' HB3' ' B' ' 35' ' ' GLU . 0.0 OUTLIER -131.12 140.43 49.99 Favored 'General case' 0 C--O 1.213 -0.82 0 N-CA-C 113.402 0.89 . . . . 0.95 113.402 -178.684 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 48' ' ' LYS . . . . . 0.63 ' HE2' ' HG3' ' B' ' 51' ' ' PRO . 4.9 ptmt -38.2 -16.72 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.393 0 N-CA-C 118.747 2.869 . . . . 0.64 118.747 -168.175 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 49' ' ' TYR . . . . . 0.733 ' HB3' ' HB2' ' B' ' 33' ' ' PRO . 39.5 t80 72.32 -51.51 0.7 Allowed 'General case' 0 N--CA 1.485 1.309 0 CA-C-N 119.241 0.928 . . . . 1.26 113.247 176.481 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 50' ' ' SER . . . . . 0.449 ' OG ' ' HD3' ' B' ' 51' ' ' PRO . 1.4 p -51.7 -51.5 69.51 Favored Pre-proline 0 CA--C 1.541 0.613 0 CA-C-N 116.069 -0.514 . . . . 1.22 112.051 -172.581 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 51' ' ' PRO . . . . . 0.63 ' HG3' ' HE2' ' B' ' 48' ' ' LYS . 24.2 Cg_endo -95.42 16.41 0.91 Allowed 'Trans proline' 0 C--N 1.351 0.687 0 C-N-CA 122.45 2.1 . . . . 0.56 111.582 167.735 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 52' ' ' ILE . . . . . 0.43 HG13 HD23 ' B' ' 55' ' ' LEU . 3.4 mt 53.2 -130.66 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 N-CA-C 108.083 -1.08 . . . . 0.73 108.083 -170.566 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 53' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -112.97 19.53 17.19 Favored 'General case' 0 C--N 1.307 -1.277 0 C-N-CA 120.432 -0.507 . . . . 1.86 111.285 177.615 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 54' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 178.6 -55.96 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.568 -0.742 . . . . 2.62 110.715 -175.294 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 55' ' ' LEU . . . . . 0.43 HD23 HG13 ' B' ' 52' ' ' ILE . 0.2 OUTLIER . . . . . 0 C--O 1.25 1.114 0 CA-C-N 115.172 -0.922 . . . . 2.64 109.303 -175.828 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 24.7 ttt . . . . . 0 N--CA 1.48 1.032 0 CA-C-O 120.738 0.304 . . . . 5.91 110.836 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.55 ' HB3' HG13 ' B' ' 38' ' ' VAL . 30.0 mmmt -112.26 -117.04 0.31 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.089 0.471 . . . . 3.71 111.922 -173.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.422 ' HA ' ' HB2' ' B' ' 37' ' ' PHE . . . 72.53 143.29 0.06 Allowed 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 114.406 -1.27 . . . . 0.72 112.723 179.079 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.828 ' H ' ' HB2' ' B' ' 37' ' ' PHE . 19.2 p -130.84 -54.86 1.06 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 114.792 -1.095 . . . . 0.41 110.458 179.052 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 84.58 54.06 3.05 Favored Glycine 0 N--CA 1.446 -0.654 0 C-N-CA 120.434 -0.888 . . . . 0.32 112.458 173.319 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.902 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.6 tp -108.84 108.96 26.6 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 N-CA-C 109.404 -0.591 . . . . 0.31 109.404 171.235 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.757 HG21 ' CD1' ' B' ' 49' ' ' TYR . 36.5 t -83.0 135.92 23.85 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-O 120.905 0.383 . . . . 0.28 111.286 -179.435 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.528 ' HB3' HD11 ' B' ' 36' ' ' ILE . 5.3 tpt180 -129.63 114.79 16.47 Favored 'General case' 0 N--CA 1.446 -0.642 0 N-CA-C 107.85 -1.167 . . . . 1.99 107.85 -176.771 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.722 HH11 ' HG3' ' B' ' 33' ' ' PRO . 3.7 tpp180 -81.73 103.43 11.42 Favored 'General case' 0 CA--C 1.509 -0.618 0 N-CA-C 108.047 -1.094 . . . . 2.8 108.047 174.19 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.662 ' O ' ' HB3' ' A' ' 11' ' ' ASP . 0.2 OUTLIER -14.5 -106.61 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.039 0 O-C-N 125.7 1.875 . . . . 0.33 114.367 -176.295 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . 0.662 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 4.6 p-10 158.86 -169.06 0.0 OUTLIER 'General case' 0 CA--C 1.511 -0.547 0 N-CA-C 107.917 -1.142 . . . . 1.13 107.917 175.23 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -70.61 -8.92 55.25 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.952 0.406 . . . . 2.26 111.086 -178.686 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.403 HD12 HG13 ' B' ' 17' ' ' VAL . 1.6 tm? -107.82 -62.14 1.48 Allowed 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.763 -0.458 . . . . 0.53 109.763 175.205 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 134.36 22.34 0.71 Allowed Glycine 0 N--CA 1.445 -0.75 0 C-N-CA 120.455 -0.878 . . . . 0.22 113.264 179.288 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.566 ' HB3' ' HB3' ' B' ' 15' ' ' ARG . 1.5 mpt_? -80.99 150.44 28.91 Favored 'General case' 0 CA--C 1.51 -0.588 0 O-C-N 121.913 -0.757 . . . . 0.69 110.813 -179.885 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.597 HG21 HD13 ' B' ' 46' ' ' LEU . 70.9 t -109.91 98.78 7.49 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.284 0 N-CA-C 107.581 -1.266 . . . . 1.24 107.581 168.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.554 ' HA ' ' HA ' ' B' ' 15' ' ' ARG . 61.7 t -67.25 101.66 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 CA-C-N 115.501 -0.772 . . . . 0.28 109.577 -176.138 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.611 HG23 HD13 ' A' ' 22' ' ' ILE . 8.5 mt -93.55 111.77 53.8 Favored Pre-proline 0 C--N 1.322 -0.6 0 CA-C-N 116.022 -0.536 . . . . 0.77 110.72 -177.836 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.687 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 95.7 Cg_exo -50.31 152.51 8.26 Favored 'Trans proline' 0 N--CA 1.458 -0.579 0 C-N-CA 122.944 2.429 . . . . 0.32 112.893 173.963 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.825 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -67.24 -14.26 62.74 Favored 'General case' 0 C--O 1.21 -0.988 0 CA-C-N 115.668 -0.696 . . . . 1.57 111.237 -179.851 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.687 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 15.4 pt-20 -62.65 -25.36 68.09 Favored 'General case' 0 C--O 1.238 0.495 0 CA-C-O 120.88 0.372 . . . . 1.32 111.752 -179.322 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.611 HD13 HG23 ' A' ' 18' ' ' ILE . 5.3 mp -86.63 -47.17 16.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 108.257 -1.016 . . . . 0.35 108.257 -177.72 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . 0.639 ' HA ' ' HB2' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -61.12 -27.19 68.2 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.172 -0.922 . . . . 1.5 109.038 174.043 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 38.8 ttp180 -64.27 -52.29 59.36 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 114.829 -1.078 . . . . 2.96 110.564 175.088 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 21.7 m -63.93 -28.18 69.65 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-O 121.154 0.502 . . . . 0.4 110.992 174.28 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.639 ' HB2' ' HA ' ' A' ' 23' ' ' ARG . 2.4 mm? -64.05 -19.99 65.61 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.795 -0.639 . . . . 0.36 110.043 172.636 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.408 HH11 ' HD3' ' A' ' 27' ' ' ARG . 0.2 OUTLIER 71.44 22.26 4.27 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.01 -0.995 . . . . 3.2 110.105 -177.609 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.782 HG22 ' H ' ' A' ' 29' ' ' ARG . 6.1 mt -121.03 -167.35 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.674 0 CA-C-N 115.155 -0.93 . . . . 0.48 109.118 -177.424 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.782 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.3 OUTLIER -146.01 -156.47 0.71 Allowed 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 118.037 0.38 . . . . 2.4 111.943 -174.335 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -72.86 48.6 0.21 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 122.197 0.998 . . . . 1.23 111.904 -179.214 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.684 ' N ' HD11 ' B' ' 10' ' ' ILE . . . -166.14 24.9 0.15 Allowed Glycine 0 N--CA 1.443 -0.876 0 CA-C-N 113.804 -1.544 . . . . 0.36 109.863 174.69 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.494 ' O ' HG13 ' B' ' 10' ' ' ILE . 19.8 t0 -87.67 127.63 57.54 Favored Pre-proline 0 CA--C 1.516 -0.348 0 CA-C-N 114.771 -0.715 . . . . 1.26 109.377 174.883 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.712 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 3.8 Cg_endo -82.36 154.31 16.27 Favored 'Trans proline' 0 N--CA 1.438 -1.773 0 C-N-CA 122.26 1.973 . . . . 1.3 110.676 174.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.739 ' O ' ' HA ' ' B' ' 7' ' ' VAL . 0.5 OUTLIER -142.68 149.62 39.09 Favored 'General case' 0 C--N 1.307 -1.262 0 C-N-CA 120.133 -0.627 . . . . 0.38 109.507 172.688 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.949 ' HB3' ' HD2' ' A' ' 47' ' ' LYS . 38.1 tt0 -108.55 111.1 22.77 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 108.524 -0.917 . . . . 1.12 108.524 -176.182 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 1.033 HG13 HD22 ' A' ' 46' ' ' LEU . 2.2 mp -85.85 109.48 18.58 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.794 0 O-C-N 124.972 1.42 . . . . 0.39 109.211 -176.239 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . 0.967 ' HD2' ' HA ' ' B' ' 3' ' ' ALA . 0.5 OUTLIER -149.37 124.72 10.23 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 115.683 -0.69 . . . . 1.15 109.431 177.736 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.538 ' HA ' ' HA ' ' A' ' 44' ' ' VAL . 2.0 p -80.52 133.08 30.25 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.953 0 CA-C-O 121.214 0.53 . . . . 0.17 110.566 -179.221 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.522 ' HB3' ' HG2' ' A' ' 40' ' ' ARG . 27.2 t0 -81.21 -58.07 3.22 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 114.154 -1.385 . . . . 1.11 111.453 -174.447 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . 0.567 ' HG3' ' HG3' ' A' ' 43' ' ' GLU . 1.3 ptm180 -125.6 -99.52 0.4 Allowed 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.134 -0.939 . . . . 2.29 112.74 -166.086 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 34.7 t70 -84.11 -75.67 0.33 Allowed 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.168 0.508 . . . . 1.53 110.757 -175.735 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.491 ' HA3' HD11 ' B' ' 26' ' ' LEU . . . -135.11 24.88 3.38 Favored Glycine 0 N--CA 1.441 -0.979 0 CA-C-N 115.534 -0.757 . . . . 0.32 111.313 178.735 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.633 ' HB3' HG23 ' B' ' 45' ' ' ILE . 2.1 mt-10 -93.6 109.91 21.53 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.048 -0.723 . . . . 1.97 109.048 178.473 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.538 ' HA ' ' HA ' ' A' ' 38' ' ' VAL . 1.5 t -90.41 130.51 39.53 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 N-CA-C 109.22 -0.659 . . . . 0.14 109.22 178.015 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.74 HG13 HG13 ' B' ' 45' ' ' ILE . 1.5 mp -108.79 117.91 55.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 N-CA-C 108.456 -0.942 . . . . 0.14 108.456 -175.595 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 1.049 HD11 HD11 ' B' ' 46' ' ' LEU . 0.3 OUTLIER -109.7 115.16 29.35 Favored 'General case' 0 C--N 1.314 -0.939 0 N-CA-C 108.743 -0.836 . . . . 0.23 108.743 176.936 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.949 ' HD2' ' HB3' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -123.11 151.26 42.24 Favored 'General case' 0 C--O 1.215 -0.74 0 C-N-CA 118.808 -1.157 . . . . 0.76 111.99 179.594 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.659 ' HA ' ' O ' ' A' ' 33' ' ' PRO . 2.0 ptmt -42.12 -16.78 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.93 0 N-CA-C 117.377 2.362 . . . . 0.32 117.377 -168.058 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 0.735 ' CD1' HG21 ' B' ' 7' ' ' VAL . 23.0 t80 73.19 -53.87 0.7 Allowed 'General case' 0 N--CA 1.473 0.676 0 CA-C-N 118.321 0.509 . . . . 1.28 112.301 174.101 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.7 ' OG ' ' HD3' ' A' ' 51' ' ' PRO . 4.3 p -54.07 -44.42 98.36 Favored Pre-proline 0 CA--C 1.543 0.676 0 CA-C-N 116.131 -0.486 . . . . 1.36 111.804 -175.378 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.7 ' HD3' ' OG ' ' A' ' 50' ' ' SER . 94.5 Cg_endo -102.29 21.44 0.17 Allowed 'Trans proline' 0 N--CA 1.452 -0.969 0 C-N-CA 123.082 2.521 . . . . 0.58 111.75 168.164 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.456 HD12 HD23 ' A' ' 55' ' ' LEU . 0.2 OUTLIER 46.52 -148.08 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.235 0.328 0 CA-C-N 115.78 -0.645 . . . . 0.78 110.347 -176.751 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 23.8 m -85.28 79.28 9.57 Favored 'General case' 0 N--CA 1.446 -0.657 0 C-N-CA 120.812 -0.355 . . . . 1.96 110.108 172.756 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 43.4 tt0 66.01 81.24 0.21 Allowed 'General case' 0 CA--C 1.534 0.33 0 CA-C-O 121.281 0.563 . . . . 2.89 110.937 178.333 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.516 ' HB2' ' O ' ' A' ' 51' ' ' PRO . 0.7 OUTLIER . . . . . 0 C--O 1.251 1.14 0 CA-C-O 118.562 -0.733 . . . . 2.65 109.489 179.037 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 25.8 ttt . . . . . 0 N--CA 1.479 0.983 0 CA-C-O 120.63 0.252 . . . . 6.17 111.139 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 2' ' ' LYS . . . . . 0.428 ' HB3' ' H ' ' B' ' 3' ' ' ALA . 30.4 mmmt -110.23 -161.87 0.77 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.617 -0.265 . . . . 3.61 111.422 -176.53 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 3' ' ' ALA . . . . . 0.967 ' HA ' ' HD2' ' A' ' 37' ' ' PHE . . . 137.57 160.02 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 125.182 1.393 . . . . 0.86 109.147 -163.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 4' ' ' THR . . . . . 0.735 ' H ' ' HB2' ' A' ' 37' ' ' PHE . 2.1 p -152.7 -47.86 0.1 Allowed 'General case' 0 C--N 1.324 -0.52 0 O-C-N 123.671 0.607 . . . . 0.43 109.563 174.083 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 72.53 53.1 8.93 Favored Glycine 0 N--CA 1.452 -0.254 0 CA-C-N 114.989 -1.005 . . . . 0.33 113.134 171.256 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 6' ' ' ILE . . . . . 0.855 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.3 tp -109.13 112.18 39.37 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.801 0 N-CA-C 109.124 -0.695 . . . . 0.3 109.124 171.895 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . 0.739 ' HA ' ' O ' ' A' ' 34' ' ' LEU . 39.7 t -84.4 136.03 23.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-O 120.94 0.4 . . . . 0.27 110.974 -179.501 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.573 ' CZ ' HG23 ' B' ' 17' ' ' VAL . 1.4 tpt180 -129.61 114.71 16.38 Favored 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 107.665 -1.235 . . . . 1.69 107.665 -178.603 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 9' ' ' ARG . . . . . 0.534 ' HA ' ' HA ' ' A' ' 33' ' ' PRO . 0.0 OUTLIER -80.81 103.06 10.39 Favored 'General case' 0 CA--C 1.51 -0.582 0 N-CA-C 107.933 -1.136 . . . . 2.71 107.933 173.903 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 10' ' ' ILE . . . . . 0.684 HD11 ' N ' ' A' ' 31' ' ' GLY . 0.2 OUTLIER -13.54 -105.54 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.085 0 O-C-N 125.611 1.82 . . . . 0.34 114.509 -176.627 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . 0.493 ' H ' HD13 ' B' ' 10' ' ' ILE . 34.8 p30 156.99 -160.71 0.0 OUTLIER 'General case' 0 CA--C 1.508 -0.637 0 C-N-CA 124.379 1.072 . . . . 1.18 108.25 171.735 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -71.96 -8.29 53.63 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 121.085 0.469 . . . . 2.39 110.766 -176.81 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 13' ' ' LEU . . . . . 0.408 HD12 HG13 ' A' ' 17' ' ' VAL . 2.1 tm? -114.72 -57.97 2.2 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.343 -0.39 . . . . 0.4 109.973 -179.8 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 133.03 17.42 1.15 Allowed Glycine 0 N--CA 1.441 -0.967 0 C-N-CA 120.595 -0.812 . . . . 0.21 113.784 179.532 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 15' ' ' ARG . . . . . 0.566 ' HB3' ' HB3' ' A' ' 15' ' ' ARG . 0.2 OUTLIER -81.5 150.52 28.22 Favored 'General case' 0 CA--C 1.507 -0.694 0 CA-C-N 118.764 1.282 . . . . 0.9 110.962 -179.256 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 16' ' ' VAL . . . . . 0.542 HG21 HD13 ' A' ' 46' ' ' LEU . 98.2 t -108.98 100.72 11.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 CA-C-N 114.318 -1.31 . . . . 1.27 107.549 171.064 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 17' ' ' VAL . . . . . 0.573 HG23 ' CZ ' ' B' ' 8' ' ' ARG . 37.8 t -69.54 103.21 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.078 0 CA-C-N 115.832 -0.622 . . . . 0.27 109.654 -174.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . 0.478 HD11 HD12 ' B' ' 46' ' ' LEU . 6.8 mt -91.98 112.39 54.61 Favored Pre-proline 0 N--CA 1.446 -0.647 0 CA-C-O 121.477 0.656 . . . . 0.82 110.981 -177.768 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . 0.696 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 67.7 Cg_exo -49.1 142.9 19.6 Favored 'Trans proline' 0 N--CA 1.46 -0.484 0 C-N-CA 123.379 2.719 . . . . 0.3 112.456 171.511 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 20' ' ' LYS . . . . . 0.987 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -61.36 -15.1 32.82 Favored 'General case' 0 C--O 1.211 -0.938 0 CA-C-N 115.313 -0.858 . . . . 1.77 111.4 179.525 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . 0.696 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 10.0 pt-20 -63.37 -22.84 67.12 Favored 'General case' 0 C--O 1.238 0.486 0 N-CA-C 112.117 0.414 . . . . 1.92 112.117 179.625 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 22' ' ' ILE . . . . . 0.402 HD13 HG23 ' B' ' 18' ' ' ILE . 5.3 mp -87.09 -47.97 15.68 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.29 0 N-CA-C 108.61 -0.885 . . . . 0.44 108.61 -179.371 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 23' ' ' ARG . . . . . 0.586 ' HA ' ' HB2' ' B' ' 26' ' ' LEU . 0.0 OUTLIER -60.06 -27.98 67.42 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.356 -0.838 . . . . 1.4 109.27 173.234 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 24' ' ' ARG . . . . . . . . . . . . . 43.5 ttp180 -65.45 -52.76 50.83 Favored 'General case' 0 N--CA 1.446 -0.654 0 CA-C-N 114.676 -1.147 . . . . 3.19 110.683 175.7 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 21.3 m -64.77 -26.67 68.45 Favored 'General case' 0 N--CA 1.449 -0.508 0 CA-C-O 121.355 0.597 . . . . 0.4 110.667 175.421 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.586 ' HB2' ' HA ' ' B' ' 23' ' ' ARG . 1.7 mm? -64.85 -18.97 65.61 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.46 -0.791 . . . . 0.33 110.59 173.754 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 27' ' ' ARG . . . . . . . . . . . . . 19.6 tpt180 74.4 22.32 2.19 Favored 'General case' 0 C--N 1.34 0.166 0 O-C-N 124.136 0.897 . . . . 3.28 109.772 -178.034 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 28' ' ' ILE . . . . . 0.896 HG22 ' H ' ' B' ' 29' ' ' ARG . 6.6 mt -123.28 -163.19 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.343 -0.844 . . . . 0.37 110.287 -174.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 29' ' ' ARG . . . . . 0.896 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -152.44 -159.31 0.99 Allowed 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 112.025 0.379 . . . . 2.15 112.025 -170.392 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 30' ' ' GLU . . . . . 0.467 ' H ' ' HB2' ' B' ' 29' ' ' ARG . 0.9 OUTLIER -73.92 36.94 0.1 Allowed 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 121.849 0.833 . . . . 1.18 111.961 -177.464 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . 0.576 ' CA ' HD11 ' A' ' 10' ' ' ILE . . . -153.93 30.42 0.74 Allowed Glycine 0 N--CA 1.442 -0.93 0 N-CA-C 109.757 -1.337 . . . . 0.35 109.757 171.658 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 32' ' ' ASP . . . . . 0.505 ' HB2' ' CG2' ' B' ' 28' ' ' ILE . 12.3 t70 -86.7 128.78 55.2 Favored Pre-proline 0 C--N 1.324 -0.543 0 CA-C-N 114.81 -0.695 . . . . 1.29 109.948 174.197 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 33' ' ' PRO . . . . . 0.754 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 10.3 Cg_endo -84.88 148.93 10.9 Favored 'Trans proline' 0 N--CA 1.435 -1.919 0 C-N-CA 122.402 2.068 . . . . 1.1 110.785 173.474 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.717 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.7 OUTLIER -137.55 148.63 46.09 Favored 'General case' 0 C--N 1.302 -1.471 0 N-CA-C 109.631 -0.507 . . . . 0.44 109.631 173.64 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 35' ' ' GLU . . . . . 0.708 ' O ' ' HA ' ' B' ' 46' ' ' LEU . 46.8 tt0 -105.16 111.74 24.6 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 107.9 -1.148 . . . . 1.1 107.9 -178.178 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 36' ' ' ILE . . . . . 1.107 HG13 HD22 ' B' ' 46' ' ' LEU . 3.0 mp -86.73 109.86 19.53 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.943 0 O-C-N 124.417 1.073 . . . . 0.62 109.06 -178.604 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 37' ' ' PHE . . . . . 0.828 ' HB2' ' H ' ' A' ' 4' ' ' THR . 12.1 p90 -151.0 131.97 14.25 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 116.158 -0.474 . . . . 1.2 109.966 174.796 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 38' ' ' VAL . . . . . 0.55 HG13 ' HB3' ' A' ' 2' ' ' LYS . 1.9 p -80.08 142.33 14.07 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.01 0 CA-C-O 120.949 0.404 . . . . 0.2 110.352 -178.584 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 39' ' ' ASP . . . . . 0.458 ' HB2' ' CD1' ' B' ' 45' ' ' ILE . 25.8 t0 -92.08 -47.52 7.22 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.556 -0.747 . . . . 1.14 111.618 -175.026 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 40' ' ' ARG . . . . . 0.559 ' HG3' ' HG3' ' B' ' 43' ' ' GLU . 0.0 OUTLIER -134.08 -100.82 0.25 Allowed 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 112.767 0.655 . . . . 2.71 112.767 -168.12 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 25.1 t70 -83.09 -71.92 0.47 Allowed 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.422 0.63 . . . . 1.32 110.767 -176.182 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 42' ' ' GLY . . . . . 0.482 ' HA3' ' HD2' ' A' ' 48' ' ' LYS . . . -139.73 25.77 2.68 Favored Glycine 0 CA--C 1.501 -0.801 0 CA-C-N 115.41 -0.814 . . . . 0.34 111.179 178.868 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 43' ' ' GLU . . . . . 0.559 ' HG3' ' HG3' ' B' ' 40' ' ' ARG . 2.7 mt-10 -92.72 109.15 20.57 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 109.226 -0.657 . . . . 2.07 109.226 178.629 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 44' ' ' VAL . . . . . 0.514 ' HA ' ' HA ' ' B' ' 38' ' ' VAL . 1.7 t -89.13 130.48 38.41 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 N-CA-C 109.122 -0.696 . . . . 0.13 109.122 178.09 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 45' ' ' ILE . . . . . 0.74 HG13 HG13 ' A' ' 45' ' ' ILE . 1.7 mp -108.19 118.85 56.68 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 N-CA-C 108.138 -1.06 . . . . 0.12 108.138 -176.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 46' ' ' LEU . . . . . 1.107 HD22 HG13 ' B' ' 36' ' ' ILE . 0.5 OUTLIER -110.26 115.77 30.3 Favored 'General case' 0 C--N 1.317 -0.847 0 N-CA-C 108.819 -0.808 . . . . 0.15 108.819 176.648 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 47' ' ' LYS . . . . . 0.537 ' O ' ' HA ' ' B' ' 34' ' ' LEU . 0.0 OUTLIER -126.57 149.99 49.1 Favored 'General case' 0 C--N 1.317 -0.847 0 C-N-CA 119.178 -1.009 . . . . 0.95 112.626 -177.724 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 48' ' ' LYS . . . . . 0.684 ' HE2' ' HG3' ' B' ' 51' ' ' PRO . 3.4 ptmt -41.7 -14.18 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.064 0 N-CA-C 118.007 2.595 . . . . 0.64 118.007 -167.643 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 49' ' ' TYR . . . . . 0.757 ' CD1' HG21 ' A' ' 7' ' ' VAL . 30.9 t80 72.41 -56.62 0.65 Allowed 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 113.004 0.742 . . . . 1.26 113.004 173.145 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 50' ' ' SER . . . . . 0.718 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 8.3 t -52.28 -52.7 60.27 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.26 -0.427 . . . . 1.22 110.778 -174.031 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 51' ' ' PRO . . . . . 0.718 ' HD3' ' HB3' ' B' ' 50' ' ' SER . 47.2 Cg_endo -92.33 14.29 1.74 Allowed 'Trans proline' 0 N--CA 1.454 -0.806 0 C-N-CA 122.155 1.903 . . . . 0.56 111.84 170.421 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 52' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER 49.97 -144.99 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 115.52 -0.764 . . . . 0.73 109.76 -177.184 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 53' ' ' SER . . . . . . . . . . . . . 17.7 m -83.8 77.97 9.79 Favored 'General case' 0 C--N 1.321 -0.646 0 C-N-CA 120.544 -0.462 . . . . 1.86 110.174 176.688 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 54' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 65.99 85.23 0.14 Allowed 'General case' 0 CA--C 1.531 0.217 0 CA-C-O 121.248 0.547 . . . . 2.62 110.572 178.593 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 55' ' ' LEU . . . . . 0.452 ' HA ' HD22 ' B' ' 55' ' ' LEU . 0.6 OUTLIER . . . . . 0 C--O 1.249 1.026 0 CA-C-O 118.703 -0.665 . . . . 2.64 109.498 -178.251 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 65.7 mtt . . . . . 0 N--CA 1.48 1.058 0 N-CA-C 109.227 -0.657 . . . . 5.91 109.227 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.69 ' HA ' ' CE ' ' A' ' 2' ' ' LYS . 1.1 mmpt? -81.1 -126.32 0.02 OUTLIER 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 120.851 -0.339 . . . . 3.71 110.368 174.064 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.59 ' HA ' ' HD2' ' B' ' 37' ' ' PHE . . . 65.96 107.03 0.04 OUTLIER 'General case' 0 C--N 1.32 -0.706 0 O-C-N 123.846 0.717 . . . . 0.72 111.844 -179.006 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.542 ' OG1' ' HA ' ' B' ' 37' ' ' PHE . 11.7 p -97.05 -45.76 6.44 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.547 -0.752 . . . . 0.41 111.602 -179.4 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 70.51 48.93 33.78 Favored Glycine 0 N--CA 1.443 -0.866 0 C-N-CA 120.58 -0.819 . . . . 0.32 112.919 174.155 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.783 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.0 OUTLIER -104.94 113.1 41.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 N-CA-C 108.407 -0.96 . . . . 0.31 108.407 173.997 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.755 HG21 ' CD1' ' B' ' 49' ' ' TYR . 28.3 t -83.58 134.65 26.47 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-O 121.211 0.529 . . . . 0.28 110.94 -178.319 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.593 ' HB3' ' CD1' ' B' ' 36' ' ' ILE . 9.0 tpp180 -131.0 119.54 22.2 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 107.818 -1.178 . . . . 1.99 107.818 -176.583 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.452 ' N ' ' HD3' ' A' ' 8' ' ' ARG . 44.8 ttp180 -79.27 108.36 12.72 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 108.613 -0.884 . . . . 2.8 108.613 170.713 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.832 HG23 HD11 ' B' ' 34' ' ' LEU . 0.2 OUTLIER -16.19 -102.65 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 O-C-N 125.593 1.808 . . . . 0.33 114.492 -177.724 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . 0.606 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 3.1 p-10 162.89 -160.92 0.0 OUTLIER 'General case' 0 CA--C 1.509 -0.602 0 N-CA-C 107.826 -1.176 . . . . 1.13 107.826 175.542 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 25.0 m-20 -70.72 -22.09 62.47 Favored 'General case' 0 C--N 1.321 -0.663 0 O-C-N 123.384 0.428 . . . . 2.26 110.812 -178.78 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.459 HD22 ' HE2' ' B' ' 20' ' ' LYS . 3.0 tm? -102.88 -61.46 1.4 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.27 -0.423 . . . . 0.53 110.305 179.682 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.524 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 144.48 16.65 0.21 Allowed Glycine 0 N--CA 1.442 -0.93 0 C-N-CA 120.768 -0.729 . . . . 0.22 112.513 -178.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.553 ' HB3' ' HB3' ' B' ' 15' ' ' ARG . 2.8 mpt_? -71.5 145.84 48.92 Favored 'General case' 0 CA--C 1.504 -0.793 0 CA-C-O 121.522 0.677 . . . . 0.69 110.456 -179.278 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.82 HG21 HD13 ' B' ' 46' ' ' LEU . 97.5 t -103.76 94.08 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.53 0 N-CA-C 107.146 -1.427 . . . . 1.24 107.146 168.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.552 ' HA ' ' HA ' ' B' ' 15' ' ' ARG . 59.7 t -67.22 97.62 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.844 0 CA-C-N 114.891 -1.049 . . . . 0.28 110.137 -172.809 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.716 HG23 HD13 ' A' ' 22' ' ' ILE . 17.4 mt -98.54 111.23 59.59 Favored Pre-proline 0 C--N 1.326 -0.45 0 CA-C-N 115.594 -0.73 . . . . 0.77 111.11 -175.6 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.783 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 48.6 Cg_exo -46.74 150.41 2.55 Favored 'Trans proline' 0 N--CA 1.458 -0.577 0 C-N-CA 123.183 2.588 . . . . 0.32 113.859 175.041 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.944 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -64.49 -12.62 45.93 Favored 'General case' 0 C--O 1.207 -1.176 0 CA-C-N 115.164 -0.926 . . . . 1.57 111.219 176.61 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.783 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 12.7 pt-20 -64.88 -22.62 67.03 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 118.436 0.562 . . . . 1.32 111.246 176.372 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.716 HD13 HG23 ' A' ' 18' ' ' ILE . 5.1 mp -88.06 -44.31 15.72 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.404 0 N-CA-C 108.889 -0.782 . . . . 0.35 108.889 179.167 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . 0.72 ' HG3' ' HA ' ' A' ' 20' ' ' LYS . 1.1 ppt_? -61.12 -26.25 67.54 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 122.284 1.04 . . . . 1.5 108.636 172.05 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.534 ' HB3' ' O ' ' A' ' 21' ' ' GLU . 32.0 ttt180 -64.03 -52.37 59.77 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 113.741 -1.572 . . . . 2.96 110.628 174.914 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 40.3 m -62.73 -30.35 71.36 Favored 'General case' 0 N--CA 1.455 -0.223 0 CA-C-O 121.062 0.458 . . . . 0.4 110.995 172.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.616 ' HB2' ' HA ' ' A' ' 23' ' ' ARG . 2.6 mm? -63.49 -18.98 64.35 Favored 'General case' 0 CA--C 1.519 -0.23 0 CA-C-N 115.952 -0.567 . . . . 0.36 109.94 174.662 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.413 HH11 ' HD2' ' A' ' 27' ' ' ARG . 11.3 mmt180 67.69 23.38 8.7 Favored 'General case' 0 N--CA 1.451 -0.408 0 CA-C-N 115.277 -0.874 . . . . 3.2 109.915 -178.079 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.838 HG22 ' H ' ' A' ' 29' ' ' ARG . 11.8 mt -124.32 -167.61 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 CA-C-N 114.479 -1.237 . . . . 0.48 108.161 -178.161 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.838 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.2 OUTLIER -142.63 -158.55 0.88 Allowed 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 118.403 0.547 . . . . 2.4 112.116 -175.464 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 5.7 mp0 -72.9 47.19 0.18 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 122.221 1.01 . . . . 1.23 111.942 -179.514 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.661 ' N ' HD11 ' B' ' 10' ' ' ILE . . . -163.08 24.91 0.2 Allowed Glycine 0 N--CA 1.445 -0.71 0 CA-C-N 113.801 -1.545 . . . . 0.36 109.867 175.115 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.47 ' O ' HG13 ' B' ' 10' ' ' ILE . 18.1 t0 -87.97 130.81 45.07 Favored Pre-proline 0 CA--C 1.514 -0.423 0 CA-C-N 114.446 -0.877 . . . . 1.26 109.367 174.247 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.686 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 3.2 Cg_endo -82.32 153.44 16.15 Favored 'Trans proline' 0 N--CA 1.438 -1.762 0 C-N-CA 122.172 1.915 . . . . 1.3 110.634 174.668 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.846 HD11 HG23 ' B' ' 10' ' ' ILE . 0.5 OUTLIER -140.72 151.68 44.7 Favored 'General case' 0 N--CA 1.433 -1.319 0 C-N-CA 119.866 -0.734 . . . . 0.38 109.663 171.439 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.74 ' HB3' ' HD2' ' A' ' 47' ' ' LYS . 86.0 tt0 -105.13 111.31 24.03 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.606 -1.257 . . . . 1.12 107.606 -178.523 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 1.016 HG13 HD22 ' A' ' 46' ' ' LEU . 2.9 mp -87.14 109.01 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.744 0 O-C-N 124.722 1.263 . . . . 0.39 109.116 -178.893 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . 0.654 ' HD2' ' HA ' ' B' ' 3' ' ' ALA . 1.0 OUTLIER -149.23 127.72 12.3 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 115.987 -0.551 . . . . 1.15 109.835 176.833 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.47 ' CG1' ' HD3' ' B' ' 2' ' ' LYS . 1.3 p -81.81 132.49 31.35 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.999 0 CA-C-O 121.612 0.72 . . . . 0.17 110.657 -179.878 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.568 ' HB3' ' HG2' ' A' ' 40' ' ' ARG . 19.7 t70 -79.94 -49.89 11.22 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 114.236 -1.347 . . . . 1.11 111.672 -173.746 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . 0.568 ' HG2' ' HB3' ' A' ' 39' ' ' ASP . 1.7 ptm180 -133.65 -96.83 0.29 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.48 -0.782 . . . . 2.29 112.96 -167.069 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -88.6 -70.38 0.65 Allowed 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.089 0.471 . . . . 1.53 111.024 -174.311 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.432 ' O ' ' HA ' ' B' ' 47' ' ' LYS . . . -139.67 22.84 2.82 Favored Glycine 0 N--CA 1.445 -0.741 0 CA-C-N 115.596 -0.729 . . . . 0.32 111.279 -179.344 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.552 ' HB3' HG23 ' B' ' 45' ' ' ILE . 1.7 mt-10 -95.4 113.06 24.69 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 109.483 -0.562 . . . . 1.97 109.483 179.275 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.476 ' CG1' HG23 ' A' ' 36' ' ' ILE . 1.4 t -91.15 131.26 38.77 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 N-CA-C 109.425 -0.583 . . . . 0.14 109.425 177.182 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.804 HG13 HG13 ' B' ' 45' ' ' ILE . 1.6 mp -109.69 118.06 55.99 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 108.072 -1.084 . . . . 0.14 108.072 -176.568 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 1.031 HD11 HD11 ' B' ' 46' ' ' LEU . 0.3 OUTLIER -112.54 116.69 30.63 Favored 'General case' 0 C--N 1.315 -0.933 0 O-C-N 123.796 0.685 . . . . 0.23 109.467 178.813 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.74 ' HD2' ' HB3' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -127.64 153.59 46.26 Favored 'General case' 0 C--O 1.215 -0.722 0 C-N-CA 118.662 -1.215 . . . . 0.76 112.216 178.56 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.643 ' HG3' ' HG2' ' A' ' 51' ' ' PRO . 1.1 ptmt -41.24 -17.42 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.026 0 N-CA-C 117.497 2.406 . . . . 0.32 117.497 -168.88 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 0.808 ' CD1' HG21 ' B' ' 7' ' ' VAL . 17.4 t80 75.82 -53.59 0.63 Allowed 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 112.418 0.525 . . . . 1.28 112.418 173.379 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.677 ' HB3' ' HD3' ' A' ' 51' ' ' PRO . 8.3 t -51.57 -49.71 81.16 Favored Pre-proline 0 CA--C 1.538 0.498 0 CA-C-N 116.219 -0.446 . . . . 1.36 111.099 -177.184 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.677 ' HD3' ' HB3' ' A' ' 50' ' ' SER . 27.8 Cg_endo -93.82 9.12 2.25 Favored 'Trans proline' 0 N--CA 1.455 -0.749 0 C-N-CA 122.647 2.231 . . . . 0.58 111.663 171.706 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.434 HG13 ' C ' ' A' ' 51' ' ' PRO . 1.1 mt 53.69 -149.35 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 CA-C-N 115.439 -0.8 . . . . 0.78 109.326 -175.038 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.433 ' O ' ' N ' ' A' ' 55' ' ' LEU . 3.6 m -78.52 89.3 4.47 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.342 -0.614 . . . . 1.96 109.342 174.388 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.627 ' O ' ' HB2' ' A' ' 55' ' ' LEU . 11.9 pt-20 54.42 -64.54 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.95 0 O-C-N 124.991 1.432 . . . . 2.89 111.865 -170.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.627 ' HB2' ' O ' ' A' ' 54' ' ' GLU . 0.2 OUTLIER . . . . . 0 C--O 1.249 1.066 0 C-N-CA 124.788 1.235 . . . . 2.65 108.526 173.471 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 26.5 ttt . . . . . 0 N--CA 1.481 1.111 0 CA-C-O 120.991 0.425 . . . . 6.17 110.149 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 2' ' ' LYS . . . . . 0.84 ' HE2' ' HA ' ' B' ' 2' ' ' LYS . 1.4 mmpt? 43.87 -143.3 0.14 Allowed 'General case' 0 N--CA 1.47 0.558 0 CA-C-N 115.615 -0.72 . . . . 3.61 112.503 -176.144 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 3' ' ' ALA . . . . . 0.654 ' HA ' ' HD2' ' A' ' 37' ' ' PHE . . . 66.01 106.82 0.04 OUTLIER 'General case' 0 C--O 1.233 0.208 0 O-C-N 123.856 0.723 . . . . 0.86 111.303 -174.687 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 4' ' ' THR . . . . . 0.531 ' OG1' ' HA ' ' A' ' 37' ' ' PHE . 7.5 p -94.73 -48.14 6.18 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.909 -0.587 . . . . 0.43 111.675 -179.174 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 72.24 48.33 25.7 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.939 -0.648 . . . . 0.33 112.976 174.84 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 6' ' ' ILE . . . . . 0.746 HG23 ' HB ' ' A' ' 36' ' ' ILE . 0.9 OUTLIER -106.11 112.1 37.95 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 N-CA-C 108.731 -0.84 . . . . 0.3 108.731 174.83 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . 0.808 HG21 ' CD1' ' A' ' 49' ' ' TYR . 35.2 t -83.56 136.66 22.35 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 CA-C-O 120.952 0.405 . . . . 0.27 111.167 -178.887 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.514 ' HD3' ' N ' ' B' ' 9' ' ' ARG . 1.0 OUTLIER -133.17 123.77 26.25 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 107.296 -1.372 . . . . 1.69 107.296 179.128 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 9' ' ' ARG . . . . . 0.514 ' N ' ' HD3' ' B' ' 8' ' ' ARG . 0.1 OUTLIER -82.31 103.33 11.82 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 108.267 -1.012 . . . . 2.71 108.267 173.219 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 10' ' ' ILE . . . . . 0.846 HG23 HD11 ' A' ' 34' ' ' LEU . 0.2 OUTLIER -10.32 -106.02 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 O-C-N 125.444 1.715 . . . . 0.34 114.9 -176.746 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . 0.604 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 2.5 p-10 163.1 -168.29 0.01 OUTLIER 'General case' 0 CA--C 1.51 -0.575 0 N-CA-C 106.586 -1.635 . . . . 1.18 106.586 177.174 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 52.7 m-20 -77.06 -2.87 36.28 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 118.418 0.553 . . . . 2.39 110.995 -176.804 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 13' ' ' LEU . . . . . 0.425 ' H ' ' CG ' ' B' ' 11' ' ' ASP . 2.1 tm? -106.56 -61.8 1.48 Allowed 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.781 -0.645 . . . . 0.4 109.794 174.689 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 138.14 17.01 0.63 Allowed Glycine 0 N--CA 1.445 -0.722 0 CA-C-N 115.947 -0.57 . . . . 0.21 112.093 -176.869 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 15' ' ' ARG . . . . . 0.553 ' HB3' ' HB3' ' A' ' 15' ' ' ARG . 1.6 mpt_? -70.36 143.1 52.04 Favored 'General case' 0 CA--C 1.506 -0.724 0 CA-C-O 121.536 0.684 . . . . 0.9 110.481 -179.718 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 16' ' ' VAL . . . . . 0.715 HG21 HD13 ' A' ' 46' ' ' LEU . 81.1 t -104.69 94.34 3.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 N-CA-C 107.343 -1.354 . . . . 1.27 107.343 167.465 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 17' ' ' VAL . . . . . 0.528 HG22 ' HG2' ' A' ' 15' ' ' ARG . 40.8 t -67.13 98.49 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-N 115.188 -0.915 . . . . 0.27 110.169 -171.1 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . 0.524 ' HB ' ' O ' ' A' ' 14' ' ' GLY . 11.4 mt -96.75 112.74 61.26 Favored Pre-proline 0 N--CA 1.447 -0.58 0 CA-C-N 115.535 -0.757 . . . . 0.82 110.932 -177.477 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . 0.621 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 85.6 Cg_exo -51.67 154.31 9.54 Favored 'Trans proline' 0 N--CA 1.456 -0.68 0 C-N-CA 122.626 2.217 . . . . 0.3 113.508 173.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 20' ' ' LYS . . . . . 0.783 ' HA ' ' HG3' ' B' ' 23' ' ' ARG . 0.0 OUTLIER -68.37 -13.37 62.24 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-N 114.828 -1.078 . . . . 1.77 111.1 178.384 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . 0.621 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 9.8 pt-20 -66.36 -20.24 66.03 Favored 'General case' 0 C--N 1.322 -0.595 0 C-N-CA 120.327 -0.549 . . . . 1.92 111.568 176.141 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 22' ' ' ILE . . . . . 0.49 HD13 HG23 ' B' ' 18' ' ' ILE . 5.4 mp -88.56 -45.21 15.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 N-CA-C 108.863 -0.791 . . . . 0.44 108.863 177.265 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 23' ' ' ARG . . . . . 0.783 ' HG3' ' HA ' ' B' ' 20' ' ' LYS . 0.3 OUTLIER -59.92 -25.11 64.88 Favored 'General case' 0 N--CA 1.472 0.636 0 CA-C-O 121.989 0.899 . . . . 1.4 108.789 171.996 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 24' ' ' ARG . . . . . 0.429 ' HB3' ' O ' ' B' ' 21' ' ' GLU . 35.3 ttm180 -65.17 -52.52 54.49 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 114.018 -1.446 . . . . 3.19 110.971 174.012 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 31.7 m -63.08 -29.16 70.59 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 120.54 -0.464 . . . . 0.4 110.906 173.756 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.581 ' HB2' ' HA ' ' B' ' 23' ' ' ARG . 2.6 mm? -63.34 -20.05 65.17 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.947 -0.57 . . . . 0.33 110.057 174.337 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 27' ' ' ARG . . . . . 0.414 ' HA ' ' HD3' ' B' ' 27' ' ' ARG . 25.0 mmt180 68.11 24.72 7.62 Favored 'General case' 0 N--CA 1.453 -0.306 0 CA-C-N 115.286 -0.87 . . . . 3.28 109.904 -177.381 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 28' ' ' ILE . . . . . 0.901 HG22 ' H ' ' B' ' 29' ' ' ARG . 12.6 mt -125.17 -161.43 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 114.793 -1.094 . . . . 0.37 109.294 -177.243 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 29' ' ' ARG . . . . . 0.901 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.1 OUTLIER -149.41 -160.79 1.22 Allowed 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 112.144 0.424 . . . . 2.15 112.144 -173.123 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 30' ' ' GLU . . . . . 0.428 ' N ' ' HD2' ' B' ' 29' ' ' ARG . 3.2 mp0 -71.12 37.82 0.05 Allowed 'General case' 0 N--CA 1.464 0.232 0 CA-C-O 121.523 0.677 . . . . 1.18 112.55 -178.629 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . 0.586 ' N ' HD11 ' A' ' 10' ' ' ILE . . . -152.03 18.5 0.84 Allowed Glycine 0 N--CA 1.443 -0.884 0 N-CA-C 110.339 -1.104 . . . . 0.35 110.339 173.469 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 32' ' ' ASP . . . . . 0.487 ' O ' HG13 ' A' ' 10' ' ' ILE . 18.3 t70 -78.32 129.14 75.93 Favored Pre-proline 0 C--N 1.326 -0.433 0 CA-C-N 115.054 -0.573 . . . . 1.29 109.595 174.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 33' ' ' PRO . . . . . 0.721 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 5.1 Cg_endo -82.16 150.05 15.55 Favored 'Trans proline' 0 N--CA 1.436 -1.853 0 C-N-CA 122.586 2.191 . . . . 1.1 110.697 173.242 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.832 HD11 HG23 ' A' ' 10' ' ' ILE . 0.7 OUTLIER -136.85 150.66 48.42 Favored 'General case' 0 C--N 1.306 -1.304 0 N-CA-C 109.674 -0.491 . . . . 0.44 109.674 173.693 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 35' ' ' GLU . . . . . 0.766 ' O ' ' HA ' ' B' ' 46' ' ' LEU . 38.0 tt0 -105.31 112.92 26.21 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 107.577 -1.268 . . . . 1.1 107.577 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 36' ' ' ILE . . . . . 0.981 HG13 HD22 ' B' ' 46' ' ' LEU . 3.3 mp -89.12 109.85 20.77 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 O-C-N 124.878 1.361 . . . . 0.62 109.198 -178.807 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 37' ' ' PHE . . . . . 0.896 ' HE1' ' HZ1' ' B' ' 47' ' ' LYS . 2.1 p90 -149.28 131.33 15.33 Favored 'General case' 0 C--N 1.317 -0.835 0 N-CA-C 109.694 -0.484 . . . . 1.2 109.694 175.013 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 38' ' ' VAL . . . . . 0.628 HG13 ' HB3' ' A' ' 2' ' ' LYS . 1.2 p -82.09 135.38 25.05 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 CA-C-O 121.367 0.603 . . . . 0.2 110.852 179.753 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 39' ' ' ASP . . . . . 0.465 ' HB2' ' CD1' ' B' ' 45' ' ' ILE . 35.8 t70 -81.07 -50.74 9.28 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 114.354 -1.294 . . . . 1.14 111.255 -174.675 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 40' ' ' ARG . . . . . 0.547 ' HD3' ' OE1' ' B' ' 43' ' ' GLU . 0.9 OUTLIER -134.22 -105.04 0.23 Allowed 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.908 -0.587 . . . . 2.71 112.347 -169.937 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 24.0 t70 -78.19 -70.48 0.48 Allowed 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.086 0.47 . . . . 1.32 111.362 -176.354 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 42' ' ' GLY . . . . . 0.441 ' HA3' ' HD2' ' A' ' 48' ' ' LYS . . . -139.72 25.17 2.71 Favored Glycine 0 N--CA 1.442 -0.906 0 C-N-CA 120.449 -0.881 . . . . 0.34 111.978 -177.933 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 43' ' ' GLU . . . . . 0.555 ' HB3' HG23 ' A' ' 45' ' ' ILE . 3.2 mt-10 -95.43 113.68 25.36 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.901 -0.407 . . . . 2.07 109.901 178.083 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 44' ' ' VAL . . . . . 0.502 ' CG1' HG23 ' B' ' 36' ' ' ILE . 1.5 t -91.13 130.73 39.85 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 N-CA-C 109.602 -0.518 . . . . 0.13 109.602 176.133 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 45' ' ' ILE . . . . . 0.804 HG13 HG13 ' A' ' 45' ' ' ILE . 1.7 mp -109.41 118.13 56.03 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 N-CA-C 108.262 -1.014 . . . . 0.12 108.262 -177.446 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 46' ' ' LEU . . . . . 1.031 HD11 HD11 ' A' ' 46' ' ' LEU . 0.3 OUTLIER -113.02 116.8 30.49 Favored 'General case' 0 C--N 1.314 -0.935 0 O-C-N 123.665 0.603 . . . . 0.15 109.571 178.916 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 47' ' ' LYS . . . . . 0.896 ' HZ1' ' HE1' ' B' ' 37' ' ' PHE . 0.0 OUTLIER -126.81 155.28 43.11 Favored 'General case' 0 C--N 1.32 -0.694 0 C-N-CA 118.85 -1.14 . . . . 0.95 111.97 179.096 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 48' ' ' LYS . . . . . 0.624 ' HA ' ' O ' ' B' ' 33' ' ' PRO . 6.5 ptmt -49.58 -7.67 0.03 OUTLIER 'General case' 0 N--CA 1.476 0.873 0 N-CA-C 117.102 2.26 . . . . 0.64 117.102 -166.011 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 49' ' ' TYR . . . . . 0.755 ' CD1' HG21 ' A' ' 7' ' ' VAL . 19.7 t80 73.8 -52.92 0.69 Allowed 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 112.73 0.641 . . . . 1.26 112.73 170.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 50' ' ' SER . . . . . 0.712 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 26.9 t -50.6 -52.89 51.74 Favored Pre-proline 0 CA--C 1.541 0.628 0 CA-C-N 116.059 -0.519 . . . . 1.22 111.177 -175.48 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 51' ' ' PRO . . . . . 0.712 ' HD3' ' HB3' ' B' ' 50' ' ' SER . 59.8 Cg_endo -93.55 12.87 1.73 Allowed 'Trans proline' 0 C--N 1.352 0.754 0 C-N-CA 122.438 2.092 . . . . 0.56 111.791 171.293 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 52' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER 50.15 -144.76 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.236 0.361 0 CA-C-N 115.323 -0.853 . . . . 0.73 109.619 -175.734 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 53' ' ' SER . . . . . . . . . . . . . 1.5 m -77.2 74.69 3.77 Favored 'General case' 0 C--N 1.323 -0.586 0 C-N-CA 120.807 -0.357 . . . . 1.86 110.68 176.243 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 54' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 49.07 22.28 0.58 Allowed 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 124.322 1.049 . . . . 2.62 112.998 179.446 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 55' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.251 1.174 0 C-N-CA 123.682 0.793 . . . . 2.64 111.806 179.791 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 18.8 mmt . . . . . 0 N--CA 1.481 1.083 0 CA-C-O 120.876 0.37 . . . . 5.91 110.718 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.419 ' HB3' HG13 ' B' ' 38' ' ' VAL . 25.7 mmmt -109.53 -135.02 0.35 Allowed 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.951 -0.568 . . . . 3.71 110.297 178.441 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.437 ' HA ' ' HB2' ' B' ' 37' ' ' PHE . . . 65.6 97.15 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.464 0 O-C-N 123.98 0.8 . . . . 0.72 111.24 -177.431 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.5 ' OG1' ' HA ' ' B' ' 37' ' ' PHE . 18.2 p -87.5 -45.89 10.08 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.563 -0.744 . . . . 0.41 111.365 -178.536 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.453 ' H ' ' HB3' ' B' ' 37' ' ' PHE . . . 73.15 48.39 19.97 Favored Glycine 0 N--CA 1.444 -0.796 0 C-N-CA 120.829 -0.701 . . . . 0.32 112.969 173.149 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.798 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.5 tp -106.46 107.4 22.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 N-CA-C 109.155 -0.683 . . . . 0.31 109.155 174.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.693 HG21 ' CD1' ' B' ' 49' ' ' TYR . 55.7 t -76.05 136.61 24.43 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.909 0 CA-C-O 121.414 0.626 . . . . 0.28 110.527 179.852 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.58 ' HB3' ' CD1' ' B' ' 36' ' ' ILE . 2.5 tpp180 -130.94 116.22 17.57 Favored 'General case' 0 N--CA 1.433 -1.304 0 N-CA-C 107.069 -1.456 . . . . 1.99 107.069 -179.661 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.553 ' C ' HD12 ' A' ' 10' ' ' ILE . 0.2 OUTLIER -82.48 101.68 10.85 Favored 'General case' 0 C--N 1.315 -0.931 0 N-CA-C 108.123 -1.066 . . . . 2.8 108.123 175.63 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.947 HG23 HD11 ' B' ' 34' ' ' LEU . 0.2 OUTLIER -7.05 -105.18 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.035 0 O-C-N 125.583 1.802 . . . . 0.33 114.681 -177.909 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . 0.511 ' H ' HD13 ' A' ' 10' ' ' ILE . 47.6 p30 163.1 -151.33 0.0 OUTLIER 'General case' 0 CA--C 1.512 -0.482 0 C-N-CA 123.609 0.763 . . . . 1.13 109.013 176.356 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -78.91 -9.75 59.6 Favored 'General case' 0 C--N 1.325 -0.492 0 O-C-N 123.244 0.34 . . . . 2.26 111.288 -177.215 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -117.31 -58.06 2.08 Favored 'General case' 0 C--N 1.326 -0.454 0 O-C-N 122.237 -0.289 . . . . 0.53 110.292 -178.679 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.416 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 138.89 16.6 0.58 Allowed Glycine 0 N--CA 1.445 -0.748 0 C-N-CA 120.593 -0.813 . . . . 0.22 113.321 -177.922 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.618 ' HG2' HG22 ' B' ' 17' ' ' VAL . 0.8 OUTLIER -76.29 150.52 36.94 Favored 'General case' 0 CA--C 1.509 -0.603 0 CA-C-N 118.02 0.91 . . . . 0.69 109.837 177.406 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.738 HG21 HD13 ' B' ' 46' ' ' LEU . 54.3 t -106.73 96.87 4.98 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.29 0 N-CA-C 107.436 -1.32 . . . . 1.24 107.436 171.32 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.616 HG22 ' HG2' ' B' ' 15' ' ' ARG . 62.2 t -68.65 100.94 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.825 0 CA-C-N 115.366 -0.834 . . . . 0.28 110.06 -173.771 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.706 HG23 HD13 ' A' ' 22' ' ' ILE . 8.0 mt -93.83 114.9 64.3 Favored Pre-proline 0 N--CA 1.446 -0.641 0 CA-C-N 115.603 -0.726 . . . . 0.77 111.053 -177.171 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.592 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 30.9 Cg_exo -44.73 143.87 3.87 Favored 'Trans proline' 0 CA--C 1.513 -0.536 0 C-N-CA 123.403 2.736 . . . . 0.32 113.137 171.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.874 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -59.38 -15.82 19.02 Favored 'General case' 0 C--O 1.214 -0.797 0 CA-C-N 115.258 -0.883 . . . . 1.57 111.363 178.185 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.592 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 10.0 pt-20 -67.86 -21.06 65.19 Favored 'General case' 0 C--O 1.236 0.348 0 N-CA-C 111.63 0.233 . . . . 1.32 111.63 -177.51 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.706 HD13 HG23 ' A' ' 18' ' ' ILE . 5.0 mp -87.68 -49.16 14.8 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.369 0 N-CA-C 107.842 -1.17 . . . . 0.35 107.842 -179.414 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . 0.639 ' HD3' ' N ' ' A' ' 24' ' ' ARG . 0.0 OUTLIER -51.69 -34.5 38.8 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-O 121.768 0.794 . . . . 1.5 109.769 168.296 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.639 ' N ' ' HD3' ' A' ' 23' ' ' ARG . 9.3 ttm180 -60.99 -51.89 67.32 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 114.771 -1.104 . . . . 2.96 110.943 177.506 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 27.5 m -65.19 -27.82 68.96 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-O 121.406 0.622 . . . . 0.4 110.587 175.187 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.847 ' HB3' HG13 ' A' ' 28' ' ' ILE . 2.3 mm? -65.01 -18.99 65.77 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.405 -0.816 . . . . 0.36 111.211 175.375 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.509 ' HB2' ' O ' ' A' ' 26' ' ' LEU . 5.7 mpt_? 71.42 14.72 6.35 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 123.437 0.695 . . . . 3.2 111.06 -174.307 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.847 HG13 ' HB3' ' A' ' 26' ' ' LEU . 2.9 mt -109.4 -157.21 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 CA-C-N 115.773 -0.649 . . . . 0.48 109.647 -175.71 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.74 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.2 OUTLIER -161.79 -153.79 0.3 Allowed 'General case' 0 C--N 1.325 -0.494 0 C-N-CA 123.026 0.53 . . . . 2.4 110.298 -176.211 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -71.5 44.79 0.1 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 122.097 0.951 . . . . 1.23 111.516 178.039 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.633 ' N ' HD11 ' B' ' 10' ' ' ILE . . . -161.36 33.87 0.38 Allowed Glycine 0 N--CA 1.441 -0.996 0 CA-C-N 114.331 -1.304 . . . . 0.36 110.496 177.656 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.461 ' HA ' ' HD3' ' A' ' 33' ' ' PRO . 29.2 t0 -94.45 119.4 66.44 Favored Pre-proline 0 C--N 1.327 -0.391 0 CA-C-N 115.168 -0.516 . . . . 1.26 109.753 176.453 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.629 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 3.3 Cg_endo -88.01 63.93 3.5 Favored 'Trans proline' 0 N--CA 1.452 -0.956 0 C-N-CA 123.916 3.077 . . . . 1.3 113.957 -177.214 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.589 HD12 ' H ' ' A' ' 34' ' ' LEU . 0.9 OUTLIER -64.66 154.54 36.21 Favored 'General case' 0 C--N 1.292 -1.924 0 C-N-CA 118.328 -1.349 . . . . 0.38 111.841 -177.128 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.763 ' O ' ' HA ' ' A' ' 46' ' ' LEU . 35.0 tt0 -109.4 113.5 26.37 Favored 'General case' 0 CA--C 1.494 -1.175 0 CA-C-N 113.369 -1.741 . . . . 1.12 108.291 -174.437 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.84 HG13 HD22 ' A' ' 46' ' ' LEU . 2.7 mp -84.4 109.49 17.74 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 O-C-N 124.143 0.902 . . . . 0.39 109.647 -178.836 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . 0.746 ' HD1' ' HA ' ' B' ' 3' ' ' ALA . 0.6 OUTLIER -149.31 121.48 8.33 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-O 121.228 0.537 . . . . 1.15 109.878 175.771 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.556 HG13 ' HB3' ' B' ' 2' ' ' LYS . 1.9 p -80.38 135.86 24.49 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.047 0 CA-C-O 121.208 0.527 . . . . 0.17 110.351 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.481 ' HB3' ' HG3' ' A' ' 40' ' ' ARG . 14.3 t70 -86.08 -40.33 15.84 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 114.99 -1.004 . . . . 1.11 111.529 -173.261 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . 0.481 ' HG3' ' HB3' ' A' ' 39' ' ' ASP . 8.3 mtp180 -132.08 -81.44 0.5 Allowed 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 112.788 0.662 . . . . 2.29 112.788 -163.061 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -122.19 -65.75 1.09 Allowed 'General case' 0 CA--C 1.507 -0.69 0 CA-C-O 121.581 0.705 . . . . 1.53 109.962 -176.18 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.546 ' O ' ' HA ' ' B' ' 47' ' ' LYS . . . -133.1 12.58 5.02 Favored Glycine 0 N--CA 1.438 -1.213 0 CA-C-N 114.816 -1.084 . . . . 0.32 111.638 -178.171 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.589 ' HB3' HG23 ' B' ' 45' ' ' ILE . 0.9 OUTLIER -92.57 105.97 18.04 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 108.757 -0.831 . . . . 1.97 108.757 177.346 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.55 HG11 HG23 ' A' ' 36' ' ' ILE . 2.4 t -89.67 131.24 37.43 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 N-CA-C 109.29 -0.633 . . . . 0.14 109.29 177.764 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.803 HG13 HG13 ' B' ' 45' ' ' ILE . 1.6 mp -108.85 116.07 51.02 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 N-CA-C 108.054 -1.091 . . . . 0.14 108.054 -176.028 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 1.048 HD11 HD11 ' B' ' 46' ' ' LEU . 0.7 OUTLIER -106.35 117.66 34.62 Favored 'General case' 0 C--N 1.316 -0.86 0 O-C-N 123.883 0.74 . . . . 0.23 109.402 178.418 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.756 ' HD2' ' HB3' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -129.49 143.82 51.0 Favored 'General case' 0 C--O 1.214 -0.773 0 C-N-CA 119.265 -0.974 . . . . 0.76 112.597 178.752 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.706 ' HG3' ' HG2' ' A' ' 51' ' ' PRO . 3.0 ptmt -39.86 -12.82 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.288 0 N-CA-C 117.833 2.531 . . . . 0.32 117.833 -169.921 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 0.629 ' HB3' ' HB2' ' A' ' 33' ' ' PRO . 27.9 t80 70.63 -57.11 0.59 Allowed 'General case' 0 N--CA 1.478 0.952 0 N-CA-C 113.437 0.903 . . . . 1.28 113.437 175.242 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.408 ' HB2' ' HD3' ' A' ' 51' ' ' PRO . 19.0 m -52.88 -52.64 63.05 Favored Pre-proline 0 CA--C 1.54 0.595 0 CA-C-N 115.644 -0.707 . . . . 1.36 111.951 -174.46 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.706 ' HG2' ' HG3' ' A' ' 48' ' ' LYS . 75.2 Cg_endo -90.55 10.65 2.87 Favored 'Trans proline' 0 C--N 1.35 0.618 0 C-N-CA 122.246 1.964 . . . . 0.58 111.726 168.615 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.412 HG13 ' C ' ' A' ' 51' ' ' PRO . 1.0 OUTLIER 55.04 -147.74 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.511 0 CA-C-N 115.261 -0.882 . . . . 0.78 109.726 -175.565 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.614 ' HA ' ' HG3' ' A' ' 47' ' ' LYS . 34.1 m -76.91 -15.95 59.52 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-O 121.694 0.759 . . . . 1.96 110.436 179.03 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.58 ' O ' ' HB2' ' A' ' 55' ' ' LEU . 31.6 tt0 169.02 -55.72 0.01 OUTLIER 'General case' 0 C--N 1.313 -1.02 0 CA-C-N 113.663 -1.608 . . . . 2.89 106.799 -172.118 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.58 ' HB2' ' O ' ' A' ' 54' ' ' GLU . 0.2 OUTLIER . . . . . 0 C--O 1.248 1.017 0 O-C-N 125.121 1.513 . . . . 2.65 108.936 169.604 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 23.5 mmt . . . . . 0 N--CA 1.48 1.065 0 N-CA-C 109.852 -0.425 . . . . 6.17 109.852 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 2' ' ' LYS . . . . . 0.556 ' HB3' HG13 ' A' ' 38' ' ' VAL . 24.4 mmmt -98.27 -131.63 0.22 Allowed 'General case' 0 C--N 1.326 -0.431 0 C-N-CA 121.128 -0.229 . . . . 3.61 111.367 -179.14 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 3' ' ' ALA . . . . . 0.746 ' HA ' ' HD1' ' A' ' 37' ' ' PHE . . . 69.09 89.12 0.1 Allowed 'General case' 0 C--N 1.325 -0.46 0 O-C-N 124.057 0.848 . . . . 0.86 110.985 -174.875 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 4' ' ' THR . . . . . 0.537 ' OG1' ' HA ' ' A' ' 37' ' ' PHE . 12.5 p -80.66 -45.74 16.71 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.354 -0.839 . . . . 0.43 111.944 -176.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 71.2 47.93 34.31 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 121.031 -0.604 . . . . 0.33 112.911 174.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 6' ' ' ILE . . . . . 0.808 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.1 tp -105.76 107.33 22.38 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 N-CA-C 109.263 -0.643 . . . . 0.3 109.263 175.443 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . 0.605 HG21 ' CD1' ' A' ' 49' ' ' TYR . 37.6 t -77.96 134.84 27.47 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.842 0 CA-C-N 115.627 -0.715 . . . . 0.27 110.412 -178.838 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . . . . . . . . . 1.4 tpp180 -131.04 116.63 18.04 Favored 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 107.018 -1.475 . . . . 1.69 107.018 177.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 9' ' ' ARG . . . . . 0.518 ' HA ' ' HA ' ' A' ' 33' ' ' PRO . 13.9 ttt180 -79.03 103.45 8.98 Favored 'General case' 0 CA--C 1.505 -0.753 0 N-CA-C 108.381 -0.97 . . . . 2.71 108.381 174.53 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 10' ' ' ILE . . . . . 0.633 HD11 ' N ' ' A' ' 31' ' ' GLY . 0.3 OUTLIER -9.93 -106.15 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 O-C-N 125.895 1.997 . . . . 0.34 114.845 -176.599 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . 0.588 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 3.2 p-10 165.58 -164.42 0.01 OUTLIER 'General case' 0 CA--C 1.514 -0.405 0 N-CA-C 107.628 -1.249 . . . . 1.18 107.628 178.842 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 24.3 t70 -72.58 -10.63 60.02 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.012 0.434 . . . . 2.39 111.051 -179.014 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 13' ' ' LEU . . . . . 0.444 ' H ' ' CG ' ' B' ' 11' ' ' ASP . 2.4 tm? -108.47 -62.02 1.52 Allowed 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.4 -0.364 . . . . 0.4 110.922 -179.337 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 139.34 21.57 0.39 Allowed Glycine 0 N--CA 1.446 -0.688 0 C-N-CA 120.799 -0.715 . . . . 0.21 112.0 -177.246 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 15' ' ' ARG . . . . . 0.616 ' HG2' HG22 ' A' ' 17' ' ' VAL . 1.7 mpt_? -75.44 150.12 38.36 Favored 'General case' 0 CA--C 1.505 -0.771 0 CA-C-O 121.617 0.723 . . . . 0.9 110.394 177.527 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 16' ' ' VAL . . . . . 0.801 HG21 HD13 ' A' ' 46' ' ' LEU . 61.4 t -108.18 92.74 2.17 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 N-CA-C 107.487 -1.301 . . . . 1.27 107.487 167.267 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 17' ' ' VAL . . . . . 0.618 HG22 ' HG2' ' A' ' 15' ' ' ARG . 46.8 t -67.34 98.54 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.79 0 CA-C-N 115.59 -0.732 . . . . 0.27 109.99 -173.133 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . 0.416 ' HB ' ' O ' ' A' ' 14' ' ' GLY . 8.7 mt -92.19 112.8 56.84 Favored Pre-proline 0 N--CA 1.445 -0.677 0 CA-C-N 115.415 -0.811 . . . . 0.82 110.819 -177.842 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . 0.621 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 71.0 Cg_exo -49.29 147.2 12.22 Favored 'Trans proline' 0 N--CA 1.458 -0.581 0 C-N-CA 123.23 2.62 . . . . 0.3 112.669 173.043 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 20' ' ' LYS . . . . . 1.043 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -64.81 -14.86 60.66 Favored 'General case' 0 C--O 1.211 -0.932 0 CA-C-N 115.387 -0.824 . . . . 1.77 111.369 -177.793 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . 0.621 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 1.1 pm0 -63.15 -23.88 67.64 Favored 'General case' 0 N--CA 1.47 0.54 0 N-CA-C 112.201 0.445 . . . . 1.92 112.201 176.71 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 5.3 mp -87.01 -50.34 14.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 108.032 -1.099 . . . . 0.44 108.032 -178.357 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 23' ' ' ARG . . . . . 0.574 ' HA ' ' HB2' ' B' ' 26' ' ' LEU . 0.0 OUTLIER -56.08 -27.97 55.77 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.098 -0.956 . . . . 1.4 110.061 170.497 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 24' ' ' ARG . . . . . 0.438 ' HB3' ' HA ' ' B' ' 21' ' ' GLU . 8.2 ttm180 -64.13 -53.2 53.33 Favored 'General case' 0 CA--C 1.507 -0.687 0 CA-C-N 115.23 -0.895 . . . . 3.19 110.903 173.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 28.3 m -67.06 -22.41 65.86 Favored 'General case' 0 N--CA 1.445 -0.698 0 CA-C-O 121.614 0.721 . . . . 0.4 110.22 178.485 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.574 ' HB2' ' HA ' ' B' ' 23' ' ' ARG . 1.9 mm? -67.83 -18.85 64.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.08 -0.963 . . . . 0.33 110.655 173.489 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 27' ' ' ARG . . . . . 0.439 ' HB2' ' O ' ' B' ' 26' ' ' LEU . 7.2 mpt_? 68.52 21.0 8.27 Favored 'General case' 0 C--O 1.234 0.245 0 C-N-CA 123.517 0.727 . . . . 3.28 110.475 -174.367 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 28' ' ' ILE . . . . . 0.874 HG22 ' H ' ' B' ' 29' ' ' ARG . 6.6 mt -116.91 -163.67 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.462 -0.79 . . . . 0.37 109.434 -177.669 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 29' ' ' ARG . . . . . 0.874 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -156.06 -151.38 0.33 Allowed 'General case' 0 C--N 1.32 -0.681 0 C-N-CA 122.338 0.255 . . . . 2.15 110.723 -173.942 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 30' ' ' GLU . . . . . 0.451 ' H ' ' HB2' ' B' ' 29' ' ' ARG . 0.7 OUTLIER -73.43 36.74 0.09 Allowed 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 122.166 0.984 . . . . 1.18 111.669 -179.522 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . 0.599 ' CA ' HD11 ' A' ' 10' ' ' ILE . . . -154.12 39.63 0.67 Allowed Glycine 0 N--CA 1.434 -1.436 0 CA-C-N 114.107 -1.406 . . . . 0.35 110.026 175.105 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 32' ' ' ASP . . . . . 0.465 ' HA ' ' HD3' ' B' ' 33' ' ' PRO . 9.5 t0 -95.96 119.66 64.33 Favored Pre-proline 0 C--N 1.325 -0.493 0 CA-C-O 121.256 0.55 . . . . 1.29 110.049 175.147 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 33' ' ' PRO . . . . . 0.702 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 4.4 Cg_endo -87.07 76.35 2.27 Favored 'Trans proline' 0 C--O 1.205 -1.145 0 C-N-CA 123.547 2.831 . . . . 1.1 113.268 -178.905 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.947 HD11 HG23 ' A' ' 10' ' ' ILE . 0.1 OUTLIER -72.12 150.5 43.8 Favored 'General case' 0 C--N 1.284 -2.249 0 C-N-CA 117.776 -1.569 . . . . 0.44 111.343 -178.963 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 35' ' ' GLU . . . . . 0.766 ' O ' ' HA ' ' B' ' 46' ' ' LEU . 42.7 tt0 -105.1 115.32 30.07 Favored 'General case' 0 CA--C 1.492 -1.264 0 CA-C-N 114.067 -1.424 . . . . 1.1 107.822 -179.143 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 36' ' ' ILE . . . . . 0.922 HG13 HD22 ' B' ' 46' ' ' LEU . 3.1 mp -88.19 108.8 19.03 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 O-C-N 124.168 0.918 . . . . 0.62 109.336 -178.443 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 37' ' ' PHE . . . . . 0.5 ' HA ' ' OG1' ' A' ' 4' ' ' THR . 12.3 p90 -149.74 126.41 11.01 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 116.159 -0.473 . . . . 1.2 110.064 175.142 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 38' ' ' VAL . . . . . 0.532 ' HA ' ' HA ' ' B' ' 44' ' ' VAL . 0.8 OUTLIER -80.23 138.57 19.59 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-O 121.29 0.567 . . . . 0.2 110.571 -179.561 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 39' ' ' ASP . . . . . 0.683 ' HB3' ' HG3' ' B' ' 40' ' ' ARG . 8.1 t70 -80.9 -46.13 15.69 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 114.751 -1.113 . . . . 1.14 110.577 -177.726 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 40' ' ' ARG . . . . . 0.683 ' HG3' ' HB3' ' B' ' 39' ' ' ASP . 23.8 mtp180 -133.33 -92.53 0.35 Allowed 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.928 -0.578 . . . . 2.71 112.34 -166.55 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 41' ' ' ASP . . . . . 0.4 ' H ' ' HB2' ' B' ' 40' ' ' ARG . 18.4 t70 -102.3 -75.59 0.6 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.314 0.578 . . . . 1.32 110.395 -176.881 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 42' ' ' GLY . . . . . 0.523 ' O ' ' HA ' ' A' ' 47' ' ' LYS . . . -124.99 18.86 6.98 Favored Glycine 0 N--CA 1.44 -1.091 0 CA-C-N 115.376 -0.829 . . . . 0.34 112.201 -179.341 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 43' ' ' GLU . . . . . 0.516 ' HB3' HG23 ' A' ' 45' ' ' ILE . 1.3 mt-10 -93.52 104.91 17.01 Favored 'General case' 0 CA--C 1.51 -0.595 0 N-CA-C 108.932 -0.766 . . . . 2.07 108.932 176.533 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 44' ' ' VAL . . . . . 0.532 ' HA ' ' HA ' ' B' ' 38' ' ' VAL . 2.2 t -89.53 131.24 37.31 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 N-CA-C 109.441 -0.577 . . . . 0.13 109.441 177.194 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 45' ' ' ILE . . . . . 0.803 HG13 HG13 ' A' ' 45' ' ' ILE . 1.7 mp -108.04 117.5 53.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.463 0 N-CA-C 108.031 -1.1 . . . . 0.12 108.031 -176.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 46' ' ' LEU . . . . . 1.048 HD11 HD11 ' A' ' 46' ' ' LEU . 1.6 mt -108.53 117.24 33.66 Favored 'General case' 0 C--N 1.317 -0.813 0 O-C-N 123.9 0.75 . . . . 0.15 109.776 178.391 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 47' ' ' LYS . . . . . 0.658 ' HG3' ' HA ' ' B' ' 53' ' ' SER . 0.0 OUTLIER -130.15 147.34 51.87 Favored 'General case' 0 C--O 1.214 -0.8 0 C-N-CA 119.199 -1.0 . . . . 0.95 113.129 -179.919 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 48' ' ' LYS . . . . . 0.58 ' HG3' ' CG ' ' B' ' 51' ' ' PRO . 3.5 ptmt -44.83 -7.91 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.409 0 N-CA-C 118.065 2.617 . . . . 0.64 118.065 -168.781 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 49' ' ' TYR . . . . . 0.702 ' HB3' ' HB2' ' B' ' 33' ' ' PRO . 32.5 t80 69.72 -57.5 0.55 Allowed 'General case' 0 N--CA 1.48 1.051 0 N-CA-C 113.727 1.01 . . . . 1.26 113.727 173.506 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 50' ' ' SER . . . . . 0.681 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 9.1 t -51.24 -56.28 21.53 Favored Pre-proline 0 CA--C 1.539 0.528 0 CA-C-N 115.932 -0.576 . . . . 1.22 111.134 -173.484 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 51' ' ' PRO . . . . . 0.681 ' HD3' ' HB3' ' B' ' 50' ' ' SER . 59.1 Cg_endo -87.21 8.24 4.43 Favored 'Trans proline' 0 C--N 1.351 0.666 0 C-N-CA 122.174 1.916 . . . . 0.56 111.968 170.396 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 52' ' ' ILE . . . . . . . . . . . . . 1.6 mt 56.16 -147.91 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.341 0 CA-C-N 115.137 -0.938 . . . . 0.73 108.863 -175.002 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 53' ' ' SER . . . . . 0.658 ' HA ' ' HG3' ' B' ' 47' ' ' LYS . 61.0 m -74.73 -21.03 59.59 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.946 0.879 . . . . 1.86 109.932 -179.634 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 54' ' ' GLU . . . . . 0.517 ' O ' ' HB2' ' B' ' 55' ' ' LEU . 41.5 tt0 178.04 -54.0 0.01 OUTLIER 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 113.485 -1.689 . . . . 2.62 106.869 -174.629 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 55' ' ' LEU . . . . . 0.517 ' HB2' ' O ' ' B' ' 54' ' ' GLU . 0.3 OUTLIER . . . . . 0 C--O 1.251 1.148 0 CA-C-N 114.535 -1.211 . . . . 2.64 109.312 165.827 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 26.3 ptt? . . . . . 0 N--CA 1.482 1.149 0 CA-C-O 120.35 0.119 . . . . 5.91 110.937 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.714 ' HB3' HG13 ' B' ' 38' ' ' VAL . 24.3 mmmt 51.08 -111.68 0.57 Allowed 'General case' 0 CA--C 1.517 -0.294 0 CA-C-N 116.279 -0.419 . . . . 3.71 111.912 -176.076 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.451 ' HA ' ' HB2' ' B' ' 37' ' ' PHE . . . 58.13 89.48 0.05 Allowed 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 114.972 -1.013 . . . . 0.72 111.639 -178.668 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.552 ' OG1' ' HA ' ' B' ' 37' ' ' PHE . 11.8 p -81.21 -35.1 31.73 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.579 -0.737 . . . . 0.41 111.647 -179.297 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.585 ' H ' ' CB ' ' B' ' 37' ' ' PHE . . . 57.51 47.67 86.53 Favored Glycine 0 N--CA 1.445 -0.73 0 CA-C-N 115.735 -0.666 . . . . 0.32 112.68 173.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.697 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.8 tp -105.9 104.06 16.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 108.807 -0.812 . . . . 0.31 108.807 175.22 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.676 HG21 ' CG ' ' B' ' 49' ' ' TYR . 52.9 t -74.9 135.17 27.88 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.873 0 CA-C-N 115.522 -0.763 . . . . 0.28 109.943 179.481 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.541 ' HB3' HD13 ' B' ' 36' ' ' ILE . 1.7 tpp180 -131.84 117.13 18.12 Favored 'General case' 0 N--CA 1.431 -1.415 0 N-CA-C 106.899 -1.519 . . . . 1.99 106.899 -177.6 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.542 ' C ' HD12 ' A' ' 10' ' ' ILE . 0.0 OUTLIER -78.44 101.74 7.46 Favored 'General case' 0 C--N 1.314 -0.954 0 N-CA-C 107.924 -1.139 . . . . 2.8 107.924 174.913 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.806 HG23 HD11 ' B' ' 34' ' ' LEU . 0.2 OUTLIER -5.63 -105.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.195 0 O-C-N 125.445 1.715 . . . . 0.33 114.587 -176.753 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . 0.604 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 2.4 p-10 165.99 -162.49 0.01 OUTLIER 'General case' 0 CA--C 1.513 -0.472 0 N-CA-C 107.935 -1.135 . . . . 1.13 107.935 177.611 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 30.4 m-20 -76.45 -6.7 52.86 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 120.744 0.307 . . . . 2.26 111.301 -178.255 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.428 ' H ' ' CG ' ' A' ' 11' ' ' ASP . 2.9 tm? -114.75 -59.16 2.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.661 -0.245 . . . . 0.53 110.996 178.589 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.449 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 140.1 13.78 0.58 Allowed Glycine 0 N--CA 1.448 -0.5 0 C-N-CA 120.432 -0.889 . . . . 0.22 113.096 -178.805 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.765 ' HG2' HG22 ' B' ' 17' ' ' VAL . 0.9 OUTLIER -77.43 154.98 32.1 Favored 'General case' 0 CA--C 1.501 -0.933 0 N-CA-C 109.231 -0.655 . . . . 0.69 109.231 176.011 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.921 HG11 HD13 ' B' ' 46' ' ' LEU . 1.5 m -109.88 112.13 39.17 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.59 0 N-CA-C 107.355 -1.35 . . . . 1.24 107.355 166.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.68 HG22 ' HG2' ' B' ' 15' ' ' ARG . 59.6 t -73.16 95.94 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.427 -1.588 0 CA-C-N 114.449 -1.25 . . . . 0.28 109.657 -174.875 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.611 HG23 HD13 ' A' ' 22' ' ' ILE . 11.0 mt -86.28 110.92 35.13 Favored Pre-proline 0 N--CA 1.446 -0.641 0 CA-C-N 115.218 -0.901 . . . . 0.77 110.251 -179.588 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.597 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 67.5 Cg_exo -47.37 144.51 9.67 Favored 'Trans proline' 0 N--CA 1.459 -0.535 0 C-N-CA 123.115 2.544 . . . . 0.32 112.261 173.594 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.939 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -59.95 -15.29 20.78 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.775 -0.648 . . . . 1.57 111.706 -178.493 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.597 ' HG2' ' HB2' ' A' ' 19' ' ' PRO . 12.8 pt-20 -67.6 -19.79 65.29 Favored 'General case' 0 C--O 1.237 0.437 0 N-CA-C 112.062 0.393 . . . . 1.32 112.062 -178.723 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.611 HD13 HG23 ' A' ' 18' ' ' ILE . 4.8 mp -87.43 -44.45 16.04 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 N-CA-C 108.125 -1.065 . . . . 0.35 108.125 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . 0.677 ' HA ' ' HB2' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -60.68 -30.52 69.97 Favored 'General case' 0 CA--C 1.521 -0.166 0 CA-C-O 121.883 0.849 . . . . 1.5 109.093 171.208 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 63.2 ttt180 -61.33 -51.49 68.61 Favored 'General case' 0 N--CA 1.441 -0.894 0 CA-C-N 114.619 -1.173 . . . . 2.96 110.455 176.187 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 22.7 m -66.68 -21.94 66.09 Favored 'General case' 0 CA--C 1.535 0.392 0 CA-C-O 121.527 0.679 . . . . 0.4 110.654 174.094 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.864 ' HB3' HG13 ' A' ' 28' ' ' ILE . 2.3 mm? -71.94 -18.14 62.03 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.964 -0.562 . . . . 0.36 110.605 174.201 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.429 ' HB2' ' O ' ' A' ' 26' ' ' LEU . 9.0 mpt_? 66.21 23.18 10.9 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-N 116.006 -0.543 . . . . 3.2 110.625 -175.069 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.864 HG13 ' HB3' ' A' ' 26' ' ' LEU . 2.6 mt -113.92 -154.61 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 115.865 -0.607 . . . . 0.48 109.91 -178.44 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.693 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -162.34 -156.3 0.41 Allowed 'General case' 0 C--N 1.321 -0.653 0 C-N-CA 122.686 0.394 . . . . 2.4 110.674 -173.951 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . 0.417 ' H ' ' HB2' ' A' ' 29' ' ' ARG . 1.8 mp0 -74.9 44.1 0.22 Allowed 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 122.132 0.968 . . . . 1.23 111.025 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.706 ' N ' HD11 ' B' ' 10' ' ' ILE . . . -156.98 26.3 0.5 Allowed Glycine 0 N--CA 1.439 -1.137 0 CA-C-N 114.055 -1.43 . . . . 0.36 110.999 176.757 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.418 ' HA ' ' HD3' ' A' ' 33' ' ' PRO . 9.2 t0 -85.7 122.5 73.12 Favored Pre-proline 0 C--N 1.327 -0.379 0 CA-C-O 121.108 0.48 . . . . 1.26 110.111 176.321 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.637 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 3.8 Cg_endo -91.08 62.81 1.28 Allowed 'Trans proline' 0 N--CA 1.451 -0.986 0 C-N-CA 123.855 3.037 . . . . 1.3 114.253 -175.684 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.978 HD11 HG23 ' B' ' 10' ' ' ILE . 0.0 OUTLIER -61.22 153.97 24.73 Favored 'General case' 0 C--N 1.298 -1.646 0 C-N-CA 118.884 -1.127 . . . . 0.38 112.046 -178.536 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.77 ' HB3' ' HB3' ' A' ' 47' ' ' LYS . 39.4 tt0 -107.84 113.83 27.34 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 112.938 -1.937 . . . . 1.12 107.392 -176.253 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.811 ' HB ' HG23 ' B' ' 6' ' ' ILE . 2.4 mp -86.32 107.34 16.53 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.058 0 N-CA-C 109.136 -0.69 . . . . 0.39 109.136 -179.481 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . 0.575 ' CB ' ' H ' ' B' ' 5' ' ' GLY . 2.2 p90 -149.17 120.88 8.07 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-O 121.44 0.638 . . . . 1.15 109.937 176.169 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.696 HG13 ' HB3' ' B' ' 2' ' ' LYS . 1.5 p -80.5 137.56 21.25 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.987 0 CA-C-N 115.803 -0.635 . . . . 0.17 110.555 -178.126 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.554 ' HB3' ' HG2' ' A' ' 40' ' ' ARG . 7.5 t70 -76.22 -40.91 50.95 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 114.831 -1.077 . . . . 1.11 111.669 -171.16 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . 0.554 ' HG2' ' HB3' ' A' ' 39' ' ' ASP . 0.3 OUTLIER -150.62 -74.77 0.15 Allowed 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 112.859 0.689 . . . . 2.29 112.859 -168.753 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -106.29 -74.16 0.66 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.171 0.51 . . . . 1.53 111.431 -175.688 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.534 ' HA3' HD11 ' B' ' 26' ' ' LEU . . . -135.82 12.74 4.21 Favored Glycine 0 N--CA 1.443 -0.866 0 CA-C-N 115.123 -0.944 . . . . 0.32 111.891 -175.738 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.503 ' O ' HG23 ' A' ' 38' ' ' VAL . 2.5 pm0 -92.82 106.77 18.69 Favored 'General case' 0 N--CA 1.446 -0.66 0 N-CA-C 110.051 -0.352 . . . . 1.97 110.051 175.183 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.623 HG11 HG23 ' A' ' 36' ' ' ILE . 2.5 t -87.57 134.84 26.78 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 N-CA-C 109.259 -0.645 . . . . 0.14 109.259 178.356 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.709 HG13 HG13 ' B' ' 45' ' ' ILE . 1.5 mp -110.69 118.11 56.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 N-CA-C 108.491 -0.929 . . . . 0.14 108.491 -178.077 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.953 HD11 HD11 ' B' ' 46' ' ' LEU . 6.8 mt -103.3 119.05 38.13 Favored 'General case' 0 C--N 1.32 -0.715 0 O-C-N 124.229 0.956 . . . . 0.23 109.906 -179.541 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.77 ' HB3' ' HB3' ' A' ' 35' ' ' GLU . 16.6 ttmt -121.2 130.2 53.58 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-N 115.434 -0.803 . . . . 0.76 111.905 -170.704 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.613 ' HE2' ' HG3' ' A' ' 51' ' ' PRO . 3.2 ptmt -45.23 -12.97 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 115.937 1.828 . . . . 0.32 115.937 -174.313 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 0.687 ' CD1' HG21 ' B' ' 7' ' ' VAL . 34.4 t80 68.36 -56.7 0.5 Allowed 'General case' 0 N--CA 1.473 0.69 0 C-N-CA 124.623 1.169 . . . . 1.28 114.046 174.224 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.402 ' HB2' ' HD3' ' A' ' 51' ' ' PRO . 36.1 m -53.41 -48.08 93.96 Favored Pre-proline 0 CA--C 1.542 0.636 0 CA-C-N 115.683 -0.69 . . . . 1.36 112.052 -173.691 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.613 ' HG3' ' HE2' ' A' ' 48' ' ' LYS . 60.6 Cg_endo -93.54 10.82 2.04 Favored 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 122.272 1.981 . . . . 0.58 111.779 167.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.4 ' H ' ' C ' ' A' ' 49' ' ' TYR . 1.0 OUTLIER 52.18 -141.43 0.02 OUTLIER 'Isoleucine or valine' 0 C--O 1.233 0.218 0 N-CA-C 108.304 -0.998 . . . . 0.78 108.304 -171.35 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.627 ' OG ' ' HE2' ' A' ' 47' ' ' LYS . 3.0 m -106.97 113.89 27.64 Favored 'General case' 0 C--N 1.312 -1.026 0 C-N-CA 120.175 -0.61 . . . . 1.96 109.577 170.048 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.424 ' CD ' HH12 ' B' ' 40' ' ' ARG . 44.9 mt-10 73.48 -31.82 0.23 Allowed 'General case' 0 N--CA 1.466 0.339 0 N-CA-C 113.055 0.761 . . . . 2.89 113.055 175.003 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.444 HD22 ' HA ' ' A' ' 55' ' ' LEU . 0.5 OUTLIER . . . . . 0 C--O 1.248 1.009 0 C-N-CA 123.254 0.622 . . . . 2.65 110.082 -178.164 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 26.5 ptt? . . . . . 0 N--CA 1.482 1.157 0 CA-C-O 120.359 0.123 . . . . 6.17 110.816 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 2' ' ' LYS . . . . . 0.696 ' HB3' HG13 ' A' ' 38' ' ' VAL . 28.7 mmmt 58.59 -113.97 0.72 Allowed 'General case' 0 CA--C 1.517 -0.288 0 O-C-N 123.396 0.435 . . . . 3.61 110.479 -173.016 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 3' ' ' ALA . . . . . 0.417 ' HA ' ' HD2' ' A' ' 37' ' ' PHE . . . 58.2 91.85 0.04 OUTLIER 'General case' 0 C--N 1.318 -0.802 0 O-C-N 124.354 1.033 . . . . 0.86 111.766 179.899 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 4' ' ' THR . . . . . 0.473 ' OG1' ' HA ' ' A' ' 37' ' ' PHE . 12.0 p -84.67 -34.94 22.91 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.63 -0.714 . . . . 0.43 111.633 -178.221 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 5' ' ' GLY . . . . . 0.575 ' H ' ' CB ' ' A' ' 37' ' ' PHE . . . 58.43 48.07 86.15 Favored Glycine 0 N--CA 1.449 -0.487 0 CA-C-N 115.601 -0.727 . . . . 0.33 113.052 174.655 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 6' ' ' ILE . . . . . 0.811 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.4 tp -105.23 104.34 16.78 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 N-CA-C 109.224 -0.658 . . . . 0.3 109.224 175.817 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . 0.687 HG21 ' CD1' ' A' ' 49' ' ' TYR . 27.5 t -74.79 134.12 30.1 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.841 0 CA-C-N 115.462 -0.79 . . . . 0.27 110.083 -179.714 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.515 ' HD3' ' N ' ' B' ' 9' ' ' ARG . 0.3 OUTLIER -131.97 120.06 21.94 Favored 'General case' 0 N--CA 1.441 -0.918 0 N-CA-C 106.862 -1.532 . . . . 1.69 106.862 179.132 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 9' ' ' ARG . . . . . 0.548 ' HA ' ' HA ' ' A' ' 33' ' ' PRO . 41.9 ttp180 -78.95 103.27 8.78 Favored 'General case' 0 N--CA 1.441 -0.903 0 N-CA-C 108.667 -0.864 . . . . 2.71 108.667 174.481 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 10' ' ' ILE . . . . . 0.978 HG23 HD11 ' A' ' 34' ' ' LEU . 0.3 OUTLIER -7.59 -100.38 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 O-C-N 125.66 1.85 . . . . 0.34 114.189 -175.31 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . 0.609 ' H ' HD13 ' B' ' 10' ' ' ILE . 13.5 p-10 161.54 -157.15 0.0 OUTLIER 'General case' 0 CA--C 1.505 -0.767 0 N-CA-C 107.889 -1.152 . . . . 1.18 107.889 175.088 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -88.64 22.69 2.51 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 120.688 0.28 . . . . 2.39 111.214 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 13' ' ' LEU . . . . . 0.411 ' HB3' ' HD2' ' B' ' 15' ' ' ARG . 2.3 tm? -137.86 -55.21 0.67 Allowed 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 109.862 -0.421 . . . . 0.4 109.862 175.564 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 14' ' ' GLY . . . . . 0.427 ' O ' ' HB ' ' A' ' 18' ' ' ILE . . . 131.97 11.85 2.0 Favored Glycine 0 N--CA 1.444 -0.8 0 C-N-CA 120.896 -0.669 . . . . 0.21 112.491 -177.83 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 15' ' ' ARG . . . . . 0.68 ' HG2' HG22 ' A' ' 17' ' ' VAL . 0.9 OUTLIER -74.11 152.14 39.95 Favored 'General case' 0 CA--C 1.504 -0.809 0 CA-C-O 121.445 0.641 . . . . 0.9 109.511 175.47 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 16' ' ' VAL . . . . . 0.736 HG13 HG13 ' A' ' 16' ' ' VAL . 0.2 OUTLIER -109.06 105.79 19.48 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 N-CA-C 107.697 -1.224 . . . . 1.27 107.697 167.641 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 17' ' ' VAL . . . . . 0.765 HG22 ' HG2' ' A' ' 15' ' ' ARG . 41.0 t -72.63 95.03 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.168 0 CA-C-N 114.724 -1.125 . . . . 0.27 109.827 -173.505 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . 0.574 HG23 HD13 ' B' ' 22' ' ' ILE . 11.7 mt -87.56 112.56 49.29 Favored Pre-proline 0 N--CA 1.445 -0.724 0 CA-C-N 115.436 -0.802 . . . . 0.82 110.503 -179.689 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . 0.692 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 84.9 Cg_exo -49.12 146.69 12.24 Favored 'Trans proline' 0 N--CA 1.459 -0.534 0 C-N-CA 123.045 2.497 . . . . 0.3 112.612 173.2 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 20' ' ' LYS . . . . . 0.917 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -60.79 -15.29 28.3 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.76 -0.655 . . . . 1.77 111.956 -179.357 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . 0.692 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 11.5 pt-20 -65.48 -21.12 66.6 Favored 'General case' 0 CA--C 1.536 0.428 0 N-CA-C 112.211 0.449 . . . . 1.92 112.211 -179.784 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 22' ' ' ILE . . . . . 0.574 HD13 HG23 ' B' ' 18' ' ' ILE . 5.2 mp -86.76 -48.78 15.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 108.264 -1.013 . . . . 0.44 108.264 179.835 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 23' ' ' ARG . . . . . 0.602 ' HA ' ' HB2' ' B' ' 26' ' ' LEU . 0.0 OUTLIER -55.89 -30.28 61.3 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 115.429 -0.805 . . . . 1.4 109.258 170.39 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 24' ' ' ARG . . . . . 0.597 ' N ' ' HD3' ' B' ' 23' ' ' ARG . 37.2 ttt180 -62.9 -52.35 63.42 Favored 'General case' 0 N--CA 1.45 -0.444 0 CA-C-N 114.772 -1.104 . . . . 3.19 110.858 176.427 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 51.6 m -64.22 -28.45 69.75 Favored 'General case' 0 CA--C 1.53 0.206 0 CA-C-O 121.17 0.509 . . . . 0.4 110.811 173.629 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.617 ' HB3' HG13 ' B' ' 28' ' ' ILE . 1.6 mm? -66.21 -18.78 65.56 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.755 -0.657 . . . . 0.33 111.315 175.436 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 27' ' ' ARG . . . . . 0.459 ' HB2' ' O ' ' B' ' 26' ' ' LEU . 11.0 mpt_? 68.21 16.22 9.37 Favored 'General case' 0 N--CA 1.467 0.378 0 C-N-CA 123.192 0.597 . . . . 3.28 111.095 -174.608 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 28' ' ' ILE . . . . . 0.906 HG22 ' H ' ' B' ' 29' ' ' ARG . 7.8 mt -109.05 -160.8 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 115.825 -0.625 . . . . 0.37 109.725 -175.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 29' ' ' ARG . . . . . 0.906 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -157.89 -153.84 0.41 Allowed 'General case' 0 C--N 1.328 -0.365 0 C-N-CA 122.386 0.275 . . . . 2.15 110.826 -177.691 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 30' ' ' GLU . . . . . 0.416 ' H ' ' HB2' ' B' ' 29' ' ' ARG . 1.9 mp0 -70.57 40.19 0.05 Allowed 'General case' 0 N--CA 1.468 0.466 0 CA-C-O 121.537 0.684 . . . . 1.18 112.043 178.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . 0.668 ' N ' HD11 ' A' ' 10' ' ' ILE . . . -155.38 34.09 0.65 Allowed Glycine 0 N--CA 1.437 -1.234 0 CA-C-N 115.097 -0.956 . . . . 0.35 111.106 175.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 32' ' ' ASP . . . . . 0.518 ' HB2' HG21 ' B' ' 28' ' ' ILE . 15.9 t0 -93.22 124.59 57.38 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.105 0.479 . . . . 1.29 110.706 176.534 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 33' ' ' PRO . . . . . 0.676 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 3.3 Cg_endo -87.56 75.83 2.16 Favored 'Trans proline' 0 C--O 1.206 -1.09 0 C-N-CA 124.011 3.141 . . . . 1.1 113.68 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.806 HD11 HG23 ' A' ' 10' ' ' ILE . 1.0 OUTLIER -71.47 148.79 46.48 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.021 -1.472 . . . . 0.44 110.771 179.87 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 35' ' ' GLU . . . . . 0.687 ' O ' ' HA ' ' B' ' 46' ' ' LEU . 43.8 tt0 -103.78 110.74 22.96 Favored 'General case' 0 C--N 1.305 -1.345 0 CA-C-N 114.417 -1.265 . . . . 1.1 107.625 -179.836 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 36' ' ' ILE . . . . . 0.954 HG13 HD22 ' B' ' 46' ' ' LEU . 2.3 mp -85.94 109.27 18.38 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.731 0 O-C-N 124.048 0.842 . . . . 0.62 109.236 -178.493 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 37' ' ' PHE . . . . . 0.585 ' CB ' ' H ' ' A' ' 5' ' ' GLY . 14.4 p90 -149.4 123.38 9.39 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 115.832 -0.622 . . . . 1.2 109.631 175.561 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 38' ' ' VAL . . . . . 0.714 HG13 ' HB3' ' A' ' 2' ' ' LYS . 1.4 p -79.91 136.05 24.26 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 CA-C-O 121.424 0.63 . . . . 0.2 110.229 -178.416 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 39' ' ' ASP . . . . . 0.589 ' OD1' ' HD3' ' B' ' 40' ' ' ARG . 12.6 t70 -69.48 -53.9 16.9 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 114.215 -1.357 . . . . 1.14 111.244 -173.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 40' ' ' ARG . . . . . 0.589 ' HD3' ' OD1' ' B' ' 39' ' ' ASP . 0.0 OUTLIER -139.34 -71.22 0.4 Allowed 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 113.019 0.748 . . . . 2.71 113.019 -174.308 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -106.48 -68.42 0.88 Allowed 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 112.089 0.403 . . . . 1.32 112.089 -173.153 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 42' ' ' GLY . . . . . 0.458 ' HA3' ' HD2' ' A' ' 48' ' ' LYS . . . -140.94 12.52 2.87 Favored Glycine 0 CA--C 1.501 -0.823 0 C-N-CA 120.71 -0.757 . . . . 0.34 111.862 -175.465 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 43' ' ' GLU . . . . . 0.587 ' HA ' ' O ' ' A' ' 46' ' ' LEU . 2.3 pm0 -93.05 104.96 17.12 Favored 'General case' 0 N--CA 1.443 -0.803 0 N-CA-C 109.568 -0.53 . . . . 2.07 109.568 174.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 44' ' ' VAL . . . . . 0.623 ' HA ' ' HA ' ' B' ' 38' ' ' VAL . 2.1 t -87.37 131.68 34.58 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 N-CA-C 109.696 -0.483 . . . . 0.13 109.696 179.329 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 45' ' ' ILE . . . . . 0.709 HG13 HG13 ' A' ' 45' ' ' ILE . 1.7 mp -108.29 118.47 55.99 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 N-CA-C 108.414 -0.958 . . . . 0.12 108.414 -177.592 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 46' ' ' LEU . . . . . 0.954 HD22 HG13 ' B' ' 36' ' ' ILE . 0.6 OUTLIER -109.9 117.1 32.93 Favored 'General case' 0 C--N 1.318 -0.788 0 O-C-N 123.612 0.57 . . . . 0.15 109.915 178.844 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 47' ' ' LYS . . . . . 0.591 ' HE3' ' HB3' ' B' ' 35' ' ' GLU . 0.0 OUTLIER -130.09 142.45 50.6 Favored 'General case' 0 C--N 1.318 -0.765 0 C-N-CA 119.617 -0.833 . . . . 0.95 112.877 -178.332 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 48' ' ' LYS . . . . . 0.573 ' HE2' ' HG3' ' B' ' 51' ' ' PRO . 4.3 ptmt -43.19 -9.2 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.638 0 N-CA-C 118.112 2.634 . . . . 0.64 118.112 -168.264 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 49' ' ' TYR . . . . . 0.676 ' CG ' HG21 ' A' ' 7' ' ' VAL . 5.9 t80 68.38 -52.75 0.55 Allowed 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 114.067 1.136 . . . . 1.26 114.067 174.326 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 50' ' ' SER . . . . . 0.634 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 32.2 t -51.55 -57.14 15.49 Favored Pre-proline 0 CA--C 1.535 0.386 0 C-N-CA 122.417 0.287 . . . . 1.22 111.099 -173.55 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 51' ' ' PRO . . . . . 0.644 ' O ' ' HB2' ' B' ' 55' ' ' LEU . 74.8 Cg_endo -85.01 9.07 4.3 Favored 'Trans proline' 0 C--N 1.35 0.652 0 C-N-CA 122.011 1.808 . . . . 0.56 111.159 170.174 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 52' ' ' ILE . . . . . 0.452 HG13 HD23 ' B' ' 55' ' ' LEU . 1.2 mt 50.98 -138.79 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 CA-C-N 114.814 -1.085 . . . . 0.73 108.666 -171.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 53' ' ' SER . . . . . 0.5 ' O ' ' HB2' ' B' ' 54' ' ' GLU . 0.1 OUTLIER -107.43 120.29 41.76 Favored 'General case' 0 N--CA 1.43 -1.455 0 N-CA-C 109.095 -0.705 . . . . 1.86 109.095 172.514 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 54' ' ' GLU . . . . . 0.5 ' HB2' ' O ' ' B' ' 53' ' ' SER . 1.8 mp0 73.41 -61.37 0.5 Allowed 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 123.821 0.848 . . . . 2.62 111.973 -176.395 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 55' ' ' LEU . . . . . 0.644 ' HB2' ' O ' ' B' ' 51' ' ' PRO . 0.9 OUTLIER . . . . . 0 C--O 1.249 1.078 0 O-C-N 123.85 0.719 . . . . 2.64 109.302 -172.389 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 74.1 mtm . . . . . 0 N--CA 1.478 0.96 0 N-CA-C 110.079 -0.341 . . . . 5.91 110.079 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.599 ' HB2' HG13 ' B' ' 38' ' ' VAL . 0.0 OUTLIER -124.77 -171.25 2.31 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 116.451 -0.34 . . . . 3.71 110.815 -174.651 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.591 ' HA ' ' HD2' ' B' ' 37' ' ' PHE . . . 64.35 113.51 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.359 0 CA-C-O 121.74 0.781 . . . . 0.72 111.33 -173.517 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.816 ' H ' ' HB2' ' B' ' 37' ' ' PHE . 34.4 p -125.97 -35.73 2.44 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 115.504 -0.771 . . . . 0.41 111.915 -173.73 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.514 ' H ' ' CB ' ' B' ' 37' ' ' PHE . . . 63.96 45.14 94.79 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.902 -0.666 . . . . 0.32 112.893 173.715 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.876 HG23 ' HB ' ' B' ' 36' ' ' ILE . 1.4 tp -104.11 105.2 18.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-O 121.354 0.597 . . . . 0.31 109.522 177.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.63 HG21 ' CD1' ' B' ' 49' ' ' TYR . 54.5 t -75.02 131.73 34.53 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-N 115.655 -0.702 . . . . 0.28 110.415 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.426 ' HG2' ' H ' ' A' ' 17' ' ' VAL . 2.9 tpp180 -127.58 114.6 17.62 Favored 'General case' 0 N--CA 1.434 -1.262 0 N-CA-C 106.522 -1.659 . . . . 1.99 106.522 177.781 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.505 ' C ' HD12 ' A' ' 10' ' ' ILE . 0.6 OUTLIER -78.05 101.36 6.91 Favored 'General case' 0 C--N 1.308 -1.221 0 N-CA-C 107.611 -1.255 . . . . 2.8 107.611 174.708 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.612 HD11 ' N ' ' B' ' 31' ' ' GLY . 0.3 OUTLIER -7.44 -102.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.941 0 O-C-N 125.763 1.914 . . . . 0.33 113.928 -175.385 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . 0.599 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 4.8 p-10 164.77 -159.47 0.0 OUTLIER 'General case' 0 CA--C 1.507 -0.677 0 N-CA-C 108.249 -1.019 . . . . 1.13 108.249 175.389 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 31.2 t70 -74.57 -17.84 60.67 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.014 0.435 . . . . 2.26 110.96 -179.173 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.413 ' H ' ' CG ' ' A' ' 11' ' ' ASP . 2.8 tm? -103.33 -59.07 1.77 Allowed 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.186 -0.461 . . . . 0.53 110.801 179.779 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.464 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 138.46 18.76 0.54 Allowed Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.214 -0.994 . . . . 0.22 113.211 -179.039 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.761 ' HB3' ' HB3' ' B' ' 15' ' ' ARG . 0.7 OUTLIER -81.01 157.37 25.5 Favored 'General case' 0 CA--C 1.491 -1.317 0 CA-C-N 117.965 0.882 . . . . 0.69 110.031 176.034 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.909 HG22 HG22 ' B' ' 16' ' ' VAL . 17.2 m -107.81 109.81 29.6 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.201 0 N-CA-C 106.945 -1.502 . . . . 1.24 106.945 164.77 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.812 HG22 ' HG2' ' B' ' 15' ' ' ARG . 57.6 t -71.71 94.75 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.433 -1.309 0 CA-C-N 115.091 -0.959 . . . . 0.28 109.278 -175.668 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.488 HD11 HD12 ' A' ' 46' ' ' LEU . 9.0 mt -82.37 109.79 17.9 Favored Pre-proline 0 N--CA 1.444 -0.761 0 CA-C-N 115.621 -0.718 . . . . 0.77 110.284 179.087 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.635 ' HD3' ' O ' ' A' ' 17' ' ' VAL . 95.8 Cg_exo -51.16 151.42 12.44 Favored 'Trans proline' 0 N--CA 1.454 -0.845 0 C-N-CA 123.053 2.502 . . . . 0.32 112.366 174.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.855 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -62.34 -25.14 67.74 Favored 'General case' 0 C--O 1.206 -1.194 0 CA-C-N 115.591 -0.731 . . . . 1.57 111.763 -176.823 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.3 pm0 -55.49 -25.65 38.19 Favored 'General case' 0 C--O 1.239 0.507 0 N-CA-C 112.854 0.687 . . . . 1.32 112.854 -178.447 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.464 HD13 HG23 ' A' ' 18' ' ' ILE . 5.1 mp -88.18 -46.95 15.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 108.404 -0.961 . . . . 0.35 108.404 -176.574 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . 0.526 ' NE ' ' HA ' ' A' ' 29' ' ' ARG . 0.0 OUTLIER -61.02 -30.86 70.56 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 115.158 -0.928 . . . . 1.5 109.583 174.744 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 76.7 ttt180 -63.84 -52.11 61.61 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 114.269 -1.332 . . . . 2.96 111.011 175.532 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 25.6 m -64.51 -27.99 69.35 Favored 'General case' 0 C--O 1.234 0.268 0 CA-C-O 121.137 0.494 . . . . 0.4 110.537 175.377 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.832 ' HB3' HG13 ' A' ' 28' ' ' ILE . 0.8 OUTLIER -65.23 -18.1 65.04 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.534 -0.757 . . . . 0.36 111.162 175.225 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.502 ' HB2' ' O ' ' A' ' 26' ' ' LEU . 10.4 mpt_? 70.45 20.28 6.03 Favored 'General case' 0 N--CA 1.466 0.34 0 C-N-CA 123.259 0.624 . . . . 3.2 110.529 -174.109 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.832 HG13 ' HB3' ' A' ' 26' ' ' LEU . 2.7 mt -116.43 -166.06 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 115.728 -0.669 . . . . 0.48 109.458 -176.526 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.717 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -154.76 -155.5 0.58 Allowed 'General case' 0 C--N 1.321 -0.658 0 C-N-CA 122.267 0.227 . . . . 2.4 110.677 -173.327 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . 0.412 ' H ' ' HB2' ' A' ' 29' ' ' ARG . 1.7 mp0 -75.11 44.32 0.24 Allowed 'General case' 0 C--N 1.332 -0.168 0 CA-C-O 122.122 0.963 . . . . 1.23 111.366 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.688 ' N ' HD11 ' B' ' 10' ' ' ILE . . . -154.65 19.75 0.6 Allowed Glycine 0 N--CA 1.441 -1.024 0 CA-C-N 113.833 -1.531 . . . . 0.36 110.687 175.785 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.448 ' HA ' ' HD3' ' A' ' 33' ' ' PRO . 17.7 t0 -79.65 120.23 79.47 Favored Pre-proline 0 N--CA 1.464 0.245 0 CA-C-O 121.437 0.637 . . . . 1.26 109.784 176.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.618 ' HB2' ' HB3' ' A' ' 49' ' ' TYR . 2.8 Cg_endo -88.98 56.35 2.09 Favored 'Trans proline' 0 N--CA 1.452 -0.946 0 C-N-CA 123.891 3.06 . . . . 1.3 114.165 -174.494 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.921 HD11 HG23 ' B' ' 10' ' ' ILE . 0.0 OUTLIER -59.28 154.44 16.45 Favored 'General case' 0 C--N 1.3 -1.545 0 C-N-CA 118.823 -1.151 . . . . 0.38 112.34 -173.478 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.85 ' HB3' ' HD2' ' A' ' 47' ' ' LYS . 42.7 tt0 -107.92 112.48 25.11 Favored 'General case' 0 CA--C 1.491 -1.31 0 CA-C-N 113.847 -1.524 . . . . 1.12 107.909 -175.834 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.836 ' HB ' HG23 ' B' ' 6' ' ' ILE . 2.8 mt -82.65 111.05 18.47 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 O-C-N 124.424 1.078 . . . . 0.39 109.736 -179.752 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . 0.544 ' HB2' ' H ' ' B' ' 4' ' ' THR . 0.6 OUTLIER -151.11 125.88 9.68 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-O 120.98 0.419 . . . . 1.15 110.003 173.586 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.558 HG13 ' HB2' ' B' ' 2' ' ' LYS . 1.1 p -80.5 138.76 19.21 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 CA-C-O 120.921 0.391 . . . . 0.17 110.798 -177.158 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.694 ' OD2' ' HD2' ' A' ' 40' ' ' ARG . 14.2 t70 -84.29 -49.42 8.77 Favored 'General case' 0 CA--C 1.513 -0.45 0 CA-C-N 115.802 -0.635 . . . . 1.11 111.823 -173.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . 0.694 ' HD2' ' OD2' ' A' ' 39' ' ' ASP . 0.0 OUTLIER -135.81 -96.63 0.24 Allowed 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.632 -0.713 . . . . 2.29 112.516 -165.972 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -84.85 -74.24 0.4 Allowed 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.529 0.68 . . . . 1.53 110.826 -177.03 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.653 ' HA3' HD11 ' B' ' 26' ' ' LEU . . . -138.25 26.03 2.85 Favored Glycine 0 N--CA 1.439 -1.103 0 CA-C-N 115.207 -0.906 . . . . 0.32 110.918 -178.366 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.636 ' HB3' HG23 ' B' ' 45' ' ' ILE . 2.3 mt-10 -94.89 109.2 21.22 Favored 'General case' 0 N--CA 1.446 -0.641 0 N-CA-C 109.161 -0.681 . . . . 1.97 109.161 179.028 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.588 ' CG1' HG23 ' A' ' 36' ' ' ILE . 2.0 t -89.2 131.41 36.57 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.961 0 N-CA-C 109.268 -0.641 . . . . 0.14 109.268 177.79 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.77 HG13 HG13 ' B' ' 45' ' ' ILE . 1.6 mp -110.44 115.96 51.14 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.223 0 N-CA-C 108.312 -0.996 . . . . 0.14 108.312 -176.397 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.952 HD11 HD11 ' B' ' 46' ' ' LEU . 0.3 OUTLIER -109.6 117.52 34.15 Favored 'General case' 0 C--N 1.315 -0.923 0 O-C-N 123.785 0.678 . . . . 0.23 109.643 179.803 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.85 ' HD2' ' HB3' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -130.91 144.1 51.21 Favored 'General case' 0 C--O 1.215 -0.752 0 C-N-CA 118.695 -1.202 . . . . 0.76 112.844 176.303 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.633 ' HG3' ' HD2' ' A' ' 51' ' ' PRO . 1.0 OUTLIER -20.46 -25.93 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.981 0 N-CA-C 119.532 3.16 . . . . 0.32 119.532 -179.08 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 0.729 ' CD1' HG21 ' B' ' 7' ' ' VAL . 37.0 t80 72.87 -38.48 0.42 Allowed 'General case' 0 N--CA 1.479 1.002 0 CA-C-N 119.795 1.18 . . . . 1.28 112.339 -179.036 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.662 ' HB3' ' HD3' ' A' ' 51' ' ' PRO . 26.3 t -52.32 -52.32 63.98 Favored Pre-proline 0 CA--C 1.542 0.667 0 CA-C-N 116.29 -0.414 . . . . 1.36 110.559 -177.741 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.662 ' HD3' ' HB3' ' A' ' 50' ' ' SER . 97.9 Cg_endo -92.21 7.93 3.02 Favored 'Trans proline' 0 C--N 1.355 0.896 0 C-N-CA 122.387 2.058 . . . . 0.58 111.733 167.176 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.499 ' H ' ' C ' ' A' ' 49' ' ' TYR . 0.3 OUTLIER 47.16 -150.91 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.394 0 CA-C-N 114.809 -1.087 . . . . 0.78 111.515 -179.953 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.423 ' HA ' ' HZ2' ' A' ' 47' ' ' LYS . 11.2 p -85.17 47.13 1.36 Allowed 'General case' 0 N--CA 1.443 -0.776 0 CA-C-N 115.868 -0.605 . . . . 1.96 109.799 175.054 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.406 ' HB2' ' O ' ' A' ' 53' ' ' SER . 31.5 mt-10 73.85 116.76 0.05 Allowed 'General case' 0 N--CA 1.463 0.191 0 CA-C-N 115.041 -0.981 . . . . 2.89 110.229 -175.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 4.2 mm? . . . . . 0 C--O 1.25 1.126 0 CA-C-O 118.392 -0.813 . . . . 2.65 110.252 176.924 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 71.6 mtm . . . . . 0 N--CA 1.483 1.198 0 N-CA-C 109.693 -0.484 . . . . 6.17 109.693 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 2' ' ' LYS . . . . . 0.558 ' HB2' HG13 ' A' ' 38' ' ' VAL . 0.0 OUTLIER -141.84 -172.98 3.67 Favored 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 121.044 -0.262 . . . . 3.61 110.34 -179.26 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 3' ' ' ALA . . . . . 0.534 ' HA ' ' HD2' ' A' ' 37' ' ' PHE . . . 61.36 105.34 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.474 0 C-N-CA 123.445 0.698 . . . . 0.86 111.51 -173.462 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 4' ' ' THR . . . . . 0.544 ' H ' ' HB2' ' A' ' 37' ' ' PHE . 29.0 p -114.7 -39.75 3.69 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.939 -0.573 . . . . 0.43 111.802 -174.608 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 5' ' ' GLY . . . . . 0.46 ' H ' ' CB ' ' A' ' 37' ' ' PHE . . . 67.62 45.51 76.14 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 121.107 -0.568 . . . . 0.33 112.612 177.428 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 6' ' ' ILE . . . . . 0.836 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.3 tp -103.33 105.3 18.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.514 0.673 . . . . 0.3 109.732 177.855 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . 0.729 HG21 ' CD1' ' A' ' 49' ' ' TYR . 24.3 t -74.93 131.57 34.8 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.838 0 CA-C-N 115.401 -0.818 . . . . 0.27 110.899 -179.573 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.527 ' HB3' ' CD1' ' A' ' 36' ' ' ILE . 1.7 tpp180 -128.72 116.04 18.92 Favored 'General case' 0 N--CA 1.435 -1.211 0 N-CA-C 106.867 -1.531 . . . . 1.69 106.867 178.525 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 9' ' ' ARG . . . . . 0.604 ' HA ' ' HA ' ' A' ' 33' ' ' PRO . 29.2 ttp180 -78.23 102.84 7.81 Favored 'General case' 0 C--N 1.311 -1.075 0 N-CA-C 107.897 -1.149 . . . . 2.71 107.897 173.103 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 10' ' ' ILE . . . . . 0.921 HG23 HD11 ' A' ' 34' ' ' LEU . 0.4 OUTLIER -8.57 -100.77 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 O-C-N 125.948 2.03 . . . . 0.34 113.94 -174.645 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . 0.647 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 2.8 p-10 164.28 -161.05 0.0 OUTLIER 'General case' 0 CA--C 1.512 -0.501 0 N-CA-C 108.484 -0.932 . . . . 1.18 108.484 175.676 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -75.09 -14.32 60.57 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.11 0.481 . . . . 2.39 110.283 -177.237 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 13' ' ' LEU . . . . . 0.434 ' H ' ' CG ' ' B' ' 11' ' ' ASP . 2.2 tm? -105.56 -61.03 1.54 Allowed 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.826 -0.625 . . . . 0.4 110.526 179.541 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 139.84 16.16 0.52 Allowed Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.847 -0.692 . . . . 0.21 112.357 -176.764 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 15' ' ' ARG . . . . . 0.812 ' HG2' HG22 ' A' ' 17' ' ' VAL . 2.0 mtt180 -79.74 153.87 28.93 Favored 'General case' 0 CA--C 1.501 -0.934 0 N-CA-C 109.598 -0.519 . . . . 0.9 109.598 176.668 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 16' ' ' VAL . . . . . 0.909 HG22 HG22 ' A' ' 16' ' ' VAL . 1.1 m -110.5 111.83 37.91 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.673 0 N-CA-C 107.042 -1.466 . . . . 1.27 107.042 166.884 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 17' ' ' VAL . . . . . 0.536 ' O ' ' HD3' ' B' ' 19' ' ' PRO . 62.3 t -72.71 98.62 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.165 0 CA-C-N 114.699 -1.137 . . . . 0.27 109.668 -173.713 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . 0.464 ' HB ' ' O ' ' A' ' 14' ' ' GLY . 8.9 mt -85.88 111.73 40.0 Favored Pre-proline 0 N--CA 1.443 -0.794 0 CA-C-N 115.276 -0.875 . . . . 0.82 110.43 179.799 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . 0.664 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 71.4 Cg_exo -50.24 145.4 20.72 Favored 'Trans proline' 0 N--CA 1.456 -0.721 0 C-N-CA 122.965 2.444 . . . . 0.3 112.335 173.793 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 20' ' ' LYS . . . . . 1.002 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -61.65 -15.45 39.95 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 115.465 -0.789 . . . . 1.77 111.696 179.827 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . 0.664 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 11.7 pt-20 -64.65 -25.78 68.1 Favored 'General case' 0 C--O 1.237 0.446 0 N-CA-C 112.035 0.383 . . . . 1.92 112.035 -179.197 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 22' ' ' ILE . . . . . . . . . . . . . 4.9 mp -88.65 -44.58 15.55 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.271 0 N-CA-C 107.578 -1.267 . . . . 0.44 107.578 -177.885 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 23' ' ' ARG . . . . . 0.422 ' HA ' ' HB2' ' B' ' 26' ' ' LEU . 0.0 OUTLIER -59.36 -31.02 68.82 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-N 115.08 -0.964 . . . . 1.4 109.514 174.124 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 24' ' ' ARG . . . . . 0.429 HH11 ' HD2' ' B' ' 24' ' ' ARG . 22.3 ttt85 -67.7 -49.9 60.29 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 114.767 -1.106 . . . . 3.19 110.745 177.251 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 26.2 m -65.52 -25.99 67.7 Favored 'General case' 0 CA--C 1.535 0.373 0 CA-C-O 121.412 0.625 . . . . 0.4 110.159 176.451 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.717 ' HB3' HG13 ' B' ' 28' ' ' ILE . 0.6 OUTLIER -65.91 -17.4 64.63 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.398 -0.819 . . . . 0.33 110.805 173.038 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 27' ' ' ARG . . . . . 0.422 ' HB2' ' O ' ' B' ' 26' ' ' LEU . 8.6 mpt_? 65.97 27.02 10.86 Favored 'General case' 0 C--O 1.233 0.195 0 CA-C-O 121.458 0.647 . . . . 3.28 110.032 -173.839 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 28' ' ' ILE . . . . . 0.844 HG22 ' H ' ' B' ' 29' ' ' ARG . 5.1 mt -119.84 -167.7 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.379 -0.828 . . . . 0.37 109.683 -179.311 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 29' ' ' ARG . . . . . 0.844 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -153.67 -155.59 0.61 Allowed 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 122.093 0.157 . . . . 2.15 110.934 -176.041 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 30' ' ' GLU . . . . . 0.426 ' H ' ' HB2' ' B' ' 29' ' ' ARG . 1.0 OUTLIER -73.46 39.72 0.1 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 122.104 0.954 . . . . 1.18 111.983 -178.998 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . 0.612 ' N ' HD11 ' A' ' 10' ' ' ILE . . . -151.43 26.71 0.97 Allowed Glycine 0 N--CA 1.442 -0.935 0 CA-C-N 114.232 -1.349 . . . . 0.35 110.303 172.774 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 32' ' ' ASP . . . . . 0.501 ' O ' ' HA ' ' A' ' 9' ' ' ARG . 21.9 t0 -81.7 121.14 79.3 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.183 0.516 . . . . 1.29 109.916 176.807 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 33' ' ' PRO . . . . . 0.724 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 5.2 Cg_endo -87.42 72.1 3.08 Favored 'Trans proline' 0 C--O 1.204 -1.207 0 C-N-CA 123.606 2.871 . . . . 1.1 113.437 -177.853 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.61 ' H ' HD12 ' B' ' 34' ' ' LEU . 2.2 mp -71.27 151.85 43.84 Favored 'General case' 0 C--N 1.286 -2.184 0 C-N-CA 117.779 -1.569 . . . . 0.44 111.386 -176.381 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 35' ' ' GLU . . . . . 0.958 ' HB3' ' HD2' ' B' ' 47' ' ' LYS . 44.1 tt0 -108.97 113.79 26.98 Favored 'General case' 0 CA--C 1.49 -1.351 0 CA-C-N 114.388 -1.278 . . . . 1.1 107.919 -177.822 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 36' ' ' ILE . . . . . 0.876 ' HB ' HG23 ' A' ' 6' ' ' ILE . 20.5 mt -88.43 109.99 20.59 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.905 0 O-C-N 124.78 1.3 . . . . 0.62 110.027 -176.169 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 37' ' ' PHE . . . . . 0.816 ' HB2' ' H ' ' A' ' 4' ' ' THR . 1.3 p90 -150.48 129.33 12.47 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 109.561 -0.533 . . . . 1.2 109.561 174.777 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 38' ' ' VAL . . . . . 0.599 HG13 ' HB2' ' A' ' 2' ' ' LYS . 0.9 OUTLIER -79.8 142.2 14.27 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.945 0 C-N-CA 120.834 -0.346 . . . . 0.2 110.256 -178.649 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 39' ' ' ASP . . . . . 0.511 ' OD2' ' HD2' ' B' ' 40' ' ' ARG . 38.8 t70 -87.64 -47.1 8.95 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.854 -0.612 . . . . 1.14 111.84 -175.079 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 40' ' ' ARG . . . . . 0.511 ' HD2' ' OD2' ' B' ' 39' ' ' ASP . 0.0 OUTLIER -137.08 -100.97 0.2 Allowed 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 112.535 0.569 . . . . 2.71 112.535 -175.736 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -76.36 -74.54 0.23 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.119 0.485 . . . . 1.32 111.36 -174.503 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 42' ' ' GLY . . . . . 0.548 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -136.77 25.12 3.11 Favored Glycine 0 N--CA 1.444 -0.826 0 C-N-CA 120.833 -0.699 . . . . 0.34 111.426 -178.831 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 43' ' ' GLU . . . . . 0.591 ' HB3' HG23 ' A' ' 45' ' ' ILE . 2.4 mt-10 -94.23 108.87 20.71 Favored 'General case' 0 CA--C 1.509 -0.6 0 N-CA-C 109.792 -0.448 . . . . 2.07 109.792 179.277 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 44' ' ' VAL . . . . . 0.554 ' HA ' ' HA ' ' B' ' 38' ' ' VAL . 1.5 t -88.92 131.0 37.38 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 N-CA-C 109.55 -0.537 . . . . 0.13 109.55 177.831 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 45' ' ' ILE . . . . . 0.77 HG13 HG13 ' A' ' 45' ' ' ILE . 1.7 mp -109.29 118.9 57.67 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.197 0 N-CA-C 108.405 -0.961 . . . . 0.12 108.405 -177.27 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 46' ' ' LEU . . . . . 0.952 HD11 HD11 ' A' ' 46' ' ' LEU . 0.5 OUTLIER -110.64 118.11 35.32 Favored 'General case' 0 C--N 1.316 -0.87 0 O-C-N 123.732 0.645 . . . . 0.15 109.862 178.486 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 47' ' ' LYS . . . . . 0.958 ' HD2' ' HB3' ' B' ' 35' ' ' GLU . 0.0 OUTLIER -129.19 148.11 51.1 Favored 'General case' 0 C--O 1.214 -0.81 0 C-N-CA 119.116 -1.034 . . . . 0.95 112.289 177.294 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 48' ' ' LYS . . . . . 0.592 ' HG3' ' CD ' ' B' ' 51' ' ' PRO . 2.8 ptmt -45.14 -6.28 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.235 0 N-CA-C 117.895 2.554 . . . . 0.64 117.895 -168.004 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 49' ' ' TYR . . . . . 0.724 ' HB3' ' HB2' ' B' ' 33' ' ' PRO . 24.3 t80 68.3 -36.18 0.31 Allowed 'General case' 0 N--CA 1.48 1.03 0 CA-C-N 119.372 0.987 . . . . 1.26 113.28 176.43 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 50' ' ' SER . . . . . 0.614 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 12.4 t -53.97 -47.79 95.92 Favored Pre-proline 0 CA--C 1.542 0.667 0 C-N-CA 122.588 0.355 . . . . 1.22 110.991 -177.194 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 51' ' ' PRO . . . . . 0.614 ' HD3' ' HB3' ' B' ' 50' ' ' SER . 62.6 Cg_endo -94.56 5.52 2.52 Favored 'Trans proline' 0 C--N 1.352 0.751 0 C-N-CA 122.451 2.101 . . . . 0.56 111.919 165.551 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 52' ' ' ILE . . . . . 0.516 ' H ' ' C ' ' B' ' 49' ' ' TYR . 0.6 OUTLIER 49.07 -146.43 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-N 115.083 -0.962 . . . . 0.73 110.595 -177.324 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 53' ' ' SER . . . . . 0.415 ' O ' ' HB3' ' B' ' 54' ' ' GLU . 57.2 p -84.72 36.05 0.59 Allowed 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 109.547 -0.538 . . . . 1.86 109.547 176.464 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 54' ' ' GLU . . . . . 0.415 ' HB3' ' O ' ' B' ' 53' ' ' SER . 8.9 tp10 75.97 118.42 0.05 Allowed 'General case' 0 C--N 1.341 0.201 0 C-N-CA 124.407 1.083 . . . . 2.62 110.127 -171.858 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 55' ' ' LEU . . . . . 0.4 ' HA ' HD13 ' B' ' 55' ' ' LEU . 4.3 mm? . . . . . 0 C--O 1.247 0.933 0 CA-C-O 118.275 -0.869 . . . . 2.64 110.737 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.402 ' HB3' HG21 ' A' ' 25' ' ' THR . 64.0 mtt . . . . . 0 N--CA 1.478 0.961 0 CA-C-O 120.246 0.069 . . . . 5.91 110.981 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.67 ' HA ' HG13 ' B' ' 38' ' ' VAL . 0.0 OUTLIER -95.7 175.49 6.51 Favored 'General case' 0 C--N 1.332 -0.178 0 C-N-CA 120.463 -0.495 . . . . 3.71 111.849 -179.419 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.83 ' HA ' ' HD2' ' B' ' 37' ' ' PHE . . . 56.31 82.4 0.11 Allowed 'General case' 0 CA--C 1.519 -0.225 0 CA-C-N 115.325 -0.852 . . . . 0.72 110.802 -169.232 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.473 ' OG1' ' HA ' ' B' ' 37' ' ' PHE . 15.6 p -94.08 -35.92 12.34 Favored 'General case' 0 N--CA 1.444 -0.74 0 CA-C-N 115.181 -0.918 . . . . 0.41 112.036 -176.506 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 60.93 49.37 79.42 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.969 -0.634 . . . . 0.32 112.799 176.317 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.876 HG23 ' HB ' ' B' ' 36' ' ' ILE . 0.9 OUTLIER -108.28 111.3 35.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 N-CA-C 109.379 -0.6 . . . . 0.31 109.379 175.295 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.665 HG21 ' CD1' ' B' ' 49' ' ' TYR . 48.6 t -82.38 133.96 28.03 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 CA-C-O 121.303 0.573 . . . . 0.28 111.013 -178.3 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.601 ' HB3' HD11 ' B' ' 36' ' ' ILE . 3.9 tpt180 -126.2 107.86 10.76 Favored 'General case' 0 N--CA 1.441 -0.903 0 N-CA-C 107.074 -1.454 . . . . 1.99 107.074 -178.545 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.525 ' C ' HD12 ' A' ' 10' ' ' ILE . 2.0 ttt180 -78.34 102.0 7.49 Favored 'General case' 0 CA--C 1.503 -0.847 0 N-CA-C 108.02 -1.104 . . . . 2.8 108.02 175.73 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.706 HD11 ' CA ' ' B' ' 31' ' ' GLY . 0.2 OUTLIER -10.12 -109.25 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 O-C-N 126.036 2.085 . . . . 0.33 114.551 -179.187 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . 0.63 ' HB3' ' O ' ' A' ' 10' ' ' ILE . 4.2 p-10 158.81 -167.73 0.0 OUTLIER 'General case' 0 CA--C 1.513 -0.458 0 N-CA-C 107.202 -1.407 . . . . 1.13 107.202 177.465 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -67.52 -22.78 65.42 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.013 0.435 . . . . 2.26 110.887 -178.241 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.432 HD22 ' HA ' ' A' ' 13' ' ' LEU . 2.2 tm? -95.28 -61.54 1.46 Allowed 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.081 -0.509 . . . . 0.53 109.733 177.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.575 ' O ' ' HB ' ' B' ' 18' ' ' ILE . . . 132.71 21.49 0.9 Allowed Glycine 0 N--CA 1.443 -0.892 0 C-N-CA 119.898 -1.144 . . . . 0.22 114.131 178.242 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.492 ' HA ' ' HA ' ' B' ' 17' ' ' VAL . 0.9 OUTLIER -79.01 155.08 29.01 Favored 'General case' 0 CA--C 1.504 -0.814 0 CA-C-N 118.91 1.355 . . . . 0.69 110.941 179.249 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.637 HG21 HD13 ' B' ' 46' ' ' LEU . 52.9 t -111.43 101.37 12.45 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.379 0 N-CA-C 107.39 -1.337 . . . . 1.24 107.39 169.322 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.709 HG22 ' HG2' ' B' ' 15' ' ' ARG . 65.5 t -68.21 106.91 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.016 0 CA-C-N 115.038 -0.983 . . . . 0.28 109.775 -175.767 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 31.7 mm -90.8 109.26 33.45 Favored Pre-proline 0 N--CA 1.446 -0.636 0 CA-C-N 115.79 -0.641 . . . . 0.77 110.547 -177.895 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.578 ' HD3' ' O ' ' A' ' 17' ' ' VAL . 81.0 Cg_exo -50.37 138.04 38.63 Favored 'Trans proline' 0 N--CA 1.459 -0.521 0 C-N-CA 123.015 2.476 . . . . 0.32 112.359 173.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.882 ' HD2' ' H ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -57.64 -14.21 5.12 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-N 114.947 -1.024 . . . . 1.57 112.265 179.297 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.541 ' O ' ' HB3' ' A' ' 24' ' ' ARG . 11.9 pt-20 -67.08 -25.78 66.4 Favored 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 118.088 0.404 . . . . 1.32 111.724 -178.256 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 4.5 mp -88.15 -42.73 15.1 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.321 0 N-CA-C 107.622 -1.251 . . . . 0.35 107.622 -178.081 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ARG . . . . . 0.657 ' HA ' ' HB2' ' A' ' 26' ' ' LEU . 0.0 OUTLIER -58.51 -31.78 68.21 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 114.848 -1.069 . . . . 1.5 109.145 171.936 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.541 ' HB3' ' O ' ' A' ' 21' ' ' GLU . 55.3 ttp180 -60.19 -52.85 63.56 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 114.313 -1.312 . . . . 2.96 110.785 174.092 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . 0.402 HG21 ' HB3' ' A' ' 1' ' ' MET . 17.3 m -65.85 -27.02 67.93 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-O 121.247 0.546 . . . . 0.4 110.961 174.699 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.675 ' HB3' HG13 ' A' ' 28' ' ' ILE . 1.3 mm? -64.68 -20.86 66.55 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.759 -0.655 . . . . 0.36 110.638 173.879 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 8.1 tpt180 71.17 18.83 5.66 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-O 121.793 0.806 . . . . 3.2 109.302 -176.431 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.774 HG22 ' H ' ' A' ' 29' ' ' ARG . 3.9 mt -114.9 -167.44 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 114.894 -1.048 . . . . 0.48 108.797 -177.926 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ARG . . . . . 0.774 ' H ' HG22 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -155.54 -149.63 0.27 Allowed 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 110.149 -0.315 . . . . 2.4 110.149 -173.282 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 4.6 mp0 -72.58 40.15 0.08 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.471 0.653 . . . . 1.23 111.962 178.754 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.665 ' CA ' HD11 ' B' ' 10' ' ' ILE . . . -154.87 33.37 0.67 Allowed Glycine 0 N--CA 1.438 -1.189 0 N-CA-C 110.609 -0.996 . . . . 0.36 110.609 171.592 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.5 ' HA ' ' HD3' ' A' ' 33' ' ' PRO . 45.9 t0 -90.1 116.3 66.04 Favored Pre-proline 0 C--O 1.234 0.275 0 CA-C-O 121.327 0.584 . . . . 1.26 109.602 175.742 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.553 ' HA ' ' HA ' ' B' ' 9' ' ' ARG . 1.3 Cg_endo -87.28 63.29 4.07 Favored 'Trans proline' 0 N--CA 1.454 -0.835 0 C-N-CA 123.984 3.122 . . . . 1.3 113.83 -177.064 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.616 HD12 ' H ' ' A' ' 34' ' ' LEU . 0.7 OUTLIER -63.87 153.79 35.72 Favored 'General case' 0 C--N 1.295 -1.785 0 C-N-CA 118.709 -1.196 . . . . 0.38 111.695 -175.636 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.925 ' HB3' ' HD2' ' A' ' 47' ' ' LYS . 34.4 tt0 -111.0 117.2 32.7 Favored 'General case' 0 CA--C 1.491 -1.29 0 CA-C-N 113.926 -1.488 . . . . 1.12 108.987 -173.362 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.905 ' HB ' HG23 ' B' ' 6' ' ' ILE . 3.0 mp -84.19 111.59 20.28 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.828 0 O-C-N 124.534 1.146 . . . . 0.39 109.546 -178.875 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . 0.876 ' HD2' ' HA ' ' B' ' 3' ' ' ALA . 0.3 OUTLIER -149.79 124.01 9.52 Favored 'General case' 0 C--N 1.313 -1.002 0 CA-C-O 121.13 0.491 . . . . 1.15 109.711 172.416 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.607 HG13 ' HA ' ' B' ' 2' ' ' LYS . 1.4 p -80.16 137.22 21.92 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 CA-C-O 121.198 0.523 . . . . 0.17 110.143 -179.409 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.667 ' OD2' ' HD2' ' A' ' 40' ' ' ARG . 32.3 t70 -88.24 -46.07 9.54 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.256 -0.884 . . . . 1.11 111.699 -172.877 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . 0.797 ' HG3' ' HG3' ' A' ' 43' ' ' GLU . 0.1 OUTLIER -128.19 -90.64 0.5 Allowed 'General case' 0 C--N 1.313 -1.008 0 CA-C-N 114.773 -1.103 . . . . 2.29 112.054 -162.402 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -112.74 -66.51 1.08 Allowed 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 121.02 0.438 . . . . 1.53 111.205 -176.402 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.563 ' HA3' HD11 ' B' ' 26' ' ' LEU . . . -130.33 13.68 5.67 Favored Glycine 0 CA--C 1.499 -0.914 0 C-N-CA 120.462 -0.875 . . . . 0.32 111.628 -178.309 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.797 ' HG3' ' HG3' ' A' ' 40' ' ' ARG . 0.9 OUTLIER -97.04 110.54 23.06 Favored 'General case' 0 C--N 1.319 -0.732 0 N-CA-C 109.299 -0.63 . . . . 1.97 109.299 -178.794 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.582 ' CG1' HG23 ' A' ' 36' ' ' ILE . 2.3 t -90.71 133.76 31.51 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.788 0 CA-C-N 115.718 -0.674 . . . . 0.14 109.239 177.924 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.736 HG13 HG13 ' B' ' 45' ' ' ILE . 1.7 mp -110.93 116.6 52.92 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 N-CA-C 108.644 -0.873 . . . . 0.14 108.644 -175.77 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.94 HD11 HD11 ' B' ' 46' ' ' LEU . 0.9 OUTLIER -108.08 118.36 36.54 Favored 'General case' 0 C--N 1.319 -0.76 0 O-C-N 123.764 0.665 . . . . 0.23 109.753 179.53 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.925 ' HD2' ' HB3' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -130.08 148.73 51.96 Favored 'General case' 0 C--O 1.216 -0.689 0 C-N-CA 118.849 -1.14 . . . . 0.76 113.152 178.001 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.596 ' HE2' ' HG3' ' A' ' 51' ' ' PRO . 2.2 ptmt -35.83 -19.73 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.09 0 N-CA-C 118.044 2.609 . . . . 0.32 118.044 -172.288 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 0.585 ' CD1' HG21 ' B' ' 7' ' ' VAL . 22.6 t80 74.95 -54.26 0.66 Allowed 'General case' 0 N--CA 1.475 0.822 0 C-N-CA 123.455 0.702 . . . . 1.28 112.79 177.408 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.713 ' HB3' ' HD3' ' A' ' 51' ' ' PRO . 6.8 t -52.15 -53.13 55.62 Favored Pre-proline 0 CA--C 1.541 0.601 0 CA-C-N 116.388 -0.369 . . . . 1.36 111.182 -173.675 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.713 ' HD3' ' HB3' ' A' ' 50' ' ' SER . 48.5 Cg_endo -92.98 14.39 1.6 Allowed 'Trans proline' 0 C--N 1.348 0.536 0 C-N-CA 122.376 2.051 . . . . 0.58 111.539 170.101 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.41 HG13 ' C ' ' A' ' 51' ' ' PRO . 0.9 OUTLIER 50.4 -145.5 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.235 0.306 0 CA-C-N 115.429 -0.805 . . . . 0.78 109.86 -176.861 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 3.0 m -83.94 69.57 10.31 Favored 'General case' 0 C--N 1.321 -0.643 0 C-N-CA 120.968 -0.293 . . . . 1.96 111.146 178.494 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER 65.24 18.14 11.28 Favored 'General case' 0 CA--C 1.534 0.346 0 CA-C-N 115.715 -0.675 . . . . 2.89 110.372 177.742 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 97.1 mt . . . . . 0 C--O 1.249 1.043 0 CA-C-N 115.756 -0.656 . . . . 2.65 111.497 -179.389 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 65.9 mtt . . . . . 0 N--CA 1.485 1.323 0 CA-C-O 120.66 0.267 . . . . 6.17 111.177 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 2' ' ' LYS . . . . . 0.607 ' HA ' HG13 ' A' ' 38' ' ' VAL . 0.0 OUTLIER -114.52 -177.23 3.08 Favored 'General case' 0 C--N 1.326 -0.416 0 C-N-CA 121.066 -0.254 . . . . 3.61 110.567 178.677 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 3' ' ' ALA . . . . . 0.876 ' HA ' ' HD2' ' A' ' 37' ' ' PHE . . . 51.78 76.34 0.18 Allowed 'General case' 0 CA--C 1.517 -0.296 0 O-C-N 123.849 0.718 . . . . 0.86 110.979 -174.759 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 4' ' ' THR . . . . . . . . . . . . . 20.4 p -91.68 -29.14 17.02 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.219 -0.901 . . . . 0.43 112.275 -173.607 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 5' ' ' GLY . . . . . . . . . . . . . . . 56.99 47.74 84.93 Favored Glycine 0 N--CA 1.45 -0.415 0 CA-C-N 115.711 -0.677 . . . . 0.33 112.99 175.306 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 6' ' ' ILE . . . . . 0.905 HG23 ' HB ' ' A' ' 36' ' ' ILE . 1.0 OUTLIER -107.66 109.46 28.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-O 121.178 0.513 . . . . 0.3 109.623 176.602 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 7' ' ' VAL . . . . . 0.602 ' HA ' ' HA ' ' A' ' 35' ' ' GLU . 14.7 t -80.52 135.38 25.39 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.996 0 CA-C-N 115.609 -0.723 . . . . 0.27 110.783 -177.813 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.526 ' CZ ' HG23 ' B' ' 17' ' ' VAL . 1.1 tpt180 -128.09 112.77 14.95 Favored 'General case' 0 N--CA 1.449 -0.495 0 N-CA-C 107.405 -1.331 . . . . 1.69 107.405 178.696 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 9' ' ' ARG . . . . . 0.553 ' HA ' ' HA ' ' A' ' 33' ' ' PRO . 13.2 ttt180 -78.83 104.45 9.47 Favored 'General case' 0 CA--C 1.501 -0.929 0 N-CA-C 108.287 -1.005 . . . . 2.71 108.287 174.564 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 10' ' ' ILE . . . . . 0.665 HD11 ' CA ' ' A' ' 31' ' ' GLY . 0.2 OUTLIER -15.28 -103.24 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 O-C-N 125.822 1.951 . . . . 0.34 114.65 -177.248 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 11' ' ' ASP . . . . . 0.575 ' HB3' ' O ' ' B' ' 10' ' ' ILE . 6.4 p-10 158.08 -161.08 0.0 OUTLIER 'General case' 0 CA--C 1.506 -0.727 0 N-CA-C 106.604 -1.628 . . . . 1.18 106.604 174.854 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 12' ' ' ASP . . . . . . . . . . . . . 38.4 t70 -77.04 -17.5 58.74 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.512 0.673 . . . . 2.39 110.209 -178.151 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 13' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -96.1 -61.6 1.41 Allowed 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.575 -0.739 . . . . 0.4 110.029 177.296 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 134.61 24.06 0.62 Allowed Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.477 -0.868 . . . . 0.21 112.649 179.624 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 15' ' ' ARG . . . . . 0.709 ' HG2' HG22 ' A' ' 17' ' ' VAL . 56.4 mtt180 -77.82 147.28 35.28 Favored 'General case' 0 CA--C 1.51 -0.575 0 CA-C-O 121.479 0.657 . . . . 0.9 111.175 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 16' ' ' VAL . . . . . 0.526 HG11 HD13 ' A' ' 46' ' ' LEU . 92.7 t -113.76 99.49 8.72 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.13 0 N-CA-C 107.861 -1.163 . . . . 1.27 107.861 168.335 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 17' ' ' VAL . . . . . 0.568 ' O ' ' HD3' ' B' ' 19' ' ' PRO . 60.8 t -66.41 106.33 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.847 0 CA-C-N 115.475 -0.784 . . . . 0.27 109.847 -173.635 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 18' ' ' ILE . . . . . 0.575 ' HB ' ' O ' ' A' ' 14' ' ' GLY . 22.7 mm -89.29 109.08 28.62 Favored Pre-proline 0 C--N 1.32 -0.696 0 CA-C-N 115.587 -0.733 . . . . 0.82 110.24 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . 0.632 ' HB2' ' HG2' ' B' ' 21' ' ' GLU . 93.6 Cg_exo -53.45 144.05 52.46 Favored 'Trans proline' 0 N--CA 1.454 -0.799 0 C-N-CA 122.558 2.172 . . . . 0.3 112.22 174.773 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 20' ' ' LYS . . . . . 0.989 ' H ' ' HD2' ' B' ' 20' ' ' LYS . 0.0 OUTLIER -64.64 -13.71 54.99 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 115.556 -0.747 . . . . 1.77 111.434 -179.396 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 21' ' ' GLU . . . . . 0.632 ' HG2' ' HB2' ' B' ' 19' ' ' PRO . 11.2 pt-20 -65.42 -26.32 67.92 Favored 'General case' 0 C--O 1.239 0.549 0 N-CA-C 112.688 0.625 . . . . 1.92 112.688 179.556 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 22' ' ' ILE . . . . . 0.438 ' H ' HD12 ' B' ' 22' ' ' ILE . 3.9 mp -88.58 -42.09 14.52 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.252 0 N-CA-C 107.807 -1.183 . . . . 0.44 107.807 -179.214 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 23' ' ' ARG . . . . . 0.577 ' HA ' ' HB2' ' B' ' 26' ' ' LEU . 0.0 OUTLIER -57.69 -30.24 65.33 Favored 'General case' 0 N--CA 1.461 0.125 0 CA-C-N 114.927 -1.033 . . . . 1.4 109.126 170.973 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 24' ' ' ARG . . . . . 0.535 ' HB3' ' O ' ' B' ' 21' ' ' GLU . 21.4 ttp180 -62.28 -53.17 59.06 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 114.289 -1.323 . . . . 3.19 110.942 174.838 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 25' ' ' THR . . . . . . . . . . . . . 30.4 m -62.41 -32.0 72.77 Favored 'General case' 0 C--O 1.235 0.334 0 CA-C-O 121.409 0.624 . . . . 0.4 110.557 174.278 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.663 ' HB3' HG13 ' B' ' 28' ' ' ILE . 0.9 OUTLIER -64.3 -19.86 65.7 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.212 -0.903 . . . . 0.33 110.705 176.131 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 27' ' ' ARG . . . . . 0.45 ' HD2' ' HA ' ' B' ' 27' ' ' ARG . 11.9 tpt180 68.05 22.45 8.43 Favored 'General case' 0 N--CA 1.461 0.097 0 CA-C-O 121.802 0.81 . . . . 3.28 109.906 -177.627 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 28' ' ' ILE . . . . . 0.84 HG22 ' H ' ' B' ' 29' ' ' ARG . 6.3 mt -111.92 -161.21 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.203 -0.908 . . . . 0.37 109.162 -179.306 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 29' ' ' ARG . . . . . 0.84 ' H ' HG22 ' B' ' 28' ' ' ILE . 0.0 OUTLIER -158.68 -157.37 0.61 Allowed 'General case' 0 C--N 1.32 -0.689 0 O-C-N 122.468 -0.145 . . . . 2.15 110.618 -173.229 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 30' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -70.31 43.48 0.06 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.975 0.893 . . . . 1.18 111.598 176.777 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 31' ' ' GLY . . . . . 0.706 ' CA ' HD11 ' A' ' 10' ' ' ILE . . . -161.12 36.06 0.41 Allowed Glycine 0 N--CA 1.436 -1.338 0 CA-C-N 114.282 -1.326 . . . . 0.35 110.358 174.614 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 32' ' ' ASP . . . . . 0.497 ' HA ' ' HD3' ' B' ' 33' ' ' PRO . 16.5 t0 -93.21 121.13 66.06 Favored Pre-proline 0 C--N 1.327 -0.409 0 CA-C-N 115.006 -0.597 . . . . 1.29 110.223 175.558 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 33' ' ' PRO . . . . . 0.674 ' HB2' ' HB3' ' B' ' 49' ' ' TYR . 3.9 Cg_endo -86.84 75.6 2.57 Favored 'Trans proline' 0 C--O 1.206 -1.084 0 C-N-CA 123.664 2.909 . . . . 1.1 113.31 -179.919 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.699 ' H ' HD12 ' B' ' 34' ' ' LEU . 1.4 mp -71.14 150.52 45.34 Favored 'General case' 0 C--N 1.286 -2.182 0 C-N-CA 117.909 -1.516 . . . . 0.44 111.326 -178.535 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 35' ' ' GLU . . . . . 0.783 ' HB3' ' HD2' ' B' ' 47' ' ' LYS . 45.2 tt0 -109.69 114.45 28.06 Favored 'General case' 0 CA--C 1.49 -1.343 0 CA-C-N 114.384 -1.28 . . . . 1.1 108.326 -177.656 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 36' ' ' ILE . . . . . 0.986 HG13 HD22 ' B' ' 46' ' ' LEU . 3.0 mp -87.46 112.16 22.94 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 O-C-N 124.761 1.288 . . . . 0.62 109.697 -177.221 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 37' ' ' PHE . . . . . 0.83 ' HD2' ' HA ' ' A' ' 3' ' ' ALA . 1.1 p90 -150.14 128.42 12.07 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 116.003 -0.544 . . . . 1.2 109.661 172.39 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 38' ' ' VAL . . . . . 0.67 HG13 ' HA ' ' A' ' 2' ' ' LYS . 0.6 OUTLIER -80.67 140.19 17.03 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.982 0 CA-C-O 121.281 0.563 . . . . 0.2 110.57 -179.636 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 39' ' ' ASP . . . . . 0.631 ' OD1' ' HD2' ' B' ' 40' ' ' ARG . 16.1 t70 -84.85 -50.74 7.29 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.16 -0.927 . . . . 1.14 111.731 -173.249 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 40' ' ' ARG . . . . . 0.631 ' HD2' ' OD1' ' B' ' 39' ' ' ASP . 0.0 OUTLIER -134.99 -87.15 0.38 Allowed 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 112.661 0.615 . . . . 2.71 112.661 -172.437 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 41' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -95.17 -78.81 0.44 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.025 0.44 . . . . 1.32 110.999 -175.673 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 42' ' ' GLY . . . . . 0.479 ' HA3' HD11 ' A' ' 26' ' ' LEU . . . -125.84 16.02 6.95 Favored Glycine 0 N--CA 1.443 -0.843 0 C-N-CA 120.576 -0.821 . . . . 0.34 112.043 -177.481 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 43' ' ' GLU . . . . . 0.428 ' H ' ' HG2' ' B' ' 43' ' ' GLU . 0.0 OUTLIER -92.03 107.64 19.35 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.511 -0.552 . . . . 2.07 109.511 -178.765 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 44' ' ' VAL . . . . . 0.564 ' O ' ' HA ' ' A' ' 45' ' ' ILE . 1.9 t -89.83 133.71 31.03 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.852 0 N-CA-C 109.402 -0.592 . . . . 0.13 109.402 176.441 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 45' ' ' ILE . . . . . 0.736 HG13 HG13 ' A' ' 45' ' ' ILE . 1.7 mp -110.62 119.86 60.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 N-CA-C 108.582 -0.896 . . . . 0.12 108.582 -177.281 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 46' ' ' LEU . . . . . 0.986 HD22 HG13 ' B' ' 36' ' ' ILE . 0.6 OUTLIER -112.13 117.54 32.88 Favored 'General case' 0 C--N 1.32 -0.696 0 O-C-N 123.682 0.614 . . . . 0.15 109.936 178.333 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 47' ' ' LYS . . . . . 0.783 ' HD2' ' HB3' ' B' ' 35' ' ' GLU . 0.0 OUTLIER -130.95 152.94 49.71 Favored 'General case' 0 C--O 1.213 -0.848 0 C-N-CA 119.254 -0.978 . . . . 0.95 113.033 177.516 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 48' ' ' LYS . . . . . 0.664 ' HE3' HD11 ' B' ' 28' ' ' ILE . 12.5 ptmt -49.87 -4.4 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.011 0 N-CA-C 117.713 2.486 . . . . 0.64 117.713 -166.727 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 49' ' ' TYR . . . . . 0.674 ' HB3' ' HB2' ' B' ' 33' ' ' PRO . 28.7 t80 71.73 -54.53 0.67 Allowed 'General case' 0 N--CA 1.477 0.88 0 N-CA-C 113.549 0.944 . . . . 1.26 113.549 172.027 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 50' ' ' SER . . . . . 0.69 ' HB3' ' HD3' ' B' ' 51' ' ' PRO . 9.2 t -51.55 -55.88 25.61 Favored Pre-proline 0 CA--C 1.539 0.548 0 CA-C-N 116.05 -0.523 . . . . 1.22 111.035 -173.518 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 51' ' ' PRO . . . . . 0.69 ' HD3' ' HB3' ' B' ' 50' ' ' SER . 41.3 Cg_endo -89.81 12.95 2.45 Favored 'Trans proline' 0 C--N 1.351 0.705 0 C-N-CA 122.172 1.915 . . . . 0.56 111.514 170.698 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 52' ' ' ILE . . . . . . . . . . . . . 1.1 mt 50.55 -144.57 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.199 -0.909 . . . . 0.73 109.714 -176.66 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 53' ' ' SER . . . . . 0.402 ' HA ' ' HG3' ' B' ' 47' ' ' LYS . 13.8 m -81.49 62.99 5.6 Favored 'General case' 0 C--N 1.326 -0.452 0 O-C-N 122.351 -0.218 . . . . 1.86 111.155 179.427 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 54' ' ' GLU . . . . . . . . . . . . . 7.5 tm-20 66.7 21.39 10.59 Favored 'General case' 0 CA--C 1.539 0.523 0 CA-C-O 121.523 0.678 . . . . 2.62 109.74 178.774 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 55' ' ' LEU . . . . . . . . . . . . . 95.4 mt . . . . . 0 C--O 1.251 1.149 0 CA-C-N 115.379 -0.828 . . . . 2.64 111.211 -177.171 . . . . . . . . 0 0 . 1 stop_ save_